# locus	type	ref	length	genotype	filter	pvalue	phred_qual_score	cnv_pvalue	coverage	allele_coverage	allele_ratio	allele_frequency_%	allele_frequency_%_corrected	zygosity	entry_count	maf	hrun	som_pval	gene	transcript	location	function	codon	exon	protein	coding	sift	polyphen	grantham	normalizedAlt	5000Exomes	FATHMM	NamedVariants	clinvar	cosmic	dbsnp	dgv	dra	drugbank	go	omim	pfam	phylop	dra_20170914	GRCh38_clinvar_20201226	GRCh38_cosmic_92	GRCh38_dbsnp_154	GRCh38_dgv_20200225	GRCh38_drugbank_20201029	GRCh38_esp6500_20151203	GRCh38_go_20201118	GRCh38_namedVariants_20151113	GRCh38_omim_20201202	GRCh38_pfam_33	GRCh38_phylop_20151118	GRCh38_refgene_201	MyVariantDefaultDb_GRCh38	gender
chr1:11790870	SNV	C	1	C/T	PASS	4.2364296604953655e-92	913.73		400	C=199,T=201	C=0.4975,T=0.5025	50.25	49.75	heterozygous	26	0.074	2.0		MTHFR	NM_005957.5	MTHFR:exonic:NM_005957.5	missense	CAG	12	p.Arg594Gln	c.1781G>A	1.0	0.0	43.0	T	GMAF=0.0406:AMAF=0.0297:EMAF=0.0462	0.07		Benign, other	4986586	rs2274976		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MTHFR)(dui:NBS2;dis:Core Conditions;g:MTHFR)(dui:NBS11;dis:Amino Acid Disorder;g:MTHFR)(dui:NBS57;dis:Homocystinuria;g:MTHFR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MTHFR)(dui:D002318;dis:Cardiovascular Diseases;g:MTHFR)(dui:D009422;dis:Nervous System Diseases;g:MTHFR)(dui:D014652;dis:Vascular Diseases;g:MTHFR)(dui:D009369;dis:Neoplasms;g:MTHFR)(dui:D000013;dis:Congenital Abnormalities;g:MTHFR)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MTHFR)(dui:D030342;dis:Genetic Diseases, Inborn;g:MTHFR)(dui:D009371;dis:Neoplasms by Site;g:MTHFR)(dui:D002493;dis:Central Nervous System Diseases;g:MTHFR)(dui:D007154;dis:Immune System Diseases;g:MTHFR)(dui:D004066;dis:Digestive System Diseases;g:MTHFR)(dui:D001927;dis:Brain Diseases;g:MTHFR)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MTHFR)(dui:D009370;dis:Neoplasms by Histologic Type;g:MTHFR)(dui:D005767;dis:Gastrointestinal Diseases;g:MTHFR)(dui:D008659;dis:Metabolic Diseases;g:MTHFR)(dui:D006331;dis:Heart Diseases;g:MTHFR)(dui:D004067;dis:Digestive System Neoplasms;g:MTHFR)(dui:D001523;dis:Mental Disorders;g:MTHFR)(dui:D006402;dis:Hematologic Diseases;g:MTHFR)(dui:D009748;dis:Nutrition Disorders;g:MTHFR)(dui:D044342;dis:Malnutrition;g:MTHFR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:MTHFR)(dui:D007160;dis:Immunoproliferative Disorders;g:MTHFR)(dui:D008232;dis:Lymphoproliferative Disorders;g:MTHFR)(dui:D002561;dis:Cerebrovascular Disorders;g:MTHFR)(dui:D008206;dis:Lymphatic Diseases;g:MTHFR)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MTHFR)(dui:D008661;dis:Metabolism, Inborn Errors;g:MTHFR)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MTHFR)(dui:D020138;dis:Hyperhomocysteinemia;g:MTHFR)(dui:D017202;dis:Myocardial Ischemia;g:MTHFR)(dui:D003677;dis:Deficiency Diseases;g:MTHFR)(dui:D001361;dis:Avitaminosis;g:MTHFR)(dui:D014804;dis:Vitamin B Deficiency;g:MTHFR)(dui:D009421;dis:Nervous System Malformations;g:MTHFR)(dui:D009436;dis:Neural Tube Defects;g:MTHFR)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:MTHFR)(dui:D009140;dis:Musculoskeletal Diseases;g:MTHFR)(dui:D016769;dis:Embolism and Thrombosis;g:MTHFR)(dui:D009461;dis:Neurologic Manifestations;g:MTHFR)(dui:D003327;dis:Coronary Disease;g:MTHFR)(dui:D052776;dis:Female Urogenital Diseases;g:MTHFR)(dui:D052801;dis:Male Urogenital Diseases;g:MTHFR)(dui:D008286;dis:Malabsorption Syndromes;g:MTHFR)(dui:D007938;dis:Leukemia;g:MTHFR)(dui:D009057;dis:Stomatognathic Diseases;g:MTHFR)(dui:D007945;dis:Leukemia, Lymphoid;g:MTHFR)(dui:D007410;dis:Intestinal Diseases;g:MTHFR)(dui:D012871;dis:Skin Diseases;g:MTHFR)(dui:D009059;dis:Mouth Diseases;g:MTHFR)(dui:D004700;dis:Endocrine System Diseases;g:MTHFR)(dui:D003108;dis:Colonic Diseases;g:MTHFR)(dui:D007414;dis:Intestinal Neoplasms;g:MTHFR)(dui:D015179;dis:Colorectal Neoplasms;g:MTHFR)(dui:D014565;dis:Urogenital Neoplasms;g:MTHFR)(dui:D018640;dis:Stomatognathic System Abnormalities;g:MTHFR)(dui:D019967;dis:Schizophrenia Spectrum and Other Psychotic Disorders;g:MTHFR)(dui:D003240;dis:Connective Tissue Diseases;g:MTHFR)(dui:D014570;dis:Urologic Diseases;g:MTHFR)(dui:D013927;dis:Thrombosis;g:MTHFR)(dui:D020521;dis:Stroke;g:MTHFR)(dui:D008223;dis:Lymphoma;g:MTHFR)(dui:D005831;dis:Genital Diseases, Female;g:MTHFR)(dui:D008107;dis:Liver Diseases;g:MTHFR)(dui:D009056;dis:Mouth Abnormalities;g:MTHFR)(dui:D025063;dis:Chromosome Disorders;g:MTHFR)(dui:D019954;dis:Neurobehavioral Manifestations;g:MTHFR)(dui:D008607;dis:Intellectual Disability;g:MTHFR)(dui:D000015;dis:Abnormalities, Multiple;g:MTHFR)(dui:D004314;dis:Down Syndrome;g:MTHFR)(dui:D019851;dis:Thrombophilia;g:MTHFR)(dui:D054198;dis:Precursor Cell Lymphoblastic Leukemia-Lymphoma;g:MTHFR)(dui:D007674;dis:Kidney Diseases;g:MTHFR)(dui:D013272;dis:Stomach Diseases;g:MTHFR)(dui:D020246;dis:Venous Thrombosis;g:MTHFR)(dui:D003920;dis:Diabetes Mellitus;g:MTHFR)(dui:D013274;dis:Stomach Neoplasms;g:MTHFR)(dui:D009139;dis:Musculoskeletal Abnormalities;g:MTHFR)(dui:D005832;dis:Genital Diseases, Male;g:MTHFR)(dui:D001327;dis:Autoimmune Diseases;g:MTHFR)(dui:D012559;dis:Schizophrenia;g:MTHFR)(dui:D007246;dis:Infertility;g:MTHFR)(dui:D012140;dis:Respiratory Tract Diseases;g:MTHFR)(dui:D008171;dis:Lung Diseases;g:MTHFR)(dui:D002545;dis:Brain Ischemia;g:MTHFR)(dui:D012002;dis:Rectal Diseases;g:MTHFR)(dui:D007592;dis:Joint Diseases;g:MTHFR)(dui:D001168;dis:Arthritis;g:MTHFR)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:MTHFR)(dui:D019636;dis:Neurodegenerative Diseases;g:MTHFR)(dui:D012216;dis:Rheumatic Diseases;g:MTHFR)(dui:D001172;dis:Arthritis, Rheumatoid;g:MTHFR)(dui:D005833;dis:Genital Neoplasms, Female;g:MTHFR)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MTHFR)(dui:D009008;dis:Abnormalities, Severe Teratoid;g:MTHFR)(dui:D000757;dis:Anencephaly;g:MTHFR)(dui:D003704;dis:Dementia;g:MTHFR)(dui:D019965;dis:Neurocognitive Disorders;g:MTHFR)(dui:D014591;dis:Uterine Diseases;g:MTHFR)(dui:D014594;dis:Uterine Neoplasms;g:MTHFR)(dui:D024801;dis:Tauopathies;g:MTHFR)(dui:D000544;dis:Alzheimer Disease;g:MTHFR)(dui:D007960;dis:Leukocyte Disorders;g:MTHFR)(dui:D007970;dis:Leukopenia;g:MTHFR)(dui:D013959;dis:Thyroid Diseases;g:MTHFR)(dui:D002277;dis:Carcinoma;g:MTHFR)(dui:D006967;dis:Hypersensitivity;g:MTHFR)(dui:D001157;dis:Arterial Occlusive Diseases;g:MTHFR)(dui:D008047;dis:Lip Diseases;g:MTHFR)(dui:D002971;dis:Cleft Lip;g:MTHFR)(dui:D019465;dis:Craniofacial Abnormalities;g:MTHFR)(dui:D019767;dis:Maxillofacial Abnormalities;g:MTHFR)(dui:D001161;dis:Arteriosclerosis;g:MTHFR)(dui:D018376;dis:Cardiovascular Abnormalities;g:MTHFR)(dui:D006330;dis:Heart Defects, Congenital;g:MTHFR)(dui:D013923;dis:Thromboembolism;g:MTHFR)(dui:D003110;dis:Colonic Neoplasms;g:MTHFR)(dui:D006980;dis:Hyperthyroidism;g:MTHFR)(dui:D048909;dis:Diabetes Complications;g:MTHFR)(dui:D001941;dis:Breast Diseases;g:MTHFR)(dui:D001943;dis:Breast Neoplasms;g:MTHFR)(dui:D001778;dis:Blood Coagulation Disorders;g:MTHFR)(dui:D007248;dis:Infertility, Male;g:MTHFR)(dui:D051437;dis:Renal Insufficiency;g:MTHFR)(dui:D025861;dis:Blood Coagulation Disorders, Inherited;g:MTHFR)(dui:D044882;dis:Glucose Metabolism Disorders;g:MTHFR)(dui:D000740;dis:Anemia;g:MTHFR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:MTHFR)(dui:D005759;dis:Gastroenteritis;g:MTHFR)(dui:D012678;dis:Sensation Disorders;g:MTHFR)(dui:D006086;dis:Graft vs Host Disease;g:MTHFR)(dui:D004427;dis:Ear Diseases;g:MTHFR)(dui:D006311;dis:Hearing Disorders;g:MTHFR)(dui:D034381;dis:Hearing Loss;g:MTHFR)(dui:D011248;dis:Pregnancy Complications;g:MTHFR)(dui:D000068105;dis:Bipolar and Related Disorders;g:MTHFR)(dui:D001714;dis:Bipolar Disorder;g:MTHFR)(dui:D011655;dis:Pulmonary Embolism;g:MTHFR)(dui:D004617;dis:Embolism;g:MTHFR)(dui:D003925;dis:Diabetic Angiopathies;g:MTHFR)(dui:D012142;dis:Respiratory Tract Neoplasms;g:MTHFR)(dui:D002577;dis:Uterine Cervical Diseases;g:MTHFR)(dui:D003639;dis:Hearing Loss, Sudden;g:MTHFR)(dui:D009385;dis:Neoplastic Processes;g:MTHFR)(dui:D002583;dis:Uterine Cervical Neoplasms;g:MTHFR)(dui:D013899;dis:Thoracic Neoplasms;g:MTHFR)(dui:D014571;dis:Urologic Neoplasms;g:MTHFR)(dui:D002278;dis:Carcinoma in Situ;g:MTHFR)(dui:D018290;dis:Cervical Intraepithelial Neoplasia;g:MTHFR)(dui:D005834;dis:Genital Neoplasms, Male;g:MTHFR)(dui:D011469;dis:Prostatic Diseases;g:MTHFR)(dui:D011471;dis:Prostatic Neoplasms;g:MTHFR)(dui:D008175;dis:Lung Neoplasms;g:MTHFR)(dui:D003324;dis:Coronary Artery Disease;g:MTHFR)(dui:D015448;dis:Leukemia, B-Cell;g:MTHFR)(dui:D015451;dis:Leukemia, Lymphocytic, Chronic, B-Cell;g:MTHFR)(dui:D001791;dis:Blood Platelet Disorders;g:MTHFR)(dui:D065886;dis:Neurodevelopmental Disorders;g:MTHFR)(dui:D001745;dis:Urinary Bladder Diseases;g:MTHFR)(dui:D001749;dis:Urinary Bladder Neoplasms;g:MTHFR)(dui:D056486;dis:Drug-Induced Liver Injury;g:MTHFR)(dui:D013921;dis:Thrombocytopenia;g:MTHFR)(dui:D002659;dis:Child Development Disorders, Pervasive;g:MTHFR)(dui:D002542;dis:Intracranial Embolism and Thrombosis;g:MTHFR)(dui:D020767;dis:Intracranial Thrombosis;g:MTHFR)(dui:D001321;dis:Autistic Disorder;g:MTHFR)(dui:D019964;dis:Mood Disorders;g:MTHFR)(dui:D003866;dis:Depressive Disorder;g:MTHFR)(dui:D000380;dis:Agranulocytosis;g:MTHFR)(dui:D009503;dis:Neutropenia;g:MTHFR)(dui:D023921;dis:Coronary Stenosis;g:MTHFR)(dui:D007247;dis:Infertility, Female;g:MTHFR)(dui:D012851;dis:Sinus Thrombosis, Intracranial;g:MTHFR)(dui:D001928;dis:Brain Diseases, Metabolic;g:MTHFR)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MTHFR)(dui:D018204;dis:Neoplasms, Connective and Soft Tissue;g:MTHFR)(dui:D008591;dis:Meningomyelocele;g:MTHFR)(dui:D008224;dis:Lymphoma, Follicular;g:MTHFR)(dui:D009372;dis:Neoplasms, Connective Tissue;g:MTHFR)(dui:D020258;dis:Neurotoxicity Syndromes;g:MTHFR)(dui:D052016;dis:Mucositis;g:MTHFR)(dui:D023903;dis:Coronary Restenosis;g:MTHFR)(dui:D009362;dis:Neoplasm Metastasis;g:MTHFR)(dui:D020879;dis:Neuromuscular Manifestations;g:MTHFR)(dui:D056784;dis:Leukoencephalopathies;g:MTHFR)(dui:D011618;dis:Psychotic Disorders;g:MTHFR)(dui:D009468;dis:Neuromuscular Diseases;g:MTHFR)(dui:D009135;dis:Muscular Diseases;g:MTHFR)(dui:D010523;dis:Peripheral Nervous System Diseases;g:MTHFR)(dui:D005530;dis:Foot Deformities;g:MTHFR)(dui:D005532;dis:Foot Deformities, Congenital;g:MTHFR)(dui:D006712;dis:Homocystinuria;g:MTHFR)(dui:D009128;dis:Muscle Spasticity;g:MTHFR)(dui:D017880;dis:Limb Deformities, Congenital;g:MTHFR)(dui:D000787;dis:Angina Pectoris;g:MTHFR)(dui:D003025;dis:Clubfoot;g:MTHFR)(dui:D009122;dis:Muscle Hypertonia;g:MTHFR)(dui:D038061;dis:Lower Extremity Deformities, Congenital;g:MTHFR)(dui:D017566;dis:Microvascular Angina;g:MTHFR)(dui:D001145;dis:Arrhythmias, Cardiac;g:MTHFR)(dui:D020260;dis:Heavy Metal Poisoning, Nervous System;g:MTHFR)(dui:D001281;dis:Atrial Fibrillation;g:MTHFR)(dui:D020261;dis:Arsenic Poisoning;g:MTHFR)(dui:D016889;dis:Endometrial Neoplasms;g:MTHFR)(dui:D013118;dis:Spinal Cord Diseases;g:MTHFR)(dui:D004342;dis:Drug Hypersensitivity;g:MTHFR)(dui:D007571;dis:Jaw Diseases;g:MTHFR)(dui:D007569;dis:Jaw Abnormalities;g:MTHFR)(dui:D002972;dis:Cleft Palate;g:MTHFR)(dui:D013971;dis:Thyrotoxicosis;g:MTHFR)(dui:D003872;dis:Dermatitis;g:MTHFR)(dui:D003875;dis:Drug Eruptions;g:MTHFR)(dui:D006201;dis:Hair Diseases;g:MTHFR)(dui:D007039;dis:Hypotrichosis;g:MTHFR)(dui:D046152;dis:Gastrointestinal Stromal Tumors;g:MTHFR)(dui:D000505;dis:Alopecia;g:MTHFR)(dui:D058186;dis:Acute Kidney Injury;g:MTHFR)(dui:D006973;dis:Hypertension;g:MTHFR)(dui:D008113;dis:Liver Neoplasms;g:MTHFR)	Tetrahydrofolic acid:Menadione:Methionine:Riboflavin:Benazepril:Methotrexate:Cyanocobalamin:Folic acid:Fluorouracil	GO:0031060:GO:0070829:GO:0043200:GO:0046655:GO:0045202:GO:0004489:GO:0044877:GO:0072341:GO:0001666:GO:0001843:GO:0005829:GO:0035999:GO:0009086:GO:0071949:GO:0033274:GO:0046500:GO:0006730:GO:0006555:GO:0050661:GO:0050660:GO:0042493:GO:0051593:GO:0070555:GO:0055114:GO:0050667	607093		3.2															
chr1:11790946	SNV	G	1	G/C	PASS	1.6165904169544844e-75	747.914		400	G=217,C=183	G=0.5425,C=0.4575	45.75	54.25	heterozygous	48	0.246	1.0		MTHFR	NM_005957.5	MTHFR:intronic:NM_005957.5	unknown			p.?	c.1753-48C>G				C	GMAF=0.2298:AMAF=0.1543:EMAF=0.2685					rs576853093:rs1332110504:rs3818762:rs1491370932		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MTHFR)(dui:NBS2;dis:Core Conditions;g:MTHFR)(dui:NBS11;dis:Amino Acid Disorder;g:MTHFR)(dui:NBS57;dis:Homocystinuria;g:MTHFR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MTHFR)(dui:D002318;dis:Cardiovascular Diseases;g:MTHFR)(dui:D009422;dis:Nervous System Diseases;g:MTHFR)(dui:D014652;dis:Vascular Diseases;g:MTHFR)(dui:D009369;dis:Neoplasms;g:MTHFR)(dui:D000013;dis:Congenital Abnormalities;g:MTHFR)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MTHFR)(dui:D030342;dis:Genetic Diseases, Inborn;g:MTHFR)(dui:D009371;dis:Neoplasms by Site;g:MTHFR)(dui:D002493;dis:Central Nervous System Diseases;g:MTHFR)(dui:D007154;dis:Immune System Diseases;g:MTHFR)(dui:D004066;dis:Digestive System Diseases;g:MTHFR)(dui:D001927;dis:Brain Diseases;g:MTHFR)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MTHFR)(dui:D009370;dis:Neoplasms by Histologic Type;g:MTHFR)(dui:D005767;dis:Gastrointestinal Diseases;g:MTHFR)(dui:D008659;dis:Metabolic Diseases;g:MTHFR)(dui:D006331;dis:Heart Diseases;g:MTHFR)(dui:D004067;dis:Digestive System Neoplasms;g:MTHFR)(dui:D001523;dis:Mental Disorders;g:MTHFR)(dui:D006402;dis:Hematologic Diseases;g:MTHFR)(dui:D009748;dis:Nutrition Disorders;g:MTHFR)(dui:D044342;dis:Malnutrition;g:MTHFR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:MTHFR)(dui:D007160;dis:Immunoproliferative Disorders;g:MTHFR)(dui:D008232;dis:Lymphoproliferative Disorders;g:MTHFR)(dui:D002561;dis:Cerebrovascular Disorders;g:MTHFR)(dui:D008206;dis:Lymphatic Diseases;g:MTHFR)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MTHFR)(dui:D008661;dis:Metabolism, Inborn Errors;g:MTHFR)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MTHFR)(dui:D020138;dis:Hyperhomocysteinemia;g:MTHFR)(dui:D017202;dis:Myocardial Ischemia;g:MTHFR)(dui:D003677;dis:Deficiency Diseases;g:MTHFR)(dui:D001361;dis:Avitaminosis;g:MTHFR)(dui:D014804;dis:Vitamin B Deficiency;g:MTHFR)(dui:D009421;dis:Nervous System Malformations;g:MTHFR)(dui:D009436;dis:Neural Tube Defects;g:MTHFR)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:MTHFR)(dui:D009140;dis:Musculoskeletal Diseases;g:MTHFR)(dui:D016769;dis:Embolism and Thrombosis;g:MTHFR)(dui:D009461;dis:Neurologic Manifestations;g:MTHFR)(dui:D003327;dis:Coronary Disease;g:MTHFR)(dui:D052776;dis:Female Urogenital Diseases;g:MTHFR)(dui:D052801;dis:Male Urogenital Diseases;g:MTHFR)(dui:D008286;dis:Malabsorption Syndromes;g:MTHFR)(dui:D007938;dis:Leukemia;g:MTHFR)(dui:D009057;dis:Stomatognathic Diseases;g:MTHFR)(dui:D007945;dis:Leukemia, Lymphoid;g:MTHFR)(dui:D007410;dis:Intestinal Diseases;g:MTHFR)(dui:D012871;dis:Skin Diseases;g:MTHFR)(dui:D009059;dis:Mouth Diseases;g:MTHFR)(dui:D004700;dis:Endocrine System Diseases;g:MTHFR)(dui:D003108;dis:Colonic Diseases;g:MTHFR)(dui:D007414;dis:Intestinal Neoplasms;g:MTHFR)(dui:D015179;dis:Colorectal Neoplasms;g:MTHFR)(dui:D014565;dis:Urogenital Neoplasms;g:MTHFR)(dui:D018640;dis:Stomatognathic System Abnormalities;g:MTHFR)(dui:D019967;dis:Schizophrenia Spectrum and Other Psychotic Disorders;g:MTHFR)(dui:D003240;dis:Connective Tissue Diseases;g:MTHFR)(dui:D014570;dis:Urologic Diseases;g:MTHFR)(dui:D013927;dis:Thrombosis;g:MTHFR)(dui:D020521;dis:Stroke;g:MTHFR)(dui:D008223;dis:Lymphoma;g:MTHFR)(dui:D005831;dis:Genital Diseases, Female;g:MTHFR)(dui:D008107;dis:Liver Diseases;g:MTHFR)(dui:D009056;dis:Mouth Abnormalities;g:MTHFR)(dui:D025063;dis:Chromosome Disorders;g:MTHFR)(dui:D019954;dis:Neurobehavioral Manifestations;g:MTHFR)(dui:D008607;dis:Intellectual Disability;g:MTHFR)(dui:D000015;dis:Abnormalities, Multiple;g:MTHFR)(dui:D004314;dis:Down Syndrome;g:MTHFR)(dui:D019851;dis:Thrombophilia;g:MTHFR)(dui:D054198;dis:Precursor Cell Lymphoblastic Leukemia-Lymphoma;g:MTHFR)(dui:D007674;dis:Kidney Diseases;g:MTHFR)(dui:D013272;dis:Stomach Diseases;g:MTHFR)(dui:D020246;dis:Venous Thrombosis;g:MTHFR)(dui:D003920;dis:Diabetes Mellitus;g:MTHFR)(dui:D013274;dis:Stomach Neoplasms;g:MTHFR)(dui:D009139;dis:Musculoskeletal Abnormalities;g:MTHFR)(dui:D005832;dis:Genital Diseases, Male;g:MTHFR)(dui:D001327;dis:Autoimmune Diseases;g:MTHFR)(dui:D012559;dis:Schizophrenia;g:MTHFR)(dui:D007246;dis:Infertility;g:MTHFR)(dui:D012140;dis:Respiratory Tract Diseases;g:MTHFR)(dui:D008171;dis:Lung Diseases;g:MTHFR)(dui:D002545;dis:Brain Ischemia;g:MTHFR)(dui:D012002;dis:Rectal Diseases;g:MTHFR)(dui:D007592;dis:Joint Diseases;g:MTHFR)(dui:D001168;dis:Arthritis;g:MTHFR)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:MTHFR)(dui:D019636;dis:Neurodegenerative Diseases;g:MTHFR)(dui:D012216;dis:Rheumatic Diseases;g:MTHFR)(dui:D001172;dis:Arthritis, Rheumatoid;g:MTHFR)(dui:D005833;dis:Genital Neoplasms, Female;g:MTHFR)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MTHFR)(dui:D009008;dis:Abnormalities, Severe Teratoid;g:MTHFR)(dui:D000757;dis:Anencephaly;g:MTHFR)(dui:D003704;dis:Dementia;g:MTHFR)(dui:D019965;dis:Neurocognitive Disorders;g:MTHFR)(dui:D014591;dis:Uterine Diseases;g:MTHFR)(dui:D014594;dis:Uterine Neoplasms;g:MTHFR)(dui:D024801;dis:Tauopathies;g:MTHFR)(dui:D000544;dis:Alzheimer Disease;g:MTHFR)(dui:D007960;dis:Leukocyte Disorders;g:MTHFR)(dui:D007970;dis:Leukopenia;g:MTHFR)(dui:D013959;dis:Thyroid Diseases;g:MTHFR)(dui:D002277;dis:Carcinoma;g:MTHFR)(dui:D006967;dis:Hypersensitivity;g:MTHFR)(dui:D001157;dis:Arterial Occlusive Diseases;g:MTHFR)(dui:D008047;dis:Lip Diseases;g:MTHFR)(dui:D002971;dis:Cleft Lip;g:MTHFR)(dui:D019465;dis:Craniofacial Abnormalities;g:MTHFR)(dui:D019767;dis:Maxillofacial Abnormalities;g:MTHFR)(dui:D001161;dis:Arteriosclerosis;g:MTHFR)(dui:D018376;dis:Cardiovascular Abnormalities;g:MTHFR)(dui:D006330;dis:Heart Defects, Congenital;g:MTHFR)(dui:D013923;dis:Thromboembolism;g:MTHFR)(dui:D003110;dis:Colonic Neoplasms;g:MTHFR)(dui:D006980;dis:Hyperthyroidism;g:MTHFR)(dui:D048909;dis:Diabetes Complications;g:MTHFR)(dui:D001941;dis:Breast Diseases;g:MTHFR)(dui:D001943;dis:Breast Neoplasms;g:MTHFR)(dui:D001778;dis:Blood Coagulation Disorders;g:MTHFR)(dui:D007248;dis:Infertility, Male;g:MTHFR)(dui:D051437;dis:Renal Insufficiency;g:MTHFR)(dui:D025861;dis:Blood Coagulation Disorders, Inherited;g:MTHFR)(dui:D044882;dis:Glucose Metabolism Disorders;g:MTHFR)(dui:D000740;dis:Anemia;g:MTHFR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:MTHFR)(dui:D005759;dis:Gastroenteritis;g:MTHFR)(dui:D012678;dis:Sensation Disorders;g:MTHFR)(dui:D006086;dis:Graft vs Host Disease;g:MTHFR)(dui:D004427;dis:Ear Diseases;g:MTHFR)(dui:D006311;dis:Hearing Disorders;g:MTHFR)(dui:D034381;dis:Hearing Loss;g:MTHFR)(dui:D011248;dis:Pregnancy Complications;g:MTHFR)(dui:D000068105;dis:Bipolar and Related Disorders;g:MTHFR)(dui:D001714;dis:Bipolar Disorder;g:MTHFR)(dui:D011655;dis:Pulmonary Embolism;g:MTHFR)(dui:D004617;dis:Embolism;g:MTHFR)(dui:D003925;dis:Diabetic Angiopathies;g:MTHFR)(dui:D012142;dis:Respiratory Tract Neoplasms;g:MTHFR)(dui:D002577;dis:Uterine Cervical Diseases;g:MTHFR)(dui:D003639;dis:Hearing Loss, Sudden;g:MTHFR)(dui:D009385;dis:Neoplastic Processes;g:MTHFR)(dui:D002583;dis:Uterine Cervical Neoplasms;g:MTHFR)(dui:D013899;dis:Thoracic Neoplasms;g:MTHFR)(dui:D014571;dis:Urologic Neoplasms;g:MTHFR)(dui:D002278;dis:Carcinoma in Situ;g:MTHFR)(dui:D018290;dis:Cervical Intraepithelial Neoplasia;g:MTHFR)(dui:D005834;dis:Genital Neoplasms, Male;g:MTHFR)(dui:D011469;dis:Prostatic Diseases;g:MTHFR)(dui:D011471;dis:Prostatic Neoplasms;g:MTHFR)(dui:D008175;dis:Lung Neoplasms;g:MTHFR)(dui:D003324;dis:Coronary Artery Disease;g:MTHFR)(dui:D015448;dis:Leukemia, B-Cell;g:MTHFR)(dui:D015451;dis:Leukemia, Lymphocytic, Chronic, B-Cell;g:MTHFR)(dui:D001791;dis:Blood Platelet Disorders;g:MTHFR)(dui:D065886;dis:Neurodevelopmental Disorders;g:MTHFR)(dui:D001745;dis:Urinary Bladder Diseases;g:MTHFR)(dui:D001749;dis:Urinary Bladder Neoplasms;g:MTHFR)(dui:D056486;dis:Drug-Induced Liver Injury;g:MTHFR)(dui:D013921;dis:Thrombocytopenia;g:MTHFR)(dui:D002659;dis:Child Development Disorders, Pervasive;g:MTHFR)(dui:D002542;dis:Intracranial Embolism and Thrombosis;g:MTHFR)(dui:D020767;dis:Intracranial Thrombosis;g:MTHFR)(dui:D001321;dis:Autistic Disorder;g:MTHFR)(dui:D019964;dis:Mood Disorders;g:MTHFR)(dui:D003866;dis:Depressive Disorder;g:MTHFR)(dui:D000380;dis:Agranulocytosis;g:MTHFR)(dui:D009503;dis:Neutropenia;g:MTHFR)(dui:D023921;dis:Coronary Stenosis;g:MTHFR)(dui:D007247;dis:Infertility, Female;g:MTHFR)(dui:D012851;dis:Sinus Thrombosis, Intracranial;g:MTHFR)(dui:D001928;dis:Brain Diseases, Metabolic;g:MTHFR)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MTHFR)(dui:D018204;dis:Neoplasms, Connective and Soft Tissue;g:MTHFR)(dui:D008591;dis:Meningomyelocele;g:MTHFR)(dui:D008224;dis:Lymphoma, Follicular;g:MTHFR)(dui:D009372;dis:Neoplasms, Connective Tissue;g:MTHFR)(dui:D020258;dis:Neurotoxicity Syndromes;g:MTHFR)(dui:D052016;dis:Mucositis;g:MTHFR)(dui:D023903;dis:Coronary Restenosis;g:MTHFR)(dui:D009362;dis:Neoplasm Metastasis;g:MTHFR)(dui:D020879;dis:Neuromuscular Manifestations;g:MTHFR)(dui:D056784;dis:Leukoencephalopathies;g:MTHFR)(dui:D011618;dis:Psychotic Disorders;g:MTHFR)(dui:D009468;dis:Neuromuscular Diseases;g:MTHFR)(dui:D009135;dis:Muscular Diseases;g:MTHFR)(dui:D010523;dis:Peripheral Nervous System Diseases;g:MTHFR)(dui:D005530;dis:Foot Deformities;g:MTHFR)(dui:D005532;dis:Foot Deformities, Congenital;g:MTHFR)(dui:D006712;dis:Homocystinuria;g:MTHFR)(dui:D009128;dis:Muscle Spasticity;g:MTHFR)(dui:D017880;dis:Limb Deformities, Congenital;g:MTHFR)(dui:D000787;dis:Angina Pectoris;g:MTHFR)(dui:D003025;dis:Clubfoot;g:MTHFR)(dui:D009122;dis:Muscle Hypertonia;g:MTHFR)(dui:D038061;dis:Lower Extremity Deformities, Congenital;g:MTHFR)(dui:D017566;dis:Microvascular Angina;g:MTHFR)(dui:D001145;dis:Arrhythmias, Cardiac;g:MTHFR)(dui:D020260;dis:Heavy Metal Poisoning, Nervous System;g:MTHFR)(dui:D001281;dis:Atrial Fibrillation;g:MTHFR)(dui:D020261;dis:Arsenic Poisoning;g:MTHFR)(dui:D016889;dis:Endometrial Neoplasms;g:MTHFR)(dui:D013118;dis:Spinal Cord Diseases;g:MTHFR)(dui:D004342;dis:Drug Hypersensitivity;g:MTHFR)(dui:D007571;dis:Jaw Diseases;g:MTHFR)(dui:D007569;dis:Jaw Abnormalities;g:MTHFR)(dui:D002972;dis:Cleft Palate;g:MTHFR)(dui:D013971;dis:Thyrotoxicosis;g:MTHFR)(dui:D003872;dis:Dermatitis;g:MTHFR)(dui:D003875;dis:Drug Eruptions;g:MTHFR)(dui:D006201;dis:Hair Diseases;g:MTHFR)(dui:D007039;dis:Hypotrichosis;g:MTHFR)(dui:D046152;dis:Gastrointestinal Stromal Tumors;g:MTHFR)(dui:D000505;dis:Alopecia;g:MTHFR)(dui:D058186;dis:Acute Kidney Injury;g:MTHFR)(dui:D006973;dis:Hypertension;g:MTHFR)(dui:D008113;dis:Liver Neoplasms;g:MTHFR)	Tetrahydrofolic acid:Menadione:Methionine:Riboflavin:Benazepril:Methotrexate:Cyanocobalamin:Folic acid:Fluorouracil	GO:0031060:GO:0070829:GO:0043200:GO:0046655:GO:0045202:GO:0004489:GO:0044877:GO:0072341:GO:0001666:GO:0001843:GO:0005829:GO:0035999:GO:0009086:GO:0071949:GO:0033274:GO:0046500:GO:0006730:GO:0006555:GO:0050661:GO:0050660:GO:0042493:GO:0051593:GO:0070555:GO:0055114:GO:0050667	607093		-2.26															
chr1:11791061	SNV	A	1	G/G	PASS	0.0	3962.68		398	A=0,G=398	A=0.0,G=1.0	100.0	0.0	homozygous	56	0.098	1.0		MTHFR	NM_005957.5	MTHFR:intronic:NM_005957.5	unknown			p.?	c.1752+146T>C				G						rs7518348		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MTHFR)(dui:NBS2;dis:Core Conditions;g:MTHFR)(dui:NBS11;dis:Amino Acid Disorder;g:MTHFR)(dui:NBS57;dis:Homocystinuria;g:MTHFR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MTHFR)(dui:D002318;dis:Cardiovascular Diseases;g:MTHFR)(dui:D009422;dis:Nervous System Diseases;g:MTHFR)(dui:D014652;dis:Vascular Diseases;g:MTHFR)(dui:D009369;dis:Neoplasms;g:MTHFR)(dui:D000013;dis:Congenital Abnormalities;g:MTHFR)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MTHFR)(dui:D030342;dis:Genetic Diseases, Inborn;g:MTHFR)(dui:D009371;dis:Neoplasms by Site;g:MTHFR)(dui:D002493;dis:Central Nervous System Diseases;g:MTHFR)(dui:D007154;dis:Immune System Diseases;g:MTHFR)(dui:D004066;dis:Digestive System Diseases;g:MTHFR)(dui:D001927;dis:Brain Diseases;g:MTHFR)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MTHFR)(dui:D009370;dis:Neoplasms by Histologic Type;g:MTHFR)(dui:D005767;dis:Gastrointestinal Diseases;g:MTHFR)(dui:D008659;dis:Metabolic Diseases;g:MTHFR)(dui:D006331;dis:Heart Diseases;g:MTHFR)(dui:D004067;dis:Digestive System Neoplasms;g:MTHFR)(dui:D001523;dis:Mental Disorders;g:MTHFR)(dui:D006402;dis:Hematologic Diseases;g:MTHFR)(dui:D009748;dis:Nutrition Disorders;g:MTHFR)(dui:D044342;dis:Malnutrition;g:MTHFR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:MTHFR)(dui:D007160;dis:Immunoproliferative Disorders;g:MTHFR)(dui:D008232;dis:Lymphoproliferative Disorders;g:MTHFR)(dui:D002561;dis:Cerebrovascular Disorders;g:MTHFR)(dui:D008206;dis:Lymphatic Diseases;g:MTHFR)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MTHFR)(dui:D008661;dis:Metabolism, Inborn Errors;g:MTHFR)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MTHFR)(dui:D020138;dis:Hyperhomocysteinemia;g:MTHFR)(dui:D017202;dis:Myocardial Ischemia;g:MTHFR)(dui:D003677;dis:Deficiency Diseases;g:MTHFR)(dui:D001361;dis:Avitaminosis;g:MTHFR)(dui:D014804;dis:Vitamin B Deficiency;g:MTHFR)(dui:D009421;dis:Nervous System Malformations;g:MTHFR)(dui:D009436;dis:Neural Tube Defects;g:MTHFR)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:MTHFR)(dui:D009140;dis:Musculoskeletal Diseases;g:MTHFR)(dui:D016769;dis:Embolism and Thrombosis;g:MTHFR)(dui:D009461;dis:Neurologic Manifestations;g:MTHFR)(dui:D003327;dis:Coronary Disease;g:MTHFR)(dui:D052776;dis:Female Urogenital Diseases;g:MTHFR)(dui:D052801;dis:Male Urogenital Diseases;g:MTHFR)(dui:D008286;dis:Malabsorption Syndromes;g:MTHFR)(dui:D007938;dis:Leukemia;g:MTHFR)(dui:D009057;dis:Stomatognathic Diseases;g:MTHFR)(dui:D007945;dis:Leukemia, Lymphoid;g:MTHFR)(dui:D007410;dis:Intestinal Diseases;g:MTHFR)(dui:D012871;dis:Skin Diseases;g:MTHFR)(dui:D009059;dis:Mouth Diseases;g:MTHFR)(dui:D004700;dis:Endocrine System Diseases;g:MTHFR)(dui:D003108;dis:Colonic Diseases;g:MTHFR)(dui:D007414;dis:Intestinal Neoplasms;g:MTHFR)(dui:D015179;dis:Colorectal Neoplasms;g:MTHFR)(dui:D014565;dis:Urogenital Neoplasms;g:MTHFR)(dui:D018640;dis:Stomatognathic System Abnormalities;g:MTHFR)(dui:D019967;dis:Schizophrenia Spectrum and Other Psychotic Disorders;g:MTHFR)(dui:D003240;dis:Connective Tissue Diseases;g:MTHFR)(dui:D014570;dis:Urologic Diseases;g:MTHFR)(dui:D013927;dis:Thrombosis;g:MTHFR)(dui:D020521;dis:Stroke;g:MTHFR)(dui:D008223;dis:Lymphoma;g:MTHFR)(dui:D005831;dis:Genital Diseases, Female;g:MTHFR)(dui:D008107;dis:Liver Diseases;g:MTHFR)(dui:D009056;dis:Mouth Abnormalities;g:MTHFR)(dui:D025063;dis:Chromosome Disorders;g:MTHFR)(dui:D019954;dis:Neurobehavioral Manifestations;g:MTHFR)(dui:D008607;dis:Intellectual Disability;g:MTHFR)(dui:D000015;dis:Abnormalities, Multiple;g:MTHFR)(dui:D004314;dis:Down Syndrome;g:MTHFR)(dui:D019851;dis:Thrombophilia;g:MTHFR)(dui:D054198;dis:Precursor Cell Lymphoblastic Leukemia-Lymphoma;g:MTHFR)(dui:D007674;dis:Kidney Diseases;g:MTHFR)(dui:D013272;dis:Stomach Diseases;g:MTHFR)(dui:D020246;dis:Venous Thrombosis;g:MTHFR)(dui:D003920;dis:Diabetes Mellitus;g:MTHFR)(dui:D013274;dis:Stomach Neoplasms;g:MTHFR)(dui:D009139;dis:Musculoskeletal Abnormalities;g:MTHFR)(dui:D005832;dis:Genital Diseases, Male;g:MTHFR)(dui:D001327;dis:Autoimmune Diseases;g:MTHFR)(dui:D012559;dis:Schizophrenia;g:MTHFR)(dui:D007246;dis:Infertility;g:MTHFR)(dui:D012140;dis:Respiratory Tract Diseases;g:MTHFR)(dui:D008171;dis:Lung Diseases;g:MTHFR)(dui:D002545;dis:Brain Ischemia;g:MTHFR)(dui:D012002;dis:Rectal Diseases;g:MTHFR)(dui:D007592;dis:Joint Diseases;g:MTHFR)(dui:D001168;dis:Arthritis;g:MTHFR)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:MTHFR)(dui:D019636;dis:Neurodegenerative Diseases;g:MTHFR)(dui:D012216;dis:Rheumatic Diseases;g:MTHFR)(dui:D001172;dis:Arthritis, Rheumatoid;g:MTHFR)(dui:D005833;dis:Genital Neoplasms, Female;g:MTHFR)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MTHFR)(dui:D009008;dis:Abnormalities, Severe Teratoid;g:MTHFR)(dui:D000757;dis:Anencephaly;g:MTHFR)(dui:D003704;dis:Dementia;g:MTHFR)(dui:D019965;dis:Neurocognitive Disorders;g:MTHFR)(dui:D014591;dis:Uterine Diseases;g:MTHFR)(dui:D014594;dis:Uterine Neoplasms;g:MTHFR)(dui:D024801;dis:Tauopathies;g:MTHFR)(dui:D000544;dis:Alzheimer Disease;g:MTHFR)(dui:D007960;dis:Leukocyte Disorders;g:MTHFR)(dui:D007970;dis:Leukopenia;g:MTHFR)(dui:D013959;dis:Thyroid Diseases;g:MTHFR)(dui:D002277;dis:Carcinoma;g:MTHFR)(dui:D006967;dis:Hypersensitivity;g:MTHFR)(dui:D001157;dis:Arterial Occlusive Diseases;g:MTHFR)(dui:D008047;dis:Lip Diseases;g:MTHFR)(dui:D002971;dis:Cleft Lip;g:MTHFR)(dui:D019465;dis:Craniofacial Abnormalities;g:MTHFR)(dui:D019767;dis:Maxillofacial Abnormalities;g:MTHFR)(dui:D001161;dis:Arteriosclerosis;g:MTHFR)(dui:D018376;dis:Cardiovascular Abnormalities;g:MTHFR)(dui:D006330;dis:Heart Defects, Congenital;g:MTHFR)(dui:D013923;dis:Thromboembolism;g:MTHFR)(dui:D003110;dis:Colonic Neoplasms;g:MTHFR)(dui:D006980;dis:Hyperthyroidism;g:MTHFR)(dui:D048909;dis:Diabetes Complications;g:MTHFR)(dui:D001941;dis:Breast Diseases;g:MTHFR)(dui:D001943;dis:Breast Neoplasms;g:MTHFR)(dui:D001778;dis:Blood Coagulation Disorders;g:MTHFR)(dui:D007248;dis:Infertility, Male;g:MTHFR)(dui:D051437;dis:Renal Insufficiency;g:MTHFR)(dui:D025861;dis:Blood Coagulation Disorders, Inherited;g:MTHFR)(dui:D044882;dis:Glucose Metabolism Disorders;g:MTHFR)(dui:D000740;dis:Anemia;g:MTHFR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:MTHFR)(dui:D005759;dis:Gastroenteritis;g:MTHFR)(dui:D012678;dis:Sensation Disorders;g:MTHFR)(dui:D006086;dis:Graft vs Host Disease;g:MTHFR)(dui:D004427;dis:Ear Diseases;g:MTHFR)(dui:D006311;dis:Hearing Disorders;g:MTHFR)(dui:D034381;dis:Hearing Loss;g:MTHFR)(dui:D011248;dis:Pregnancy Complications;g:MTHFR)(dui:D000068105;dis:Bipolar and Related Disorders;g:MTHFR)(dui:D001714;dis:Bipolar Disorder;g:MTHFR)(dui:D011655;dis:Pulmonary Embolism;g:MTHFR)(dui:D004617;dis:Embolism;g:MTHFR)(dui:D003925;dis:Diabetic Angiopathies;g:MTHFR)(dui:D012142;dis:Respiratory Tract Neoplasms;g:MTHFR)(dui:D002577;dis:Uterine Cervical Diseases;g:MTHFR)(dui:D003639;dis:Hearing Loss, Sudden;g:MTHFR)(dui:D009385;dis:Neoplastic Processes;g:MTHFR)(dui:D002583;dis:Uterine Cervical Neoplasms;g:MTHFR)(dui:D013899;dis:Thoracic Neoplasms;g:MTHFR)(dui:D014571;dis:Urologic Neoplasms;g:MTHFR)(dui:D002278;dis:Carcinoma in Situ;g:MTHFR)(dui:D018290;dis:Cervical Intraepithelial Neoplasia;g:MTHFR)(dui:D005834;dis:Genital Neoplasms, Male;g:MTHFR)(dui:D011469;dis:Prostatic Diseases;g:MTHFR)(dui:D011471;dis:Prostatic Neoplasms;g:MTHFR)(dui:D008175;dis:Lung Neoplasms;g:MTHFR)(dui:D003324;dis:Coronary Artery Disease;g:MTHFR)(dui:D015448;dis:Leukemia, B-Cell;g:MTHFR)(dui:D015451;dis:Leukemia, Lymphocytic, Chronic, B-Cell;g:MTHFR)(dui:D001791;dis:Blood Platelet Disorders;g:MTHFR)(dui:D065886;dis:Neurodevelopmental Disorders;g:MTHFR)(dui:D001745;dis:Urinary Bladder Diseases;g:MTHFR)(dui:D001749;dis:Urinary Bladder Neoplasms;g:MTHFR)(dui:D056486;dis:Drug-Induced Liver Injury;g:MTHFR)(dui:D013921;dis:Thrombocytopenia;g:MTHFR)(dui:D002659;dis:Child Development Disorders, Pervasive;g:MTHFR)(dui:D002542;dis:Intracranial Embolism and Thrombosis;g:MTHFR)(dui:D020767;dis:Intracranial Thrombosis;g:MTHFR)(dui:D001321;dis:Autistic Disorder;g:MTHFR)(dui:D019964;dis:Mood Disorders;g:MTHFR)(dui:D003866;dis:Depressive Disorder;g:MTHFR)(dui:D000380;dis:Agranulocytosis;g:MTHFR)(dui:D009503;dis:Neutropenia;g:MTHFR)(dui:D023921;dis:Coronary Stenosis;g:MTHFR)(dui:D007247;dis:Infertility, Female;g:MTHFR)(dui:D012851;dis:Sinus Thrombosis, Intracranial;g:MTHFR)(dui:D001928;dis:Brain Diseases, Metabolic;g:MTHFR)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MTHFR)(dui:D018204;dis:Neoplasms, Connective and Soft Tissue;g:MTHFR)(dui:D008591;dis:Meningomyelocele;g:MTHFR)(dui:D008224;dis:Lymphoma, Follicular;g:MTHFR)(dui:D009372;dis:Neoplasms, Connective Tissue;g:MTHFR)(dui:D020258;dis:Neurotoxicity Syndromes;g:MTHFR)(dui:D052016;dis:Mucositis;g:MTHFR)(dui:D023903;dis:Coronary Restenosis;g:MTHFR)(dui:D009362;dis:Neoplasm Metastasis;g:MTHFR)(dui:D020879;dis:Neuromuscular Manifestations;g:MTHFR)(dui:D056784;dis:Leukoencephalopathies;g:MTHFR)(dui:D011618;dis:Psychotic Disorders;g:MTHFR)(dui:D009468;dis:Neuromuscular Diseases;g:MTHFR)(dui:D009135;dis:Muscular Diseases;g:MTHFR)(dui:D010523;dis:Peripheral Nervous System Diseases;g:MTHFR)(dui:D005530;dis:Foot Deformities;g:MTHFR)(dui:D005532;dis:Foot Deformities, Congenital;g:MTHFR)(dui:D006712;dis:Homocystinuria;g:MTHFR)(dui:D009128;dis:Muscle Spasticity;g:MTHFR)(dui:D017880;dis:Limb Deformities, Congenital;g:MTHFR)(dui:D000787;dis:Angina Pectoris;g:MTHFR)(dui:D003025;dis:Clubfoot;g:MTHFR)(dui:D009122;dis:Muscle Hypertonia;g:MTHFR)(dui:D038061;dis:Lower Extremity Deformities, Congenital;g:MTHFR)(dui:D017566;dis:Microvascular Angina;g:MTHFR)(dui:D001145;dis:Arrhythmias, Cardiac;g:MTHFR)(dui:D020260;dis:Heavy Metal Poisoning, Nervous System;g:MTHFR)(dui:D001281;dis:Atrial Fibrillation;g:MTHFR)(dui:D020261;dis:Arsenic Poisoning;g:MTHFR)(dui:D016889;dis:Endometrial Neoplasms;g:MTHFR)(dui:D013118;dis:Spinal Cord Diseases;g:MTHFR)(dui:D004342;dis:Drug Hypersensitivity;g:MTHFR)(dui:D007571;dis:Jaw Diseases;g:MTHFR)(dui:D007569;dis:Jaw Abnormalities;g:MTHFR)(dui:D002972;dis:Cleft Palate;g:MTHFR)(dui:D013971;dis:Thyrotoxicosis;g:MTHFR)(dui:D003872;dis:Dermatitis;g:MTHFR)(dui:D003875;dis:Drug Eruptions;g:MTHFR)(dui:D006201;dis:Hair Diseases;g:MTHFR)(dui:D007039;dis:Hypotrichosis;g:MTHFR)(dui:D046152;dis:Gastrointestinal Stromal Tumors;g:MTHFR)(dui:D000505;dis:Alopecia;g:MTHFR)(dui:D058186;dis:Acute Kidney Injury;g:MTHFR)(dui:D006973;dis:Hypertension;g:MTHFR)(dui:D008113;dis:Liver Neoplasms;g:MTHFR)	Tetrahydrofolic acid:Menadione:Methionine:Riboflavin:Benazepril:Methotrexate:Cyanocobalamin:Folic acid:Fluorouracil	GO:0031060:GO:0070829:GO:0043200:GO:0046655:GO:0045202:GO:0004489:GO:0044877:GO:0072341:GO:0001666:GO:0001843:GO:0005829:GO:0035999:GO:0009086:GO:0071949:GO:0033274:GO:0046500:GO:0006730:GO:0006555:GO:0050661:GO:0050660:GO:0042493:GO:0051593:GO:0070555:GO:0055114:GO:0050667	607093		0.08															
chr1:11792243	SNV	C	1	C/T	PASS	3.535900211003903e-89	884.515		400	C=202,T=198	C=0.505,T=0.495	49.5	50.5	heterozygous	48	0.251	2.0		MTHFR	NM_005957.5	MTHFR:intronic:NM_005957.5	unknown			p.?	c.1632+35G>A				T	GMAF=0.2229:AMAF=0.1491:EMAF=0.2607					rs1476413		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MTHFR)(dui:NBS2;dis:Core Conditions;g:MTHFR)(dui:NBS11;dis:Amino Acid Disorder;g:MTHFR)(dui:NBS57;dis:Homocystinuria;g:MTHFR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MTHFR)(dui:D002318;dis:Cardiovascular Diseases;g:MTHFR)(dui:D009422;dis:Nervous System Diseases;g:MTHFR)(dui:D014652;dis:Vascular Diseases;g:MTHFR)(dui:D009369;dis:Neoplasms;g:MTHFR)(dui:D000013;dis:Congenital Abnormalities;g:MTHFR)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MTHFR)(dui:D030342;dis:Genetic Diseases, Inborn;g:MTHFR)(dui:D009371;dis:Neoplasms by Site;g:MTHFR)(dui:D002493;dis:Central Nervous System Diseases;g:MTHFR)(dui:D007154;dis:Immune System Diseases;g:MTHFR)(dui:D004066;dis:Digestive System Diseases;g:MTHFR)(dui:D001927;dis:Brain Diseases;g:MTHFR)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MTHFR)(dui:D009370;dis:Neoplasms by Histologic Type;g:MTHFR)(dui:D005767;dis:Gastrointestinal Diseases;g:MTHFR)(dui:D008659;dis:Metabolic Diseases;g:MTHFR)(dui:D006331;dis:Heart Diseases;g:MTHFR)(dui:D004067;dis:Digestive System Neoplasms;g:MTHFR)(dui:D001523;dis:Mental Disorders;g:MTHFR)(dui:D006402;dis:Hematologic Diseases;g:MTHFR)(dui:D009748;dis:Nutrition Disorders;g:MTHFR)(dui:D044342;dis:Malnutrition;g:MTHFR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:MTHFR)(dui:D007160;dis:Immunoproliferative Disorders;g:MTHFR)(dui:D008232;dis:Lymphoproliferative Disorders;g:MTHFR)(dui:D002561;dis:Cerebrovascular Disorders;g:MTHFR)(dui:D008206;dis:Lymphatic Diseases;g:MTHFR)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MTHFR)(dui:D008661;dis:Metabolism, Inborn Errors;g:MTHFR)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MTHFR)(dui:D020138;dis:Hyperhomocysteinemia;g:MTHFR)(dui:D017202;dis:Myocardial Ischemia;g:MTHFR)(dui:D003677;dis:Deficiency Diseases;g:MTHFR)(dui:D001361;dis:Avitaminosis;g:MTHFR)(dui:D014804;dis:Vitamin B Deficiency;g:MTHFR)(dui:D009421;dis:Nervous System Malformations;g:MTHFR)(dui:D009436;dis:Neural Tube Defects;g:MTHFR)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:MTHFR)(dui:D009140;dis:Musculoskeletal Diseases;g:MTHFR)(dui:D016769;dis:Embolism and Thrombosis;g:MTHFR)(dui:D009461;dis:Neurologic Manifestations;g:MTHFR)(dui:D003327;dis:Coronary Disease;g:MTHFR)(dui:D052776;dis:Female Urogenital Diseases;g:MTHFR)(dui:D052801;dis:Male Urogenital Diseases;g:MTHFR)(dui:D008286;dis:Malabsorption Syndromes;g:MTHFR)(dui:D007938;dis:Leukemia;g:MTHFR)(dui:D009057;dis:Stomatognathic Diseases;g:MTHFR)(dui:D007945;dis:Leukemia, Lymphoid;g:MTHFR)(dui:D007410;dis:Intestinal Diseases;g:MTHFR)(dui:D012871;dis:Skin Diseases;g:MTHFR)(dui:D009059;dis:Mouth Diseases;g:MTHFR)(dui:D004700;dis:Endocrine System Diseases;g:MTHFR)(dui:D003108;dis:Colonic Diseases;g:MTHFR)(dui:D007414;dis:Intestinal Neoplasms;g:MTHFR)(dui:D015179;dis:Colorectal Neoplasms;g:MTHFR)(dui:D014565;dis:Urogenital Neoplasms;g:MTHFR)(dui:D018640;dis:Stomatognathic System Abnormalities;g:MTHFR)(dui:D019967;dis:Schizophrenia Spectrum and Other Psychotic Disorders;g:MTHFR)(dui:D003240;dis:Connective Tissue Diseases;g:MTHFR)(dui:D014570;dis:Urologic Diseases;g:MTHFR)(dui:D013927;dis:Thrombosis;g:MTHFR)(dui:D020521;dis:Stroke;g:MTHFR)(dui:D008223;dis:Lymphoma;g:MTHFR)(dui:D005831;dis:Genital Diseases, Female;g:MTHFR)(dui:D008107;dis:Liver Diseases;g:MTHFR)(dui:D009056;dis:Mouth Abnormalities;g:MTHFR)(dui:D025063;dis:Chromosome Disorders;g:MTHFR)(dui:D019954;dis:Neurobehavioral Manifestations;g:MTHFR)(dui:D008607;dis:Intellectual Disability;g:MTHFR)(dui:D000015;dis:Abnormalities, Multiple;g:MTHFR)(dui:D004314;dis:Down Syndrome;g:MTHFR)(dui:D019851;dis:Thrombophilia;g:MTHFR)(dui:D054198;dis:Precursor Cell Lymphoblastic Leukemia-Lymphoma;g:MTHFR)(dui:D007674;dis:Kidney Diseases;g:MTHFR)(dui:D013272;dis:Stomach Diseases;g:MTHFR)(dui:D020246;dis:Venous Thrombosis;g:MTHFR)(dui:D003920;dis:Diabetes Mellitus;g:MTHFR)(dui:D013274;dis:Stomach Neoplasms;g:MTHFR)(dui:D009139;dis:Musculoskeletal Abnormalities;g:MTHFR)(dui:D005832;dis:Genital Diseases, Male;g:MTHFR)(dui:D001327;dis:Autoimmune Diseases;g:MTHFR)(dui:D012559;dis:Schizophrenia;g:MTHFR)(dui:D007246;dis:Infertility;g:MTHFR)(dui:D012140;dis:Respiratory Tract Diseases;g:MTHFR)(dui:D008171;dis:Lung Diseases;g:MTHFR)(dui:D002545;dis:Brain Ischemia;g:MTHFR)(dui:D012002;dis:Rectal Diseases;g:MTHFR)(dui:D007592;dis:Joint Diseases;g:MTHFR)(dui:D001168;dis:Arthritis;g:MTHFR)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:MTHFR)(dui:D019636;dis:Neurodegenerative Diseases;g:MTHFR)(dui:D012216;dis:Rheumatic Diseases;g:MTHFR)(dui:D001172;dis:Arthritis, Rheumatoid;g:MTHFR)(dui:D005833;dis:Genital Neoplasms, Female;g:MTHFR)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MTHFR)(dui:D009008;dis:Abnormalities, Severe Teratoid;g:MTHFR)(dui:D000757;dis:Anencephaly;g:MTHFR)(dui:D003704;dis:Dementia;g:MTHFR)(dui:D019965;dis:Neurocognitive Disorders;g:MTHFR)(dui:D014591;dis:Uterine Diseases;g:MTHFR)(dui:D014594;dis:Uterine Neoplasms;g:MTHFR)(dui:D024801;dis:Tauopathies;g:MTHFR)(dui:D000544;dis:Alzheimer Disease;g:MTHFR)(dui:D007960;dis:Leukocyte Disorders;g:MTHFR)(dui:D007970;dis:Leukopenia;g:MTHFR)(dui:D013959;dis:Thyroid Diseases;g:MTHFR)(dui:D002277;dis:Carcinoma;g:MTHFR)(dui:D006967;dis:Hypersensitivity;g:MTHFR)(dui:D001157;dis:Arterial Occlusive Diseases;g:MTHFR)(dui:D008047;dis:Lip Diseases;g:MTHFR)(dui:D002971;dis:Cleft Lip;g:MTHFR)(dui:D019465;dis:Craniofacial Abnormalities;g:MTHFR)(dui:D019767;dis:Maxillofacial Abnormalities;g:MTHFR)(dui:D001161;dis:Arteriosclerosis;g:MTHFR)(dui:D018376;dis:Cardiovascular Abnormalities;g:MTHFR)(dui:D006330;dis:Heart Defects, Congenital;g:MTHFR)(dui:D013923;dis:Thromboembolism;g:MTHFR)(dui:D003110;dis:Colonic Neoplasms;g:MTHFR)(dui:D006980;dis:Hyperthyroidism;g:MTHFR)(dui:D048909;dis:Diabetes Complications;g:MTHFR)(dui:D001941;dis:Breast Diseases;g:MTHFR)(dui:D001943;dis:Breast Neoplasms;g:MTHFR)(dui:D001778;dis:Blood Coagulation Disorders;g:MTHFR)(dui:D007248;dis:Infertility, Male;g:MTHFR)(dui:D051437;dis:Renal Insufficiency;g:MTHFR)(dui:D025861;dis:Blood Coagulation Disorders, Inherited;g:MTHFR)(dui:D044882;dis:Glucose Metabolism Disorders;g:MTHFR)(dui:D000740;dis:Anemia;g:MTHFR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:MTHFR)(dui:D005759;dis:Gastroenteritis;g:MTHFR)(dui:D012678;dis:Sensation Disorders;g:MTHFR)(dui:D006086;dis:Graft vs Host Disease;g:MTHFR)(dui:D004427;dis:Ear Diseases;g:MTHFR)(dui:D006311;dis:Hearing Disorders;g:MTHFR)(dui:D034381;dis:Hearing Loss;g:MTHFR)(dui:D011248;dis:Pregnancy Complications;g:MTHFR)(dui:D000068105;dis:Bipolar and Related Disorders;g:MTHFR)(dui:D001714;dis:Bipolar Disorder;g:MTHFR)(dui:D011655;dis:Pulmonary Embolism;g:MTHFR)(dui:D004617;dis:Embolism;g:MTHFR)(dui:D003925;dis:Diabetic Angiopathies;g:MTHFR)(dui:D012142;dis:Respiratory Tract Neoplasms;g:MTHFR)(dui:D002577;dis:Uterine Cervical Diseases;g:MTHFR)(dui:D003639;dis:Hearing Loss, Sudden;g:MTHFR)(dui:D009385;dis:Neoplastic Processes;g:MTHFR)(dui:D002583;dis:Uterine Cervical Neoplasms;g:MTHFR)(dui:D013899;dis:Thoracic Neoplasms;g:MTHFR)(dui:D014571;dis:Urologic Neoplasms;g:MTHFR)(dui:D002278;dis:Carcinoma in Situ;g:MTHFR)(dui:D018290;dis:Cervical Intraepithelial Neoplasia;g:MTHFR)(dui:D005834;dis:Genital Neoplasms, Male;g:MTHFR)(dui:D011469;dis:Prostatic Diseases;g:MTHFR)(dui:D011471;dis:Prostatic Neoplasms;g:MTHFR)(dui:D008175;dis:Lung Neoplasms;g:MTHFR)(dui:D003324;dis:Coronary Artery Disease;g:MTHFR)(dui:D015448;dis:Leukemia, B-Cell;g:MTHFR)(dui:D015451;dis:Leukemia, Lymphocytic, Chronic, B-Cell;g:MTHFR)(dui:D001791;dis:Blood Platelet Disorders;g:MTHFR)(dui:D065886;dis:Neurodevelopmental Disorders;g:MTHFR)(dui:D001745;dis:Urinary Bladder Diseases;g:MTHFR)(dui:D001749;dis:Urinary Bladder Neoplasms;g:MTHFR)(dui:D056486;dis:Drug-Induced Liver Injury;g:MTHFR)(dui:D013921;dis:Thrombocytopenia;g:MTHFR)(dui:D002659;dis:Child Development Disorders, Pervasive;g:MTHFR)(dui:D002542;dis:Intracranial Embolism and Thrombosis;g:MTHFR)(dui:D020767;dis:Intracranial Thrombosis;g:MTHFR)(dui:D001321;dis:Autistic Disorder;g:MTHFR)(dui:D019964;dis:Mood Disorders;g:MTHFR)(dui:D003866;dis:Depressive Disorder;g:MTHFR)(dui:D000380;dis:Agranulocytosis;g:MTHFR)(dui:D009503;dis:Neutropenia;g:MTHFR)(dui:D023921;dis:Coronary Stenosis;g:MTHFR)(dui:D007247;dis:Infertility, Female;g:MTHFR)(dui:D012851;dis:Sinus Thrombosis, Intracranial;g:MTHFR)(dui:D001928;dis:Brain Diseases, Metabolic;g:MTHFR)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MTHFR)(dui:D018204;dis:Neoplasms, Connective and Soft Tissue;g:MTHFR)(dui:D008591;dis:Meningomyelocele;g:MTHFR)(dui:D008224;dis:Lymphoma, Follicular;g:MTHFR)(dui:D009372;dis:Neoplasms, Connective Tissue;g:MTHFR)(dui:D020258;dis:Neurotoxicity Syndromes;g:MTHFR)(dui:D052016;dis:Mucositis;g:MTHFR)(dui:D023903;dis:Coronary Restenosis;g:MTHFR)(dui:D009362;dis:Neoplasm Metastasis;g:MTHFR)(dui:D020879;dis:Neuromuscular Manifestations;g:MTHFR)(dui:D056784;dis:Leukoencephalopathies;g:MTHFR)(dui:D011618;dis:Psychotic Disorders;g:MTHFR)(dui:D009468;dis:Neuromuscular Diseases;g:MTHFR)(dui:D009135;dis:Muscular Diseases;g:MTHFR)(dui:D010523;dis:Peripheral Nervous System Diseases;g:MTHFR)(dui:D005530;dis:Foot Deformities;g:MTHFR)(dui:D005532;dis:Foot Deformities, Congenital;g:MTHFR)(dui:D006712;dis:Homocystinuria;g:MTHFR)(dui:D009128;dis:Muscle Spasticity;g:MTHFR)(dui:D017880;dis:Limb Deformities, Congenital;g:MTHFR)(dui:D000787;dis:Angina Pectoris;g:MTHFR)(dui:D003025;dis:Clubfoot;g:MTHFR)(dui:D009122;dis:Muscle Hypertonia;g:MTHFR)(dui:D038061;dis:Lower Extremity Deformities, Congenital;g:MTHFR)(dui:D017566;dis:Microvascular Angina;g:MTHFR)(dui:D001145;dis:Arrhythmias, Cardiac;g:MTHFR)(dui:D020260;dis:Heavy Metal Poisoning, Nervous System;g:MTHFR)(dui:D001281;dis:Atrial Fibrillation;g:MTHFR)(dui:D020261;dis:Arsenic Poisoning;g:MTHFR)(dui:D016889;dis:Endometrial Neoplasms;g:MTHFR)(dui:D013118;dis:Spinal Cord Diseases;g:MTHFR)(dui:D004342;dis:Drug Hypersensitivity;g:MTHFR)(dui:D007571;dis:Jaw Diseases;g:MTHFR)(dui:D007569;dis:Jaw Abnormalities;g:MTHFR)(dui:D002972;dis:Cleft Palate;g:MTHFR)(dui:D013971;dis:Thyrotoxicosis;g:MTHFR)(dui:D003872;dis:Dermatitis;g:MTHFR)(dui:D003875;dis:Drug Eruptions;g:MTHFR)(dui:D006201;dis:Hair Diseases;g:MTHFR)(dui:D007039;dis:Hypotrichosis;g:MTHFR)(dui:D046152;dis:Gastrointestinal Stromal Tumors;g:MTHFR)(dui:D000505;dis:Alopecia;g:MTHFR)(dui:D058186;dis:Acute Kidney Injury;g:MTHFR)(dui:D006973;dis:Hypertension;g:MTHFR)(dui:D008113;dis:Liver Neoplasms;g:MTHFR)	Tetrahydrofolic acid:Menadione:Methionine:Riboflavin:Benazepril:Methotrexate:Cyanocobalamin:Folic acid:Fluorouracil	GO:0031060:GO:0070829:GO:0043200:GO:0046655:GO:0045202:GO:0004489:GO:0044877:GO:0072341:GO:0001666:GO:0001843:GO:0005829:GO:0035999:GO:0009086:GO:0071949:GO:0033274:GO:0046500:GO:0006730:GO:0006555:GO:0050661:GO:0050660:GO:0042493:GO:0051593:GO:0070555:GO:0055114:GO:0050667	607093		-1.12															
chr1:11794400	SNV	G	1	A/A	PASS	0.0	3923.69		397	G=1,A=396	G=0.0025,A=0.9975	99.75	0.25	homozygous	56	0.097	1.0		MTHFR	NM_005957.5	MTHFR:exonic:NM_005957.5	synonymous	TTT	8	p.Phe435=	c.1305C>T				A	GMAF=0.1095:AMAF=0.3173:EMAF=0.003			Benign		rs756018487:rs4846051		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MTHFR)(dui:NBS2;dis:Core Conditions;g:MTHFR)(dui:NBS11;dis:Amino Acid Disorder;g:MTHFR)(dui:NBS57;dis:Homocystinuria;g:MTHFR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MTHFR)(dui:D002318;dis:Cardiovascular Diseases;g:MTHFR)(dui:D009422;dis:Nervous System Diseases;g:MTHFR)(dui:D014652;dis:Vascular Diseases;g:MTHFR)(dui:D009369;dis:Neoplasms;g:MTHFR)(dui:D000013;dis:Congenital Abnormalities;g:MTHFR)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MTHFR)(dui:D030342;dis:Genetic Diseases, Inborn;g:MTHFR)(dui:D009371;dis:Neoplasms by Site;g:MTHFR)(dui:D002493;dis:Central Nervous System Diseases;g:MTHFR)(dui:D007154;dis:Immune System Diseases;g:MTHFR)(dui:D004066;dis:Digestive System Diseases;g:MTHFR)(dui:D001927;dis:Brain Diseases;g:MTHFR)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MTHFR)(dui:D009370;dis:Neoplasms by Histologic Type;g:MTHFR)(dui:D005767;dis:Gastrointestinal Diseases;g:MTHFR)(dui:D008659;dis:Metabolic Diseases;g:MTHFR)(dui:D006331;dis:Heart Diseases;g:MTHFR)(dui:D004067;dis:Digestive System Neoplasms;g:MTHFR)(dui:D001523;dis:Mental Disorders;g:MTHFR)(dui:D006402;dis:Hematologic Diseases;g:MTHFR)(dui:D009748;dis:Nutrition Disorders;g:MTHFR)(dui:D044342;dis:Malnutrition;g:MTHFR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:MTHFR)(dui:D007160;dis:Immunoproliferative Disorders;g:MTHFR)(dui:D008232;dis:Lymphoproliferative Disorders;g:MTHFR)(dui:D002561;dis:Cerebrovascular Disorders;g:MTHFR)(dui:D008206;dis:Lymphatic Diseases;g:MTHFR)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MTHFR)(dui:D008661;dis:Metabolism, Inborn Errors;g:MTHFR)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MTHFR)(dui:D020138;dis:Hyperhomocysteinemia;g:MTHFR)(dui:D017202;dis:Myocardial Ischemia;g:MTHFR)(dui:D003677;dis:Deficiency Diseases;g:MTHFR)(dui:D001361;dis:Avitaminosis;g:MTHFR)(dui:D014804;dis:Vitamin B Deficiency;g:MTHFR)(dui:D009421;dis:Nervous System Malformations;g:MTHFR)(dui:D009436;dis:Neural Tube Defects;g:MTHFR)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:MTHFR)(dui:D009140;dis:Musculoskeletal Diseases;g:MTHFR)(dui:D016769;dis:Embolism and Thrombosis;g:MTHFR)(dui:D009461;dis:Neurologic Manifestations;g:MTHFR)(dui:D003327;dis:Coronary Disease;g:MTHFR)(dui:D052776;dis:Female Urogenital Diseases;g:MTHFR)(dui:D052801;dis:Male Urogenital Diseases;g:MTHFR)(dui:D008286;dis:Malabsorption Syndromes;g:MTHFR)(dui:D007938;dis:Leukemia;g:MTHFR)(dui:D009057;dis:Stomatognathic Diseases;g:MTHFR)(dui:D007945;dis:Leukemia, Lymphoid;g:MTHFR)(dui:D007410;dis:Intestinal Diseases;g:MTHFR)(dui:D012871;dis:Skin Diseases;g:MTHFR)(dui:D009059;dis:Mouth Diseases;g:MTHFR)(dui:D004700;dis:Endocrine System Diseases;g:MTHFR)(dui:D003108;dis:Colonic Diseases;g:MTHFR)(dui:D007414;dis:Intestinal Neoplasms;g:MTHFR)(dui:D015179;dis:Colorectal Neoplasms;g:MTHFR)(dui:D014565;dis:Urogenital Neoplasms;g:MTHFR)(dui:D018640;dis:Stomatognathic System Abnormalities;g:MTHFR)(dui:D019967;dis:Schizophrenia Spectrum and Other Psychotic Disorders;g:MTHFR)(dui:D003240;dis:Connective Tissue Diseases;g:MTHFR)(dui:D014570;dis:Urologic Diseases;g:MTHFR)(dui:D013927;dis:Thrombosis;g:MTHFR)(dui:D020521;dis:Stroke;g:MTHFR)(dui:D008223;dis:Lymphoma;g:MTHFR)(dui:D005831;dis:Genital Diseases, Female;g:MTHFR)(dui:D008107;dis:Liver Diseases;g:MTHFR)(dui:D009056;dis:Mouth Abnormalities;g:MTHFR)(dui:D025063;dis:Chromosome Disorders;g:MTHFR)(dui:D019954;dis:Neurobehavioral Manifestations;g:MTHFR)(dui:D008607;dis:Intellectual Disability;g:MTHFR)(dui:D000015;dis:Abnormalities, Multiple;g:MTHFR)(dui:D004314;dis:Down Syndrome;g:MTHFR)(dui:D019851;dis:Thrombophilia;g:MTHFR)(dui:D054198;dis:Precursor Cell Lymphoblastic Leukemia-Lymphoma;g:MTHFR)(dui:D007674;dis:Kidney Diseases;g:MTHFR)(dui:D013272;dis:Stomach Diseases;g:MTHFR)(dui:D020246;dis:Venous Thrombosis;g:MTHFR)(dui:D003920;dis:Diabetes Mellitus;g:MTHFR)(dui:D013274;dis:Stomach Neoplasms;g:MTHFR)(dui:D009139;dis:Musculoskeletal Abnormalities;g:MTHFR)(dui:D005832;dis:Genital Diseases, Male;g:MTHFR)(dui:D001327;dis:Autoimmune Diseases;g:MTHFR)(dui:D012559;dis:Schizophrenia;g:MTHFR)(dui:D007246;dis:Infertility;g:MTHFR)(dui:D012140;dis:Respiratory Tract Diseases;g:MTHFR)(dui:D008171;dis:Lung Diseases;g:MTHFR)(dui:D002545;dis:Brain Ischemia;g:MTHFR)(dui:D012002;dis:Rectal Diseases;g:MTHFR)(dui:D007592;dis:Joint Diseases;g:MTHFR)(dui:D001168;dis:Arthritis;g:MTHFR)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:MTHFR)(dui:D019636;dis:Neurodegenerative Diseases;g:MTHFR)(dui:D012216;dis:Rheumatic Diseases;g:MTHFR)(dui:D001172;dis:Arthritis, Rheumatoid;g:MTHFR)(dui:D005833;dis:Genital Neoplasms, Female;g:MTHFR)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MTHFR)(dui:D009008;dis:Abnormalities, Severe Teratoid;g:MTHFR)(dui:D000757;dis:Anencephaly;g:MTHFR)(dui:D003704;dis:Dementia;g:MTHFR)(dui:D019965;dis:Neurocognitive Disorders;g:MTHFR)(dui:D014591;dis:Uterine Diseases;g:MTHFR)(dui:D014594;dis:Uterine Neoplasms;g:MTHFR)(dui:D024801;dis:Tauopathies;g:MTHFR)(dui:D000544;dis:Alzheimer Disease;g:MTHFR)(dui:D007960;dis:Leukocyte Disorders;g:MTHFR)(dui:D007970;dis:Leukopenia;g:MTHFR)(dui:D013959;dis:Thyroid Diseases;g:MTHFR)(dui:D002277;dis:Carcinoma;g:MTHFR)(dui:D006967;dis:Hypersensitivity;g:MTHFR)(dui:D001157;dis:Arterial Occlusive Diseases;g:MTHFR)(dui:D008047;dis:Lip Diseases;g:MTHFR)(dui:D002971;dis:Cleft Lip;g:MTHFR)(dui:D019465;dis:Craniofacial Abnormalities;g:MTHFR)(dui:D019767;dis:Maxillofacial Abnormalities;g:MTHFR)(dui:D001161;dis:Arteriosclerosis;g:MTHFR)(dui:D018376;dis:Cardiovascular Abnormalities;g:MTHFR)(dui:D006330;dis:Heart Defects, Congenital;g:MTHFR)(dui:D013923;dis:Thromboembolism;g:MTHFR)(dui:D003110;dis:Colonic Neoplasms;g:MTHFR)(dui:D006980;dis:Hyperthyroidism;g:MTHFR)(dui:D048909;dis:Diabetes Complications;g:MTHFR)(dui:D001941;dis:Breast Diseases;g:MTHFR)(dui:D001943;dis:Breast Neoplasms;g:MTHFR)(dui:D001778;dis:Blood Coagulation Disorders;g:MTHFR)(dui:D007248;dis:Infertility, Male;g:MTHFR)(dui:D051437;dis:Renal Insufficiency;g:MTHFR)(dui:D025861;dis:Blood Coagulation Disorders, Inherited;g:MTHFR)(dui:D044882;dis:Glucose Metabolism Disorders;g:MTHFR)(dui:D000740;dis:Anemia;g:MTHFR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:MTHFR)(dui:D005759;dis:Gastroenteritis;g:MTHFR)(dui:D012678;dis:Sensation Disorders;g:MTHFR)(dui:D006086;dis:Graft vs Host Disease;g:MTHFR)(dui:D004427;dis:Ear Diseases;g:MTHFR)(dui:D006311;dis:Hearing Disorders;g:MTHFR)(dui:D034381;dis:Hearing Loss;g:MTHFR)(dui:D011248;dis:Pregnancy Complications;g:MTHFR)(dui:D000068105;dis:Bipolar and Related Disorders;g:MTHFR)(dui:D001714;dis:Bipolar Disorder;g:MTHFR)(dui:D011655;dis:Pulmonary Embolism;g:MTHFR)(dui:D004617;dis:Embolism;g:MTHFR)(dui:D003925;dis:Diabetic Angiopathies;g:MTHFR)(dui:D012142;dis:Respiratory Tract Neoplasms;g:MTHFR)(dui:D002577;dis:Uterine Cervical Diseases;g:MTHFR)(dui:D003639;dis:Hearing Loss, Sudden;g:MTHFR)(dui:D009385;dis:Neoplastic Processes;g:MTHFR)(dui:D002583;dis:Uterine Cervical Neoplasms;g:MTHFR)(dui:D013899;dis:Thoracic Neoplasms;g:MTHFR)(dui:D014571;dis:Urologic Neoplasms;g:MTHFR)(dui:D002278;dis:Carcinoma in Situ;g:MTHFR)(dui:D018290;dis:Cervical Intraepithelial Neoplasia;g:MTHFR)(dui:D005834;dis:Genital Neoplasms, Male;g:MTHFR)(dui:D011469;dis:Prostatic Diseases;g:MTHFR)(dui:D011471;dis:Prostatic Neoplasms;g:MTHFR)(dui:D008175;dis:Lung Neoplasms;g:MTHFR)(dui:D003324;dis:Coronary Artery Disease;g:MTHFR)(dui:D015448;dis:Leukemia, B-Cell;g:MTHFR)(dui:D015451;dis:Leukemia, Lymphocytic, Chronic, B-Cell;g:MTHFR)(dui:D001791;dis:Blood Platelet Disorders;g:MTHFR)(dui:D065886;dis:Neurodevelopmental Disorders;g:MTHFR)(dui:D001745;dis:Urinary Bladder Diseases;g:MTHFR)(dui:D001749;dis:Urinary Bladder Neoplasms;g:MTHFR)(dui:D056486;dis:Drug-Induced Liver Injury;g:MTHFR)(dui:D013921;dis:Thrombocytopenia;g:MTHFR)(dui:D002659;dis:Child Development Disorders, Pervasive;g:MTHFR)(dui:D002542;dis:Intracranial Embolism and Thrombosis;g:MTHFR)(dui:D020767;dis:Intracranial Thrombosis;g:MTHFR)(dui:D001321;dis:Autistic Disorder;g:MTHFR)(dui:D019964;dis:Mood Disorders;g:MTHFR)(dui:D003866;dis:Depressive Disorder;g:MTHFR)(dui:D000380;dis:Agranulocytosis;g:MTHFR)(dui:D009503;dis:Neutropenia;g:MTHFR)(dui:D023921;dis:Coronary Stenosis;g:MTHFR)(dui:D007247;dis:Infertility, Female;g:MTHFR)(dui:D012851;dis:Sinus Thrombosis, Intracranial;g:MTHFR)(dui:D001928;dis:Brain Diseases, Metabolic;g:MTHFR)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MTHFR)(dui:D018204;dis:Neoplasms, Connective and Soft Tissue;g:MTHFR)(dui:D008591;dis:Meningomyelocele;g:MTHFR)(dui:D008224;dis:Lymphoma, Follicular;g:MTHFR)(dui:D009372;dis:Neoplasms, Connective Tissue;g:MTHFR)(dui:D020258;dis:Neurotoxicity Syndromes;g:MTHFR)(dui:D052016;dis:Mucositis;g:MTHFR)(dui:D023903;dis:Coronary Restenosis;g:MTHFR)(dui:D009362;dis:Neoplasm Metastasis;g:MTHFR)(dui:D020879;dis:Neuromuscular Manifestations;g:MTHFR)(dui:D056784;dis:Leukoencephalopathies;g:MTHFR)(dui:D011618;dis:Psychotic Disorders;g:MTHFR)(dui:D009468;dis:Neuromuscular Diseases;g:MTHFR)(dui:D009135;dis:Muscular Diseases;g:MTHFR)(dui:D010523;dis:Peripheral Nervous System Diseases;g:MTHFR)(dui:D005530;dis:Foot Deformities;g:MTHFR)(dui:D005532;dis:Foot Deformities, Congenital;g:MTHFR)(dui:D006712;dis:Homocystinuria;g:MTHFR)(dui:D009128;dis:Muscle Spasticity;g:MTHFR)(dui:D017880;dis:Limb Deformities, Congenital;g:MTHFR)(dui:D000787;dis:Angina Pectoris;g:MTHFR)(dui:D003025;dis:Clubfoot;g:MTHFR)(dui:D009122;dis:Muscle Hypertonia;g:MTHFR)(dui:D038061;dis:Lower Extremity Deformities, Congenital;g:MTHFR)(dui:D017566;dis:Microvascular Angina;g:MTHFR)(dui:D001145;dis:Arrhythmias, Cardiac;g:MTHFR)(dui:D020260;dis:Heavy Metal Poisoning, Nervous System;g:MTHFR)(dui:D001281;dis:Atrial Fibrillation;g:MTHFR)(dui:D020261;dis:Arsenic Poisoning;g:MTHFR)(dui:D016889;dis:Endometrial Neoplasms;g:MTHFR)(dui:D013118;dis:Spinal Cord Diseases;g:MTHFR)(dui:D004342;dis:Drug Hypersensitivity;g:MTHFR)(dui:D007571;dis:Jaw Diseases;g:MTHFR)(dui:D007569;dis:Jaw Abnormalities;g:MTHFR)(dui:D002972;dis:Cleft Palate;g:MTHFR)(dui:D013971;dis:Thyrotoxicosis;g:MTHFR)(dui:D003872;dis:Dermatitis;g:MTHFR)(dui:D003875;dis:Drug Eruptions;g:MTHFR)(dui:D006201;dis:Hair Diseases;g:MTHFR)(dui:D007039;dis:Hypotrichosis;g:MTHFR)(dui:D046152;dis:Gastrointestinal Stromal Tumors;g:MTHFR)(dui:D000505;dis:Alopecia;g:MTHFR)(dui:D058186;dis:Acute Kidney Injury;g:MTHFR)(dui:D006973;dis:Hypertension;g:MTHFR)(dui:D008113;dis:Liver Neoplasms;g:MTHFR)	Tetrahydrofolic acid:Menadione:Methionine:Riboflavin:Benazepril:Methotrexate:Cyanocobalamin:Folic acid:Fluorouracil	GO:0031060:GO:0070829:GO:0043200:GO:0046655:GO:0045202:GO:0004489:GO:0044877:GO:0072341:GO:0001666:GO:0001843:GO:0005829:GO:0035999:GO:0009086:GO:0071949:GO:0033274:GO:0046500:GO:0006730:GO:0006555:GO:0050661:GO:0050660:GO:0042493:GO:0051593:GO:0070555:GO:0055114:GO:0050667	607093		0.65															
chr1:11794419	SNV	T	1	T/G	PASS	2.6717757271179465e-65	645.732		400	T=229,G=171	T=0.5725,G=0.4275	42.75	57.25	heterozygous	37	0.249	3.0		MTHFR	NM_005957.5	MTHFR:exonic:NM_005957.5	missense	GCA	8	p.Glu429Ala	c.1286A>C	0.06	0.021	107.0	G	GMAF=0.2596:AMAF=0.155:EMAF=0.3131	0.96		Conflicting interpretations of pathogenicity, other	3735923	rs1801131		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MTHFR)(dui:NBS2;dis:Core Conditions;g:MTHFR)(dui:NBS11;dis:Amino Acid Disorder;g:MTHFR)(dui:NBS57;dis:Homocystinuria;g:MTHFR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MTHFR)(dui:D002318;dis:Cardiovascular Diseases;g:MTHFR)(dui:D009422;dis:Nervous System Diseases;g:MTHFR)(dui:D014652;dis:Vascular Diseases;g:MTHFR)(dui:D009369;dis:Neoplasms;g:MTHFR)(dui:D000013;dis:Congenital Abnormalities;g:MTHFR)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MTHFR)(dui:D030342;dis:Genetic Diseases, Inborn;g:MTHFR)(dui:D009371;dis:Neoplasms by Site;g:MTHFR)(dui:D002493;dis:Central Nervous System Diseases;g:MTHFR)(dui:D007154;dis:Immune System Diseases;g:MTHFR)(dui:D004066;dis:Digestive System Diseases;g:MTHFR)(dui:D001927;dis:Brain Diseases;g:MTHFR)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MTHFR)(dui:D009370;dis:Neoplasms by Histologic Type;g:MTHFR)(dui:D005767;dis:Gastrointestinal Diseases;g:MTHFR)(dui:D008659;dis:Metabolic Diseases;g:MTHFR)(dui:D006331;dis:Heart Diseases;g:MTHFR)(dui:D004067;dis:Digestive System Neoplasms;g:MTHFR)(dui:D001523;dis:Mental Disorders;g:MTHFR)(dui:D006402;dis:Hematologic Diseases;g:MTHFR)(dui:D009748;dis:Nutrition Disorders;g:MTHFR)(dui:D044342;dis:Malnutrition;g:MTHFR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:MTHFR)(dui:D007160;dis:Immunoproliferative Disorders;g:MTHFR)(dui:D008232;dis:Lymphoproliferative Disorders;g:MTHFR)(dui:D002561;dis:Cerebrovascular Disorders;g:MTHFR)(dui:D008206;dis:Lymphatic Diseases;g:MTHFR)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MTHFR)(dui:D008661;dis:Metabolism, Inborn Errors;g:MTHFR)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MTHFR)(dui:D020138;dis:Hyperhomocysteinemia;g:MTHFR)(dui:D017202;dis:Myocardial Ischemia;g:MTHFR)(dui:D003677;dis:Deficiency Diseases;g:MTHFR)(dui:D001361;dis:Avitaminosis;g:MTHFR)(dui:D014804;dis:Vitamin B Deficiency;g:MTHFR)(dui:D009421;dis:Nervous System Malformations;g:MTHFR)(dui:D009436;dis:Neural Tube Defects;g:MTHFR)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:MTHFR)(dui:D009140;dis:Musculoskeletal Diseases;g:MTHFR)(dui:D016769;dis:Embolism and Thrombosis;g:MTHFR)(dui:D009461;dis:Neurologic Manifestations;g:MTHFR)(dui:D003327;dis:Coronary Disease;g:MTHFR)(dui:D052776;dis:Female Urogenital Diseases;g:MTHFR)(dui:D052801;dis:Male Urogenital Diseases;g:MTHFR)(dui:D008286;dis:Malabsorption Syndromes;g:MTHFR)(dui:D007938;dis:Leukemia;g:MTHFR)(dui:D009057;dis:Stomatognathic Diseases;g:MTHFR)(dui:D007945;dis:Leukemia, Lymphoid;g:MTHFR)(dui:D007410;dis:Intestinal Diseases;g:MTHFR)(dui:D012871;dis:Skin Diseases;g:MTHFR)(dui:D009059;dis:Mouth Diseases;g:MTHFR)(dui:D004700;dis:Endocrine System Diseases;g:MTHFR)(dui:D003108;dis:Colonic Diseases;g:MTHFR)(dui:D007414;dis:Intestinal Neoplasms;g:MTHFR)(dui:D015179;dis:Colorectal Neoplasms;g:MTHFR)(dui:D014565;dis:Urogenital Neoplasms;g:MTHFR)(dui:D018640;dis:Stomatognathic System Abnormalities;g:MTHFR)(dui:D019967;dis:Schizophrenia Spectrum and Other Psychotic Disorders;g:MTHFR)(dui:D003240;dis:Connective Tissue Diseases;g:MTHFR)(dui:D014570;dis:Urologic Diseases;g:MTHFR)(dui:D013927;dis:Thrombosis;g:MTHFR)(dui:D020521;dis:Stroke;g:MTHFR)(dui:D008223;dis:Lymphoma;g:MTHFR)(dui:D005831;dis:Genital Diseases, Female;g:MTHFR)(dui:D008107;dis:Liver Diseases;g:MTHFR)(dui:D009056;dis:Mouth Abnormalities;g:MTHFR)(dui:D025063;dis:Chromosome Disorders;g:MTHFR)(dui:D019954;dis:Neurobehavioral Manifestations;g:MTHFR)(dui:D008607;dis:Intellectual Disability;g:MTHFR)(dui:D000015;dis:Abnormalities, Multiple;g:MTHFR)(dui:D004314;dis:Down Syndrome;g:MTHFR)(dui:D019851;dis:Thrombophilia;g:MTHFR)(dui:D054198;dis:Precursor Cell Lymphoblastic Leukemia-Lymphoma;g:MTHFR)(dui:D007674;dis:Kidney Diseases;g:MTHFR)(dui:D013272;dis:Stomach Diseases;g:MTHFR)(dui:D020246;dis:Venous Thrombosis;g:MTHFR)(dui:D003920;dis:Diabetes Mellitus;g:MTHFR)(dui:D013274;dis:Stomach Neoplasms;g:MTHFR)(dui:D009139;dis:Musculoskeletal Abnormalities;g:MTHFR)(dui:D005832;dis:Genital Diseases, Male;g:MTHFR)(dui:D001327;dis:Autoimmune Diseases;g:MTHFR)(dui:D012559;dis:Schizophrenia;g:MTHFR)(dui:D007246;dis:Infertility;g:MTHFR)(dui:D012140;dis:Respiratory Tract Diseases;g:MTHFR)(dui:D008171;dis:Lung Diseases;g:MTHFR)(dui:D002545;dis:Brain Ischemia;g:MTHFR)(dui:D012002;dis:Rectal Diseases;g:MTHFR)(dui:D007592;dis:Joint Diseases;g:MTHFR)(dui:D001168;dis:Arthritis;g:MTHFR)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:MTHFR)(dui:D019636;dis:Neurodegenerative Diseases;g:MTHFR)(dui:D012216;dis:Rheumatic Diseases;g:MTHFR)(dui:D001172;dis:Arthritis, Rheumatoid;g:MTHFR)(dui:D005833;dis:Genital Neoplasms, Female;g:MTHFR)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MTHFR)(dui:D009008;dis:Abnormalities, Severe Teratoid;g:MTHFR)(dui:D000757;dis:Anencephaly;g:MTHFR)(dui:D003704;dis:Dementia;g:MTHFR)(dui:D019965;dis:Neurocognitive Disorders;g:MTHFR)(dui:D014591;dis:Uterine Diseases;g:MTHFR)(dui:D014594;dis:Uterine Neoplasms;g:MTHFR)(dui:D024801;dis:Tauopathies;g:MTHFR)(dui:D000544;dis:Alzheimer Disease;g:MTHFR)(dui:D007960;dis:Leukocyte Disorders;g:MTHFR)(dui:D007970;dis:Leukopenia;g:MTHFR)(dui:D013959;dis:Thyroid Diseases;g:MTHFR)(dui:D002277;dis:Carcinoma;g:MTHFR)(dui:D006967;dis:Hypersensitivity;g:MTHFR)(dui:D001157;dis:Arterial Occlusive Diseases;g:MTHFR)(dui:D008047;dis:Lip Diseases;g:MTHFR)(dui:D002971;dis:Cleft Lip;g:MTHFR)(dui:D019465;dis:Craniofacial Abnormalities;g:MTHFR)(dui:D019767;dis:Maxillofacial Abnormalities;g:MTHFR)(dui:D001161;dis:Arteriosclerosis;g:MTHFR)(dui:D018376;dis:Cardiovascular Abnormalities;g:MTHFR)(dui:D006330;dis:Heart Defects, Congenital;g:MTHFR)(dui:D013923;dis:Thromboembolism;g:MTHFR)(dui:D003110;dis:Colonic Neoplasms;g:MTHFR)(dui:D006980;dis:Hyperthyroidism;g:MTHFR)(dui:D048909;dis:Diabetes Complications;g:MTHFR)(dui:D001941;dis:Breast Diseases;g:MTHFR)(dui:D001943;dis:Breast Neoplasms;g:MTHFR)(dui:D001778;dis:Blood Coagulation Disorders;g:MTHFR)(dui:D007248;dis:Infertility, Male;g:MTHFR)(dui:D051437;dis:Renal Insufficiency;g:MTHFR)(dui:D025861;dis:Blood Coagulation Disorders, Inherited;g:MTHFR)(dui:D044882;dis:Glucose Metabolism Disorders;g:MTHFR)(dui:D000740;dis:Anemia;g:MTHFR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:MTHFR)(dui:D005759;dis:Gastroenteritis;g:MTHFR)(dui:D012678;dis:Sensation Disorders;g:MTHFR)(dui:D006086;dis:Graft vs Host Disease;g:MTHFR)(dui:D004427;dis:Ear Diseases;g:MTHFR)(dui:D006311;dis:Hearing Disorders;g:MTHFR)(dui:D034381;dis:Hearing Loss;g:MTHFR)(dui:D011248;dis:Pregnancy Complications;g:MTHFR)(dui:D000068105;dis:Bipolar and Related Disorders;g:MTHFR)(dui:D001714;dis:Bipolar Disorder;g:MTHFR)(dui:D011655;dis:Pulmonary Embolism;g:MTHFR)(dui:D004617;dis:Embolism;g:MTHFR)(dui:D003925;dis:Diabetic Angiopathies;g:MTHFR)(dui:D012142;dis:Respiratory Tract Neoplasms;g:MTHFR)(dui:D002577;dis:Uterine Cervical Diseases;g:MTHFR)(dui:D003639;dis:Hearing Loss, Sudden;g:MTHFR)(dui:D009385;dis:Neoplastic Processes;g:MTHFR)(dui:D002583;dis:Uterine Cervical Neoplasms;g:MTHFR)(dui:D013899;dis:Thoracic Neoplasms;g:MTHFR)(dui:D014571;dis:Urologic Neoplasms;g:MTHFR)(dui:D002278;dis:Carcinoma in Situ;g:MTHFR)(dui:D018290;dis:Cervical Intraepithelial Neoplasia;g:MTHFR)(dui:D005834;dis:Genital Neoplasms, Male;g:MTHFR)(dui:D011469;dis:Prostatic Diseases;g:MTHFR)(dui:D011471;dis:Prostatic Neoplasms;g:MTHFR)(dui:D008175;dis:Lung Neoplasms;g:MTHFR)(dui:D003324;dis:Coronary Artery Disease;g:MTHFR)(dui:D015448;dis:Leukemia, B-Cell;g:MTHFR)(dui:D015451;dis:Leukemia, Lymphocytic, Chronic, B-Cell;g:MTHFR)(dui:D001791;dis:Blood Platelet Disorders;g:MTHFR)(dui:D065886;dis:Neurodevelopmental Disorders;g:MTHFR)(dui:D001745;dis:Urinary Bladder Diseases;g:MTHFR)(dui:D001749;dis:Urinary Bladder Neoplasms;g:MTHFR)(dui:D056486;dis:Drug-Induced Liver Injury;g:MTHFR)(dui:D013921;dis:Thrombocytopenia;g:MTHFR)(dui:D002659;dis:Child Development Disorders, Pervasive;g:MTHFR)(dui:D002542;dis:Intracranial Embolism and Thrombosis;g:MTHFR)(dui:D020767;dis:Intracranial Thrombosis;g:MTHFR)(dui:D001321;dis:Autistic Disorder;g:MTHFR)(dui:D019964;dis:Mood Disorders;g:MTHFR)(dui:D003866;dis:Depressive Disorder;g:MTHFR)(dui:D000380;dis:Agranulocytosis;g:MTHFR)(dui:D009503;dis:Neutropenia;g:MTHFR)(dui:D023921;dis:Coronary Stenosis;g:MTHFR)(dui:D007247;dis:Infertility, Female;g:MTHFR)(dui:D012851;dis:Sinus Thrombosis, Intracranial;g:MTHFR)(dui:D001928;dis:Brain Diseases, Metabolic;g:MTHFR)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MTHFR)(dui:D018204;dis:Neoplasms, Connective and Soft Tissue;g:MTHFR)(dui:D008591;dis:Meningomyelocele;g:MTHFR)(dui:D008224;dis:Lymphoma, Follicular;g:MTHFR)(dui:D009372;dis:Neoplasms, Connective Tissue;g:MTHFR)(dui:D020258;dis:Neurotoxicity Syndromes;g:MTHFR)(dui:D052016;dis:Mucositis;g:MTHFR)(dui:D023903;dis:Coronary Restenosis;g:MTHFR)(dui:D009362;dis:Neoplasm Metastasis;g:MTHFR)(dui:D020879;dis:Neuromuscular Manifestations;g:MTHFR)(dui:D056784;dis:Leukoencephalopathies;g:MTHFR)(dui:D011618;dis:Psychotic Disorders;g:MTHFR)(dui:D009468;dis:Neuromuscular Diseases;g:MTHFR)(dui:D009135;dis:Muscular Diseases;g:MTHFR)(dui:D010523;dis:Peripheral Nervous System Diseases;g:MTHFR)(dui:D005530;dis:Foot Deformities;g:MTHFR)(dui:D005532;dis:Foot Deformities, Congenital;g:MTHFR)(dui:D006712;dis:Homocystinuria;g:MTHFR)(dui:D009128;dis:Muscle Spasticity;g:MTHFR)(dui:D017880;dis:Limb Deformities, Congenital;g:MTHFR)(dui:D000787;dis:Angina Pectoris;g:MTHFR)(dui:D003025;dis:Clubfoot;g:MTHFR)(dui:D009122;dis:Muscle Hypertonia;g:MTHFR)(dui:D038061;dis:Lower Extremity Deformities, Congenital;g:MTHFR)(dui:D017566;dis:Microvascular Angina;g:MTHFR)(dui:D001145;dis:Arrhythmias, Cardiac;g:MTHFR)(dui:D020260;dis:Heavy Metal Poisoning, Nervous System;g:MTHFR)(dui:D001281;dis:Atrial Fibrillation;g:MTHFR)(dui:D020261;dis:Arsenic Poisoning;g:MTHFR)(dui:D016889;dis:Endometrial Neoplasms;g:MTHFR)(dui:D013118;dis:Spinal Cord Diseases;g:MTHFR)(dui:D004342;dis:Drug Hypersensitivity;g:MTHFR)(dui:D007571;dis:Jaw Diseases;g:MTHFR)(dui:D007569;dis:Jaw Abnormalities;g:MTHFR)(dui:D002972;dis:Cleft Palate;g:MTHFR)(dui:D013971;dis:Thyrotoxicosis;g:MTHFR)(dui:D003872;dis:Dermatitis;g:MTHFR)(dui:D003875;dis:Drug Eruptions;g:MTHFR)(dui:D006201;dis:Hair Diseases;g:MTHFR)(dui:D007039;dis:Hypotrichosis;g:MTHFR)(dui:D046152;dis:Gastrointestinal Stromal Tumors;g:MTHFR)(dui:D000505;dis:Alopecia;g:MTHFR)(dui:D058186;dis:Acute Kidney Injury;g:MTHFR)(dui:D006973;dis:Hypertension;g:MTHFR)(dui:D008113;dis:Liver Neoplasms;g:MTHFR)	Tetrahydrofolic acid:Menadione:Methionine:Riboflavin:Benazepril:Methotrexate:Cyanocobalamin:Folic acid:Fluorouracil	GO:0031060:GO:0070829:GO:0043200:GO:0046655:GO:0045202:GO:0004489:GO:0044877:GO:0072341:GO:0001666:GO:0001843:GO:0005829:GO:0035999:GO:0009086:GO:0071949:GO:0033274:GO:0046500:GO:0006730:GO:0006555:GO:0050661:GO:0050660:GO:0042493:GO:0051593:GO:0070555:GO:0055114:GO:0050667	607093		3.76															
chr1:11794698	SNV	G	1	G/A	PASS	5.84790084144494e-106	1052.33		400	G=185,A=215	G=0.4625,A=0.5375	53.75	46.25	heterozygous	39	0.421	1.0		MTHFR	NM_005957.5	MTHFR:intronic:NM_005957.5	unknown			p.?	c.1166+31C>T				A	GMAF=0.4642:AMAF=0.4346:EMAF=0.4124					rs1994798		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MTHFR)(dui:NBS2;dis:Core Conditions;g:MTHFR)(dui:NBS11;dis:Amino Acid Disorder;g:MTHFR)(dui:NBS57;dis:Homocystinuria;g:MTHFR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MTHFR)(dui:D002318;dis:Cardiovascular Diseases;g:MTHFR)(dui:D009422;dis:Nervous System Diseases;g:MTHFR)(dui:D014652;dis:Vascular Diseases;g:MTHFR)(dui:D009369;dis:Neoplasms;g:MTHFR)(dui:D000013;dis:Congenital Abnormalities;g:MTHFR)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MTHFR)(dui:D030342;dis:Genetic Diseases, Inborn;g:MTHFR)(dui:D009371;dis:Neoplasms by Site;g:MTHFR)(dui:D002493;dis:Central Nervous System Diseases;g:MTHFR)(dui:D007154;dis:Immune System Diseases;g:MTHFR)(dui:D004066;dis:Digestive System Diseases;g:MTHFR)(dui:D001927;dis:Brain Diseases;g:MTHFR)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MTHFR)(dui:D009370;dis:Neoplasms by Histologic Type;g:MTHFR)(dui:D005767;dis:Gastrointestinal Diseases;g:MTHFR)(dui:D008659;dis:Metabolic Diseases;g:MTHFR)(dui:D006331;dis:Heart Diseases;g:MTHFR)(dui:D004067;dis:Digestive System Neoplasms;g:MTHFR)(dui:D001523;dis:Mental Disorders;g:MTHFR)(dui:D006402;dis:Hematologic Diseases;g:MTHFR)(dui:D009748;dis:Nutrition Disorders;g:MTHFR)(dui:D044342;dis:Malnutrition;g:MTHFR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:MTHFR)(dui:D007160;dis:Immunoproliferative Disorders;g:MTHFR)(dui:D008232;dis:Lymphoproliferative Disorders;g:MTHFR)(dui:D002561;dis:Cerebrovascular Disorders;g:MTHFR)(dui:D008206;dis:Lymphatic Diseases;g:MTHFR)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MTHFR)(dui:D008661;dis:Metabolism, Inborn Errors;g:MTHFR)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MTHFR)(dui:D020138;dis:Hyperhomocysteinemia;g:MTHFR)(dui:D017202;dis:Myocardial Ischemia;g:MTHFR)(dui:D003677;dis:Deficiency Diseases;g:MTHFR)(dui:D001361;dis:Avitaminosis;g:MTHFR)(dui:D014804;dis:Vitamin B Deficiency;g:MTHFR)(dui:D009421;dis:Nervous System Malformations;g:MTHFR)(dui:D009436;dis:Neural Tube Defects;g:MTHFR)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:MTHFR)(dui:D009140;dis:Musculoskeletal Diseases;g:MTHFR)(dui:D016769;dis:Embolism and Thrombosis;g:MTHFR)(dui:D009461;dis:Neurologic Manifestations;g:MTHFR)(dui:D003327;dis:Coronary Disease;g:MTHFR)(dui:D052776;dis:Female Urogenital Diseases;g:MTHFR)(dui:D052801;dis:Male Urogenital Diseases;g:MTHFR)(dui:D008286;dis:Malabsorption Syndromes;g:MTHFR)(dui:D007938;dis:Leukemia;g:MTHFR)(dui:D009057;dis:Stomatognathic Diseases;g:MTHFR)(dui:D007945;dis:Leukemia, Lymphoid;g:MTHFR)(dui:D007410;dis:Intestinal Diseases;g:MTHFR)(dui:D012871;dis:Skin Diseases;g:MTHFR)(dui:D009059;dis:Mouth Diseases;g:MTHFR)(dui:D004700;dis:Endocrine System Diseases;g:MTHFR)(dui:D003108;dis:Colonic Diseases;g:MTHFR)(dui:D007414;dis:Intestinal Neoplasms;g:MTHFR)(dui:D015179;dis:Colorectal Neoplasms;g:MTHFR)(dui:D014565;dis:Urogenital Neoplasms;g:MTHFR)(dui:D018640;dis:Stomatognathic System Abnormalities;g:MTHFR)(dui:D019967;dis:Schizophrenia Spectrum and Other Psychotic Disorders;g:MTHFR)(dui:D003240;dis:Connective Tissue Diseases;g:MTHFR)(dui:D014570;dis:Urologic Diseases;g:MTHFR)(dui:D013927;dis:Thrombosis;g:MTHFR)(dui:D020521;dis:Stroke;g:MTHFR)(dui:D008223;dis:Lymphoma;g:MTHFR)(dui:D005831;dis:Genital Diseases, Female;g:MTHFR)(dui:D008107;dis:Liver Diseases;g:MTHFR)(dui:D009056;dis:Mouth Abnormalities;g:MTHFR)(dui:D025063;dis:Chromosome Disorders;g:MTHFR)(dui:D019954;dis:Neurobehavioral Manifestations;g:MTHFR)(dui:D008607;dis:Intellectual Disability;g:MTHFR)(dui:D000015;dis:Abnormalities, Multiple;g:MTHFR)(dui:D004314;dis:Down Syndrome;g:MTHFR)(dui:D019851;dis:Thrombophilia;g:MTHFR)(dui:D054198;dis:Precursor Cell Lymphoblastic Leukemia-Lymphoma;g:MTHFR)(dui:D007674;dis:Kidney Diseases;g:MTHFR)(dui:D013272;dis:Stomach Diseases;g:MTHFR)(dui:D020246;dis:Venous Thrombosis;g:MTHFR)(dui:D003920;dis:Diabetes Mellitus;g:MTHFR)(dui:D013274;dis:Stomach Neoplasms;g:MTHFR)(dui:D009139;dis:Musculoskeletal Abnormalities;g:MTHFR)(dui:D005832;dis:Genital Diseases, Male;g:MTHFR)(dui:D001327;dis:Autoimmune Diseases;g:MTHFR)(dui:D012559;dis:Schizophrenia;g:MTHFR)(dui:D007246;dis:Infertility;g:MTHFR)(dui:D012140;dis:Respiratory Tract Diseases;g:MTHFR)(dui:D008171;dis:Lung Diseases;g:MTHFR)(dui:D002545;dis:Brain Ischemia;g:MTHFR)(dui:D012002;dis:Rectal Diseases;g:MTHFR)(dui:D007592;dis:Joint Diseases;g:MTHFR)(dui:D001168;dis:Arthritis;g:MTHFR)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:MTHFR)(dui:D019636;dis:Neurodegenerative Diseases;g:MTHFR)(dui:D012216;dis:Rheumatic Diseases;g:MTHFR)(dui:D001172;dis:Arthritis, Rheumatoid;g:MTHFR)(dui:D005833;dis:Genital Neoplasms, Female;g:MTHFR)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MTHFR)(dui:D009008;dis:Abnormalities, Severe Teratoid;g:MTHFR)(dui:D000757;dis:Anencephaly;g:MTHFR)(dui:D003704;dis:Dementia;g:MTHFR)(dui:D019965;dis:Neurocognitive Disorders;g:MTHFR)(dui:D014591;dis:Uterine Diseases;g:MTHFR)(dui:D014594;dis:Uterine Neoplasms;g:MTHFR)(dui:D024801;dis:Tauopathies;g:MTHFR)(dui:D000544;dis:Alzheimer Disease;g:MTHFR)(dui:D007960;dis:Leukocyte Disorders;g:MTHFR)(dui:D007970;dis:Leukopenia;g:MTHFR)(dui:D013959;dis:Thyroid Diseases;g:MTHFR)(dui:D002277;dis:Carcinoma;g:MTHFR)(dui:D006967;dis:Hypersensitivity;g:MTHFR)(dui:D001157;dis:Arterial Occlusive Diseases;g:MTHFR)(dui:D008047;dis:Lip Diseases;g:MTHFR)(dui:D002971;dis:Cleft Lip;g:MTHFR)(dui:D019465;dis:Craniofacial Abnormalities;g:MTHFR)(dui:D019767;dis:Maxillofacial Abnormalities;g:MTHFR)(dui:D001161;dis:Arteriosclerosis;g:MTHFR)(dui:D018376;dis:Cardiovascular Abnormalities;g:MTHFR)(dui:D006330;dis:Heart Defects, Congenital;g:MTHFR)(dui:D013923;dis:Thromboembolism;g:MTHFR)(dui:D003110;dis:Colonic Neoplasms;g:MTHFR)(dui:D006980;dis:Hyperthyroidism;g:MTHFR)(dui:D048909;dis:Diabetes Complications;g:MTHFR)(dui:D001941;dis:Breast Diseases;g:MTHFR)(dui:D001943;dis:Breast Neoplasms;g:MTHFR)(dui:D001778;dis:Blood Coagulation Disorders;g:MTHFR)(dui:D007248;dis:Infertility, Male;g:MTHFR)(dui:D051437;dis:Renal Insufficiency;g:MTHFR)(dui:D025861;dis:Blood Coagulation Disorders, Inherited;g:MTHFR)(dui:D044882;dis:Glucose Metabolism Disorders;g:MTHFR)(dui:D000740;dis:Anemia;g:MTHFR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:MTHFR)(dui:D005759;dis:Gastroenteritis;g:MTHFR)(dui:D012678;dis:Sensation Disorders;g:MTHFR)(dui:D006086;dis:Graft vs Host Disease;g:MTHFR)(dui:D004427;dis:Ear Diseases;g:MTHFR)(dui:D006311;dis:Hearing Disorders;g:MTHFR)(dui:D034381;dis:Hearing Loss;g:MTHFR)(dui:D011248;dis:Pregnancy Complications;g:MTHFR)(dui:D000068105;dis:Bipolar and Related Disorders;g:MTHFR)(dui:D001714;dis:Bipolar Disorder;g:MTHFR)(dui:D011655;dis:Pulmonary Embolism;g:MTHFR)(dui:D004617;dis:Embolism;g:MTHFR)(dui:D003925;dis:Diabetic Angiopathies;g:MTHFR)(dui:D012142;dis:Respiratory Tract Neoplasms;g:MTHFR)(dui:D002577;dis:Uterine Cervical Diseases;g:MTHFR)(dui:D003639;dis:Hearing Loss, Sudden;g:MTHFR)(dui:D009385;dis:Neoplastic Processes;g:MTHFR)(dui:D002583;dis:Uterine Cervical Neoplasms;g:MTHFR)(dui:D013899;dis:Thoracic Neoplasms;g:MTHFR)(dui:D014571;dis:Urologic Neoplasms;g:MTHFR)(dui:D002278;dis:Carcinoma in Situ;g:MTHFR)(dui:D018290;dis:Cervical Intraepithelial Neoplasia;g:MTHFR)(dui:D005834;dis:Genital Neoplasms, Male;g:MTHFR)(dui:D011469;dis:Prostatic Diseases;g:MTHFR)(dui:D011471;dis:Prostatic Neoplasms;g:MTHFR)(dui:D008175;dis:Lung Neoplasms;g:MTHFR)(dui:D003324;dis:Coronary Artery Disease;g:MTHFR)(dui:D015448;dis:Leukemia, B-Cell;g:MTHFR)(dui:D015451;dis:Leukemia, Lymphocytic, Chronic, B-Cell;g:MTHFR)(dui:D001791;dis:Blood Platelet Disorders;g:MTHFR)(dui:D065886;dis:Neurodevelopmental Disorders;g:MTHFR)(dui:D001745;dis:Urinary Bladder Diseases;g:MTHFR)(dui:D001749;dis:Urinary Bladder Neoplasms;g:MTHFR)(dui:D056486;dis:Drug-Induced Liver Injury;g:MTHFR)(dui:D013921;dis:Thrombocytopenia;g:MTHFR)(dui:D002659;dis:Child Development Disorders, Pervasive;g:MTHFR)(dui:D002542;dis:Intracranial Embolism and Thrombosis;g:MTHFR)(dui:D020767;dis:Intracranial Thrombosis;g:MTHFR)(dui:D001321;dis:Autistic Disorder;g:MTHFR)(dui:D019964;dis:Mood Disorders;g:MTHFR)(dui:D003866;dis:Depressive Disorder;g:MTHFR)(dui:D000380;dis:Agranulocytosis;g:MTHFR)(dui:D009503;dis:Neutropenia;g:MTHFR)(dui:D023921;dis:Coronary Stenosis;g:MTHFR)(dui:D007247;dis:Infertility, Female;g:MTHFR)(dui:D012851;dis:Sinus Thrombosis, Intracranial;g:MTHFR)(dui:D001928;dis:Brain Diseases, Metabolic;g:MTHFR)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MTHFR)(dui:D018204;dis:Neoplasms, Connective and Soft Tissue;g:MTHFR)(dui:D008591;dis:Meningomyelocele;g:MTHFR)(dui:D008224;dis:Lymphoma, Follicular;g:MTHFR)(dui:D009372;dis:Neoplasms, Connective Tissue;g:MTHFR)(dui:D020258;dis:Neurotoxicity Syndromes;g:MTHFR)(dui:D052016;dis:Mucositis;g:MTHFR)(dui:D023903;dis:Coronary Restenosis;g:MTHFR)(dui:D009362;dis:Neoplasm Metastasis;g:MTHFR)(dui:D020879;dis:Neuromuscular Manifestations;g:MTHFR)(dui:D056784;dis:Leukoencephalopathies;g:MTHFR)(dui:D011618;dis:Psychotic Disorders;g:MTHFR)(dui:D009468;dis:Neuromuscular Diseases;g:MTHFR)(dui:D009135;dis:Muscular Diseases;g:MTHFR)(dui:D010523;dis:Peripheral Nervous System Diseases;g:MTHFR)(dui:D005530;dis:Foot Deformities;g:MTHFR)(dui:D005532;dis:Foot Deformities, Congenital;g:MTHFR)(dui:D006712;dis:Homocystinuria;g:MTHFR)(dui:D009128;dis:Muscle Spasticity;g:MTHFR)(dui:D017880;dis:Limb Deformities, Congenital;g:MTHFR)(dui:D000787;dis:Angina Pectoris;g:MTHFR)(dui:D003025;dis:Clubfoot;g:MTHFR)(dui:D009122;dis:Muscle Hypertonia;g:MTHFR)(dui:D038061;dis:Lower Extremity Deformities, Congenital;g:MTHFR)(dui:D017566;dis:Microvascular Angina;g:MTHFR)(dui:D001145;dis:Arrhythmias, Cardiac;g:MTHFR)(dui:D020260;dis:Heavy Metal Poisoning, Nervous System;g:MTHFR)(dui:D001281;dis:Atrial Fibrillation;g:MTHFR)(dui:D020261;dis:Arsenic Poisoning;g:MTHFR)(dui:D016889;dis:Endometrial Neoplasms;g:MTHFR)(dui:D013118;dis:Spinal Cord Diseases;g:MTHFR)(dui:D004342;dis:Drug Hypersensitivity;g:MTHFR)(dui:D007571;dis:Jaw Diseases;g:MTHFR)(dui:D007569;dis:Jaw Abnormalities;g:MTHFR)(dui:D002972;dis:Cleft Palate;g:MTHFR)(dui:D013971;dis:Thyrotoxicosis;g:MTHFR)(dui:D003872;dis:Dermatitis;g:MTHFR)(dui:D003875;dis:Drug Eruptions;g:MTHFR)(dui:D006201;dis:Hair Diseases;g:MTHFR)(dui:D007039;dis:Hypotrichosis;g:MTHFR)(dui:D046152;dis:Gastrointestinal Stromal Tumors;g:MTHFR)(dui:D000505;dis:Alopecia;g:MTHFR)(dui:D058186;dis:Acute Kidney Injury;g:MTHFR)(dui:D006973;dis:Hypertension;g:MTHFR)(dui:D008113;dis:Liver Neoplasms;g:MTHFR)	Tetrahydrofolic acid:Menadione:Methionine:Riboflavin:Benazepril:Methotrexate:Cyanocobalamin:Folic acid:Fluorouracil	GO:0031060:GO:0070829:GO:0043200:GO:0046655:GO:0045202:GO:0004489:GO:0044877:GO:0072341:GO:0001666:GO:0001843:GO:0005829:GO:0035999:GO:0009086:GO:0071949:GO:0033274:GO:0046500:GO:0006730:GO:0006555:GO:0050661:GO:0050660:GO:0042493:GO:0051593:GO:0070555:GO:0055114:GO:0050667	607093		-4.42															
chr1:11794839	SNV	G	1	G/A	PASS	3.743691039890356e-91	904.267		400	G=200,A=200	G=0.5,A=0.5	50.0	50.0	heterozygous	23	0.103	1.0		MTHFR	NM_005957.5	MTHFR:exonic:NM_005957.5	synonymous	AGT	7	p.Ser352=	c.1056C>T				A	GMAF=0.094:AMAF=0.0878:EMAF=0.0971	0.2		Benign	5019033	rs2066462		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MTHFR)(dui:NBS2;dis:Core Conditions;g:MTHFR)(dui:NBS11;dis:Amino Acid Disorder;g:MTHFR)(dui:NBS57;dis:Homocystinuria;g:MTHFR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MTHFR)(dui:D002318;dis:Cardiovascular Diseases;g:MTHFR)(dui:D009422;dis:Nervous System Diseases;g:MTHFR)(dui:D014652;dis:Vascular Diseases;g:MTHFR)(dui:D009369;dis:Neoplasms;g:MTHFR)(dui:D000013;dis:Congenital Abnormalities;g:MTHFR)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MTHFR)(dui:D030342;dis:Genetic Diseases, Inborn;g:MTHFR)(dui:D009371;dis:Neoplasms by Site;g:MTHFR)(dui:D002493;dis:Central Nervous System Diseases;g:MTHFR)(dui:D007154;dis:Immune System Diseases;g:MTHFR)(dui:D004066;dis:Digestive System Diseases;g:MTHFR)(dui:D001927;dis:Brain Diseases;g:MTHFR)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MTHFR)(dui:D009370;dis:Neoplasms by Histologic Type;g:MTHFR)(dui:D005767;dis:Gastrointestinal Diseases;g:MTHFR)(dui:D008659;dis:Metabolic Diseases;g:MTHFR)(dui:D006331;dis:Heart Diseases;g:MTHFR)(dui:D004067;dis:Digestive System Neoplasms;g:MTHFR)(dui:D001523;dis:Mental Disorders;g:MTHFR)(dui:D006402;dis:Hematologic Diseases;g:MTHFR)(dui:D009748;dis:Nutrition Disorders;g:MTHFR)(dui:D044342;dis:Malnutrition;g:MTHFR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:MTHFR)(dui:D007160;dis:Immunoproliferative Disorders;g:MTHFR)(dui:D008232;dis:Lymphoproliferative Disorders;g:MTHFR)(dui:D002561;dis:Cerebrovascular Disorders;g:MTHFR)(dui:D008206;dis:Lymphatic Diseases;g:MTHFR)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MTHFR)(dui:D008661;dis:Metabolism, Inborn Errors;g:MTHFR)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MTHFR)(dui:D020138;dis:Hyperhomocysteinemia;g:MTHFR)(dui:D017202;dis:Myocardial Ischemia;g:MTHFR)(dui:D003677;dis:Deficiency Diseases;g:MTHFR)(dui:D001361;dis:Avitaminosis;g:MTHFR)(dui:D014804;dis:Vitamin B Deficiency;g:MTHFR)(dui:D009421;dis:Nervous System Malformations;g:MTHFR)(dui:D009436;dis:Neural Tube Defects;g:MTHFR)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:MTHFR)(dui:D009140;dis:Musculoskeletal Diseases;g:MTHFR)(dui:D016769;dis:Embolism and Thrombosis;g:MTHFR)(dui:D009461;dis:Neurologic Manifestations;g:MTHFR)(dui:D003327;dis:Coronary Disease;g:MTHFR)(dui:D052776;dis:Female Urogenital Diseases;g:MTHFR)(dui:D052801;dis:Male Urogenital Diseases;g:MTHFR)(dui:D008286;dis:Malabsorption Syndromes;g:MTHFR)(dui:D007938;dis:Leukemia;g:MTHFR)(dui:D009057;dis:Stomatognathic Diseases;g:MTHFR)(dui:D007945;dis:Leukemia, Lymphoid;g:MTHFR)(dui:D007410;dis:Intestinal Diseases;g:MTHFR)(dui:D012871;dis:Skin Diseases;g:MTHFR)(dui:D009059;dis:Mouth Diseases;g:MTHFR)(dui:D004700;dis:Endocrine System Diseases;g:MTHFR)(dui:D003108;dis:Colonic Diseases;g:MTHFR)(dui:D007414;dis:Intestinal Neoplasms;g:MTHFR)(dui:D015179;dis:Colorectal Neoplasms;g:MTHFR)(dui:D014565;dis:Urogenital Neoplasms;g:MTHFR)(dui:D018640;dis:Stomatognathic System Abnormalities;g:MTHFR)(dui:D019967;dis:Schizophrenia Spectrum and Other Psychotic Disorders;g:MTHFR)(dui:D003240;dis:Connective Tissue Diseases;g:MTHFR)(dui:D014570;dis:Urologic Diseases;g:MTHFR)(dui:D013927;dis:Thrombosis;g:MTHFR)(dui:D020521;dis:Stroke;g:MTHFR)(dui:D008223;dis:Lymphoma;g:MTHFR)(dui:D005831;dis:Genital Diseases, Female;g:MTHFR)(dui:D008107;dis:Liver Diseases;g:MTHFR)(dui:D009056;dis:Mouth Abnormalities;g:MTHFR)(dui:D025063;dis:Chromosome Disorders;g:MTHFR)(dui:D019954;dis:Neurobehavioral Manifestations;g:MTHFR)(dui:D008607;dis:Intellectual Disability;g:MTHFR)(dui:D000015;dis:Abnormalities, Multiple;g:MTHFR)(dui:D004314;dis:Down Syndrome;g:MTHFR)(dui:D019851;dis:Thrombophilia;g:MTHFR)(dui:D054198;dis:Precursor Cell Lymphoblastic Leukemia-Lymphoma;g:MTHFR)(dui:D007674;dis:Kidney Diseases;g:MTHFR)(dui:D013272;dis:Stomach Diseases;g:MTHFR)(dui:D020246;dis:Venous Thrombosis;g:MTHFR)(dui:D003920;dis:Diabetes Mellitus;g:MTHFR)(dui:D013274;dis:Stomach Neoplasms;g:MTHFR)(dui:D009139;dis:Musculoskeletal Abnormalities;g:MTHFR)(dui:D005832;dis:Genital Diseases, Male;g:MTHFR)(dui:D001327;dis:Autoimmune Diseases;g:MTHFR)(dui:D012559;dis:Schizophrenia;g:MTHFR)(dui:D007246;dis:Infertility;g:MTHFR)(dui:D012140;dis:Respiratory Tract Diseases;g:MTHFR)(dui:D008171;dis:Lung Diseases;g:MTHFR)(dui:D002545;dis:Brain Ischemia;g:MTHFR)(dui:D012002;dis:Rectal Diseases;g:MTHFR)(dui:D007592;dis:Joint Diseases;g:MTHFR)(dui:D001168;dis:Arthritis;g:MTHFR)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:MTHFR)(dui:D019636;dis:Neurodegenerative Diseases;g:MTHFR)(dui:D012216;dis:Rheumatic Diseases;g:MTHFR)(dui:D001172;dis:Arthritis, Rheumatoid;g:MTHFR)(dui:D005833;dis:Genital Neoplasms, Female;g:MTHFR)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MTHFR)(dui:D009008;dis:Abnormalities, Severe Teratoid;g:MTHFR)(dui:D000757;dis:Anencephaly;g:MTHFR)(dui:D003704;dis:Dementia;g:MTHFR)(dui:D019965;dis:Neurocognitive Disorders;g:MTHFR)(dui:D014591;dis:Uterine Diseases;g:MTHFR)(dui:D014594;dis:Uterine Neoplasms;g:MTHFR)(dui:D024801;dis:Tauopathies;g:MTHFR)(dui:D000544;dis:Alzheimer Disease;g:MTHFR)(dui:D007960;dis:Leukocyte Disorders;g:MTHFR)(dui:D007970;dis:Leukopenia;g:MTHFR)(dui:D013959;dis:Thyroid Diseases;g:MTHFR)(dui:D002277;dis:Carcinoma;g:MTHFR)(dui:D006967;dis:Hypersensitivity;g:MTHFR)(dui:D001157;dis:Arterial Occlusive Diseases;g:MTHFR)(dui:D008047;dis:Lip Diseases;g:MTHFR)(dui:D002971;dis:Cleft Lip;g:MTHFR)(dui:D019465;dis:Craniofacial Abnormalities;g:MTHFR)(dui:D019767;dis:Maxillofacial Abnormalities;g:MTHFR)(dui:D001161;dis:Arteriosclerosis;g:MTHFR)(dui:D018376;dis:Cardiovascular Abnormalities;g:MTHFR)(dui:D006330;dis:Heart Defects, Congenital;g:MTHFR)(dui:D013923;dis:Thromboembolism;g:MTHFR)(dui:D003110;dis:Colonic Neoplasms;g:MTHFR)(dui:D006980;dis:Hyperthyroidism;g:MTHFR)(dui:D048909;dis:Diabetes Complications;g:MTHFR)(dui:D001941;dis:Breast Diseases;g:MTHFR)(dui:D001943;dis:Breast Neoplasms;g:MTHFR)(dui:D001778;dis:Blood Coagulation Disorders;g:MTHFR)(dui:D007248;dis:Infertility, Male;g:MTHFR)(dui:D051437;dis:Renal Insufficiency;g:MTHFR)(dui:D025861;dis:Blood Coagulation Disorders, Inherited;g:MTHFR)(dui:D044882;dis:Glucose Metabolism Disorders;g:MTHFR)(dui:D000740;dis:Anemia;g:MTHFR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:MTHFR)(dui:D005759;dis:Gastroenteritis;g:MTHFR)(dui:D012678;dis:Sensation Disorders;g:MTHFR)(dui:D006086;dis:Graft vs Host Disease;g:MTHFR)(dui:D004427;dis:Ear Diseases;g:MTHFR)(dui:D006311;dis:Hearing Disorders;g:MTHFR)(dui:D034381;dis:Hearing Loss;g:MTHFR)(dui:D011248;dis:Pregnancy Complications;g:MTHFR)(dui:D000068105;dis:Bipolar and Related Disorders;g:MTHFR)(dui:D001714;dis:Bipolar Disorder;g:MTHFR)(dui:D011655;dis:Pulmonary Embolism;g:MTHFR)(dui:D004617;dis:Embolism;g:MTHFR)(dui:D003925;dis:Diabetic Angiopathies;g:MTHFR)(dui:D012142;dis:Respiratory Tract Neoplasms;g:MTHFR)(dui:D002577;dis:Uterine Cervical Diseases;g:MTHFR)(dui:D003639;dis:Hearing Loss, Sudden;g:MTHFR)(dui:D009385;dis:Neoplastic Processes;g:MTHFR)(dui:D002583;dis:Uterine Cervical Neoplasms;g:MTHFR)(dui:D013899;dis:Thoracic Neoplasms;g:MTHFR)(dui:D014571;dis:Urologic Neoplasms;g:MTHFR)(dui:D002278;dis:Carcinoma in Situ;g:MTHFR)(dui:D018290;dis:Cervical Intraepithelial Neoplasia;g:MTHFR)(dui:D005834;dis:Genital Neoplasms, Male;g:MTHFR)(dui:D011469;dis:Prostatic Diseases;g:MTHFR)(dui:D011471;dis:Prostatic Neoplasms;g:MTHFR)(dui:D008175;dis:Lung Neoplasms;g:MTHFR)(dui:D003324;dis:Coronary Artery Disease;g:MTHFR)(dui:D015448;dis:Leukemia, B-Cell;g:MTHFR)(dui:D015451;dis:Leukemia, Lymphocytic, Chronic, B-Cell;g:MTHFR)(dui:D001791;dis:Blood Platelet Disorders;g:MTHFR)(dui:D065886;dis:Neurodevelopmental Disorders;g:MTHFR)(dui:D001745;dis:Urinary Bladder Diseases;g:MTHFR)(dui:D001749;dis:Urinary Bladder Neoplasms;g:MTHFR)(dui:D056486;dis:Drug-Induced Liver Injury;g:MTHFR)(dui:D013921;dis:Thrombocytopenia;g:MTHFR)(dui:D002659;dis:Child Development Disorders, Pervasive;g:MTHFR)(dui:D002542;dis:Intracranial Embolism and Thrombosis;g:MTHFR)(dui:D020767;dis:Intracranial Thrombosis;g:MTHFR)(dui:D001321;dis:Autistic Disorder;g:MTHFR)(dui:D019964;dis:Mood Disorders;g:MTHFR)(dui:D003866;dis:Depressive Disorder;g:MTHFR)(dui:D000380;dis:Agranulocytosis;g:MTHFR)(dui:D009503;dis:Neutropenia;g:MTHFR)(dui:D023921;dis:Coronary Stenosis;g:MTHFR)(dui:D007247;dis:Infertility, Female;g:MTHFR)(dui:D012851;dis:Sinus Thrombosis, Intracranial;g:MTHFR)(dui:D001928;dis:Brain Diseases, Metabolic;g:MTHFR)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MTHFR)(dui:D018204;dis:Neoplasms, Connective and Soft Tissue;g:MTHFR)(dui:D008591;dis:Meningomyelocele;g:MTHFR)(dui:D008224;dis:Lymphoma, Follicular;g:MTHFR)(dui:D009372;dis:Neoplasms, Connective Tissue;g:MTHFR)(dui:D020258;dis:Neurotoxicity Syndromes;g:MTHFR)(dui:D052016;dis:Mucositis;g:MTHFR)(dui:D023903;dis:Coronary Restenosis;g:MTHFR)(dui:D009362;dis:Neoplasm Metastasis;g:MTHFR)(dui:D020879;dis:Neuromuscular Manifestations;g:MTHFR)(dui:D056784;dis:Leukoencephalopathies;g:MTHFR)(dui:D011618;dis:Psychotic Disorders;g:MTHFR)(dui:D009468;dis:Neuromuscular Diseases;g:MTHFR)(dui:D009135;dis:Muscular Diseases;g:MTHFR)(dui:D010523;dis:Peripheral Nervous System Diseases;g:MTHFR)(dui:D005530;dis:Foot Deformities;g:MTHFR)(dui:D005532;dis:Foot Deformities, Congenital;g:MTHFR)(dui:D006712;dis:Homocystinuria;g:MTHFR)(dui:D009128;dis:Muscle Spasticity;g:MTHFR)(dui:D017880;dis:Limb Deformities, Congenital;g:MTHFR)(dui:D000787;dis:Angina Pectoris;g:MTHFR)(dui:D003025;dis:Clubfoot;g:MTHFR)(dui:D009122;dis:Muscle Hypertonia;g:MTHFR)(dui:D038061;dis:Lower Extremity Deformities, Congenital;g:MTHFR)(dui:D017566;dis:Microvascular Angina;g:MTHFR)(dui:D001145;dis:Arrhythmias, Cardiac;g:MTHFR)(dui:D020260;dis:Heavy Metal Poisoning, Nervous System;g:MTHFR)(dui:D001281;dis:Atrial Fibrillation;g:MTHFR)(dui:D020261;dis:Arsenic Poisoning;g:MTHFR)(dui:D016889;dis:Endometrial Neoplasms;g:MTHFR)(dui:D013118;dis:Spinal Cord Diseases;g:MTHFR)(dui:D004342;dis:Drug Hypersensitivity;g:MTHFR)(dui:D007571;dis:Jaw Diseases;g:MTHFR)(dui:D007569;dis:Jaw Abnormalities;g:MTHFR)(dui:D002972;dis:Cleft Palate;g:MTHFR)(dui:D013971;dis:Thyrotoxicosis;g:MTHFR)(dui:D003872;dis:Dermatitis;g:MTHFR)(dui:D003875;dis:Drug Eruptions;g:MTHFR)(dui:D006201;dis:Hair Diseases;g:MTHFR)(dui:D007039;dis:Hypotrichosis;g:MTHFR)(dui:D046152;dis:Gastrointestinal Stromal Tumors;g:MTHFR)(dui:D000505;dis:Alopecia;g:MTHFR)(dui:D058186;dis:Acute Kidney Injury;g:MTHFR)(dui:D006973;dis:Hypertension;g:MTHFR)(dui:D008113;dis:Liver Neoplasms;g:MTHFR)	Tetrahydrofolic acid:Menadione:Methionine:Riboflavin:Benazepril:Methotrexate:Cyanocobalamin:Folic acid:Fluorouracil	GO:0031060:GO:0070829:GO:0043200:GO:0046655:GO:0045202:GO:0004489:GO:0044877:GO:0072341:GO:0001666:GO:0001843:GO:0005829:GO:0035999:GO:0009086:GO:0071949:GO:0033274:GO:0046500:GO:0006730:GO:0006555:GO:0050661:GO:0050660:GO:0042493:GO:0051593:GO:0070555:GO:0055114:GO:0050667	607093		-0.56															
chr1:11796321	SNV	G	1	G/A	PASS	2.2698648518837934e-110	1096.44		399	G=180,A=219	G=0.4511,A=0.5489	54.89	45.11	heterozygous	15	0.245	2.0		MTHFR	NM_005957.5	MTHFR:exonic:NM_005957.5	missense	GTC	5	p.Ala222Val	c.665C>T	0.0	0.998	64.0	A	GMAF=0.2706:AMAF=0.1217:EMAF=0.3469	0.98		drug response	146404	rs1801133		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MTHFR)(dui:NBS2;dis:Core Conditions;g:MTHFR)(dui:NBS11;dis:Amino Acid Disorder;g:MTHFR)(dui:NBS57;dis:Homocystinuria;g:MTHFR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MTHFR)(dui:D002318;dis:Cardiovascular Diseases;g:MTHFR)(dui:D009422;dis:Nervous System Diseases;g:MTHFR)(dui:D014652;dis:Vascular Diseases;g:MTHFR)(dui:D009369;dis:Neoplasms;g:MTHFR)(dui:D000013;dis:Congenital Abnormalities;g:MTHFR)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MTHFR)(dui:D030342;dis:Genetic Diseases, Inborn;g:MTHFR)(dui:D009371;dis:Neoplasms by Site;g:MTHFR)(dui:D002493;dis:Central Nervous System Diseases;g:MTHFR)(dui:D007154;dis:Immune System Diseases;g:MTHFR)(dui:D004066;dis:Digestive System Diseases;g:MTHFR)(dui:D001927;dis:Brain Diseases;g:MTHFR)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MTHFR)(dui:D009370;dis:Neoplasms by Histologic Type;g:MTHFR)(dui:D005767;dis:Gastrointestinal Diseases;g:MTHFR)(dui:D008659;dis:Metabolic Diseases;g:MTHFR)(dui:D006331;dis:Heart Diseases;g:MTHFR)(dui:D004067;dis:Digestive System Neoplasms;g:MTHFR)(dui:D001523;dis:Mental Disorders;g:MTHFR)(dui:D006402;dis:Hematologic Diseases;g:MTHFR)(dui:D009748;dis:Nutrition Disorders;g:MTHFR)(dui:D044342;dis:Malnutrition;g:MTHFR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:MTHFR)(dui:D007160;dis:Immunoproliferative Disorders;g:MTHFR)(dui:D008232;dis:Lymphoproliferative Disorders;g:MTHFR)(dui:D002561;dis:Cerebrovascular Disorders;g:MTHFR)(dui:D008206;dis:Lymphatic Diseases;g:MTHFR)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MTHFR)(dui:D008661;dis:Metabolism, Inborn Errors;g:MTHFR)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MTHFR)(dui:D020138;dis:Hyperhomocysteinemia;g:MTHFR)(dui:D017202;dis:Myocardial Ischemia;g:MTHFR)(dui:D003677;dis:Deficiency Diseases;g:MTHFR)(dui:D001361;dis:Avitaminosis;g:MTHFR)(dui:D014804;dis:Vitamin B Deficiency;g:MTHFR)(dui:D009421;dis:Nervous System Malformations;g:MTHFR)(dui:D009436;dis:Neural Tube Defects;g:MTHFR)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:MTHFR)(dui:D009140;dis:Musculoskeletal Diseases;g:MTHFR)(dui:D016769;dis:Embolism and Thrombosis;g:MTHFR)(dui:D009461;dis:Neurologic Manifestations;g:MTHFR)(dui:D003327;dis:Coronary Disease;g:MTHFR)(dui:D052776;dis:Female Urogenital Diseases;g:MTHFR)(dui:D052801;dis:Male Urogenital Diseases;g:MTHFR)(dui:D008286;dis:Malabsorption Syndromes;g:MTHFR)(dui:D007938;dis:Leukemia;g:MTHFR)(dui:D009057;dis:Stomatognathic Diseases;g:MTHFR)(dui:D007945;dis:Leukemia, Lymphoid;g:MTHFR)(dui:D007410;dis:Intestinal Diseases;g:MTHFR)(dui:D012871;dis:Skin Diseases;g:MTHFR)(dui:D009059;dis:Mouth Diseases;g:MTHFR)(dui:D004700;dis:Endocrine System Diseases;g:MTHFR)(dui:D003108;dis:Colonic Diseases;g:MTHFR)(dui:D007414;dis:Intestinal Neoplasms;g:MTHFR)(dui:D015179;dis:Colorectal Neoplasms;g:MTHFR)(dui:D014565;dis:Urogenital Neoplasms;g:MTHFR)(dui:D018640;dis:Stomatognathic System Abnormalities;g:MTHFR)(dui:D019967;dis:Schizophrenia Spectrum and Other Psychotic Disorders;g:MTHFR)(dui:D003240;dis:Connective Tissue Diseases;g:MTHFR)(dui:D014570;dis:Urologic Diseases;g:MTHFR)(dui:D013927;dis:Thrombosis;g:MTHFR)(dui:D020521;dis:Stroke;g:MTHFR)(dui:D008223;dis:Lymphoma;g:MTHFR)(dui:D005831;dis:Genital Diseases, Female;g:MTHFR)(dui:D008107;dis:Liver Diseases;g:MTHFR)(dui:D009056;dis:Mouth Abnormalities;g:MTHFR)(dui:D025063;dis:Chromosome Disorders;g:MTHFR)(dui:D019954;dis:Neurobehavioral Manifestations;g:MTHFR)(dui:D008607;dis:Intellectual Disability;g:MTHFR)(dui:D000015;dis:Abnormalities, Multiple;g:MTHFR)(dui:D004314;dis:Down Syndrome;g:MTHFR)(dui:D019851;dis:Thrombophilia;g:MTHFR)(dui:D054198;dis:Precursor Cell Lymphoblastic Leukemia-Lymphoma;g:MTHFR)(dui:D007674;dis:Kidney Diseases;g:MTHFR)(dui:D013272;dis:Stomach Diseases;g:MTHFR)(dui:D020246;dis:Venous Thrombosis;g:MTHFR)(dui:D003920;dis:Diabetes Mellitus;g:MTHFR)(dui:D013274;dis:Stomach Neoplasms;g:MTHFR)(dui:D009139;dis:Musculoskeletal Abnormalities;g:MTHFR)(dui:D005832;dis:Genital Diseases, Male;g:MTHFR)(dui:D001327;dis:Autoimmune Diseases;g:MTHFR)(dui:D012559;dis:Schizophrenia;g:MTHFR)(dui:D007246;dis:Infertility;g:MTHFR)(dui:D012140;dis:Respiratory Tract Diseases;g:MTHFR)(dui:D008171;dis:Lung Diseases;g:MTHFR)(dui:D002545;dis:Brain Ischemia;g:MTHFR)(dui:D012002;dis:Rectal Diseases;g:MTHFR)(dui:D007592;dis:Joint Diseases;g:MTHFR)(dui:D001168;dis:Arthritis;g:MTHFR)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:MTHFR)(dui:D019636;dis:Neurodegenerative Diseases;g:MTHFR)(dui:D012216;dis:Rheumatic Diseases;g:MTHFR)(dui:D001172;dis:Arthritis, Rheumatoid;g:MTHFR)(dui:D005833;dis:Genital Neoplasms, Female;g:MTHFR)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MTHFR)(dui:D009008;dis:Abnormalities, Severe Teratoid;g:MTHFR)(dui:D000757;dis:Anencephaly;g:MTHFR)(dui:D003704;dis:Dementia;g:MTHFR)(dui:D019965;dis:Neurocognitive Disorders;g:MTHFR)(dui:D014591;dis:Uterine Diseases;g:MTHFR)(dui:D014594;dis:Uterine Neoplasms;g:MTHFR)(dui:D024801;dis:Tauopathies;g:MTHFR)(dui:D000544;dis:Alzheimer Disease;g:MTHFR)(dui:D007960;dis:Leukocyte Disorders;g:MTHFR)(dui:D007970;dis:Leukopenia;g:MTHFR)(dui:D013959;dis:Thyroid Diseases;g:MTHFR)(dui:D002277;dis:Carcinoma;g:MTHFR)(dui:D006967;dis:Hypersensitivity;g:MTHFR)(dui:D001157;dis:Arterial Occlusive Diseases;g:MTHFR)(dui:D008047;dis:Lip Diseases;g:MTHFR)(dui:D002971;dis:Cleft Lip;g:MTHFR)(dui:D019465;dis:Craniofacial Abnormalities;g:MTHFR)(dui:D019767;dis:Maxillofacial Abnormalities;g:MTHFR)(dui:D001161;dis:Arteriosclerosis;g:MTHFR)(dui:D018376;dis:Cardiovascular Abnormalities;g:MTHFR)(dui:D006330;dis:Heart Defects, Congenital;g:MTHFR)(dui:D013923;dis:Thromboembolism;g:MTHFR)(dui:D003110;dis:Colonic Neoplasms;g:MTHFR)(dui:D006980;dis:Hyperthyroidism;g:MTHFR)(dui:D048909;dis:Diabetes Complications;g:MTHFR)(dui:D001941;dis:Breast Diseases;g:MTHFR)(dui:D001943;dis:Breast Neoplasms;g:MTHFR)(dui:D001778;dis:Blood Coagulation Disorders;g:MTHFR)(dui:D007248;dis:Infertility, Male;g:MTHFR)(dui:D051437;dis:Renal Insufficiency;g:MTHFR)(dui:D025861;dis:Blood Coagulation Disorders, Inherited;g:MTHFR)(dui:D044882;dis:Glucose Metabolism Disorders;g:MTHFR)(dui:D000740;dis:Anemia;g:MTHFR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:MTHFR)(dui:D005759;dis:Gastroenteritis;g:MTHFR)(dui:D012678;dis:Sensation Disorders;g:MTHFR)(dui:D006086;dis:Graft vs Host Disease;g:MTHFR)(dui:D004427;dis:Ear Diseases;g:MTHFR)(dui:D006311;dis:Hearing Disorders;g:MTHFR)(dui:D034381;dis:Hearing Loss;g:MTHFR)(dui:D011248;dis:Pregnancy Complications;g:MTHFR)(dui:D000068105;dis:Bipolar and Related Disorders;g:MTHFR)(dui:D001714;dis:Bipolar Disorder;g:MTHFR)(dui:D011655;dis:Pulmonary Embolism;g:MTHFR)(dui:D004617;dis:Embolism;g:MTHFR)(dui:D003925;dis:Diabetic Angiopathies;g:MTHFR)(dui:D012142;dis:Respiratory Tract Neoplasms;g:MTHFR)(dui:D002577;dis:Uterine Cervical Diseases;g:MTHFR)(dui:D003639;dis:Hearing Loss, Sudden;g:MTHFR)(dui:D009385;dis:Neoplastic Processes;g:MTHFR)(dui:D002583;dis:Uterine Cervical Neoplasms;g:MTHFR)(dui:D013899;dis:Thoracic Neoplasms;g:MTHFR)(dui:D014571;dis:Urologic Neoplasms;g:MTHFR)(dui:D002278;dis:Carcinoma in Situ;g:MTHFR)(dui:D018290;dis:Cervical Intraepithelial Neoplasia;g:MTHFR)(dui:D005834;dis:Genital Neoplasms, Male;g:MTHFR)(dui:D011469;dis:Prostatic Diseases;g:MTHFR)(dui:D011471;dis:Prostatic Neoplasms;g:MTHFR)(dui:D008175;dis:Lung Neoplasms;g:MTHFR)(dui:D003324;dis:Coronary Artery Disease;g:MTHFR)(dui:D015448;dis:Leukemia, B-Cell;g:MTHFR)(dui:D015451;dis:Leukemia, Lymphocytic, Chronic, B-Cell;g:MTHFR)(dui:D001791;dis:Blood Platelet Disorders;g:MTHFR)(dui:D065886;dis:Neurodevelopmental Disorders;g:MTHFR)(dui:D001745;dis:Urinary Bladder Diseases;g:MTHFR)(dui:D001749;dis:Urinary Bladder Neoplasms;g:MTHFR)(dui:D056486;dis:Drug-Induced Liver Injury;g:MTHFR)(dui:D013921;dis:Thrombocytopenia;g:MTHFR)(dui:D002659;dis:Child Development Disorders, Pervasive;g:MTHFR)(dui:D002542;dis:Intracranial Embolism and Thrombosis;g:MTHFR)(dui:D020767;dis:Intracranial Thrombosis;g:MTHFR)(dui:D001321;dis:Autistic Disorder;g:MTHFR)(dui:D019964;dis:Mood Disorders;g:MTHFR)(dui:D003866;dis:Depressive Disorder;g:MTHFR)(dui:D000380;dis:Agranulocytosis;g:MTHFR)(dui:D009503;dis:Neutropenia;g:MTHFR)(dui:D023921;dis:Coronary Stenosis;g:MTHFR)(dui:D007247;dis:Infertility, Female;g:MTHFR)(dui:D012851;dis:Sinus Thrombosis, Intracranial;g:MTHFR)(dui:D001928;dis:Brain Diseases, Metabolic;g:MTHFR)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MTHFR)(dui:D018204;dis:Neoplasms, Connective and Soft Tissue;g:MTHFR)(dui:D008591;dis:Meningomyelocele;g:MTHFR)(dui:D008224;dis:Lymphoma, Follicular;g:MTHFR)(dui:D009372;dis:Neoplasms, Connective Tissue;g:MTHFR)(dui:D020258;dis:Neurotoxicity Syndromes;g:MTHFR)(dui:D052016;dis:Mucositis;g:MTHFR)(dui:D023903;dis:Coronary Restenosis;g:MTHFR)(dui:D009362;dis:Neoplasm Metastasis;g:MTHFR)(dui:D020879;dis:Neuromuscular Manifestations;g:MTHFR)(dui:D056784;dis:Leukoencephalopathies;g:MTHFR)(dui:D011618;dis:Psychotic Disorders;g:MTHFR)(dui:D009468;dis:Neuromuscular Diseases;g:MTHFR)(dui:D009135;dis:Muscular Diseases;g:MTHFR)(dui:D010523;dis:Peripheral Nervous System Diseases;g:MTHFR)(dui:D005530;dis:Foot Deformities;g:MTHFR)(dui:D005532;dis:Foot Deformities, Congenital;g:MTHFR)(dui:D006712;dis:Homocystinuria;g:MTHFR)(dui:D009128;dis:Muscle Spasticity;g:MTHFR)(dui:D017880;dis:Limb Deformities, Congenital;g:MTHFR)(dui:D000787;dis:Angina Pectoris;g:MTHFR)(dui:D003025;dis:Clubfoot;g:MTHFR)(dui:D009122;dis:Muscle Hypertonia;g:MTHFR)(dui:D038061;dis:Lower Extremity Deformities, Congenital;g:MTHFR)(dui:D017566;dis:Microvascular Angina;g:MTHFR)(dui:D001145;dis:Arrhythmias, Cardiac;g:MTHFR)(dui:D020260;dis:Heavy Metal Poisoning, Nervous System;g:MTHFR)(dui:D001281;dis:Atrial Fibrillation;g:MTHFR)(dui:D020261;dis:Arsenic Poisoning;g:MTHFR)(dui:D016889;dis:Endometrial Neoplasms;g:MTHFR)(dui:D013118;dis:Spinal Cord Diseases;g:MTHFR)(dui:D004342;dis:Drug Hypersensitivity;g:MTHFR)(dui:D007571;dis:Jaw Diseases;g:MTHFR)(dui:D007569;dis:Jaw Abnormalities;g:MTHFR)(dui:D002972;dis:Cleft Palate;g:MTHFR)(dui:D013971;dis:Thyrotoxicosis;g:MTHFR)(dui:D003872;dis:Dermatitis;g:MTHFR)(dui:D003875;dis:Drug Eruptions;g:MTHFR)(dui:D006201;dis:Hair Diseases;g:MTHFR)(dui:D007039;dis:Hypotrichosis;g:MTHFR)(dui:D046152;dis:Gastrointestinal Stromal Tumors;g:MTHFR)(dui:D000505;dis:Alopecia;g:MTHFR)(dui:D058186;dis:Acute Kidney Injury;g:MTHFR)(dui:D006973;dis:Hypertension;g:MTHFR)(dui:D008113;dis:Liver Neoplasms;g:MTHFR)	Tetrahydrofolic acid:Menadione:Methionine:Riboflavin:Benazepril:Methotrexate:Cyanocobalamin:Folic acid:Fluorouracil	GO:0031060:GO:0070829:GO:0043200:GO:0046655:GO:0045202:GO:0004489:GO:0044877:GO:0072341:GO:0001666:GO:0001843:GO:0005829:GO:0035999:GO:0009086:GO:0071949:GO:0033274:GO:0046500:GO:0006730:GO:0006555:GO:0050661:GO:0050660:GO:0042493:GO:0051593:GO:0070555:GO:0055114:GO:0050667	607093		9.14															
chr1:11802707	INDEL	C	1	C/CT	PASS	1.0437584393235484e-20	199.814		399	C=226,CT=173	C=0.5664,CT=0.4336	43.36	56.64	heterozygous	23	0.101	4.0		MTHFR	NM_005957.5	MTHFR:intronic:NM_005957.5	unknown			p.?	c.236+173_236+174insA				CT						rs55645287		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MTHFR)(dui:NBS2;dis:Core Conditions;g:MTHFR)(dui:NBS11;dis:Amino Acid Disorder;g:MTHFR)(dui:NBS57;dis:Homocystinuria;g:MTHFR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MTHFR)(dui:D002318;dis:Cardiovascular Diseases;g:MTHFR)(dui:D009422;dis:Nervous System Diseases;g:MTHFR)(dui:D014652;dis:Vascular Diseases;g:MTHFR)(dui:D009369;dis:Neoplasms;g:MTHFR)(dui:D000013;dis:Congenital Abnormalities;g:MTHFR)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MTHFR)(dui:D030342;dis:Genetic Diseases, Inborn;g:MTHFR)(dui:D009371;dis:Neoplasms by Site;g:MTHFR)(dui:D002493;dis:Central Nervous System Diseases;g:MTHFR)(dui:D007154;dis:Immune System Diseases;g:MTHFR)(dui:D004066;dis:Digestive System Diseases;g:MTHFR)(dui:D001927;dis:Brain Diseases;g:MTHFR)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MTHFR)(dui:D009370;dis:Neoplasms by Histologic Type;g:MTHFR)(dui:D005767;dis:Gastrointestinal Diseases;g:MTHFR)(dui:D008659;dis:Metabolic Diseases;g:MTHFR)(dui:D006331;dis:Heart Diseases;g:MTHFR)(dui:D004067;dis:Digestive System Neoplasms;g:MTHFR)(dui:D001523;dis:Mental Disorders;g:MTHFR)(dui:D006402;dis:Hematologic Diseases;g:MTHFR)(dui:D009748;dis:Nutrition Disorders;g:MTHFR)(dui:D044342;dis:Malnutrition;g:MTHFR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:MTHFR)(dui:D007160;dis:Immunoproliferative Disorders;g:MTHFR)(dui:D008232;dis:Lymphoproliferative Disorders;g:MTHFR)(dui:D002561;dis:Cerebrovascular Disorders;g:MTHFR)(dui:D008206;dis:Lymphatic Diseases;g:MTHFR)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MTHFR)(dui:D008661;dis:Metabolism, Inborn Errors;g:MTHFR)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MTHFR)(dui:D020138;dis:Hyperhomocysteinemia;g:MTHFR)(dui:D017202;dis:Myocardial Ischemia;g:MTHFR)(dui:D003677;dis:Deficiency Diseases;g:MTHFR)(dui:D001361;dis:Avitaminosis;g:MTHFR)(dui:D014804;dis:Vitamin B Deficiency;g:MTHFR)(dui:D009421;dis:Nervous System Malformations;g:MTHFR)(dui:D009436;dis:Neural Tube Defects;g:MTHFR)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:MTHFR)(dui:D009140;dis:Musculoskeletal Diseases;g:MTHFR)(dui:D016769;dis:Embolism and Thrombosis;g:MTHFR)(dui:D009461;dis:Neurologic Manifestations;g:MTHFR)(dui:D003327;dis:Coronary Disease;g:MTHFR)(dui:D052776;dis:Female Urogenital Diseases;g:MTHFR)(dui:D052801;dis:Male Urogenital Diseases;g:MTHFR)(dui:D008286;dis:Malabsorption Syndromes;g:MTHFR)(dui:D007938;dis:Leukemia;g:MTHFR)(dui:D009057;dis:Stomatognathic Diseases;g:MTHFR)(dui:D007945;dis:Leukemia, Lymphoid;g:MTHFR)(dui:D007410;dis:Intestinal Diseases;g:MTHFR)(dui:D012871;dis:Skin Diseases;g:MTHFR)(dui:D009059;dis:Mouth Diseases;g:MTHFR)(dui:D004700;dis:Endocrine System Diseases;g:MTHFR)(dui:D003108;dis:Colonic Diseases;g:MTHFR)(dui:D007414;dis:Intestinal Neoplasms;g:MTHFR)(dui:D015179;dis:Colorectal Neoplasms;g:MTHFR)(dui:D014565;dis:Urogenital Neoplasms;g:MTHFR)(dui:D018640;dis:Stomatognathic System Abnormalities;g:MTHFR)(dui:D019967;dis:Schizophrenia Spectrum and Other Psychotic Disorders;g:MTHFR)(dui:D003240;dis:Connective Tissue Diseases;g:MTHFR)(dui:D014570;dis:Urologic Diseases;g:MTHFR)(dui:D013927;dis:Thrombosis;g:MTHFR)(dui:D020521;dis:Stroke;g:MTHFR)(dui:D008223;dis:Lymphoma;g:MTHFR)(dui:D005831;dis:Genital Diseases, Female;g:MTHFR)(dui:D008107;dis:Liver Diseases;g:MTHFR)(dui:D009056;dis:Mouth Abnormalities;g:MTHFR)(dui:D025063;dis:Chromosome Disorders;g:MTHFR)(dui:D019954;dis:Neurobehavioral Manifestations;g:MTHFR)(dui:D008607;dis:Intellectual Disability;g:MTHFR)(dui:D000015;dis:Abnormalities, Multiple;g:MTHFR)(dui:D004314;dis:Down Syndrome;g:MTHFR)(dui:D019851;dis:Thrombophilia;g:MTHFR)(dui:D054198;dis:Precursor Cell Lymphoblastic Leukemia-Lymphoma;g:MTHFR)(dui:D007674;dis:Kidney Diseases;g:MTHFR)(dui:D013272;dis:Stomach Diseases;g:MTHFR)(dui:D020246;dis:Venous Thrombosis;g:MTHFR)(dui:D003920;dis:Diabetes Mellitus;g:MTHFR)(dui:D013274;dis:Stomach Neoplasms;g:MTHFR)(dui:D009139;dis:Musculoskeletal Abnormalities;g:MTHFR)(dui:D005832;dis:Genital Diseases, Male;g:MTHFR)(dui:D001327;dis:Autoimmune Diseases;g:MTHFR)(dui:D012559;dis:Schizophrenia;g:MTHFR)(dui:D007246;dis:Infertility;g:MTHFR)(dui:D012140;dis:Respiratory Tract Diseases;g:MTHFR)(dui:D008171;dis:Lung Diseases;g:MTHFR)(dui:D002545;dis:Brain Ischemia;g:MTHFR)(dui:D012002;dis:Rectal Diseases;g:MTHFR)(dui:D007592;dis:Joint Diseases;g:MTHFR)(dui:D001168;dis:Arthritis;g:MTHFR)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:MTHFR)(dui:D019636;dis:Neurodegenerative Diseases;g:MTHFR)(dui:D012216;dis:Rheumatic Diseases;g:MTHFR)(dui:D001172;dis:Arthritis, Rheumatoid;g:MTHFR)(dui:D005833;dis:Genital Neoplasms, Female;g:MTHFR)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MTHFR)(dui:D009008;dis:Abnormalities, Severe Teratoid;g:MTHFR)(dui:D000757;dis:Anencephaly;g:MTHFR)(dui:D003704;dis:Dementia;g:MTHFR)(dui:D019965;dis:Neurocognitive Disorders;g:MTHFR)(dui:D014591;dis:Uterine Diseases;g:MTHFR)(dui:D014594;dis:Uterine Neoplasms;g:MTHFR)(dui:D024801;dis:Tauopathies;g:MTHFR)(dui:D000544;dis:Alzheimer Disease;g:MTHFR)(dui:D007960;dis:Leukocyte Disorders;g:MTHFR)(dui:D007970;dis:Leukopenia;g:MTHFR)(dui:D013959;dis:Thyroid Diseases;g:MTHFR)(dui:D002277;dis:Carcinoma;g:MTHFR)(dui:D006967;dis:Hypersensitivity;g:MTHFR)(dui:D001157;dis:Arterial Occlusive Diseases;g:MTHFR)(dui:D008047;dis:Lip Diseases;g:MTHFR)(dui:D002971;dis:Cleft Lip;g:MTHFR)(dui:D019465;dis:Craniofacial Abnormalities;g:MTHFR)(dui:D019767;dis:Maxillofacial Abnormalities;g:MTHFR)(dui:D001161;dis:Arteriosclerosis;g:MTHFR)(dui:D018376;dis:Cardiovascular Abnormalities;g:MTHFR)(dui:D006330;dis:Heart Defects, Congenital;g:MTHFR)(dui:D013923;dis:Thromboembolism;g:MTHFR)(dui:D003110;dis:Colonic Neoplasms;g:MTHFR)(dui:D006980;dis:Hyperthyroidism;g:MTHFR)(dui:D048909;dis:Diabetes Complications;g:MTHFR)(dui:D001941;dis:Breast Diseases;g:MTHFR)(dui:D001943;dis:Breast Neoplasms;g:MTHFR)(dui:D001778;dis:Blood Coagulation Disorders;g:MTHFR)(dui:D007248;dis:Infertility, Male;g:MTHFR)(dui:D051437;dis:Renal Insufficiency;g:MTHFR)(dui:D025861;dis:Blood Coagulation Disorders, Inherited;g:MTHFR)(dui:D044882;dis:Glucose Metabolism Disorders;g:MTHFR)(dui:D000740;dis:Anemia;g:MTHFR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:MTHFR)(dui:D005759;dis:Gastroenteritis;g:MTHFR)(dui:D012678;dis:Sensation Disorders;g:MTHFR)(dui:D006086;dis:Graft vs Host Disease;g:MTHFR)(dui:D004427;dis:Ear Diseases;g:MTHFR)(dui:D006311;dis:Hearing Disorders;g:MTHFR)(dui:D034381;dis:Hearing Loss;g:MTHFR)(dui:D011248;dis:Pregnancy Complications;g:MTHFR)(dui:D000068105;dis:Bipolar and Related Disorders;g:MTHFR)(dui:D001714;dis:Bipolar Disorder;g:MTHFR)(dui:D011655;dis:Pulmonary Embolism;g:MTHFR)(dui:D004617;dis:Embolism;g:MTHFR)(dui:D003925;dis:Diabetic Angiopathies;g:MTHFR)(dui:D012142;dis:Respiratory Tract Neoplasms;g:MTHFR)(dui:D002577;dis:Uterine Cervical Diseases;g:MTHFR)(dui:D003639;dis:Hearing Loss, Sudden;g:MTHFR)(dui:D009385;dis:Neoplastic Processes;g:MTHFR)(dui:D002583;dis:Uterine Cervical Neoplasms;g:MTHFR)(dui:D013899;dis:Thoracic Neoplasms;g:MTHFR)(dui:D014571;dis:Urologic Neoplasms;g:MTHFR)(dui:D002278;dis:Carcinoma in Situ;g:MTHFR)(dui:D018290;dis:Cervical Intraepithelial Neoplasia;g:MTHFR)(dui:D005834;dis:Genital Neoplasms, Male;g:MTHFR)(dui:D011469;dis:Prostatic Diseases;g:MTHFR)(dui:D011471;dis:Prostatic Neoplasms;g:MTHFR)(dui:D008175;dis:Lung Neoplasms;g:MTHFR)(dui:D003324;dis:Coronary Artery Disease;g:MTHFR)(dui:D015448;dis:Leukemia, B-Cell;g:MTHFR)(dui:D015451;dis:Leukemia, Lymphocytic, Chronic, B-Cell;g:MTHFR)(dui:D001791;dis:Blood Platelet Disorders;g:MTHFR)(dui:D065886;dis:Neurodevelopmental Disorders;g:MTHFR)(dui:D001745;dis:Urinary Bladder Diseases;g:MTHFR)(dui:D001749;dis:Urinary Bladder Neoplasms;g:MTHFR)(dui:D056486;dis:Drug-Induced Liver Injury;g:MTHFR)(dui:D013921;dis:Thrombocytopenia;g:MTHFR)(dui:D002659;dis:Child Development Disorders, Pervasive;g:MTHFR)(dui:D002542;dis:Intracranial Embolism and Thrombosis;g:MTHFR)(dui:D020767;dis:Intracranial Thrombosis;g:MTHFR)(dui:D001321;dis:Autistic Disorder;g:MTHFR)(dui:D019964;dis:Mood Disorders;g:MTHFR)(dui:D003866;dis:Depressive Disorder;g:MTHFR)(dui:D000380;dis:Agranulocytosis;g:MTHFR)(dui:D009503;dis:Neutropenia;g:MTHFR)(dui:D023921;dis:Coronary Stenosis;g:MTHFR)(dui:D007247;dis:Infertility, Female;g:MTHFR)(dui:D012851;dis:Sinus Thrombosis, Intracranial;g:MTHFR)(dui:D001928;dis:Brain Diseases, Metabolic;g:MTHFR)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MTHFR)(dui:D018204;dis:Neoplasms, Connective and Soft Tissue;g:MTHFR)(dui:D008591;dis:Meningomyelocele;g:MTHFR)(dui:D008224;dis:Lymphoma, Follicular;g:MTHFR)(dui:D009372;dis:Neoplasms, Connective Tissue;g:MTHFR)(dui:D020258;dis:Neurotoxicity Syndromes;g:MTHFR)(dui:D052016;dis:Mucositis;g:MTHFR)(dui:D023903;dis:Coronary Restenosis;g:MTHFR)(dui:D009362;dis:Neoplasm Metastasis;g:MTHFR)(dui:D020879;dis:Neuromuscular Manifestations;g:MTHFR)(dui:D056784;dis:Leukoencephalopathies;g:MTHFR)(dui:D011618;dis:Psychotic Disorders;g:MTHFR)(dui:D009468;dis:Neuromuscular Diseases;g:MTHFR)(dui:D009135;dis:Muscular Diseases;g:MTHFR)(dui:D010523;dis:Peripheral Nervous System Diseases;g:MTHFR)(dui:D005530;dis:Foot Deformities;g:MTHFR)(dui:D005532;dis:Foot Deformities, Congenital;g:MTHFR)(dui:D006712;dis:Homocystinuria;g:MTHFR)(dui:D009128;dis:Muscle Spasticity;g:MTHFR)(dui:D017880;dis:Limb Deformities, Congenital;g:MTHFR)(dui:D000787;dis:Angina Pectoris;g:MTHFR)(dui:D003025;dis:Clubfoot;g:MTHFR)(dui:D009122;dis:Muscle Hypertonia;g:MTHFR)(dui:D038061;dis:Lower Extremity Deformities, Congenital;g:MTHFR)(dui:D017566;dis:Microvascular Angina;g:MTHFR)(dui:D001145;dis:Arrhythmias, Cardiac;g:MTHFR)(dui:D020260;dis:Heavy Metal Poisoning, Nervous System;g:MTHFR)(dui:D001281;dis:Atrial Fibrillation;g:MTHFR)(dui:D020261;dis:Arsenic Poisoning;g:MTHFR)(dui:D016889;dis:Endometrial Neoplasms;g:MTHFR)(dui:D013118;dis:Spinal Cord Diseases;g:MTHFR)(dui:D004342;dis:Drug Hypersensitivity;g:MTHFR)(dui:D007571;dis:Jaw Diseases;g:MTHFR)(dui:D007569;dis:Jaw Abnormalities;g:MTHFR)(dui:D002972;dis:Cleft Palate;g:MTHFR)(dui:D013971;dis:Thyrotoxicosis;g:MTHFR)(dui:D003872;dis:Dermatitis;g:MTHFR)(dui:D003875;dis:Drug Eruptions;g:MTHFR)(dui:D006201;dis:Hair Diseases;g:MTHFR)(dui:D007039;dis:Hypotrichosis;g:MTHFR)(dui:D046152;dis:Gastrointestinal Stromal Tumors;g:MTHFR)(dui:D000505;dis:Alopecia;g:MTHFR)(dui:D058186;dis:Acute Kidney Injury;g:MTHFR)(dui:D006973;dis:Hypertension;g:MTHFR)(dui:D008113;dis:Liver Neoplasms;g:MTHFR)	Tetrahydrofolic acid:Menadione:Methionine:Riboflavin:Benazepril:Methotrexate:Cyanocobalamin:Folic acid:Fluorouracil	GO:0031060:GO:0070829:GO:0043200:GO:0046655:GO:0045202:GO:0004489:GO:0044877:GO:0072341:GO:0001666:GO:0001843:GO:0005829:GO:0035999:GO:0009086:GO:0071949:GO:0033274:GO:0046500:GO:0006730:GO:0006555:GO:0050661:GO:0050660:GO:0042493:GO:0051593:GO:0070555:GO:0055114:GO:0050667	607093		0.8															
chr1:11802721	SNV	A	1	A/G	PASS	2.6797852971525093e-65	645.719		400	A=229,G=171	A=0.5725,G=0.4275	42.75	57.25	heterozygous	23	0.129	1.0		MTHFR	NM_005957.5	MTHFR:intronic:NM_005957.5	unknown			p.?	c.236+160T>C				G						rs17367504		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MTHFR)(dui:NBS2;dis:Core Conditions;g:MTHFR)(dui:NBS11;dis:Amino Acid Disorder;g:MTHFR)(dui:NBS57;dis:Homocystinuria;g:MTHFR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MTHFR)(dui:D002318;dis:Cardiovascular Diseases;g:MTHFR)(dui:D009422;dis:Nervous System Diseases;g:MTHFR)(dui:D014652;dis:Vascular Diseases;g:MTHFR)(dui:D009369;dis:Neoplasms;g:MTHFR)(dui:D000013;dis:Congenital Abnormalities;g:MTHFR)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MTHFR)(dui:D030342;dis:Genetic Diseases, Inborn;g:MTHFR)(dui:D009371;dis:Neoplasms by Site;g:MTHFR)(dui:D002493;dis:Central Nervous System Diseases;g:MTHFR)(dui:D007154;dis:Immune System Diseases;g:MTHFR)(dui:D004066;dis:Digestive System Diseases;g:MTHFR)(dui:D001927;dis:Brain Diseases;g:MTHFR)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MTHFR)(dui:D009370;dis:Neoplasms by Histologic Type;g:MTHFR)(dui:D005767;dis:Gastrointestinal Diseases;g:MTHFR)(dui:D008659;dis:Metabolic Diseases;g:MTHFR)(dui:D006331;dis:Heart Diseases;g:MTHFR)(dui:D004067;dis:Digestive System Neoplasms;g:MTHFR)(dui:D001523;dis:Mental Disorders;g:MTHFR)(dui:D006402;dis:Hematologic Diseases;g:MTHFR)(dui:D009748;dis:Nutrition Disorders;g:MTHFR)(dui:D044342;dis:Malnutrition;g:MTHFR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:MTHFR)(dui:D007160;dis:Immunoproliferative Disorders;g:MTHFR)(dui:D008232;dis:Lymphoproliferative Disorders;g:MTHFR)(dui:D002561;dis:Cerebrovascular Disorders;g:MTHFR)(dui:D008206;dis:Lymphatic Diseases;g:MTHFR)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MTHFR)(dui:D008661;dis:Metabolism, Inborn Errors;g:MTHFR)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MTHFR)(dui:D020138;dis:Hyperhomocysteinemia;g:MTHFR)(dui:D017202;dis:Myocardial Ischemia;g:MTHFR)(dui:D003677;dis:Deficiency Diseases;g:MTHFR)(dui:D001361;dis:Avitaminosis;g:MTHFR)(dui:D014804;dis:Vitamin B Deficiency;g:MTHFR)(dui:D009421;dis:Nervous System Malformations;g:MTHFR)(dui:D009436;dis:Neural Tube Defects;g:MTHFR)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:MTHFR)(dui:D009140;dis:Musculoskeletal Diseases;g:MTHFR)(dui:D016769;dis:Embolism and Thrombosis;g:MTHFR)(dui:D009461;dis:Neurologic Manifestations;g:MTHFR)(dui:D003327;dis:Coronary Disease;g:MTHFR)(dui:D052776;dis:Female Urogenital Diseases;g:MTHFR)(dui:D052801;dis:Male Urogenital Diseases;g:MTHFR)(dui:D008286;dis:Malabsorption Syndromes;g:MTHFR)(dui:D007938;dis:Leukemia;g:MTHFR)(dui:D009057;dis:Stomatognathic Diseases;g:MTHFR)(dui:D007945;dis:Leukemia, Lymphoid;g:MTHFR)(dui:D007410;dis:Intestinal Diseases;g:MTHFR)(dui:D012871;dis:Skin Diseases;g:MTHFR)(dui:D009059;dis:Mouth Diseases;g:MTHFR)(dui:D004700;dis:Endocrine System Diseases;g:MTHFR)(dui:D003108;dis:Colonic Diseases;g:MTHFR)(dui:D007414;dis:Intestinal Neoplasms;g:MTHFR)(dui:D015179;dis:Colorectal Neoplasms;g:MTHFR)(dui:D014565;dis:Urogenital Neoplasms;g:MTHFR)(dui:D018640;dis:Stomatognathic System Abnormalities;g:MTHFR)(dui:D019967;dis:Schizophrenia Spectrum and Other Psychotic Disorders;g:MTHFR)(dui:D003240;dis:Connective Tissue Diseases;g:MTHFR)(dui:D014570;dis:Urologic Diseases;g:MTHFR)(dui:D013927;dis:Thrombosis;g:MTHFR)(dui:D020521;dis:Stroke;g:MTHFR)(dui:D008223;dis:Lymphoma;g:MTHFR)(dui:D005831;dis:Genital Diseases, Female;g:MTHFR)(dui:D008107;dis:Liver Diseases;g:MTHFR)(dui:D009056;dis:Mouth Abnormalities;g:MTHFR)(dui:D025063;dis:Chromosome Disorders;g:MTHFR)(dui:D019954;dis:Neurobehavioral Manifestations;g:MTHFR)(dui:D008607;dis:Intellectual Disability;g:MTHFR)(dui:D000015;dis:Abnormalities, Multiple;g:MTHFR)(dui:D004314;dis:Down Syndrome;g:MTHFR)(dui:D019851;dis:Thrombophilia;g:MTHFR)(dui:D054198;dis:Precursor Cell Lymphoblastic Leukemia-Lymphoma;g:MTHFR)(dui:D007674;dis:Kidney Diseases;g:MTHFR)(dui:D013272;dis:Stomach Diseases;g:MTHFR)(dui:D020246;dis:Venous Thrombosis;g:MTHFR)(dui:D003920;dis:Diabetes Mellitus;g:MTHFR)(dui:D013274;dis:Stomach Neoplasms;g:MTHFR)(dui:D009139;dis:Musculoskeletal Abnormalities;g:MTHFR)(dui:D005832;dis:Genital Diseases, Male;g:MTHFR)(dui:D001327;dis:Autoimmune Diseases;g:MTHFR)(dui:D012559;dis:Schizophrenia;g:MTHFR)(dui:D007246;dis:Infertility;g:MTHFR)(dui:D012140;dis:Respiratory Tract Diseases;g:MTHFR)(dui:D008171;dis:Lung Diseases;g:MTHFR)(dui:D002545;dis:Brain Ischemia;g:MTHFR)(dui:D012002;dis:Rectal Diseases;g:MTHFR)(dui:D007592;dis:Joint Diseases;g:MTHFR)(dui:D001168;dis:Arthritis;g:MTHFR)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:MTHFR)(dui:D019636;dis:Neurodegenerative Diseases;g:MTHFR)(dui:D012216;dis:Rheumatic Diseases;g:MTHFR)(dui:D001172;dis:Arthritis, Rheumatoid;g:MTHFR)(dui:D005833;dis:Genital Neoplasms, Female;g:MTHFR)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MTHFR)(dui:D009008;dis:Abnormalities, Severe Teratoid;g:MTHFR)(dui:D000757;dis:Anencephaly;g:MTHFR)(dui:D003704;dis:Dementia;g:MTHFR)(dui:D019965;dis:Neurocognitive Disorders;g:MTHFR)(dui:D014591;dis:Uterine Diseases;g:MTHFR)(dui:D014594;dis:Uterine Neoplasms;g:MTHFR)(dui:D024801;dis:Tauopathies;g:MTHFR)(dui:D000544;dis:Alzheimer Disease;g:MTHFR)(dui:D007960;dis:Leukocyte Disorders;g:MTHFR)(dui:D007970;dis:Leukopenia;g:MTHFR)(dui:D013959;dis:Thyroid Diseases;g:MTHFR)(dui:D002277;dis:Carcinoma;g:MTHFR)(dui:D006967;dis:Hypersensitivity;g:MTHFR)(dui:D001157;dis:Arterial Occlusive Diseases;g:MTHFR)(dui:D008047;dis:Lip Diseases;g:MTHFR)(dui:D002971;dis:Cleft Lip;g:MTHFR)(dui:D019465;dis:Craniofacial Abnormalities;g:MTHFR)(dui:D019767;dis:Maxillofacial Abnormalities;g:MTHFR)(dui:D001161;dis:Arteriosclerosis;g:MTHFR)(dui:D018376;dis:Cardiovascular Abnormalities;g:MTHFR)(dui:D006330;dis:Heart Defects, Congenital;g:MTHFR)(dui:D013923;dis:Thromboembolism;g:MTHFR)(dui:D003110;dis:Colonic Neoplasms;g:MTHFR)(dui:D006980;dis:Hyperthyroidism;g:MTHFR)(dui:D048909;dis:Diabetes Complications;g:MTHFR)(dui:D001941;dis:Breast Diseases;g:MTHFR)(dui:D001943;dis:Breast Neoplasms;g:MTHFR)(dui:D001778;dis:Blood Coagulation Disorders;g:MTHFR)(dui:D007248;dis:Infertility, Male;g:MTHFR)(dui:D051437;dis:Renal Insufficiency;g:MTHFR)(dui:D025861;dis:Blood Coagulation Disorders, Inherited;g:MTHFR)(dui:D044882;dis:Glucose Metabolism Disorders;g:MTHFR)(dui:D000740;dis:Anemia;g:MTHFR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:MTHFR)(dui:D005759;dis:Gastroenteritis;g:MTHFR)(dui:D012678;dis:Sensation Disorders;g:MTHFR)(dui:D006086;dis:Graft vs Host Disease;g:MTHFR)(dui:D004427;dis:Ear Diseases;g:MTHFR)(dui:D006311;dis:Hearing Disorders;g:MTHFR)(dui:D034381;dis:Hearing Loss;g:MTHFR)(dui:D011248;dis:Pregnancy Complications;g:MTHFR)(dui:D000068105;dis:Bipolar and Related Disorders;g:MTHFR)(dui:D001714;dis:Bipolar Disorder;g:MTHFR)(dui:D011655;dis:Pulmonary Embolism;g:MTHFR)(dui:D004617;dis:Embolism;g:MTHFR)(dui:D003925;dis:Diabetic Angiopathies;g:MTHFR)(dui:D012142;dis:Respiratory Tract Neoplasms;g:MTHFR)(dui:D002577;dis:Uterine Cervical Diseases;g:MTHFR)(dui:D003639;dis:Hearing Loss, Sudden;g:MTHFR)(dui:D009385;dis:Neoplastic Processes;g:MTHFR)(dui:D002583;dis:Uterine Cervical Neoplasms;g:MTHFR)(dui:D013899;dis:Thoracic Neoplasms;g:MTHFR)(dui:D014571;dis:Urologic Neoplasms;g:MTHFR)(dui:D002278;dis:Carcinoma in Situ;g:MTHFR)(dui:D018290;dis:Cervical Intraepithelial Neoplasia;g:MTHFR)(dui:D005834;dis:Genital Neoplasms, Male;g:MTHFR)(dui:D011469;dis:Prostatic Diseases;g:MTHFR)(dui:D011471;dis:Prostatic Neoplasms;g:MTHFR)(dui:D008175;dis:Lung Neoplasms;g:MTHFR)(dui:D003324;dis:Coronary Artery Disease;g:MTHFR)(dui:D015448;dis:Leukemia, B-Cell;g:MTHFR)(dui:D015451;dis:Leukemia, Lymphocytic, Chronic, B-Cell;g:MTHFR)(dui:D001791;dis:Blood Platelet Disorders;g:MTHFR)(dui:D065886;dis:Neurodevelopmental Disorders;g:MTHFR)(dui:D001745;dis:Urinary Bladder Diseases;g:MTHFR)(dui:D001749;dis:Urinary Bladder Neoplasms;g:MTHFR)(dui:D056486;dis:Drug-Induced Liver Injury;g:MTHFR)(dui:D013921;dis:Thrombocytopenia;g:MTHFR)(dui:D002659;dis:Child Development Disorders, Pervasive;g:MTHFR)(dui:D002542;dis:Intracranial Embolism and Thrombosis;g:MTHFR)(dui:D020767;dis:Intracranial Thrombosis;g:MTHFR)(dui:D001321;dis:Autistic Disorder;g:MTHFR)(dui:D019964;dis:Mood Disorders;g:MTHFR)(dui:D003866;dis:Depressive Disorder;g:MTHFR)(dui:D000380;dis:Agranulocytosis;g:MTHFR)(dui:D009503;dis:Neutropenia;g:MTHFR)(dui:D023921;dis:Coronary Stenosis;g:MTHFR)(dui:D007247;dis:Infertility, Female;g:MTHFR)(dui:D012851;dis:Sinus Thrombosis, Intracranial;g:MTHFR)(dui:D001928;dis:Brain Diseases, Metabolic;g:MTHFR)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MTHFR)(dui:D018204;dis:Neoplasms, Connective and Soft Tissue;g:MTHFR)(dui:D008591;dis:Meningomyelocele;g:MTHFR)(dui:D008224;dis:Lymphoma, Follicular;g:MTHFR)(dui:D009372;dis:Neoplasms, Connective Tissue;g:MTHFR)(dui:D020258;dis:Neurotoxicity Syndromes;g:MTHFR)(dui:D052016;dis:Mucositis;g:MTHFR)(dui:D023903;dis:Coronary Restenosis;g:MTHFR)(dui:D009362;dis:Neoplasm Metastasis;g:MTHFR)(dui:D020879;dis:Neuromuscular Manifestations;g:MTHFR)(dui:D056784;dis:Leukoencephalopathies;g:MTHFR)(dui:D011618;dis:Psychotic Disorders;g:MTHFR)(dui:D009468;dis:Neuromuscular Diseases;g:MTHFR)(dui:D009135;dis:Muscular Diseases;g:MTHFR)(dui:D010523;dis:Peripheral Nervous System Diseases;g:MTHFR)(dui:D005530;dis:Foot Deformities;g:MTHFR)(dui:D005532;dis:Foot Deformities, Congenital;g:MTHFR)(dui:D006712;dis:Homocystinuria;g:MTHFR)(dui:D009128;dis:Muscle Spasticity;g:MTHFR)(dui:D017880;dis:Limb Deformities, Congenital;g:MTHFR)(dui:D000787;dis:Angina Pectoris;g:MTHFR)(dui:D003025;dis:Clubfoot;g:MTHFR)(dui:D009122;dis:Muscle Hypertonia;g:MTHFR)(dui:D038061;dis:Lower Extremity Deformities, Congenital;g:MTHFR)(dui:D017566;dis:Microvascular Angina;g:MTHFR)(dui:D001145;dis:Arrhythmias, Cardiac;g:MTHFR)(dui:D020260;dis:Heavy Metal Poisoning, Nervous System;g:MTHFR)(dui:D001281;dis:Atrial Fibrillation;g:MTHFR)(dui:D020261;dis:Arsenic Poisoning;g:MTHFR)(dui:D016889;dis:Endometrial Neoplasms;g:MTHFR)(dui:D013118;dis:Spinal Cord Diseases;g:MTHFR)(dui:D004342;dis:Drug Hypersensitivity;g:MTHFR)(dui:D007571;dis:Jaw Diseases;g:MTHFR)(dui:D007569;dis:Jaw Abnormalities;g:MTHFR)(dui:D002972;dis:Cleft Palate;g:MTHFR)(dui:D013971;dis:Thyrotoxicosis;g:MTHFR)(dui:D003872;dis:Dermatitis;g:MTHFR)(dui:D003875;dis:Drug Eruptions;g:MTHFR)(dui:D006201;dis:Hair Diseases;g:MTHFR)(dui:D007039;dis:Hypotrichosis;g:MTHFR)(dui:D046152;dis:Gastrointestinal Stromal Tumors;g:MTHFR)(dui:D000505;dis:Alopecia;g:MTHFR)(dui:D058186;dis:Acute Kidney Injury;g:MTHFR)(dui:D006973;dis:Hypertension;g:MTHFR)(dui:D008113;dis:Liver Neoplasms;g:MTHFR)	Tetrahydrofolic acid:Menadione:Methionine:Riboflavin:Benazepril:Methotrexate:Cyanocobalamin:Folic acid:Fluorouracil	GO:0031060:GO:0070829:GO:0043200:GO:0046655:GO:0045202:GO:0004489:GO:0044877:GO:0072341:GO:0001666:GO:0001843:GO:0005829:GO:0035999:GO:0009086:GO:0071949:GO:0033274:GO:0046500:GO:0006730:GO:0006555:GO:0050661:GO:0050660:GO:0042493:GO:0051593:GO:0070555:GO:0055114:GO:0050667	607093		-1.03															
chr1:11803000	SNV	G	1	G/A	PASS	1.2019876348698718e-84	839.201		400	G=207,A=193	G=0.5175,A=0.4825	48.25	51.75	heterozygous	23	0.102	4.0		MTHFR	NM_005957.5	MTHFR:exonic:NM_005957.5	synonymous	CCT	2	p.Pro39=	c.117C>T				A	GMAF=0.0897:AMAF=0.0783:EMAF=0.0956	0.01		Benign	5019072	rs2066470		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MTHFR)(dui:NBS2;dis:Core Conditions;g:MTHFR)(dui:NBS11;dis:Amino Acid Disorder;g:MTHFR)(dui:NBS57;dis:Homocystinuria;g:MTHFR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MTHFR)(dui:D002318;dis:Cardiovascular Diseases;g:MTHFR)(dui:D009422;dis:Nervous System Diseases;g:MTHFR)(dui:D014652;dis:Vascular Diseases;g:MTHFR)(dui:D009369;dis:Neoplasms;g:MTHFR)(dui:D000013;dis:Congenital Abnormalities;g:MTHFR)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MTHFR)(dui:D030342;dis:Genetic Diseases, Inborn;g:MTHFR)(dui:D009371;dis:Neoplasms by Site;g:MTHFR)(dui:D002493;dis:Central Nervous System Diseases;g:MTHFR)(dui:D007154;dis:Immune System Diseases;g:MTHFR)(dui:D004066;dis:Digestive System Diseases;g:MTHFR)(dui:D001927;dis:Brain Diseases;g:MTHFR)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MTHFR)(dui:D009370;dis:Neoplasms by Histologic Type;g:MTHFR)(dui:D005767;dis:Gastrointestinal Diseases;g:MTHFR)(dui:D008659;dis:Metabolic Diseases;g:MTHFR)(dui:D006331;dis:Heart Diseases;g:MTHFR)(dui:D004067;dis:Digestive System Neoplasms;g:MTHFR)(dui:D001523;dis:Mental Disorders;g:MTHFR)(dui:D006402;dis:Hematologic Diseases;g:MTHFR)(dui:D009748;dis:Nutrition Disorders;g:MTHFR)(dui:D044342;dis:Malnutrition;g:MTHFR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:MTHFR)(dui:D007160;dis:Immunoproliferative Disorders;g:MTHFR)(dui:D008232;dis:Lymphoproliferative Disorders;g:MTHFR)(dui:D002561;dis:Cerebrovascular Disorders;g:MTHFR)(dui:D008206;dis:Lymphatic Diseases;g:MTHFR)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MTHFR)(dui:D008661;dis:Metabolism, Inborn Errors;g:MTHFR)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MTHFR)(dui:D020138;dis:Hyperhomocysteinemia;g:MTHFR)(dui:D017202;dis:Myocardial Ischemia;g:MTHFR)(dui:D003677;dis:Deficiency Diseases;g:MTHFR)(dui:D001361;dis:Avitaminosis;g:MTHFR)(dui:D014804;dis:Vitamin B Deficiency;g:MTHFR)(dui:D009421;dis:Nervous System Malformations;g:MTHFR)(dui:D009436;dis:Neural Tube Defects;g:MTHFR)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:MTHFR)(dui:D009140;dis:Musculoskeletal Diseases;g:MTHFR)(dui:D016769;dis:Embolism and Thrombosis;g:MTHFR)(dui:D009461;dis:Neurologic Manifestations;g:MTHFR)(dui:D003327;dis:Coronary Disease;g:MTHFR)(dui:D052776;dis:Female Urogenital Diseases;g:MTHFR)(dui:D052801;dis:Male Urogenital Diseases;g:MTHFR)(dui:D008286;dis:Malabsorption Syndromes;g:MTHFR)(dui:D007938;dis:Leukemia;g:MTHFR)(dui:D009057;dis:Stomatognathic Diseases;g:MTHFR)(dui:D007945;dis:Leukemia, Lymphoid;g:MTHFR)(dui:D007410;dis:Intestinal Diseases;g:MTHFR)(dui:D012871;dis:Skin Diseases;g:MTHFR)(dui:D009059;dis:Mouth Diseases;g:MTHFR)(dui:D004700;dis:Endocrine System Diseases;g:MTHFR)(dui:D003108;dis:Colonic Diseases;g:MTHFR)(dui:D007414;dis:Intestinal Neoplasms;g:MTHFR)(dui:D015179;dis:Colorectal Neoplasms;g:MTHFR)(dui:D014565;dis:Urogenital Neoplasms;g:MTHFR)(dui:D018640;dis:Stomatognathic System Abnormalities;g:MTHFR)(dui:D019967;dis:Schizophrenia Spectrum and Other Psychotic Disorders;g:MTHFR)(dui:D003240;dis:Connective Tissue Diseases;g:MTHFR)(dui:D014570;dis:Urologic Diseases;g:MTHFR)(dui:D013927;dis:Thrombosis;g:MTHFR)(dui:D020521;dis:Stroke;g:MTHFR)(dui:D008223;dis:Lymphoma;g:MTHFR)(dui:D005831;dis:Genital Diseases, Female;g:MTHFR)(dui:D008107;dis:Liver Diseases;g:MTHFR)(dui:D009056;dis:Mouth Abnormalities;g:MTHFR)(dui:D025063;dis:Chromosome Disorders;g:MTHFR)(dui:D019954;dis:Neurobehavioral Manifestations;g:MTHFR)(dui:D008607;dis:Intellectual Disability;g:MTHFR)(dui:D000015;dis:Abnormalities, Multiple;g:MTHFR)(dui:D004314;dis:Down Syndrome;g:MTHFR)(dui:D019851;dis:Thrombophilia;g:MTHFR)(dui:D054198;dis:Precursor Cell Lymphoblastic Leukemia-Lymphoma;g:MTHFR)(dui:D007674;dis:Kidney Diseases;g:MTHFR)(dui:D013272;dis:Stomach Diseases;g:MTHFR)(dui:D020246;dis:Venous Thrombosis;g:MTHFR)(dui:D003920;dis:Diabetes Mellitus;g:MTHFR)(dui:D013274;dis:Stomach Neoplasms;g:MTHFR)(dui:D009139;dis:Musculoskeletal Abnormalities;g:MTHFR)(dui:D005832;dis:Genital Diseases, Male;g:MTHFR)(dui:D001327;dis:Autoimmune Diseases;g:MTHFR)(dui:D012559;dis:Schizophrenia;g:MTHFR)(dui:D007246;dis:Infertility;g:MTHFR)(dui:D012140;dis:Respiratory Tract Diseases;g:MTHFR)(dui:D008171;dis:Lung Diseases;g:MTHFR)(dui:D002545;dis:Brain Ischemia;g:MTHFR)(dui:D012002;dis:Rectal Diseases;g:MTHFR)(dui:D007592;dis:Joint Diseases;g:MTHFR)(dui:D001168;dis:Arthritis;g:MTHFR)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:MTHFR)(dui:D019636;dis:Neurodegenerative Diseases;g:MTHFR)(dui:D012216;dis:Rheumatic Diseases;g:MTHFR)(dui:D001172;dis:Arthritis, Rheumatoid;g:MTHFR)(dui:D005833;dis:Genital Neoplasms, Female;g:MTHFR)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MTHFR)(dui:D009008;dis:Abnormalities, Severe Teratoid;g:MTHFR)(dui:D000757;dis:Anencephaly;g:MTHFR)(dui:D003704;dis:Dementia;g:MTHFR)(dui:D019965;dis:Neurocognitive Disorders;g:MTHFR)(dui:D014591;dis:Uterine Diseases;g:MTHFR)(dui:D014594;dis:Uterine Neoplasms;g:MTHFR)(dui:D024801;dis:Tauopathies;g:MTHFR)(dui:D000544;dis:Alzheimer Disease;g:MTHFR)(dui:D007960;dis:Leukocyte Disorders;g:MTHFR)(dui:D007970;dis:Leukopenia;g:MTHFR)(dui:D013959;dis:Thyroid Diseases;g:MTHFR)(dui:D002277;dis:Carcinoma;g:MTHFR)(dui:D006967;dis:Hypersensitivity;g:MTHFR)(dui:D001157;dis:Arterial Occlusive Diseases;g:MTHFR)(dui:D008047;dis:Lip Diseases;g:MTHFR)(dui:D002971;dis:Cleft Lip;g:MTHFR)(dui:D019465;dis:Craniofacial Abnormalities;g:MTHFR)(dui:D019767;dis:Maxillofacial Abnormalities;g:MTHFR)(dui:D001161;dis:Arteriosclerosis;g:MTHFR)(dui:D018376;dis:Cardiovascular Abnormalities;g:MTHFR)(dui:D006330;dis:Heart Defects, Congenital;g:MTHFR)(dui:D013923;dis:Thromboembolism;g:MTHFR)(dui:D003110;dis:Colonic Neoplasms;g:MTHFR)(dui:D006980;dis:Hyperthyroidism;g:MTHFR)(dui:D048909;dis:Diabetes Complications;g:MTHFR)(dui:D001941;dis:Breast Diseases;g:MTHFR)(dui:D001943;dis:Breast Neoplasms;g:MTHFR)(dui:D001778;dis:Blood Coagulation Disorders;g:MTHFR)(dui:D007248;dis:Infertility, Male;g:MTHFR)(dui:D051437;dis:Renal Insufficiency;g:MTHFR)(dui:D025861;dis:Blood Coagulation Disorders, Inherited;g:MTHFR)(dui:D044882;dis:Glucose Metabolism Disorders;g:MTHFR)(dui:D000740;dis:Anemia;g:MTHFR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:MTHFR)(dui:D005759;dis:Gastroenteritis;g:MTHFR)(dui:D012678;dis:Sensation Disorders;g:MTHFR)(dui:D006086;dis:Graft vs Host Disease;g:MTHFR)(dui:D004427;dis:Ear Diseases;g:MTHFR)(dui:D006311;dis:Hearing Disorders;g:MTHFR)(dui:D034381;dis:Hearing Loss;g:MTHFR)(dui:D011248;dis:Pregnancy Complications;g:MTHFR)(dui:D000068105;dis:Bipolar and Related Disorders;g:MTHFR)(dui:D001714;dis:Bipolar Disorder;g:MTHFR)(dui:D011655;dis:Pulmonary Embolism;g:MTHFR)(dui:D004617;dis:Embolism;g:MTHFR)(dui:D003925;dis:Diabetic Angiopathies;g:MTHFR)(dui:D012142;dis:Respiratory Tract Neoplasms;g:MTHFR)(dui:D002577;dis:Uterine Cervical Diseases;g:MTHFR)(dui:D003639;dis:Hearing Loss, Sudden;g:MTHFR)(dui:D009385;dis:Neoplastic Processes;g:MTHFR)(dui:D002583;dis:Uterine Cervical Neoplasms;g:MTHFR)(dui:D013899;dis:Thoracic Neoplasms;g:MTHFR)(dui:D014571;dis:Urologic Neoplasms;g:MTHFR)(dui:D002278;dis:Carcinoma in Situ;g:MTHFR)(dui:D018290;dis:Cervical Intraepithelial Neoplasia;g:MTHFR)(dui:D005834;dis:Genital Neoplasms, Male;g:MTHFR)(dui:D011469;dis:Prostatic Diseases;g:MTHFR)(dui:D011471;dis:Prostatic Neoplasms;g:MTHFR)(dui:D008175;dis:Lung Neoplasms;g:MTHFR)(dui:D003324;dis:Coronary Artery Disease;g:MTHFR)(dui:D015448;dis:Leukemia, B-Cell;g:MTHFR)(dui:D015451;dis:Leukemia, Lymphocytic, Chronic, B-Cell;g:MTHFR)(dui:D001791;dis:Blood Platelet Disorders;g:MTHFR)(dui:D065886;dis:Neurodevelopmental Disorders;g:MTHFR)(dui:D001745;dis:Urinary Bladder Diseases;g:MTHFR)(dui:D001749;dis:Urinary Bladder Neoplasms;g:MTHFR)(dui:D056486;dis:Drug-Induced Liver Injury;g:MTHFR)(dui:D013921;dis:Thrombocytopenia;g:MTHFR)(dui:D002659;dis:Child Development Disorders, Pervasive;g:MTHFR)(dui:D002542;dis:Intracranial Embolism and Thrombosis;g:MTHFR)(dui:D020767;dis:Intracranial Thrombosis;g:MTHFR)(dui:D001321;dis:Autistic Disorder;g:MTHFR)(dui:D019964;dis:Mood Disorders;g:MTHFR)(dui:D003866;dis:Depressive Disorder;g:MTHFR)(dui:D000380;dis:Agranulocytosis;g:MTHFR)(dui:D009503;dis:Neutropenia;g:MTHFR)(dui:D023921;dis:Coronary Stenosis;g:MTHFR)(dui:D007247;dis:Infertility, Female;g:MTHFR)(dui:D012851;dis:Sinus Thrombosis, Intracranial;g:MTHFR)(dui:D001928;dis:Brain Diseases, Metabolic;g:MTHFR)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MTHFR)(dui:D018204;dis:Neoplasms, Connective and Soft Tissue;g:MTHFR)(dui:D008591;dis:Meningomyelocele;g:MTHFR)(dui:D008224;dis:Lymphoma, Follicular;g:MTHFR)(dui:D009372;dis:Neoplasms, Connective Tissue;g:MTHFR)(dui:D020258;dis:Neurotoxicity Syndromes;g:MTHFR)(dui:D052016;dis:Mucositis;g:MTHFR)(dui:D023903;dis:Coronary Restenosis;g:MTHFR)(dui:D009362;dis:Neoplasm Metastasis;g:MTHFR)(dui:D020879;dis:Neuromuscular Manifestations;g:MTHFR)(dui:D056784;dis:Leukoencephalopathies;g:MTHFR)(dui:D011618;dis:Psychotic Disorders;g:MTHFR)(dui:D009468;dis:Neuromuscular Diseases;g:MTHFR)(dui:D009135;dis:Muscular Diseases;g:MTHFR)(dui:D010523;dis:Peripheral Nervous System Diseases;g:MTHFR)(dui:D005530;dis:Foot Deformities;g:MTHFR)(dui:D005532;dis:Foot Deformities, Congenital;g:MTHFR)(dui:D006712;dis:Homocystinuria;g:MTHFR)(dui:D009128;dis:Muscle Spasticity;g:MTHFR)(dui:D017880;dis:Limb Deformities, Congenital;g:MTHFR)(dui:D000787;dis:Angina Pectoris;g:MTHFR)(dui:D003025;dis:Clubfoot;g:MTHFR)(dui:D009122;dis:Muscle Hypertonia;g:MTHFR)(dui:D038061;dis:Lower Extremity Deformities, Congenital;g:MTHFR)(dui:D017566;dis:Microvascular Angina;g:MTHFR)(dui:D001145;dis:Arrhythmias, Cardiac;g:MTHFR)(dui:D020260;dis:Heavy Metal Poisoning, Nervous System;g:MTHFR)(dui:D001281;dis:Atrial Fibrillation;g:MTHFR)(dui:D020261;dis:Arsenic Poisoning;g:MTHFR)(dui:D016889;dis:Endometrial Neoplasms;g:MTHFR)(dui:D013118;dis:Spinal Cord Diseases;g:MTHFR)(dui:D004342;dis:Drug Hypersensitivity;g:MTHFR)(dui:D007571;dis:Jaw Diseases;g:MTHFR)(dui:D007569;dis:Jaw Abnormalities;g:MTHFR)(dui:D002972;dis:Cleft Palate;g:MTHFR)(dui:D013971;dis:Thyrotoxicosis;g:MTHFR)(dui:D003872;dis:Dermatitis;g:MTHFR)(dui:D003875;dis:Drug Eruptions;g:MTHFR)(dui:D006201;dis:Hair Diseases;g:MTHFR)(dui:D007039;dis:Hypotrichosis;g:MTHFR)(dui:D046152;dis:Gastrointestinal Stromal Tumors;g:MTHFR)(dui:D000505;dis:Alopecia;g:MTHFR)(dui:D058186;dis:Acute Kidney Injury;g:MTHFR)(dui:D006973;dis:Hypertension;g:MTHFR)(dui:D008113;dis:Liver Neoplasms;g:MTHFR)	Tetrahydrofolic acid:Menadione:Methionine:Riboflavin:Benazepril:Methotrexate:Cyanocobalamin:Folic acid:Fluorouracil	GO:0031060:GO:0070829:GO:0043200:GO:0046655:GO:0045202:GO:0004489:GO:0044877:GO:0072341:GO:0001666:GO:0001843:GO:0005829:GO:0035999:GO:0009086:GO:0071949:GO:0033274:GO:0046500:GO:0006730:GO:0006555:GO:0050661:GO:0050660:GO:0042493:GO:0051593:GO:0070555:GO:0055114:GO:0050667	607093		-7.56															
chr1:23808231	SNV	T	1	C/C	PASS	0.0	4003.26		400	T=0,C=400	T=0.0,C=1.0	100.0	0.0	homozygous	56	0.113	1.0		HMGCL	NM_000191.3	HMGCL:exonic:NM_000191.3	synonymous	CTG	7	p.Leu218=	c.654A>G				C	GMAF=0.0737:AMAF=0.039:EMAF=0.0915			Benign		rs719400		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:HMGCL)(dui:NBS2;dis:Core Conditions;g:HMGCL)(dui:NBS9;dis:Organic Acid Condition;g:HMGCL)(dui:NBS46;dis:3-Hydroxy-3-methylglutaric aciduria;g:HMGCL)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:HMGCL)(dui:D008659;dis:Metabolic Diseases;g:HMGCL)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:HMGCL)(dui:D030342;dis:Genetic Diseases, Inborn;g:HMGCL)(dui:D008661;dis:Metabolism, Inborn Errors;g:HMGCL)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:HMGCL)	3-hydroxyglutaric acid	GO:0005198:GO:0006552:GO:0042594:GO:0007584:GO:0005782:GO:0046951:GO:0007005:GO:0000287:GO:0006637:GO:0031406:GO:0005777:GO:0006625:GO:0000062:GO:0005759:GO:0046872:GO:0001889:GO:0004419:GO:0005739:GO:0006629:GO:0005829:GO:0030145:GO:0032991:GO:0070542	613898	PF00682	1.23															
chr1:23817442	SNV	A	1	G/G	PASS	0.0	3718.5		399	A=7,G=392	A=0.0175,G=0.9825	98.25	1.75	homozygous	56	0.112	1.0		HMGCL	NM_000191.3	HMGCL:intronic:NM_000191.3	unknown			p.?	c.252+34T>C				G	GMAF=0.0735:AMAF=0.039:EMAF=0.0912			Benign		rs2076344		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:HMGCL)(dui:NBS2;dis:Core Conditions;g:HMGCL)(dui:NBS9;dis:Organic Acid Condition;g:HMGCL)(dui:NBS46;dis:3-Hydroxy-3-methylglutaric aciduria;g:HMGCL)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:HMGCL)(dui:D008659;dis:Metabolic Diseases;g:HMGCL)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:HMGCL)(dui:D030342;dis:Genetic Diseases, Inborn;g:HMGCL)(dui:D008661;dis:Metabolism, Inborn Errors;g:HMGCL)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:HMGCL)	3-hydroxyglutaric acid	GO:0005198:GO:0006552:GO:0042594:GO:0007584:GO:0005782:GO:0046951:GO:0007005:GO:0000287:GO:0006637:GO:0031406:GO:0005777:GO:0006625:GO:0000062:GO:0005759:GO:0046872:GO:0001889:GO:0004419:GO:0005739:GO:0006629:GO:0005829:GO:0030145:GO:0032991:GO:0070542	613898	PF00682	-1.17															
chr1:45508256	SNV	G	1	G/A	PASS	3.098846042012105e-57	565.088		400	G=239,A=161	G=0.5975,A=0.4025	40.25	59.75	heterozygous	47	0.475	1.0		MMACHC	NM_015506.3	MMACHC:exonic:NM_015506.3	synonymous	GTA	3	p.Val107=	c.321G>A				A	GMAF=0.4162:AMAF=0.3723:EMAF=0.437	0.12		Benign	6288212	rs2275276		(dui:NBS9;dis:Organic Acid Condition;g:MMACHC)(dui:NBS11;dis:Amino Acid Disorder;g:MMACHC)(dui:NBS43;dis:Methylmalonic acidemia;g:MMACHC)(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMACHC)(dui:NBS2;dis:Core Conditions;g:MMACHC)(dui:NBS57;dis:Homocystinuria;g:MMACHC)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMACHC)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMACHC)(dui:D008659;dis:Metabolic Diseases;g:MMACHC)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMACHC)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMACHC)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMACHC)(dui:D009748;dis:Nutrition Disorders;g:MMACHC)(dui:D044342;dis:Malnutrition;g:MMACHC)(dui:D003677;dis:Deficiency Diseases;g:MMACHC)(dui:D020138;dis:Hyperhomocysteinemia;g:MMACHC)(dui:D001361;dis:Avitaminosis;g:MMACHC)(dui:D014804;dis:Vitamin B Deficiency;g:MMACHC)(dui:D009422;dis:Nervous System Diseases;g:MMACHC)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MMACHC)(dui:D002493;dis:Central Nervous System Diseases;g:MMACHC)(dui:D003240;dis:Connective Tissue Diseases;g:MMACHC)(dui:D001927;dis:Brain Diseases;g:MMACHC)(dui:D001928;dis:Brain Diseases, Metabolic;g:MMACHC)(dui:D006712;dis:Homocystinuria;g:MMACHC)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MMACHC)(dui:D014806;dis:Vitamin B 12 Deficiency;g:MMACHC)(dui:D005128;dis:Eye Diseases;g:MMACHC)(dui:D012164;dis:Retinal Diseases;g:MMACHC)(dui:D012162;dis:Retinal Degeneration;g:MMACHC)(dui:D008268;dis:Macular Degeneration;g:MMACHC)	Hydroxocobalamin:Cyanocobalamin	GO:0071949:GO:0042803:GO:0032451:GO:0009235:GO:0005515:GO:0043295:GO:0005737:GO:0016491:GO:0006749:GO:0031419:GO:0005829:GO:0055114:GO:0016740:GO:0070988:GO:0033787	609831	PF16690	-0.88															
chr1:75728544	INDEL	GT	1	G/G	PASS	1.1481536214968889e-262	2619.4		396	GT=0,G=396	GT=0.0,G=1.0	100.0	0.0	homozygous	56	0.0	4.0		ACADM	NM_000016.6	ACADM:intronic:NM_000016.6	unknown			p.?	c.118+57delT				G				Benign		rs1454388372:rs75993895:rs1173791164:rs796117827		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADM)(dui:NBS2;dis:Core Conditions;g:ACADM)(dui:NBS10;dis:Fatty Acid Oxidation Disorder;g:ACADM)(dui:NBS51;dis:Medium-chain acyl-CoA dehydrogenase deficiency;g:ACADM)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADM)(dui:D008659;dis:Metabolic Diseases;g:ACADM)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADM)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADM)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADM)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADM)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADM)(dui:D004066;dis:Digestive System Diseases;g:ACADM)(dui:D008107;dis:Liver Diseases;g:ACADM)(dui:D048550;dis:Hepatic Insufficiency;g:ACADM)(dui:D017093;dis:Liver Failure;g:ACADM)(dui:D005767;dis:Gastrointestinal Diseases;g:ACADM)(dui:D009748;dis:Nutrition Disorders;g:ACADM)(dui:D005759;dis:Gastroenteritis;g:ACADM)(dui:D007410;dis:Intestinal Diseases;g:ACADM)(dui:D044343;dis:Overnutrition;g:ACADM)(dui:D004760;dis:Enterocolitis;g:ACADM)(dui:D009765;dis:Obesity;g:ACADM)(dui:D020345;dis:Enterocolitis, Necrotizing;g:ACADM)	Octanoyl-Coenzyme A:3-thiaoctanoyl-CoA:Flavin adenine dinucleotide	GO:0042802:GO:0045329:GO:0003995:GO:0005634:GO:0006635:GO:0033539:GO:0031966:GO:0070991:GO:0005759:GO:0050660:GO:0051793:GO:0019254:GO:0005739:GO:0051791:GO:0055114:GO:0019216:GO:0030424	607008	PF02771:PF02770:PF00441:PF08028	0.2,0.0															
chr1:75728621	SNV	A	1	A/G	PASS	2.678551494532296e-86	855.721		400	A=205,G=195	A=0.5125,G=0.4875	48.75	51.25	heterozygous	55	0.104	2.0		ACADM	NM_000016.6	ACADM:intronic:NM_000016.6	unknown			p.?	c.118+133A>G				G						rs1146572		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADM)(dui:NBS2;dis:Core Conditions;g:ACADM)(dui:NBS10;dis:Fatty Acid Oxidation Disorder;g:ACADM)(dui:NBS51;dis:Medium-chain acyl-CoA dehydrogenase deficiency;g:ACADM)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADM)(dui:D008659;dis:Metabolic Diseases;g:ACADM)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADM)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADM)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADM)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADM)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADM)(dui:D004066;dis:Digestive System Diseases;g:ACADM)(dui:D008107;dis:Liver Diseases;g:ACADM)(dui:D048550;dis:Hepatic Insufficiency;g:ACADM)(dui:D017093;dis:Liver Failure;g:ACADM)(dui:D005767;dis:Gastrointestinal Diseases;g:ACADM)(dui:D009748;dis:Nutrition Disorders;g:ACADM)(dui:D005759;dis:Gastroenteritis;g:ACADM)(dui:D007410;dis:Intestinal Diseases;g:ACADM)(dui:D044343;dis:Overnutrition;g:ACADM)(dui:D004760;dis:Enterocolitis;g:ACADM)(dui:D009765;dis:Obesity;g:ACADM)(dui:D020345;dis:Enterocolitis, Necrotizing;g:ACADM)	Octanoyl-Coenzyme A:3-thiaoctanoyl-CoA:Flavin adenine dinucleotide	GO:0042802:GO:0045329:GO:0003995:GO:0005634:GO:0006635:GO:0033539:GO:0031966:GO:0070991:GO:0005759:GO:0050660:GO:0051793:GO:0019254:GO:0005739:GO:0051791:GO:0055114:GO:0019216:GO:0030424	607008	PF02771:PF02770:PF00441:PF08028	-0.18															
chr1:100206504	SNV	T	1	C/C	PASS	0.0	3998.93		400	T=0,C=400	T=0.0,C=1.0	100.0	0.0	homozygous	56	0.108	1.0		DBT	NM_001918.5	DBT:exonic:NM_001918.5	missense	GGT	9	p.Ser384Gly	c.1150A>G	1.0	0.0	56.0	C	GMAF=0.1408:AMAF=0.2251:EMAF=0.0976			Benign		rs12021720		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:DBT)(dui:NBS2;dis:Core Conditions;g:DBT)(dui:NBS11;dis:Amino Acid Disorder;g:DBT)(dui:NBS56;dis:Maple syrup urine disease;g:DBT)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:DBT)(dui:D009422;dis:Nervous System Diseases;g:DBT)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:DBT)(dui:D002493;dis:Central Nervous System Diseases;g:DBT)(dui:D008659;dis:Metabolic Diseases;g:DBT)(dui:D030342;dis:Genetic Diseases, Inborn;g:DBT)(dui:D001927;dis:Brain Diseases;g:DBT)(dui:D001928;dis:Brain Diseases, Metabolic;g:DBT)(dui:D008661;dis:Metabolism, Inborn Errors;g:DBT)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:DBT)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:DBT)(dui:D008375;dis:Maple Syrup Urine Disease;g:DBT)		GO:0009083:GO:0031405:GO:0031625:GO:0005947:GO:0016407:GO:0005737:GO:0005759:GO:0005739:GO:0043754:GO:0042645	248610	PF02817:PF00198:PF00364	1.94															
chr1:100240871	SNV	T	1	T/C	PASS	2.621802661510428e-88	875.814		400	T=203,C=197	T=0.5075,C=0.4925	49.25	50.75	heterozygous	1		1.0		DBT	NM_001918.5	DBT:exonic:NM_001918.5	missense	TGT	2	p.Tyr22Cys	c.65A>G	0.01	0.0	194.0	C						rs757196736		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:DBT)(dui:NBS2;dis:Core Conditions;g:DBT)(dui:NBS11;dis:Amino Acid Disorder;g:DBT)(dui:NBS56;dis:Maple syrup urine disease;g:DBT)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:DBT)(dui:D009422;dis:Nervous System Diseases;g:DBT)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:DBT)(dui:D002493;dis:Central Nervous System Diseases;g:DBT)(dui:D008659;dis:Metabolic Diseases;g:DBT)(dui:D030342;dis:Genetic Diseases, Inborn;g:DBT)(dui:D001927;dis:Brain Diseases;g:DBT)(dui:D001928;dis:Brain Diseases, Metabolic;g:DBT)(dui:D008661;dis:Metabolism, Inborn Errors;g:DBT)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:DBT)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:DBT)(dui:D008375;dis:Maple Syrup Urine Disease;g:DBT)		GO:0009083:GO:0031405:GO:0031625:GO:0005947:GO:0016407:GO:0005737:GO:0005759:GO:0005739:GO:0043754:GO:0042645	248610	PF02817:PF00198:PF00364	0.97															
chr1:115033402	SNV	A	1	G/G	PASS	0.0	3933.48		400	A=2,G=398	A=0.005,G=0.995	99.5	0.5	homozygous	55	0.016	1.0		TSHB	NM_000549.5	TSHB:exonic:NM_000549.5	missense	GCA	2	p.Thr14Ala	c.40A>G	0.32	0.0	58.0	G	GMAF=0.0248:AMAF=0.0057:EMAF=0.0345			Benign		rs10776792		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TSHB)(dui:NBS2;dis:Core Conditions;g:TSHB)(dui:NBS12;dis:Endocrine Disorder;g:TSHB)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TSHB)(dui:D004700;dis:Endocrine System Diseases;g:TSHB)(dui:D013959;dis:Thyroid Diseases;g:TSHB)(dui:D007037;dis:Hypothyroidism;g:TSHB)(dui:D009140;dis:Musculoskeletal Diseases;g:TSHB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TSHB)(dui:D001847;dis:Bone Diseases;g:TSHB)(dui:D001849;dis:Bone Diseases, Endocrine;g:TSHB)(dui:D004392;dis:Dwarfism;g:TSHB)(dui:D030342;dis:Genetic Diseases, Inborn;g:TSHB)(dui:D001848;dis:Bone Diseases, Developmental;g:TSHB)(dui:D003409;dis:Congenital Hypothyroidism;g:TSHB)(dui:D009422;dis:Nervous System Diseases;g:TSHB)(dui:D001523;dis:Mental Disorders;g:TSHB)(dui:D000068105;dis:Bipolar and Related Disorders;g:TSHB)(dui:D009461;dis:Neurologic Manifestations;g:TSHB)(dui:D001714;dis:Bipolar Disorder;g:TSHB)(dui:D019954;dis:Neurobehavioral Manifestations;g:TSHB)(dui:D003244;dis:Consciousness Disorders;g:TSHB)(dui:D014474;dis:Unconsciousness;g:TSHB)(dui:D003128;dis:Coma;g:TSHB)		GO:0005615:GO:0043627:GO:0007186:GO:0005737:GO:0051592:GO:0007267:GO:0009653:GO:0016486:GO:0033189:GO:0005576:GO:0005179:GO:0009755	188540		0.21															
chr1:115033861	SNV	C	1	G/G	PASS	0.0	3825.72		398	C=5,G=393	C=0.0126,G=0.9874	98.74	1.2600000000000051	homozygous	15	0.439	3.0		TSHB	NM_000549.5	TSHB:intronic:NM_000549.5	unknown			p.?	c.163-112C>G				G						rs28566771		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TSHB)(dui:NBS2;dis:Core Conditions;g:TSHB)(dui:NBS12;dis:Endocrine Disorder;g:TSHB)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TSHB)(dui:D004700;dis:Endocrine System Diseases;g:TSHB)(dui:D013959;dis:Thyroid Diseases;g:TSHB)(dui:D007037;dis:Hypothyroidism;g:TSHB)(dui:D009140;dis:Musculoskeletal Diseases;g:TSHB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TSHB)(dui:D001847;dis:Bone Diseases;g:TSHB)(dui:D001849;dis:Bone Diseases, Endocrine;g:TSHB)(dui:D004392;dis:Dwarfism;g:TSHB)(dui:D030342;dis:Genetic Diseases, Inborn;g:TSHB)(dui:D001848;dis:Bone Diseases, Developmental;g:TSHB)(dui:D003409;dis:Congenital Hypothyroidism;g:TSHB)(dui:D009422;dis:Nervous System Diseases;g:TSHB)(dui:D001523;dis:Mental Disorders;g:TSHB)(dui:D000068105;dis:Bipolar and Related Disorders;g:TSHB)(dui:D009461;dis:Neurologic Manifestations;g:TSHB)(dui:D001714;dis:Bipolar Disorder;g:TSHB)(dui:D019954;dis:Neurobehavioral Manifestations;g:TSHB)(dui:D003244;dis:Consciousness Disorders;g:TSHB)(dui:D014474;dis:Unconsciousness;g:TSHB)(dui:D003128;dis:Coma;g:TSHB)		GO:0005615:GO:0043627:GO:0007186:GO:0005737:GO:0051592:GO:0007267:GO:0009653:GO:0016486:GO:0033189:GO:0005576:GO:0005179:GO:0009755	188540		-0.51															
chr2:1423015	SNV	G	1	G/A	PASS	3.350425766809556e-90	894.749		400	G=201,A=199	G=0.5025,A=0.4975	49.75	50.25	heterozygous	23	0.231	1.0		TPO	NM_000547.5	TPO:intronic:NM_000547.5	unknown			p.?	c.95-30G>A				A	GMAF=0.2137:AMAF=0.1841:EMAF=0.229					rs2276701		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	0.15															
chr2:1433391	SNV	A	1	A/C	PASS	5.626003525795336e-94	932.498		400	A=197,C=203	A=0.4925,C=0.5075	50.75	49.25	heterozygous	41	0.399	1.0		TPO	NM_000547.5	TPO:intronic:NM_000547.5	unknown			p.?	c.180-47A>C				C	GMAF=0.3166:AMAF=0.4721:EMAF=0.237					rs1473936		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-1.5															
chr2:1433638	SNV	C	1	C/T	PASS	8.143291852092347e-82	810.892		400	C=210,T=190	C=0.525,T=0.475	47.5	52.5	heterozygous	29	0.437	1.0		TPO	NM_000547.5	TPO:intronic:NM_000547.5	unknown			p.?	c.349+31C>T				T	GMAF=0.4955:AMAF=0.2935:EMAF=0.4009					rs4927578		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-0.12															
chr2:1456034	SNV	A	1	G/G	PASS	0.0	3978.42		399	A=0,G=399	A=0.0,G=1.0	100.0	0.0	homozygous	56	0.065	1.0		TPO	NM_000547.5	TPO:intronic:NM_000547.5	unknown			p.?	c.613-42A>G				G	GMAF=0.0716:AMAF=0.104:EMAF=0.055					rs4927610:rs1036271161		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-0.86															
chr2:1456232	SNV	G	1	G/T	PASS	4.5071291210910194e-97	963.461		400	G=194,T=206	G=0.485,T=0.515	51.5	48.5	heterozygous	49	0.365	4.0		TPO	NM_000547.5	TPO:exonic:NM_000547.5	missense	TCT	7	p.Ala257Ser	c.769G>T	0.13	0.056	99.0	T	GMAF=0.3813:AMAF=0.3761:EMAF=0.384	0.1		Benign	7302182	rs4927611		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	0.75															
chr2:1456368	SNV	A	1	A/G	PASS	1.0478521287135712e-97	969.797		390	A=186,G=204	A=0.4769,G=0.5231	52.31	47.69	heterozygous	49	0.363	3.0		TPO	NM_000547.5	TPO:intronic:NM_000547.5	unknown			p.?	c.819+86A>G				G	GMAF=0.3765:AMAF=0.3656:EMAF=0.3812					rs4927612		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	0.09															
chr2:1477383	SNV	G	1	G/T	PASS	1.9155787029869149e-84	837.177		397	G=205,T=192	G=0.5164,T=0.4836	48.36	51.64	heterozygous	31	0.408	1.0		TPO	NM_000547.5	TPO:exonic:NM_000547.5	missense	TCG	8	p.Ala373Ser	c.1117G>T	1.0	0.005	99.0	T	GMAF=0.4069:AMAF=0.3165:EMAF=0.4479	0.03		Benign	3749597	rs2280132		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	0.12															
chr2:1477459	SNV	G	1	G/C	PASS	9.822001587742458e-98	970.078		400	G=193,C=207	G=0.4825,C=0.5175	51.75	48.25	heterozygous	55	0.29	1.0		TPO	NM_000547.5	TPO:exonic:NM_000547.5	missense	ACC	8	p.Ser398Thr	c.1193G>C	0.05	0.999	58.0	C	GMAF=0.2184:AMAF=0.1362:EMAF=0.2602	0.89		Benign	1579950	rs2175977		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	1.05															
chr2:1484896	SNV	T	1	T/C	PASS	6.117866558211229e-79	782.134		400	T=213,C=187	T=0.5325,C=0.4675	46.75	53.25	heterozygous	55	0.403	2.0		TPO	NM_000547.5	TPO:intronic:NM_000547.5	unknown			p.?	c.1597+42T>C				C	GMAF=0.4494:AMAF=0.3093:EMAF=0.4789					rs6715129		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	0.34															
chr2:1494031	SNV	C	1	C/T	PASS	1.661881296024283e-85	847.794		400	C=206,T=194	C=0.515,T=0.485	48.5	51.5	heterozygous	48	0.359	1.0		TPO	NM_000547.5	TPO:exonic:NM_000547.5	synonymous	GAT	11	p.Asp666=	c.1998C>T				T	GMAF=0.3505:AMAF=0.3221:EMAF=0.3651	0.01		Benign	3757660	rs780537993:rs1126797		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-5.14															
chr2:1495956	SNV	C	1	C/T	PASS	2.1507998622981143e-76	756.674		400	C=216,T=184	C=0.54,T=0.46	46.0	54.0	heterozygous	49	0.273	1.0		TPO	NM_000547.5	TPO:intronic:NM_000547.5	unknown			p.?	c.2007-33C>T				T	GMAF=0.2825:AMAF=0.2245:EMAF=0.3123					rs2276704		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-0.1															
chr2:1496127	SNV	C	1	C/T	PASS	3.01647687316223e-79	785.205		399	C=212,T=187	C=0.5313,T=0.4687	46.87	53.13	heterozygous	48	0.439	4.0		TPO	NM_000547.5	TPO:exonic:NM_000547.5	synonymous	CCT	12	p.Pro715=	c.2145C>T				T	GMAF=0.413:AMAF=0.4414:EMAF=0.3985	0.04		Benign	1685440	rs732608		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-2.72															
chr2:1496155	SNV	A	1	A/C	PASS	9.685008361475276e-85	840.139		394	A=202,C=192	A=0.5127,C=0.4873	48.73	51.27	heterozygous	55	0.498	1.0		TPO	NM_000547.5	TPO:exonic:NM_000547.5	missense	CCT	12	p.Thr725Pro	c.2173A>C	1.0	0.0	38.0	C	GMAF=0.4703:AMAF=0.3926:EMAF=0.4001	0.03		Benign	3812428	rs732609		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	2.92															
chr2:1503900	SNV	G	1	G/A	PASS	2.2506087344336e-55	546.477		400	G=241,A=159	G=0.6025,A=0.3975	39.75	60.25	heterozygous	1	0.003	5.0		TPO	NM_000547.5	TPO:intronic:NM_000547.5	unknown			p.?	c.2387-48G>A				A	GMAF=0.0053:AMAF=7.0E-4:EMAF=0.0077					rs191583790		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	0.63															
chr2:1516904	SNV	T	1	T/C	PASS	3.304456201934589e-68	674.809		398	T=224,C=174	T=0.5628,C=0.4372	43.72	56.28	heterozygous	55	0.336	1.0		TPO	NM_000547.5	TPO:exonic:NM_000547.5	missense	GCG	15	p.Val847Ala	c.2540T>C	1.0	0.0	64.0	C	GMAF=0.3867:AMAF=0.2288:EMAF=0.4677	0.0		Benign	148793	rs1126799		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	0.63															
chr2:1542555	SNV	C	1	C/G	PASS	2.5433141059879383e-88	875.946		400	C=203,G=197	C=0.5075,G=0.4925	49.25	50.75	heterozygous	31	0.353	2.0		TPO	NM_000547.5	TPO:utr_3:NM_000547.5	unknown		17	p.?	c.*81C>G				G	GMAF=0.3815:AMAF=0.2384:EMAF=0.4437	0.0		Benign	4001255	rs1042589		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-1.2															
chr2:1542589	SNV	G	1	G/T	PASS	2.796404549398227e-65	645.534		400	G=229,T=171	G=0.5725,T=0.4275	42.75	57.25	heterozygous	42	0.095	3.0		TPO	NM_000547.5	TPO:utr_3:NM_000547.5	unknown		17	p.?	c.*115G>T				T	GMAF=0.0727:AMAF=0.0195:EMAF=0.0959	0.01		Benign	5653833	rs28915689:rs1353412577:rs1558451361		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	0.06															
chr2:149571002	SNV	C	1	T/T	PASS	8.649679187756602e-136	1350.63		136	C=0,T=136	C=0.0,T=1.0	100.0	0.0	homozygous	48	0.378	1.0		MMADHC	NM_015702.3	MMADHC:intronic:NM_015702.3	unknown			p.?	c.696+83G>A				T						rs4500908		(dui:NBS9;dis:Organic Acid Condition;g:MMADHC)(dui:NBS11;dis:Amino Acid Disorder;g:MMADHC)(dui:NBS43;dis:Methylmalonic acidemia;g:MMADHC)(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMADHC)(dui:NBS2;dis:Core Conditions;g:MMADHC)(dui:NBS57;dis:Homocystinuria;g:MMADHC)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMADHC)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMADHC)(dui:D008659;dis:Metabolic Diseases;g:MMADHC)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMADHC)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMADHC)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMADHC)		GO:0005515:GO:0005737:GO:0005739:GO:0005829:GO:0009235	611935	PF10229	-0.28															
chr2:149575863	SNV	C	1	G/G	PASS	0.0	3884.23		398	C=3,G=395	C=0.0075,G=0.9925	99.25	0.75	homozygous	48	0.378	2.0		MMADHC	NM_015702.3	MMADHC:intronic:NM_015702.3	unknown			p.?	c.479-22G>C				G	GMAF=0.3774:AMAF=0.3115:EMAF=0.2178			Likely benign		rs12232959		(dui:NBS9;dis:Organic Acid Condition;g:MMADHC)(dui:NBS11;dis:Amino Acid Disorder;g:MMADHC)(dui:NBS43;dis:Methylmalonic acidemia;g:MMADHC)(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMADHC)(dui:NBS2;dis:Core Conditions;g:MMADHC)(dui:NBS57;dis:Homocystinuria;g:MMADHC)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMADHC)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMADHC)(dui:D008659;dis:Metabolic Diseases;g:MMADHC)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMADHC)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMADHC)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMADHC)		GO:0005515:GO:0005737:GO:0005739:GO:0005829:GO:0009235	611935	PF10229	-2.14															
chr2:149575955	SNV	G	1	T/T	PASS	0.0	3997.27		400	G=0,T=400	G=0.0,T=1.0	100.0	0.0	homozygous	48	0.369	1.0		MMADHC	NM_015702.3	MMADHC:intronic:NM_015702.3	unknown			p.?	c.479-114C>A				T						rs10932467		(dui:NBS9;dis:Organic Acid Condition;g:MMADHC)(dui:NBS11;dis:Amino Acid Disorder;g:MMADHC)(dui:NBS43;dis:Methylmalonic acidemia;g:MMADHC)(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMADHC)(dui:NBS2;dis:Core Conditions;g:MMADHC)(dui:NBS57;dis:Homocystinuria;g:MMADHC)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMADHC)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMADHC)(dui:D008659;dis:Metabolic Diseases;g:MMADHC)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMADHC)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMADHC)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMADHC)		GO:0005515:GO:0005737:GO:0005739:GO:0005829:GO:0009235	611935	PF10229	-1.8															
chr2:149576462	SNV	C	1	T/T	PASS	0.0	3993.47		400	C=0,T=400	C=0.0,T=1.0	100.0	0.0	homozygous	55	0.24	1.0		MMADHC	NM_015702.3	MMADHC:exonic:NM_015702.3	synonymous	CAA	5	p.Gln151=	c.453G>A				T	GMAF=0.2261:AMAF=0.4839:EMAF=0.094	0.38		Benign	7128893	rs11545261		(dui:NBS9;dis:Organic Acid Condition;g:MMADHC)(dui:NBS11;dis:Amino Acid Disorder;g:MMADHC)(dui:NBS43;dis:Methylmalonic acidemia;g:MMADHC)(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMADHC)(dui:NBS2;dis:Core Conditions;g:MMADHC)(dui:NBS57;dis:Homocystinuria;g:MMADHC)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMADHC)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMADHC)(dui:D008659;dis:Metabolic Diseases;g:MMADHC)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMADHC)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMADHC)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMADHC)		GO:0005515:GO:0005737:GO:0005739:GO:0005829:GO:0009235	611935	PF10229	-0.09															
chr2:149579375	INDEL	C	2	CAA/CAA	PASS	3.4040818970103145e-275	2744.68		396	C=0,CAA=396	C=0.0,CAA=1.0	100.0	0.0	homozygous	48	0.352	2.0		MMADHC	NM_015702.3	MMADHC:intronic:NM_015702.3	unknown			p.?	c.372+55_372+56insTT				CAA						rs36108609:rs1573878596		(dui:NBS9;dis:Organic Acid Condition;g:MMADHC)(dui:NBS11;dis:Amino Acid Disorder;g:MMADHC)(dui:NBS43;dis:Methylmalonic acidemia;g:MMADHC)(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMADHC)(dui:NBS2;dis:Core Conditions;g:MMADHC)(dui:NBS57;dis:Homocystinuria;g:MMADHC)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMADHC)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMADHC)(dui:D008659;dis:Metabolic Diseases;g:MMADHC)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMADHC)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMADHC)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMADHC)		GO:0005515:GO:0005737:GO:0005739:GO:0005829:GO:0009235	611935	PF10229	-1.05															
chr2:149587175	SNV	C	1	G/G	PASS	0.0	4003.2		400	C=0,G=400	C=0.0,G=1.0	100.0	0.0	homozygous	55	0.311	1.0		MMADHC|MMADHC-DT	NM_015702.3|NR_110240.1	MMADHC:intronic:NM_015702.3|MMADHC-DT:upstream:NR_110240.1	unknown|	|	|	p.?|	c.-52-26G>C|	|	|	|	G|	GMAF=0.2632:AMAF=0.3497:EMAF=0.0949					rs4667420		(dui:NBS9;dis:Organic Acid Condition;g:MMADHC)(dui:NBS11;dis:Amino Acid Disorder;g:MMADHC)(dui:NBS43;dis:Methylmalonic acidemia;g:MMADHC)(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMADHC)(dui:NBS2;dis:Core Conditions;g:MMADHC)(dui:NBS57;dis:Homocystinuria;g:MMADHC)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMADHC)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMADHC)(dui:D008659;dis:Metabolic Diseases;g:MMADHC)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMADHC)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMADHC)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMADHC)		GO:0005515:GO:0005737:GO:0005739:GO:0005829:GO:0009235	611935	PF10229	-0.12															
chr3:49421681	SNV	A	1	C/C	PASS	0.0	3848.32		400	A=5,C=395	A=0.0125,C=0.9875	98.75	1.25	homozygous	55	0.417	3.0		AMT|NICN1	NR_028435.2|NM_032316.3	AMT:intronic_nc:NR_028435.2|NICN1:downstream:NM_032316.3	|unknown	|	|	|p.?	|c.*3152T>G	|	|	|	|C						rs4855873		(dui:D009750;dis:Nutritional and Metabolic Diseases;g:AMT)(dui:D008659;dis:Metabolic Diseases;g:AMT)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:AMT)(dui:D009422;dis:Nervous System Diseases;g:AMT)(dui:D030342;dis:Genetic Diseases, Inborn;g:AMT)(dui:D008661;dis:Metabolism, Inborn Errors;g:AMT)(dui:D002493;dis:Central Nervous System Diseases;g:AMT)(dui:D001927;dis:Brain Diseases;g:AMT)(dui:D001928;dis:Brain Diseases, Metabolic;g:AMT)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:AMT)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:AMT)(dui:D020158;dis:Hyperglycinemia, Nonketotic;g:AMT)	Tetrahydrofolic acid:NADH:5-methyltetrahydrofolic acid:Glycine	GO:0005515:GO:0005654:GO:0005874	238310:611516		1.08															
chr3:183017394	SNV	C	1	A/A	PASS	0.0	4003.31		400	C=0,A=400	C=0.0,A=1.0	100.0	0.0	homozygous	55	0.047	1.0		MCCC1	NM_020166.5	MCCC1:intronic:NM_020166.5	unknown			p.?	c.1978-57G>T				A	GMAF=0.0675:AMAF=0.065:EMAF=0.0685					rs6786878		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MCCC1)(dui:NBS2;dis:Core Conditions;g:MCCC1)(dui:NBS9;dis:Organic Acid Condition;g:MCCC1)(dui:NBS45;dis:3-Methylcrotonyl-CoA carboxylase deficiency;g:MCCC1)(dui:D009422;dis:Nervous System Diseases;g:MCCC1)(dui:D002493;dis:Central Nervous System Diseases;g:MCCC1)(dui:D001927;dis:Brain Diseases;g:MCCC1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MCCC1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MCCC1)(dui:D008659;dis:Metabolic Diseases;g:MCCC1)(dui:D030342;dis:Genetic Diseases, Inborn;g:MCCC1)(dui:D001928;dis:Brain Diseases, Metabolic;g:MCCC1)(dui:D008661;dis:Metabolism, Inborn Errors;g:MCCC1)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MCCC1)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MCCC1)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:MCCC1)(dui:D019636;dis:Neurodegenerative Diseases;g:MCCC1)(dui:D009069;dis:Movement Disorders;g:MCCC1)(dui:D010300;dis:Parkinson Disease;g:MCCC1)(dui:D001480;dis:Basal Ganglia Diseases;g:MCCC1)(dui:D020734;dis:Parkinsonian Disorders;g:MCCC1)	Biotin	GO:0009083:GO:0009374:GO:1905202:GO:0006552:GO:0004075:GO:0004485:GO:0002169:GO:0005524:GO:0005515:GO:0006768:GO:0005759:GO:0046872:GO:0005739:GO:0005829:GO:0016421	609010	PF08443:PF07478:PF02222:PF00364:PF02786:PF02785:PF00289:PF02655	-0.36															
chr3:183037179	SNV	A	1	A/G	PASS	3.34272000137864e-62	614.759		348	A=193,G=155	A=0.5546,G=0.4454	44.54	55.46	heterozygous	8	0.103	4.0		MCCC1	NM_020166.5	MCCC1:intronic:NM_020166.5	unknown			p.?	c.1594+39T>C				G	GMAF=0.0603:AMAF=0.1221:EMAF=0.0286			Benign		rs2270969		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MCCC1)(dui:NBS2;dis:Core Conditions;g:MCCC1)(dui:NBS9;dis:Organic Acid Condition;g:MCCC1)(dui:NBS45;dis:3-Methylcrotonyl-CoA carboxylase deficiency;g:MCCC1)(dui:D009422;dis:Nervous System Diseases;g:MCCC1)(dui:D002493;dis:Central Nervous System Diseases;g:MCCC1)(dui:D001927;dis:Brain Diseases;g:MCCC1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MCCC1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MCCC1)(dui:D008659;dis:Metabolic Diseases;g:MCCC1)(dui:D030342;dis:Genetic Diseases, Inborn;g:MCCC1)(dui:D001928;dis:Brain Diseases, Metabolic;g:MCCC1)(dui:D008661;dis:Metabolism, Inborn Errors;g:MCCC1)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MCCC1)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MCCC1)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:MCCC1)(dui:D019636;dis:Neurodegenerative Diseases;g:MCCC1)(dui:D009069;dis:Movement Disorders;g:MCCC1)(dui:D010300;dis:Parkinson Disease;g:MCCC1)(dui:D001480;dis:Basal Ganglia Diseases;g:MCCC1)(dui:D020734;dis:Parkinsonian Disorders;g:MCCC1)	Biotin	GO:0009083:GO:0009374:GO:1905202:GO:0006552:GO:0004075:GO:0004485:GO:0002169:GO:0005524:GO:0005515:GO:0006768:GO:0005759:GO:0046872:GO:0005739:GO:0005829:GO:0016421	609010	PF08443:PF07478:PF02222:PF00364:PF02786:PF02785:PF00289:PF02655	1.6															
chr3:183037421	SNV	T	1	G/G	PASS	0.0	3952.06		399	T=1,G=398	T=0.0025,G=0.9975	99.75	0.25	homozygous	33	0.465	1.0		MCCC1	NM_020166.5	MCCC1:exonic:NM_020166.5	missense	CCC	13	p.His464Pro	c.1391A>C	0.01	0.0	77.0	G	GMAF=0.4152:AMAF=0.2876:EMAF=0.2629	0.92		Benign	4002526	rs2270968		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MCCC1)(dui:NBS2;dis:Core Conditions;g:MCCC1)(dui:NBS9;dis:Organic Acid Condition;g:MCCC1)(dui:NBS45;dis:3-Methylcrotonyl-CoA carboxylase deficiency;g:MCCC1)(dui:D009422;dis:Nervous System Diseases;g:MCCC1)(dui:D002493;dis:Central Nervous System Diseases;g:MCCC1)(dui:D001927;dis:Brain Diseases;g:MCCC1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MCCC1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MCCC1)(dui:D008659;dis:Metabolic Diseases;g:MCCC1)(dui:D030342;dis:Genetic Diseases, Inborn;g:MCCC1)(dui:D001928;dis:Brain Diseases, Metabolic;g:MCCC1)(dui:D008661;dis:Metabolism, Inborn Errors;g:MCCC1)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MCCC1)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MCCC1)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:MCCC1)(dui:D019636;dis:Neurodegenerative Diseases;g:MCCC1)(dui:D009069;dis:Movement Disorders;g:MCCC1)(dui:D010300;dis:Parkinson Disease;g:MCCC1)(dui:D001480;dis:Basal Ganglia Diseases;g:MCCC1)(dui:D020734;dis:Parkinsonian Disorders;g:MCCC1)	Biotin	GO:0009083:GO:0009374:GO:1905202:GO:0006552:GO:0004075:GO:0004485:GO:0002169:GO:0005524:GO:0005515:GO:0006768:GO:0005759:GO:0046872:GO:0005739:GO:0005829:GO:0016421	609010	PF08443:PF07478:PF02222:PF00364:PF02786:PF02785:PF00289:PF02655	1.12															
chr3:183072461	SNV	G	1	A/A	PASS	0.0	3956.99		399	G=1,A=398	G=0.0025,A=0.9975	99.75	0.25	homozygous	55	0.084	1.0		MCCC1	NM_020166.5	MCCC1:exonic:NM_020166.5	synonymous	CTT	5	p.Leu132=	c.396C>T				A	GMAF=0.1147:AMAF=0.2034:EMAF=0.0692			Benign		rs7622479		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MCCC1)(dui:NBS2;dis:Core Conditions;g:MCCC1)(dui:NBS9;dis:Organic Acid Condition;g:MCCC1)(dui:NBS45;dis:3-Methylcrotonyl-CoA carboxylase deficiency;g:MCCC1)(dui:D009422;dis:Nervous System Diseases;g:MCCC1)(dui:D002493;dis:Central Nervous System Diseases;g:MCCC1)(dui:D001927;dis:Brain Diseases;g:MCCC1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MCCC1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MCCC1)(dui:D008659;dis:Metabolic Diseases;g:MCCC1)(dui:D030342;dis:Genetic Diseases, Inborn;g:MCCC1)(dui:D001928;dis:Brain Diseases, Metabolic;g:MCCC1)(dui:D008661;dis:Metabolism, Inborn Errors;g:MCCC1)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MCCC1)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MCCC1)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:MCCC1)(dui:D019636;dis:Neurodegenerative Diseases;g:MCCC1)(dui:D009069;dis:Movement Disorders;g:MCCC1)(dui:D010300;dis:Parkinson Disease;g:MCCC1)(dui:D001480;dis:Basal Ganglia Diseases;g:MCCC1)(dui:D020734;dis:Parkinsonian Disorders;g:MCCC1)	Biotin	GO:0009083:GO:0009374:GO:1905202:GO:0006552:GO:0004075:GO:0004485:GO:0002169:GO:0005524:GO:0005515:GO:0006768:GO:0005759:GO:0046872:GO:0005739:GO:0005829:GO:0016421	609010	PF08443:PF07478:PF02222:PF00364:PF02786:PF02785:PF00289:PF02655	0.89															
chr4:145639084	SNV	A	1	A/G	PASS	2.92280606593194e-78	775.342		400	A=214,G=186	A=0.535,G=0.465	46.5	53.5	heterozygous	8	0.05	2.0		MMAA	NM_001375644.1	MMAA:utr_5:NM_001375644.1	unknown		2	p.?	c.-56A>G				G				Benign		rs4835011		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMAA)(dui:NBS2;dis:Core Conditions;g:MMAA)(dui:NBS9;dis:Organic Acid Condition;g:MMAA)(dui:NBS43;dis:Methylmalonic acidemia;g:MMAA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMAA)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMAA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMAA)(dui:D008659;dis:Metabolic Diseases;g:MMAA)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMAA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMAA)	Hydroxocobalamin:Cyanocobalamin		607481		1.3															
chr4:145650988	SNV	G	1	G/A	PASS	2.32166738279317e-76	756.342		400	G=216,A=184	G=0.54,A=0.46	46.0	54.0	heterozygous	33	0.277	2.0		MMAA	NM_001375644.1	MMAA:intronic:NM_001375644.1	unknown			p.?	c.734-74G>A				A						rs11721510		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMAA)(dui:NBS2;dis:Core Conditions;g:MMAA)(dui:NBS9;dis:Organic Acid Condition;g:MMAA)(dui:NBS43;dis:Methylmalonic acidemia;g:MMAA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMAA)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMAA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMAA)(dui:D008659;dis:Metabolic Diseases;g:MMAA)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMAA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMAA)	Hydroxocobalamin:Cyanocobalamin		607481		-0.22															
chr4:158680524	SNV	C	1	T/T	PASS	0.0	3967.2		400	C=1,T=399	C=0.0025,T=0.9975	99.75	0.25	homozygous	48	0.327	1.0		ETFDH	NM_004453.4	ETFDH:exonic:NM_004453.4	missense	ATA	2	p.Thr31Ile	c.92C>T	0.1	0.0	89.0	T	GMAF=0.3434:AMAF=0.2596:EMAF=0.14	0.84		Benign	4158888	rs11559290		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ETFDH)(dui:NBS3;dis:Secondary Conditions;g:ETFDH)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ETFDH)(dui:NBS24;dis:Glutaric acidemia type II;g:ETFDH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ETFDH)(dui:D008659;dis:Metabolic Diseases;g:ETFDH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ETFDH)(dui:D030342;dis:Genetic Diseases, Inborn;g:ETFDH)(dui:D008661;dis:Metabolism, Inborn Errors;g:ETFDH)(dui:D028361;dis:Mitochondrial Diseases;g:ETFDH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ETFDH)(dui:D054069;dis:Multiple Acyl Coenzyme A Dehydrogenase Deficiency;g:ETFDH)(dui:D009748;dis:Nutrition Disorders;g:ETFDH)(dui:D044343;dis:Overnutrition;g:ETFDH)(dui:D009765;dis:Obesity;g:ETFDH)	Metformin:2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol	GO:0009055:GO:0022904:GO:0043783:GO:0004174:GO:0022900:GO:0048039:GO:0006979:GO:0031305:GO:0033539:GO:0005515:GO:0031966:GO:0048038:GO:0005759:GO:0016491:GO:0046872:GO:0050660:GO:0051539	231675	PF01946:PF13450:PF05187:PF00890	1.1															
chr4:158684553	SNV	A	1	A/G	PASS	2.750426223030357e-99	985.606		398	A=190,G=208	A=0.4774,G=0.5226	52.26	47.74	heterozygous	1	0.001	1.0		ETFDH	NM_004453.4	ETFDH:intronic:NM_004453.4	unknown			p.?	c.406-39A>G				G	GMAF=1.0E-4:AMAF=0.0:EMAF=1.0E-4					rs369257704		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ETFDH)(dui:NBS3;dis:Secondary Conditions;g:ETFDH)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ETFDH)(dui:NBS24;dis:Glutaric acidemia type II;g:ETFDH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ETFDH)(dui:D008659;dis:Metabolic Diseases;g:ETFDH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ETFDH)(dui:D030342;dis:Genetic Diseases, Inborn;g:ETFDH)(dui:D008661;dis:Metabolism, Inborn Errors;g:ETFDH)(dui:D028361;dis:Mitochondrial Diseases;g:ETFDH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ETFDH)(dui:D054069;dis:Multiple Acyl Coenzyme A Dehydrogenase Deficiency;g:ETFDH)(dui:D009748;dis:Nutrition Disorders;g:ETFDH)(dui:D044343;dis:Overnutrition;g:ETFDH)(dui:D009765;dis:Obesity;g:ETFDH)	Metformin:2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol	GO:0009055:GO:0022904:GO:0043783:GO:0004174:GO:0022900:GO:0048039:GO:0006979:GO:0031305:GO:0033539:GO:0005515:GO:0031966:GO:0048038:GO:0005759:GO:0016491:GO:0046872:GO:0050660:GO:0051539	231675	PF01946:PF13450:PF05187:PF00890	-0.4															
chr4:158698883	SNV	A	1	A/C	PASS	4.4988343245653336e-93	923.469		400	A=198,C=202	A=0.495,C=0.505	50.5	49.5	heterozygous	16	0.295	4.0		ETFDH	NM_004453.4	ETFDH:intronic:NM_004453.4	unknown			p.?	c.973-104A>C				C						rs7679753		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ETFDH)(dui:NBS3;dis:Secondary Conditions;g:ETFDH)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ETFDH)(dui:NBS24;dis:Glutaric acidemia type II;g:ETFDH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ETFDH)(dui:D008659;dis:Metabolic Diseases;g:ETFDH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ETFDH)(dui:D030342;dis:Genetic Diseases, Inborn;g:ETFDH)(dui:D008661;dis:Metabolism, Inborn Errors;g:ETFDH)(dui:D028361;dis:Mitochondrial Diseases;g:ETFDH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ETFDH)(dui:D054069;dis:Multiple Acyl Coenzyme A Dehydrogenase Deficiency;g:ETFDH)(dui:D009748;dis:Nutrition Disorders;g:ETFDH)(dui:D044343;dis:Overnutrition;g:ETFDH)(dui:D009765;dis:Obesity;g:ETFDH)	Metformin:2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol	GO:0009055:GO:0022904:GO:0043783:GO:0004174:GO:0022900:GO:0048039:GO:0006979:GO:0031305:GO:0033539:GO:0005515:GO:0031966:GO:0048038:GO:0005759:GO:0016491:GO:0046872:GO:0050660:GO:0051539	231675	PF01946:PF13450:PF05187:PF00890	-3.15															
chr4:158708662	SNV	A	1	A/C	PASS	5.274727156616856e-94	932.778		400	A=197,C=203	A=0.4925,C=0.5075	50.75	49.25	heterozygous	16	0.181	1.0		ETFDH|PPID	NM_004453.4|NM_005038.3	ETFDH:utr_3:NM_004453.4|PPID:downstream:NM_005038.3	unknown|unknown	|	13|	p.?|p.?	c.*135A>C|c.*1074T>G	|	|	|	C|C				Benign		rs939962290:rs17843966		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ETFDH)(dui:NBS3;dis:Secondary Conditions;g:ETFDH)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ETFDH)(dui:NBS24;dis:Glutaric acidemia type II;g:ETFDH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ETFDH)(dui:D008659;dis:Metabolic Diseases;g:ETFDH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ETFDH)(dui:D030342;dis:Genetic Diseases, Inborn;g:ETFDH)(dui:D008661;dis:Metabolism, Inborn Errors;g:ETFDH)(dui:D028361;dis:Mitochondrial Diseases;g:ETFDH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ETFDH)(dui:D054069;dis:Multiple Acyl Coenzyme A Dehydrogenase Deficiency;g:ETFDH)(dui:D009748;dis:Nutrition Disorders;g:ETFDH)(dui:D044343;dis:Overnutrition;g:ETFDH)(dui:D009765;dis:Obesity;g:ETFDH)	Metformin:2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol	GO:0009055:GO:0022904:GO:0015031:GO:0061077:GO:0043783:GO:0022900:GO:0048039:GO:0000413:GO:0005730:GO:0005654:GO:0000122:GO:0006979:GO:0033539:GO:0071492:GO:0016491:GO:0006915:GO:0005829:GO:0034389:GO:0050714:GO:0045070:GO:0030544:GO:0016018:GO:0031072:GO:0065003:GO:0004174:GO:0008134:GO:0006457:GO:0005634:GO:0031305:GO:0003755:GO:0005515:GO:0031966:GO:0048038:GO:0019076:GO:0005759:GO:0046872:GO:0050660:GO:0005737:GO:0043065:GO:0051879:GO:0051539:GO:0030331	231675:601753	PF01946:PF13450:PF05187:PF00890	0.52															
chr5:71626789	SNV	G	1	A/A	PASS	0.0	3993.25		399	G=0,A=399	G=0.0,A=1.0	100.0	0.0	homozygous	55	0.186	1.0		MCCC2	NM_022132.5	MCCC2:intronic:NM_022132.5	unknown			p.?	c.738+36G>A				A	GMAF=0.2032:AMAF=0.2797:EMAF=0.164			Benign		rs12516456		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MCCC2)(dui:NBS2;dis:Core Conditions;g:MCCC2)(dui:NBS9;dis:Organic Acid Condition;g:MCCC2)(dui:NBS45;dis:3-Methylcrotonyl-CoA carboxylase deficiency;g:MCCC2)(dui:D009422;dis:Nervous System Diseases;g:MCCC2)(dui:D002493;dis:Central Nervous System Diseases;g:MCCC2)(dui:D001927;dis:Brain Diseases;g:MCCC2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MCCC2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MCCC2)(dui:D008659;dis:Metabolic Diseases;g:MCCC2)(dui:D030342;dis:Genetic Diseases, Inborn;g:MCCC2)(dui:D008661;dis:Metabolism, Inborn Errors;g:MCCC2)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MCCC2)(dui:D001928;dis:Brain Diseases, Metabolic;g:MCCC2)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MCCC2)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:MCCC2)	Biotin	GO:0002169:GO:0005524:GO:0005515:GO:0006768:GO:0009083:GO:0005759:GO:1905202:GO:0005739:GO:0006552:GO:0005829:GO:0015936:GO:0004485	609014	PF01039	-0.73															
chr5:71635139	SNV	A	1	A/G	PASS	5.964856499193742e-83	822.244		399	A=208,G=191	A=0.5213,G=0.4787	47.87	52.13	heterozygous	27	0.33	1.0		MCCC2	NM_022132.5	MCCC2:intronic:NM_022132.5	unknown			p.?	c.904-12A>G				G	GMAF=0.2889:AMAF=0.1416:EMAF=0.3643			Benign		rs277984		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MCCC2)(dui:NBS2;dis:Core Conditions;g:MCCC2)(dui:NBS9;dis:Organic Acid Condition;g:MCCC2)(dui:NBS45;dis:3-Methylcrotonyl-CoA carboxylase deficiency;g:MCCC2)(dui:D009422;dis:Nervous System Diseases;g:MCCC2)(dui:D002493;dis:Central Nervous System Diseases;g:MCCC2)(dui:D001927;dis:Brain Diseases;g:MCCC2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MCCC2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MCCC2)(dui:D008659;dis:Metabolic Diseases;g:MCCC2)(dui:D030342;dis:Genetic Diseases, Inborn;g:MCCC2)(dui:D008661;dis:Metabolism, Inborn Errors;g:MCCC2)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MCCC2)(dui:D001928;dis:Brain Diseases, Metabolic;g:MCCC2)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MCCC2)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:MCCC2)	Biotin	GO:0002169:GO:0005524:GO:0005515:GO:0006768:GO:0009083:GO:0005759:GO:1905202:GO:0005739:GO:0006552:GO:0005829:GO:0015936:GO:0004485	609014	PF01039	-1.82															
chr5:71649248	SNV	A	1	G/G	PASS	0.0	3994.13		400	A=0,G=400	A=0.0,G=1.0	100.0	0.0	homozygous	55	0.149	1.0		MCCC2	NM_022132.5	MCCC2:exonic:NM_022132.5	synonymous	GCG	14	p.Ala456=	c.1368A>G				G	GMAF=0.1868:AMAF=0.2935:EMAF=0.1321	0.07		Benign	4407210	rs10064079		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MCCC2)(dui:NBS2;dis:Core Conditions;g:MCCC2)(dui:NBS9;dis:Organic Acid Condition;g:MCCC2)(dui:NBS45;dis:3-Methylcrotonyl-CoA carboxylase deficiency;g:MCCC2)(dui:D009422;dis:Nervous System Diseases;g:MCCC2)(dui:D002493;dis:Central Nervous System Diseases;g:MCCC2)(dui:D001927;dis:Brain Diseases;g:MCCC2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MCCC2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MCCC2)(dui:D008659;dis:Metabolic Diseases;g:MCCC2)(dui:D030342;dis:Genetic Diseases, Inborn;g:MCCC2)(dui:D008661;dis:Metabolism, Inborn Errors;g:MCCC2)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MCCC2)(dui:D001928;dis:Brain Diseases, Metabolic;g:MCCC2)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MCCC2)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:MCCC2)	Biotin	GO:0002169:GO:0005524:GO:0005515:GO:0006768:GO:0009083:GO:0005759:GO:1905202:GO:0005739:GO:0006552:GO:0005829:GO:0015936:GO:0004485	609014	PF01039	-1.2															
chr5:71652827	SNV	G	1	A/A	PASS	0.0	3934.86		400	G=2,A=398	G=0.005,A=0.995	99.5	0.5	homozygous	55	0.186	1.0		MCCC2	NM_022132.5	MCCC2:intronic:NM_022132.5	unknown			p.?	c.1574+73G>A				A						rs2242372		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MCCC2)(dui:NBS2;dis:Core Conditions;g:MCCC2)(dui:NBS9;dis:Organic Acid Condition;g:MCCC2)(dui:NBS45;dis:3-Methylcrotonyl-CoA carboxylase deficiency;g:MCCC2)(dui:D009422;dis:Nervous System Diseases;g:MCCC2)(dui:D002493;dis:Central Nervous System Diseases;g:MCCC2)(dui:D001927;dis:Brain Diseases;g:MCCC2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MCCC2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MCCC2)(dui:D008659;dis:Metabolic Diseases;g:MCCC2)(dui:D030342;dis:Genetic Diseases, Inborn;g:MCCC2)(dui:D008661;dis:Metabolism, Inborn Errors;g:MCCC2)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MCCC2)(dui:D001928;dis:Brain Diseases, Metabolic;g:MCCC2)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MCCC2)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:MCCC2)	Biotin	GO:0002169:GO:0005524:GO:0005515:GO:0006768:GO:0009083:GO:0005759:GO:1905202:GO:0005739:GO:0006552:GO:0005829:GO:0015936:GO:0004485	609014	PF01039	0.28															
chr6:32038540	SNV	C	1	T/T	PASS	8.749837752274221e-103	1020.58		108	C=2,T=106	C=0.0185,T=0.9815	98.15	1.8499999999999943	homozygous	56		2.0		CYP21A2	NM_000500.9	CYP21A2:exonic:NM_000500.9	synonymous	TTG	1	p.Leu40=	c.118C>T				T		0.61		Benign	4160891	rs6468		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	0.09															
chr6:32038560	SNV	C	1	C/A	PASS	6.579607697293421e-31	301.818		97	C=41,A=56	C=0.4227,A=0.5773	57.73	42.27	heterozygous	55		4.0		CYP21A2	NM_000500.9	CYP21A2:exonic:NM_000500.9	synonymous	CCA	1	p.Pro46=	c.138C>A				A		0.05		Benign	4160892	rs6464		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	0.44															
chr6:32038820	SNV	C	1	C/T	PASS	1.3137114949600658e-29	288.815		147	C=79,T=68	C=0.5374,T=0.4626	46.26	53.74	heterozygous	55	0.288	2.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.292+9C>T				T				Benign		rs6462		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-1.82															
chr6:32039027	SNV	C	1	A/A	PASS	1.2971792709839546e-218	2178.87		220	C=0,A=220	C=0.0,A=1.0	100.0	0.0	homozygous	15	0.176	2.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.293-67C>A				A						rs6451:rs1562756023		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-0.11															
chr6:32039046	SNV	A	1	G/G	PASS	2.754228703338152e-179	1785.6		221	A=17,G=204	A=0.0769,G=0.9231	92.31	7.689999999999998	homozygous	7	0.038	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.293-48A>G				G	GMAF=0.0115:AMAF=0.0135:EMAF=0.0105					rs66933575:rs59064806		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	1.41															
chr6:32039050	SNV	G	1	T/T	PASS	1.1297959146727908e-176	1759.47		217	G=17,T=200	G=0.0783,T=0.9217	92.17	7.829999999999998	homozygous	7	0.038	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.293-44G>T				T						rs66933575:rs6453		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-0.25															
chr6:32039055	MNV	CA	2	GG/GG	PASS	1.5417004529496184e-178	1778.12		219	CA=17,GG=202	CA=0.0776,GG=0.9224	92.24	7.760000000000005	0	1	0.036	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.293-39_293-38delinsGG				GG						rs58256870:rs66933575:rs35147842:rs202093120		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-0.34,-0.29															
chr6:32039081	SNV	C	1	A/A	PASS	3.935500754557765e-169	1684.05		216	C=20,A=196	C=0.0926,A=0.9074	90.74	9.260000000000003	homozygous	37	0.348	2.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.293-13C>A				A	GMAF=0.3707:AMAF=0.3445:EMAF=0.384			Conflicting interpretations of pathogenicity		rs6467:rs1267808195		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-0.23															
chr6:32039286	SNV	C	1	T/T	PASS	0.0	3982.0		398	C=0,T=398	C=0.0,T=1.0	100.0	0.0	homozygous	22	0.313	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.447+38C>T				T	GMAF=0.2787:AMAF=0.295:EMAF=0.2704			Benign		rs6466		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	0.86															
chr6:32039847	MNV	AC	2	AC/GT	PASS	1.489018179128521e-83	828.271		400	AC=208,GT=192	AC=0.52,GT=0.48	48.0	52.0	0	1	0.173:0.174	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.738+12_738+13delinsGT				GT	GMAF=0.034:AMAF=0.0545:EMAF=0.0235			Uncertain significance		rs193922547:rs6458:rs6459:rs1554305325:rs71552100		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-1.57,-3.0															
chr6:32040013	SNV	C	1	G/G	PASS	2.594179362118908e-135	1345.86		142	C=2,G=140	C=0.0141,G=0.9859	98.59	1.4099999999999966	homozygous	22	0.214	1.0		CYP21A2	NM_000500.9	CYP21A2:exonic:NM_000500.9	synonymous	CTG	7	p.Leu249=	c.747C>G				G		0.01		Benign	4003960	rs6477		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	0.02															
chr6:32040072	SNV	G	1	G/C	PASS	9.088662990655896e-44	430.415		159	G=73,C=86	G=0.4591,C=0.5409	54.09	45.91	heterozygous	16	0.196	1.0		CYP21A2	NM_000500.9	CYP21A2:exonic:NM_000500.9	missense	ACC	7	p.Ser269Thr	c.806G>C	0.18	0.022	58.0	C	GMAF=0.1412:AMAF=0.2191:EMAF=0.0978	0.05		Benign	7226575	rs760900241:rs6472		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-0.98															
chr6:39927671	SNV	T	1	C/C	PASS	0.0	3346.51		342	T=1,C=341	T=0.0029,C=0.9971	99.71	0.2900000000000062	homozygous	44	0.377	2.0		MOCS1	NM_001358530.2	MOCS1:intronic:NM_001358530.2	unknown			p.?	c.124-216A>G				C				Benign		rs3008822		(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MOCS1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MOCS1)(dui:D008659;dis:Metabolic Diseases;g:MOCS1)(dui:D030342;dis:Genetic Diseases, Inborn;g:MOCS1)(dui:D008661;dis:Metabolism, Inborn Errors;g:MOCS1)(dui:D008664;dis:Metal Metabolism, Inborn Errors;g:MOCS1)			603707	PF01967:PF04055:PF06463:PF13353	-0.93															
chr6:49435569	SNV	T	1	C/C	PASS	0.0	3946.34		398	T=1,C=397	T=0.0025,C=0.9975	99.75	0.25	homozygous	55	0.451	1.0		MMUT	NM_000255.4	MMUT:exonic:NM_000255.4	missense	GTA	12	p.Ile671Val	c.2011A>G	1.0	0.0	29.0	C	GMAF=0.393:AMAF=0.4122:EMAF=0.3833	0.25		Benign	4004063	rs8589		.		GO:0019626:GO:0042802:GO:0042803:GO:0009791:GO:0004494:GO:0009235:GO:0043547:GO:0072341:GO:0005515:GO:0005737:GO:0005759:GO:0046872:GO:0003924:GO:0031419:GO:0005739:GO:0050667	609058	PF02310:PF01642	3.9															
chr6:49441774	SNV	G	1	G/C	PASS	1.7013748158992063e-85	847.692		400	G=206,C=194	G=0.515,C=0.485	48.5	51.5	heterozygous	41	0.329	1.0		MMUT	NM_000255.4	MMUT:intronic:NM_000255.4	unknown			p.?	c.1808+66C>G				C						rs9473555		.		GO:0019626:GO:0042802:GO:0042803:GO:0009791:GO:0004494:GO:0009235:GO:0043547:GO:0072341:GO:0005515:GO:0005737:GO:0005759:GO:0046872:GO:0003924:GO:0031419:GO:0005739:GO:0050667	609058	PF02310:PF01642	0.46															
chr6:49444720	SNV	C	1	C/T	PASS	1.703334724040892e-98	977.687		398	C=191,T=207	C=0.4799,T=0.5201	52.01	47.99	heterozygous	41	0.266	1.0		MMUT	NM_000255.4	MMUT:exonic:NM_000255.4	missense	CAT	9	p.Arg532His	c.1595G>A	0.0	0.225	29.0	T	GMAF=0.3135:AMAF=0.2108:EMAF=0.366	0.03		Benign	5001998	rs1141321		.		GO:0019626:GO:0042802:GO:0042803:GO:0009791:GO:0004494:GO:0009235:GO:0043547:GO:0072341:GO:0005515:GO:0005737:GO:0005759:GO:0046872:GO:0003924:GO:0031419:GO:0005739:GO:0050667	609058	PF02310:PF01642	-0.01															
chr6:49447735	SNV	C	1	C/T	PASS	7.948771267887266e-91	900.997		350	C=164,T=186	C=0.4686,T=0.5314	53.14	46.86	heterozygous	15	0.086	1.0		MMUT	NM_000255.4	MMUT:exonic:NM_000255.4	missense	ACT	8	p.Ala499Thr	c.1495G>A	1.0	0.003	58.0	T	GMAF=0.1033:AMAF=0.0988:EMAF=0.1057	0.1		Benign/Likely benign	6351958	rs2229385		.		GO:0019626:GO:0042802:GO:0042803:GO:0009791:GO:0004494:GO:0009235:GO:0043547:GO:0072341:GO:0005515:GO:0005737:GO:0005759:GO:0046872:GO:0003924:GO:0031419:GO:0005739:GO:0050667	609058	PF02310:PF01642	0.42															
chr6:49457808	SNV	C	1	T/T	PASS	0.0	3964.49		400	C=1,T=399	C=0.0025,T=0.9975	99.75	0.25	homozygous	55	0.449	1.0		MMUT	NM_000255.4	MMUT:exonic:NM_000255.4	synonymous	AAA	3	p.Lys212=	c.636G>A				T	GMAF=0.3984:AMAF=0.4274:EMAF=0.3836	0.39		Benign	6350580	rs2229384		.		GO:0019626:GO:0042802:GO:0042803:GO:0009791:GO:0004494:GO:0009235:GO:0043547:GO:0072341:GO:0005515:GO:0005737:GO:0005759:GO:0046872:GO:0003924:GO:0031419:GO:0005739:GO:0050667	609058	PF02310:PF01642	0.67															
chr7:117536538	INDEL	TGATT	4	T/T	PASS	0.0	3818.9		386	TGATT=0,T=386	TGATT=0.0,T=1.0	100.0	0.0	homozygous	48		1.0		CFTR	NM_000492.4	CFTR:intronic:NM_000492.4	unknown			p.?	c.744-9_744-6delGATT				T						rs1584787644:rs397508793:rs387906367:rs1584787639:rs1554380751:rs878854022		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		0.15,0.0,0.0,-0.48,2.25															
chr7:117536684	SNV	C	1	T/T	PASS	0.0	3838.9		400	C=4,T=396	C=0.01,T=0.99	99.0	1.0	homozygous	1	0.05	2.0		CFTR	NM_000492.4	CFTR:intronic:NM_000492.4	unknown			p.?	c.869+11C>T				T	GMAF=0.1304:AMAF=0.067:EMAF=0.1629			Benign		rs1800503		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		-0.61															
chr7:117559403	SNV	A	1	G/G	PASS	0.0	3938.34		400	A=1,G=399	A=0.0025,G=0.9975	99.75	0.25	homozygous	48	0.337	1.0		CFTR|CFTR-AS1	NM_000492.4|NR_149084.1	CFTR:intronic:NM_000492.4|CFTR-AS1:intronic_nc:NR_149084.1	unknown|	|	|	p.?|	c.1393-61A>G|	|	|	|	G|				Benign		rs34855237		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		0.3															
chr7:117559479	SNV	G	1	A/A	PASS	0.0	3847.53		400	G=5,A=395	G=0.0125,A=0.9875	98.75	1.25	homozygous	48	0.418	2.0		CFTR|CFTR-AS1	NM_000492.4|NR_149084.1	CFTR:exonic:NM_000492.4|CFTR-AS1:intronic_nc:NR_149084.1	missense|	ATG|	11|	p.Val470Met|	c.1408G>A|	1.0|	0.0|	21.0|	A|	GMAF=0.4024:AMAF=0.1496:EMAF=0.4681	0.39	M470V	Benign/Likely benign	3762337	rs397508204:rs213950		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		2.57															
chr8:142875392	SNV	A	1	A/C	PASS	2.859565178927494e-75	745.437		399	A=215,C=184	A=0.5388,C=0.4612	46.12	53.88	heterozygous	55	0.259	2.0		CYP11B1	NM_000497.4	CYP11B1:intronic:NM_000497.4	unknown			p.?	c.1122-80T>G				C						rs6395		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		-2.29															
chr8:142875509	SNV	T	1	T/C	PASS	1.2971792709839545e-102	1018.87		400	T=187,C=213	T=0.4675,C=0.5325	53.25	46.75	heterozygous	55	0.24	1.0		CYP11B1	NM_000497.4	CYP11B1:intronic:NM_000497.4	unknown			p.?	c.1122-197A>G				C						rs6392		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		-2.07															
chr8:142876440	SNV	G	1	G/A	PASS	6.266138646723313e-104	1032.03		400	G=187,A=213	G=0.4675,A=0.5325	53.25	46.75	heterozygous	55	0.315	1.0		CYP11B1	NM_000497.4	CYP11B1:intronic:NM_000497.4	unknown			p.?	c.800-45C>T				A	GMAF=0.4197:AMAF=0.3926:EMAF=0.4336					rs7822986		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		-1.98															
chr8:142876563	SNV	A	1	A/C	PASS	5.074578790806467e-37	362.946		219	A=125,C=94	A=0.5708,C=0.4292	42.92	57.08	heterozygous	55	0.382	2.0		CYP11B1	NM_000497.4	CYP11B1:intronic:NM_000497.4	unknown			p.?	c.799+119T>G				C						rs10956991		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		-3.19															
chr8:142877011	SNV	C	1	C/T	PASS	6.397348354826442e-103	1021.94		400	C=188,T=212	C=0.47,T=0.53	53.0	47.0	heterozygous	55	0.436	1.0		CYP11B1	NM_000497.4	CYP11B1:intronic:NM_000497.4	unknown			p.?	c.595+12G>A				T	GMAF=0.4845:AMAF=0.3736:EMAF=0.4587			Benign		rs6387		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		-3.01															
chr8:142877264	SNV	G	1	G/A	PASS	6.543347723737517e-78	771.842		400	G=212,A=188	G=0.53,A=0.47	47.0	53.0	heterozygous	8	0.012	1.0		CYP11B1	NM_000497.4	CYP11B1:intronic:NM_000497.4	unknown			p.?	c.396-42C>T				A	GMAF=0.0213:AMAF=0.0052:EMAF=0.0296					rs61751146		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		-2.37															
chr8:142879181	SNV	G	1	G/A	PASS	1.4584783945478813e-95	948.361		398	G=193,A=205	G=0.4849,A=0.5151	51.51	48.49	heterozygous	47	0.303	1.0		CYP11B1	NM_000497.4	CYP11B1:exonic:NM_000497.4	synonymous	GAT	2	p.Asp82=	c.246C>T				A	GMAF=0.3283:AMAF=0.1117:EMAF=0.4393	0.01		Benign	4162721	rs5283		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		-0.46															
chr8:142879589	SNV	T	1	T/C	PASS	3.664375746478273e-79	784.36		330	T=161,C=169	T=0.4879,C=0.5121	51.21	48.79	heterozygous	55	0.416	1.0		CYP11B1	NM_000497.4	CYP11B1:exonic:NM_000497.4	synonymous	CTG	1	p.Leu75=	c.225A>G				C	GMAF=0.4923:AMAF=0.4424:EMAF=0.4588	0.05		Benign	6338105	rs6410		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		-0.64															
chr10:102831636	SNV	G	1	G/T	PASS	5.2360043658576025e-80	792.81		397	G=210,T=187	G=0.529,T=0.471	47.1	52.9	heterozygous	25	0.18	1.0		CYP17A1	NM_000102.4	CYP17A1:intronic:NM_000102.4	unknown			p.?	c.1140-25C>A				T	GMAF=0.0847:AMAF=0.0645:EMAF=0.0951					rs17115100		(dui:D004700;dis:Endocrine System Diseases;g:CYP17A1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP17A1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP17A1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP17A1)(dui:D006058;dis:Gonadal Disorders;g:CYP17A1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP17A1)(dui:D008659;dis:Metabolic Diseases;g:CYP17A1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP17A1)(dui:D000013;dis:Congenital Abnormalities;g:CYP17A1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP17A1)(dui:D012734;dis:Disorders of Sex Development;g:CYP17A1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP17A1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP17A1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP17A1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP17A1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP17A1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP17A1)(dui:D009369;dis:Neoplasms;g:CYP17A1)(dui:D009371;dis:Neoplasms by Site;g:CYP17A1)(dui:D004066;dis:Digestive System Diseases;g:CYP17A1)(dui:D008107;dis:Liver Diseases;g:CYP17A1)(dui:D009422;dis:Nervous System Diseases;g:CYP17A1)(dui:D005831;dis:Genital Diseases, Female;g:CYP17A1)(dui:D005832;dis:Genital Diseases, Male;g:CYP17A1)(dui:D002493;dis:Central Nervous System Diseases;g:CYP17A1)(dui:D001927;dis:Brain Diseases;g:CYP17A1)(dui:D007246;dis:Infertility;g:CYP17A1)(dui:D014565;dis:Urogenital Neoplasms;g:CYP17A1)(dui:D010049;dis:Ovarian Diseases;g:CYP17A1)(dui:D000291;dis:Adnexal Diseases;g:CYP17A1)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CYP17A1)(dui:D011469;dis:Prostatic Diseases;g:CYP17A1)(dui:D012871;dis:Skin Diseases;g:CYP17A1)(dui:D001941;dis:Breast Diseases;g:CYP17A1)(dui:D003560;dis:Cysts;g:CYP17A1)(dui:D010048;dis:Ovarian Cysts;g:CYP17A1)(dui:D001943;dis:Breast Neoplasms;g:CYP17A1)(dui:D005834;dis:Genital Neoplasms, Male;g:CYP17A1)(dui:D009370;dis:Neoplasms by Histologic Type;g:CYP17A1)(dui:D011471;dis:Prostatic Neoplasms;g:CYP17A1)(dui:D002318;dis:Cardiovascular Diseases;g:CYP17A1)(dui:D004067;dis:Digestive System Neoplasms;g:CYP17A1)(dui:D014652;dis:Vascular Diseases;g:CYP17A1)(dui:D019636;dis:Neurodegenerative Diseases;g:CYP17A1)(dui:D006973;dis:Hypertension;g:CYP17A1)(dui:D009069;dis:Movement Disorders;g:CYP17A1)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:CYP17A1)(dui:D001523;dis:Mental Disorders;g:CYP17A1)(dui:D002277;dis:Carcinoma;g:CYP17A1)(dui:D010300;dis:Parkinson Disease;g:CYP17A1)(dui:D001480;dis:Basal Ganglia Diseases;g:CYP17A1)(dui:D020734;dis:Parkinsonian Disorders;g:CYP17A1)(dui:D000230;dis:Adenocarcinoma;g:CYP17A1)(dui:D008113;dis:Liver Neoplasms;g:CYP17A1)(dui:D007247;dis:Infertility, Female;g:CYP17A1)(dui:D020018;dis:Sexual Dysfunctions, Psychological;g:CYP17A1)(dui:D006528;dis:Carcinoma, Hepatocellular;g:CYP17A1)(dui:D007006;dis:Hypogonadism;g:CYP17A1)(dui:D007248;dis:Infertility, Male;g:CYP17A1)(dui:D010900;dis:Pituitary Diseases;g:CYP17A1)(dui:D005234;dis:Fatty Liver;g:CYP17A1)(dui:D007018;dis:Hypopituitarism;g:CYP17A1)(dui:D008103;dis:Liver Cirrhosis;g:CYP17A1)(dui:D014883;dis:Water-Electrolyte Imbalance;g:CYP17A1)(dui:D006947;dis:Hyperkalemia;g:CYP17A1)(dui:D006974;dis:Hypertension, Malignant;g:CYP17A1)(dui:D007027;dis:Hypothalamic Diseases;g:CYP17A1)(dui:D008106;dis:Liver Cirrhosis, Experimental;g:CYP17A1)(dui:D065626;dis:Non-alcoholic Fatty Liver Disease;g:CYP17A1)	Stanolone:Dexamethasone:Ketoconazole:Nabiximols:Abiraterone:Medical Cannabis:Cannabidiol:Clomifene:Aldosterone:NADH:Spironolactone:Aminophenazone:Dexamethasone acetate:Progesterone:Prasterone	GO:0019825:GO:0042448:GO:0008202:GO:0005783:GO:0006694:GO:0043025:GO:0042446:GO:0020037:GO:0005789:GO:0006704:GO:0007548:GO:0006702:GO:0005506:GO:0004508:GO:0047442:GO:0055114:GO:0030424	609300	PF00067	-0.12															
chr10:102832918	SNV	G	1	G/C	PASS	1.971968621279829e-76	757.051		400	G=216,C=184	G=0.54,C=0.46	46.0	54.0	heterozygous	32	0.35	1.0		CYP17A1	NM_000102.4	CYP17A1:intronic:NM_000102.4	unknown			p.?	c.969+75C>G				C						rs3740397		(dui:D004700;dis:Endocrine System Diseases;g:CYP17A1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP17A1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP17A1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP17A1)(dui:D006058;dis:Gonadal Disorders;g:CYP17A1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP17A1)(dui:D008659;dis:Metabolic Diseases;g:CYP17A1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP17A1)(dui:D000013;dis:Congenital Abnormalities;g:CYP17A1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP17A1)(dui:D012734;dis:Disorders of Sex Development;g:CYP17A1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP17A1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP17A1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP17A1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP17A1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP17A1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP17A1)(dui:D009369;dis:Neoplasms;g:CYP17A1)(dui:D009371;dis:Neoplasms by Site;g:CYP17A1)(dui:D004066;dis:Digestive System Diseases;g:CYP17A1)(dui:D008107;dis:Liver Diseases;g:CYP17A1)(dui:D009422;dis:Nervous System Diseases;g:CYP17A1)(dui:D005831;dis:Genital Diseases, Female;g:CYP17A1)(dui:D005832;dis:Genital Diseases, Male;g:CYP17A1)(dui:D002493;dis:Central Nervous System Diseases;g:CYP17A1)(dui:D001927;dis:Brain Diseases;g:CYP17A1)(dui:D007246;dis:Infertility;g:CYP17A1)(dui:D014565;dis:Urogenital Neoplasms;g:CYP17A1)(dui:D010049;dis:Ovarian Diseases;g:CYP17A1)(dui:D000291;dis:Adnexal Diseases;g:CYP17A1)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CYP17A1)(dui:D011469;dis:Prostatic Diseases;g:CYP17A1)(dui:D012871;dis:Skin Diseases;g:CYP17A1)(dui:D001941;dis:Breast Diseases;g:CYP17A1)(dui:D003560;dis:Cysts;g:CYP17A1)(dui:D010048;dis:Ovarian Cysts;g:CYP17A1)(dui:D001943;dis:Breast Neoplasms;g:CYP17A1)(dui:D005834;dis:Genital Neoplasms, Male;g:CYP17A1)(dui:D009370;dis:Neoplasms by Histologic Type;g:CYP17A1)(dui:D011471;dis:Prostatic Neoplasms;g:CYP17A1)(dui:D002318;dis:Cardiovascular Diseases;g:CYP17A1)(dui:D004067;dis:Digestive System Neoplasms;g:CYP17A1)(dui:D014652;dis:Vascular Diseases;g:CYP17A1)(dui:D019636;dis:Neurodegenerative Diseases;g:CYP17A1)(dui:D006973;dis:Hypertension;g:CYP17A1)(dui:D009069;dis:Movement Disorders;g:CYP17A1)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:CYP17A1)(dui:D001523;dis:Mental Disorders;g:CYP17A1)(dui:D002277;dis:Carcinoma;g:CYP17A1)(dui:D010300;dis:Parkinson Disease;g:CYP17A1)(dui:D001480;dis:Basal Ganglia Diseases;g:CYP17A1)(dui:D020734;dis:Parkinsonian Disorders;g:CYP17A1)(dui:D000230;dis:Adenocarcinoma;g:CYP17A1)(dui:D008113;dis:Liver Neoplasms;g:CYP17A1)(dui:D007247;dis:Infertility, Female;g:CYP17A1)(dui:D020018;dis:Sexual Dysfunctions, Psychological;g:CYP17A1)(dui:D006528;dis:Carcinoma, Hepatocellular;g:CYP17A1)(dui:D007006;dis:Hypogonadism;g:CYP17A1)(dui:D007248;dis:Infertility, Male;g:CYP17A1)(dui:D010900;dis:Pituitary Diseases;g:CYP17A1)(dui:D005234;dis:Fatty Liver;g:CYP17A1)(dui:D007018;dis:Hypopituitarism;g:CYP17A1)(dui:D008103;dis:Liver Cirrhosis;g:CYP17A1)(dui:D014883;dis:Water-Electrolyte Imbalance;g:CYP17A1)(dui:D006947;dis:Hyperkalemia;g:CYP17A1)(dui:D006974;dis:Hypertension, Malignant;g:CYP17A1)(dui:D007027;dis:Hypothalamic Diseases;g:CYP17A1)(dui:D008106;dis:Liver Cirrhosis, Experimental;g:CYP17A1)(dui:D065626;dis:Non-alcoholic Fatty Liver Disease;g:CYP17A1)	Stanolone:Dexamethasone:Ketoconazole:Nabiximols:Abiraterone:Medical Cannabis:Cannabidiol:Clomifene:Aldosterone:NADH:Spironolactone:Aminophenazone:Dexamethasone acetate:Progesterone:Prasterone	GO:0019825:GO:0042448:GO:0008202:GO:0005783:GO:0006694:GO:0043025:GO:0042446:GO:0020037:GO:0005789:GO:0006704:GO:0007548:GO:0006702:GO:0005506:GO:0004508:GO:0047442:GO:0055114:GO:0030424	609300	PF00067	0.26															
chr10:102834750	SNV	A	1	A/G	PASS	1.112243816565983e-76	759.538		400	A=216,G=184	A=0.54,G=0.46	46.0	54.0	heterozygous	25	0.219	1.0		CYP17A1	NM_000102.4	CYP17A1:intronic:NM_000102.4	unknown			p.?	c.666+35T>C				G	GMAF=0.1249:AMAF=0.18:EMAF=0.0967					rs1004467		(dui:D004700;dis:Endocrine System Diseases;g:CYP17A1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP17A1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP17A1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP17A1)(dui:D006058;dis:Gonadal Disorders;g:CYP17A1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP17A1)(dui:D008659;dis:Metabolic Diseases;g:CYP17A1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP17A1)(dui:D000013;dis:Congenital Abnormalities;g:CYP17A1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP17A1)(dui:D012734;dis:Disorders of Sex Development;g:CYP17A1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP17A1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP17A1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP17A1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP17A1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP17A1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP17A1)(dui:D009369;dis:Neoplasms;g:CYP17A1)(dui:D009371;dis:Neoplasms by Site;g:CYP17A1)(dui:D004066;dis:Digestive System Diseases;g:CYP17A1)(dui:D008107;dis:Liver Diseases;g:CYP17A1)(dui:D009422;dis:Nervous System Diseases;g:CYP17A1)(dui:D005831;dis:Genital Diseases, Female;g:CYP17A1)(dui:D005832;dis:Genital Diseases, Male;g:CYP17A1)(dui:D002493;dis:Central Nervous System Diseases;g:CYP17A1)(dui:D001927;dis:Brain Diseases;g:CYP17A1)(dui:D007246;dis:Infertility;g:CYP17A1)(dui:D014565;dis:Urogenital Neoplasms;g:CYP17A1)(dui:D010049;dis:Ovarian Diseases;g:CYP17A1)(dui:D000291;dis:Adnexal Diseases;g:CYP17A1)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CYP17A1)(dui:D011469;dis:Prostatic Diseases;g:CYP17A1)(dui:D012871;dis:Skin Diseases;g:CYP17A1)(dui:D001941;dis:Breast Diseases;g:CYP17A1)(dui:D003560;dis:Cysts;g:CYP17A1)(dui:D010048;dis:Ovarian Cysts;g:CYP17A1)(dui:D001943;dis:Breast Neoplasms;g:CYP17A1)(dui:D005834;dis:Genital Neoplasms, Male;g:CYP17A1)(dui:D009370;dis:Neoplasms by Histologic Type;g:CYP17A1)(dui:D011471;dis:Prostatic Neoplasms;g:CYP17A1)(dui:D002318;dis:Cardiovascular Diseases;g:CYP17A1)(dui:D004067;dis:Digestive System Neoplasms;g:CYP17A1)(dui:D014652;dis:Vascular Diseases;g:CYP17A1)(dui:D019636;dis:Neurodegenerative Diseases;g:CYP17A1)(dui:D006973;dis:Hypertension;g:CYP17A1)(dui:D009069;dis:Movement Disorders;g:CYP17A1)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:CYP17A1)(dui:D001523;dis:Mental Disorders;g:CYP17A1)(dui:D002277;dis:Carcinoma;g:CYP17A1)(dui:D010300;dis:Parkinson Disease;g:CYP17A1)(dui:D001480;dis:Basal Ganglia Diseases;g:CYP17A1)(dui:D020734;dis:Parkinsonian Disorders;g:CYP17A1)(dui:D000230;dis:Adenocarcinoma;g:CYP17A1)(dui:D008113;dis:Liver Neoplasms;g:CYP17A1)(dui:D007247;dis:Infertility, Female;g:CYP17A1)(dui:D020018;dis:Sexual Dysfunctions, Psychological;g:CYP17A1)(dui:D006528;dis:Carcinoma, Hepatocellular;g:CYP17A1)(dui:D007006;dis:Hypogonadism;g:CYP17A1)(dui:D007248;dis:Infertility, Male;g:CYP17A1)(dui:D010900;dis:Pituitary Diseases;g:CYP17A1)(dui:D005234;dis:Fatty Liver;g:CYP17A1)(dui:D007018;dis:Hypopituitarism;g:CYP17A1)(dui:D008103;dis:Liver Cirrhosis;g:CYP17A1)(dui:D014883;dis:Water-Electrolyte Imbalance;g:CYP17A1)(dui:D006947;dis:Hyperkalemia;g:CYP17A1)(dui:D006974;dis:Hypertension, Malignant;g:CYP17A1)(dui:D007027;dis:Hypothalamic Diseases;g:CYP17A1)(dui:D008106;dis:Liver Cirrhosis, Experimental;g:CYP17A1)(dui:D065626;dis:Non-alcoholic Fatty Liver Disease;g:CYP17A1)	Stanolone:Dexamethasone:Ketoconazole:Nabiximols:Abiraterone:Medical Cannabis:Cannabidiol:Clomifene:Aldosterone:NADH:Spironolactone:Aminophenazone:Dexamethasone acetate:Progesterone:Prasterone	GO:0019825:GO:0042448:GO:0008202:GO:0005783:GO:0006694:GO:0043025:GO:0042446:GO:0020037:GO:0005789:GO:0006704:GO:0007548:GO:0006702:GO:0005506:GO:0004508:GO:0047442:GO:0055114:GO:0030424	609300	PF00067	-0.23															
chr10:102837167	SNV	C	1	C/A	PASS	1.7183039957263107e-75	747.649		329	C=164,A=165	C=0.4985,A=0.5015	50.15	49.85	heterozygous	32	0.41	2.0		CYP17A1	NM_000102.4	CYP17A1:exonic:NM_000102.4	synonymous	TCT	1	p.Ser65=	c.195G>T				A	GMAF=0.3833:AMAF=0.3616:EMAF=0.3944	0.17		Benign	3751499	rs6163		(dui:D004700;dis:Endocrine System Diseases;g:CYP17A1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP17A1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP17A1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP17A1)(dui:D006058;dis:Gonadal Disorders;g:CYP17A1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP17A1)(dui:D008659;dis:Metabolic Diseases;g:CYP17A1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP17A1)(dui:D000013;dis:Congenital Abnormalities;g:CYP17A1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP17A1)(dui:D012734;dis:Disorders of Sex Development;g:CYP17A1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP17A1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP17A1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP17A1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP17A1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP17A1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP17A1)(dui:D009369;dis:Neoplasms;g:CYP17A1)(dui:D009371;dis:Neoplasms by Site;g:CYP17A1)(dui:D004066;dis:Digestive System Diseases;g:CYP17A1)(dui:D008107;dis:Liver Diseases;g:CYP17A1)(dui:D009422;dis:Nervous System Diseases;g:CYP17A1)(dui:D005831;dis:Genital Diseases, Female;g:CYP17A1)(dui:D005832;dis:Genital Diseases, Male;g:CYP17A1)(dui:D002493;dis:Central Nervous System Diseases;g:CYP17A1)(dui:D001927;dis:Brain Diseases;g:CYP17A1)(dui:D007246;dis:Infertility;g:CYP17A1)(dui:D014565;dis:Urogenital Neoplasms;g:CYP17A1)(dui:D010049;dis:Ovarian Diseases;g:CYP17A1)(dui:D000291;dis:Adnexal Diseases;g:CYP17A1)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CYP17A1)(dui:D011469;dis:Prostatic Diseases;g:CYP17A1)(dui:D012871;dis:Skin Diseases;g:CYP17A1)(dui:D001941;dis:Breast Diseases;g:CYP17A1)(dui:D003560;dis:Cysts;g:CYP17A1)(dui:D010048;dis:Ovarian Cysts;g:CYP17A1)(dui:D001943;dis:Breast Neoplasms;g:CYP17A1)(dui:D005834;dis:Genital Neoplasms, Male;g:CYP17A1)(dui:D009370;dis:Neoplasms by Histologic Type;g:CYP17A1)(dui:D011471;dis:Prostatic Neoplasms;g:CYP17A1)(dui:D002318;dis:Cardiovascular Diseases;g:CYP17A1)(dui:D004067;dis:Digestive System Neoplasms;g:CYP17A1)(dui:D014652;dis:Vascular Diseases;g:CYP17A1)(dui:D019636;dis:Neurodegenerative Diseases;g:CYP17A1)(dui:D006973;dis:Hypertension;g:CYP17A1)(dui:D009069;dis:Movement Disorders;g:CYP17A1)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:CYP17A1)(dui:D001523;dis:Mental Disorders;g:CYP17A1)(dui:D002277;dis:Carcinoma;g:CYP17A1)(dui:D010300;dis:Parkinson Disease;g:CYP17A1)(dui:D001480;dis:Basal Ganglia Diseases;g:CYP17A1)(dui:D020734;dis:Parkinsonian Disorders;g:CYP17A1)(dui:D000230;dis:Adenocarcinoma;g:CYP17A1)(dui:D008113;dis:Liver Neoplasms;g:CYP17A1)(dui:D007247;dis:Infertility, Female;g:CYP17A1)(dui:D020018;dis:Sexual Dysfunctions, Psychological;g:CYP17A1)(dui:D006528;dis:Carcinoma, Hepatocellular;g:CYP17A1)(dui:D007006;dis:Hypogonadism;g:CYP17A1)(dui:D007248;dis:Infertility, Male;g:CYP17A1)(dui:D010900;dis:Pituitary Diseases;g:CYP17A1)(dui:D005234;dis:Fatty Liver;g:CYP17A1)(dui:D007018;dis:Hypopituitarism;g:CYP17A1)(dui:D008103;dis:Liver Cirrhosis;g:CYP17A1)(dui:D014883;dis:Water-Electrolyte Imbalance;g:CYP17A1)(dui:D006947;dis:Hyperkalemia;g:CYP17A1)(dui:D006974;dis:Hypertension, Malignant;g:CYP17A1)(dui:D007027;dis:Hypothalamic Diseases;g:CYP17A1)(dui:D008106;dis:Liver Cirrhosis, Experimental;g:CYP17A1)(dui:D065626;dis:Non-alcoholic Fatty Liver Disease;g:CYP17A1)	Stanolone:Dexamethasone:Ketoconazole:Nabiximols:Abiraterone:Medical Cannabis:Cannabidiol:Clomifene:Aldosterone:NADH:Spironolactone:Aminophenazone:Dexamethasone acetate:Progesterone:Prasterone	GO:0019825:GO:0042448:GO:0008202:GO:0005783:GO:0006694:GO:0043025:GO:0042446:GO:0020037:GO:0005789:GO:0006704:GO:0007548:GO:0006702:GO:0005506:GO:0004508:GO:0047442:GO:0055114:GO:0030424	609300	PF00067	-0.04															
chr10:102837224	SNV	G	1	G/A	PASS	3.1834644175564095e-95	944.971		399	G=195,A=204	G=0.4887,A=0.5113	51.13	48.87	heterozygous	39	0.443	1.0		CYP17A1	NM_000102.4	CYP17A1:exonic:NM_000102.4	synonymous	CAT	1	p.His46=	c.138C>T				A	GMAF=0.3949:AMAF=0.3645:EMAF=0.4105	0.02		Benign	3751500	rs6162		(dui:D004700;dis:Endocrine System Diseases;g:CYP17A1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP17A1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP17A1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP17A1)(dui:D006058;dis:Gonadal Disorders;g:CYP17A1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP17A1)(dui:D008659;dis:Metabolic Diseases;g:CYP17A1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP17A1)(dui:D000013;dis:Congenital Abnormalities;g:CYP17A1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP17A1)(dui:D012734;dis:Disorders of Sex Development;g:CYP17A1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP17A1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP17A1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP17A1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP17A1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP17A1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP17A1)(dui:D009369;dis:Neoplasms;g:CYP17A1)(dui:D009371;dis:Neoplasms by Site;g:CYP17A1)(dui:D004066;dis:Digestive System Diseases;g:CYP17A1)(dui:D008107;dis:Liver Diseases;g:CYP17A1)(dui:D009422;dis:Nervous System Diseases;g:CYP17A1)(dui:D005831;dis:Genital Diseases, Female;g:CYP17A1)(dui:D005832;dis:Genital Diseases, Male;g:CYP17A1)(dui:D002493;dis:Central Nervous System Diseases;g:CYP17A1)(dui:D001927;dis:Brain Diseases;g:CYP17A1)(dui:D007246;dis:Infertility;g:CYP17A1)(dui:D014565;dis:Urogenital Neoplasms;g:CYP17A1)(dui:D010049;dis:Ovarian Diseases;g:CYP17A1)(dui:D000291;dis:Adnexal Diseases;g:CYP17A1)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CYP17A1)(dui:D011469;dis:Prostatic Diseases;g:CYP17A1)(dui:D012871;dis:Skin Diseases;g:CYP17A1)(dui:D001941;dis:Breast Diseases;g:CYP17A1)(dui:D003560;dis:Cysts;g:CYP17A1)(dui:D010048;dis:Ovarian Cysts;g:CYP17A1)(dui:D001943;dis:Breast Neoplasms;g:CYP17A1)(dui:D005834;dis:Genital Neoplasms, Male;g:CYP17A1)(dui:D009370;dis:Neoplasms by Histologic Type;g:CYP17A1)(dui:D011471;dis:Prostatic Neoplasms;g:CYP17A1)(dui:D002318;dis:Cardiovascular Diseases;g:CYP17A1)(dui:D004067;dis:Digestive System Neoplasms;g:CYP17A1)(dui:D014652;dis:Vascular Diseases;g:CYP17A1)(dui:D019636;dis:Neurodegenerative Diseases;g:CYP17A1)(dui:D006973;dis:Hypertension;g:CYP17A1)(dui:D009069;dis:Movement Disorders;g:CYP17A1)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:CYP17A1)(dui:D001523;dis:Mental Disorders;g:CYP17A1)(dui:D002277;dis:Carcinoma;g:CYP17A1)(dui:D010300;dis:Parkinson Disease;g:CYP17A1)(dui:D001480;dis:Basal Ganglia Diseases;g:CYP17A1)(dui:D020734;dis:Parkinsonian Disorders;g:CYP17A1)(dui:D000230;dis:Adenocarcinoma;g:CYP17A1)(dui:D008113;dis:Liver Neoplasms;g:CYP17A1)(dui:D007247;dis:Infertility, Female;g:CYP17A1)(dui:D020018;dis:Sexual Dysfunctions, Psychological;g:CYP17A1)(dui:D006528;dis:Carcinoma, Hepatocellular;g:CYP17A1)(dui:D007006;dis:Hypogonadism;g:CYP17A1)(dui:D007248;dis:Infertility, Male;g:CYP17A1)(dui:D010900;dis:Pituitary Diseases;g:CYP17A1)(dui:D005234;dis:Fatty Liver;g:CYP17A1)(dui:D007018;dis:Hypopituitarism;g:CYP17A1)(dui:D008103;dis:Liver Cirrhosis;g:CYP17A1)(dui:D014883;dis:Water-Electrolyte Imbalance;g:CYP17A1)(dui:D006947;dis:Hyperkalemia;g:CYP17A1)(dui:D006974;dis:Hypertension, Malignant;g:CYP17A1)(dui:D007027;dis:Hypothalamic Diseases;g:CYP17A1)(dui:D008106;dis:Liver Cirrhosis, Experimental;g:CYP17A1)(dui:D065626;dis:Non-alcoholic Fatty Liver Disease;g:CYP17A1)	Stanolone:Dexamethasone:Ketoconazole:Nabiximols:Abiraterone:Medical Cannabis:Cannabidiol:Clomifene:Aldosterone:NADH:Spironolactone:Aminophenazone:Dexamethasone acetate:Progesterone:Prasterone	GO:0019825:GO:0042448:GO:0008202:GO:0005783:GO:0006694:GO:0043025:GO:0042446:GO:0020037:GO:0005789:GO:0006704:GO:0007548:GO:0006702:GO:0005506:GO:0004508:GO:0047442:GO:0055114:GO:0030424	609300	PF00067	-0.11															
chr10:102837395	SNV	A	1	A/G	PASS	4.4668359215096925e-112	1113.5		400	A=179,G=221	A=0.4475,G=0.5525	55.25	44.75	heterozygous	32	0.41	1.0		CYP17A1	NM_000102.4	CYP17A1:utr_5:NM_000102.4	unknown		1	p.?	c.-34T>C				G	GMAF=0.3823:AMAF=0.3608:EMAF=0.3934			Benign		rs743572		(dui:D004700;dis:Endocrine System Diseases;g:CYP17A1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP17A1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP17A1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP17A1)(dui:D006058;dis:Gonadal Disorders;g:CYP17A1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP17A1)(dui:D008659;dis:Metabolic Diseases;g:CYP17A1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP17A1)(dui:D000013;dis:Congenital Abnormalities;g:CYP17A1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP17A1)(dui:D012734;dis:Disorders of Sex Development;g:CYP17A1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP17A1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP17A1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP17A1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP17A1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP17A1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP17A1)(dui:D009369;dis:Neoplasms;g:CYP17A1)(dui:D009371;dis:Neoplasms by Site;g:CYP17A1)(dui:D004066;dis:Digestive System Diseases;g:CYP17A1)(dui:D008107;dis:Liver Diseases;g:CYP17A1)(dui:D009422;dis:Nervous System Diseases;g:CYP17A1)(dui:D005831;dis:Genital Diseases, Female;g:CYP17A1)(dui:D005832;dis:Genital Diseases, Male;g:CYP17A1)(dui:D002493;dis:Central Nervous System Diseases;g:CYP17A1)(dui:D001927;dis:Brain Diseases;g:CYP17A1)(dui:D007246;dis:Infertility;g:CYP17A1)(dui:D014565;dis:Urogenital Neoplasms;g:CYP17A1)(dui:D010049;dis:Ovarian Diseases;g:CYP17A1)(dui:D000291;dis:Adnexal Diseases;g:CYP17A1)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CYP17A1)(dui:D011469;dis:Prostatic Diseases;g:CYP17A1)(dui:D012871;dis:Skin Diseases;g:CYP17A1)(dui:D001941;dis:Breast Diseases;g:CYP17A1)(dui:D003560;dis:Cysts;g:CYP17A1)(dui:D010048;dis:Ovarian Cysts;g:CYP17A1)(dui:D001943;dis:Breast Neoplasms;g:CYP17A1)(dui:D005834;dis:Genital Neoplasms, Male;g:CYP17A1)(dui:D009370;dis:Neoplasms by Histologic Type;g:CYP17A1)(dui:D011471;dis:Prostatic Neoplasms;g:CYP17A1)(dui:D002318;dis:Cardiovascular Diseases;g:CYP17A1)(dui:D004067;dis:Digestive System Neoplasms;g:CYP17A1)(dui:D014652;dis:Vascular Diseases;g:CYP17A1)(dui:D019636;dis:Neurodegenerative Diseases;g:CYP17A1)(dui:D006973;dis:Hypertension;g:CYP17A1)(dui:D009069;dis:Movement Disorders;g:CYP17A1)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:CYP17A1)(dui:D001523;dis:Mental Disorders;g:CYP17A1)(dui:D002277;dis:Carcinoma;g:CYP17A1)(dui:D010300;dis:Parkinson Disease;g:CYP17A1)(dui:D001480;dis:Basal Ganglia Diseases;g:CYP17A1)(dui:D020734;dis:Parkinsonian Disorders;g:CYP17A1)(dui:D000230;dis:Adenocarcinoma;g:CYP17A1)(dui:D008113;dis:Liver Neoplasms;g:CYP17A1)(dui:D007247;dis:Infertility, Female;g:CYP17A1)(dui:D020018;dis:Sexual Dysfunctions, Psychological;g:CYP17A1)(dui:D006528;dis:Carcinoma, Hepatocellular;g:CYP17A1)(dui:D007006;dis:Hypogonadism;g:CYP17A1)(dui:D007248;dis:Infertility, Male;g:CYP17A1)(dui:D010900;dis:Pituitary Diseases;g:CYP17A1)(dui:D005234;dis:Fatty Liver;g:CYP17A1)(dui:D007018;dis:Hypopituitarism;g:CYP17A1)(dui:D008103;dis:Liver Cirrhosis;g:CYP17A1)(dui:D014883;dis:Water-Electrolyte Imbalance;g:CYP17A1)(dui:D006947;dis:Hyperkalemia;g:CYP17A1)(dui:D006974;dis:Hypertension, Malignant;g:CYP17A1)(dui:D007027;dis:Hypothalamic Diseases;g:CYP17A1)(dui:D008106;dis:Liver Cirrhosis, Experimental;g:CYP17A1)(dui:D065626;dis:Non-alcoholic Fatty Liver Disease;g:CYP17A1)	Stanolone:Dexamethasone:Ketoconazole:Nabiximols:Abiraterone:Medical Cannabis:Cannabidiol:Clomifene:Aldosterone:NADH:Spironolactone:Aminophenazone:Dexamethasone acetate:Progesterone:Prasterone	GO:0019825:GO:0042448:GO:0008202:GO:0005783:GO:0006694:GO:0043025:GO:0042446:GO:0020037:GO:0005789:GO:0006704:GO:0007548:GO:0006702:GO:0005506:GO:0004508:GO:0047442:GO:0055114:GO:0030424	609300	PF00067	-0.52															
chr10:123041337	SNV	C	1	T/T	PASS	0.0	3986.06		400	C=0,T=400	C=0.0,T=1.0	100.0	0.0	homozygous	33	0.228	1.0		ACADSB	NM_001609.4	ACADSB:exonic:NM_001609.4	synonymous	CAT	5	p.His213=	c.639C>T				T	GMAF=0.2281:AMAF=0.2156:EMAF=0.2345	0.02		Benign	3997809	rs1140591		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADSB)(dui:NBS3;dis:Secondary Conditions;g:ACADSB)(dui:NBS18;dis:2-Methylbutyrylglycinuria;g:ACADSB)(dui:NBS4;dis:Organic Acid Condition;g:ACADSB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADSB)(dui:D008659;dis:Metabolic Diseases;g:ACADSB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADSB)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADSB)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADSB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ACADSB)(dui:D001523;dis:Mental Disorders;g:ACADSB)(dui:D065886;dis:Neurodevelopmental Disorders;g:ACADSB)(dui:D002659;dis:Child Development Disorders, Pervasive;g:ACADSB)(dui:D001321;dis:Autistic Disorder;g:ACADSB)	Valproic acid:Isoleucine	GO:0003853:GO:0042802:GO:0009083:GO:0005759:GO:0050660:GO:0016937:GO:0005739:GO:0102035:GO:0006550:GO:0055114:GO:0006631	600301		-1.56															
chr11:5226503	SNV	A	1	A/C	PASS	7.423351070366103e-88	871.294		398	A=202,C=196	A=0.5075,C=0.4925	49.25	50.75	heterozygous	56	0.369	1.0		HBB	NM_000518.5	HBB:intronic:NM_000518.5	unknown			p.?	c.315+74T>G				C				Benign		rs7480526		(dui:D006425;dis:Hemic and Lymphatic Diseases;g:HBB)(dui:D006402;dis:Hematologic Diseases;g:HBB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:HBB)(dui:D030342;dis:Genetic Diseases, Inborn;g:HBB)(dui:D000740;dis:Anemia;g:HBB)(dui:D000743;dis:Anemia, Hemolytic;g:HBB)(dui:D000745;dis:Anemia, Hemolytic, Congenital;g:HBB)(dui:D006453;dis:Hemoglobinopathies;g:HBB)(dui:NBS1;dis:Recommended Newborn Screening Panels;g:HBB)(dui:NBS13;dis:Hemoglobin Disorder;g:HBB)(dui:NBS2;dis:Core Conditions;g:HBB)(dui:NBS67;dis:Hb SS-disease (sickle cell anemia);g:HBB)(dui:NBS68;dis:Hb beta zero-thalassemia;g:HBB)(dui:D013789;dis:Thalassemia;g:HBB)(dui:D017086;dis:beta-Thalassemia;g:HBB)(dui:D000755;dis:Anemia, Sickle Cell;g:HBB)(dui:D017085;dis:alpha-Thalassemia;g:HBB)(dui:D055538;dis:delta-Thalassemia;g:HBB)(dui:D006450;dis:Hemoglobin SC Disease;g:HBB)(dui:D001855;dis:Bone Marrow Diseases;g:HBB)(dui:D009196;dis:Myeloproliferative Disorders;g:HBB)(dui:D006445;dis:Hemoglobin C Disease;g:HBB)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:HBB)(dui:D012871;dis:Skin Diseases;g:HBB)(dui:D011086;dis:Polycythemia;g:HBB)(dui:D008708;dis:Methemoglobinemia;g:HBB)(dui:D017486;dis:Acneiform Eruptions;g:HBB)(dui:D054506;dis:Chloracne;g:HBB)(dui:D011087;dis:Polycythemia Vera;g:HBB)	2,6-dicarboxynaphthalene:Sodium ferric gluconate complex:Oxygen:Zinc chloride:4-Carboxycinnamic Acid:2-[(2-methoxy-5-methylphenoxy)methyl]pyridine:2-[4-({[(3,5-DICHLOROPHENYL)AMINO]CARBONYL}AMINO)PHENOXY]-2-METHYLPROPANOIC ACID:Ferric pyrophosphate citrate:Pentaerythritol tetranitrate:Efaproxiral:Zinc sulfate, unspecified form:Zinc:Sebacic acid:Trimesic acid:Zinc acetate:Copper:Ferric pyrophosphate:Iron Dextran:4-[(5-methoxy-2-methylphenoxy)methyl]pyridine:Nitrous acid	GO:0045429:GO:0015671:GO:0030492:GO:0007596:GO:0005576:GO:1904813:GO:0070062:GO:0031838:GO:0072562:GO:0005829:GO:0015701:GO:0070527:GO:0019825:GO:0030185:GO:1904724:GO:0043177:GO:0043312:GO:0042542:GO:0005344:GO:0006898:GO:0008217:GO:0020037:GO:0042744:GO:0005833:GO:0004601:GO:0005615:GO:0005515:GO:0070293:GO:0046872:GO:0071682:GO:0098869:GO:0010942:GO:0031721:GO:0031720	141900	PF00042	0.17															
chr11:5226561	SNV	C	1	G/G	PASS	0.0	3991.39		400	C=0,G=400	C=0.0,G=1.0	100.0	0.0	homozygous	55	0.28	1.0		HBB	NM_000518.5	HBB:intronic:NM_000518.5	unknown			p.?	c.315+16G>C				G	GMAF=0.1491:AMAF=0.1297:EMAF=0.159			Benign/Likely benign		rs10768683		(dui:D006425;dis:Hemic and Lymphatic Diseases;g:HBB)(dui:D006402;dis:Hematologic Diseases;g:HBB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:HBB)(dui:D030342;dis:Genetic Diseases, Inborn;g:HBB)(dui:D000740;dis:Anemia;g:HBB)(dui:D000743;dis:Anemia, Hemolytic;g:HBB)(dui:D000745;dis:Anemia, Hemolytic, Congenital;g:HBB)(dui:D006453;dis:Hemoglobinopathies;g:HBB)(dui:NBS1;dis:Recommended Newborn Screening Panels;g:HBB)(dui:NBS13;dis:Hemoglobin Disorder;g:HBB)(dui:NBS2;dis:Core Conditions;g:HBB)(dui:NBS67;dis:Hb SS-disease (sickle cell anemia);g:HBB)(dui:NBS68;dis:Hb beta zero-thalassemia;g:HBB)(dui:D013789;dis:Thalassemia;g:HBB)(dui:D017086;dis:beta-Thalassemia;g:HBB)(dui:D000755;dis:Anemia, Sickle Cell;g:HBB)(dui:D017085;dis:alpha-Thalassemia;g:HBB)(dui:D055538;dis:delta-Thalassemia;g:HBB)(dui:D006450;dis:Hemoglobin SC Disease;g:HBB)(dui:D001855;dis:Bone Marrow Diseases;g:HBB)(dui:D009196;dis:Myeloproliferative Disorders;g:HBB)(dui:D006445;dis:Hemoglobin C Disease;g:HBB)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:HBB)(dui:D012871;dis:Skin Diseases;g:HBB)(dui:D011086;dis:Polycythemia;g:HBB)(dui:D008708;dis:Methemoglobinemia;g:HBB)(dui:D017486;dis:Acneiform Eruptions;g:HBB)(dui:D054506;dis:Chloracne;g:HBB)(dui:D011087;dis:Polycythemia Vera;g:HBB)	2,6-dicarboxynaphthalene:Sodium ferric gluconate complex:Oxygen:Zinc chloride:4-Carboxycinnamic Acid:2-[(2-methoxy-5-methylphenoxy)methyl]pyridine:2-[4-({[(3,5-DICHLOROPHENYL)AMINO]CARBONYL}AMINO)PHENOXY]-2-METHYLPROPANOIC ACID:Ferric pyrophosphate citrate:Pentaerythritol tetranitrate:Efaproxiral:Zinc sulfate, unspecified form:Zinc:Sebacic acid:Trimesic acid:Zinc acetate:Copper:Ferric pyrophosphate:Iron Dextran:4-[(5-methoxy-2-methylphenoxy)methyl]pyridine:Nitrous acid	GO:0045429:GO:0015671:GO:0030492:GO:0007596:GO:0005576:GO:1904813:GO:0070062:GO:0031838:GO:0072562:GO:0005829:GO:0015701:GO:0070527:GO:0019825:GO:0030185:GO:1904724:GO:0043177:GO:0043312:GO:0042542:GO:0005344:GO:0006898:GO:0008217:GO:0020037:GO:0042744:GO:0005833:GO:0004601:GO:0005615:GO:0005515:GO:0070293:GO:0046872:GO:0071682:GO:0098869:GO:0010942:GO:0031721:GO:0031720	141900	PF00042	-3.19															
chr11:5227013	SNV	A	1	G/G	PASS	0.0	3960.57		396	A=0,G=396	A=0.0,G=1.0	100.0	0.0	homozygous	55	0.286	1.0		HBB	NM_000518.5	HBB:exonic:NM_000518.5	synonymous	CAC	1	p.His3=	c.9T>C				G	GMAF=0.1513:AMAF=0.1361:EMAF=0.1591	0.1		Benign	6484194	rs713040:rs63750898:rs63750407		(dui:D006425;dis:Hemic and Lymphatic Diseases;g:HBB)(dui:D006402;dis:Hematologic Diseases;g:HBB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:HBB)(dui:D030342;dis:Genetic Diseases, Inborn;g:HBB)(dui:D000740;dis:Anemia;g:HBB)(dui:D000743;dis:Anemia, Hemolytic;g:HBB)(dui:D000745;dis:Anemia, Hemolytic, Congenital;g:HBB)(dui:D006453;dis:Hemoglobinopathies;g:HBB)(dui:NBS1;dis:Recommended Newborn Screening Panels;g:HBB)(dui:NBS13;dis:Hemoglobin Disorder;g:HBB)(dui:NBS2;dis:Core Conditions;g:HBB)(dui:NBS67;dis:Hb SS-disease (sickle cell anemia);g:HBB)(dui:NBS68;dis:Hb beta zero-thalassemia;g:HBB)(dui:D013789;dis:Thalassemia;g:HBB)(dui:D017086;dis:beta-Thalassemia;g:HBB)(dui:D000755;dis:Anemia, Sickle Cell;g:HBB)(dui:D017085;dis:alpha-Thalassemia;g:HBB)(dui:D055538;dis:delta-Thalassemia;g:HBB)(dui:D006450;dis:Hemoglobin SC Disease;g:HBB)(dui:D001855;dis:Bone Marrow Diseases;g:HBB)(dui:D009196;dis:Myeloproliferative Disorders;g:HBB)(dui:D006445;dis:Hemoglobin C Disease;g:HBB)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:HBB)(dui:D012871;dis:Skin Diseases;g:HBB)(dui:D011086;dis:Polycythemia;g:HBB)(dui:D008708;dis:Methemoglobinemia;g:HBB)(dui:D017486;dis:Acneiform Eruptions;g:HBB)(dui:D054506;dis:Chloracne;g:HBB)(dui:D011087;dis:Polycythemia Vera;g:HBB)	2,6-dicarboxynaphthalene:Sodium ferric gluconate complex:Oxygen:Zinc chloride:4-Carboxycinnamic Acid:2-[(2-methoxy-5-methylphenoxy)methyl]pyridine:2-[4-({[(3,5-DICHLOROPHENYL)AMINO]CARBONYL}AMINO)PHENOXY]-2-METHYLPROPANOIC ACID:Ferric pyrophosphate citrate:Pentaerythritol tetranitrate:Efaproxiral:Zinc sulfate, unspecified form:Zinc:Sebacic acid:Trimesic acid:Zinc acetate:Copper:Ferric pyrophosphate:Iron Dextran:4-[(5-methoxy-2-methylphenoxy)methyl]pyridine:Nitrous acid	GO:0045429:GO:0015671:GO:0030492:GO:0007596:GO:0005576:GO:1904813:GO:0070062:GO:0031838:GO:0072562:GO:0005829:GO:0015701:GO:0070527:GO:0019825:GO:0030185:GO:1904724:GO:0043177:GO:0043312:GO:0042542:GO:0005344:GO:0006898:GO:0008217:GO:0020037:GO:0042744:GO:0005833:GO:0004601:GO:0005615:GO:0005515:GO:0070293:GO:0046872:GO:0071682:GO:0098869:GO:0010942:GO:0031721:GO:0031720	141900	PF00042	-0.89															
chr11:68780792	SNV	C	1	A/A	PASS	0.0	3993.33		399	C=0,A=398	C=0.0,A=1.0	99.75	0.25	homozygous	49	0.107	1.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.1353-47G>T				A	GMAF=0.0881:AMAF=0.1534:EMAF=0.0546					rs750602950:rs3019576		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	-0.99															
chr11:68781872	SNV	A	1	G/G	PASS	0.0	3690.23		399	A=10,G=389	A=0.0251,G=0.9749	97.49	2.510000000000005	homozygous	56	0.107	3.0		CPT1A	NM_001876.4	CPT1A:exonic:NM_001876.4	synonymous	TTC	11	p.Phe417=	c.1251T>C				G	GMAF=0.088:AMAF=0.153:EMAF=0.0547			Benign		rs755361411:rs2228502		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.3															
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	3.7818125611095065e-17	164.223		17	AAA=0,GCT=17	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															
chr11:108121598	SNV	T	1	T/A	PASS	5.2287755531344464e-80	792.816		400	T=212,A=188	T=0.53,A=0.47	47.0	53.0	heterozygous	30	0.314	1.0		ACAT1	NM_000019.4	ACAT1:utr_5:NM_000019.4	unknown		1	p.?	c.-9T>A				A	GMAF=0.1976:AMAF=0.0792:EMAF=0.2582			Benign		rs3741055:rs34512802		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACAT1)(dui:NBS2;dis:Core Conditions;g:ACAT1)(dui:NBS48;dis:beta-Ketothiolase deficiency;g:ACAT1)(dui:NBS9;dis:Organic Acid Condition;g:ACAT1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACAT1)(dui:D008659;dis:Metabolic Diseases;g:ACAT1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACAT1)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACAT1)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACAT1)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ACAT1)(dui:D052801;dis:Male Urogenital Diseases;g:ACAT1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:ACAT1)(dui:D014570;dis:Urologic Diseases;g:ACAT1)(dui:D052776;dis:Female Urogenital Diseases;g:ACAT1)(dui:D007674;dis:Kidney Diseases;g:ACAT1)(dui:D051437;dis:Renal Insufficiency;g:ACAT1)(dui:D051436;dis:Renal Insufficiency, Chronic;g:ACAT1)(dui:D007676;dis:Kidney Failure, Chronic;g:ACAT1)(dui:D009422;dis:Nervous System Diseases;g:ACAT1)(dui:D002493;dis:Central Nervous System Diseases;g:ACAT1)(dui:D001927;dis:Brain Diseases;g:ACAT1)(dui:D009461;dis:Neurologic Manifestations;g:ACAT1)(dui:D012640;dis:Seizures;g:ACAT1)(dui:D004827;dis:Epilepsy;g:ACAT1)	Nabiximols:Sulfasalazine:Medical Cannabis:Cannabidiol	GO:0006085:GO:0042594:GO:0046952:GO:0046356:GO:0046951:GO:0003985:GO:0006635:GO:0070062:GO:0003988:GO:0001889:GO:0016453:GO:0072229:GO:0042802:GO:0009083:GO:1902860:GO:0006550:GO:1902224:GO:0007420:GO:0014070:GO:0009725:GO:0060612:GO:0030955:GO:0005759:GO:0005739:GO:0015937:GO:0034435:GO:0015936:GO:0019899	607809	PF02803:PF00108:PF00109	-1.31															
chr11:108121619	SNV	G	1	G/C	PASS	9.638290236239899e-82	810.16		400	G=210,C=190	G=0.525,C=0.475	47.5	52.5	heterozygous	30	0.332	2.0		ACAT1	NM_000019.4	ACAT1:exonic:NM_000019.4	missense	CCG	1	p.Ala5Pro	c.13G>C	0.01	0.61	27.0	C	GMAF=0.2097:AMAF=0.1224:EMAF=0.2544	0.24		Benign	3752118	rs3741056:rs1591350265		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACAT1)(dui:NBS2;dis:Core Conditions;g:ACAT1)(dui:NBS48;dis:beta-Ketothiolase deficiency;g:ACAT1)(dui:NBS9;dis:Organic Acid Condition;g:ACAT1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACAT1)(dui:D008659;dis:Metabolic Diseases;g:ACAT1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACAT1)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACAT1)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACAT1)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ACAT1)(dui:D052801;dis:Male Urogenital Diseases;g:ACAT1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:ACAT1)(dui:D014570;dis:Urologic Diseases;g:ACAT1)(dui:D052776;dis:Female Urogenital Diseases;g:ACAT1)(dui:D007674;dis:Kidney Diseases;g:ACAT1)(dui:D051437;dis:Renal Insufficiency;g:ACAT1)(dui:D051436;dis:Renal Insufficiency, Chronic;g:ACAT1)(dui:D007676;dis:Kidney Failure, Chronic;g:ACAT1)(dui:D009422;dis:Nervous System Diseases;g:ACAT1)(dui:D002493;dis:Central Nervous System Diseases;g:ACAT1)(dui:D001927;dis:Brain Diseases;g:ACAT1)(dui:D009461;dis:Neurologic Manifestations;g:ACAT1)(dui:D012640;dis:Seizures;g:ACAT1)(dui:D004827;dis:Epilepsy;g:ACAT1)	Nabiximols:Sulfasalazine:Medical Cannabis:Cannabidiol	GO:0006085:GO:0042594:GO:0046952:GO:0046356:GO:0046951:GO:0003985:GO:0006635:GO:0070062:GO:0003988:GO:0001889:GO:0016453:GO:0072229:GO:0042802:GO:0009083:GO:1902860:GO:0006550:GO:1902224:GO:0007420:GO:0014070:GO:0009725:GO:0060612:GO:0030955:GO:0005759:GO:0005739:GO:0015937:GO:0034435:GO:0015936:GO:0019899	607809	PF02803:PF00108:PF00109	-0.17															
chr11:108141783	INDEL	A	4	AAAGT/AAAGT	PASS	0.0	3789.23		392	A=2,AAAGT=390	A=0.0051,AAAGT=0.9949	99.49	0.5100000000000051	homozygous	49	0.007:0.003	5.0		ACAT1	NM_000019.4	ACAT1:intronic:NM_000019.4	unknown			p.?	c.826+83_826+84insAAGT				AAAGT				Benign		rs10682490:rs34420529		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACAT1)(dui:NBS2;dis:Core Conditions;g:ACAT1)(dui:NBS48;dis:beta-Ketothiolase deficiency;g:ACAT1)(dui:NBS9;dis:Organic Acid Condition;g:ACAT1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACAT1)(dui:D008659;dis:Metabolic Diseases;g:ACAT1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACAT1)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACAT1)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACAT1)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ACAT1)(dui:D052801;dis:Male Urogenital Diseases;g:ACAT1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:ACAT1)(dui:D014570;dis:Urologic Diseases;g:ACAT1)(dui:D052776;dis:Female Urogenital Diseases;g:ACAT1)(dui:D007674;dis:Kidney Diseases;g:ACAT1)(dui:D051437;dis:Renal Insufficiency;g:ACAT1)(dui:D051436;dis:Renal Insufficiency, Chronic;g:ACAT1)(dui:D007676;dis:Kidney Failure, Chronic;g:ACAT1)(dui:D009422;dis:Nervous System Diseases;g:ACAT1)(dui:D002493;dis:Central Nervous System Diseases;g:ACAT1)(dui:D001927;dis:Brain Diseases;g:ACAT1)(dui:D009461;dis:Neurologic Manifestations;g:ACAT1)(dui:D012640;dis:Seizures;g:ACAT1)(dui:D004827;dis:Epilepsy;g:ACAT1)	Nabiximols:Sulfasalazine:Medical Cannabis:Cannabidiol	GO:0006085:GO:0042594:GO:0046952:GO:0046356:GO:0046951:GO:0003985:GO:0006635:GO:0070062:GO:0003988:GO:0001889:GO:0016453:GO:0072229:GO:0042802:GO:0009083:GO:1902860:GO:0006550:GO:1902224:GO:0007420:GO:0014070:GO:0009725:GO:0060612:GO:0030955:GO:0005759:GO:0005739:GO:0015937:GO:0034435:GO:0015936:GO:0019899	607809	PF02803:PF00108:PF00109	1.38															
chr11:108144072	SNV	C	1	C/T	PASS	2.830088391787982e-96	955.482		323	C=139,T=184	C=0.4303,T=0.5697	56.97	43.03	heterozygous	30	0.308	1.0		ACAT1	NM_000019.4	ACAT1:intronic:NM_000019.4	unknown			p.?	c.1005+25C>T				T	GMAF=0.2437:AMAF=0.0902:EMAF=0.3222					rs10890819		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACAT1)(dui:NBS2;dis:Core Conditions;g:ACAT1)(dui:NBS48;dis:beta-Ketothiolase deficiency;g:ACAT1)(dui:NBS9;dis:Organic Acid Condition;g:ACAT1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACAT1)(dui:D008659;dis:Metabolic Diseases;g:ACAT1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACAT1)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACAT1)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACAT1)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ACAT1)(dui:D052801;dis:Male Urogenital Diseases;g:ACAT1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:ACAT1)(dui:D014570;dis:Urologic Diseases;g:ACAT1)(dui:D052776;dis:Female Urogenital Diseases;g:ACAT1)(dui:D007674;dis:Kidney Diseases;g:ACAT1)(dui:D051437;dis:Renal Insufficiency;g:ACAT1)(dui:D051436;dis:Renal Insufficiency, Chronic;g:ACAT1)(dui:D007676;dis:Kidney Failure, Chronic;g:ACAT1)(dui:D009422;dis:Nervous System Diseases;g:ACAT1)(dui:D002493;dis:Central Nervous System Diseases;g:ACAT1)(dui:D001927;dis:Brain Diseases;g:ACAT1)(dui:D009461;dis:Neurologic Manifestations;g:ACAT1)(dui:D012640;dis:Seizures;g:ACAT1)(dui:D004827;dis:Epilepsy;g:ACAT1)	Nabiximols:Sulfasalazine:Medical Cannabis:Cannabidiol	GO:0006085:GO:0042594:GO:0046952:GO:0046356:GO:0046951:GO:0003985:GO:0006635:GO:0070062:GO:0003988:GO:0001889:GO:0016453:GO:0072229:GO:0042802:GO:0009083:GO:1902860:GO:0006550:GO:1902224:GO:0007420:GO:0014070:GO:0009725:GO:0060612:GO:0030955:GO:0005759:GO:0005739:GO:0015937:GO:0034435:GO:0015936:GO:0019899	607809	PF02803:PF00108:PF00109	-0.31															
chr12:56004670	SNV	G	1	C/C	PASS	0.0	3937.13		397	G=1,C=396	G=0.0025,C=0.9975	99.75	0.25	homozygous	56	0.237	2.0		SUOX	NM_001032387.2	SUOX:exonic:NM_001032387.2	synonymous	TCC	4	p.Ser427=	c.1281G>C				C	GMAF=0.2642:AMAF=0.3768:EMAF=0.0802			Benign		rs1565799723:rs773115		(dui:D009750;dis:Nutritional and Metabolic Diseases;g:SUOX)(dui:D008659;dis:Metabolic Diseases;g:SUOX)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:SUOX)(dui:D030342;dis:Genetic Diseases, Inborn;g:SUOX)(dui:D008661;dis:Metabolism, Inborn Errors;g:SUOX)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:SUOX)(dui:D007154;dis:Immune System Diseases;g:SUOX)(dui:D004700;dis:Endocrine System Diseases;g:SUOX)(dui:D001327;dis:Autoimmune Diseases;g:SUOX)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:SUOX)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:SUOX)(dui:D009140;dis:Musculoskeletal Diseases;g:SUOX)(dui:D009369;dis:Neoplasms;g:SUOX)(dui:D003240;dis:Connective Tissue Diseases;g:SUOX)(dui:D003560;dis:Cysts;g:SUOX)(dui:D006058;dis:Gonadal Disorders;g:SUOX)(dui:D007592;dis:Joint Diseases;g:SUOX)(dui:D012216;dis:Rheumatic Diseases;g:SUOX)(dui:D052776;dis:Female Urogenital Diseases;g:SUOX)(dui:D001168;dis:Arthritis;g:SUOX)(dui:D001172;dis:Arthritis, Rheumatoid;g:SUOX)(dui:D005831;dis:Genital Diseases, Female;g:SUOX)(dui:D010048;dis:Ovarian Cysts;g:SUOX)(dui:D010049;dis:Ovarian Diseases;g:SUOX)(dui:D000291;dis:Adnexal Diseases;g:SUOX)(dui:D011085;dis:Polycystic Ovary Syndrome;g:SUOX)	{[2-Amino-4-oxo-6,7-di(sulfanyl-S)-3,5,5a,8,9a,10-hexahydro-4H-pyrano[3,2-g]pteridin-8-yl]methyl dihydrogenato(2-) phosphate}(dioxo)sulfanylmolybdenum	GO:0005758:GO:0005515:GO:0006790:GO:0070221:GO:0005759:GO:0005739:GO:0008482:GO:0030151:GO:0020037:GO:0043546	606887	PF00173:PF00174:PF03404	-1.35															
chr12:102843690	SNV	G	1	C/C	PASS	0.0	3977.16		397	G=0,C=397	G=0.0,C=1.0	100.0	0.0	homozygous	55	0.16	1.0		PAH	NM_001354304.2	PAH:exonic:NM_001354304.2	synonymous	CTG	12	p.Leu385=	c.1155C>G				C	GMAF=0.1728:AMAF=0.1959:EMAF=0.161			Benign		rs772897		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PAH)(dui:NBS2;dis:Core Conditions;g:PAH)(dui:NBS11;dis:Amino Acid Disorder;g:PAH)(dui:NBS58;dis:Phenylketonuria;g:PAH)(dui:D009422;dis:Nervous System Diseases;g:PAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PAH)(dui:D008659;dis:Metabolic Diseases;g:PAH)(dui:D002493;dis:Central Nervous System Diseases;g:PAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:PAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:PAH)(dui:D001927;dis:Brain Diseases;g:PAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:PAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:PAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PAH)(dui:D010661;dis:Phenylketonurias;g:PAH)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:PAH)(dui:D011248;dis:Pregnancy Complications;g:PAH)(dui:D017042;dis:Phenylketonuria, Maternal;g:PAH)	Sapropterin:L-erythro-7,8-dihydrobiopterin:Quinonoid 7,8-Tetrahydrobiopterin:Phenylalanine:beta-2-Thienyl-L-alanine:Norepinephrine:Cupric sulfate:D-norleucine:Droxidopa		612349	PF00351:PF01842	-0.1															
chr12:102846852	SNV	C	1	C/A	PASS	7.095777679633873e-102	1011.49		400	C=189,A=211	C=0.4725,A=0.5275	52.75	47.25	heterozygous	47	0.27	2.0		PAH	NM_001354304.2	PAH:intronic:NM_001354304.2	unknown			p.?	c.969+43G>T				A	GMAF=0.3666:AMAF=0.2685:EMAF=0.4169			Benign		rs1522306		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PAH)(dui:NBS2;dis:Core Conditions;g:PAH)(dui:NBS11;dis:Amino Acid Disorder;g:PAH)(dui:NBS58;dis:Phenylketonuria;g:PAH)(dui:D009422;dis:Nervous System Diseases;g:PAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PAH)(dui:D008659;dis:Metabolic Diseases;g:PAH)(dui:D002493;dis:Central Nervous System Diseases;g:PAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:PAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:PAH)(dui:D001927;dis:Brain Diseases;g:PAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:PAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:PAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PAH)(dui:D010661;dis:Phenylketonurias;g:PAH)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:PAH)(dui:D011248;dis:Pregnancy Complications;g:PAH)(dui:D017042;dis:Phenylketonuria, Maternal;g:PAH)	Sapropterin:L-erythro-7,8-dihydrobiopterin:Quinonoid 7,8-Tetrahydrobiopterin:Phenylalanine:beta-2-Thienyl-L-alanine:Norepinephrine:Cupric sulfate:D-norleucine:Droxidopa		612349	PF00351:PF01842	-1.11															
chr12:102855146	SNV	C	1	T/T	PASS	0.0	3969.7		400	C=1,T=399	C=0.0025,T=0.9975	99.75	0.25	homozygous	55	0.454	1.0		PAH	NM_001354304.2	PAH:exonic:NM_001354304.2	synonymous	CAA	7	p.Gln232=	c.696G>A				T	GMAF=0.3465:AMAF=0.2317:EMAF=0.4052	0.02		Benign	7233325	rs1126758		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PAH)(dui:NBS2;dis:Core Conditions;g:PAH)(dui:NBS11;dis:Amino Acid Disorder;g:PAH)(dui:NBS58;dis:Phenylketonuria;g:PAH)(dui:D009422;dis:Nervous System Diseases;g:PAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PAH)(dui:D008659;dis:Metabolic Diseases;g:PAH)(dui:D002493;dis:Central Nervous System Diseases;g:PAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:PAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:PAH)(dui:D001927;dis:Brain Diseases;g:PAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:PAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:PAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PAH)(dui:D010661;dis:Phenylketonurias;g:PAH)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:PAH)(dui:D011248;dis:Pregnancy Complications;g:PAH)(dui:D017042;dis:Phenylketonuria, Maternal;g:PAH)	Sapropterin:L-erythro-7,8-dihydrobiopterin:Quinonoid 7,8-Tetrahydrobiopterin:Phenylalanine:beta-2-Thienyl-L-alanine:Norepinephrine:Cupric sulfate:D-norleucine:Droxidopa		612349	PF00351:PF01842	-2.59															
chr12:102855386	SNV	C	1	C/T	PASS	1.164126029410498e-120	1199.34		400	C=171,T=229	C=0.4275,T=0.5725	57.25	42.75	heterozygous	47	0.235	1.0		PAH	NM_001354304.2	PAH:intronic:NM_001354304.2	unknown			p.?	c.510-54G>A				T				Benign		rs2251905		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PAH)(dui:NBS2;dis:Core Conditions;g:PAH)(dui:NBS11;dis:Amino Acid Disorder;g:PAH)(dui:NBS58;dis:Phenylketonuria;g:PAH)(dui:D009422;dis:Nervous System Diseases;g:PAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PAH)(dui:D008659;dis:Metabolic Diseases;g:PAH)(dui:D002493;dis:Central Nervous System Diseases;g:PAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:PAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:PAH)(dui:D001927;dis:Brain Diseases;g:PAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:PAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:PAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PAH)(dui:D010661;dis:Phenylketonurias;g:PAH)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:PAH)(dui:D011248;dis:Pregnancy Complications;g:PAH)(dui:D017042;dis:Phenylketonuria, Maternal;g:PAH)	Sapropterin:L-erythro-7,8-dihydrobiopterin:Quinonoid 7,8-Tetrahydrobiopterin:Phenylalanine:beta-2-Thienyl-L-alanine:Norepinephrine:Cupric sulfate:D-norleucine:Droxidopa		612349	PF00351:PF01842	-4.26															
chr12:102877415	SNV	G	1	G/A	PASS	1.4374740058743685e-84	838.424		400	G=207,A=193	G=0.5175,A=0.4825	48.25	51.75	heterozygous	47	0.294	2.0		PAH	NM_001354304.2	PAH:intronic:NM_001354304.2	unknown			p.?	c.441+47C>T				A	GMAF=0.3828:AMAF=0.2851:EMAF=0.4329			Benign		rs1718301		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PAH)(dui:NBS2;dis:Core Conditions;g:PAH)(dui:NBS11;dis:Amino Acid Disorder;g:PAH)(dui:NBS58;dis:Phenylketonuria;g:PAH)(dui:D009422;dis:Nervous System Diseases;g:PAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PAH)(dui:D008659;dis:Metabolic Diseases;g:PAH)(dui:D002493;dis:Central Nervous System Diseases;g:PAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:PAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:PAH)(dui:D001927;dis:Brain Diseases;g:PAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:PAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:PAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PAH)(dui:D010661;dis:Phenylketonurias;g:PAH)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:PAH)(dui:D011248;dis:Pregnancy Complications;g:PAH)(dui:D017042;dis:Phenylketonuria, Maternal;g:PAH)	Sapropterin:L-erythro-7,8-dihydrobiopterin:Quinonoid 7,8-Tetrahydrobiopterin:Phenylalanine:beta-2-Thienyl-L-alanine:Norepinephrine:Cupric sulfate:D-norleucine:Droxidopa		612349	PF00351:PF01842	-1.57															
chr12:102912772	SNV	A	1	A/G	PASS	1.131357864119534e-74	739.464		400	A=218,G=182	A=0.545,G=0.455	45.5	54.5	heterozygous	24	0.217	3.0		PAH	NM_001354304.2	PAH:intronic:NM_001354304.2	unknown			p.?	c.168+19T>C				G	GMAF=0.2069:AMAF=0.2916:EMAF=0.1635			Benign		rs17842947		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PAH)(dui:NBS2;dis:Core Conditions;g:PAH)(dui:NBS11;dis:Amino Acid Disorder;g:PAH)(dui:NBS58;dis:Phenylketonuria;g:PAH)(dui:D009422;dis:Nervous System Diseases;g:PAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PAH)(dui:D008659;dis:Metabolic Diseases;g:PAH)(dui:D002493;dis:Central Nervous System Diseases;g:PAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:PAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:PAH)(dui:D001927;dis:Brain Diseases;g:PAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:PAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:PAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PAH)(dui:D010661;dis:Phenylketonurias;g:PAH)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:PAH)(dui:D011248;dis:Pregnancy Complications;g:PAH)(dui:D017042;dis:Phenylketonuria, Maternal;g:PAH)	Sapropterin:L-erythro-7,8-dihydrobiopterin:Quinonoid 7,8-Tetrahydrobiopterin:Phenylalanine:beta-2-Thienyl-L-alanine:Norepinephrine:Cupric sulfate:D-norleucine:Droxidopa		612349	PF00351:PF01842	2.01															
chr12:102917009	SNV	G	1	G/A	PASS	1.4893610777109214e-67	668.27		274	G=132,A=142	G=0.4818,A=0.5182	51.82	48.18	heterozygous	30	0.364	2.0		PAH	NM_001354304.2	PAH:intronic:NM_001354304.2	unknown			p.?	c.60+62C>T				A	GMAF=0.3771:AMAF=0.487:EMAF=0.318			Benign		rs1522296		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PAH)(dui:NBS2;dis:Core Conditions;g:PAH)(dui:NBS11;dis:Amino Acid Disorder;g:PAH)(dui:NBS58;dis:Phenylketonuria;g:PAH)(dui:D009422;dis:Nervous System Diseases;g:PAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PAH)(dui:D008659;dis:Metabolic Diseases;g:PAH)(dui:D002493;dis:Central Nervous System Diseases;g:PAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:PAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:PAH)(dui:D001927;dis:Brain Diseases;g:PAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:PAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:PAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PAH)(dui:D010661;dis:Phenylketonurias;g:PAH)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:PAH)(dui:D011248;dis:Pregnancy Complications;g:PAH)(dui:D017042;dis:Phenylketonuria, Maternal;g:PAH)	Sapropterin:L-erythro-7,8-dihydrobiopterin:Quinonoid 7,8-Tetrahydrobiopterin:Phenylalanine:beta-2-Thienyl-L-alanine:Norepinephrine:Cupric sulfate:D-norleucine:Droxidopa		612349	PF00351:PF01842	-0.51															
chr12:109557065	SNV	A	1	T/T	PASS	0.0	3979.18		398	A=0,T=398	A=0.0,T=1.0	100.0	0.0	homozygous	30	0.487	1.0		MMAB	NM_052845.4	MMAB:exonic:NM_052845.4	missense	AAG	9	p.Met239Lys	c.716T>A	1.0	0.0	95.0	T	GMAF=0.4037:AMAF=0.2792:EMAF=0.4676	0.12		Benign	3752888	rs9593		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMAB)(dui:NBS2;dis:Core Conditions;g:MMAB)(dui:NBS9;dis:Organic Acid Condition;g:MMAB)(dui:NBS43;dis:Methylmalonic acidemia;g:MMAB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMAB)(dui:D008659;dis:Metabolic Diseases;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMAB)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMAB)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMAB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMAB)	Cyanocobalamin	GO:0005524:GO:0005515:GO:0005759:GO:0031419:GO:0008817:GO:0009235	607568	PF01923	-0.02															
chr12:109565014	SNV	A	1	G/G	PASS	0.0	4003.3		400	A=0,G=400	A=0.0,G=1.0	100.0	0.0	homozygous	30	0.482	2.0		MMAB	NM_052845.4	MMAB:intronic:NM_052845.4	unknown			p.?	c.348+105T>C				G				Benign		rs10850380		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMAB)(dui:NBS2;dis:Core Conditions;g:MMAB)(dui:NBS9;dis:Organic Acid Condition;g:MMAB)(dui:NBS43;dis:Methylmalonic acidemia;g:MMAB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMAB)(dui:D008659;dis:Metabolic Diseases;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMAB)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMAB)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMAB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMAB)	Cyanocobalamin	GO:0005524:GO:0005515:GO:0005759:GO:0031419:GO:0008817:GO:0009235	607568	PF01923	0.41															
chr12:109568707	SNV	A	1	A/G	PASS	1.9547895108776672e-76	757.089		400	A=216,G=184	A=0.54,G=0.46	46.0	54.0	heterozygous	8	0.295	1.0		MMAB	NM_052845.4	MMAB:intronic:NM_052845.4	unknown			p.?	c.290+63T>C				G						rs11836136		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMAB)(dui:NBS2;dis:Core Conditions;g:MMAB)(dui:NBS9;dis:Organic Acid Condition;g:MMAB)(dui:NBS43;dis:Methylmalonic acidemia;g:MMAB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMAB)(dui:D008659;dis:Metabolic Diseases;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMAB)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMAB)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMAB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMAB)	Cyanocobalamin	GO:0005524:GO:0005515:GO:0005759:GO:0031419:GO:0008817:GO:0009235	607568	PF01923	-0.31															
chr12:109571747	INDEL	G	1	G/GA	PASS	3.0521087222420104e-34	335.154		399	G=203,GA=196	G=0.5088,GA=0.4912	49.12	50.88	heterozygous	1	0.016	1.0		MMAB	NM_052845.4	MMAB:intronic:NM_052845.4	unknown			p.?	c.135-38_135-37insT				GA	GMAF=5.0E-4:AMAF=7.0E-4:EMAF=4.0E-4					rs140204601		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMAB)(dui:NBS2;dis:Core Conditions;g:MMAB)(dui:NBS9;dis:Organic Acid Condition;g:MMAB)(dui:NBS43;dis:Methylmalonic acidemia;g:MMAB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMAB)(dui:D008659;dis:Metabolic Diseases;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMAB)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMAB)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMAB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMAB)	Cyanocobalamin	GO:0005524:GO:0005515:GO:0005759:GO:0031419:GO:0008817:GO:0009235	607568	PF01923	-1.82															
chr12:109573424	MNV	GC	2	GC/TT	PASS	3.3970348320338674e-70	694.689		400	GC=223,TT=177	GC=0.5575,TT=0.4425	44.25	55.75	0	1	0.285	1.0		MMAB|MVK	NM_052845.4|NM_001114185.3	MMAB:exonic:NM_052845.4|MVK:upstream:NM_001114185.3	missense|unknown	|	1|	p.Arg19Gln|p.?	c.56_57delGCinsAA|c.-1399GC>TT	0.07|	0.873|	43.0|	TT|TT	GMAF=0.3091:AMAF=0.3917:EMAF=0.267	0.71		Benign/Likely benign	3752891	rs10774774:rs10774775:rs36013132:rs748526009:rs879684260:rs1555276196:rs1555276197		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMAB)(dui:NBS2;dis:Core Conditions;g:MMAB)(dui:NBS9;dis:Organic Acid Condition;g:MMAB)(dui:NBS43;dis:Methylmalonic acidemia;g:MMAB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMAB)(dui:D008659;dis:Metabolic Diseases;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMAB)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMAB)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMAB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MVK)(dui:D030342;dis:Genetic Diseases, Inborn;g:MVK)(dui:D009422;dis:Nervous System Diseases;g:MVK)(dui:D056660;dis:Hereditary Autoinflammatory Diseases;g:MVK)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MVK)(dui:D008659;dis:Metabolic Diseases;g:MVK)(dui:D002493;dis:Central Nervous System Diseases;g:MVK)(dui:D001927;dis:Brain Diseases;g:MVK)(dui:D008661;dis:Metabolism, Inborn Errors;g:MVK)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MVK)(dui:D007154;dis:Immune System Diseases;g:MVK)(dui:D006402;dis:Hematologic Diseases;g:MVK)(dui:D007160;dis:Immunoproliferative Disorders;g:MVK)(dui:D001796;dis:Blood Protein Disorders;g:MVK)(dui:D001928;dis:Brain Diseases, Metabolic;g:MVK)(dui:D006942;dis:Hypergammaglobulinemia;g:MVK)(dui:D018901;dis:Peroxisomal Disorders;g:MVK)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MVK)(dui:D054078;dis:Mevalonate Kinase Deficiency;g:MVK)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MVK)(dui:D012871;dis:Skin Diseases;g:MVK)(dui:D012873;dis:Skin Diseases, Genetic;g:MVK)(dui:D007642;dis:Keratosis;g:MVK)(dui:D017499;dis:Porokeratosis;g:MVK)(dui:D009461;dis:Neurologic Manifestations;g:MVK)(dui:D004066;dis:Digestive System Diseases;g:MVK)(dui:D010146;dis:Pain;g:MVK)(dui:D009369;dis:Neoplasms;g:MVK)(dui:D008107;dis:Liver Diseases;g:MVK)(dui:D009371;dis:Neoplasms by Site;g:MVK)(dui:D004067;dis:Digestive System Neoplasms;g:MVK)(dui:D008113;dis:Liver Neoplasms;g:MVK)(dui:D009370;dis:Neoplasms by Histologic Type;g:MVK)(dui:D009140;dis:Musculoskeletal Diseases;g:MVK)(dui:D007592;dis:Joint Diseases;g:MVK)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MVK)(dui:D002277;dis:Carcinoma;g:MVK)(dui:D006528;dis:Carcinoma, Hepatocellular;g:MVK)(dui:D000230;dis:Adenocarcinoma;g:MVK)(dui:D018771;dis:Arthralgia;g:MVK)(dui:D005076;dis:Exanthema;g:MVK)	Farnesyl thiopyrophosphate:Cyanocobalamin	GO:0042802:GO:0050728:GO:0006695:GO:0004496:GO:0009235:GO:0008299:GO:0000287:GO:0005524:GO:0005777:GO:0005515:GO:0045540:GO:0005759:GO:0019287:GO:0043231:GO:0031419:GO:0008817:GO:0005829:GO:0016310	251170:607568	PF01923	-0.05,1.26															
chr12:120737096	SNV	T	1	T/C	PASS	1.3103882795738373e-83	828.826		400	T=208,C=192	T=0.52,C=0.48	48.0	52.0	heterozygous	55	0.409	1.0		ACADS	NM_000017.4	ACADS:exonic:NM_000017.4	synonymous	CGC	3	p.Arg107=	c.321T>C				C	GMAF=0.4932:AMAF=0.3756:EMAF=0.4466	0.28		Benign	3765623	rs1064795254:rs3914		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADS)(dui:NBS21;dis:Short-chain acyl-CoA dehydrogenase deficiency;g:ACADS)(dui:NBS3;dis:Secondary Conditions;g:ACADS)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ACADS)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADS)(dui:D008659;dis:Metabolic Diseases;g:ACADS)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADS)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADS)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADS)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADS)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADS)	Acetoacetyl-CoA:NADH:Flavin adenine dinucleotide	GO:0003995:GO:0005634:GO:0005813:GO:0006635:GO:0033539:GO:0005759:GO:0050660:GO:0004085:GO:0005739:GO:0046359:GO:0005654	606885	PF02771:PF02770:PF00441:PF08028	-0.18															
chr12:120738181	SNV	T	1	T/C	PASS	1.1303163247387071e-90	899.468		398	T=199,C=199	T=0.5,C=0.5	50.0	50.0	heterozygous	55	0.406	1.0		ACADS	NM_000017.4	ACADS:intronic:NM_000017.4	unknown			p.?	c.625-99T>C				C						rs555404		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADS)(dui:NBS21;dis:Short-chain acyl-CoA dehydrogenase deficiency;g:ACADS)(dui:NBS3;dis:Secondary Conditions;g:ACADS)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ACADS)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADS)(dui:D008659;dis:Metabolic Diseases;g:ACADS)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADS)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADS)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADS)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADS)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADS)	Acetoacetyl-CoA:NADH:Flavin adenine dinucleotide	GO:0003995:GO:0005634:GO:0005813:GO:0006635:GO:0033539:GO:0005759:GO:0050660:GO:0004085:GO:0005739:GO:0046359:GO:0005654	606885	PF02771:PF02770:PF00441:PF08028	-2.88															
chr12:120738280	SNV	G	1	G/A	PASS	2.6031548313741496e-88	875.845		400	G=203,A=197	G=0.5075,A=0.4925	49.25	50.75	heterozygous	23	0.182	3.0		ACADS	NM_000017.4	ACADS:exonic:NM_000017.4	missense	AGC	6	p.Gly209Ser	c.625G>A	0.01	0.664	56.0	A	GMAF=0.1968:AMAF=0.0645:EMAF=0.2647	0.97		Benign/Likely benign	3752964	rs1799958		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADS)(dui:NBS21;dis:Short-chain acyl-CoA dehydrogenase deficiency;g:ACADS)(dui:NBS3;dis:Secondary Conditions;g:ACADS)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ACADS)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADS)(dui:D008659;dis:Metabolic Diseases;g:ACADS)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADS)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADS)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADS)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADS)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADS)	Acetoacetyl-CoA:NADH:Flavin adenine dinucleotide	GO:0003995:GO:0005634:GO:0005813:GO:0006635:GO:0033539:GO:0005759:GO:0050660:GO:0004085:GO:0005739:GO:0046359:GO:0005654	606885	PF02771:PF02770:PF00441:PF08028	9.56															
chr12:120738876	SNV	C	1	C/T	PASS	8.384940786218153e-74	730.765		400	C=219,T=181	C=0.5475,T=0.4525	45.25	54.75	heterozygous	55	0.327	1.0		ACADS	NM_000017.4	ACADS:exonic:NM_000017.4	synonymous	CGT	8	p.Arg330=	c.990C>T				T	GMAF=0.408:AMAF=0.1235:EMAF=0.4462	0.02		Benign	4146720	rs796051906:rs1555244280:rs3915		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADS)(dui:NBS21;dis:Short-chain acyl-CoA dehydrogenase deficiency;g:ACADS)(dui:NBS3;dis:Secondary Conditions;g:ACADS)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ACADS)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADS)(dui:D008659;dis:Metabolic Diseases;g:ACADS)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADS)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADS)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADS)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADS)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADS)	Acetoacetyl-CoA:NADH:Flavin adenine dinucleotide	GO:0003995:GO:0005634:GO:0005813:GO:0006635:GO:0033539:GO:0005759:GO:0050660:GO:0004085:GO:0005739:GO:0046359:GO:0005654	606885	PF02771:PF02770:PF00441:PF08028	-1.49															
chr12:120739469	SNV	G	1	G/C	PASS	3.155004623374592e-105	1045.01		399	G=185,C=214	G=0.4637,C=0.5363	53.63	46.37	heterozygous	23	0.193	2.0		ACADS	NM_000017.4	ACADS:utr_3:NM_000017.4	unknown		10	p.?	c.*21G>C				C	GMAF=0.1979:AMAF=0.0849:EMAF=0.2557			Benign		rs3916		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADS)(dui:NBS21;dis:Short-chain acyl-CoA dehydrogenase deficiency;g:ACADS)(dui:NBS3;dis:Secondary Conditions;g:ACADS)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ACADS)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADS)(dui:D008659;dis:Metabolic Diseases;g:ACADS)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADS)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADS)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADS)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADS)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADS)	Acetoacetyl-CoA:NADH:Flavin adenine dinucleotide	GO:0003995:GO:0005634:GO:0005813:GO:0006635:GO:0033539:GO:0005759:GO:0050660:GO:0004085:GO:0005739:GO:0046359:GO:0005654	606885	PF02771:PF02770:PF00441:PF08028	-1.11															
chr13:100268802	SNV	A	1	G/G	PASS	0.0	3671.41		398	A=7,G=391	A=0.0176,G=0.9824	98.24	1.7600000000000051	homozygous	56	0.084	1.0		PCCA	NR_148031.2	PCCA:intronic_nc:NR_148031.2										GMAF=0.0825:AMAF=0.2419:EMAF=8.0E-4			Benign		rs4306370		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PCCA)(dui:NBS2;dis:Core Conditions;g:PCCA)(dui:NBS9;dis:Organic Acid Condition;g:PCCA)(dui:NBS42;dis:Propionic acidemia;g:PCCA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PCCA)(dui:D008659;dis:Metabolic Diseases;g:PCCA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PCCA)(dui:D030342;dis:Genetic Diseases, Inborn;g:PCCA)(dui:D008661;dis:Metabolism, Inborn Errors;g:PCCA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PCCA)(dui:D056693;dis:Propionic Acidemia;g:PCCA)(dui:D005128;dis:Eye Diseases;g:PCCA)(dui:D012030;dis:Refractive Errors;g:PCCA)	Biotin		232000	PF08443:PF07478:PF00364:PF02222:PF02786:PF02785:PF00289	-0.76															
chr13:100368441	SNV	A	1	A/G	PASS	3.419794425137136e-102	1014.66		399	A=188,G=211	A=0.4712,G=0.5288	52.88	47.12	heterozygous	55	0.447	1.0		PCCA	NR_148031.2	PCCA:intronic_nc:NR_148031.2										GMAF=0.3177:AMAF=0.4921:EMAF=0.2284			Benign		rs9518061		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PCCA)(dui:NBS2;dis:Core Conditions;g:PCCA)(dui:NBS9;dis:Organic Acid Condition;g:PCCA)(dui:NBS42;dis:Propionic acidemia;g:PCCA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PCCA)(dui:D008659;dis:Metabolic Diseases;g:PCCA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PCCA)(dui:D030342;dis:Genetic Diseases, Inborn;g:PCCA)(dui:D008661;dis:Metabolism, Inborn Errors;g:PCCA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PCCA)(dui:D056693;dis:Propionic Acidemia;g:PCCA)(dui:D005128;dis:Eye Diseases;g:PCCA)(dui:D012030;dis:Refractive Errors;g:PCCA)	Biotin		232000	PF08443:PF07478:PF00364:PF02222:PF02786:PF02785:PF00289	2.28															
chr13:100368672	SNV	T	1	T/A	PASS	4.115285784355134e-79	783.856		400	T=213,A=187	T=0.5325,A=0.4675	46.75	53.25	heterozygous	7	0.096	3.0		PCCA	NR_148031.2	PCCA:intronic_nc:NR_148031.2													Benign		rs10508043		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PCCA)(dui:NBS2;dis:Core Conditions;g:PCCA)(dui:NBS9;dis:Organic Acid Condition;g:PCCA)(dui:NBS42;dis:Propionic acidemia;g:PCCA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PCCA)(dui:D008659;dis:Metabolic Diseases;g:PCCA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PCCA)(dui:D030342;dis:Genetic Diseases, Inborn;g:PCCA)(dui:D008661;dis:Metabolism, Inborn Errors;g:PCCA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PCCA)(dui:D056693;dis:Propionic Acidemia;g:PCCA)(dui:D005128;dis:Eye Diseases;g:PCCA)(dui:D012030;dis:Refractive Errors;g:PCCA)	Biotin		232000	PF08443:PF07478:PF00364:PF02222:PF02786:PF02785:PF00289	0.85															
chr15:40407739	SNV	T	1	T/C	PASS	1.1264190846286631e-68	679.483		398	T=222,C=176	T=0.5578,C=0.4422	44.22	55.78	heterozygous	47	0.352	1.0		IVD	NR_148925.2	IVD:intronic_nc:NR_148925.2										GMAF=0.4044:AMAF=0.485:EMAF=0.3478			Benign		rs2289331		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:IVD)(dui:NBS2;dis:Core Conditions;g:IVD)(dui:NBS9;dis:Organic Acid Condition;g:IVD)(dui:NBS44;dis:Isovaleric acidemia;g:IVD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:IVD)(dui:D030342;dis:Genetic Diseases, Inborn;g:IVD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:IVD)(dui:D008659;dis:Metabolic Diseases;g:IVD)(dui:D008661;dis:Metabolism, Inborn Errors;g:IVD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:IVD)(dui:D012140;dis:Respiratory Tract Diseases;g:IVD)(dui:D008171;dis:Lung Diseases;g:IVD)(dui:D017563;dis:Lung Diseases, Interstitial;g:IVD)	Coenzyme A persulfide:Flavin adenine dinucleotide		607036		-1.6															
chr15:40407823	SNV	C	1	C/T	PASS	2.2903402217221724e-87	866.401		400	C=204,T=196	C=0.51,T=0.49	49.0	51.0	heterozygous	47	0.473	2.0		IVD	NR_148925.2	IVD:intronic_nc:NR_148925.2															rs10518693:rs1566932254:rs1219352520		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:IVD)(dui:NBS2;dis:Core Conditions;g:IVD)(dui:NBS9;dis:Organic Acid Condition;g:IVD)(dui:NBS44;dis:Isovaleric acidemia;g:IVD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:IVD)(dui:D030342;dis:Genetic Diseases, Inborn;g:IVD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:IVD)(dui:D008659;dis:Metabolic Diseases;g:IVD)(dui:D008661;dis:Metabolism, Inborn Errors;g:IVD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:IVD)(dui:D012140;dis:Respiratory Tract Diseases;g:IVD)(dui:D008171;dis:Lung Diseases;g:IVD)(dui:D017563;dis:Lung Diseases, Interstitial;g:IVD)	Coenzyme A persulfide:Flavin adenine dinucleotide		607036		0.04															
chr15:40411410	SNV	A	1	G/G	PASS	0.0	3966.74		399	A=0,G=399	A=0.0,G=1.0	100.0	0.0	homozygous	56	0.022	1.0		IVD	NR_148925.2	IVD:intronic_nc:NR_148925.2													Benign		rs4924466		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:IVD)(dui:NBS2;dis:Core Conditions;g:IVD)(dui:NBS9;dis:Organic Acid Condition;g:IVD)(dui:NBS44;dis:Isovaleric acidemia;g:IVD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:IVD)(dui:D030342;dis:Genetic Diseases, Inborn;g:IVD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:IVD)(dui:D008659;dis:Metabolic Diseases;g:IVD)(dui:D008661;dis:Metabolism, Inborn Errors;g:IVD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:IVD)(dui:D012140;dis:Respiratory Tract Diseases;g:IVD)(dui:D008171;dis:Lung Diseases;g:IVD)(dui:D017563;dis:Lung Diseases, Interstitial;g:IVD)	Coenzyme A persulfide:Flavin adenine dinucleotide		607036		0.1															
chr15:40412906	SNV	A	1	A/G	PASS	7.331620890272138e-96	951.348		400	A=195,G=205	A=0.4875,G=0.5125	51.25	48.75	heterozygous	55	0.317	1.0		IVD	NR_148925.2	IVD:intronic_nc:NR_148925.2															rs2289330		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:IVD)(dui:NBS2;dis:Core Conditions;g:IVD)(dui:NBS9;dis:Organic Acid Condition;g:IVD)(dui:NBS44;dis:Isovaleric acidemia;g:IVD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:IVD)(dui:D030342;dis:Genetic Diseases, Inborn;g:IVD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:IVD)(dui:D008659;dis:Metabolic Diseases;g:IVD)(dui:D008661;dis:Metabolism, Inborn Errors;g:IVD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:IVD)(dui:D012140;dis:Respiratory Tract Diseases;g:IVD)(dui:D008171;dis:Lung Diseases;g:IVD)(dui:D017563;dis:Lung Diseases, Interstitial;g:IVD)	Coenzyme A persulfide:Flavin adenine dinucleotide		607036		0.42															
chr15:40412960	SNV	T	1	T/C	PASS	3.3542853083268754e-98	974.744		399	T=192,C=207	T=0.4812,C=0.5188	51.88	48.12	heterozygous	47	0.466	1.0		IVD	NR_148925.2	IVD:intronic_nc:NR_148925.2										GMAF=0.3293:AMAF=0.2031:EMAF=0.394			Benign		rs2289329		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:IVD)(dui:NBS2;dis:Core Conditions;g:IVD)(dui:NBS9;dis:Organic Acid Condition;g:IVD)(dui:NBS44;dis:Isovaleric acidemia;g:IVD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:IVD)(dui:D030342;dis:Genetic Diseases, Inborn;g:IVD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:IVD)(dui:D008659;dis:Metabolic Diseases;g:IVD)(dui:D008661;dis:Metabolism, Inborn Errors;g:IVD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:IVD)(dui:D012140;dis:Respiratory Tract Diseases;g:IVD)(dui:D008171;dis:Lung Diseases;g:IVD)(dui:D017563;dis:Lung Diseases, Interstitial;g:IVD)	Coenzyme A persulfide:Flavin adenine dinucleotide		607036		0.94															
chr15:40416223	SNV	A	1	A/G	PASS	1.2229254976262502e-78	779.126		400	A=213,G=187	A=0.5325,G=0.4675	46.75	53.25	heterozygous	55	0.368	1.0		IVD	NR_148925.2	IVD:intronic_nc:NR_148925.2										GMAF=0.4227:AMAF=0.4324:EMAF=0.3485			Benign		rs11070270		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:IVD)(dui:NBS2;dis:Core Conditions;g:IVD)(dui:NBS9;dis:Organic Acid Condition;g:IVD)(dui:NBS44;dis:Isovaleric acidemia;g:IVD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:IVD)(dui:D030342;dis:Genetic Diseases, Inborn;g:IVD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:IVD)(dui:D008659;dis:Metabolic Diseases;g:IVD)(dui:D008661;dis:Metabolism, Inborn Errors;g:IVD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:IVD)(dui:D012140;dis:Respiratory Tract Diseases;g:IVD)(dui:D008171;dis:Lung Diseases;g:IVD)(dui:D017563;dis:Lung Diseases, Interstitial;g:IVD)	Coenzyme A persulfide:Flavin adenine dinucleotide		607036		0.49															
chr15:76226005	INDEL	C	5	CCCTTA/CCCTTA	PASS	0.0	3786.51		383	C=0,CCCTTA=383	C=0.0,CCCTTA=1.0	100.0	0.0	homozygous	49	0.031	2.0		ETFA	NM_000126.4	ETFA:intronic:NM_000126.4	unknown			p.?	c.883-77_883-76insTAAGG				CCCTTA						rs11281932:rs112972949		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ETFA)(dui:NBS3;dis:Secondary Conditions;g:ETFA)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ETFA)(dui:NBS24;dis:Glutaric acidemia type II;g:ETFA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ETFA)(dui:D008659;dis:Metabolic Diseases;g:ETFA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ETFA)(dui:D030342;dis:Genetic Diseases, Inborn;g:ETFA)(dui:D008661;dis:Metabolism, Inborn Errors;g:ETFA)(dui:D028361;dis:Mitochondrial Diseases;g:ETFA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ETFA)(dui:D054069;dis:Multiple Acyl Coenzyme A Dehydrogenase Deficiency;g:ETFA)(dui:D009140;dis:Musculoskeletal Diseases;g:ETFA)(dui:D007592;dis:Joint Diseases;g:ETFA)(dui:D012216;dis:Rheumatic Diseases;g:ETFA)(dui:D001168;dis:Arthritis;g:ETFA)(dui:D009369;dis:Neoplasms;g:ETFA)(dui:D009370;dis:Neoplasms by Histologic Type;g:ETFA)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:ETFA)(dui:D004066;dis:Digestive System Diseases;g:ETFA)(dui:D009371;dis:Neoplasms by Site;g:ETFA)(dui:D008107;dis:Liver Diseases;g:ETFA)(dui:D002277;dis:Carcinoma;g:ETFA)(dui:D000230;dis:Adenocarcinoma;g:ETFA)(dui:D004067;dis:Digestive System Neoplasms;g:ETFA)(dui:D008113;dis:Liver Neoplasms;g:ETFA)(dui:D010003;dis:Osteoarthritis;g:ETFA)(dui:D006528;dis:Carcinoma, Hepatocellular;g:ETFA)		GO:0033539:GO:0005515:GO:0005759:GO:0016491:GO:0050660:GO:0009055:GO:0005739:GO:0022904	608053	PF00766:PF01012	0.16															
chr15:76292577	SNV	C	1	C/A	PASS	1.665328827785047e-89	887.785		399	C=201,A=198	C=0.5038,A=0.4962	49.62	50.38	heterozygous	1	0.001	1.0		ETFA	NM_000126.4	ETFA:intronic:NM_000126.4	unknown			p.?	c.268+42G>T				A						rs529953777		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ETFA)(dui:NBS3;dis:Secondary Conditions;g:ETFA)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ETFA)(dui:NBS24;dis:Glutaric acidemia type II;g:ETFA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ETFA)(dui:D008659;dis:Metabolic Diseases;g:ETFA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ETFA)(dui:D030342;dis:Genetic Diseases, Inborn;g:ETFA)(dui:D008661;dis:Metabolism, Inborn Errors;g:ETFA)(dui:D028361;dis:Mitochondrial Diseases;g:ETFA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ETFA)(dui:D054069;dis:Multiple Acyl Coenzyme A Dehydrogenase Deficiency;g:ETFA)(dui:D009140;dis:Musculoskeletal Diseases;g:ETFA)(dui:D007592;dis:Joint Diseases;g:ETFA)(dui:D012216;dis:Rheumatic Diseases;g:ETFA)(dui:D001168;dis:Arthritis;g:ETFA)(dui:D009369;dis:Neoplasms;g:ETFA)(dui:D009370;dis:Neoplasms by Histologic Type;g:ETFA)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:ETFA)(dui:D004066;dis:Digestive System Diseases;g:ETFA)(dui:D009371;dis:Neoplasms by Site;g:ETFA)(dui:D008107;dis:Liver Diseases;g:ETFA)(dui:D002277;dis:Carcinoma;g:ETFA)(dui:D000230;dis:Adenocarcinoma;g:ETFA)(dui:D004067;dis:Digestive System Neoplasms;g:ETFA)(dui:D008113;dis:Liver Neoplasms;g:ETFA)(dui:D010003;dis:Osteoarthritis;g:ETFA)(dui:D006528;dis:Carcinoma, Hepatocellular;g:ETFA)		GO:0033539:GO:0005515:GO:0005759:GO:0016491:GO:0050660:GO:0009055:GO:0005739:GO:0022904	608053	PF00766:PF01012	-0.09															
chr15:80158047	SNV	G	1	G/A	PASS	4.7260683689833325e-99	983.255		400	G=192,A=208	G=0.48,A=0.52	52.0	48.0	heterozygous	40	0.493	1.0		FAH	NM_000137.4	FAH:intronic:NM_000137.4	unknown			p.?	c.82-13G>A				A	GMAF=0.4463:AMAF=0.3221:EMAF=0.49			Benign		rs1370275		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-4.7															
chr15:80159733	SNV	T	1	T/C	PASS	6.354772390486166e-25	241.969		128	T=70,C=58	T=0.5469,C=0.4531	45.31	54.69	heterozygous	48	0.367	6.0		FAH	NM_000137.4	FAH:intronic:NM_000137.4	unknown			p.?	c.193-23T>C				C	GMAF=0.3974:AMAF=0.3865:EMAF=0.4029			Benign		rs1370274		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	0.14															
chr15:80159926	SNV	G	1	G/A	PASS	9.826525828295236e-49	480.076		189	G=89,A=100	G=0.4709,A=0.5291	52.91	47.09	heterozygous	55	0.36	2.0		FAH	NM_000137.4	FAH:intronic:NM_000137.4	unknown			p.?	c.314+49G>A				A	GMAF=0.3919:AMAF=0.3684:EMAF=0.404			Benign		rs1370273:rs1404883356		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-0.57															
chr15:80168182	SNV	A	1	A/G	PASS	2.898010802529703e-89	885.379		400	A=202,G=198	A=0.505,G=0.495	49.5	50.5	heterozygous	55	0.221	1.0		FAH	NM_000137.4	FAH:intronic:NM_000137.4	unknown			p.?	c.553+33A>G				G	GMAF=0.273:AMAF=0.2453:EMAF=0.2871			Benign		rs1545119		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	0.21															
chr15:80175284	SNV	G	1	G/T	PASS	4.860713235201269e-93	923.133		400	G=198,T=202	G=0.495,T=0.505	50.5	49.5	heterozygous	47	0.447	3.0		FAH	NM_000137.4	FAH:intronic:NM_000137.4	unknown			p.?	c.913+193G>T				T						rs1863768		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-0.01															
chr15:80180089	SNV	C	1	C/A	PASS	5.058246620031065e-108	1072.96		400	C=183,A=217	C=0.4575,A=0.5425	54.25	45.75	heterozygous	47	0.33	2.0		FAH	NM_000137.4	FAH:intronic:NM_000137.4	unknown			p.?	c.961-35C>A				A	GMAF=0.406:AMAF=0.4737:EMAF=0.3713			Benign		rs2043691		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.01															
chr16:71570009	SNV	C	1	A/A	PASS	0.0	3634.93		383	C=2,A=381	C=0.0052,A=0.9948	99.48	0.519999999999996	homozygous	40	0.433	5.0		TAT|TAT-AS1	NM_000353.3|NR_103851.1	TAT:intronic:NM_000353.3|TAT-AS1:intronic_nc:NR_103851.1	unknown|	|	|	p.?|	c.1042-72G>T|	|	|	|	A|						rs172650:rs1413052063		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TAT)(dui:NBS3;dis:Secondary Conditions;g:TAT)(dui:NBS6;dis:Amino Acid Disorder;g:TAT)(dui:NBS37;dis:Tyrosinemia type II;g:TAT)(dui:NBS38;dis:Tyrosinemia type III;g:TAT)(dui:D009422;dis:Nervous System Diseases;g:TAT)(dui:D002493;dis:Central Nervous System Diseases;g:TAT)(dui:D001927;dis:Brain Diseases;g:TAT)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:TAT)(dui:D008659;dis:Metabolic Diseases;g:TAT)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TAT)(dui:D030342;dis:Genetic Diseases, Inborn;g:TAT)(dui:D008661;dis:Metabolism, Inborn Errors;g:TAT)(dui:D001928;dis:Brain Diseases, Metabolic;g:TAT)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:TAT)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:TAT)(dui:D020176;dis:Tyrosinemias;g:TAT)	Pyridoxal phosphate:Tyrosine:Glutamic acid:Phenylalanine	GO:0030170:GO:0042802:GO:0046689:GO:0006572:GO:0009058:GO:0005575:GO:0006103:GO:0006979:GO:0006536:GO:0005515:GO:0006559:GO:0004838:GO:0005739:GO:0051384:GO:0005829:GO:0016597	613018	PF07706:PF00155:PF00266	0.63															
chr16:71573481	SNV	T	1	G/G	PASS	0.0	3983.89		398	T=0,G=398	T=0.0,G=1.0	100.0	0.0	homozygous	40	0.414	1.0		TAT	NM_000353.3	TAT:intronic:NM_000353.3	unknown			p.?	c.408+58A>C				G	GMAF=0.3121:AMAF=0.229:EMAF=0.3482					rs2432520		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TAT)(dui:NBS3;dis:Secondary Conditions;g:TAT)(dui:NBS6;dis:Amino Acid Disorder;g:TAT)(dui:NBS37;dis:Tyrosinemia type II;g:TAT)(dui:NBS38;dis:Tyrosinemia type III;g:TAT)(dui:D009422;dis:Nervous System Diseases;g:TAT)(dui:D002493;dis:Central Nervous System Diseases;g:TAT)(dui:D001927;dis:Brain Diseases;g:TAT)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:TAT)(dui:D008659;dis:Metabolic Diseases;g:TAT)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TAT)(dui:D030342;dis:Genetic Diseases, Inborn;g:TAT)(dui:D008661;dis:Metabolism, Inborn Errors;g:TAT)(dui:D001928;dis:Brain Diseases, Metabolic;g:TAT)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:TAT)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:TAT)(dui:D020176;dis:Tyrosinemias;g:TAT)	Pyridoxal phosphate:Tyrosine:Glutamic acid:Phenylalanine	GO:0030170:GO:0042802:GO:0046689:GO:0006572:GO:0009058:GO:0005575:GO:0006103:GO:0006979:GO:0006536:GO:0005515:GO:0006559:GO:0004838:GO:0005739:GO:0051384:GO:0005829:GO:0016597	613018	PF07706:PF00155:PF00266	0.9															
chr16:71576283	SNV	G	1	G/A	PASS	5.542427233834035e-96	952.563		400	G=195,A=205	G=0.4875,A=0.5125	51.25	48.75	heterozygous	1	0.008	3.0		TAT	NM_000353.3	TAT:exonic:NM_000353.3	missense	TCC	2	p.Pro45Ser	c.133C>T	0.05	0.009	74.0	A		0.96		Benign	5712746	rs575372249		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TAT)(dui:NBS3;dis:Secondary Conditions;g:TAT)(dui:NBS6;dis:Amino Acid Disorder;g:TAT)(dui:NBS37;dis:Tyrosinemia type II;g:TAT)(dui:NBS38;dis:Tyrosinemia type III;g:TAT)(dui:D009422;dis:Nervous System Diseases;g:TAT)(dui:D002493;dis:Central Nervous System Diseases;g:TAT)(dui:D001927;dis:Brain Diseases;g:TAT)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:TAT)(dui:D008659;dis:Metabolic Diseases;g:TAT)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TAT)(dui:D030342;dis:Genetic Diseases, Inborn;g:TAT)(dui:D008661;dis:Metabolism, Inborn Errors;g:TAT)(dui:D001928;dis:Brain Diseases, Metabolic;g:TAT)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:TAT)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:TAT)(dui:D020176;dis:Tyrosinemias;g:TAT)	Pyridoxal phosphate:Tyrosine:Glutamic acid:Phenylalanine	GO:0030170:GO:0042802:GO:0046689:GO:0006572:GO:0009058:GO:0005575:GO:0006103:GO:0006979:GO:0006536:GO:0005515:GO:0006559:GO:0004838:GO:0005739:GO:0051384:GO:0005829:GO:0016597	613018	PF07706:PF00155:PF00266	3.83															
chr16:71576373	SNV	G	1	G/A	PASS	3.2284941217125323e-103	1024.91		399	G=187,A=212	G=0.4687,A=0.5313	53.13	46.87	heterozygous	1	0.144	4.0		TAT	NM_000353.3	TAT:exonic:NM_000353.3	missense	TCC	2	p.Pro15Ser	c.43C>T	0.12	0.0	74.0	A	GMAF=0.1757:AMAF=0.1965:EMAF=0.1651	0.57		Benign	3755038	rs74344827:rs1399846963		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TAT)(dui:NBS3;dis:Secondary Conditions;g:TAT)(dui:NBS6;dis:Amino Acid Disorder;g:TAT)(dui:NBS37;dis:Tyrosinemia type II;g:TAT)(dui:NBS38;dis:Tyrosinemia type III;g:TAT)(dui:D009422;dis:Nervous System Diseases;g:TAT)(dui:D002493;dis:Central Nervous System Diseases;g:TAT)(dui:D001927;dis:Brain Diseases;g:TAT)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:TAT)(dui:D008659;dis:Metabolic Diseases;g:TAT)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TAT)(dui:D030342;dis:Genetic Diseases, Inborn;g:TAT)(dui:D008661;dis:Metabolism, Inborn Errors;g:TAT)(dui:D001928;dis:Brain Diseases, Metabolic;g:TAT)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:TAT)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:TAT)(dui:D020176;dis:Tyrosinemias;g:TAT)	Pyridoxal phosphate:Tyrosine:Glutamic acid:Phenylalanine	GO:0030170:GO:0042802:GO:0046689:GO:0006572:GO:0009058:GO:0005575:GO:0006103:GO:0006979:GO:0006536:GO:0005515:GO:0006559:GO:0004838:GO:0005739:GO:0051384:GO:0005829:GO:0016597	613018	PF07706:PF00155:PF00266	1.21															
chr17:7217786	SNV	C	1	C/A	PASS	4.886523593428418e-109	1083.11		400	C=182,A=218	C=0.455,A=0.545	54.5	45.5	heterozygous	1	0.014	2.0		DLG4	NR_135527.1	DLG4:intronic_nc:NR_135527.1															rs72839706		(dui:D009422;dis:Nervous System Diseases;g:DLG4)(dui:D009461;dis:Neurologic Manifestations;g:DLG4)(dui:D002318;dis:Cardiovascular Diseases;g:DLG4)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:DLG4)(dui:D030342;dis:Genetic Diseases, Inborn;g:DLG4)(dui:D000013;dis:Congenital Abnormalities;g:DLG4)(dui:D006331;dis:Heart Diseases;g:DLG4)(dui:D006349;dis:Heart Valve Diseases;g:DLG4)(dui:D008607;dis:Intellectual Disability;g:DLG4)(dui:D019954;dis:Neurobehavioral Manifestations;g:DLG4)(dui:D025063;dis:Chromosome Disorders;g:DLG4)(dui:D001024;dis:Aortic Valve Stenosis;g:DLG4)(dui:D018980;dis:Williams Syndrome;g:DLG4)(dui:D021921;dis:Aortic Stenosis, Supravalvular;g:DLG4)(dui:D001523;dis:Mental Disorders;g:DLG4)(dui:D065886;dis:Neurodevelopmental Disorders;g:DLG4)(dui:D002659;dis:Child Development Disorders, Pervasive;g:DLG4)(dui:D002493;dis:Central Nervous System Diseases;g:DLG4)(dui:D001927;dis:Brain Diseases;g:DLG4)(dui:D009369;dis:Neoplasms;g:DLG4)(dui:D004700;dis:Endocrine System Diseases;g:DLG4)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:DLG4)(dui:D003560;dis:Cysts;g:DLG4)(dui:D006058;dis:Gonadal Disorders;g:DLG4)(dui:D052776;dis:Female Urogenital Diseases;g:DLG4)(dui:D005831;dis:Genital Diseases, Female;g:DLG4)(dui:D010048;dis:Ovarian Cysts;g:DLG4)(dui:D010049;dis:Ovarian Diseases;g:DLG4)(dui:D000291;dis:Adnexal Diseases;g:DLG4)(dui:D011085;dis:Polycystic Ovary Syndrome;g:DLG4)	Guanidine:Guanosine-5'-Monophosphate		600966:602887	PF13180:PF00018:PF00625:PF07653:PF10608:PF00595:PF10600	-0.38															
chr17:7221421	INDEL	ACTGCCCTAGGTCAGGAA	17	ACTGCCCTAGGTCAGGAA/A	PASS	1.1376272858233869e-259	2589.44		342	ACTGCCCTAGGTCAGGAA=36,A=306	ACTGCCCTAGGTCAGGAA=0.1053,A=0.8947	89.47	10.53	homozygous	40	0.002	1.0		ACADVL	NM_000018.4	ACADVL:intronic:NM_000018.4	unknown			p.?	c.478-116_478-100delCTGCCCTAGGTCAGGAA				A						rs750835287:rs1567562754:rs80162838:rs78100429:rs535609436:rs35999860:rs147519793:rs1416225920:rs1184230081:rs1322109465:rs386795011:rs374828700:rs907034423:rs7503586:rs370388543:rs201760717:rs1031535036		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADVL)(dui:NBS2;dis:Core Conditions;g:ACADVL)(dui:NBS10;dis:Fatty Acid Oxidation Disorder;g:ACADVL)(dui:NBS52;dis:Very long-chain acyl-CoA dehydrogenase deficiency;g:ACADVL)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADVL)(dui:D008659;dis:Metabolic Diseases;g:ACADVL)(dui:D009422;dis:Nervous System Diseases;g:ACADVL)(dui:D009140;dis:Musculoskeletal Diseases;g:ACADVL)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADVL)(dui:D009135;dis:Muscular Diseases;g:ACADVL)(dui:D009468;dis:Neuromuscular Diseases;g:ACADVL)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADVL)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADVL)(dui:D028361;dis:Mitochondrial Diseases;g:ACADVL)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADVL)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADVL)		GO:0036498:GO:0005730:GO:0004466:GO:0005654:GO:0009409:GO:0006635:GO:0033539:GO:0000062:GO:0046322:GO:0005829:GO:0031314:GO:0045717:GO:0042802:GO:0015980:GO:0042645:GO:0090181:GO:0003995:GO:0030855:GO:0005515:GO:0031966:GO:0005759:GO:0050660:GO:0001659:GO:0005739:GO:0017099	609575	PF02771:PF02770:PF00441:PF08028	-0.78,0.12,0.1,-0.17,-0.72,-1.03,-0.35,-0.01,-1.94,-0.18,1.36,-1.92,-0.66,0.83,-0.02,0.03,-0.03,-0.45															
chr17:7221449	SNV	T	1	T/C	PASS	2.0888151080233405e-82	816.801		377	T=192,C=185	T=0.5093,C=0.4907	49.07	50.93	heterozygous	48	0.478	1.0		ACADVL	NM_000018.4	ACADVL:intronic:NM_000018.4	unknown			p.?	c.478-89T>C				C						rs77493353:rs1416225920:rs9646410:rs386795011:rs386795012:rs374828700:rs1567562793		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADVL)(dui:NBS2;dis:Core Conditions;g:ACADVL)(dui:NBS10;dis:Fatty Acid Oxidation Disorder;g:ACADVL)(dui:NBS52;dis:Very long-chain acyl-CoA dehydrogenase deficiency;g:ACADVL)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADVL)(dui:D008659;dis:Metabolic Diseases;g:ACADVL)(dui:D009422;dis:Nervous System Diseases;g:ACADVL)(dui:D009140;dis:Musculoskeletal Diseases;g:ACADVL)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADVL)(dui:D009135;dis:Muscular Diseases;g:ACADVL)(dui:D009468;dis:Neuromuscular Diseases;g:ACADVL)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADVL)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADVL)(dui:D028361;dis:Mitochondrial Diseases;g:ACADVL)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADVL)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADVL)		GO:0036498:GO:0005730:GO:0004466:GO:0005654:GO:0009409:GO:0006635:GO:0033539:GO:0000062:GO:0046322:GO:0005829:GO:0031314:GO:0045717:GO:0042802:GO:0015980:GO:0042645:GO:0090181:GO:0003995:GO:0030855:GO:0005515:GO:0031966:GO:0005759:GO:0050660:GO:0001659:GO:0005739:GO:0017099	609575	PF02771:PF02770:PF00441:PF08028	0.0															
chr17:7224399	SNV	T	1	C/C	PASS	0.0	3901.26		398	T=2,C=396	T=0.005,C=0.995	99.5	0.5	homozygous	48	0.48	1.0		ACADVL|DVL2	NM_000018.4|NM_004422.3	ACADVL:intronic:NM_000018.4|DVL2:downstream:NM_004422.3	unknown|unknown	|	|	p.?|p.?	c.1605+6T>C|c.*1466A>G	|	|	|	C|C	GMAF=0.4383:AMAF=0.4362:EMAF=0.3739	0.07		Benign	7228542	rs17671352:rs1064795676		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADVL)(dui:NBS2;dis:Core Conditions;g:ACADVL)(dui:NBS10;dis:Fatty Acid Oxidation Disorder;g:ACADVL)(dui:NBS52;dis:Very long-chain acyl-CoA dehydrogenase deficiency;g:ACADVL)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADVL)(dui:D008659;dis:Metabolic Diseases;g:ACADVL)(dui:D009422;dis:Nervous System Diseases;g:ACADVL)(dui:D009140;dis:Musculoskeletal Diseases;g:ACADVL)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADVL)(dui:D009135;dis:Muscular Diseases;g:ACADVL)(dui:D009468;dis:Neuromuscular Diseases;g:ACADVL)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADVL)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADVL)(dui:D028361;dis:Mitochondrial Diseases;g:ACADVL)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADVL)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADVL)		GO:0036498:GO:0016328:GO:0043507:GO:0016604:GO:0090179:GO:0061098:GO:0022007:GO:0051091:GO:0043621:GO:0007379:GO:0043547:GO:0004466:GO:0006635:GO:0033539:GO:0005109:GO:0045177:GO:0000062:GO:0048365:GO:0005829:GO:0031314:GO:0019901:GO:0019904:GO:0090103:GO:0150012:GO:0045334:GO:0090181:GO:0030855:GO:0005634:GO:0005515:GO:0005759:GO:0017099:GO:0034613:GO:0003151:GO:0005730:GO:0045944:GO:0005654:GO:0009409:GO:0007507:GO:0001843:GO:0044340:GO:0046322:GO:0031410:GO:0060070:GO:0060071:GO:0016235:GO:0045717:GO:0061024:GO:0042802:GO:0015980:GO:0006355:GO:1904886:GO:0042645:GO:0003995:GO:0090090:GO:0031966:GO:0050660:GO:0005737:GO:0001659:GO:0005739:GO:0001934:GO:0035329:GO:0030674:GO:0035567	609575:602151	PF02771:PF02770:PF00441:PF08028	-0.25															
chr19:12891586	SNV	G	1	C/C	PASS	0.0	3991.69		399	G=0,C=399	G=0.0,C=1.0	100.0	0.0	homozygous	29	0.253	2.0		GCDH	NR_102317.1	GCDH:exonic_nc:NR_102317.1			3							GMAF=0.3233:AMAF=0.2298:EMAF=0.3639					rs1799918		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:GCDH)(dui:NBS2;dis:Core Conditions;g:GCDH)(dui:NBS9;dis:Organic Acid Condition;g:GCDH)(dui:NBS49;dis:Glutaric acidemia type I;g:GCDH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:GCDH)(dui:D008659;dis:Metabolic Diseases;g:GCDH)(dui:D009422;dis:Nervous System Diseases;g:GCDH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:GCDH)(dui:D002493;dis:Central Nervous System Diseases;g:GCDH)(dui:D030342;dis:Genetic Diseases, Inborn;g:GCDH)(dui:D008661;dis:Metabolism, Inborn Errors;g:GCDH)(dui:D001927;dis:Brain Diseases;g:GCDH)(dui:D001928;dis:Brain Diseases, Metabolic;g:GCDH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:GCDH)	S-4-Nitrobutyryl-CoA:Flavin adenine dinucleotide		608801	PF02771:PF02770:PF00441:PF08028	0.59															
chr19:12897793	SNV	G	1	G/T	PASS	2.624218543384337e-297	2965.81		399	G=45,T=354	G=0.1128,T=0.8872	88.72	11.28	heterozygous	37	0.25	7.0		GCDH|SYCE2	NR_102317.1|NM_001105578.2	GCDH:exonic_nc:NR_102317.1|SYCE2:downstream:NM_001105578.2	|unknown	|	10|	|p.?	|c.*1548C>A	|	|	|	|T	GMAF=0.3071:AMAF=0.2072:EMAF=0.3583	0.09		Benign	2816924:6039891:3756351	rs1060218:rs1486220652		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:GCDH)(dui:NBS2;dis:Core Conditions;g:GCDH)(dui:NBS9;dis:Organic Acid Condition;g:GCDH)(dui:NBS49;dis:Glutaric acidemia type I;g:GCDH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:GCDH)(dui:D008659;dis:Metabolic Diseases;g:GCDH)(dui:D009422;dis:Nervous System Diseases;g:GCDH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:GCDH)(dui:D002493;dis:Central Nervous System Diseases;g:GCDH)(dui:D030342;dis:Genetic Diseases, Inborn;g:GCDH)(dui:D008661;dis:Metabolism, Inborn Errors;g:GCDH)(dui:D001927;dis:Brain Diseases;g:GCDH)(dui:D001928;dis:Brain Diseases, Metabolic;g:GCDH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:GCDH)	S-4-Nitrobutyryl-CoA:Flavin adenine dinucleotide	GO:0051301:GO:0005515:GO:0007130:GO:0000801:GO:0005654	611487:608801	PF02771:PF02770:PF00441:PF08028	-1.11															
chr19:12899706	SNV	A	1	G/G	PASS	0.0	3966.11		396	A=0,G=396	A=0.0,G=1.0	100.0	0.0	homozygous	55	0.28	1.0		GCDH|SYCE2	NR_102317.1|NM_001105578.2	GCDH:exonic_nc:NR_102317.1|SYCE2:intronic:NM_001105578.2	|unknown	|	11|	|p.?	|c.612+298T>C	|	|	|	|G	GMAF=0.3611:AMAF=0.1756:EMAF=0.4546	0.11		Benign	7218541	rs8012		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:GCDH)(dui:NBS2;dis:Core Conditions;g:GCDH)(dui:NBS9;dis:Organic Acid Condition;g:GCDH)(dui:NBS49;dis:Glutaric acidemia type I;g:GCDH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:GCDH)(dui:D008659;dis:Metabolic Diseases;g:GCDH)(dui:D009422;dis:Nervous System Diseases;g:GCDH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:GCDH)(dui:D002493;dis:Central Nervous System Diseases;g:GCDH)(dui:D030342;dis:Genetic Diseases, Inborn;g:GCDH)(dui:D008661;dis:Metabolism, Inborn Errors;g:GCDH)(dui:D001927;dis:Brain Diseases;g:GCDH)(dui:D001928;dis:Brain Diseases, Metabolic;g:GCDH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:GCDH)	S-4-Nitrobutyryl-CoA:Flavin adenine dinucleotide	GO:0051301:GO:0005515:GO:0007130:GO:0000801:GO:0005654	611487:608801	PF02771:PF02770:PF01442:PF00441:PF08028	0.32															
chr19:41397766	SNV	A	1	A/G	PASS	1.5381546403029758e-113	1128.13		396	A=175,G=221	A=0.4419,G=0.5581	55.81	44.19	heterozygous	55	0.418	3.0		EXOSC5|BCKDHA	NM_020158.4|NM_001164783.2	EXOSC5:upstream:NM_020158.4|BCKDHA:upstream:NM_001164783.2	unknown|unknown	|	|	p.?|p.?	c.-438T>C|c.-62A>G	|	|	|	G|G						rs892044		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHA)(dui:NBS2;dis:Core Conditions;g:BCKDHA)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHA)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHA)(dui:D008659;dis:Metabolic Diseases;g:BCKDHA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHA)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHA)(dui:D009422;dis:Nervous System Diseases;g:BCKDHA)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHA)(dui:D001927;dis:Brain Diseases;g:BCKDHA)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHA)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHA)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHA)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHA)(dui:D009369;dis:Neoplasms;g:EXOSC5)(dui:D009371;dis:Neoplasms by Site;g:EXOSC5)(dui:D004066;dis:Digestive System Diseases;g:EXOSC5)(dui:D004067;dis:Digestive System Neoplasms;g:EXOSC5)(dui:D005767;dis:Gastrointestinal Diseases;g:EXOSC5)(dui:D005770;dis:Gastrointestinal Neoplasms;g:EXOSC5)(dui:D013272;dis:Stomach Diseases;g:EXOSC5)(dui:D013274;dis:Stomach Neoplasms;g:EXOSC5)		GO:0034475:GO:0043928:GO:0045006:GO:0043488:GO:0006364:GO:0005730:GO:0000178:GO:0005654:GO:0003863:GO:0071051:GO:0003723:GO:0005947:GO:0003826:GO:0016075:GO:0005829:GO:0051607:GO:0034427:GO:0016831:GO:0090503:GO:0009083:GO:0004532:GO:0000177:GO:0000176:GO:0000175:GO:0005515:GO:0005759:GO:0046872:GO:0005737:GO:0005739:GO:0035327:GO:0071028:GO:0055114	606492:608348		0.08															
chr19:41397770	SNV	A	1	G/G	PASS	0.0	3893.27		397	A=2,G=395	A=0.005,G=0.995	99.5	0.5	homozygous	56	0.02	1.0		EXOSC5|BCKDHA	NM_020158.4|NM_001164783.2	EXOSC5:upstream:NM_020158.4|BCKDHA:upstream:NM_001164783.2	unknown|unknown	|	|	p.?|p.?	c.-442T>C|c.-58A>G	|	|	|	G|G						rs892043		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHA)(dui:NBS2;dis:Core Conditions;g:BCKDHA)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHA)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHA)(dui:D008659;dis:Metabolic Diseases;g:BCKDHA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHA)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHA)(dui:D009422;dis:Nervous System Diseases;g:BCKDHA)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHA)(dui:D001927;dis:Brain Diseases;g:BCKDHA)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHA)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHA)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHA)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHA)(dui:D009369;dis:Neoplasms;g:EXOSC5)(dui:D009371;dis:Neoplasms by Site;g:EXOSC5)(dui:D004066;dis:Digestive System Diseases;g:EXOSC5)(dui:D004067;dis:Digestive System Neoplasms;g:EXOSC5)(dui:D005767;dis:Gastrointestinal Diseases;g:EXOSC5)(dui:D005770;dis:Gastrointestinal Neoplasms;g:EXOSC5)(dui:D013272;dis:Stomach Diseases;g:EXOSC5)(dui:D013274;dis:Stomach Neoplasms;g:EXOSC5)		GO:0034475:GO:0043928:GO:0045006:GO:0043488:GO:0006364:GO:0005730:GO:0000178:GO:0005654:GO:0003863:GO:0071051:GO:0003723:GO:0005947:GO:0003826:GO:0016075:GO:0005829:GO:0051607:GO:0034427:GO:0016831:GO:0090503:GO:0009083:GO:0004532:GO:0000177:GO:0000176:GO:0000175:GO:0005515:GO:0005759:GO:0046872:GO:0005737:GO:0005739:GO:0035327:GO:0071028:GO:0055114	606492:608348		0.12															
chr19:41414039	SNV	A	1	A/C	PASS	2.629662420030213e-88	875.801		400	A=203,C=197	A=0.5075,C=0.4925	49.25	50.75	heterozygous	55	0.384	1.0		BCKDHA	NM_001164783.2	BCKDHA:intronic:NM_001164783.2	unknown			p.?	c.376-10A>C				C	GMAF=0.3239:AMAF=0.1902:EMAF=0.3924	0.01		Benign	4000746	rs3213861		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHA)(dui:NBS2;dis:Core Conditions;g:BCKDHA)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHA)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHA)(dui:D008659;dis:Metabolic Diseases;g:BCKDHA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHA)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHA)(dui:D009422;dis:Nervous System Diseases;g:BCKDHA)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHA)(dui:D001927;dis:Brain Diseases;g:BCKDHA)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHA)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHA)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHA)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHA)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0046872:GO:0003826:GO:0005739:GO:0055114:GO:0016831	608348	PF00676	-0.51															
chr19:41422431	SNV	T	1	T/C	PASS	4.944245193336888e-75	743.059		398	T=216,C=182	T=0.5427,C=0.4573	45.73	54.27	heterozygous	55	0.382	1.0		BCKDHA	NM_001164783.2	BCKDHA:intronic:NM_001164783.2	unknown			p.?	c.853+61T>C				C						rs284651		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHA)(dui:NBS2;dis:Core Conditions;g:BCKDHA)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHA)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHA)(dui:D008659;dis:Metabolic Diseases;g:BCKDHA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHA)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHA)(dui:D009422;dis:Nervous System Diseases;g:BCKDHA)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHA)(dui:D001927;dis:Brain Diseases;g:BCKDHA)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHA)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHA)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHA)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHA)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0046872:GO:0003826:GO:0005739:GO:0055114:GO:0016831	608348	PF00676	-2.12															
chr19:41422747	SNV	C	1	C/T	PASS	4.178303666466307e-124	1233.79		399	C=167,T=232	C=0.4185,T=0.5815	58.15	41.85	heterozygous	55	0.384	2.0		BCKDHA	NM_001164783.2	BCKDHA:exonic:NM_001164783.2	synonymous	TTT	7	p.Phe323=	c.969C>T				T	GMAF=0.3239:AMAF=0.1902:EMAF=0.3924	0.92		Benign	3933055	rs284652:rs112312448		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHA)(dui:NBS2;dis:Core Conditions;g:BCKDHA)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHA)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHA)(dui:D008659;dis:Metabolic Diseases;g:BCKDHA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHA)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHA)(dui:D009422;dis:Nervous System Diseases;g:BCKDHA)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHA)(dui:D001927;dis:Brain Diseases;g:BCKDHA)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHA)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHA)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHA)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHA)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0046872:GO:0003826:GO:0005739:GO:0055114:GO:0016831	608348	PF00676	2.87															
chr19:41422796	SNV	C	1	C/T	PASS	1.4092887984218778e-107	1068.51		394	C=179,T=215	C=0.4543,T=0.5457	54.57	45.43	heterozygous	33	0.257	5.0		BCKDHA	NM_001164783.2	BCKDHA:intronic:NM_001164783.2	unknown			p.?	c.992+26C>T				T	GMAF=0.3824:AMAF=0.264:EMAF=0.4431			Benign/Likely benign		rs284653		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHA)(dui:NBS2;dis:Core Conditions;g:BCKDHA)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHA)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHA)(dui:D008659;dis:Metabolic Diseases;g:BCKDHA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHA)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHA)(dui:D009422;dis:Nervous System Diseases;g:BCKDHA)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHA)(dui:D001927;dis:Brain Diseases;g:BCKDHA)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHA)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHA)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHA)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHA)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0046872:GO:0003826:GO:0005739:GO:0055114:GO:0016831	608348	PF00676	-0.25															
chr19:41422819	SNV	G	1	G/A	PASS	5.956621435290182e-134	1332.25		400	G=159,A=241	G=0.3975,A=0.6025	60.25	39.75	heterozygous	55	0.414	1.0		BCKDHA	NM_001164783.2	BCKDHA:intronic:NM_001164783.2	unknown			p.?	c.992+49G>A				A	GMAF=0.3565:AMAF=0.2855:EMAF=0.3929			Benign/Likely benign		rs284654		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHA)(dui:NBS2;dis:Core Conditions;g:BCKDHA)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHA)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHA)(dui:D008659;dis:Metabolic Diseases;g:BCKDHA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHA)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHA)(dui:D009422;dis:Nervous System Diseases;g:BCKDHA)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHA)(dui:D001927;dis:Brain Diseases;g:BCKDHA)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHA)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHA)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHA)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHA)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0046872:GO:0003826:GO:0005739:GO:0055114:GO:0016831	608348	PF00676	-1.91															
chr19:41422860	SNV	C	1	C/T	PASS	2.013260626097176e-76	756.961		400	C=216,T=184	C=0.54,T=0.46	46.0	54.0	heterozygous	55	0.386	2.0		BCKDHA	NM_001164783.2	BCKDHA:intronic:NM_001164783.2	unknown			p.?	c.992+90C>T				T						rs284655		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHA)(dui:NBS2;dis:Core Conditions;g:BCKDHA)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHA)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHA)(dui:D008659;dis:Metabolic Diseases;g:BCKDHA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHA)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHA)(dui:D009422;dis:Nervous System Diseases;g:BCKDHA)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHA)(dui:D001927;dis:Brain Diseases;g:BCKDHA)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHA)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHA)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHA)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHA)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0046872:GO:0003826:GO:0005739:GO:0055114:GO:0016831	608348	PF00676	0.58															
chr19:41424491	SNV	A	1	A/G	PASS	8.635748781703864e-87	860.637		398	A=203,G=195	A=0.5101,G=0.4899	49.0	51.0	heterozygous	55	0.383	1.0		BCKDHA|B3GNT8	NM_001164783.2|NM_198540.2	BCKDHA:exonic:NM_001164783.2|B3GNT8:downstream:NM_198540.2	synonymous|unknown	CTG|	9|	p.Leu406=|p.?	c.1218A>G|c.*1094T>C	|	|	|	G|G	GMAF=0.323:AMAF=0.1895:EMAF=0.3914	0.15		Benign	7239888	rs4674		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHA)(dui:NBS2;dis:Core Conditions;g:BCKDHA)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHA)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHA)(dui:D008659;dis:Metabolic Diseases;g:BCKDHA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHA)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHA)(dui:D009422;dis:Nervous System Diseases;g:BCKDHA)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHA)(dui:D001927;dis:Brain Diseases;g:BCKDHA)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHA)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHA)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHA)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHA)		GO:0009083:GO:0016758:GO:0008375:GO:0006486:GO:0008532:GO:0000139:GO:0005794:GO:0008376:GO:0003863:GO:0005515:GO:0070062:GO:0005947:GO:0005759:GO:0046872:GO:0003826:GO:0005739:GO:0016262:GO:0016021:GO:0055114:GO:0016266:GO:0030311:GO:0016831	615357:608348	PF00676	0.76															
chr19:45529477	INDEL	CAG	2	CAG/C	PASS	2.576321157002499e-107	1065.89		397	CAG=181,C=216	CAG=0.4559,C=0.5441	54.41	45.59	heterozygous	29	0.148	1.0		OPA3												GMAF=0.1345:AMAF=0.1308:EMAF=0.1363					rs1599947393:rs149252540:rs1599947386		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:OPA3)(dui:NBS3;dis:Secondary Conditions;g:OPA3)(dui:NBS4;dis:Organic Acid Condition;g:OPA3)(dui:NBS19;dis:3-Methylglutaconic aciduria;g:OPA3)(dui:D009422;dis:Nervous System Diseases;g:OPA3)(dui:D005128;dis:Eye Diseases;g:OPA3)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:OPA3)(dui:D030342;dis:Genetic Diseases, Inborn;g:OPA3)(dui:D003389;dis:Cranial Nerve Diseases;g:OPA3)(dui:D009901;dis:Optic Nerve Diseases;g:OPA3)(dui:D019636;dis:Neurodegenerative Diseases;g:OPA3)(dui:D009896;dis:Optic Atrophy;g:OPA3)(dui:D020271;dis:Heredodegenerative Disorders, Nervous System;g:OPA3)(dui:D015785;dis:Eye Diseases, Hereditary;g:OPA3)(dui:D015418;dis:Optic Atrophies, Hereditary;g:OPA3)(dui:D007905;dis:Lens Diseases;g:OPA3)(dui:D002386;dis:Cataract;g:OPA3)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:OPA3)(dui:D008659;dis:Metabolic Diseases;g:OPA3)(dui:D009461;dis:Neurologic Manifestations;g:OPA3)(dui:D000013;dis:Congenital Abnormalities;g:OPA3)(dui:D002493;dis:Central Nervous System Diseases;g:OPA3)(dui:D009421;dis:Nervous System Malformations;g:OPA3)(dui:D009468;dis:Neuromuscular Diseases;g:OPA3)(dui:D008661;dis:Metabolism, Inborn Errors;g:OPA3)(dui:D009069;dis:Movement Disorders;g:OPA3)(dui:D010523;dis:Peripheral Nervous System Diseases;g:OPA3)(dui:D015417;dis:Hereditary Sensory and Motor Neuropathy;g:OPA3)(dui:D020820;dis:Dyskinesias;g:OPA3)(dui:D002819;dis:Chorea;g:OPA3)(dui:D011115;dis:Polyneuropathies;g:OPA3)(dui:D015419;dis:Spastic Paraplegia, Hereditary;g:OPA3)			606580		-0.36,-0.32,4.25															
chr19:45529583	SNV	G	1	G/C	PASS	1.3886730268999395e-70	698.574		397	G=220,C=177	G=0.5542,C=0.4458	44.58	55.42	heterozygous	34	0.309	4.0		OPA3																	rs12971437		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:OPA3)(dui:NBS3;dis:Secondary Conditions;g:OPA3)(dui:NBS4;dis:Organic Acid Condition;g:OPA3)(dui:NBS19;dis:3-Methylglutaconic aciduria;g:OPA3)(dui:D009422;dis:Nervous System Diseases;g:OPA3)(dui:D005128;dis:Eye Diseases;g:OPA3)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:OPA3)(dui:D030342;dis:Genetic Diseases, Inborn;g:OPA3)(dui:D003389;dis:Cranial Nerve Diseases;g:OPA3)(dui:D009901;dis:Optic Nerve Diseases;g:OPA3)(dui:D019636;dis:Neurodegenerative Diseases;g:OPA3)(dui:D009896;dis:Optic Atrophy;g:OPA3)(dui:D020271;dis:Heredodegenerative Disorders, Nervous System;g:OPA3)(dui:D015785;dis:Eye Diseases, Hereditary;g:OPA3)(dui:D015418;dis:Optic Atrophies, Hereditary;g:OPA3)(dui:D007905;dis:Lens Diseases;g:OPA3)(dui:D002386;dis:Cataract;g:OPA3)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:OPA3)(dui:D008659;dis:Metabolic Diseases;g:OPA3)(dui:D009461;dis:Neurologic Manifestations;g:OPA3)(dui:D000013;dis:Congenital Abnormalities;g:OPA3)(dui:D002493;dis:Central Nervous System Diseases;g:OPA3)(dui:D009421;dis:Nervous System Malformations;g:OPA3)(dui:D009468;dis:Neuromuscular Diseases;g:OPA3)(dui:D008661;dis:Metabolism, Inborn Errors;g:OPA3)(dui:D009069;dis:Movement Disorders;g:OPA3)(dui:D010523;dis:Peripheral Nervous System Diseases;g:OPA3)(dui:D015417;dis:Hereditary Sensory and Motor Neuropathy;g:OPA3)(dui:D020820;dis:Dyskinesias;g:OPA3)(dui:D002819;dis:Chorea;g:OPA3)(dui:D011115;dis:Polyneuropathies;g:OPA3)(dui:D015419;dis:Spastic Paraplegia, Hereditary;g:OPA3)			606580		-0.72															
chr19:45553823	SNV	A	1	G/G	PASS	0.0	3991.59		399	A=0,G=399	A=0.0,G=1.0	100.0	0.0	homozygous	48	0.233	1.0		OPA3	NM_025136.4	OPA3:exonic:NM_025136.4	synonymous	GCC	2	p.Ala77=	c.231T>C				G	GMAF=0.3174:AMAF=0.2398:EMAF=0.3572	0.09		Benign	439792	rs3826860		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:OPA3)(dui:NBS3;dis:Secondary Conditions;g:OPA3)(dui:NBS4;dis:Organic Acid Condition;g:OPA3)(dui:NBS19;dis:3-Methylglutaconic aciduria;g:OPA3)(dui:D009422;dis:Nervous System Diseases;g:OPA3)(dui:D005128;dis:Eye Diseases;g:OPA3)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:OPA3)(dui:D030342;dis:Genetic Diseases, Inborn;g:OPA3)(dui:D003389;dis:Cranial Nerve Diseases;g:OPA3)(dui:D009901;dis:Optic Nerve Diseases;g:OPA3)(dui:D019636;dis:Neurodegenerative Diseases;g:OPA3)(dui:D009896;dis:Optic Atrophy;g:OPA3)(dui:D020271;dis:Heredodegenerative Disorders, Nervous System;g:OPA3)(dui:D015785;dis:Eye Diseases, Hereditary;g:OPA3)(dui:D015418;dis:Optic Atrophies, Hereditary;g:OPA3)(dui:D007905;dis:Lens Diseases;g:OPA3)(dui:D002386;dis:Cataract;g:OPA3)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:OPA3)(dui:D008659;dis:Metabolic Diseases;g:OPA3)(dui:D009461;dis:Neurologic Manifestations;g:OPA3)(dui:D000013;dis:Congenital Abnormalities;g:OPA3)(dui:D002493;dis:Central Nervous System Diseases;g:OPA3)(dui:D009421;dis:Nervous System Malformations;g:OPA3)(dui:D009468;dis:Neuromuscular Diseases;g:OPA3)(dui:D008661;dis:Metabolism, Inborn Errors;g:OPA3)(dui:D009069;dis:Movement Disorders;g:OPA3)(dui:D010523;dis:Peripheral Nervous System Diseases;g:OPA3)(dui:D015417;dis:Hereditary Sensory and Motor Neuropathy;g:OPA3)(dui:D020820;dis:Dyskinesias;g:OPA3)(dui:D002819;dis:Chorea;g:OPA3)(dui:D011115;dis:Polyneuropathies;g:OPA3)(dui:D015419;dis:Spastic Paraplegia, Hereditary;g:OPA3)		GO:0070584:GO:0005739:GO:0050905:GO:0045444:GO:0007601:GO:0019216:GO:0040008:GO:0050896:GO:0060348	606580	PF07047	-0.93															
chr19:51347036	SNV	G	1	G/A	PASS	2.6711605988438822e-79	785.733		399	G=212,A=187	G=0.5313,A=0.4687	46.87	53.13	heterozygous	20	0.42	1.0		ETFB	NM_001985.3	ETFB:exonic:NM_001985.3	missense	ATG	5	p.Thr154Met	c.461C>T	0.01	0.98	81.0	A	GMAF=0.4582:AMAF=0.4911:EMAF=0.4413	0.94		Benign	3721676	rs1130426		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ETFB)(dui:NBS3;dis:Secondary Conditions;g:ETFB)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ETFB)(dui:NBS24;dis:Glutaric acidemia type II;g:ETFB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ETFB)(dui:D008659;dis:Metabolic Diseases;g:ETFB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ETFB)(dui:D030342;dis:Genetic Diseases, Inborn;g:ETFB)(dui:D008661;dis:Metabolism, Inborn Errors;g:ETFB)(dui:D028361;dis:Mitochondrial Diseases;g:ETFB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ETFB)(dui:D054069;dis:Multiple Acyl Coenzyme A Dehydrogenase Deficiency;g:ETFB)		GO:0033539:GO:0005515:GO:0005759:GO:0009055:GO:0005739:GO:0022904	130410	PF01012	3.13															
chr19:51347148	SNV	T	1	T/C	PASS	4.501943082824361e-93	923.466		400	T=198,C=202	T=0.495,C=0.505	50.5	49.5	heterozygous	12	0.117	1.0		ETFB	NM_001985.3	ETFB:intronic:NM_001985.3	unknown			p.?	c.439-90A>G				C						rs8112687		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ETFB)(dui:NBS3;dis:Secondary Conditions;g:ETFB)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ETFB)(dui:NBS24;dis:Glutaric acidemia type II;g:ETFB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ETFB)(dui:D008659;dis:Metabolic Diseases;g:ETFB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ETFB)(dui:D030342;dis:Genetic Diseases, Inborn;g:ETFB)(dui:D008661;dis:Metabolism, Inborn Errors;g:ETFB)(dui:D028361;dis:Mitochondrial Diseases;g:ETFB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ETFB)(dui:D054069;dis:Multiple Acyl Coenzyme A Dehydrogenase Deficiency;g:ETFB)		GO:0033539:GO:0005515:GO:0005759:GO:0009055:GO:0005739:GO:0022904	130410	PF01012	-1.71															
chr19:51347231	SNV	T	1	T/C	PASS	5.787619883491244e-67	662.375		400	T=227,C=173	T=0.5675,C=0.4325	43.25	56.75	heterozygous	20	0.456	5.0		ETFB	NM_001985.3	ETFB:intronic:NM_001985.3	unknown			p.?	c.439-173A>G				C				Benign		rs8112785		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ETFB)(dui:NBS3;dis:Secondary Conditions;g:ETFB)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ETFB)(dui:NBS24;dis:Glutaric acidemia type II;g:ETFB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ETFB)(dui:D008659;dis:Metabolic Diseases;g:ETFB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ETFB)(dui:D030342;dis:Genetic Diseases, Inborn;g:ETFB)(dui:D008661;dis:Metabolism, Inborn Errors;g:ETFB)(dui:D028361;dis:Mitochondrial Diseases;g:ETFB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ETFB)(dui:D054069;dis:Multiple Acyl Coenzyme A Dehydrogenase Deficiency;g:ETFB)		GO:0033539:GO:0005515:GO:0005759:GO:0009055:GO:0005739:GO:0022904	130410	PF01012	-0.49															
chr19:51347252	SNV	C	1	C/T	PASS	9.68946949978737e-83	820.137		400	C=209,T=191	C=0.5225,T=0.4775	47.75	52.25	heterozygous	12	0.116	1.0		ETFB	NM_001985.3	ETFB:intronic:NM_001985.3	unknown			p.?	c.439-194G>A				T				Benign		rs8111973		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ETFB)(dui:NBS3;dis:Secondary Conditions;g:ETFB)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ETFB)(dui:NBS24;dis:Glutaric acidemia type II;g:ETFB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ETFB)(dui:D008659;dis:Metabolic Diseases;g:ETFB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ETFB)(dui:D030342;dis:Genetic Diseases, Inborn;g:ETFB)(dui:D008661;dis:Metabolism, Inborn Errors;g:ETFB)(dui:D028361;dis:Mitochondrial Diseases;g:ETFB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ETFB)(dui:D054069;dis:Multiple Acyl Coenzyme A Dehydrogenase Deficiency;g:ETFB)		GO:0033539:GO:0005515:GO:0005759:GO:0009055:GO:0005739:GO:0022904	130410	PF01012	-0.6															
chr21:43067723	SNV	C	1	G/G	PASS	2.6242185433845093e-200	1995.81		208	C=2,G=206	C=0.0096,G=0.9904	99.04	0.9599999999999936	homozygous	1		1.0		CBS	NM_001320298.1	CBS:intronic:NM_001320298.1	unknown			p.?	c.316+786G>C				G						rs376062751		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CBS)(dui:NBS2;dis:Core Conditions;g:CBS)(dui:NBS11;dis:Amino Acid Disorder;g:CBS)(dui:NBS57;dis:Homocystinuria;g:CBS)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CBS)(dui:D008659;dis:Metabolic Diseases;g:CBS)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CBS)(dui:D030342;dis:Genetic Diseases, Inborn;g:CBS)(dui:D008661;dis:Metabolism, Inborn Errors;g:CBS)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:CBS)(dui:D020138;dis:Hyperhomocysteinemia;g:CBS)(dui:D009422;dis:Nervous System Diseases;g:CBS)(dui:D002493;dis:Central Nervous System Diseases;g:CBS)(dui:D001927;dis:Brain Diseases;g:CBS)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CBS)(dui:D003240;dis:Connective Tissue Diseases;g:CBS)(dui:D001928;dis:Brain Diseases, Metabolic;g:CBS)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:CBS)(dui:D006712;dis:Homocystinuria;g:CBS)(dui:D009748;dis:Nutrition Disorders;g:CBS)(dui:D044342;dis:Malnutrition;g:CBS)(dui:D003677;dis:Deficiency Diseases;g:CBS)(dui:D001361;dis:Avitaminosis;g:CBS)(dui:D014804;dis:Vitamin B Deficiency;g:CBS)(dui:D008286;dis:Malabsorption Syndromes;g:CBS)(dui:D002318;dis:Cardiovascular Diseases;g:CBS)(dui:D009369;dis:Neoplasms;g:CBS)(dui:D014652;dis:Vascular Diseases;g:CBS)(dui:D009370;dis:Neoplasms by Histologic Type;g:CBS)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:CBS)(dui:D007154;dis:Immune System Diseases;g:CBS)(dui:D007160;dis:Immunoproliferative Disorders;g:CBS)(dui:D008232;dis:Lymphoproliferative Disorders;g:CBS)(dui:D008206;dis:Lymphatic Diseases;g:CBS)(dui:D008223;dis:Lymphoma;g:CBS)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:CBS)(dui:D004700;dis:Endocrine System Diseases;g:CBS)(dui:D003920;dis:Diabetes Mellitus;g:CBS)(dui:D044882;dis:Glucose Metabolism Disorders;g:CBS)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CBS)(dui:D006973;dis:Hypertension;g:CBS)	Pyridoxal phosphate:Ademetionine:Cysteine:Serine	GO:0030170:GO:0006563:GO:0004122:GO:0006565:GO:0072341:GO:0042262:GO:0019344:GO:0019343:GO:0005829:GO:0019346:GO:0070025:GO:0070026:GO:0019448:GO:0019825:GO:0070814:GO:0042802:GO:0042803:GO:0043418:GO:1904047:GO:0006535:GO:0020037:GO:0005634:GO:0005515:GO:0031625:GO:0050421:GO:0005737:GO:0046872:GO:0055114:GO:0050667:GO:0019899	613381	PF00291:PF00571	-0.05															
chrX:30308866	SNV	C	1	T/T	PASS	2.449063241844802e-257	2566.11		257	C=0,T=257	C=0.0,T=1.0	100.0	0.0	homozygous	32	0.477	2.0		NR0B1	NM_000475.5	NR0B1:exonic:NM_000475.5	synonymous	CGA	1	p.Arg166=	c.498G>A				T	GMAF=0.2828:AMAF=0.4339:EMAF=0.1968	0.08		Benign	3759465	rs2269345		(dui:D004700;dis:Endocrine System Diseases;g:NR0B1)(dui:D006058;dis:Gonadal Disorders;g:NR0B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:NR0B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:NR0B1)(dui:D052776;dis:Female Urogenital Diseases;g:NR0B1)(dui:D052801;dis:Male Urogenital Diseases;g:NR0B1)(dui:D000013;dis:Congenital Abnormalities;g:NR0B1)(dui:D014564;dis:Urogenital Abnormalities;g:NR0B1)(dui:D012734;dis:Disorders of Sex Development;g:NR0B1)(dui:D006059;dis:Gonadal Dysgenesis;g:NR0B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:NR0B1)(dui:D000307;dis:Adrenal Gland Diseases;g:NR0B1)(dui:D007006;dis:Hypogonadism;g:NR0B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:NR0B1)(dui:D008659;dis:Metabolic Diseases;g:NR0B1)(dui:D000309;dis:Adrenal Insufficiency;g:NR0B1)(dui:D058490;dis:46, XY Disorders of Sex Development;g:NR0B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:NR0B1)(dui:D040181;dis:Genetic Diseases, X-Linked;g:NR0B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:NR0B1)(dui:D011629;dis:Puberty, Precocious;g:NR0B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:NR0B1)(dui:D047808;dis:Adrenogenital Syndrome;g:NR0B1)(dui:D006061;dis:Gonadal Dysgenesis, 46,XY;g:NR0B1)	Dexamethasone:Dexamethasone acetate	GO:0008584:GO:0033144:GO:0016607:GO:0034451:GO:0008104:GO:0060008:GO:0021854:GO:0006367:GO:0005654:GO:0000122:GO:0003723:GO:0045892:GO:0043231:GO:0032448:GO:0035258:GO:0030325:GO:0010894:GO:0019904:GO:0042803:GO:0007283:GO:0043433:GO:0008134:GO:0021983:GO:0042788:GO:0005634:GO:0030238:GO:0005515:GO:0000790:GO:0008406:GO:0005737:GO:0050682:GO:0003714:GO:0016020:GO:0035902:GO:0033327	300473	PF14046:PF00104	0.48															
chrX:154532293	SNV	G	1	A/A	PASS	1.9588446735059968e-182	1817.08		190	G=3,A=187	G=0.0158,A=0.9842	98.42	1.5799999999999983	homozygous	45		2.0		G6PD	NM_001042351.3	G6PD:intronic:NM_001042351.3	unknown			p.?	c.1365-13C>T				A	GMAF=0.3923:AMAF=0.1523:EMAF=0.1327					rs2071429		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:G6PD)(dui:NBS3;dis:Secondary Conditions;g:G6PD)(dui:NBS39;dis:Hb carrier other than C,D,E,S,O-Arab;g:G6PD)(dui:NBS7;dis:Hemoglobin Disorder;g:G6PD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:G6PD)(dui:D030342;dis:Genetic Diseases, Inborn;g:G6PD)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:G6PD)(dui:D006402;dis:Hematologic Diseases;g:G6PD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:G6PD)(dui:D000740;dis:Anemia;g:G6PD)(dui:D008659;dis:Metabolic Diseases;g:G6PD)(dui:D000743;dis:Anemia, Hemolytic;g:G6PD)(dui:D000745;dis:Anemia, Hemolytic, Congenital;g:G6PD)(dui:D008661;dis:Metabolism, Inborn Errors;g:G6PD)(dui:D005955;dis:Glucosephosphate Dehydrogenase Deficiency;g:G6PD)(dui:D040181;dis:Genetic Diseases, X-Linked;g:G6PD)(dui:D002239;dis:Carbohydrate Metabolism, Inborn Errors;g:G6PD)(dui:D052801;dis:Male Urogenital Diseases;g:G6PD)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:G6PD)(dui:D014570;dis:Urologic Diseases;g:G6PD)(dui:D052776;dis:Female Urogenital Diseases;g:G6PD)(dui:D007674;dis:Kidney Diseases;g:G6PD)(dui:D004066;dis:Digestive System Diseases;g:G6PD)(dui:D002318;dis:Cardiovascular Diseases;g:G6PD)(dui:D014652;dis:Vascular Diseases;g:G6PD)(dui:D008107;dis:Liver Diseases;g:G6PD)(dui:D007154;dis:Immune System Diseases;g:G6PD)(dui:D007153;dis:Immunologic Deficiency Syndromes;g:G6PD)(dui:D007960;dis:Leukocyte Disorders;g:G6PD)(dui:D010585;dis:Phagocyte Bactericidal Dysfunction;g:G6PD)(dui:D009422;dis:Nervous System Diseases;g:G6PD)(dui:D002493;dis:Central Nervous System Diseases;g:G6PD)(dui:D001927;dis:Brain Diseases;g:G6PD)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:G6PD)(dui:D012871;dis:Skin Diseases;g:G6PD)(dui:D004700;dis:Endocrine System Diseases;g:G6PD)(dui:D044882;dis:Glucose Metabolism Disorders;g:G6PD)(dui:D005236;dis:Favism;g:G6PD)(dui:D000746;dis:Anemia, Hemolytic, Congenital Nonspherocytic;g:G6PD)(dui:D003920;dis:Diabetes Mellitus;g:G6PD)(dui:D002561;dis:Cerebrovascular Disorders;g:G6PD)(dui:D001928;dis:Brain Diseases, Metabolic;g:G6PD)(dui:D009748;dis:Nutrition Disorders;g:G6PD)(dui:D006105;dis:Granulomatous Disease, Chronic;g:G6PD)(dui:D052439;dis:Lipid Metabolism Disorders;g:G6PD)(dui:D002545;dis:Brain Ischemia;g:G6PD)(dui:D003872;dis:Dermatitis;g:G6PD)(dui:D017443;dis:Skin Diseases, Eczematous;g:G6PD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:G6PD)(dui:D003877;dis:Dermatitis, Contact;g:G6PD)(dui:D006946;dis:Hyperinsulinism;g:G6PD)(dui:D050171;dis:Dyslipidemias;g:G6PD)(dui:D051437;dis:Renal Insufficiency;g:G6PD)(dui:D006949;dis:Hyperlipidemias;g:G6PD)(dui:D007333;dis:Insulin Resistance;g:G6PD)(dui:D058186;dis:Acute Kidney Injury;g:G6PD)	Nicotinamide adenine dinucleotide phosphate:Glycolic acid:16-Bromoepiandrosterone:Artenimol	GO:0032094:GO:0010041:GO:0009051:GO:0061052:GO:0034451:GO:0006740:GO:0006006:GO:0043523:GO:0004345:GO:0009898:GO:0043249:GO:1904879:GO:0045471:GO:0070062:GO:0043231:GO:0006739:GO:0019322:GO:0005829:GO:0010734:GO:2000378:GO:0042802:GO:0042803:GO:0006098:GO:0006695:GO:0014070:GO:0021762:GO:0005536:GO:0005634:GO:0050661:GO:0051156:GO:0005515:GO:0005737:GO:0006749:GO:0006629:GO:0016020:GO:0034599:GO:0055114:GO:0046390	305900	PF00479:PF02781	-0.82															
chrX:154532439	SNV	A	1	G/G	PASS	0.0	4003.32		400	A=0,G=400	A=0.0,G=1.0	100.0	0.0	homozygous	46		1.0		G6PD	NM_001042351.3	G6PD:exonic:NM_001042351.3	synonymous	TAC	11	p.Tyr437=	c.1311T>C				G	GMAF=0.1667:AMAF=0.2605:EMAF=0.1133			Benign		rs2230037		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:G6PD)(dui:NBS3;dis:Secondary Conditions;g:G6PD)(dui:NBS39;dis:Hb carrier other than C,D,E,S,O-Arab;g:G6PD)(dui:NBS7;dis:Hemoglobin Disorder;g:G6PD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:G6PD)(dui:D030342;dis:Genetic Diseases, Inborn;g:G6PD)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:G6PD)(dui:D006402;dis:Hematologic Diseases;g:G6PD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:G6PD)(dui:D000740;dis:Anemia;g:G6PD)(dui:D008659;dis:Metabolic Diseases;g:G6PD)(dui:D000743;dis:Anemia, Hemolytic;g:G6PD)(dui:D000745;dis:Anemia, Hemolytic, Congenital;g:G6PD)(dui:D008661;dis:Metabolism, Inborn Errors;g:G6PD)(dui:D005955;dis:Glucosephosphate Dehydrogenase Deficiency;g:G6PD)(dui:D040181;dis:Genetic Diseases, X-Linked;g:G6PD)(dui:D002239;dis:Carbohydrate Metabolism, Inborn Errors;g:G6PD)(dui:D052801;dis:Male Urogenital Diseases;g:G6PD)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:G6PD)(dui:D014570;dis:Urologic Diseases;g:G6PD)(dui:D052776;dis:Female Urogenital Diseases;g:G6PD)(dui:D007674;dis:Kidney Diseases;g:G6PD)(dui:D004066;dis:Digestive System Diseases;g:G6PD)(dui:D002318;dis:Cardiovascular Diseases;g:G6PD)(dui:D014652;dis:Vascular Diseases;g:G6PD)(dui:D008107;dis:Liver Diseases;g:G6PD)(dui:D007154;dis:Immune System Diseases;g:G6PD)(dui:D007153;dis:Immunologic Deficiency Syndromes;g:G6PD)(dui:D007960;dis:Leukocyte Disorders;g:G6PD)(dui:D010585;dis:Phagocyte Bactericidal Dysfunction;g:G6PD)(dui:D009422;dis:Nervous System Diseases;g:G6PD)(dui:D002493;dis:Central Nervous System Diseases;g:G6PD)(dui:D001927;dis:Brain Diseases;g:G6PD)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:G6PD)(dui:D012871;dis:Skin Diseases;g:G6PD)(dui:D004700;dis:Endocrine System Diseases;g:G6PD)(dui:D044882;dis:Glucose Metabolism Disorders;g:G6PD)(dui:D005236;dis:Favism;g:G6PD)(dui:D000746;dis:Anemia, Hemolytic, Congenital Nonspherocytic;g:G6PD)(dui:D003920;dis:Diabetes Mellitus;g:G6PD)(dui:D002561;dis:Cerebrovascular Disorders;g:G6PD)(dui:D001928;dis:Brain Diseases, Metabolic;g:G6PD)(dui:D009748;dis:Nutrition Disorders;g:G6PD)(dui:D006105;dis:Granulomatous Disease, Chronic;g:G6PD)(dui:D052439;dis:Lipid Metabolism Disorders;g:G6PD)(dui:D002545;dis:Brain Ischemia;g:G6PD)(dui:D003872;dis:Dermatitis;g:G6PD)(dui:D017443;dis:Skin Diseases, Eczematous;g:G6PD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:G6PD)(dui:D003877;dis:Dermatitis, Contact;g:G6PD)(dui:D006946;dis:Hyperinsulinism;g:G6PD)(dui:D050171;dis:Dyslipidemias;g:G6PD)(dui:D051437;dis:Renal Insufficiency;g:G6PD)(dui:D006949;dis:Hyperlipidemias;g:G6PD)(dui:D007333;dis:Insulin Resistance;g:G6PD)(dui:D058186;dis:Acute Kidney Injury;g:G6PD)	Nicotinamide adenine dinucleotide phosphate:Glycolic acid:16-Bromoepiandrosterone:Artenimol	GO:0032094:GO:0010041:GO:0009051:GO:0061052:GO:0034451:GO:0006740:GO:0006006:GO:0043523:GO:0004345:GO:0009898:GO:0043249:GO:1904879:GO:0045471:GO:0070062:GO:0043231:GO:0006739:GO:0019322:GO:0005829:GO:0010734:GO:2000378:GO:0042802:GO:0042803:GO:0006098:GO:0006695:GO:0014070:GO:0021762:GO:0005536:GO:0005634:GO:0050661:GO:0051156:GO:0005515:GO:0005737:GO:0006749:GO:0006629:GO:0016020:GO:0034599:GO:0055114:GO:0046390	305900	PF00479:PF02781	-2.64															
chr1:11794698	SNV	G	1	A/A	PASS	0.0	4003.2		400	G=0,A=400	G=0.0,A=1.0	100.0	0.0	homozygous	39	0.421	1.0		MTHFR	NM_005957.5	MTHFR:intronic:NM_005957.5	unknown			p.?	c.1166+31C>T				A	GMAF=0.4642:AMAF=0.4346:EMAF=0.4124					rs1994798		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MTHFR)(dui:NBS2;dis:Core Conditions;g:MTHFR)(dui:NBS11;dis:Amino Acid Disorder;g:MTHFR)(dui:NBS57;dis:Homocystinuria;g:MTHFR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MTHFR)(dui:D002318;dis:Cardiovascular Diseases;g:MTHFR)(dui:D009422;dis:Nervous System Diseases;g:MTHFR)(dui:D014652;dis:Vascular Diseases;g:MTHFR)(dui:D009369;dis:Neoplasms;g:MTHFR)(dui:D000013;dis:Congenital Abnormalities;g:MTHFR)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MTHFR)(dui:D030342;dis:Genetic Diseases, Inborn;g:MTHFR)(dui:D009371;dis:Neoplasms by Site;g:MTHFR)(dui:D002493;dis:Central Nervous System Diseases;g:MTHFR)(dui:D007154;dis:Immune System Diseases;g:MTHFR)(dui:D004066;dis:Digestive System Diseases;g:MTHFR)(dui:D001927;dis:Brain Diseases;g:MTHFR)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MTHFR)(dui:D009370;dis:Neoplasms by Histologic Type;g:MTHFR)(dui:D005767;dis:Gastrointestinal Diseases;g:MTHFR)(dui:D008659;dis:Metabolic Diseases;g:MTHFR)(dui:D006331;dis:Heart Diseases;g:MTHFR)(dui:D004067;dis:Digestive System Neoplasms;g:MTHFR)(dui:D001523;dis:Mental Disorders;g:MTHFR)(dui:D006402;dis:Hematologic Diseases;g:MTHFR)(dui:D009748;dis:Nutrition Disorders;g:MTHFR)(dui:D044342;dis:Malnutrition;g:MTHFR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:MTHFR)(dui:D007160;dis:Immunoproliferative Disorders;g:MTHFR)(dui:D008232;dis:Lymphoproliferative Disorders;g:MTHFR)(dui:D002561;dis:Cerebrovascular Disorders;g:MTHFR)(dui:D008206;dis:Lymphatic Diseases;g:MTHFR)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MTHFR)(dui:D008661;dis:Metabolism, Inborn Errors;g:MTHFR)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MTHFR)(dui:D020138;dis:Hyperhomocysteinemia;g:MTHFR)(dui:D017202;dis:Myocardial Ischemia;g:MTHFR)(dui:D003677;dis:Deficiency Diseases;g:MTHFR)(dui:D001361;dis:Avitaminosis;g:MTHFR)(dui:D014804;dis:Vitamin B Deficiency;g:MTHFR)(dui:D009421;dis:Nervous System Malformations;g:MTHFR)(dui:D009436;dis:Neural Tube Defects;g:MTHFR)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:MTHFR)(dui:D009140;dis:Musculoskeletal Diseases;g:MTHFR)(dui:D016769;dis:Embolism and Thrombosis;g:MTHFR)(dui:D009461;dis:Neurologic Manifestations;g:MTHFR)(dui:D003327;dis:Coronary Disease;g:MTHFR)(dui:D052776;dis:Female Urogenital Diseases;g:MTHFR)(dui:D052801;dis:Male Urogenital Diseases;g:MTHFR)(dui:D008286;dis:Malabsorption Syndromes;g:MTHFR)(dui:D007938;dis:Leukemia;g:MTHFR)(dui:D009057;dis:Stomatognathic Diseases;g:MTHFR)(dui:D007945;dis:Leukemia, Lymphoid;g:MTHFR)(dui:D007410;dis:Intestinal Diseases;g:MTHFR)(dui:D012871;dis:Skin Diseases;g:MTHFR)(dui:D009059;dis:Mouth Diseases;g:MTHFR)(dui:D004700;dis:Endocrine System Diseases;g:MTHFR)(dui:D003108;dis:Colonic Diseases;g:MTHFR)(dui:D007414;dis:Intestinal Neoplasms;g:MTHFR)(dui:D015179;dis:Colorectal Neoplasms;g:MTHFR)(dui:D014565;dis:Urogenital Neoplasms;g:MTHFR)(dui:D018640;dis:Stomatognathic System Abnormalities;g:MTHFR)(dui:D019967;dis:Schizophrenia Spectrum and Other Psychotic Disorders;g:MTHFR)(dui:D003240;dis:Connective Tissue Diseases;g:MTHFR)(dui:D014570;dis:Urologic Diseases;g:MTHFR)(dui:D013927;dis:Thrombosis;g:MTHFR)(dui:D020521;dis:Stroke;g:MTHFR)(dui:D008223;dis:Lymphoma;g:MTHFR)(dui:D005831;dis:Genital Diseases, Female;g:MTHFR)(dui:D008107;dis:Liver Diseases;g:MTHFR)(dui:D009056;dis:Mouth Abnormalities;g:MTHFR)(dui:D025063;dis:Chromosome Disorders;g:MTHFR)(dui:D019954;dis:Neurobehavioral Manifestations;g:MTHFR)(dui:D008607;dis:Intellectual Disability;g:MTHFR)(dui:D000015;dis:Abnormalities, Multiple;g:MTHFR)(dui:D004314;dis:Down Syndrome;g:MTHFR)(dui:D019851;dis:Thrombophilia;g:MTHFR)(dui:D054198;dis:Precursor Cell Lymphoblastic Leukemia-Lymphoma;g:MTHFR)(dui:D007674;dis:Kidney Diseases;g:MTHFR)(dui:D013272;dis:Stomach Diseases;g:MTHFR)(dui:D020246;dis:Venous Thrombosis;g:MTHFR)(dui:D003920;dis:Diabetes Mellitus;g:MTHFR)(dui:D013274;dis:Stomach Neoplasms;g:MTHFR)(dui:D009139;dis:Musculoskeletal Abnormalities;g:MTHFR)(dui:D005832;dis:Genital Diseases, Male;g:MTHFR)(dui:D001327;dis:Autoimmune Diseases;g:MTHFR)(dui:D012559;dis:Schizophrenia;g:MTHFR)(dui:D007246;dis:Infertility;g:MTHFR)(dui:D012140;dis:Respiratory Tract Diseases;g:MTHFR)(dui:D008171;dis:Lung Diseases;g:MTHFR)(dui:D002545;dis:Brain Ischemia;g:MTHFR)(dui:D012002;dis:Rectal Diseases;g:MTHFR)(dui:D007592;dis:Joint Diseases;g:MTHFR)(dui:D001168;dis:Arthritis;g:MTHFR)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:MTHFR)(dui:D019636;dis:Neurodegenerative Diseases;g:MTHFR)(dui:D012216;dis:Rheumatic Diseases;g:MTHFR)(dui:D001172;dis:Arthritis, Rheumatoid;g:MTHFR)(dui:D005833;dis:Genital Neoplasms, Female;g:MTHFR)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MTHFR)(dui:D009008;dis:Abnormalities, Severe Teratoid;g:MTHFR)(dui:D000757;dis:Anencephaly;g:MTHFR)(dui:D003704;dis:Dementia;g:MTHFR)(dui:D019965;dis:Neurocognitive Disorders;g:MTHFR)(dui:D014591;dis:Uterine Diseases;g:MTHFR)(dui:D014594;dis:Uterine Neoplasms;g:MTHFR)(dui:D024801;dis:Tauopathies;g:MTHFR)(dui:D000544;dis:Alzheimer Disease;g:MTHFR)(dui:D007960;dis:Leukocyte Disorders;g:MTHFR)(dui:D007970;dis:Leukopenia;g:MTHFR)(dui:D013959;dis:Thyroid Diseases;g:MTHFR)(dui:D002277;dis:Carcinoma;g:MTHFR)(dui:D006967;dis:Hypersensitivity;g:MTHFR)(dui:D001157;dis:Arterial Occlusive Diseases;g:MTHFR)(dui:D008047;dis:Lip Diseases;g:MTHFR)(dui:D002971;dis:Cleft Lip;g:MTHFR)(dui:D019465;dis:Craniofacial Abnormalities;g:MTHFR)(dui:D019767;dis:Maxillofacial Abnormalities;g:MTHFR)(dui:D001161;dis:Arteriosclerosis;g:MTHFR)(dui:D018376;dis:Cardiovascular Abnormalities;g:MTHFR)(dui:D006330;dis:Heart Defects, Congenital;g:MTHFR)(dui:D013923;dis:Thromboembolism;g:MTHFR)(dui:D003110;dis:Colonic Neoplasms;g:MTHFR)(dui:D006980;dis:Hyperthyroidism;g:MTHFR)(dui:D048909;dis:Diabetes Complications;g:MTHFR)(dui:D001941;dis:Breast Diseases;g:MTHFR)(dui:D001943;dis:Breast Neoplasms;g:MTHFR)(dui:D001778;dis:Blood Coagulation Disorders;g:MTHFR)(dui:D007248;dis:Infertility, Male;g:MTHFR)(dui:D051437;dis:Renal Insufficiency;g:MTHFR)(dui:D025861;dis:Blood Coagulation Disorders, Inherited;g:MTHFR)(dui:D044882;dis:Glucose Metabolism Disorders;g:MTHFR)(dui:D000740;dis:Anemia;g:MTHFR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:MTHFR)(dui:D005759;dis:Gastroenteritis;g:MTHFR)(dui:D012678;dis:Sensation Disorders;g:MTHFR)(dui:D006086;dis:Graft vs Host Disease;g:MTHFR)(dui:D004427;dis:Ear Diseases;g:MTHFR)(dui:D006311;dis:Hearing Disorders;g:MTHFR)(dui:D034381;dis:Hearing Loss;g:MTHFR)(dui:D011248;dis:Pregnancy Complications;g:MTHFR)(dui:D000068105;dis:Bipolar and Related Disorders;g:MTHFR)(dui:D001714;dis:Bipolar Disorder;g:MTHFR)(dui:D011655;dis:Pulmonary Embolism;g:MTHFR)(dui:D004617;dis:Embolism;g:MTHFR)(dui:D003925;dis:Diabetic Angiopathies;g:MTHFR)(dui:D012142;dis:Respiratory Tract Neoplasms;g:MTHFR)(dui:D002577;dis:Uterine Cervical Diseases;g:MTHFR)(dui:D003639;dis:Hearing Loss, Sudden;g:MTHFR)(dui:D009385;dis:Neoplastic Processes;g:MTHFR)(dui:D002583;dis:Uterine Cervical Neoplasms;g:MTHFR)(dui:D013899;dis:Thoracic Neoplasms;g:MTHFR)(dui:D014571;dis:Urologic Neoplasms;g:MTHFR)(dui:D002278;dis:Carcinoma in Situ;g:MTHFR)(dui:D018290;dis:Cervical Intraepithelial Neoplasia;g:MTHFR)(dui:D005834;dis:Genital Neoplasms, Male;g:MTHFR)(dui:D011469;dis:Prostatic Diseases;g:MTHFR)(dui:D011471;dis:Prostatic Neoplasms;g:MTHFR)(dui:D008175;dis:Lung Neoplasms;g:MTHFR)(dui:D003324;dis:Coronary Artery Disease;g:MTHFR)(dui:D015448;dis:Leukemia, B-Cell;g:MTHFR)(dui:D015451;dis:Leukemia, Lymphocytic, Chronic, B-Cell;g:MTHFR)(dui:D001791;dis:Blood Platelet Disorders;g:MTHFR)(dui:D065886;dis:Neurodevelopmental Disorders;g:MTHFR)(dui:D001745;dis:Urinary Bladder Diseases;g:MTHFR)(dui:D001749;dis:Urinary Bladder Neoplasms;g:MTHFR)(dui:D056486;dis:Drug-Induced Liver Injury;g:MTHFR)(dui:D013921;dis:Thrombocytopenia;g:MTHFR)(dui:D002659;dis:Child Development Disorders, Pervasive;g:MTHFR)(dui:D002542;dis:Intracranial Embolism and Thrombosis;g:MTHFR)(dui:D020767;dis:Intracranial Thrombosis;g:MTHFR)(dui:D001321;dis:Autistic Disorder;g:MTHFR)(dui:D019964;dis:Mood Disorders;g:MTHFR)(dui:D003866;dis:Depressive Disorder;g:MTHFR)(dui:D000380;dis:Agranulocytosis;g:MTHFR)(dui:D009503;dis:Neutropenia;g:MTHFR)(dui:D023921;dis:Coronary Stenosis;g:MTHFR)(dui:D007247;dis:Infertility, Female;g:MTHFR)(dui:D012851;dis:Sinus Thrombosis, Intracranial;g:MTHFR)(dui:D001928;dis:Brain Diseases, Metabolic;g:MTHFR)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MTHFR)(dui:D018204;dis:Neoplasms, Connective and Soft Tissue;g:MTHFR)(dui:D008591;dis:Meningomyelocele;g:MTHFR)(dui:D008224;dis:Lymphoma, Follicular;g:MTHFR)(dui:D009372;dis:Neoplasms, Connective Tissue;g:MTHFR)(dui:D020258;dis:Neurotoxicity Syndromes;g:MTHFR)(dui:D052016;dis:Mucositis;g:MTHFR)(dui:D023903;dis:Coronary Restenosis;g:MTHFR)(dui:D009362;dis:Neoplasm Metastasis;g:MTHFR)(dui:D020879;dis:Neuromuscular Manifestations;g:MTHFR)(dui:D056784;dis:Leukoencephalopathies;g:MTHFR)(dui:D011618;dis:Psychotic Disorders;g:MTHFR)(dui:D009468;dis:Neuromuscular Diseases;g:MTHFR)(dui:D009135;dis:Muscular Diseases;g:MTHFR)(dui:D010523;dis:Peripheral Nervous System Diseases;g:MTHFR)(dui:D005530;dis:Foot Deformities;g:MTHFR)(dui:D005532;dis:Foot Deformities, Congenital;g:MTHFR)(dui:D006712;dis:Homocystinuria;g:MTHFR)(dui:D009128;dis:Muscle Spasticity;g:MTHFR)(dui:D017880;dis:Limb Deformities, Congenital;g:MTHFR)(dui:D000787;dis:Angina Pectoris;g:MTHFR)(dui:D003025;dis:Clubfoot;g:MTHFR)(dui:D009122;dis:Muscle Hypertonia;g:MTHFR)(dui:D038061;dis:Lower Extremity Deformities, Congenital;g:MTHFR)(dui:D017566;dis:Microvascular Angina;g:MTHFR)(dui:D001145;dis:Arrhythmias, Cardiac;g:MTHFR)(dui:D020260;dis:Heavy Metal Poisoning, Nervous System;g:MTHFR)(dui:D001281;dis:Atrial Fibrillation;g:MTHFR)(dui:D020261;dis:Arsenic Poisoning;g:MTHFR)(dui:D016889;dis:Endometrial Neoplasms;g:MTHFR)(dui:D013118;dis:Spinal Cord Diseases;g:MTHFR)(dui:D004342;dis:Drug Hypersensitivity;g:MTHFR)(dui:D007571;dis:Jaw Diseases;g:MTHFR)(dui:D007569;dis:Jaw Abnormalities;g:MTHFR)(dui:D002972;dis:Cleft Palate;g:MTHFR)(dui:D013971;dis:Thyrotoxicosis;g:MTHFR)(dui:D003872;dis:Dermatitis;g:MTHFR)(dui:D003875;dis:Drug Eruptions;g:MTHFR)(dui:D006201;dis:Hair Diseases;g:MTHFR)(dui:D007039;dis:Hypotrichosis;g:MTHFR)(dui:D046152;dis:Gastrointestinal Stromal Tumors;g:MTHFR)(dui:D000505;dis:Alopecia;g:MTHFR)(dui:D058186;dis:Acute Kidney Injury;g:MTHFR)(dui:D006973;dis:Hypertension;g:MTHFR)(dui:D008113;dis:Liver Neoplasms;g:MTHFR)	Tetrahydrofolic acid:Menadione:Methionine:Riboflavin:Benazepril:Methotrexate:Cyanocobalamin:Folic acid:Fluorouracil	GO:0031060:GO:0070829:GO:0043200:GO:0046655:GO:0045202:GO:0004489:GO:0044877:GO:0072341:GO:0001666:GO:0001843:GO:0005829:GO:0035999:GO:0009086:GO:0071949:GO:0033274:GO:0046500:GO:0006730:GO:0006555:GO:0050661:GO:0050660:GO:0042493:GO:0051593:GO:0070555:GO:0055114:GO:0050667	607093		-4.42															M
chr1:75728621	SNV	A	1	G/G	PASS	0.0	3906.55		400	A=3,G=397	A=0.0075,G=0.9925	99.25	0.75	homozygous	55	0.104	2.0		ACADM	NM_000016.6	ACADM:intronic:NM_000016.6	unknown			p.?	c.118+133A>G				G						rs1146572		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADM)(dui:NBS2;dis:Core Conditions;g:ACADM)(dui:NBS10;dis:Fatty Acid Oxidation Disorder;g:ACADM)(dui:NBS51;dis:Medium-chain acyl-CoA dehydrogenase deficiency;g:ACADM)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADM)(dui:D008659;dis:Metabolic Diseases;g:ACADM)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADM)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADM)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADM)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADM)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADM)(dui:D004066;dis:Digestive System Diseases;g:ACADM)(dui:D008107;dis:Liver Diseases;g:ACADM)(dui:D048550;dis:Hepatic Insufficiency;g:ACADM)(dui:D017093;dis:Liver Failure;g:ACADM)(dui:D005767;dis:Gastrointestinal Diseases;g:ACADM)(dui:D009748;dis:Nutrition Disorders;g:ACADM)(dui:D005759;dis:Gastroenteritis;g:ACADM)(dui:D007410;dis:Intestinal Diseases;g:ACADM)(dui:D044343;dis:Overnutrition;g:ACADM)(dui:D004760;dis:Enterocolitis;g:ACADM)(dui:D009765;dis:Obesity;g:ACADM)(dui:D020345;dis:Enterocolitis, Necrotizing;g:ACADM)	Octanoyl-Coenzyme A:3-thiaoctanoyl-CoA:Flavin adenine dinucleotide	GO:0042802:GO:0045329:GO:0003995:GO:0005634:GO:0006635:GO:0033539:GO:0031966:GO:0070991:GO:0005759:GO:0050660:GO:0051793:GO:0019254:GO:0005739:GO:0051791:GO:0055114:GO:0019216:GO:0030424	607008	PF02771:PF02770:PF00441:PF08028	-0.18															M
chr1:100216031	SNV	A	1	A/G	PASS	3.4673685045252533e-87	864.6		397	A=202,G=195	A=0.5088,G=0.4912	49.12	50.88	heterozygous	11	0.003	1.0		DBT	NM_001918.5	DBT:exonic:NM_001918.5	missense	CCA	6	p.Ser242Pro	c.724T>C	0.02	0.002	74.0	G	GMAF=0.0072:AMAF=0.0011:EMAF=0.0103			Benign/Likely benign		rs146249007		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:DBT)(dui:NBS2;dis:Core Conditions;g:DBT)(dui:NBS11;dis:Amino Acid Disorder;g:DBT)(dui:NBS56;dis:Maple syrup urine disease;g:DBT)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:DBT)(dui:D009422;dis:Nervous System Diseases;g:DBT)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:DBT)(dui:D002493;dis:Central Nervous System Diseases;g:DBT)(dui:D008659;dis:Metabolic Diseases;g:DBT)(dui:D030342;dis:Genetic Diseases, Inborn;g:DBT)(dui:D001927;dis:Brain Diseases;g:DBT)(dui:D001928;dis:Brain Diseases, Metabolic;g:DBT)(dui:D008661;dis:Metabolism, Inborn Errors;g:DBT)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:DBT)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:DBT)(dui:D008375;dis:Maple Syrup Urine Disease;g:DBT)		GO:0009083:GO:0031405:GO:0031625:GO:0005947:GO:0016407:GO:0005737:GO:0005759:GO:0005739:GO:0043754:GO:0042645	248610	PF02817:PF00198:PF00364	0.9															M
chr1:100235416	INDEL	C	1	C/CT	PASS	0.0001056306616171	39.7621		388	C=264,CT=124	C=0.6804,CT=0.3196	31.96	68.03999999999999	heterozygous	11	0.003	6.0		DBT	NM_001918.5	DBT:intronic:NM_001918.5	unknown			p.?	c.251+19_251+20insA				CT	GMAF=0.0077:AMAF=0.0014:EMAF=0.0109			Benign/Likely benign		rs1557958683:rs201469612		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:DBT)(dui:NBS2;dis:Core Conditions;g:DBT)(dui:NBS11;dis:Amino Acid Disorder;g:DBT)(dui:NBS56;dis:Maple syrup urine disease;g:DBT)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:DBT)(dui:D009422;dis:Nervous System Diseases;g:DBT)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:DBT)(dui:D002493;dis:Central Nervous System Diseases;g:DBT)(dui:D008659;dis:Metabolic Diseases;g:DBT)(dui:D030342;dis:Genetic Diseases, Inborn;g:DBT)(dui:D001927;dis:Brain Diseases;g:DBT)(dui:D001928;dis:Brain Diseases, Metabolic;g:DBT)(dui:D008661;dis:Metabolism, Inborn Errors;g:DBT)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:DBT)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:DBT)(dui:D008375;dis:Maple Syrup Urine Disease;g:DBT)		GO:0009083:GO:0031405:GO:0031625:GO:0005947:GO:0016407:GO:0005737:GO:0005759:GO:0005739:GO:0043754:GO:0042645	248610	PF02817:PF00198:PF00364	-1.3															M
chr2:1423168	SNV	G	1	G/T	PASS	3.2210687912834025e-104	1034.92		399	G=186,T=213	G=0.4662,T=0.5338	53.38	46.62	heterozygous	18	0.054	1.0		TPO	NM_000547.5	TPO:intronic:NM_000547.5	unknown			p.?	c.179+39G>T				T	GMAF=0.0123:AMAF=0.0343:EMAF=0.001					rs28909374		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-4.09															M
chr2:1433391	SNV	A	1	C/C	PASS	0.0	3981.24		398	A=0,C=398	A=0.0,C=1.0	100.0	0.0	homozygous	41	0.399	1.0		TPO	NM_000547.5	TPO:intronic:NM_000547.5	unknown			p.?	c.180-47A>C				C	GMAF=0.3166:AMAF=0.4721:EMAF=0.237					rs1473936		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-1.5															M
chr2:1433432	SNV	C	1	C/A	PASS	2.831391995799367e-75	745.48		397	C=215,A=182	C=0.5416,A=0.4584	45.84	54.16	heterozygous	18	0.05	2.0		TPO	NM_000547.5	TPO:intronic:NM_000547.5	unknown			p.?	c.180-6C>A				A	GMAF=0.0073:AMAF=0.0195:EMAF=0.001	0.06		Benign	4001203	rs78253418		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	0.98															M
chr2:1484896	SNV	T	1	C/C	PASS	5.675446054085721e-261	2602.46		299	T=15,C=284	T=0.0502,C=0.9498	94.98	5.019999999999996	homozygous	55	0.403	2.0		TPO	NM_000547.5	TPO:intronic:NM_000547.5	unknown			p.?	c.1597+42T>C				C	GMAF=0.4494:AMAF=0.3093:EMAF=0.4789					rs6715129		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	0.34															M
chr2:1487951	SNV	G	1	G/A	PASS	5.615649583575207e-83	822.506		399	G=208,A=191	G=0.5213,A=0.4787	47.87	52.13	heterozygous	18	0.043	1.0		TPO	NM_000547.5	TPO:exonic:NM_000547.5	synonymous	GCA	10	p.Ala576=	c.1728G>A				A	GMAF=0.0049:AMAF=0.0016:EMAF=0.0066	0.02		Benign	148792	rs78406347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-5.25															M
chr2:1494059	SNV	G	1	G/A	PASS	2.723955447120832e-88	875.648		400	G=203,A=197	G=0.5075,A=0.4925	49.25	50.75	heterozygous	18	0.125	1.0		TPO	NM_000547.5	TPO:intronic:NM_000547.5	unknown			p.?	c.2006+20G>A				A	GMAF=0.0928:AMAF=0.1963:EMAF=0.0398			Benign		rs10189329		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-1.97															M
chr2:1516904	SNV	T	1	C/C	PASS	0.0	3393.67		341	T=0,C=341	T=0.0,C=1.0	100.0	0.0	homozygous	55	0.336	1.0		TPO	NM_000547.5	TPO:exonic:NM_000547.5	missense	GCG	15	p.Val847Ala	c.2540T>C	1.0	0.0	64.0	C	GMAF=0.3867:AMAF=0.2288:EMAF=0.4677	0		Benign	148793	rs1126799		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	0.63															M
chr2:149571002	SNV	C	1	C/T	PASS	4.809500785491018e-32	313.179		148	C=77,T=71	C=0.5203,T=0.4797	47.97	52.03	heterozygous	48	0.378	1.0		MMADHC	NM_015702.3	MMADHC:intronic:NM_015702.3	unknown			p.?	c.696+83G>A				T						rs4500908		(dui:NBS9;dis:Organic Acid Condition;g:MMADHC)(dui:NBS11;dis:Amino Acid Disorder;g:MMADHC)(dui:NBS43;dis:Methylmalonic acidemia;g:MMADHC)(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMADHC)(dui:NBS2;dis:Core Conditions;g:MMADHC)(dui:NBS57;dis:Homocystinuria;g:MMADHC)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMADHC)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMADHC)(dui:D008659;dis:Metabolic Diseases;g:MMADHC)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMADHC)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMADHC)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMADHC)		GO:0005515:GO:0005737:GO:0005739:GO:0005829:GO:0009235	611935	PF10229	-0.28															M
chr2:149575863	SNV	C	1	C/G	PASS	2.306747188720142e-109	1086.37		399	C=181,G=218	C=0.4536,G=0.5464	54.64	45.36	heterozygous	48	0.378	2.0		MMADHC	NM_015702.3	MMADHC:intronic:NM_015702.3	unknown			p.?	c.479-22G>C				G	GMAF=0.3774:AMAF=0.3115:EMAF=0.2178			Likely benign		rs12232959		(dui:NBS9;dis:Organic Acid Condition;g:MMADHC)(dui:NBS11;dis:Amino Acid Disorder;g:MMADHC)(dui:NBS43;dis:Methylmalonic acidemia;g:MMADHC)(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMADHC)(dui:NBS2;dis:Core Conditions;g:MMADHC)(dui:NBS57;dis:Homocystinuria;g:MMADHC)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMADHC)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMADHC)(dui:D008659;dis:Metabolic Diseases;g:MMADHC)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMADHC)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMADHC)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMADHC)		GO:0005515:GO:0005737:GO:0005739:GO:0005829:GO:0009235	611935	PF10229	-2.14															M
chr2:149575955	SNV	G	1	G/T	PASS	2.1379620895022242e-107	1066.7		400	G=183,T=217	G=0.4575,T=0.5425	54.25	45.75	heterozygous	48	0.369	1.0		MMADHC	NM_015702.3	MMADHC:intronic:NM_015702.3	unknown			p.?	c.479-114C>A				T						rs10932467		(dui:NBS9;dis:Organic Acid Condition;g:MMADHC)(dui:NBS11;dis:Amino Acid Disorder;g:MMADHC)(dui:NBS43;dis:Methylmalonic acidemia;g:MMADHC)(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMADHC)(dui:NBS2;dis:Core Conditions;g:MMADHC)(dui:NBS57;dis:Homocystinuria;g:MMADHC)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMADHC)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMADHC)(dui:D008659;dis:Metabolic Diseases;g:MMADHC)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMADHC)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMADHC)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMADHC)		GO:0005515:GO:0005737:GO:0005739:GO:0005829:GO:0009235	611935	PF10229	-1.8															M
chr2:149579375	INDEL	C	2	C/CAA	PASS	1.7827892225796729e-37	367.489		395	C=202,CAA=193	C=0.5114,CAA=0.4886	48.86	51.14	heterozygous	48	0.352	2.0		MMADHC	NM_015702.3	MMADHC:intronic:NM_015702.3	unknown			p.?	c.372+55_372+56insTT				CAA						rs36108609:rs1573878596		(dui:NBS9;dis:Organic Acid Condition;g:MMADHC)(dui:NBS11;dis:Amino Acid Disorder;g:MMADHC)(dui:NBS43;dis:Methylmalonic acidemia;g:MMADHC)(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMADHC)(dui:NBS2;dis:Core Conditions;g:MMADHC)(dui:NBS57;dis:Homocystinuria;g:MMADHC)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMADHC)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMADHC)(dui:D008659;dis:Metabolic Diseases;g:MMADHC)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMADHC)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMADHC)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMADHC)		GO:0005515:GO:0005737:GO:0005739:GO:0005829:GO:0009235	611935	PF10229	-1.05															M
chr3:183037421	SNV	T	1	T/G	PASS	1.2621181145707578e-82	818.989		399	T=208,G=191	T=0.5213,G=0.4787	47.87	52.13	heterozygous	33	0.465	1.0		MCCC1	NM_020166.5	MCCC1:exonic:NM_020166.5	missense	CCC	13	p.His464Pro	c.1391A>C	0.01	0.0	77.0	G	GMAF=0.4152:AMAF=0.2876:EMAF=0.2629	0.92		Benign	4002526	rs2270968		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MCCC1)(dui:NBS2;dis:Core Conditions;g:MCCC1)(dui:NBS9;dis:Organic Acid Condition;g:MCCC1)(dui:NBS45;dis:3-Methylcrotonyl-CoA carboxylase deficiency;g:MCCC1)(dui:D009422;dis:Nervous System Diseases;g:MCCC1)(dui:D002493;dis:Central Nervous System Diseases;g:MCCC1)(dui:D001927;dis:Brain Diseases;g:MCCC1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MCCC1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MCCC1)(dui:D008659;dis:Metabolic Diseases;g:MCCC1)(dui:D030342;dis:Genetic Diseases, Inborn;g:MCCC1)(dui:D001928;dis:Brain Diseases, Metabolic;g:MCCC1)(dui:D008661;dis:Metabolism, Inborn Errors;g:MCCC1)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MCCC1)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MCCC1)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:MCCC1)(dui:D019636;dis:Neurodegenerative Diseases;g:MCCC1)(dui:D009069;dis:Movement Disorders;g:MCCC1)(dui:D010300;dis:Parkinson Disease;g:MCCC1)(dui:D001480;dis:Basal Ganglia Diseases;g:MCCC1)(dui:D020734;dis:Parkinsonian Disorders;g:MCCC1)	Biotin	GO:0009083:GO:0009374:GO:1905202:GO:0006552:GO:0004075:GO:0004485:GO:0002169:GO:0005524:GO:0005515:GO:0006768:GO:0005759:GO:0046872:GO:0005739:GO:0005829:GO:0016421	609010	PF08443:PF07478:PF02222:PF00364:PF02786:PF02785:PF00289:PF02655	1.12															M
chr4:145655266	SNV	G	1	G/C	PASS	1.6634126503701834e-85	847.79		400	G=206,C=194	G=0.515,C=0.485	48.5	51.5	heterozygous	11	0.081	1.0		MMAA	NM_001375644.1	MMAA:exonic:NM_001375644.1	missense	CAC	7	p.Gln363His	c.1089G>C	0.05	0.001	24.0	C	GMAF=0.051:AMAF=0.0458:EMAF=0.0536	0.93:0.95		Benign	7081209:7302484	rs2270655		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMAA)(dui:NBS2;dis:Core Conditions;g:MMAA)(dui:NBS9;dis:Organic Acid Condition;g:MMAA)(dui:NBS43;dis:Methylmalonic acidemia;g:MMAA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMAA)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMAA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMAA)(dui:D008659;dis:Metabolic Diseases;g:MMAA)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMAA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMAA)	Hydroxocobalamin:Cyanocobalamin		607481		3.25															M
chr5:71626789	SNV	G	1	G/A	PASS	5.3223079582835474e-58	572.739		291	G=155,A=136	G=0.5326,A=0.4674	46.74	53.26	heterozygous	55	0.186	1.0		MCCC2	NM_022132.5	MCCC2:intronic:NM_022132.5	unknown			p.?	c.738+36G>A				A	GMAF=0.2032:AMAF=0.2797:EMAF=0.164			Benign		rs12516456		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MCCC2)(dui:NBS2;dis:Core Conditions;g:MCCC2)(dui:NBS9;dis:Organic Acid Condition;g:MCCC2)(dui:NBS45;dis:3-Methylcrotonyl-CoA carboxylase deficiency;g:MCCC2)(dui:D009422;dis:Nervous System Diseases;g:MCCC2)(dui:D002493;dis:Central Nervous System Diseases;g:MCCC2)(dui:D001927;dis:Brain Diseases;g:MCCC2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MCCC2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MCCC2)(dui:D008659;dis:Metabolic Diseases;g:MCCC2)(dui:D030342;dis:Genetic Diseases, Inborn;g:MCCC2)(dui:D008661;dis:Metabolism, Inborn Errors;g:MCCC2)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MCCC2)(dui:D001928;dis:Brain Diseases, Metabolic;g:MCCC2)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MCCC2)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:MCCC2)	Biotin	GO:0002169:GO:0005524:GO:0005515:GO:0006768:GO:0009083:GO:0005759:GO:1905202:GO:0005739:GO:0006552:GO:0005829:GO:0015936:GO:0004485	609014	PF01039	-0.73															M
chr5:71649248	SNV	A	1	A/G	PASS	3.288516308759799e-95	944.83		399	A=195,G=204	A=0.4887,G=0.5113	51.13	48.87	heterozygous	55	0.149	1.0		MCCC2	NM_022132.5	MCCC2:exonic:NM_022132.5	synonymous	GCG	14	p.Ala456=	c.1368A>G				G	GMAF=0.1868:AMAF=0.2935:EMAF=0.1321	0.07		Benign	4407210	rs10064079		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MCCC2)(dui:NBS2;dis:Core Conditions;g:MCCC2)(dui:NBS9;dis:Organic Acid Condition;g:MCCC2)(dui:NBS45;dis:3-Methylcrotonyl-CoA carboxylase deficiency;g:MCCC2)(dui:D009422;dis:Nervous System Diseases;g:MCCC2)(dui:D002493;dis:Central Nervous System Diseases;g:MCCC2)(dui:D001927;dis:Brain Diseases;g:MCCC2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MCCC2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MCCC2)(dui:D008659;dis:Metabolic Diseases;g:MCCC2)(dui:D030342;dis:Genetic Diseases, Inborn;g:MCCC2)(dui:D008661;dis:Metabolism, Inborn Errors;g:MCCC2)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MCCC2)(dui:D001928;dis:Brain Diseases, Metabolic;g:MCCC2)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MCCC2)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:MCCC2)	Biotin	GO:0002169:GO:0005524:GO:0005515:GO:0006768:GO:0009083:GO:0005759:GO:1905202:GO:0005739:GO:0006552:GO:0005829:GO:0015936:GO:0004485	609014	PF01039	-1.2															M
chr5:71652827	SNV	G	1	G/A	PASS	3.2553673247163035e-78	774.874		400	G=214,A=186	G=0.535,A=0.465	46.5	53.5	heterozygous	55	0.186	1.0		MCCC2	NM_022132.5	MCCC2:intronic:NM_022132.5	unknown			p.?	c.1574+73G>A				A						rs2242372		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MCCC2)(dui:NBS2;dis:Core Conditions;g:MCCC2)(dui:NBS9;dis:Organic Acid Condition;g:MCCC2)(dui:NBS45;dis:3-Methylcrotonyl-CoA carboxylase deficiency;g:MCCC2)(dui:D009422;dis:Nervous System Diseases;g:MCCC2)(dui:D002493;dis:Central Nervous System Diseases;g:MCCC2)(dui:D001927;dis:Brain Diseases;g:MCCC2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MCCC2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MCCC2)(dui:D008659;dis:Metabolic Diseases;g:MCCC2)(dui:D030342;dis:Genetic Diseases, Inborn;g:MCCC2)(dui:D008661;dis:Metabolism, Inborn Errors;g:MCCC2)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MCCC2)(dui:D001928;dis:Brain Diseases, Metabolic;g:MCCC2)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MCCC2)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:MCCC2)	Biotin	GO:0002169:GO:0005524:GO:0005515:GO:0006768:GO:0009083:GO:0005759:GO:1905202:GO:0005739:GO:0006552:GO:0005829:GO:0015936:GO:0004485	609014	PF01039	0.28															M
chr6:32038450	INDEL	CTGC	3	C/C	PASS	2.2029264630534023e-239	2386.57		246	CTGC=0,C=246	CTGC=0.0,C=1.0	100.0	0.0	homozygous	18		1.0		CYP21A2	NM_000500.9	CYP21A2:exonic:NM_000500.9	nonframeshiftDeletion		1	p.Leu10del	c.29_31delTGC				C	GMAF=0.1888:AMAF=0.0762:EMAF=0.2467					rs1554304337:rs28381641:rs1401750531:rs1424110213:rs1170743134:rs764653902		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	0.35,0.73,1.19,-1.31															M
chr6:32038820	SNV	C	1	T/T	PASS	1.9467043530014167e-84	837.107		85	C=0,T=85	C=0.0,T=1.0	100.0	0.0	homozygous	55	0.288	2.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.292+9C>T				T				Benign		rs6462		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-1.82															M
chr6:32038844	SNV	A	1	C/C	PASS	1.9386526359521813e-85	847.125		88	A=1,C=87	A=0.0114,C=0.9886	98.86	1.1400000000000006	homozygous	24	0.218	7.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.292+33A>C				C	GMAF=0.2224:AMAF=0.0745:EMAF=0.2975					rs755425808:rs6463		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	1.04															M
chr6:32038878	SNV	C	1	T/T	PASS	5.025739801095915e-91	902.988		90	C=0,T=90	C=0.0,T=1.0	100.0	0.0	homozygous	39	0.218	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.292+67C>T				T						rs6449		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-2.74															M
chr6:32039109	SNV	G	1	G/A	PASS	3.246459579514043e-07	64.8859		35	G=20,A=15	G=0.5714,A=0.4286	42.86	57.14	heterozygous	25	0.215	2.0		CYP21A2	NM_000500.9	CYP21A2:exonic:NM_000500.9	missense	AAG	3	p.Arg103Lys	c.308G>A	0.48	0.0	26.0	A	GMAF=0.2315:AMAF=0.0693:EMAF=0.3145	0		Benign	1319109	rs6474		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-0.6															M
chr6:32040216	SNV	G	1	G/C	PASS	9.609482495282797e-51	500.173		374	G=227,C=147	G=0.607,C=0.393	39.3	60.7	heterozygous	11	0.024	4.0		CYP21A2|TNXB	NM_000500.9|NM_001365276.2	CYP21A2:intronic:NM_000500.9|TNXB:downstream:NM_001365276.2	unknown|unknown	|	|	p.?|p.?	c.939+11G>C|c.*1133C>G	|	|	|	C|C				Benign		rs6442		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:TNXB)(dui:D003240;dis:Connective Tissue Diseases;g:TNXB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TNXB)(dui:D030342;dis:Genetic Diseases, Inborn;g:TNXB)(dui:D012871;dis:Skin Diseases;g:TNXB)(dui:D002318;dis:Cardiovascular Diseases;g:TNXB)(dui:D014652;dis:Vascular Diseases;g:TNXB)(dui:D012873;dis:Skin Diseases, Genetic;g:TNXB)(dui:D000013;dis:Congenital Abnormalities;g:TNXB)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:TNXB)(dui:D006402;dis:Hematologic Diseases;g:TNXB)(dui:D003095;dis:Collagen Diseases;g:TNXB)(dui:D006474;dis:Hemorrhagic Disorders;g:TNXB)(dui:D012868;dis:Skin Abnormalities;g:TNXB)(dui:D020141;dis:Hemostatic Disorders;g:TNXB)(dui:D004535;dis:Ehlers-Danlos Syndrome;g:TNXB)(dui:D007154;dis:Immune System Diseases;g:TNXB)(dui:D001327;dis:Autoimmune Diseases;g:TNXB)(dui:D008180;dis:Lupus Erythematosus, Systemic;g:TNXB)(dui:D005128;dis:Eye Diseases;g:TNXB)(dui:D012164;dis:Retinal Diseases;g:TNXB)(dui:D012162;dis:Retinal Degeneration;g:TNXB)(dui:D008268;dis:Macular Degeneration;g:TNXB)(dui:D006967;dis:Hypersensitivity;g:TNXB)(dui:D003872;dis:Dermatitis;g:TNXB)(dui:D006969;dis:Hypersensitivity, Immediate;g:TNXB)(dui:D006973;dis:Hypertension;g:TNXB)(dui:D017443;dis:Skin Diseases, Eczematous;g:TNXB)(dui:D003876;dis:Dermatitis, Atopic;g:TNXB)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	600985:613815	PF00067	1.61															M
chr6:39916058	SNV	A	1	A/T	PASS	1.1585105685247379e-70	699.361		299	A=147,T=152	A=0.4916,T=0.5084	50.84	49.16	heterozygous	11	0.063	1.0		MOCS1	NM_001358530.2	MOCS1:intronic:NM_001358530.2	unknown			p.?	c.583+10T>A				T	GMAF=0.0624:AMAF=0.0645:EMAF=0.0614			Benign		rs34757428		(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MOCS1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MOCS1)(dui:D008659;dis:Metabolic Diseases;g:MOCS1)(dui:D030342;dis:Genetic Diseases, Inborn;g:MOCS1)(dui:D008661;dis:Metabolism, Inborn Errors;g:MOCS1)(dui:D008664;dis:Metal Metabolism, Inborn Errors;g:MOCS1)			603707	PF01967:PF04055:PF06463:PF13353	-0.19															M
chr6:49441774	SNV	G	1	C/C	PASS	0.0	4002.92		400	G=0,C=400	G=0.0,C=1.0	100.0	0.0	homozygous	41	0.329	1.0		MMUT	NM_000255.4	MMUT:intronic:NM_000255.4	unknown			p.?	c.1808+66C>G				C						rs9473555		.		GO:0019626:GO:0042802:GO:0042803:GO:0009791:GO:0004494:GO:0009235:GO:0043547:GO:0072341:GO:0005515:GO:0005737:GO:0005759:GO:0046872:GO:0003924:GO:0031419:GO:0005739:GO:0050667	609058	PF02310:PF01642	0.46															M
chr6:49444720	SNV	C	1	T/T	PASS	0.0	4003.33		400	C=0,T=400	C=0.0,T=1.0	100.0	0.0	homozygous	41	0.266	1.0		MMUT	NM_000255.4	MMUT:exonic:NM_000255.4	missense	CAT	9	p.Arg532His	c.1595G>A	0.0	0.225	29.0	T	GMAF=0.3135:AMAF=0.2108:EMAF=0.366	0.03		Benign	5001998	rs1141321		.		GO:0019626:GO:0042802:GO:0042803:GO:0009791:GO:0004494:GO:0009235:GO:0043547:GO:0072341:GO:0005515:GO:0005737:GO:0005759:GO:0046872:GO:0003924:GO:0031419:GO:0005739:GO:0050667	609058	PF02310:PF01642	-0.01															M
chr6:80107031	SNV	T	1	T/C	PASS	1.5969819223382974e-54	537.967		266	T=140,C=126	T=0.5263,C=0.4737	47.37	52.63	heterozygous	47	0.388	1.0		BCKDHB	NM_000056.4	BCKDHB:intronic:NM_000056.4	unknown			p.?	c.196+142T>C				C						rs35447745		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHB)(dui:NBS2;dis:Core Conditions;g:BCKDHB)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHB)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHB)(dui:D008659;dis:Metabolic Diseases;g:BCKDHB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHB)(dui:D009422;dis:Nervous System Diseases;g:BCKDHB)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHB)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHB)(dui:D001927;dis:Brain Diseases;g:BCKDHB)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHB)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHB)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHB)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHB)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0005739:GO:0003826:GO:0007584:GO:0055114:GO:0005730	248611	PF02779:PF02780	-1.0															M
chr6:80127522	SNV	A	1	A/G	PASS	6.318296466918913e-37	361.994		265	A=160,G=105	A=0.6038,G=0.3962	39.62	60.38	heterozygous	47	0.388	3.0		BCKDHB	NM_000056.4	BCKDHB:intronic:NM_000056.4	unknown			p.?	c.197-25A>G				G	GMAF=0.323:AMAF=0.1148:EMAF=0.4297			Benign		rs9448893		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHB)(dui:NBS2;dis:Core Conditions;g:BCKDHB)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHB)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHB)(dui:D008659;dis:Metabolic Diseases;g:BCKDHB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHB)(dui:D009422;dis:Nervous System Diseases;g:BCKDHB)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHB)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHB)(dui:D001927;dis:Brain Diseases;g:BCKDHB)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHB)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHB)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHB)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHB)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0005739:GO:0003826:GO:0007584:GO:0055114:GO:0005730	248611	PF02779:PF02780	0.45															M
chr6:80167654	SNV	C	1	C/T	PASS	1.897579587720841e-86	857.218		400	C=205,T=195	C=0.5125,T=0.4875	48.75	51.25	heterozygous	19	0.13	2.0		BCKDHB	NM_000056.4	BCKDHB:intronic:NM_000056.4	unknown			p.?	c.344-24C>T				T	GMAF=0.0657:AMAF=0.0985:EMAF=0.0488			Benign/Likely benign		rs73479953		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHB)(dui:NBS2;dis:Core Conditions;g:BCKDHB)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHB)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHB)(dui:D008659;dis:Metabolic Diseases;g:BCKDHB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHB)(dui:D009422;dis:Nervous System Diseases;g:BCKDHB)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHB)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHB)(dui:D001927;dis:Brain Diseases;g:BCKDHB)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHB)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHB)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHB)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHB)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0005739:GO:0003826:GO:0007584:GO:0055114:GO:0005730	248611	PF02779:PF02780	-1.74															M
chr6:80168795	SNV	G	1	A/A	PASS	4.860041749236718e-07	63.1336		7	G=0,A=7	G=0.0,A=1.0	100.0	0.0	homozygous	18	0.0	3.0		BCKDHB	NM_000056.4	BCKDHB:intronic:NM_000056.4	unknown			p.?	c.478-80G>A				A						rs72908865		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHB)(dui:NBS2;dis:Core Conditions;g:BCKDHB)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHB)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHB)(dui:D008659;dis:Metabolic Diseases;g:BCKDHB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHB)(dui:D009422;dis:Nervous System Diseases;g:BCKDHB)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHB)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHB)(dui:D001927;dis:Brain Diseases;g:BCKDHB)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHB)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHB)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHB)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHB)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0005739:GO:0003826:GO:0007584:GO:0055114:GO:0005730	248611	PF02779:PF02780	0.72															M
chr6:80203260	SNV	C	1	C/T	PASS	1.7906058540352948e-121	1207.47		398	C=169,T=229	C=0.4246,T=0.5754	57.54	42.46	heterozygous	19	0.13	2.0		BCKDHB	NM_000056.4	BCKDHB:intronic:NM_000056.4	unknown			p.?	c.951+48C>T				T	GMAF=0.0658:AMAF=0.0987:EMAF=0.049			Benign/Likely benign		rs3749896		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHB)(dui:NBS2;dis:Core Conditions;g:BCKDHB)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHB)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHB)(dui:D008659;dis:Metabolic Diseases;g:BCKDHB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHB)(dui:D009422;dis:Nervous System Diseases;g:BCKDHB)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHB)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHB)(dui:D001927;dis:Brain Diseases;g:BCKDHB)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHB)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHB)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHB)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHB)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0005739:GO:0003826:GO:0007584:GO:0055114:GO:0005730	248611	PF02779:PF02780	-0.16															M
chr6:80272984	SNV	G	1	G/A	PASS	4.141903726220978e-92	913.828		400	G=199,A=201	G=0.4975,A=0.5025	50.25	49.75	heterozygous	47	0.403	1.0		BCKDHB	NM_000056.4	BCKDHB:intronic:NM_000056.4	unknown			p.?	c.952-151G>A				A						rs9341811		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHB)(dui:NBS2;dis:Core Conditions;g:BCKDHB)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHB)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHB)(dui:D008659;dis:Metabolic Diseases;g:BCKDHB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHB)(dui:D009422;dis:Nervous System Diseases;g:BCKDHB)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHB)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHB)(dui:D001927;dis:Brain Diseases;g:BCKDHB)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHB)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHB)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHB)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHB)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0005739:GO:0003826:GO:0007584:GO:0055114:GO:0005730	248611	PF02779:PF02780	-0.85															M
chr7:117548629	INDEL	T	4	T/TGTGT	PASS	1.4699413265138498e-32	318.327		118	T=46,TGTGT=72	T=0.3898,TGTGT=0.6102	61.02	38.98	heterozygous	25	0.071:0.003	0.0		CFTR|CFTR-AS1	NM_000492.4|NR_149084.1	CFTR:intronic:NM_000492.4|CFTR-AS1:intronic_nc:NR_149084.1	unknown|	|	|	p.?|	c.1210-12_1210-11insGTGT|	|	|	|	TGTGT|			5T			rs4148705:rs1584793368:rs1805177:rs765376630:rs1399483116		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		0.56															M
chr7:117595001	SNV	T	1	G/G	PASS	0.0	3992.62		399	T=0,G=399	T=0.0,G=1.0	100.0	0.0	homozygous	47	0.479	1.0		CFTR	NM_000492.4	CFTR:exonic:NM_000492.4	synonymous	ACG	15	p.Thr854=	c.2562T>G				G	GMAF=0.4028:AMAF=0.3813:EMAF=0.2922	0.13		Benign/Likely benign	4161733	rs1584813846:rs1554389814:rs397508396:rs1042077		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		0.28															M
chr8:142875392	SNV	A	1	C/C	PASS	0.0	3971.46		398	A=0,C=398	A=0.0,C=1.0	100.0	0.0	homozygous	55	0.259	2.0		CYP11B1	NM_000497.4	CYP11B1:intronic:NM_000497.4	unknown			p.?	c.1122-80T>G				C						rs6395		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		-2.29															M
chr8:142875509	SNV	T	1	C/C	PASS	0.0	3940.66		400	T=1,C=399	T=0.0025,C=0.9975	99.75	0.25	homozygous	55	0.24	1.0		CYP11B1	NM_000497.4	CYP11B1:intronic:NM_000497.4	unknown			p.?	c.1122-197A>G				C						rs6392		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		-2.07															M
chr8:142876440	SNV	G	1	A/A	PASS	0.0	4003.33		400	G=0,A=400	G=0.0,A=1.0	100.0	0.0	homozygous	55	0.315	1.0		CYP11B1	NM_000497.4	CYP11B1:intronic:NM_000497.4	unknown			p.?	c.800-45C>T				A	GMAF=0.4197:AMAF=0.3926:EMAF=0.4336					rs7822986		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		-1.98															M
chr8:142876563	SNV	A	1	C/C	PASS	1.023292992280733e-130	1299.9		159	A=12,C=147	A=0.0755,C=0.9245	92.45	7.549999999999997	homozygous	55	0.382	2.0		CYP11B1	NM_000497.4	CYP11B1:intronic:NM_000497.4	unknown			p.?	c.799+119T>G				C						rs10956991		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		-3.19															M
chr8:142877011	SNV	C	1	T/T	PASS	0.0	4003.32		400	C=0,T=400	C=0.0,T=1.0	100.0	0.0	homozygous	55	0.436	1.0		CYP11B1	NM_000497.4	CYP11B1:intronic:NM_000497.4	unknown			p.?	c.595+12G>A				T	GMAF=0.4845:AMAF=0.3736:EMAF=0.4587			Benign		rs6387		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		-3.01															M
chr8:142879181	SNV	G	1	A/A	PASS	0.0	3625.76		375	G=3,A=372	G=0.008,A=0.992	99.2	0.7999999999999972	homozygous	47	0.303	1.0		CYP11B1	NM_000497.4	CYP11B1:exonic:NM_000497.4	synonymous	GAT	2	p.Asp82=	c.246C>T				A	GMAF=0.3283:AMAF=0.1117:EMAF=0.4393	0.01		Benign	4162721	rs5283		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		-0.46															M
chr8:142879589	SNV	T	1	C/C	PASS	2.88403150312647e-262	2615.4		263	T=0,C=263	T=0.0,C=1.0	100.0	0.0	homozygous	55	0.416	1.0		CYP11B1	NM_000497.4	CYP11B1:exonic:NM_000497.4	synonymous	CTG	1	p.Leu75=	c.225A>G				C	GMAF=0.4923:AMAF=0.4424:EMAF=0.4588	0.05		Benign	6338105	rs6410		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		-0.64															M
chr10:102831636	SNV	G	1	T/T	PASS	0.0	3983.68		399	G=0,T=399	G=0.0,T=1.0	100.0	0.0	homozygous	25	0.18	1.0		CYP17A1	NM_000102.4	CYP17A1:intronic:NM_000102.4	unknown			p.?	c.1140-25C>A				T	GMAF=0.0847:AMAF=0.0645:EMAF=0.0951					rs17115100		(dui:D004700;dis:Endocrine System Diseases;g:CYP17A1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP17A1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP17A1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP17A1)(dui:D006058;dis:Gonadal Disorders;g:CYP17A1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP17A1)(dui:D008659;dis:Metabolic Diseases;g:CYP17A1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP17A1)(dui:D000013;dis:Congenital Abnormalities;g:CYP17A1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP17A1)(dui:D012734;dis:Disorders of Sex Development;g:CYP17A1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP17A1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP17A1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP17A1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP17A1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP17A1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP17A1)(dui:D009369;dis:Neoplasms;g:CYP17A1)(dui:D009371;dis:Neoplasms by Site;g:CYP17A1)(dui:D004066;dis:Digestive System Diseases;g:CYP17A1)(dui:D008107;dis:Liver Diseases;g:CYP17A1)(dui:D009422;dis:Nervous System Diseases;g:CYP17A1)(dui:D005831;dis:Genital Diseases, Female;g:CYP17A1)(dui:D005832;dis:Genital Diseases, Male;g:CYP17A1)(dui:D002493;dis:Central Nervous System Diseases;g:CYP17A1)(dui:D001927;dis:Brain Diseases;g:CYP17A1)(dui:D007246;dis:Infertility;g:CYP17A1)(dui:D014565;dis:Urogenital Neoplasms;g:CYP17A1)(dui:D010049;dis:Ovarian Diseases;g:CYP17A1)(dui:D000291;dis:Adnexal Diseases;g:CYP17A1)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CYP17A1)(dui:D011469;dis:Prostatic Diseases;g:CYP17A1)(dui:D012871;dis:Skin Diseases;g:CYP17A1)(dui:D001941;dis:Breast Diseases;g:CYP17A1)(dui:D003560;dis:Cysts;g:CYP17A1)(dui:D010048;dis:Ovarian Cysts;g:CYP17A1)(dui:D001943;dis:Breast Neoplasms;g:CYP17A1)(dui:D005834;dis:Genital Neoplasms, Male;g:CYP17A1)(dui:D009370;dis:Neoplasms by Histologic Type;g:CYP17A1)(dui:D011471;dis:Prostatic Neoplasms;g:CYP17A1)(dui:D002318;dis:Cardiovascular Diseases;g:CYP17A1)(dui:D004067;dis:Digestive System Neoplasms;g:CYP17A1)(dui:D014652;dis:Vascular Diseases;g:CYP17A1)(dui:D019636;dis:Neurodegenerative Diseases;g:CYP17A1)(dui:D006973;dis:Hypertension;g:CYP17A1)(dui:D009069;dis:Movement Disorders;g:CYP17A1)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:CYP17A1)(dui:D001523;dis:Mental Disorders;g:CYP17A1)(dui:D002277;dis:Carcinoma;g:CYP17A1)(dui:D010300;dis:Parkinson Disease;g:CYP17A1)(dui:D001480;dis:Basal Ganglia Diseases;g:CYP17A1)(dui:D020734;dis:Parkinsonian Disorders;g:CYP17A1)(dui:D000230;dis:Adenocarcinoma;g:CYP17A1)(dui:D008113;dis:Liver Neoplasms;g:CYP17A1)(dui:D007247;dis:Infertility, Female;g:CYP17A1)(dui:D020018;dis:Sexual Dysfunctions, Psychological;g:CYP17A1)(dui:D006528;dis:Carcinoma, Hepatocellular;g:CYP17A1)(dui:D007006;dis:Hypogonadism;g:CYP17A1)(dui:D007248;dis:Infertility, Male;g:CYP17A1)(dui:D010900;dis:Pituitary Diseases;g:CYP17A1)(dui:D005234;dis:Fatty Liver;g:CYP17A1)(dui:D007018;dis:Hypopituitarism;g:CYP17A1)(dui:D008103;dis:Liver Cirrhosis;g:CYP17A1)(dui:D014883;dis:Water-Electrolyte Imbalance;g:CYP17A1)(dui:D006947;dis:Hyperkalemia;g:CYP17A1)(dui:D006974;dis:Hypertension, Malignant;g:CYP17A1)(dui:D007027;dis:Hypothalamic Diseases;g:CYP17A1)(dui:D008106;dis:Liver Cirrhosis, Experimental;g:CYP17A1)(dui:D065626;dis:Non-alcoholic Fatty Liver Disease;g:CYP17A1)	Stanolone:Dexamethasone:Ketoconazole:Nabiximols:Abiraterone:Medical Cannabis:Cannabidiol:Clomifene:Aldosterone:NADH:Spironolactone:Aminophenazone:Dexamethasone acetate:Progesterone:Prasterone	GO:0019825:GO:0042448:GO:0008202:GO:0005783:GO:0006694:GO:0043025:GO:0042446:GO:0020037:GO:0005789:GO:0006704:GO:0007548:GO:0006702:GO:0005506:GO:0004508:GO:0047442:GO:0055114:GO:0030424	609300	PF00067	-0.12															M
chr10:102832918	SNV	G	1	C/C	PASS	0.0	3910.77		400	G=2,C=398	G=0.005,C=0.995	99.5	0.5	homozygous	32	0.35	1.0		CYP17A1	NM_000102.4	CYP17A1:intronic:NM_000102.4	unknown			p.?	c.969+75C>G				C						rs3740397		(dui:D004700;dis:Endocrine System Diseases;g:CYP17A1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP17A1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP17A1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP17A1)(dui:D006058;dis:Gonadal Disorders;g:CYP17A1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP17A1)(dui:D008659;dis:Metabolic Diseases;g:CYP17A1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP17A1)(dui:D000013;dis:Congenital Abnormalities;g:CYP17A1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP17A1)(dui:D012734;dis:Disorders of Sex Development;g:CYP17A1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP17A1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP17A1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP17A1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP17A1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP17A1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP17A1)(dui:D009369;dis:Neoplasms;g:CYP17A1)(dui:D009371;dis:Neoplasms by Site;g:CYP17A1)(dui:D004066;dis:Digestive System Diseases;g:CYP17A1)(dui:D008107;dis:Liver Diseases;g:CYP17A1)(dui:D009422;dis:Nervous System Diseases;g:CYP17A1)(dui:D005831;dis:Genital Diseases, Female;g:CYP17A1)(dui:D005832;dis:Genital Diseases, Male;g:CYP17A1)(dui:D002493;dis:Central Nervous System Diseases;g:CYP17A1)(dui:D001927;dis:Brain Diseases;g:CYP17A1)(dui:D007246;dis:Infertility;g:CYP17A1)(dui:D014565;dis:Urogenital Neoplasms;g:CYP17A1)(dui:D010049;dis:Ovarian Diseases;g:CYP17A1)(dui:D000291;dis:Adnexal Diseases;g:CYP17A1)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CYP17A1)(dui:D011469;dis:Prostatic Diseases;g:CYP17A1)(dui:D012871;dis:Skin Diseases;g:CYP17A1)(dui:D001941;dis:Breast Diseases;g:CYP17A1)(dui:D003560;dis:Cysts;g:CYP17A1)(dui:D010048;dis:Ovarian Cysts;g:CYP17A1)(dui:D001943;dis:Breast Neoplasms;g:CYP17A1)(dui:D005834;dis:Genital Neoplasms, Male;g:CYP17A1)(dui:D009370;dis:Neoplasms by Histologic Type;g:CYP17A1)(dui:D011471;dis:Prostatic Neoplasms;g:CYP17A1)(dui:D002318;dis:Cardiovascular Diseases;g:CYP17A1)(dui:D004067;dis:Digestive System Neoplasms;g:CYP17A1)(dui:D014652;dis:Vascular Diseases;g:CYP17A1)(dui:D019636;dis:Neurodegenerative Diseases;g:CYP17A1)(dui:D006973;dis:Hypertension;g:CYP17A1)(dui:D009069;dis:Movement Disorders;g:CYP17A1)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:CYP17A1)(dui:D001523;dis:Mental Disorders;g:CYP17A1)(dui:D002277;dis:Carcinoma;g:CYP17A1)(dui:D010300;dis:Parkinson Disease;g:CYP17A1)(dui:D001480;dis:Basal Ganglia Diseases;g:CYP17A1)(dui:D020734;dis:Parkinsonian Disorders;g:CYP17A1)(dui:D000230;dis:Adenocarcinoma;g:CYP17A1)(dui:D008113;dis:Liver Neoplasms;g:CYP17A1)(dui:D007247;dis:Infertility, Female;g:CYP17A1)(dui:D020018;dis:Sexual Dysfunctions, Psychological;g:CYP17A1)(dui:D006528;dis:Carcinoma, Hepatocellular;g:CYP17A1)(dui:D007006;dis:Hypogonadism;g:CYP17A1)(dui:D007248;dis:Infertility, Male;g:CYP17A1)(dui:D010900;dis:Pituitary Diseases;g:CYP17A1)(dui:D005234;dis:Fatty Liver;g:CYP17A1)(dui:D007018;dis:Hypopituitarism;g:CYP17A1)(dui:D008103;dis:Liver Cirrhosis;g:CYP17A1)(dui:D014883;dis:Water-Electrolyte Imbalance;g:CYP17A1)(dui:D006947;dis:Hyperkalemia;g:CYP17A1)(dui:D006974;dis:Hypertension, Malignant;g:CYP17A1)(dui:D007027;dis:Hypothalamic Diseases;g:CYP17A1)(dui:D008106;dis:Liver Cirrhosis, Experimental;g:CYP17A1)(dui:D065626;dis:Non-alcoholic Fatty Liver Disease;g:CYP17A1)	Stanolone:Dexamethasone:Ketoconazole:Nabiximols:Abiraterone:Medical Cannabis:Cannabidiol:Clomifene:Aldosterone:NADH:Spironolactone:Aminophenazone:Dexamethasone acetate:Progesterone:Prasterone	GO:0019825:GO:0042448:GO:0008202:GO:0005783:GO:0006694:GO:0043025:GO:0042446:GO:0020037:GO:0005789:GO:0006704:GO:0007548:GO:0006702:GO:0005506:GO:0004508:GO:0047442:GO:0055114:GO:0030424	609300	PF00067	0.26															M
chr10:102834750	SNV	A	1	G/G	PASS	5.07e-321	3202.95		322	A=0,G=322	A=0.0,G=1.0	100.0	0.0	homozygous	25	0.219	1.0		CYP17A1	NM_000102.4	CYP17A1:intronic:NM_000102.4	unknown			p.?	c.666+35T>C				G	GMAF=0.1249:AMAF=0.18:EMAF=0.0967					rs1004467		(dui:D004700;dis:Endocrine System Diseases;g:CYP17A1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP17A1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP17A1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP17A1)(dui:D006058;dis:Gonadal Disorders;g:CYP17A1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP17A1)(dui:D008659;dis:Metabolic Diseases;g:CYP17A1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP17A1)(dui:D000013;dis:Congenital Abnormalities;g:CYP17A1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP17A1)(dui:D012734;dis:Disorders of Sex Development;g:CYP17A1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP17A1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP17A1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP17A1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP17A1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP17A1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP17A1)(dui:D009369;dis:Neoplasms;g:CYP17A1)(dui:D009371;dis:Neoplasms by Site;g:CYP17A1)(dui:D004066;dis:Digestive System Diseases;g:CYP17A1)(dui:D008107;dis:Liver Diseases;g:CYP17A1)(dui:D009422;dis:Nervous System Diseases;g:CYP17A1)(dui:D005831;dis:Genital Diseases, Female;g:CYP17A1)(dui:D005832;dis:Genital Diseases, Male;g:CYP17A1)(dui:D002493;dis:Central Nervous System Diseases;g:CYP17A1)(dui:D001927;dis:Brain Diseases;g:CYP17A1)(dui:D007246;dis:Infertility;g:CYP17A1)(dui:D014565;dis:Urogenital Neoplasms;g:CYP17A1)(dui:D010049;dis:Ovarian Diseases;g:CYP17A1)(dui:D000291;dis:Adnexal Diseases;g:CYP17A1)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CYP17A1)(dui:D011469;dis:Prostatic Diseases;g:CYP17A1)(dui:D012871;dis:Skin Diseases;g:CYP17A1)(dui:D001941;dis:Breast Diseases;g:CYP17A1)(dui:D003560;dis:Cysts;g:CYP17A1)(dui:D010048;dis:Ovarian Cysts;g:CYP17A1)(dui:D001943;dis:Breast Neoplasms;g:CYP17A1)(dui:D005834;dis:Genital Neoplasms, Male;g:CYP17A1)(dui:D009370;dis:Neoplasms by Histologic Type;g:CYP17A1)(dui:D011471;dis:Prostatic Neoplasms;g:CYP17A1)(dui:D002318;dis:Cardiovascular Diseases;g:CYP17A1)(dui:D004067;dis:Digestive System Neoplasms;g:CYP17A1)(dui:D014652;dis:Vascular Diseases;g:CYP17A1)(dui:D019636;dis:Neurodegenerative Diseases;g:CYP17A1)(dui:D006973;dis:Hypertension;g:CYP17A1)(dui:D009069;dis:Movement Disorders;g:CYP17A1)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:CYP17A1)(dui:D001523;dis:Mental Disorders;g:CYP17A1)(dui:D002277;dis:Carcinoma;g:CYP17A1)(dui:D010300;dis:Parkinson Disease;g:CYP17A1)(dui:D001480;dis:Basal Ganglia Diseases;g:CYP17A1)(dui:D020734;dis:Parkinsonian Disorders;g:CYP17A1)(dui:D000230;dis:Adenocarcinoma;g:CYP17A1)(dui:D008113;dis:Liver Neoplasms;g:CYP17A1)(dui:D007247;dis:Infertility, Female;g:CYP17A1)(dui:D020018;dis:Sexual Dysfunctions, Psychological;g:CYP17A1)(dui:D006528;dis:Carcinoma, Hepatocellular;g:CYP17A1)(dui:D007006;dis:Hypogonadism;g:CYP17A1)(dui:D007248;dis:Infertility, Male;g:CYP17A1)(dui:D010900;dis:Pituitary Diseases;g:CYP17A1)(dui:D005234;dis:Fatty Liver;g:CYP17A1)(dui:D007018;dis:Hypopituitarism;g:CYP17A1)(dui:D008103;dis:Liver Cirrhosis;g:CYP17A1)(dui:D014883;dis:Water-Electrolyte Imbalance;g:CYP17A1)(dui:D006947;dis:Hyperkalemia;g:CYP17A1)(dui:D006974;dis:Hypertension, Malignant;g:CYP17A1)(dui:D007027;dis:Hypothalamic Diseases;g:CYP17A1)(dui:D008106;dis:Liver Cirrhosis, Experimental;g:CYP17A1)(dui:D065626;dis:Non-alcoholic Fatty Liver Disease;g:CYP17A1)	Stanolone:Dexamethasone:Ketoconazole:Nabiximols:Abiraterone:Medical Cannabis:Cannabidiol:Clomifene:Aldosterone:NADH:Spironolactone:Aminophenazone:Dexamethasone acetate:Progesterone:Prasterone	GO:0019825:GO:0042448:GO:0008202:GO:0005783:GO:0006694:GO:0043025:GO:0042446:GO:0020037:GO:0005789:GO:0006704:GO:0007548:GO:0006702:GO:0005506:GO:0004508:GO:0047442:GO:0055114:GO:0030424	609300	PF00067	-0.23															M
chr10:102837167	SNV	C	1	A/A	PASS	1.002305238077911e-186	1859.99		189	C=1,A=188	C=0.0053,A=0.9947	99.47	0.5300000000000011	homozygous	32	0.41	2.0		CYP17A1	NM_000102.4	CYP17A1:exonic:NM_000102.4	synonymous	TCT	1	p.Ser65=	c.195G>T				A	GMAF=0.3833:AMAF=0.3616:EMAF=0.3944	0.17		Benign	3751499	rs6163		(dui:D004700;dis:Endocrine System Diseases;g:CYP17A1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP17A1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP17A1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP17A1)(dui:D006058;dis:Gonadal Disorders;g:CYP17A1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP17A1)(dui:D008659;dis:Metabolic Diseases;g:CYP17A1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP17A1)(dui:D000013;dis:Congenital Abnormalities;g:CYP17A1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP17A1)(dui:D012734;dis:Disorders of Sex Development;g:CYP17A1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP17A1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP17A1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP17A1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP17A1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP17A1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP17A1)(dui:D009369;dis:Neoplasms;g:CYP17A1)(dui:D009371;dis:Neoplasms by Site;g:CYP17A1)(dui:D004066;dis:Digestive System Diseases;g:CYP17A1)(dui:D008107;dis:Liver Diseases;g:CYP17A1)(dui:D009422;dis:Nervous System Diseases;g:CYP17A1)(dui:D005831;dis:Genital Diseases, Female;g:CYP17A1)(dui:D005832;dis:Genital Diseases, Male;g:CYP17A1)(dui:D002493;dis:Central Nervous System Diseases;g:CYP17A1)(dui:D001927;dis:Brain Diseases;g:CYP17A1)(dui:D007246;dis:Infertility;g:CYP17A1)(dui:D014565;dis:Urogenital Neoplasms;g:CYP17A1)(dui:D010049;dis:Ovarian Diseases;g:CYP17A1)(dui:D000291;dis:Adnexal Diseases;g:CYP17A1)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CYP17A1)(dui:D011469;dis:Prostatic Diseases;g:CYP17A1)(dui:D012871;dis:Skin Diseases;g:CYP17A1)(dui:D001941;dis:Breast Diseases;g:CYP17A1)(dui:D003560;dis:Cysts;g:CYP17A1)(dui:D010048;dis:Ovarian Cysts;g:CYP17A1)(dui:D001943;dis:Breast Neoplasms;g:CYP17A1)(dui:D005834;dis:Genital Neoplasms, Male;g:CYP17A1)(dui:D009370;dis:Neoplasms by Histologic Type;g:CYP17A1)(dui:D011471;dis:Prostatic Neoplasms;g:CYP17A1)(dui:D002318;dis:Cardiovascular Diseases;g:CYP17A1)(dui:D004067;dis:Digestive System Neoplasms;g:CYP17A1)(dui:D014652;dis:Vascular Diseases;g:CYP17A1)(dui:D019636;dis:Neurodegenerative Diseases;g:CYP17A1)(dui:D006973;dis:Hypertension;g:CYP17A1)(dui:D009069;dis:Movement Disorders;g:CYP17A1)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:CYP17A1)(dui:D001523;dis:Mental Disorders;g:CYP17A1)(dui:D002277;dis:Carcinoma;g:CYP17A1)(dui:D010300;dis:Parkinson Disease;g:CYP17A1)(dui:D001480;dis:Basal Ganglia Diseases;g:CYP17A1)(dui:D020734;dis:Parkinsonian Disorders;g:CYP17A1)(dui:D000230;dis:Adenocarcinoma;g:CYP17A1)(dui:D008113;dis:Liver Neoplasms;g:CYP17A1)(dui:D007247;dis:Infertility, Female;g:CYP17A1)(dui:D020018;dis:Sexual Dysfunctions, Psychological;g:CYP17A1)(dui:D006528;dis:Carcinoma, Hepatocellular;g:CYP17A1)(dui:D007006;dis:Hypogonadism;g:CYP17A1)(dui:D007248;dis:Infertility, Male;g:CYP17A1)(dui:D010900;dis:Pituitary Diseases;g:CYP17A1)(dui:D005234;dis:Fatty Liver;g:CYP17A1)(dui:D007018;dis:Hypopituitarism;g:CYP17A1)(dui:D008103;dis:Liver Cirrhosis;g:CYP17A1)(dui:D014883;dis:Water-Electrolyte Imbalance;g:CYP17A1)(dui:D006947;dis:Hyperkalemia;g:CYP17A1)(dui:D006974;dis:Hypertension, Malignant;g:CYP17A1)(dui:D007027;dis:Hypothalamic Diseases;g:CYP17A1)(dui:D008106;dis:Liver Cirrhosis, Experimental;g:CYP17A1)(dui:D065626;dis:Non-alcoholic Fatty Liver Disease;g:CYP17A1)	Stanolone:Dexamethasone:Ketoconazole:Nabiximols:Abiraterone:Medical Cannabis:Cannabidiol:Clomifene:Aldosterone:NADH:Spironolactone:Aminophenazone:Dexamethasone acetate:Progesterone:Prasterone	GO:0019825:GO:0042448:GO:0008202:GO:0005783:GO:0006694:GO:0043025:GO:0042446:GO:0020037:GO:0005789:GO:0006704:GO:0007548:GO:0006702:GO:0005506:GO:0004508:GO:0047442:GO:0055114:GO:0030424	609300	PF00067	-0.04															M
chr10:102837224	SNV	G	1	A/A	PASS	0.0	3966.52		400	G=1,A=399	G=0.0025,A=0.9975	99.75	0.25	homozygous	39	0.443	1.0		CYP17A1	NM_000102.4	CYP17A1:exonic:NM_000102.4	synonymous	CAT	1	p.His46=	c.138C>T				A	GMAF=0.3949:AMAF=0.3645:EMAF=0.4105	0.02		Benign	3751500	rs6162		(dui:D004700;dis:Endocrine System Diseases;g:CYP17A1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP17A1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP17A1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP17A1)(dui:D006058;dis:Gonadal Disorders;g:CYP17A1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP17A1)(dui:D008659;dis:Metabolic Diseases;g:CYP17A1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP17A1)(dui:D000013;dis:Congenital Abnormalities;g:CYP17A1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP17A1)(dui:D012734;dis:Disorders of Sex Development;g:CYP17A1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP17A1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP17A1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP17A1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP17A1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP17A1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP17A1)(dui:D009369;dis:Neoplasms;g:CYP17A1)(dui:D009371;dis:Neoplasms by Site;g:CYP17A1)(dui:D004066;dis:Digestive System Diseases;g:CYP17A1)(dui:D008107;dis:Liver Diseases;g:CYP17A1)(dui:D009422;dis:Nervous System Diseases;g:CYP17A1)(dui:D005831;dis:Genital Diseases, Female;g:CYP17A1)(dui:D005832;dis:Genital Diseases, Male;g:CYP17A1)(dui:D002493;dis:Central Nervous System Diseases;g:CYP17A1)(dui:D001927;dis:Brain Diseases;g:CYP17A1)(dui:D007246;dis:Infertility;g:CYP17A1)(dui:D014565;dis:Urogenital Neoplasms;g:CYP17A1)(dui:D010049;dis:Ovarian Diseases;g:CYP17A1)(dui:D000291;dis:Adnexal Diseases;g:CYP17A1)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CYP17A1)(dui:D011469;dis:Prostatic Diseases;g:CYP17A1)(dui:D012871;dis:Skin Diseases;g:CYP17A1)(dui:D001941;dis:Breast Diseases;g:CYP17A1)(dui:D003560;dis:Cysts;g:CYP17A1)(dui:D010048;dis:Ovarian Cysts;g:CYP17A1)(dui:D001943;dis:Breast Neoplasms;g:CYP17A1)(dui:D005834;dis:Genital Neoplasms, Male;g:CYP17A1)(dui:D009370;dis:Neoplasms by Histologic Type;g:CYP17A1)(dui:D011471;dis:Prostatic Neoplasms;g:CYP17A1)(dui:D002318;dis:Cardiovascular Diseases;g:CYP17A1)(dui:D004067;dis:Digestive System Neoplasms;g:CYP17A1)(dui:D014652;dis:Vascular Diseases;g:CYP17A1)(dui:D019636;dis:Neurodegenerative Diseases;g:CYP17A1)(dui:D006973;dis:Hypertension;g:CYP17A1)(dui:D009069;dis:Movement Disorders;g:CYP17A1)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:CYP17A1)(dui:D001523;dis:Mental Disorders;g:CYP17A1)(dui:D002277;dis:Carcinoma;g:CYP17A1)(dui:D010300;dis:Parkinson Disease;g:CYP17A1)(dui:D001480;dis:Basal Ganglia Diseases;g:CYP17A1)(dui:D020734;dis:Parkinsonian Disorders;g:CYP17A1)(dui:D000230;dis:Adenocarcinoma;g:CYP17A1)(dui:D008113;dis:Liver Neoplasms;g:CYP17A1)(dui:D007247;dis:Infertility, Female;g:CYP17A1)(dui:D020018;dis:Sexual Dysfunctions, Psychological;g:CYP17A1)(dui:D006528;dis:Carcinoma, Hepatocellular;g:CYP17A1)(dui:D007006;dis:Hypogonadism;g:CYP17A1)(dui:D007248;dis:Infertility, Male;g:CYP17A1)(dui:D010900;dis:Pituitary Diseases;g:CYP17A1)(dui:D005234;dis:Fatty Liver;g:CYP17A1)(dui:D007018;dis:Hypopituitarism;g:CYP17A1)(dui:D008103;dis:Liver Cirrhosis;g:CYP17A1)(dui:D014883;dis:Water-Electrolyte Imbalance;g:CYP17A1)(dui:D006947;dis:Hyperkalemia;g:CYP17A1)(dui:D006974;dis:Hypertension, Malignant;g:CYP17A1)(dui:D007027;dis:Hypothalamic Diseases;g:CYP17A1)(dui:D008106;dis:Liver Cirrhosis, Experimental;g:CYP17A1)(dui:D065626;dis:Non-alcoholic Fatty Liver Disease;g:CYP17A1)	Stanolone:Dexamethasone:Ketoconazole:Nabiximols:Abiraterone:Medical Cannabis:Cannabidiol:Clomifene:Aldosterone:NADH:Spironolactone:Aminophenazone:Dexamethasone acetate:Progesterone:Prasterone	GO:0019825:GO:0042448:GO:0008202:GO:0005783:GO:0006694:GO:0043025:GO:0042446:GO:0020037:GO:0005789:GO:0006704:GO:0007548:GO:0006702:GO:0005506:GO:0004508:GO:0047442:GO:0055114:GO:0030424	609300	PF00067	-0.11															M
chr10:102837395	SNV	A	1	G/G	PASS	0.0	4003.15		400	A=0,G=400	A=0.0,G=1.0	100.0	0.0	homozygous	32	0.41	1.0		CYP17A1	NM_000102.4	CYP17A1:utr_5:NM_000102.4	unknown		1	p.?	c.-34T>C				G	GMAF=0.3823:AMAF=0.3608:EMAF=0.3934			Benign		rs743572		(dui:D004700;dis:Endocrine System Diseases;g:CYP17A1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP17A1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP17A1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP17A1)(dui:D006058;dis:Gonadal Disorders;g:CYP17A1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP17A1)(dui:D008659;dis:Metabolic Diseases;g:CYP17A1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP17A1)(dui:D000013;dis:Congenital Abnormalities;g:CYP17A1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP17A1)(dui:D012734;dis:Disorders of Sex Development;g:CYP17A1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP17A1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP17A1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP17A1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP17A1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP17A1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP17A1)(dui:D009369;dis:Neoplasms;g:CYP17A1)(dui:D009371;dis:Neoplasms by Site;g:CYP17A1)(dui:D004066;dis:Digestive System Diseases;g:CYP17A1)(dui:D008107;dis:Liver Diseases;g:CYP17A1)(dui:D009422;dis:Nervous System Diseases;g:CYP17A1)(dui:D005831;dis:Genital Diseases, Female;g:CYP17A1)(dui:D005832;dis:Genital Diseases, Male;g:CYP17A1)(dui:D002493;dis:Central Nervous System Diseases;g:CYP17A1)(dui:D001927;dis:Brain Diseases;g:CYP17A1)(dui:D007246;dis:Infertility;g:CYP17A1)(dui:D014565;dis:Urogenital Neoplasms;g:CYP17A1)(dui:D010049;dis:Ovarian Diseases;g:CYP17A1)(dui:D000291;dis:Adnexal Diseases;g:CYP17A1)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CYP17A1)(dui:D011469;dis:Prostatic Diseases;g:CYP17A1)(dui:D012871;dis:Skin Diseases;g:CYP17A1)(dui:D001941;dis:Breast Diseases;g:CYP17A1)(dui:D003560;dis:Cysts;g:CYP17A1)(dui:D010048;dis:Ovarian Cysts;g:CYP17A1)(dui:D001943;dis:Breast Neoplasms;g:CYP17A1)(dui:D005834;dis:Genital Neoplasms, Male;g:CYP17A1)(dui:D009370;dis:Neoplasms by Histologic Type;g:CYP17A1)(dui:D011471;dis:Prostatic Neoplasms;g:CYP17A1)(dui:D002318;dis:Cardiovascular Diseases;g:CYP17A1)(dui:D004067;dis:Digestive System Neoplasms;g:CYP17A1)(dui:D014652;dis:Vascular Diseases;g:CYP17A1)(dui:D019636;dis:Neurodegenerative Diseases;g:CYP17A1)(dui:D006973;dis:Hypertension;g:CYP17A1)(dui:D009069;dis:Movement Disorders;g:CYP17A1)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:CYP17A1)(dui:D001523;dis:Mental Disorders;g:CYP17A1)(dui:D002277;dis:Carcinoma;g:CYP17A1)(dui:D010300;dis:Parkinson Disease;g:CYP17A1)(dui:D001480;dis:Basal Ganglia Diseases;g:CYP17A1)(dui:D020734;dis:Parkinsonian Disorders;g:CYP17A1)(dui:D000230;dis:Adenocarcinoma;g:CYP17A1)(dui:D008113;dis:Liver Neoplasms;g:CYP17A1)(dui:D007247;dis:Infertility, Female;g:CYP17A1)(dui:D020018;dis:Sexual Dysfunctions, Psychological;g:CYP17A1)(dui:D006528;dis:Carcinoma, Hepatocellular;g:CYP17A1)(dui:D007006;dis:Hypogonadism;g:CYP17A1)(dui:D007248;dis:Infertility, Male;g:CYP17A1)(dui:D010900;dis:Pituitary Diseases;g:CYP17A1)(dui:D005234;dis:Fatty Liver;g:CYP17A1)(dui:D007018;dis:Hypopituitarism;g:CYP17A1)(dui:D008103;dis:Liver Cirrhosis;g:CYP17A1)(dui:D014883;dis:Water-Electrolyte Imbalance;g:CYP17A1)(dui:D006947;dis:Hyperkalemia;g:CYP17A1)(dui:D006974;dis:Hypertension, Malignant;g:CYP17A1)(dui:D007027;dis:Hypothalamic Diseases;g:CYP17A1)(dui:D008106;dis:Liver Cirrhosis, Experimental;g:CYP17A1)(dui:D065626;dis:Non-alcoholic Fatty Liver Disease;g:CYP17A1)	Stanolone:Dexamethasone:Ketoconazole:Nabiximols:Abiraterone:Medical Cannabis:Cannabidiol:Clomifene:Aldosterone:NADH:Spironolactone:Aminophenazone:Dexamethasone acetate:Progesterone:Prasterone	GO:0019825:GO:0042448:GO:0008202:GO:0005783:GO:0006694:GO:0043025:GO:0042446:GO:0020037:GO:0005789:GO:0006704:GO:0007548:GO:0006702:GO:0005506:GO:0004508:GO:0047442:GO:0055114:GO:0030424	609300	PF00067	-0.52															M
chr10:123040644	SNV	C	1	C/G	PASS	5.679367867720042e-96	952.457		400	C=195,G=205	C=0.4875,G=0.5125	51.25	48.75	heterozygous	11		2.0		ACADSB	NM_001609.4	ACADSB:exonic:NM_001609.4	missense	AGC	4	p.Thr161Ser	c.482C>G	0.01	0.058	58.0	G								(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADSB)(dui:NBS3;dis:Secondary Conditions;g:ACADSB)(dui:NBS18;dis:2-Methylbutyrylglycinuria;g:ACADSB)(dui:NBS4;dis:Organic Acid Condition;g:ACADSB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADSB)(dui:D008659;dis:Metabolic Diseases;g:ACADSB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADSB)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADSB)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADSB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ACADSB)(dui:D001523;dis:Mental Disorders;g:ACADSB)(dui:D065886;dis:Neurodevelopmental Disorders;g:ACADSB)(dui:D002659;dis:Child Development Disorders, Pervasive;g:ACADSB)(dui:D001321;dis:Autistic Disorder;g:ACADSB)	Valproic acid:Isoleucine	GO:0003853:GO:0042802:GO:0009083:GO:0005759:GO:0050660:GO:0016937:GO:0005739:GO:0102035:GO:0006550:GO:0055114:GO:0006631	600301		2.91															M
chr10:123041039	INDEL	AT	1	A/A	PASS	1.0471285480509242e-170	1699.8		305	AT=0,A=305	AT=0.0,A=1.0	100.0	0.0	homozygous	18	0.035	6.0		ACADSB	NM_001609.4	ACADSB:intronic:NM_001609.4	unknown			p.?	c.511-169delT				A						rs1589741386:rs11300559		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADSB)(dui:NBS3;dis:Secondary Conditions;g:ACADSB)(dui:NBS18;dis:2-Methylbutyrylglycinuria;g:ACADSB)(dui:NBS4;dis:Organic Acid Condition;g:ACADSB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADSB)(dui:D008659;dis:Metabolic Diseases;g:ACADSB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADSB)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADSB)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADSB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ACADSB)(dui:D001523;dis:Mental Disorders;g:ACADSB)(dui:D065886;dis:Neurodevelopmental Disorders;g:ACADSB)(dui:D002659;dis:Child Development Disorders, Pervasive;g:ACADSB)(dui:D001321;dis:Autistic Disorder;g:ACADSB)	Valproic acid:Isoleucine	GO:0003853:GO:0042802:GO:0009083:GO:0005759:GO:0050660:GO:0016937:GO:0005739:GO:0102035:GO:0006550:GO:0055114:GO:0006631	600301		-0.13,0.0															M
chr11:5226496	SNV	G	1	G/A	PASS	4.9181299526830836e-98	973.082		388	G=184,A=204	G=0.4742,A=0.5258	52.58	47.42	heterozygous	40	0.099	1.0		HBB	NM_000518.5	HBB:intronic:NM_000518.5	unknown			p.?	c.315+81C>T				A				Benign		rs7946748		(dui:D006425;dis:Hemic and Lymphatic Diseases;g:HBB)(dui:D006402;dis:Hematologic Diseases;g:HBB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:HBB)(dui:D030342;dis:Genetic Diseases, Inborn;g:HBB)(dui:D000740;dis:Anemia;g:HBB)(dui:D000743;dis:Anemia, Hemolytic;g:HBB)(dui:D000745;dis:Anemia, Hemolytic, Congenital;g:HBB)(dui:D006453;dis:Hemoglobinopathies;g:HBB)(dui:NBS1;dis:Recommended Newborn Screening Panels;g:HBB)(dui:NBS13;dis:Hemoglobin Disorder;g:HBB)(dui:NBS2;dis:Core Conditions;g:HBB)(dui:NBS67;dis:Hb SS-disease (sickle cell anemia);g:HBB)(dui:NBS68;dis:Hb beta zero-thalassemia;g:HBB)(dui:D013789;dis:Thalassemia;g:HBB)(dui:D017086;dis:beta-Thalassemia;g:HBB)(dui:D000755;dis:Anemia, Sickle Cell;g:HBB)(dui:D017085;dis:alpha-Thalassemia;g:HBB)(dui:D055538;dis:delta-Thalassemia;g:HBB)(dui:D006450;dis:Hemoglobin SC Disease;g:HBB)(dui:D001855;dis:Bone Marrow Diseases;g:HBB)(dui:D009196;dis:Myeloproliferative Disorders;g:HBB)(dui:D006445;dis:Hemoglobin C Disease;g:HBB)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:HBB)(dui:D012871;dis:Skin Diseases;g:HBB)(dui:D011086;dis:Polycythemia;g:HBB)(dui:D008708;dis:Methemoglobinemia;g:HBB)(dui:D017486;dis:Acneiform Eruptions;g:HBB)(dui:D054506;dis:Chloracne;g:HBB)(dui:D011087;dis:Polycythemia Vera;g:HBB)	2,6-dicarboxynaphthalene:Sodium ferric gluconate complex:Oxygen:Zinc chloride:4-Carboxycinnamic Acid:2-[(2-methoxy-5-methylphenoxy)methyl]pyridine:2-[4-({[(3,5-DICHLOROPHENYL)AMINO]CARBONYL}AMINO)PHENOXY]-2-METHYLPROPANOIC ACID:Ferric pyrophosphate citrate:Pentaerythritol tetranitrate:Efaproxiral:Zinc sulfate, unspecified form:Zinc:Sebacic acid:Trimesic acid:Zinc acetate:Copper:Ferric pyrophosphate:Iron Dextran:4-[(5-methoxy-2-methylphenoxy)methyl]pyridine:Nitrous acid	GO:0045429:GO:0015671:GO:0030492:GO:0007596:GO:0005576:GO:1904813:GO:0070062:GO:0031838:GO:0072562:GO:0005829:GO:0015701:GO:0070527:GO:0019825:GO:0030185:GO:1904724:GO:0043177:GO:0043312:GO:0042542:GO:0005344:GO:0006898:GO:0008217:GO:0020037:GO:0042744:GO:0005833:GO:0004601:GO:0005615:GO:0005515:GO:0070293:GO:0046872:GO:0071682:GO:0098869:GO:0010942:GO:0031721:GO:0031720	141900	PF00042	-0.45															M
chr11:5226561	SNV	C	1	C/G	PASS	4.00774425280436e-78	773.971		400	C=214,G=186	C=0.535,G=0.465	46.5	53.5	heterozygous	55	0.28	1.0		HBB	NM_000518.5	HBB:intronic:NM_000518.5	unknown			p.?	c.315+16G>C				G	GMAF=0.1491:AMAF=0.1297:EMAF=0.159			Benign/Likely benign		rs10768683		(dui:D006425;dis:Hemic and Lymphatic Diseases;g:HBB)(dui:D006402;dis:Hematologic Diseases;g:HBB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:HBB)(dui:D030342;dis:Genetic Diseases, Inborn;g:HBB)(dui:D000740;dis:Anemia;g:HBB)(dui:D000743;dis:Anemia, Hemolytic;g:HBB)(dui:D000745;dis:Anemia, Hemolytic, Congenital;g:HBB)(dui:D006453;dis:Hemoglobinopathies;g:HBB)(dui:NBS1;dis:Recommended Newborn Screening Panels;g:HBB)(dui:NBS13;dis:Hemoglobin Disorder;g:HBB)(dui:NBS2;dis:Core Conditions;g:HBB)(dui:NBS67;dis:Hb SS-disease (sickle cell anemia);g:HBB)(dui:NBS68;dis:Hb beta zero-thalassemia;g:HBB)(dui:D013789;dis:Thalassemia;g:HBB)(dui:D017086;dis:beta-Thalassemia;g:HBB)(dui:D000755;dis:Anemia, Sickle Cell;g:HBB)(dui:D017085;dis:alpha-Thalassemia;g:HBB)(dui:D055538;dis:delta-Thalassemia;g:HBB)(dui:D006450;dis:Hemoglobin SC Disease;g:HBB)(dui:D001855;dis:Bone Marrow Diseases;g:HBB)(dui:D009196;dis:Myeloproliferative Disorders;g:HBB)(dui:D006445;dis:Hemoglobin C Disease;g:HBB)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:HBB)(dui:D012871;dis:Skin Diseases;g:HBB)(dui:D011086;dis:Polycythemia;g:HBB)(dui:D008708;dis:Methemoglobinemia;g:HBB)(dui:D017486;dis:Acneiform Eruptions;g:HBB)(dui:D054506;dis:Chloracne;g:HBB)(dui:D011087;dis:Polycythemia Vera;g:HBB)	2,6-dicarboxynaphthalene:Sodium ferric gluconate complex:Oxygen:Zinc chloride:4-Carboxycinnamic Acid:2-[(2-methoxy-5-methylphenoxy)methyl]pyridine:2-[4-({[(3,5-DICHLOROPHENYL)AMINO]CARBONYL}AMINO)PHENOXY]-2-METHYLPROPANOIC ACID:Ferric pyrophosphate citrate:Pentaerythritol tetranitrate:Efaproxiral:Zinc sulfate, unspecified form:Zinc:Sebacic acid:Trimesic acid:Zinc acetate:Copper:Ferric pyrophosphate:Iron Dextran:4-[(5-methoxy-2-methylphenoxy)methyl]pyridine:Nitrous acid	GO:0045429:GO:0015671:GO:0030492:GO:0007596:GO:0005576:GO:1904813:GO:0070062:GO:0031838:GO:0072562:GO:0005829:GO:0015701:GO:0070527:GO:0019825:GO:0030185:GO:1904724:GO:0043177:GO:0043312:GO:0042542:GO:0005344:GO:0006898:GO:0008217:GO:0020037:GO:0042744:GO:0005833:GO:0004601:GO:0005615:GO:0005515:GO:0070293:GO:0046872:GO:0071682:GO:0098869:GO:0010942:GO:0031721:GO:0031720	141900	PF00042	-3.19															M
chr11:5227013	SNV	A	1	A/G	PASS	3.0136998743411634e-88	875.209		400	A=203,G=197	A=0.5075,G=0.4925	49.25	50.75	heterozygous	55	0.286	1.0		HBB	NM_000518.5	HBB:exonic:NM_000518.5	synonymous	CAC	1	p.His3=	c.9T>C				G	GMAF=0.1513:AMAF=0.1361:EMAF=0.1591	0.1		Benign	6484194	rs713040:rs63750898:rs63750407		(dui:D006425;dis:Hemic and Lymphatic Diseases;g:HBB)(dui:D006402;dis:Hematologic Diseases;g:HBB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:HBB)(dui:D030342;dis:Genetic Diseases, Inborn;g:HBB)(dui:D000740;dis:Anemia;g:HBB)(dui:D000743;dis:Anemia, Hemolytic;g:HBB)(dui:D000745;dis:Anemia, Hemolytic, Congenital;g:HBB)(dui:D006453;dis:Hemoglobinopathies;g:HBB)(dui:NBS1;dis:Recommended Newborn Screening Panels;g:HBB)(dui:NBS13;dis:Hemoglobin Disorder;g:HBB)(dui:NBS2;dis:Core Conditions;g:HBB)(dui:NBS67;dis:Hb SS-disease (sickle cell anemia);g:HBB)(dui:NBS68;dis:Hb beta zero-thalassemia;g:HBB)(dui:D013789;dis:Thalassemia;g:HBB)(dui:D017086;dis:beta-Thalassemia;g:HBB)(dui:D000755;dis:Anemia, Sickle Cell;g:HBB)(dui:D017085;dis:alpha-Thalassemia;g:HBB)(dui:D055538;dis:delta-Thalassemia;g:HBB)(dui:D006450;dis:Hemoglobin SC Disease;g:HBB)(dui:D001855;dis:Bone Marrow Diseases;g:HBB)(dui:D009196;dis:Myeloproliferative Disorders;g:HBB)(dui:D006445;dis:Hemoglobin C Disease;g:HBB)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:HBB)(dui:D012871;dis:Skin Diseases;g:HBB)(dui:D011086;dis:Polycythemia;g:HBB)(dui:D008708;dis:Methemoglobinemia;g:HBB)(dui:D017486;dis:Acneiform Eruptions;g:HBB)(dui:D054506;dis:Chloracne;g:HBB)(dui:D011087;dis:Polycythemia Vera;g:HBB)	2,6-dicarboxynaphthalene:Sodium ferric gluconate complex:Oxygen:Zinc chloride:4-Carboxycinnamic Acid:2-[(2-methoxy-5-methylphenoxy)methyl]pyridine:2-[4-({[(3,5-DICHLOROPHENYL)AMINO]CARBONYL}AMINO)PHENOXY]-2-METHYLPROPANOIC ACID:Ferric pyrophosphate citrate:Pentaerythritol tetranitrate:Efaproxiral:Zinc sulfate, unspecified form:Zinc:Sebacic acid:Trimesic acid:Zinc acetate:Copper:Ferric pyrophosphate:Iron Dextran:4-[(5-methoxy-2-methylphenoxy)methyl]pyridine:Nitrous acid	GO:0045429:GO:0015671:GO:0030492:GO:0007596:GO:0005576:GO:1904813:GO:0070062:GO:0031838:GO:0072562:GO:0005829:GO:0015701:GO:0070527:GO:0019825:GO:0030185:GO:1904724:GO:0043177:GO:0043312:GO:0042542:GO:0005344:GO:0006898:GO:0008217:GO:0020037:GO:0042744:GO:0005833:GO:0004601:GO:0005615:GO:0005515:GO:0070293:GO:0046872:GO:0071682:GO:0098869:GO:0010942:GO:0031721:GO:0031720	141900	PF00042	-0.89															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	4.854896771016029e-07	63.1382		7	AAA=0,GCT=7	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr11:68807709	SNV	G	1	G/A	PASS	6.194410750767837e-89	882.08		390	G=195,A=195	G=0.5,A=0.5	50.0	50.0	heterozygous	19	0.017	1.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.282-71C>T				A						rs41302431		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	-1.97															M
chr11:108142634	SNV	C	1	T/T	PASS	0.0	3957.87		399	C=1,T=398	C=0.0025,T=0.9975	99.75	0.25	homozygous	25	0.262	1.0		ACAT1	NM_000019.4	ACAT1:intronic:NM_000019.4	unknown			p.?	c.940+84C>T				T						rs12794010		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACAT1)(dui:NBS2;dis:Core Conditions;g:ACAT1)(dui:NBS48;dis:beta-Ketothiolase deficiency;g:ACAT1)(dui:NBS9;dis:Organic Acid Condition;g:ACAT1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACAT1)(dui:D008659;dis:Metabolic Diseases;g:ACAT1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACAT1)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACAT1)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACAT1)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ACAT1)(dui:D052801;dis:Male Urogenital Diseases;g:ACAT1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:ACAT1)(dui:D014570;dis:Urologic Diseases;g:ACAT1)(dui:D052776;dis:Female Urogenital Diseases;g:ACAT1)(dui:D007674;dis:Kidney Diseases;g:ACAT1)(dui:D051437;dis:Renal Insufficiency;g:ACAT1)(dui:D051436;dis:Renal Insufficiency, Chronic;g:ACAT1)(dui:D007676;dis:Kidney Failure, Chronic;g:ACAT1)(dui:D009422;dis:Nervous System Diseases;g:ACAT1)(dui:D002493;dis:Central Nervous System Diseases;g:ACAT1)(dui:D001927;dis:Brain Diseases;g:ACAT1)(dui:D009461;dis:Neurologic Manifestations;g:ACAT1)(dui:D012640;dis:Seizures;g:ACAT1)(dui:D004827;dis:Epilepsy;g:ACAT1)	Nabiximols:Sulfasalazine:Medical Cannabis:Cannabidiol	GO:0006085:GO:0042594:GO:0046952:GO:0046356:GO:0046951:GO:0003985:GO:0006635:GO:0070062:GO:0003988:GO:0001889:GO:0016453:GO:0072229:GO:0042802:GO:0009083:GO:1902860:GO:0006550:GO:1902224:GO:0007420:GO:0014070:GO:0009725:GO:0060612:GO:0030955:GO:0005759:GO:0005739:GO:0015937:GO:0034435:GO:0015936:GO:0019899	607809	PF02803:PF00108:PF00109	0.95															M
chr12:102846852	SNV	C	1	A/A	PASS	0.0	3797.6		391	C=3,A=388	C=0.0077,A=0.9923	99.23	0.769999999999996	homozygous	47	0.27	2.0		PAH	NM_001354304.2	PAH:intronic:NM_001354304.2	unknown			p.?	c.969+43G>T				A	GMAF=0.3666:AMAF=0.2685:EMAF=0.4169			Benign		rs1522306		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PAH)(dui:NBS2;dis:Core Conditions;g:PAH)(dui:NBS11;dis:Amino Acid Disorder;g:PAH)(dui:NBS58;dis:Phenylketonuria;g:PAH)(dui:D009422;dis:Nervous System Diseases;g:PAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PAH)(dui:D008659;dis:Metabolic Diseases;g:PAH)(dui:D002493;dis:Central Nervous System Diseases;g:PAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:PAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:PAH)(dui:D001927;dis:Brain Diseases;g:PAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:PAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:PAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PAH)(dui:D010661;dis:Phenylketonurias;g:PAH)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:PAH)(dui:D011248;dis:Pregnancy Complications;g:PAH)(dui:D017042;dis:Phenylketonuria, Maternal;g:PAH)	Sapropterin:L-erythro-7,8-dihydrobiopterin:Quinonoid 7,8-Tetrahydrobiopterin:Phenylalanine:beta-2-Thienyl-L-alanine:Norepinephrine:Cupric sulfate:D-norleucine:Droxidopa		612349	PF00351:PF01842	-1.11															M
chr12:102855386	SNV	C	1	T/T	PASS	0.0	4002.99		400	C=0,T=400	C=0.0,T=1.0	100.0	0.0	homozygous	47	0.235	1.0		PAH	NM_001354304.2	PAH:intronic:NM_001354304.2	unknown			p.?	c.510-54G>A				T				Benign		rs2251905		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PAH)(dui:NBS2;dis:Core Conditions;g:PAH)(dui:NBS11;dis:Amino Acid Disorder;g:PAH)(dui:NBS58;dis:Phenylketonuria;g:PAH)(dui:D009422;dis:Nervous System Diseases;g:PAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PAH)(dui:D008659;dis:Metabolic Diseases;g:PAH)(dui:D002493;dis:Central Nervous System Diseases;g:PAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:PAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:PAH)(dui:D001927;dis:Brain Diseases;g:PAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:PAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:PAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PAH)(dui:D010661;dis:Phenylketonurias;g:PAH)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:PAH)(dui:D011248;dis:Pregnancy Complications;g:PAH)(dui:D017042;dis:Phenylketonuria, Maternal;g:PAH)	Sapropterin:L-erythro-7,8-dihydrobiopterin:Quinonoid 7,8-Tetrahydrobiopterin:Phenylalanine:beta-2-Thienyl-L-alanine:Norepinephrine:Cupric sulfate:D-norleucine:Droxidopa		612349	PF00351:PF01842	-4.26															M
chr12:102877415	SNV	G	1	A/A	PASS	3.169567463043733e-252	2514.99		269	G=6,A=263	G=0.0223,A=0.9777	97.77	2.230000000000004	homozygous	47	0.294	2.0		PAH	NM_001354304.2	PAH:intronic:NM_001354304.2	unknown			p.?	c.441+47C>T				A	GMAF=0.3828:AMAF=0.2851:EMAF=0.4329			Benign		rs1718301		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PAH)(dui:NBS2;dis:Core Conditions;g:PAH)(dui:NBS11;dis:Amino Acid Disorder;g:PAH)(dui:NBS58;dis:Phenylketonuria;g:PAH)(dui:D009422;dis:Nervous System Diseases;g:PAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PAH)(dui:D008659;dis:Metabolic Diseases;g:PAH)(dui:D002493;dis:Central Nervous System Diseases;g:PAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:PAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:PAH)(dui:D001927;dis:Brain Diseases;g:PAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:PAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:PAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PAH)(dui:D010661;dis:Phenylketonurias;g:PAH)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:PAH)(dui:D011248;dis:Pregnancy Complications;g:PAH)(dui:D017042;dis:Phenylketonuria, Maternal;g:PAH)	Sapropterin:L-erythro-7,8-dihydrobiopterin:Quinonoid 7,8-Tetrahydrobiopterin:Phenylalanine:beta-2-Thienyl-L-alanine:Norepinephrine:Cupric sulfate:D-norleucine:Droxidopa		612349	PF00351:PF01842	-1.57															M
chr12:120737096	SNV	T	1	C/C	PASS	0.0	3964.31		399	T=0,C=399	T=0.0,C=1.0	100.0	0.0	homozygous	55	0.409	1.0		ACADS	NM_000017.4	ACADS:exonic:NM_000017.4	synonymous	CGC	3	p.Arg107=	c.321T>C				C	GMAF=0.4932:AMAF=0.3756:EMAF=0.4466	0.28		Benign	3765623	rs1064795254:rs3914		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADS)(dui:NBS21;dis:Short-chain acyl-CoA dehydrogenase deficiency;g:ACADS)(dui:NBS3;dis:Secondary Conditions;g:ACADS)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ACADS)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADS)(dui:D008659;dis:Metabolic Diseases;g:ACADS)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADS)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADS)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADS)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADS)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADS)	Acetoacetyl-CoA:NADH:Flavin adenine dinucleotide	GO:0003995:GO:0005634:GO:0005813:GO:0006635:GO:0033539:GO:0005759:GO:0050660:GO:0004085:GO:0005739:GO:0046359:GO:0005654	606885	PF02771:PF02770:PF00441:PF08028	-0.18															M
chr12:120738181	SNV	T	1	C/C	PASS	0.0	3993.13		399	T=0,C=399	T=0.0,C=1.0	100.0	0.0	homozygous	55	0.406	1.0		ACADS	NM_000017.4	ACADS:intronic:NM_000017.4	unknown			p.?	c.625-99T>C				C						rs555404		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADS)(dui:NBS21;dis:Short-chain acyl-CoA dehydrogenase deficiency;g:ACADS)(dui:NBS3;dis:Secondary Conditions;g:ACADS)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ACADS)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADS)(dui:D008659;dis:Metabolic Diseases;g:ACADS)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADS)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADS)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADS)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADS)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADS)	Acetoacetyl-CoA:NADH:Flavin adenine dinucleotide	GO:0003995:GO:0005634:GO:0005813:GO:0006635:GO:0033539:GO:0005759:GO:0050660:GO:0004085:GO:0005739:GO:0046359:GO:0005654	606885	PF02771:PF02770:PF00441:PF08028	-2.88															M
chr12:120738876	SNV	C	1	T/T	PASS	0.0	3996.22		400	C=0,T=400	C=0.0,T=1.0	100.0	0.0	homozygous	55	0.327	1.0		ACADS	NM_000017.4	ACADS:exonic:NM_000017.4	synonymous	CGT	8	p.Arg330=	c.990C>T				T	GMAF=0.408:AMAF=0.1235:EMAF=0.4462	0.02		Benign	4146720	rs796051906:rs1555244280:rs3915		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADS)(dui:NBS21;dis:Short-chain acyl-CoA dehydrogenase deficiency;g:ACADS)(dui:NBS3;dis:Secondary Conditions;g:ACADS)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ACADS)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADS)(dui:D008659;dis:Metabolic Diseases;g:ACADS)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADS)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADS)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADS)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADS)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADS)	Acetoacetyl-CoA:NADH:Flavin adenine dinucleotide	GO:0003995:GO:0005634:GO:0005813:GO:0006635:GO:0033539:GO:0005759:GO:0050660:GO:0004085:GO:0005739:GO:0046359:GO:0005654	606885	PF02771:PF02770:PF00441:PF08028	-1.49															M
chr13:20189202	SNV	C	1	C/T	PASS	4.103930524610086e-92	913.868		400	C=199,T=201	C=0.4975,T=0.5025	50.25	49.75	heterozygous	32	0.027	1.0		GJB2	NM_004004.6	GJB2:exonic:NM_004004.6	missense	CAC	2	p.Arg127His	c.380G>A			29.0	T	GMAF=0.0023:AMAF=9.0E-4:EMAF=0.003	0.45		Conflicting interpretations of pathogenicity	5052088	rs111033196		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:GJB2)(dui:NBS2;dis:Core Conditions;g:GJB2)(dui:NBS14;dis:Other Disorder;g:GJB2)(dui:NBS75;dis:Hearing Loss;g:GJB2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:GJB2)(dui:D000013;dis:Congenital Abnormalities;g:GJB2)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:GJB2)(dui:D012871;dis:Skin Diseases;g:GJB2)(dui:D009422;dis:Nervous System Diseases;g:GJB2)(dui:D009461;dis:Neurologic Manifestations;g:GJB2)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:GJB2)(dui:D004427;dis:Ear Diseases;g:GJB2)(dui:D012678;dis:Sensation Disorders;g:GJB2)(dui:D006311;dis:Hearing Disorders;g:GJB2)(dui:D034381;dis:Hearing Loss;g:GJB2)(dui:D007642;dis:Keratosis;g:GJB2)(dui:D006319;dis:Hearing Loss, Sensorineural;g:GJB2)(dui:D030342;dis:Genetic Diseases, Inborn;g:GJB2)(dui:D000015;dis:Abnormalities, Multiple;g:GJB2)(dui:D012873;dis:Skin Diseases, Genetic;g:GJB2)(dui:D009140;dis:Musculoskeletal Diseases;g:GJB2)(dui:D007645;dis:Keratoderma, Palmoplantar;g:GJB2)(dui:D006226;dis:Hand Deformities;g:GJB2)(dui:D009139;dis:Musculoskeletal Abnormalities;g:GJB2)(dui:D006228;dis:Hand Deformities, Congenital;g:GJB2)(dui:D017880;dis:Limb Deformities, Congenital;g:GJB2)(dui:D038062;dis:Upper Extremity Deformities, Congenital;g:GJB2)(dui:D012868;dis:Skin Abnormalities;g:GJB2)(dui:D007232;dis:Infant, Newborn, Diseases;g:GJB2)(dui:D007057;dis:Ichthyosis;g:GJB2)(dui:D005128;dis:Eye Diseases;g:GJB2)(dui:D003638;dis:Deafness;g:GJB2)(dui:D003316;dis:Corneal Diseases;g:GJB2)(dui:D007634;dis:Keratitis;g:GJB2)(dui:D009369;dis:Neoplasms;g:GJB2)(dui:D009371;dis:Neoplasms by Site;g:GJB2)(dui:D004066;dis:Digestive System Diseases;g:GJB2)(dui:D017444;dis:Skin Diseases, Papulosquamous;g:GJB2)(dui:D011565;dis:Psoriasis;g:GJB2)(dui:D004700;dis:Endocrine System Diseases;g:GJB2)(dui:D003240;dis:Connective Tissue Diseases;g:GJB2)(dui:D012874;dis:Skin Diseases, Infectious;g:GJB2)(dui:D002481;dis:Cellulitis;g:GJB2)(dui:D012878;dis:Skin Neoplasms;g:GJB2)(dui:D013543;dis:Sweat Gland Diseases;g:GJB2)(dui:D016575;dis:Hidradenitis;g:GJB2)(dui:D017192;dis:Skin Diseases, Bacterial;g:GJB2)(dui:D017497;dis:Hidradenitis Suppurativa;g:GJB2)		GO:0016328:GO:0048839:GO:1903763:GO:0032570:GO:0046677:GO:1905867:GO:0046697:GO:0005793:GO:0044752:GO:0005921:GO:0007605:GO:0005887:GO:0032526:GO:0002931:GO:0005922:GO:0071377:GO:0005509:GO:1990349:GO:0097449:GO:0005829:GO:0042802:GO:0055085:GO:0007267:GO:0005243:GO:0007568:GO:0005886:GO:0005515:GO:0048471:GO:0044297:GO:0010644:GO:0032355:GO:0016264:GO:0034599:GO:0032496:GO:0071549	121011	PF00029	0.67															M
chr13:20222791	INDEL	AT	1	AT/A	PASS	1.2042038184717625e-29	289.193		395	AT=138,A=257	AT=0.3494,A=0.6506	65.06	34.94	heterozygous	11		7.0		GJB6	NM_001110220.2	GJB6:exonic:NM_001110220.2	frameshiftDeletion	ATC	4	p.Asn230IlefsTer7	c.689delA				A	GMAF=6.0E-4:AMAF=0.0:EMAF=0.001					rs398124237		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:GJB6)(dui:NBS2;dis:Core Conditions;g:GJB6)(dui:NBS14;dis:Other Disorder;g:GJB6)(dui:NBS75;dis:Hearing Loss;g:GJB6)(dui:D009422;dis:Nervous System Diseases;g:GJB6)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:GJB6)(dui:D012871;dis:Skin Diseases;g:GJB6)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:GJB6)(dui:D030342;dis:Genetic Diseases, Inborn;g:GJB6)(dui:D000013;dis:Congenital Abnormalities;g:GJB6)(dui:D000015;dis:Abnormalities, Multiple;g:GJB6)(dui:D012873;dis:Skin Diseases, Genetic;g:GJB6)(dui:D012868;dis:Skin Abnormalities;g:GJB6)(dui:D004476;dis:Ectodermal Dysplasia;g:GJB6)(dui:D009461;dis:Neurologic Manifestations;g:GJB6)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:GJB6)(dui:D004427;dis:Ear Diseases;g:GJB6)(dui:D006311;dis:Hearing Disorders;g:GJB6)(dui:D012678;dis:Sensation Disorders;g:GJB6)(dui:D034381;dis:Hearing Loss;g:GJB6)(dui:D006319;dis:Hearing Loss, Sensorineural;g:GJB6)(dui:D002493;dis:Central Nervous System Diseases;g:GJB6)(dui:D001927;dis:Brain Diseases;g:GJB6)(dui:D004827;dis:Epilepsy;g:GJB6)		GO:0048839:GO:1903763:GO:0008285:GO:0005921:GO:0007605:GO:0005922:GO:0071333:GO:0048487:GO:0006915:GO:1990349:GO:0005829:GO:0051602:GO:0035633:GO:0055085:GO:0007267:GO:0005243:GO:0005884:GO:0007568:GO:0008017:GO:0051015:GO:0005515:GO:0042471:GO:0010644:GO:0016021:GO:0016264:GO:0030054:GO:0032496:GO:0016324	604418	PF00029	-0.6,2.5															M
chr15:40405996	INDEL	GCCCCAAGGCCTCCTTCCTGCCTGGT	25	GCCCCAAGGCCTCCTTCCTGCCTGGT/G	PASS	7.481695005111461e-78	771.26		386	GCCCCAAGGCCTCCTTCCTGCCTGGT=204,G=182	GCCCCAAGGCCTCCTTCCTGCCTGGT=0.5285,G=0.4715	47.15	52.85	heterozygous	11	0.0	4.0		IVD	NR_148925.2	IVD:exonic_nc:NR_148925.2			1							GMAF=0.0583:AMAF=0.0209:EMAF=0.0776					rs776474354:rs373206450:rs1595751032:rs1361784904:rs761343713:rs1293826929:rs551337019:rs148239901:rs906489051:rs1357668930:rs1046280910:rs1323472436:rs1433088894:rs769380776:rs1217174067:rs1555402915:rs1555402927		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:IVD)(dui:NBS2;dis:Core Conditions;g:IVD)(dui:NBS9;dis:Organic Acid Condition;g:IVD)(dui:NBS44;dis:Isovaleric acidemia;g:IVD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:IVD)(dui:D030342;dis:Genetic Diseases, Inborn;g:IVD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:IVD)(dui:D008659;dis:Metabolic Diseases;g:IVD)(dui:D008661;dis:Metabolism, Inborn Errors;g:IVD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:IVD)(dui:D012140;dis:Respiratory Tract Diseases;g:IVD)(dui:D008171;dis:Lung Diseases;g:IVD)(dui:D017563;dis:Lung Diseases, Interstitial;g:IVD)	Coenzyme A persulfide:Flavin adenine dinucleotide		607036		1.31,-0.04,-0.08,-0.03,-2.28,-0.33,0.47,0.68,2.57,-0.06,0.65,0.28,-0.35,-1.14,-0.07,-0.66,1.27,0.64,-1.36,-0.64,-0.18,-3.46,-1.35,-0.03,0.87,-1.07															M
chr15:40407739	SNV	T	1	C/C	PASS	0.0	3935.99		396	T=0,C=396	T=0.0,C=1.0	100.0	0.0	homozygous	47	0.352	1.0		IVD	NR_148925.2	IVD:intronic_nc:NR_148925.2										GMAF=0.4044:AMAF=0.485:EMAF=0.3478			Benign		rs2289331		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:IVD)(dui:NBS2;dis:Core Conditions;g:IVD)(dui:NBS9;dis:Organic Acid Condition;g:IVD)(dui:NBS44;dis:Isovaleric acidemia;g:IVD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:IVD)(dui:D030342;dis:Genetic Diseases, Inborn;g:IVD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:IVD)(dui:D008659;dis:Metabolic Diseases;g:IVD)(dui:D008661;dis:Metabolism, Inborn Errors;g:IVD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:IVD)(dui:D012140;dis:Respiratory Tract Diseases;g:IVD)(dui:D008171;dis:Lung Diseases;g:IVD)(dui:D017563;dis:Lung Diseases, Interstitial;g:IVD)	Coenzyme A persulfide:Flavin adenine dinucleotide		607036		-1.6															M
chr15:40410915	SNV	A	1	A/G	PASS	1.888426125223435e-65	647.239		286	A=143,G=143	A=0.5,G=0.5	50.0	50.0	heterozygous	11	0.044	3.0		IVD	NR_148925.2	IVD:intronic_nc:NR_148925.2															rs8033938		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:IVD)(dui:NBS2;dis:Core Conditions;g:IVD)(dui:NBS9;dis:Organic Acid Condition;g:IVD)(dui:NBS44;dis:Isovaleric acidemia;g:IVD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:IVD)(dui:D030342;dis:Genetic Diseases, Inborn;g:IVD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:IVD)(dui:D008659;dis:Metabolic Diseases;g:IVD)(dui:D008661;dis:Metabolism, Inborn Errors;g:IVD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:IVD)(dui:D012140;dis:Respiratory Tract Diseases;g:IVD)(dui:D008171;dis:Lung Diseases;g:IVD)(dui:D017563;dis:Lung Diseases, Interstitial;g:IVD)	Coenzyme A persulfide:Flavin adenine dinucleotide		607036		0.32															M
chr15:40412906	SNV	A	1	G/G	PASS	0.0	3991.02		399	A=0,G=399	A=0.0,G=1.0	100.0	0.0	homozygous	55	0.317	1.0		IVD	NR_148925.2	IVD:intronic_nc:NR_148925.2															rs2289330		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:IVD)(dui:NBS2;dis:Core Conditions;g:IVD)(dui:NBS9;dis:Organic Acid Condition;g:IVD)(dui:NBS44;dis:Isovaleric acidemia;g:IVD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:IVD)(dui:D030342;dis:Genetic Diseases, Inborn;g:IVD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:IVD)(dui:D008659;dis:Metabolic Diseases;g:IVD)(dui:D008661;dis:Metabolism, Inborn Errors;g:IVD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:IVD)(dui:D012140;dis:Respiratory Tract Diseases;g:IVD)(dui:D008171;dis:Lung Diseases;g:IVD)(dui:D017563;dis:Lung Diseases, Interstitial;g:IVD)	Coenzyme A persulfide:Flavin adenine dinucleotide		607036		0.42															M
chr15:40416223	SNV	A	1	G/G	PASS	0.0	3992.92		400	A=0,G=400	A=0.0,G=1.0	100.0	0.0	homozygous	55	0.368	1.0		IVD	NR_148925.2	IVD:intronic_nc:NR_148925.2										GMAF=0.4227:AMAF=0.4324:EMAF=0.3485			Benign		rs11070270		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:IVD)(dui:NBS2;dis:Core Conditions;g:IVD)(dui:NBS9;dis:Organic Acid Condition;g:IVD)(dui:NBS44;dis:Isovaleric acidemia;g:IVD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:IVD)(dui:D030342;dis:Genetic Diseases, Inborn;g:IVD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:IVD)(dui:D008659;dis:Metabolic Diseases;g:IVD)(dui:D008661;dis:Metabolism, Inborn Errors;g:IVD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:IVD)(dui:D012140;dis:Respiratory Tract Diseases;g:IVD)(dui:D008171;dis:Lung Diseases;g:IVD)(dui:D017563;dis:Lung Diseases, Interstitial;g:IVD)	Coenzyme A persulfide:Flavin adenine dinucleotide		607036		0.49															M
chr15:40416445	SNV	C	1	C/T	PASS	7.350214276467985e-48	471.337		224	C=116,T=108	C=0.5179,T=0.4821	48.21	51.79	heterozygous	11	0.043	1.0		IVD	NR_148925.2	IVD:intronic_nc:NR_148925.2															rs112366697		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:IVD)(dui:NBS2;dis:Core Conditions;g:IVD)(dui:NBS9;dis:Organic Acid Condition;g:IVD)(dui:NBS44;dis:Isovaleric acidemia;g:IVD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:IVD)(dui:D030342;dis:Genetic Diseases, Inborn;g:IVD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:IVD)(dui:D008659;dis:Metabolic Diseases;g:IVD)(dui:D008661;dis:Metabolism, Inborn Errors;g:IVD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:IVD)(dui:D012140;dis:Respiratory Tract Diseases;g:IVD)(dui:D008171;dis:Lung Diseases;g:IVD)(dui:D017563;dis:Lung Diseases, Interstitial;g:IVD)	Coenzyme A persulfide:Flavin adenine dinucleotide		607036		0.14															M
chr15:40416502	SNV	C	1	C/T	PASS	2.0706180713346528e-41	406.839		210	C=113,T=97	C=0.5381,T=0.4619	46.19	53.81	heterozygous	11	0.043	2.0		IVD	NR_148925.2	IVD:intronic_nc:NR_148925.2															rs111540938		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:IVD)(dui:NBS2;dis:Core Conditions;g:IVD)(dui:NBS9;dis:Organic Acid Condition;g:IVD)(dui:NBS44;dis:Isovaleric acidemia;g:IVD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:IVD)(dui:D030342;dis:Genetic Diseases, Inborn;g:IVD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:IVD)(dui:D008659;dis:Metabolic Diseases;g:IVD)(dui:D008661;dis:Metabolism, Inborn Errors;g:IVD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:IVD)(dui:D012140;dis:Respiratory Tract Diseases;g:IVD)(dui:D008171;dis:Lung Diseases;g:IVD)(dui:D017563;dis:Lung Diseases, Interstitial;g:IVD)	Coenzyme A persulfide:Flavin adenine dinucleotide		607036		0.44															M
chr15:76231430	SNV	T	1	T/C	PASS	2.4338846965042127e-93	926.137		399	T=197,C=202	T=0.4937,C=0.5063	50.63	49.37	heterozygous	11	0.047	1.0		ETFA	NM_000126.4	ETFA:intronic:NM_000126.4	unknown			p.?	c.817-32A>G				C	GMAF=0.0776:AMAF=0.0612:EMAF=0.086					rs62030234		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ETFA)(dui:NBS3;dis:Secondary Conditions;g:ETFA)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ETFA)(dui:NBS24;dis:Glutaric acidemia type II;g:ETFA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ETFA)(dui:D008659;dis:Metabolic Diseases;g:ETFA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ETFA)(dui:D030342;dis:Genetic Diseases, Inborn;g:ETFA)(dui:D008661;dis:Metabolism, Inborn Errors;g:ETFA)(dui:D028361;dis:Mitochondrial Diseases;g:ETFA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ETFA)(dui:D054069;dis:Multiple Acyl Coenzyme A Dehydrogenase Deficiency;g:ETFA)(dui:D009140;dis:Musculoskeletal Diseases;g:ETFA)(dui:D007592;dis:Joint Diseases;g:ETFA)(dui:D012216;dis:Rheumatic Diseases;g:ETFA)(dui:D001168;dis:Arthritis;g:ETFA)(dui:D009369;dis:Neoplasms;g:ETFA)(dui:D009370;dis:Neoplasms by Histologic Type;g:ETFA)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:ETFA)(dui:D004066;dis:Digestive System Diseases;g:ETFA)(dui:D009371;dis:Neoplasms by Site;g:ETFA)(dui:D008107;dis:Liver Diseases;g:ETFA)(dui:D002277;dis:Carcinoma;g:ETFA)(dui:D000230;dis:Adenocarcinoma;g:ETFA)(dui:D004067;dis:Digestive System Neoplasms;g:ETFA)(dui:D008113;dis:Liver Neoplasms;g:ETFA)(dui:D010003;dis:Osteoarthritis;g:ETFA)(dui:D006528;dis:Carcinoma, Hepatocellular;g:ETFA)		GO:0033539:GO:0005515:GO:0005759:GO:0016491:GO:0050660:GO:0009055:GO:0005739:GO:0022904	608053	PF00766:PF01012	-0.53															M
chr15:80152950	SNV	G	1	G/C	PASS	1.3816562311673273e-52	518.596		164	G=68,C=96	G=0.4146,C=0.5854	58.54	41.46	heterozygous	40	0.186	5.0		FAH	NM_000137.4	FAH:upstream:NM_000137.4	unknown			p.?	c.-105G>C				C				Benign		rs112474268		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-2.77															M
chr15:80153170	INDEL	A	1	A/AG	PASS	6.311026445054071e-17	161.999		218	A=114,AG=104	A=0.5229,AG=0.4771	47.71	52.29	heterozygous	19	0.352	3.0		FAH	NM_000137.4	FAH:intronic:NM_000137.4	unknown			p.?	c.81+35_81+36insG				AG	GMAF=0.2324:AMAF=0.4252:EMAF=0.1328			Benign		rs1595888567:rs1465203494:rs1567112918:rs60184934:rs534453827:rs757176902		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-0.07															M
chr15:80153209	INDEL	AGTGGA	5	AGTGGA/A	PASS	2.4104603938084325e-19	186.179		157	AGTGGA=102,A=55	AGTGGA=0.6497,A=0.3503	35.03	64.97	heterozygous	26	0.0	1.0		FAH	NM_000137.4	FAH:intronic:NM_000137.4	unknown			p.?	c.81+75_81+79delGTGGA				A						rs1567112946:rs534184772:rs1361931262:rs1316986199:rs867498731:rs1341663234		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.35,0.39,0.16,0.21,0.17,-0.94															M
chr15:80159733	SNV	T	1	C/C	PASS	6.426877173170089e-112	1111.92		130	T=7,C=123	T=0.0538,C=0.9462	94.62	5.379999999999996	homozygous	48	0.367	6.0		FAH	NM_000137.4	FAH:intronic:NM_000137.4	unknown			p.?	c.193-23T>C				C	GMAF=0.3974:AMAF=0.3865:EMAF=0.4029			Benign		rs1370274		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	0.14															M
chr15:80159830	SNV	G	1	G/C	PASS	9.84691071376934e-45	440.067		162	G=74,C=88	G=0.4568,C=0.5432	54.32	45.68	heterozygous	25	0.06	1.0		FAH	NM_000137.4	FAH:exonic:NM_000137.4	synonymous	CTC	3	p.Leu89=	c.267G>C				C	GMAF=0.0822:AMAF=0.0774:EMAF=0.0847	0.74		Benign	3999621	rs33929922		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	1.56															M
chr15:80159926	SNV	G	1	A/A	PASS	5.223961889991411e-171	1702.82		173	G=0,A=173	G=0.0,A=1.0	100.0	0.0	homozygous	55	0.36	2.0		FAH	NM_000137.4	FAH:intronic:NM_000137.4	unknown			p.?	c.314+49G>A				A	GMAF=0.3919:AMAF=0.3684:EMAF=0.404			Benign		rs1370273:rs1404883356		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-0.57															M
chr15:80168182	SNV	A	1	G/G	PASS	0.0	3983.57		398	A=0,G=398	A=0.0,G=1.0	100.0	0.0	homozygous	55	0.221	1.0		FAH	NM_000137.4	FAH:intronic:NM_000137.4	unknown			p.?	c.553+33A>G				G	GMAF=0.273:AMAF=0.2453:EMAF=0.2871			Benign		rs1545119		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	0.21															M
chr15:80172327	SNV	A	1	A/G	PASS	2.565074598777443e-94	935.909		399	A=196,G=203	A=0.4912,G=0.5088	50.88	49.12	heterozygous	26	0.236	1.0		FAH	NM_000137.4	FAH:intronic:NM_000137.4	unknown			p.?	c.706+79A>G				G						rs7180031		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-0.7															M
chr15:80186247	MNV	ACCCC	5	ACCCC/CTTTG	PASS	7.903145908644514e-73	721.022		387	ACCCC=210,CTTTG=177	ACCCC=0.5426,CTTTG=0.4574	45.74	54.26	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															M
chr15:80186257	INDEL	AC	1	AC/A	PASS	1.2316859857363514e-33	329.095		398	AC=210,A=188	AC=0.5276,A=0.4724	47.24	52.76	heterozygous	25	0.112	3.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*48AC>A				A	GMAF=0.1042:AMAF=0.0643:EMAF=0.1249			Likely benign		rs200464452:rs755736456:rs749985438		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.97,0.39															M
chr15:80186303	SNV	T	1	T/C	PASS	8.048222975884944e-82	810.943		400	T=210,C=190	T=0.525,C=0.475	47.5	52.5	heterozygous	25	0.113	2.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*94T>C				C				Benign		rs1049194		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-0.25															M
chr16:71570009	SNV	C	1	C/A	PASS	3.148473193387334e-68	675.019		290	C=143,A=147	C=0.4931,A=0.5069	50.69	49.31	heterozygous	40	0.433	5.0		TAT|TAT-AS1	NM_000353.3|NR_103851.1	TAT:intronic:NM_000353.3|TAT-AS1:intronic_nc:NR_103851.1	unknown|	|	|	p.?|	c.1042-72G>T|	|	|	|	A|						rs172650:rs1413052063		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TAT)(dui:NBS3;dis:Secondary Conditions;g:TAT)(dui:NBS6;dis:Amino Acid Disorder;g:TAT)(dui:NBS37;dis:Tyrosinemia type II;g:TAT)(dui:NBS38;dis:Tyrosinemia type III;g:TAT)(dui:D009422;dis:Nervous System Diseases;g:TAT)(dui:D002493;dis:Central Nervous System Diseases;g:TAT)(dui:D001927;dis:Brain Diseases;g:TAT)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:TAT)(dui:D008659;dis:Metabolic Diseases;g:TAT)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TAT)(dui:D030342;dis:Genetic Diseases, Inborn;g:TAT)(dui:D008661;dis:Metabolism, Inborn Errors;g:TAT)(dui:D001928;dis:Brain Diseases, Metabolic;g:TAT)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:TAT)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:TAT)(dui:D020176;dis:Tyrosinemias;g:TAT)	Pyridoxal phosphate:Tyrosine:Glutamic acid:Phenylalanine	GO:0030170:GO:0042802:GO:0046689:GO:0006572:GO:0009058:GO:0005575:GO:0006103:GO:0006979:GO:0006536:GO:0005515:GO:0006559:GO:0004838:GO:0005739:GO:0051384:GO:0005829:GO:0016597	613018	PF07706:PF00155:PF00266	0.63															M
chr16:71573481	SNV	T	1	T/G	PASS	3.3511973196770638e-90	894.748		400	T=201,G=199	T=0.5025,G=0.4975	49.75	50.25	heterozygous	40	0.414	1.0		TAT	NM_000353.3	TAT:intronic:NM_000353.3	unknown			p.?	c.408+58A>C				G	GMAF=0.3121:AMAF=0.229:EMAF=0.3482					rs2432520		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TAT)(dui:NBS3;dis:Secondary Conditions;g:TAT)(dui:NBS6;dis:Amino Acid Disorder;g:TAT)(dui:NBS37;dis:Tyrosinemia type II;g:TAT)(dui:NBS38;dis:Tyrosinemia type III;g:TAT)(dui:D009422;dis:Nervous System Diseases;g:TAT)(dui:D002493;dis:Central Nervous System Diseases;g:TAT)(dui:D001927;dis:Brain Diseases;g:TAT)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:TAT)(dui:D008659;dis:Metabolic Diseases;g:TAT)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TAT)(dui:D030342;dis:Genetic Diseases, Inborn;g:TAT)(dui:D008661;dis:Metabolism, Inborn Errors;g:TAT)(dui:D001928;dis:Brain Diseases, Metabolic;g:TAT)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:TAT)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:TAT)(dui:D020176;dis:Tyrosinemias;g:TAT)	Pyridoxal phosphate:Tyrosine:Glutamic acid:Phenylalanine	GO:0030170:GO:0042802:GO:0046689:GO:0006572:GO:0009058:GO:0005575:GO:0006103:GO:0006979:GO:0006536:GO:0005515:GO:0006559:GO:0004838:GO:0005739:GO:0051384:GO:0005829:GO:0016597	613018	PF07706:PF00155:PF00266	0.9															M
chr17:7221421	INDEL	ACTGCCCTAGGTCAGGAA	17	ACTGCCCTAGGTCAGGAA/A	PASS	8.466423722659152e-65	640.723		345	ACTGCCCTAGGTCAGGAA=188,A=157	ACTGCCCTAGGTCAGGAA=0.5449,A=0.4551	45.51	54.49	heterozygous	40	0.002	1.0		ACADVL	NM_000018.4	ACADVL:intronic:NM_000018.4	unknown			p.?	c.478-116_478-100delCTGCCCTAGGTCAGGAA				A						rs750835287:rs1567562754:rs80162838:rs78100429:rs535609436:rs35999860:rs147519793:rs1416225920:rs1184230081:rs1322109465:rs386795011:rs374828700:rs907034423:rs7503586:rs370388543:rs201760717:rs1031535036		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADVL)(dui:NBS2;dis:Core Conditions;g:ACADVL)(dui:NBS10;dis:Fatty Acid Oxidation Disorder;g:ACADVL)(dui:NBS52;dis:Very long-chain acyl-CoA dehydrogenase deficiency;g:ACADVL)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADVL)(dui:D008659;dis:Metabolic Diseases;g:ACADVL)(dui:D009422;dis:Nervous System Diseases;g:ACADVL)(dui:D009140;dis:Musculoskeletal Diseases;g:ACADVL)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADVL)(dui:D009135;dis:Muscular Diseases;g:ACADVL)(dui:D009468;dis:Neuromuscular Diseases;g:ACADVL)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADVL)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADVL)(dui:D028361;dis:Mitochondrial Diseases;g:ACADVL)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADVL)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADVL)		GO:0036498:GO:0005730:GO:0004466:GO:0005654:GO:0009409:GO:0006635:GO:0033539:GO:0000062:GO:0046322:GO:0005829:GO:0031314:GO:0045717:GO:0042802:GO:0015980:GO:0042645:GO:0090181:GO:0003995:GO:0030855:GO:0005515:GO:0031966:GO:0005759:GO:0050660:GO:0001659:GO:0005739:GO:0017099	609575	PF02771:PF02770:PF00441:PF08028	-0.78,0.12,0.1,-0.17,-0.72,-1.03,-0.35,-0.01,-1.94,-0.18,1.36,-1.92,-0.66,0.83,-0.02,0.03,-0.03,-0.45															M
chr17:7224399	SNV	T	1	T/C	PASS	5.843862649556606e-87	862.333		398	T=203,C=195	T=0.5101,C=0.4899	49.0	51.0	heterozygous	48	0.48	1.0		ACADVL|DVL2	NM_000018.4|NM_004422.3	ACADVL:intronic:NM_000018.4|DVL2:downstream:NM_004422.3	unknown|unknown	|	|	p.?|p.?	c.1605+6T>C|c.*1466A>G	|	|	|	C|C	GMAF=0.4383:AMAF=0.4362:EMAF=0.3739	0.07		Benign	7228542	rs17671352:rs1064795676		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADVL)(dui:NBS2;dis:Core Conditions;g:ACADVL)(dui:NBS10;dis:Fatty Acid Oxidation Disorder;g:ACADVL)(dui:NBS52;dis:Very long-chain acyl-CoA dehydrogenase deficiency;g:ACADVL)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADVL)(dui:D008659;dis:Metabolic Diseases;g:ACADVL)(dui:D009422;dis:Nervous System Diseases;g:ACADVL)(dui:D009140;dis:Musculoskeletal Diseases;g:ACADVL)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADVL)(dui:D009135;dis:Muscular Diseases;g:ACADVL)(dui:D009468;dis:Neuromuscular Diseases;g:ACADVL)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADVL)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADVL)(dui:D028361;dis:Mitochondrial Diseases;g:ACADVL)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADVL)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADVL)		GO:0036498:GO:0016328:GO:0043507:GO:0016604:GO:0090179:GO:0061098:GO:0022007:GO:0051091:GO:0043621:GO:0007379:GO:0043547:GO:0004466:GO:0006635:GO:0033539:GO:0005109:GO:0045177:GO:0000062:GO:0048365:GO:0005829:GO:0031314:GO:0019901:GO:0019904:GO:0090103:GO:0150012:GO:0045334:GO:0090181:GO:0030855:GO:0005634:GO:0005515:GO:0005759:GO:0017099:GO:0034613:GO:0003151:GO:0005730:GO:0045944:GO:0005654:GO:0009409:GO:0007507:GO:0001843:GO:0044340:GO:0046322:GO:0031410:GO:0060070:GO:0060071:GO:0016235:GO:0045717:GO:0061024:GO:0042802:GO:0015980:GO:0006355:GO:1904886:GO:0042645:GO:0003995:GO:0090090:GO:0031966:GO:0050660:GO:0005737:GO:0001659:GO:0005739:GO:0001934:GO:0035329:GO:0030674:GO:0035567	609575:602151	PF02771:PF02770:PF00441:PF08028	-0.25															M
chr19:41397766	SNV	A	1	G/G	PASS	0.0	3966.36		400	A=1,G=399	A=0.0025,G=0.9975	99.75	0.25	homozygous	55	0.418	3.0		EXOSC5|BCKDHA	NM_020158.4|NM_001164783.2	EXOSC5:upstream:NM_020158.4|BCKDHA:upstream:NM_001164783.2	unknown|unknown	|	|	p.?|p.?	c.-438T>C|c.-62A>G	|	|	|	G|G						rs892044		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHA)(dui:NBS2;dis:Core Conditions;g:BCKDHA)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHA)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHA)(dui:D008659;dis:Metabolic Diseases;g:BCKDHA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHA)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHA)(dui:D009422;dis:Nervous System Diseases;g:BCKDHA)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHA)(dui:D001927;dis:Brain Diseases;g:BCKDHA)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHA)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHA)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHA)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHA)(dui:D009369;dis:Neoplasms;g:EXOSC5)(dui:D009371;dis:Neoplasms by Site;g:EXOSC5)(dui:D004066;dis:Digestive System Diseases;g:EXOSC5)(dui:D004067;dis:Digestive System Neoplasms;g:EXOSC5)(dui:D005767;dis:Gastrointestinal Diseases;g:EXOSC5)(dui:D005770;dis:Gastrointestinal Neoplasms;g:EXOSC5)(dui:D013272;dis:Stomach Diseases;g:EXOSC5)(dui:D013274;dis:Stomach Neoplasms;g:EXOSC5)		GO:0034475:GO:0043928:GO:0045006:GO:0043488:GO:0006364:GO:0005730:GO:0000178:GO:0005654:GO:0003863:GO:0071051:GO:0003723:GO:0005947:GO:0003826:GO:0016075:GO:0005829:GO:0051607:GO:0034427:GO:0016831:GO:0090503:GO:0009083:GO:0004532:GO:0000177:GO:0000176:GO:0000175:GO:0005515:GO:0005759:GO:0046872:GO:0005737:GO:0005739:GO:0035327:GO:0071028:GO:0055114	606492:608348		0.08															M
chr19:41414039	SNV	A	1	C/C	PASS	0.0	3990.19		399	A=0,C=399	A=0.0,C=1.0	100.0	0.0	homozygous	55	0.384	1.0		BCKDHA	NM_001164783.2	BCKDHA:intronic:NM_001164783.2	unknown			p.?	c.376-10A>C				C	GMAF=0.3239:AMAF=0.1902:EMAF=0.3924	0.01		Benign	4000746	rs3213861		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHA)(dui:NBS2;dis:Core Conditions;g:BCKDHA)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHA)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHA)(dui:D008659;dis:Metabolic Diseases;g:BCKDHA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHA)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHA)(dui:D009422;dis:Nervous System Diseases;g:BCKDHA)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHA)(dui:D001927;dis:Brain Diseases;g:BCKDHA)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHA)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHA)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHA)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHA)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0046872:GO:0003826:GO:0005739:GO:0055114:GO:0016831	608348	PF00676	-0.51															M
chr19:41422431	SNV	T	1	C/C	PASS	0.0	3982.4		400	T=0,C=400	T=0.0,C=1.0	100.0	0.0	homozygous	55	0.382	1.0		BCKDHA	NM_001164783.2	BCKDHA:intronic:NM_001164783.2	unknown			p.?	c.853+61T>C				C						rs284651		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHA)(dui:NBS2;dis:Core Conditions;g:BCKDHA)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHA)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHA)(dui:D008659;dis:Metabolic Diseases;g:BCKDHA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHA)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHA)(dui:D009422;dis:Nervous System Diseases;g:BCKDHA)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHA)(dui:D001927;dis:Brain Diseases;g:BCKDHA)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHA)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHA)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHA)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHA)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0046872:GO:0003826:GO:0005739:GO:0055114:GO:0016831	608348	PF00676	-2.12															M
chr19:41422747	SNV	C	1	T/T	PASS	0.0	3923.24		400	C=2,T=398	C=0.005,T=0.995	99.5	0.5	homozygous	55	0.384	2.0		BCKDHA	NM_001164783.2	BCKDHA:exonic:NM_001164783.2	synonymous	TTT	7	p.Phe323=	c.969C>T				T	GMAF=0.3239:AMAF=0.1902:EMAF=0.3924	0.92		Benign	3933055	rs284652:rs112312448		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHA)(dui:NBS2;dis:Core Conditions;g:BCKDHA)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHA)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHA)(dui:D008659;dis:Metabolic Diseases;g:BCKDHA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHA)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHA)(dui:D009422;dis:Nervous System Diseases;g:BCKDHA)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHA)(dui:D001927;dis:Brain Diseases;g:BCKDHA)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHA)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHA)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHA)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHA)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0046872:GO:0003826:GO:0005739:GO:0055114:GO:0016831	608348	PF00676	2.87															M
chr19:41422796	SNV	C	1	T/T	PASS	0.0	3588.42		394	C=12,T=382	C=0.0305,T=0.9695	96.95	3.049999999999997	homozygous	33	0.257	5.0		BCKDHA	NM_001164783.2	BCKDHA:intronic:NM_001164783.2	unknown			p.?	c.992+26C>T				T	GMAF=0.3824:AMAF=0.264:EMAF=0.4431			Benign/Likely benign		rs284653		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHA)(dui:NBS2;dis:Core Conditions;g:BCKDHA)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHA)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHA)(dui:D008659;dis:Metabolic Diseases;g:BCKDHA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHA)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHA)(dui:D009422;dis:Nervous System Diseases;g:BCKDHA)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHA)(dui:D001927;dis:Brain Diseases;g:BCKDHA)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHA)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHA)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHA)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHA)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0046872:GO:0003826:GO:0005739:GO:0055114:GO:0016831	608348	PF00676	-0.25															M
chr19:41422819	SNV	G	1	A/A	PASS	0.0	3967.04		400	G=1,A=399	G=0.0025,A=0.9975	99.75	0.25	homozygous	55	0.414	1.0		BCKDHA	NM_001164783.2	BCKDHA:intronic:NM_001164783.2	unknown			p.?	c.992+49G>A				A	GMAF=0.3565:AMAF=0.2855:EMAF=0.3929			Benign/Likely benign		rs284654		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHA)(dui:NBS2;dis:Core Conditions;g:BCKDHA)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHA)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHA)(dui:D008659;dis:Metabolic Diseases;g:BCKDHA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHA)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHA)(dui:D009422;dis:Nervous System Diseases;g:BCKDHA)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHA)(dui:D001927;dis:Brain Diseases;g:BCKDHA)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHA)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHA)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHA)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHA)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0046872:GO:0003826:GO:0005739:GO:0055114:GO:0016831	608348	PF00676	-1.91															M
chr19:41422860	SNV	C	1	T/T	PASS	0.0	3936.49		400	C=2,T=398	C=0.005,T=0.995	99.5	0.5	homozygous	55	0.386	2.0		BCKDHA	NM_001164783.2	BCKDHA:intronic:NM_001164783.2	unknown			p.?	c.992+90C>T				T						rs284655		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHA)(dui:NBS2;dis:Core Conditions;g:BCKDHA)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHA)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHA)(dui:D008659;dis:Metabolic Diseases;g:BCKDHA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHA)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHA)(dui:D009422;dis:Nervous System Diseases;g:BCKDHA)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHA)(dui:D001927;dis:Brain Diseases;g:BCKDHA)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHA)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHA)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHA)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHA)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0046872:GO:0003826:GO:0005739:GO:0055114:GO:0016831	608348	PF00676	0.58															M
chr19:41424491	SNV	A	1	G/G	PASS	0.0	3993.27		399	A=0,G=399	A=0.0,G=1.0	100.0	0.0	homozygous	55	0.383	1.0		BCKDHA|B3GNT8	NM_001164783.2|NM_198540.2	BCKDHA:exonic:NM_001164783.2|B3GNT8:downstream:NM_198540.2	synonymous|unknown	CTG|	9|	p.Leu406=|p.?	c.1218A>G|c.*1094T>C	|	|	|	G|G	GMAF=0.323:AMAF=0.1895:EMAF=0.3914	0.15		Benign	7239888	rs4674		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHA)(dui:NBS2;dis:Core Conditions;g:BCKDHA)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHA)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHA)(dui:D008659;dis:Metabolic Diseases;g:BCKDHA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHA)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHA)(dui:D009422;dis:Nervous System Diseases;g:BCKDHA)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHA)(dui:D001927;dis:Brain Diseases;g:BCKDHA)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHA)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHA)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHA)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHA)		GO:0009083:GO:0016758:GO:0008375:GO:0006486:GO:0008532:GO:0000139:GO:0005794:GO:0008376:GO:0003863:GO:0005515:GO:0070062:GO:0005947:GO:0005759:GO:0046872:GO:0003826:GO:0005739:GO:0016262:GO:0016021:GO:0055114:GO:0016266:GO:0030311:GO:0016831	615357:608348	PF00676	0.76															M
chr19:51347173	SNV	G	1	G/A	PASS	3.8663396210936e-91	904.127		398	G=198,A=200	G=0.4975,A=0.5025	50.25	49.75	heterozygous	11	0.022	1.0		ETFB	NM_001985.3	ETFB:intronic:NM_001985.3	unknown			p.?	c.439-115C>T				A						rs74903528		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ETFB)(dui:NBS3;dis:Secondary Conditions;g:ETFB)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ETFB)(dui:NBS24;dis:Glutaric acidemia type II;g:ETFB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ETFB)(dui:D008659;dis:Metabolic Diseases;g:ETFB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ETFB)(dui:D030342;dis:Genetic Diseases, Inborn;g:ETFB)(dui:D008661;dis:Metabolism, Inborn Errors;g:ETFB)(dui:D028361;dis:Mitochondrial Diseases;g:ETFB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ETFB)(dui:D054069;dis:Multiple Acyl Coenzyme A Dehydrogenase Deficiency;g:ETFB)		GO:0033539:GO:0005515:GO:0005759:GO:0009055:GO:0005739:GO:0022904	130410	PF01012	-1.02															M
chr19:51366092	SNV	G	1	G/A	PASS	3.74714069514405e-97	964.263		399	G=193,A=206	G=0.4837,A=0.5163	51.63	48.37	heterozygous	11	0.366	2.0		ETFB	NM_001985.3	ETFB:intronic:NM_001985.3	unknown			p.?	c.57+178C>T				A						rs3786625		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ETFB)(dui:NBS3;dis:Secondary Conditions;g:ETFB)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ETFB)(dui:NBS24;dis:Glutaric acidemia type II;g:ETFB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ETFB)(dui:D008659;dis:Metabolic Diseases;g:ETFB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ETFB)(dui:D030342;dis:Genetic Diseases, Inborn;g:ETFB)(dui:D008661;dis:Metabolism, Inborn Errors;g:ETFB)(dui:D028361;dis:Mitochondrial Diseases;g:ETFB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ETFB)(dui:D054069;dis:Multiple Acyl Coenzyme A Dehydrogenase Deficiency;g:ETFB)		GO:0033539:GO:0005515:GO:0005759:GO:0009055:GO:0005739:GO:0022904	130410	PF01012	0.73															M
chrX:30308866	SNV	C	1	C/T	PASS	2.581665671701643e-89	885.881		370	C=180,T=190	C=0.4865,T=0.5135	51.35	48.65	heterozygous	32	0.477	2.0		NR0B1	NM_000475.5	NR0B1:exonic:NM_000475.5	synonymous	CGA	1	p.Arg166=	c.498G>A				T	GMAF=0.2828:AMAF=0.4339:EMAF=0.1968	0.08		Benign	3759465	rs2269345		(dui:D004700;dis:Endocrine System Diseases;g:NR0B1)(dui:D006058;dis:Gonadal Disorders;g:NR0B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:NR0B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:NR0B1)(dui:D052776;dis:Female Urogenital Diseases;g:NR0B1)(dui:D052801;dis:Male Urogenital Diseases;g:NR0B1)(dui:D000013;dis:Congenital Abnormalities;g:NR0B1)(dui:D014564;dis:Urogenital Abnormalities;g:NR0B1)(dui:D012734;dis:Disorders of Sex Development;g:NR0B1)(dui:D006059;dis:Gonadal Dysgenesis;g:NR0B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:NR0B1)(dui:D000307;dis:Adrenal Gland Diseases;g:NR0B1)(dui:D007006;dis:Hypogonadism;g:NR0B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:NR0B1)(dui:D008659;dis:Metabolic Diseases;g:NR0B1)(dui:D000309;dis:Adrenal Insufficiency;g:NR0B1)(dui:D058490;dis:46, XY Disorders of Sex Development;g:NR0B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:NR0B1)(dui:D040181;dis:Genetic Diseases, X-Linked;g:NR0B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:NR0B1)(dui:D011629;dis:Puberty, Precocious;g:NR0B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:NR0B1)(dui:D047808;dis:Adrenogenital Syndrome;g:NR0B1)(dui:D006061;dis:Gonadal Dysgenesis, 46,XY;g:NR0B1)	Dexamethasone:Dexamethasone acetate	GO:0008584:GO:0033144:GO:0016607:GO:0034451:GO:0008104:GO:0060008:GO:0021854:GO:0006367:GO:0005654:GO:0000122:GO:0003723:GO:0045892:GO:0043231:GO:0032448:GO:0035258:GO:0030325:GO:0010894:GO:0019904:GO:0042803:GO:0007283:GO:0043433:GO:0008134:GO:0021983:GO:0042788:GO:0005634:GO:0030238:GO:0005515:GO:0000790:GO:0008406:GO:0005737:GO:0050682:GO:0003714:GO:0016020:GO:0035902:GO:0033327	300473	PF14046:PF00104	0.48															M
chrX:30309117	SNV	T	1	T/A	PASS	9.468474197117176e-05	40.2372		28	T=17,A=11	T=0.6071,A=0.3929	39.29	60.71	heterozygous	11		1.0		NR0B1	NM_000475.5	NR0B1:exonic:NM_000475.5	missense	TTG	1	p.Met83Leu	c.247A>T	0.12	0.005	15.0	A						rs1425603148		(dui:D004700;dis:Endocrine System Diseases;g:NR0B1)(dui:D006058;dis:Gonadal Disorders;g:NR0B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:NR0B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:NR0B1)(dui:D052776;dis:Female Urogenital Diseases;g:NR0B1)(dui:D052801;dis:Male Urogenital Diseases;g:NR0B1)(dui:D000013;dis:Congenital Abnormalities;g:NR0B1)(dui:D014564;dis:Urogenital Abnormalities;g:NR0B1)(dui:D012734;dis:Disorders of Sex Development;g:NR0B1)(dui:D006059;dis:Gonadal Dysgenesis;g:NR0B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:NR0B1)(dui:D000307;dis:Adrenal Gland Diseases;g:NR0B1)(dui:D007006;dis:Hypogonadism;g:NR0B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:NR0B1)(dui:D008659;dis:Metabolic Diseases;g:NR0B1)(dui:D000309;dis:Adrenal Insufficiency;g:NR0B1)(dui:D058490;dis:46, XY Disorders of Sex Development;g:NR0B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:NR0B1)(dui:D040181;dis:Genetic Diseases, X-Linked;g:NR0B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:NR0B1)(dui:D011629;dis:Puberty, Precocious;g:NR0B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:NR0B1)(dui:D047808;dis:Adrenogenital Syndrome;g:NR0B1)(dui:D006061;dis:Gonadal Dysgenesis, 46,XY;g:NR0B1)	Dexamethasone:Dexamethasone acetate	GO:0008584:GO:0033144:GO:0016607:GO:0034451:GO:0008104:GO:0060008:GO:0021854:GO:0006367:GO:0005654:GO:0000122:GO:0003723:GO:0045892:GO:0043231:GO:0032448:GO:0035258:GO:0030325:GO:0010894:GO:0019904:GO:0042803:GO:0007283:GO:0043433:GO:0008134:GO:0021983:GO:0042788:GO:0005634:GO:0030238:GO:0005515:GO:0000790:GO:0008406:GO:0005737:GO:0050682:GO:0003714:GO:0016020:GO:0035902:GO:0033327	300473	PF14046:PF00104	0.93															M
chrX:154532293	SNV	G	1	G/A	PASS	1.2638630002312563e-40	398.983		246	G=141,A=105	G=0.5732,A=0.4268	42.68	57.32	hemizygous	45		2.0		G6PD	NM_001042351.3	G6PD:intronic:NM_001042351.3	unknown			p.?	c.1365-13C>T				A	GMAF=0.3923:AMAF=0.1523:EMAF=0.1327					rs2071429		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:G6PD)(dui:NBS3;dis:Secondary Conditions;g:G6PD)(dui:NBS39;dis:Hb carrier other than C,D,E,S,O-Arab;g:G6PD)(dui:NBS7;dis:Hemoglobin Disorder;g:G6PD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:G6PD)(dui:D030342;dis:Genetic Diseases, Inborn;g:G6PD)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:G6PD)(dui:D006402;dis:Hematologic Diseases;g:G6PD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:G6PD)(dui:D000740;dis:Anemia;g:G6PD)(dui:D008659;dis:Metabolic Diseases;g:G6PD)(dui:D000743;dis:Anemia, Hemolytic;g:G6PD)(dui:D000745;dis:Anemia, Hemolytic, Congenital;g:G6PD)(dui:D008661;dis:Metabolism, Inborn Errors;g:G6PD)(dui:D005955;dis:Glucosephosphate Dehydrogenase Deficiency;g:G6PD)(dui:D040181;dis:Genetic Diseases, X-Linked;g:G6PD)(dui:D002239;dis:Carbohydrate Metabolism, Inborn Errors;g:G6PD)(dui:D052801;dis:Male Urogenital Diseases;g:G6PD)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:G6PD)(dui:D014570;dis:Urologic Diseases;g:G6PD)(dui:D052776;dis:Female Urogenital Diseases;g:G6PD)(dui:D007674;dis:Kidney Diseases;g:G6PD)(dui:D004066;dis:Digestive System Diseases;g:G6PD)(dui:D002318;dis:Cardiovascular Diseases;g:G6PD)(dui:D014652;dis:Vascular Diseases;g:G6PD)(dui:D008107;dis:Liver Diseases;g:G6PD)(dui:D007154;dis:Immune System Diseases;g:G6PD)(dui:D007153;dis:Immunologic Deficiency Syndromes;g:G6PD)(dui:D007960;dis:Leukocyte Disorders;g:G6PD)(dui:D010585;dis:Phagocyte Bactericidal Dysfunction;g:G6PD)(dui:D009422;dis:Nervous System Diseases;g:G6PD)(dui:D002493;dis:Central Nervous System Diseases;g:G6PD)(dui:D001927;dis:Brain Diseases;g:G6PD)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:G6PD)(dui:D012871;dis:Skin Diseases;g:G6PD)(dui:D004700;dis:Endocrine System Diseases;g:G6PD)(dui:D044882;dis:Glucose Metabolism Disorders;g:G6PD)(dui:D005236;dis:Favism;g:G6PD)(dui:D000746;dis:Anemia, Hemolytic, Congenital Nonspherocytic;g:G6PD)(dui:D003920;dis:Diabetes Mellitus;g:G6PD)(dui:D002561;dis:Cerebrovascular Disorders;g:G6PD)(dui:D001928;dis:Brain Diseases, Metabolic;g:G6PD)(dui:D009748;dis:Nutrition Disorders;g:G6PD)(dui:D006105;dis:Granulomatous Disease, Chronic;g:G6PD)(dui:D052439;dis:Lipid Metabolism Disorders;g:G6PD)(dui:D002545;dis:Brain Ischemia;g:G6PD)(dui:D003872;dis:Dermatitis;g:G6PD)(dui:D017443;dis:Skin Diseases, Eczematous;g:G6PD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:G6PD)(dui:D003877;dis:Dermatitis, Contact;g:G6PD)(dui:D006946;dis:Hyperinsulinism;g:G6PD)(dui:D050171;dis:Dyslipidemias;g:G6PD)(dui:D051437;dis:Renal Insufficiency;g:G6PD)(dui:D006949;dis:Hyperlipidemias;g:G6PD)(dui:D007333;dis:Insulin Resistance;g:G6PD)(dui:D058186;dis:Acute Kidney Injury;g:G6PD)	Nicotinamide adenine dinucleotide phosphate:Glycolic acid:16-Bromoepiandrosterone:Artenimol	GO:0032094:GO:0010041:GO:0009051:GO:0061052:GO:0034451:GO:0006740:GO:0006006:GO:0043523:GO:0004345:GO:0009898:GO:0043249:GO:1904879:GO:0045471:GO:0070062:GO:0043231:GO:0006739:GO:0019322:GO:0005829:GO:0010734:GO:2000378:GO:0042802:GO:0042803:GO:0006098:GO:0006695:GO:0014070:GO:0021762:GO:0005536:GO:0005634:GO:0050661:GO:0051156:GO:0005515:GO:0005737:GO:0006749:GO:0006629:GO:0016020:GO:0034599:GO:0055114:GO:0046390	305900	PF00479:PF02781	-0.82															M
chrX:154532439	SNV	A	1	G/G	PASS	0.0	4003.33		400	A=0,G=400	A=0.0,G=1.0	100.0	0.0	hemizygous	46		1.0		G6PD	NM_001042351.3	G6PD:exonic:NM_001042351.3	synonymous	TAC	11	p.Tyr437=	c.1311T>C				G	GMAF=0.1667:AMAF=0.2605:EMAF=0.1133			Benign		rs2230037		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:G6PD)(dui:NBS3;dis:Secondary Conditions;g:G6PD)(dui:NBS39;dis:Hb carrier other than C,D,E,S,O-Arab;g:G6PD)(dui:NBS7;dis:Hemoglobin Disorder;g:G6PD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:G6PD)(dui:D030342;dis:Genetic Diseases, Inborn;g:G6PD)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:G6PD)(dui:D006402;dis:Hematologic Diseases;g:G6PD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:G6PD)(dui:D000740;dis:Anemia;g:G6PD)(dui:D008659;dis:Metabolic Diseases;g:G6PD)(dui:D000743;dis:Anemia, Hemolytic;g:G6PD)(dui:D000745;dis:Anemia, Hemolytic, Congenital;g:G6PD)(dui:D008661;dis:Metabolism, Inborn Errors;g:G6PD)(dui:D005955;dis:Glucosephosphate Dehydrogenase Deficiency;g:G6PD)(dui:D040181;dis:Genetic Diseases, X-Linked;g:G6PD)(dui:D002239;dis:Carbohydrate Metabolism, Inborn Errors;g:G6PD)(dui:D052801;dis:Male Urogenital Diseases;g:G6PD)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:G6PD)(dui:D014570;dis:Urologic Diseases;g:G6PD)(dui:D052776;dis:Female Urogenital Diseases;g:G6PD)(dui:D007674;dis:Kidney Diseases;g:G6PD)(dui:D004066;dis:Digestive System Diseases;g:G6PD)(dui:D002318;dis:Cardiovascular Diseases;g:G6PD)(dui:D014652;dis:Vascular Diseases;g:G6PD)(dui:D008107;dis:Liver Diseases;g:G6PD)(dui:D007154;dis:Immune System Diseases;g:G6PD)(dui:D007153;dis:Immunologic Deficiency Syndromes;g:G6PD)(dui:D007960;dis:Leukocyte Disorders;g:G6PD)(dui:D010585;dis:Phagocyte Bactericidal Dysfunction;g:G6PD)(dui:D009422;dis:Nervous System Diseases;g:G6PD)(dui:D002493;dis:Central Nervous System Diseases;g:G6PD)(dui:D001927;dis:Brain Diseases;g:G6PD)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:G6PD)(dui:D012871;dis:Skin Diseases;g:G6PD)(dui:D004700;dis:Endocrine System Diseases;g:G6PD)(dui:D044882;dis:Glucose Metabolism Disorders;g:G6PD)(dui:D005236;dis:Favism;g:G6PD)(dui:D000746;dis:Anemia, Hemolytic, Congenital Nonspherocytic;g:G6PD)(dui:D003920;dis:Diabetes Mellitus;g:G6PD)(dui:D002561;dis:Cerebrovascular Disorders;g:G6PD)(dui:D001928;dis:Brain Diseases, Metabolic;g:G6PD)(dui:D009748;dis:Nutrition Disorders;g:G6PD)(dui:D006105;dis:Granulomatous Disease, Chronic;g:G6PD)(dui:D052439;dis:Lipid Metabolism Disorders;g:G6PD)(dui:D002545;dis:Brain Ischemia;g:G6PD)(dui:D003872;dis:Dermatitis;g:G6PD)(dui:D017443;dis:Skin Diseases, Eczematous;g:G6PD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:G6PD)(dui:D003877;dis:Dermatitis, Contact;g:G6PD)(dui:D006946;dis:Hyperinsulinism;g:G6PD)(dui:D050171;dis:Dyslipidemias;g:G6PD)(dui:D051437;dis:Renal Insufficiency;g:G6PD)(dui:D006949;dis:Hyperlipidemias;g:G6PD)(dui:D007333;dis:Insulin Resistance;g:G6PD)(dui:D058186;dis:Acute Kidney Injury;g:G6PD)	Nicotinamide adenine dinucleotide phosphate:Glycolic acid:16-Bromoepiandrosterone:Artenimol	GO:0032094:GO:0010041:GO:0009051:GO:0061052:GO:0034451:GO:0006740:GO:0006006:GO:0043523:GO:0004345:GO:0009898:GO:0043249:GO:1904879:GO:0045471:GO:0070062:GO:0043231:GO:0006739:GO:0019322:GO:0005829:GO:0010734:GO:2000378:GO:0042802:GO:0042803:GO:0006098:GO:0006695:GO:0014070:GO:0021762:GO:0005536:GO:0005634:GO:0050661:GO:0051156:GO:0005515:GO:0005737:GO:0006749:GO:0006629:GO:0016020:GO:0034599:GO:0055114:GO:0046390	305900	PF00479:PF02781	-2.64															M
chr1:11790946	SNV	G	1	C/C	PASS	2.4210290467364e-311	3106.16		400	G=38,C=362	G=0.095,C=0.905	90.5	9.5	homozygous	47	0.246	1.0		MTHFR	NM_005957.5	MTHFR:intronic:NM_005957.5	unknown			p.?	c.1753-48C>G				C	GMAF=0.2298:AMAF=0.1543:EMAF=0.2685					rs576853093:rs1332110504:rs3818762:rs1491370932		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MTHFR)(dui:NBS2;dis:Core Conditions;g:MTHFR)(dui:NBS11;dis:Amino Acid Disorder;g:MTHFR)(dui:NBS57;dis:Homocystinuria;g:MTHFR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MTHFR)(dui:D002318;dis:Cardiovascular Diseases;g:MTHFR)(dui:D009422;dis:Nervous System Diseases;g:MTHFR)(dui:D014652;dis:Vascular Diseases;g:MTHFR)(dui:D009369;dis:Neoplasms;g:MTHFR)(dui:D000013;dis:Congenital Abnormalities;g:MTHFR)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MTHFR)(dui:D030342;dis:Genetic Diseases, Inborn;g:MTHFR)(dui:D009371;dis:Neoplasms by Site;g:MTHFR)(dui:D002493;dis:Central Nervous System Diseases;g:MTHFR)(dui:D007154;dis:Immune System Diseases;g:MTHFR)(dui:D004066;dis:Digestive System Diseases;g:MTHFR)(dui:D001927;dis:Brain Diseases;g:MTHFR)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MTHFR)(dui:D009370;dis:Neoplasms by Histologic Type;g:MTHFR)(dui:D005767;dis:Gastrointestinal Diseases;g:MTHFR)(dui:D008659;dis:Metabolic Diseases;g:MTHFR)(dui:D006331;dis:Heart Diseases;g:MTHFR)(dui:D004067;dis:Digestive System Neoplasms;g:MTHFR)(dui:D001523;dis:Mental Disorders;g:MTHFR)(dui:D006402;dis:Hematologic Diseases;g:MTHFR)(dui:D009748;dis:Nutrition Disorders;g:MTHFR)(dui:D044342;dis:Malnutrition;g:MTHFR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:MTHFR)(dui:D007160;dis:Immunoproliferative Disorders;g:MTHFR)(dui:D008232;dis:Lymphoproliferative Disorders;g:MTHFR)(dui:D002561;dis:Cerebrovascular Disorders;g:MTHFR)(dui:D008206;dis:Lymphatic Diseases;g:MTHFR)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MTHFR)(dui:D008661;dis:Metabolism, Inborn Errors;g:MTHFR)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MTHFR)(dui:D020138;dis:Hyperhomocysteinemia;g:MTHFR)(dui:D017202;dis:Myocardial Ischemia;g:MTHFR)(dui:D003677;dis:Deficiency Diseases;g:MTHFR)(dui:D001361;dis:Avitaminosis;g:MTHFR)(dui:D014804;dis:Vitamin B Deficiency;g:MTHFR)(dui:D009421;dis:Nervous System Malformations;g:MTHFR)(dui:D009436;dis:Neural Tube Defects;g:MTHFR)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:MTHFR)(dui:D009140;dis:Musculoskeletal Diseases;g:MTHFR)(dui:D016769;dis:Embolism and Thrombosis;g:MTHFR)(dui:D009461;dis:Neurologic Manifestations;g:MTHFR)(dui:D003327;dis:Coronary Disease;g:MTHFR)(dui:D052776;dis:Female Urogenital Diseases;g:MTHFR)(dui:D052801;dis:Male Urogenital Diseases;g:MTHFR)(dui:D008286;dis:Malabsorption Syndromes;g:MTHFR)(dui:D007938;dis:Leukemia;g:MTHFR)(dui:D009057;dis:Stomatognathic Diseases;g:MTHFR)(dui:D007945;dis:Leukemia, Lymphoid;g:MTHFR)(dui:D007410;dis:Intestinal Diseases;g:MTHFR)(dui:D012871;dis:Skin Diseases;g:MTHFR)(dui:D009059;dis:Mouth Diseases;g:MTHFR)(dui:D004700;dis:Endocrine System Diseases;g:MTHFR)(dui:D003108;dis:Colonic Diseases;g:MTHFR)(dui:D007414;dis:Intestinal Neoplasms;g:MTHFR)(dui:D015179;dis:Colorectal Neoplasms;g:MTHFR)(dui:D014565;dis:Urogenital Neoplasms;g:MTHFR)(dui:D018640;dis:Stomatognathic System Abnormalities;g:MTHFR)(dui:D019967;dis:Schizophrenia Spectrum and Other Psychotic Disorders;g:MTHFR)(dui:D003240;dis:Connective Tissue Diseases;g:MTHFR)(dui:D014570;dis:Urologic Diseases;g:MTHFR)(dui:D013927;dis:Thrombosis;g:MTHFR)(dui:D020521;dis:Stroke;g:MTHFR)(dui:D008223;dis:Lymphoma;g:MTHFR)(dui:D005831;dis:Genital Diseases, Female;g:MTHFR)(dui:D008107;dis:Liver Diseases;g:MTHFR)(dui:D009056;dis:Mouth Abnormalities;g:MTHFR)(dui:D025063;dis:Chromosome Disorders;g:MTHFR)(dui:D019954;dis:Neurobehavioral Manifestations;g:MTHFR)(dui:D008607;dis:Intellectual Disability;g:MTHFR)(dui:D000015;dis:Abnormalities, Multiple;g:MTHFR)(dui:D004314;dis:Down Syndrome;g:MTHFR)(dui:D019851;dis:Thrombophilia;g:MTHFR)(dui:D054198;dis:Precursor Cell Lymphoblastic Leukemia-Lymphoma;g:MTHFR)(dui:D007674;dis:Kidney Diseases;g:MTHFR)(dui:D013272;dis:Stomach Diseases;g:MTHFR)(dui:D020246;dis:Venous Thrombosis;g:MTHFR)(dui:D003920;dis:Diabetes Mellitus;g:MTHFR)(dui:D013274;dis:Stomach Neoplasms;g:MTHFR)(dui:D009139;dis:Musculoskeletal Abnormalities;g:MTHFR)(dui:D005832;dis:Genital Diseases, Male;g:MTHFR)(dui:D001327;dis:Autoimmune Diseases;g:MTHFR)(dui:D012559;dis:Schizophrenia;g:MTHFR)(dui:D007246;dis:Infertility;g:MTHFR)(dui:D012140;dis:Respiratory Tract Diseases;g:MTHFR)(dui:D008171;dis:Lung Diseases;g:MTHFR)(dui:D002545;dis:Brain Ischemia;g:MTHFR)(dui:D012002;dis:Rectal Diseases;g:MTHFR)(dui:D007592;dis:Joint Diseases;g:MTHFR)(dui:D001168;dis:Arthritis;g:MTHFR)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:MTHFR)(dui:D019636;dis:Neurodegenerative Diseases;g:MTHFR)(dui:D012216;dis:Rheumatic Diseases;g:MTHFR)(dui:D001172;dis:Arthritis, Rheumatoid;g:MTHFR)(dui:D005833;dis:Genital Neoplasms, Female;g:MTHFR)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MTHFR)(dui:D009008;dis:Abnormalities, Severe Teratoid;g:MTHFR)(dui:D000757;dis:Anencephaly;g:MTHFR)(dui:D003704;dis:Dementia;g:MTHFR)(dui:D019965;dis:Neurocognitive Disorders;g:MTHFR)(dui:D014591;dis:Uterine Diseases;g:MTHFR)(dui:D014594;dis:Uterine Neoplasms;g:MTHFR)(dui:D024801;dis:Tauopathies;g:MTHFR)(dui:D000544;dis:Alzheimer Disease;g:MTHFR)(dui:D007960;dis:Leukocyte Disorders;g:MTHFR)(dui:D007970;dis:Leukopenia;g:MTHFR)(dui:D013959;dis:Thyroid Diseases;g:MTHFR)(dui:D002277;dis:Carcinoma;g:MTHFR)(dui:D006967;dis:Hypersensitivity;g:MTHFR)(dui:D001157;dis:Arterial Occlusive Diseases;g:MTHFR)(dui:D008047;dis:Lip Diseases;g:MTHFR)(dui:D002971;dis:Cleft Lip;g:MTHFR)(dui:D019465;dis:Craniofacial Abnormalities;g:MTHFR)(dui:D019767;dis:Maxillofacial Abnormalities;g:MTHFR)(dui:D001161;dis:Arteriosclerosis;g:MTHFR)(dui:D018376;dis:Cardiovascular Abnormalities;g:MTHFR)(dui:D006330;dis:Heart Defects, Congenital;g:MTHFR)(dui:D013923;dis:Thromboembolism;g:MTHFR)(dui:D003110;dis:Colonic Neoplasms;g:MTHFR)(dui:D006980;dis:Hyperthyroidism;g:MTHFR)(dui:D048909;dis:Diabetes Complications;g:MTHFR)(dui:D001941;dis:Breast Diseases;g:MTHFR)(dui:D001943;dis:Breast Neoplasms;g:MTHFR)(dui:D001778;dis:Blood Coagulation Disorders;g:MTHFR)(dui:D007248;dis:Infertility, Male;g:MTHFR)(dui:D051437;dis:Renal Insufficiency;g:MTHFR)(dui:D025861;dis:Blood Coagulation Disorders, Inherited;g:MTHFR)(dui:D044882;dis:Glucose Metabolism Disorders;g:MTHFR)(dui:D000740;dis:Anemia;g:MTHFR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:MTHFR)(dui:D005759;dis:Gastroenteritis;g:MTHFR)(dui:D012678;dis:Sensation Disorders;g:MTHFR)(dui:D006086;dis:Graft vs Host Disease;g:MTHFR)(dui:D004427;dis:Ear Diseases;g:MTHFR)(dui:D006311;dis:Hearing Disorders;g:MTHFR)(dui:D034381;dis:Hearing Loss;g:MTHFR)(dui:D011248;dis:Pregnancy Complications;g:MTHFR)(dui:D000068105;dis:Bipolar and Related Disorders;g:MTHFR)(dui:D001714;dis:Bipolar Disorder;g:MTHFR)(dui:D011655;dis:Pulmonary Embolism;g:MTHFR)(dui:D004617;dis:Embolism;g:MTHFR)(dui:D003925;dis:Diabetic Angiopathies;g:MTHFR)(dui:D012142;dis:Respiratory Tract Neoplasms;g:MTHFR)(dui:D002577;dis:Uterine Cervical Diseases;g:MTHFR)(dui:D003639;dis:Hearing Loss, Sudden;g:MTHFR)(dui:D009385;dis:Neoplastic Processes;g:MTHFR)(dui:D002583;dis:Uterine Cervical Neoplasms;g:MTHFR)(dui:D013899;dis:Thoracic Neoplasms;g:MTHFR)(dui:D014571;dis:Urologic Neoplasms;g:MTHFR)(dui:D002278;dis:Carcinoma in Situ;g:MTHFR)(dui:D018290;dis:Cervical Intraepithelial Neoplasia;g:MTHFR)(dui:D005834;dis:Genital Neoplasms, Male;g:MTHFR)(dui:D011469;dis:Prostatic Diseases;g:MTHFR)(dui:D011471;dis:Prostatic Neoplasms;g:MTHFR)(dui:D008175;dis:Lung Neoplasms;g:MTHFR)(dui:D003324;dis:Coronary Artery Disease;g:MTHFR)(dui:D015448;dis:Leukemia, B-Cell;g:MTHFR)(dui:D015451;dis:Leukemia, Lymphocytic, Chronic, B-Cell;g:MTHFR)(dui:D001791;dis:Blood Platelet Disorders;g:MTHFR)(dui:D065886;dis:Neurodevelopmental Disorders;g:MTHFR)(dui:D001745;dis:Urinary Bladder Diseases;g:MTHFR)(dui:D001749;dis:Urinary Bladder Neoplasms;g:MTHFR)(dui:D056486;dis:Drug-Induced Liver Injury;g:MTHFR)(dui:D013921;dis:Thrombocytopenia;g:MTHFR)(dui:D002659;dis:Child Development Disorders, Pervasive;g:MTHFR)(dui:D002542;dis:Intracranial Embolism and Thrombosis;g:MTHFR)(dui:D020767;dis:Intracranial Thrombosis;g:MTHFR)(dui:D001321;dis:Autistic Disorder;g:MTHFR)(dui:D019964;dis:Mood Disorders;g:MTHFR)(dui:D003866;dis:Depressive Disorder;g:MTHFR)(dui:D000380;dis:Agranulocytosis;g:MTHFR)(dui:D009503;dis:Neutropenia;g:MTHFR)(dui:D023921;dis:Coronary Stenosis;g:MTHFR)(dui:D007247;dis:Infertility, Female;g:MTHFR)(dui:D012851;dis:Sinus Thrombosis, Intracranial;g:MTHFR)(dui:D001928;dis:Brain Diseases, Metabolic;g:MTHFR)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MTHFR)(dui:D018204;dis:Neoplasms, Connective and Soft Tissue;g:MTHFR)(dui:D008591;dis:Meningomyelocele;g:MTHFR)(dui:D008224;dis:Lymphoma, Follicular;g:MTHFR)(dui:D009372;dis:Neoplasms, Connective Tissue;g:MTHFR)(dui:D020258;dis:Neurotoxicity Syndromes;g:MTHFR)(dui:D052016;dis:Mucositis;g:MTHFR)(dui:D023903;dis:Coronary Restenosis;g:MTHFR)(dui:D009362;dis:Neoplasm Metastasis;g:MTHFR)(dui:D020879;dis:Neuromuscular Manifestations;g:MTHFR)(dui:D056784;dis:Leukoencephalopathies;g:MTHFR)(dui:D011618;dis:Psychotic Disorders;g:MTHFR)(dui:D009468;dis:Neuromuscular Diseases;g:MTHFR)(dui:D009135;dis:Muscular Diseases;g:MTHFR)(dui:D010523;dis:Peripheral Nervous System Diseases;g:MTHFR)(dui:D005530;dis:Foot Deformities;g:MTHFR)(dui:D005532;dis:Foot Deformities, Congenital;g:MTHFR)(dui:D006712;dis:Homocystinuria;g:MTHFR)(dui:D009128;dis:Muscle Spasticity;g:MTHFR)(dui:D017880;dis:Limb Deformities, Congenital;g:MTHFR)(dui:D000787;dis:Angina Pectoris;g:MTHFR)(dui:D003025;dis:Clubfoot;g:MTHFR)(dui:D009122;dis:Muscle Hypertonia;g:MTHFR)(dui:D038061;dis:Lower Extremity Deformities, Congenital;g:MTHFR)(dui:D017566;dis:Microvascular Angina;g:MTHFR)(dui:D001145;dis:Arrhythmias, Cardiac;g:MTHFR)(dui:D020260;dis:Heavy Metal Poisoning, Nervous System;g:MTHFR)(dui:D001281;dis:Atrial Fibrillation;g:MTHFR)(dui:D020261;dis:Arsenic Poisoning;g:MTHFR)(dui:D016889;dis:Endometrial Neoplasms;g:MTHFR)(dui:D013118;dis:Spinal Cord Diseases;g:MTHFR)(dui:D004342;dis:Drug Hypersensitivity;g:MTHFR)(dui:D007571;dis:Jaw Diseases;g:MTHFR)(dui:D007569;dis:Jaw Abnormalities;g:MTHFR)(dui:D002972;dis:Cleft Palate;g:MTHFR)(dui:D013971;dis:Thyrotoxicosis;g:MTHFR)(dui:D003872;dis:Dermatitis;g:MTHFR)(dui:D003875;dis:Drug Eruptions;g:MTHFR)(dui:D006201;dis:Hair Diseases;g:MTHFR)(dui:D007039;dis:Hypotrichosis;g:MTHFR)(dui:D046152;dis:Gastrointestinal Stromal Tumors;g:MTHFR)(dui:D000505;dis:Alopecia;g:MTHFR)(dui:D058186;dis:Acute Kidney Injury;g:MTHFR)(dui:D006973;dis:Hypertension;g:MTHFR)(dui:D008113;dis:Liver Neoplasms;g:MTHFR)	Tetrahydrofolic acid:Menadione:Methionine:Riboflavin:Benazepril:Methotrexate:Cyanocobalamin:Folic acid:Fluorouracil	GO:0031060:GO:0070829:GO:0043200:GO:0046655:GO:0045202:GO:0004489:GO:0044877:GO:0072341:GO:0001666:GO:0001843:GO:0005829:GO:0035999:GO:0009086:GO:0071949:GO:0033274:GO:0046500:GO:0006730:GO:0006555:GO:0050661:GO:0050660:GO:0042493:GO:0051593:GO:0070555:GO:0055114:GO:0050667	607093		-2.26															M
chr1:11792243	SNV	C	1	T/T	PASS	0.0	3967.0		400	C=1,T=399	C=0.0025,T=0.9975	99.75	0.25	homozygous	47	0.251	2.0		MTHFR	NM_005957.5	MTHFR:intronic:NM_005957.5	unknown			p.?	c.1632+35G>A				T	GMAF=0.2229:AMAF=0.1491:EMAF=0.2607					rs1476413		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MTHFR)(dui:NBS2;dis:Core Conditions;g:MTHFR)(dui:NBS11;dis:Amino Acid Disorder;g:MTHFR)(dui:NBS57;dis:Homocystinuria;g:MTHFR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MTHFR)(dui:D002318;dis:Cardiovascular Diseases;g:MTHFR)(dui:D009422;dis:Nervous System Diseases;g:MTHFR)(dui:D014652;dis:Vascular Diseases;g:MTHFR)(dui:D009369;dis:Neoplasms;g:MTHFR)(dui:D000013;dis:Congenital Abnormalities;g:MTHFR)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MTHFR)(dui:D030342;dis:Genetic Diseases, Inborn;g:MTHFR)(dui:D009371;dis:Neoplasms by Site;g:MTHFR)(dui:D002493;dis:Central Nervous System Diseases;g:MTHFR)(dui:D007154;dis:Immune System Diseases;g:MTHFR)(dui:D004066;dis:Digestive System Diseases;g:MTHFR)(dui:D001927;dis:Brain Diseases;g:MTHFR)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MTHFR)(dui:D009370;dis:Neoplasms by Histologic Type;g:MTHFR)(dui:D005767;dis:Gastrointestinal Diseases;g:MTHFR)(dui:D008659;dis:Metabolic Diseases;g:MTHFR)(dui:D006331;dis:Heart Diseases;g:MTHFR)(dui:D004067;dis:Digestive System Neoplasms;g:MTHFR)(dui:D001523;dis:Mental Disorders;g:MTHFR)(dui:D006402;dis:Hematologic Diseases;g:MTHFR)(dui:D009748;dis:Nutrition Disorders;g:MTHFR)(dui:D044342;dis:Malnutrition;g:MTHFR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:MTHFR)(dui:D007160;dis:Immunoproliferative Disorders;g:MTHFR)(dui:D008232;dis:Lymphoproliferative Disorders;g:MTHFR)(dui:D002561;dis:Cerebrovascular Disorders;g:MTHFR)(dui:D008206;dis:Lymphatic Diseases;g:MTHFR)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MTHFR)(dui:D008661;dis:Metabolism, Inborn Errors;g:MTHFR)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MTHFR)(dui:D020138;dis:Hyperhomocysteinemia;g:MTHFR)(dui:D017202;dis:Myocardial Ischemia;g:MTHFR)(dui:D003677;dis:Deficiency Diseases;g:MTHFR)(dui:D001361;dis:Avitaminosis;g:MTHFR)(dui:D014804;dis:Vitamin B Deficiency;g:MTHFR)(dui:D009421;dis:Nervous System Malformations;g:MTHFR)(dui:D009436;dis:Neural Tube Defects;g:MTHFR)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:MTHFR)(dui:D009140;dis:Musculoskeletal Diseases;g:MTHFR)(dui:D016769;dis:Embolism and Thrombosis;g:MTHFR)(dui:D009461;dis:Neurologic Manifestations;g:MTHFR)(dui:D003327;dis:Coronary Disease;g:MTHFR)(dui:D052776;dis:Female Urogenital Diseases;g:MTHFR)(dui:D052801;dis:Male Urogenital Diseases;g:MTHFR)(dui:D008286;dis:Malabsorption Syndromes;g:MTHFR)(dui:D007938;dis:Leukemia;g:MTHFR)(dui:D009057;dis:Stomatognathic Diseases;g:MTHFR)(dui:D007945;dis:Leukemia, Lymphoid;g:MTHFR)(dui:D007410;dis:Intestinal Diseases;g:MTHFR)(dui:D012871;dis:Skin Diseases;g:MTHFR)(dui:D009059;dis:Mouth Diseases;g:MTHFR)(dui:D004700;dis:Endocrine System Diseases;g:MTHFR)(dui:D003108;dis:Colonic Diseases;g:MTHFR)(dui:D007414;dis:Intestinal Neoplasms;g:MTHFR)(dui:D015179;dis:Colorectal Neoplasms;g:MTHFR)(dui:D014565;dis:Urogenital Neoplasms;g:MTHFR)(dui:D018640;dis:Stomatognathic System Abnormalities;g:MTHFR)(dui:D019967;dis:Schizophrenia Spectrum and Other Psychotic Disorders;g:MTHFR)(dui:D003240;dis:Connective Tissue Diseases;g:MTHFR)(dui:D014570;dis:Urologic Diseases;g:MTHFR)(dui:D013927;dis:Thrombosis;g:MTHFR)(dui:D020521;dis:Stroke;g:MTHFR)(dui:D008223;dis:Lymphoma;g:MTHFR)(dui:D005831;dis:Genital Diseases, Female;g:MTHFR)(dui:D008107;dis:Liver Diseases;g:MTHFR)(dui:D009056;dis:Mouth Abnormalities;g:MTHFR)(dui:D025063;dis:Chromosome Disorders;g:MTHFR)(dui:D019954;dis:Neurobehavioral Manifestations;g:MTHFR)(dui:D008607;dis:Intellectual Disability;g:MTHFR)(dui:D000015;dis:Abnormalities, Multiple;g:MTHFR)(dui:D004314;dis:Down Syndrome;g:MTHFR)(dui:D019851;dis:Thrombophilia;g:MTHFR)(dui:D054198;dis:Precursor Cell Lymphoblastic Leukemia-Lymphoma;g:MTHFR)(dui:D007674;dis:Kidney Diseases;g:MTHFR)(dui:D013272;dis:Stomach Diseases;g:MTHFR)(dui:D020246;dis:Venous Thrombosis;g:MTHFR)(dui:D003920;dis:Diabetes Mellitus;g:MTHFR)(dui:D013274;dis:Stomach Neoplasms;g:MTHFR)(dui:D009139;dis:Musculoskeletal Abnormalities;g:MTHFR)(dui:D005832;dis:Genital Diseases, Male;g:MTHFR)(dui:D001327;dis:Autoimmune Diseases;g:MTHFR)(dui:D012559;dis:Schizophrenia;g:MTHFR)(dui:D007246;dis:Infertility;g:MTHFR)(dui:D012140;dis:Respiratory Tract Diseases;g:MTHFR)(dui:D008171;dis:Lung Diseases;g:MTHFR)(dui:D002545;dis:Brain Ischemia;g:MTHFR)(dui:D012002;dis:Rectal Diseases;g:MTHFR)(dui:D007592;dis:Joint Diseases;g:MTHFR)(dui:D001168;dis:Arthritis;g:MTHFR)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:MTHFR)(dui:D019636;dis:Neurodegenerative Diseases;g:MTHFR)(dui:D012216;dis:Rheumatic Diseases;g:MTHFR)(dui:D001172;dis:Arthritis, Rheumatoid;g:MTHFR)(dui:D005833;dis:Genital Neoplasms, Female;g:MTHFR)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MTHFR)(dui:D009008;dis:Abnormalities, Severe Teratoid;g:MTHFR)(dui:D000757;dis:Anencephaly;g:MTHFR)(dui:D003704;dis:Dementia;g:MTHFR)(dui:D019965;dis:Neurocognitive Disorders;g:MTHFR)(dui:D014591;dis:Uterine Diseases;g:MTHFR)(dui:D014594;dis:Uterine Neoplasms;g:MTHFR)(dui:D024801;dis:Tauopathies;g:MTHFR)(dui:D000544;dis:Alzheimer Disease;g:MTHFR)(dui:D007960;dis:Leukocyte Disorders;g:MTHFR)(dui:D007970;dis:Leukopenia;g:MTHFR)(dui:D013959;dis:Thyroid Diseases;g:MTHFR)(dui:D002277;dis:Carcinoma;g:MTHFR)(dui:D006967;dis:Hypersensitivity;g:MTHFR)(dui:D001157;dis:Arterial Occlusive Diseases;g:MTHFR)(dui:D008047;dis:Lip Diseases;g:MTHFR)(dui:D002971;dis:Cleft Lip;g:MTHFR)(dui:D019465;dis:Craniofacial Abnormalities;g:MTHFR)(dui:D019767;dis:Maxillofacial Abnormalities;g:MTHFR)(dui:D001161;dis:Arteriosclerosis;g:MTHFR)(dui:D018376;dis:Cardiovascular Abnormalities;g:MTHFR)(dui:D006330;dis:Heart Defects, Congenital;g:MTHFR)(dui:D013923;dis:Thromboembolism;g:MTHFR)(dui:D003110;dis:Colonic Neoplasms;g:MTHFR)(dui:D006980;dis:Hyperthyroidism;g:MTHFR)(dui:D048909;dis:Diabetes Complications;g:MTHFR)(dui:D001941;dis:Breast Diseases;g:MTHFR)(dui:D001943;dis:Breast Neoplasms;g:MTHFR)(dui:D001778;dis:Blood Coagulation Disorders;g:MTHFR)(dui:D007248;dis:Infertility, Male;g:MTHFR)(dui:D051437;dis:Renal Insufficiency;g:MTHFR)(dui:D025861;dis:Blood Coagulation Disorders, Inherited;g:MTHFR)(dui:D044882;dis:Glucose Metabolism Disorders;g:MTHFR)(dui:D000740;dis:Anemia;g:MTHFR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:MTHFR)(dui:D005759;dis:Gastroenteritis;g:MTHFR)(dui:D012678;dis:Sensation Disorders;g:MTHFR)(dui:D006086;dis:Graft vs Host Disease;g:MTHFR)(dui:D004427;dis:Ear Diseases;g:MTHFR)(dui:D006311;dis:Hearing Disorders;g:MTHFR)(dui:D034381;dis:Hearing Loss;g:MTHFR)(dui:D011248;dis:Pregnancy Complications;g:MTHFR)(dui:D000068105;dis:Bipolar and Related Disorders;g:MTHFR)(dui:D001714;dis:Bipolar Disorder;g:MTHFR)(dui:D011655;dis:Pulmonary Embolism;g:MTHFR)(dui:D004617;dis:Embolism;g:MTHFR)(dui:D003925;dis:Diabetic Angiopathies;g:MTHFR)(dui:D012142;dis:Respiratory Tract Neoplasms;g:MTHFR)(dui:D002577;dis:Uterine Cervical Diseases;g:MTHFR)(dui:D003639;dis:Hearing Loss, Sudden;g:MTHFR)(dui:D009385;dis:Neoplastic Processes;g:MTHFR)(dui:D002583;dis:Uterine Cervical Neoplasms;g:MTHFR)(dui:D013899;dis:Thoracic Neoplasms;g:MTHFR)(dui:D014571;dis:Urologic Neoplasms;g:MTHFR)(dui:D002278;dis:Carcinoma in Situ;g:MTHFR)(dui:D018290;dis:Cervical Intraepithelial Neoplasia;g:MTHFR)(dui:D005834;dis:Genital Neoplasms, Male;g:MTHFR)(dui:D011469;dis:Prostatic Diseases;g:MTHFR)(dui:D011471;dis:Prostatic Neoplasms;g:MTHFR)(dui:D008175;dis:Lung Neoplasms;g:MTHFR)(dui:D003324;dis:Coronary Artery Disease;g:MTHFR)(dui:D015448;dis:Leukemia, B-Cell;g:MTHFR)(dui:D015451;dis:Leukemia, Lymphocytic, Chronic, B-Cell;g:MTHFR)(dui:D001791;dis:Blood Platelet Disorders;g:MTHFR)(dui:D065886;dis:Neurodevelopmental Disorders;g:MTHFR)(dui:D001745;dis:Urinary Bladder Diseases;g:MTHFR)(dui:D001749;dis:Urinary Bladder Neoplasms;g:MTHFR)(dui:D056486;dis:Drug-Induced Liver Injury;g:MTHFR)(dui:D013921;dis:Thrombocytopenia;g:MTHFR)(dui:D002659;dis:Child Development Disorders, Pervasive;g:MTHFR)(dui:D002542;dis:Intracranial Embolism and Thrombosis;g:MTHFR)(dui:D020767;dis:Intracranial Thrombosis;g:MTHFR)(dui:D001321;dis:Autistic Disorder;g:MTHFR)(dui:D019964;dis:Mood Disorders;g:MTHFR)(dui:D003866;dis:Depressive Disorder;g:MTHFR)(dui:D000380;dis:Agranulocytosis;g:MTHFR)(dui:D009503;dis:Neutropenia;g:MTHFR)(dui:D023921;dis:Coronary Stenosis;g:MTHFR)(dui:D007247;dis:Infertility, Female;g:MTHFR)(dui:D012851;dis:Sinus Thrombosis, Intracranial;g:MTHFR)(dui:D001928;dis:Brain Diseases, Metabolic;g:MTHFR)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MTHFR)(dui:D018204;dis:Neoplasms, Connective and Soft Tissue;g:MTHFR)(dui:D008591;dis:Meningomyelocele;g:MTHFR)(dui:D008224;dis:Lymphoma, Follicular;g:MTHFR)(dui:D009372;dis:Neoplasms, Connective Tissue;g:MTHFR)(dui:D020258;dis:Neurotoxicity Syndromes;g:MTHFR)(dui:D052016;dis:Mucositis;g:MTHFR)(dui:D023903;dis:Coronary Restenosis;g:MTHFR)(dui:D009362;dis:Neoplasm Metastasis;g:MTHFR)(dui:D020879;dis:Neuromuscular Manifestations;g:MTHFR)(dui:D056784;dis:Leukoencephalopathies;g:MTHFR)(dui:D011618;dis:Psychotic Disorders;g:MTHFR)(dui:D009468;dis:Neuromuscular Diseases;g:MTHFR)(dui:D009135;dis:Muscular Diseases;g:MTHFR)(dui:D010523;dis:Peripheral Nervous System Diseases;g:MTHFR)(dui:D005530;dis:Foot Deformities;g:MTHFR)(dui:D005532;dis:Foot Deformities, Congenital;g:MTHFR)(dui:D006712;dis:Homocystinuria;g:MTHFR)(dui:D009128;dis:Muscle Spasticity;g:MTHFR)(dui:D017880;dis:Limb Deformities, Congenital;g:MTHFR)(dui:D000787;dis:Angina Pectoris;g:MTHFR)(dui:D003025;dis:Clubfoot;g:MTHFR)(dui:D009122;dis:Muscle Hypertonia;g:MTHFR)(dui:D038061;dis:Lower Extremity Deformities, Congenital;g:MTHFR)(dui:D017566;dis:Microvascular Angina;g:MTHFR)(dui:D001145;dis:Arrhythmias, Cardiac;g:MTHFR)(dui:D020260;dis:Heavy Metal Poisoning, Nervous System;g:MTHFR)(dui:D001281;dis:Atrial Fibrillation;g:MTHFR)(dui:D020261;dis:Arsenic Poisoning;g:MTHFR)(dui:D016889;dis:Endometrial Neoplasms;g:MTHFR)(dui:D013118;dis:Spinal Cord Diseases;g:MTHFR)(dui:D004342;dis:Drug Hypersensitivity;g:MTHFR)(dui:D007571;dis:Jaw Diseases;g:MTHFR)(dui:D007569;dis:Jaw Abnormalities;g:MTHFR)(dui:D002972;dis:Cleft Palate;g:MTHFR)(dui:D013971;dis:Thyrotoxicosis;g:MTHFR)(dui:D003872;dis:Dermatitis;g:MTHFR)(dui:D003875;dis:Drug Eruptions;g:MTHFR)(dui:D006201;dis:Hair Diseases;g:MTHFR)(dui:D007039;dis:Hypotrichosis;g:MTHFR)(dui:D046152;dis:Gastrointestinal Stromal Tumors;g:MTHFR)(dui:D000505;dis:Alopecia;g:MTHFR)(dui:D058186;dis:Acute Kidney Injury;g:MTHFR)(dui:D006973;dis:Hypertension;g:MTHFR)(dui:D008113;dis:Liver Neoplasms;g:MTHFR)	Tetrahydrofolic acid:Menadione:Methionine:Riboflavin:Benazepril:Methotrexate:Cyanocobalamin:Folic acid:Fluorouracil	GO:0031060:GO:0070829:GO:0043200:GO:0046655:GO:0045202:GO:0004489:GO:0044877:GO:0072341:GO:0001666:GO:0001843:GO:0005829:GO:0035999:GO:0009086:GO:0071949:GO:0033274:GO:0046500:GO:0006730:GO:0006555:GO:0050661:GO:0050660:GO:0042493:GO:0051593:GO:0070555:GO:0055114:GO:0050667	607093		-1.12															M
chr1:11792459	SNV	C	1	C/T	PASS	5.236004365857602e-95	942.81		400	C=196,T=204	C=0.49,T=0.51	51.0	49.0	heterozygous	8	0.031	1.0		MTHFR	NM_005957.5	MTHFR:intronic:NM_005957.5	unknown			p.?	c.1531-80G>A				T						rs17375901		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MTHFR)(dui:NBS2;dis:Core Conditions;g:MTHFR)(dui:NBS11;dis:Amino Acid Disorder;g:MTHFR)(dui:NBS57;dis:Homocystinuria;g:MTHFR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MTHFR)(dui:D002318;dis:Cardiovascular Diseases;g:MTHFR)(dui:D009422;dis:Nervous System Diseases;g:MTHFR)(dui:D014652;dis:Vascular Diseases;g:MTHFR)(dui:D009369;dis:Neoplasms;g:MTHFR)(dui:D000013;dis:Congenital Abnormalities;g:MTHFR)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MTHFR)(dui:D030342;dis:Genetic Diseases, Inborn;g:MTHFR)(dui:D009371;dis:Neoplasms by Site;g:MTHFR)(dui:D002493;dis:Central Nervous System Diseases;g:MTHFR)(dui:D007154;dis:Immune System Diseases;g:MTHFR)(dui:D004066;dis:Digestive System Diseases;g:MTHFR)(dui:D001927;dis:Brain Diseases;g:MTHFR)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MTHFR)(dui:D009370;dis:Neoplasms by Histologic Type;g:MTHFR)(dui:D005767;dis:Gastrointestinal Diseases;g:MTHFR)(dui:D008659;dis:Metabolic Diseases;g:MTHFR)(dui:D006331;dis:Heart Diseases;g:MTHFR)(dui:D004067;dis:Digestive System Neoplasms;g:MTHFR)(dui:D001523;dis:Mental Disorders;g:MTHFR)(dui:D006402;dis:Hematologic Diseases;g:MTHFR)(dui:D009748;dis:Nutrition Disorders;g:MTHFR)(dui:D044342;dis:Malnutrition;g:MTHFR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:MTHFR)(dui:D007160;dis:Immunoproliferative Disorders;g:MTHFR)(dui:D008232;dis:Lymphoproliferative Disorders;g:MTHFR)(dui:D002561;dis:Cerebrovascular Disorders;g:MTHFR)(dui:D008206;dis:Lymphatic Diseases;g:MTHFR)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MTHFR)(dui:D008661;dis:Metabolism, Inborn Errors;g:MTHFR)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MTHFR)(dui:D020138;dis:Hyperhomocysteinemia;g:MTHFR)(dui:D017202;dis:Myocardial Ischemia;g:MTHFR)(dui:D003677;dis:Deficiency Diseases;g:MTHFR)(dui:D001361;dis:Avitaminosis;g:MTHFR)(dui:D014804;dis:Vitamin B Deficiency;g:MTHFR)(dui:D009421;dis:Nervous System Malformations;g:MTHFR)(dui:D009436;dis:Neural Tube Defects;g:MTHFR)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:MTHFR)(dui:D009140;dis:Musculoskeletal Diseases;g:MTHFR)(dui:D016769;dis:Embolism and Thrombosis;g:MTHFR)(dui:D009461;dis:Neurologic Manifestations;g:MTHFR)(dui:D003327;dis:Coronary Disease;g:MTHFR)(dui:D052776;dis:Female Urogenital Diseases;g:MTHFR)(dui:D052801;dis:Male Urogenital Diseases;g:MTHFR)(dui:D008286;dis:Malabsorption Syndromes;g:MTHFR)(dui:D007938;dis:Leukemia;g:MTHFR)(dui:D009057;dis:Stomatognathic Diseases;g:MTHFR)(dui:D007945;dis:Leukemia, Lymphoid;g:MTHFR)(dui:D007410;dis:Intestinal Diseases;g:MTHFR)(dui:D012871;dis:Skin Diseases;g:MTHFR)(dui:D009059;dis:Mouth Diseases;g:MTHFR)(dui:D004700;dis:Endocrine System Diseases;g:MTHFR)(dui:D003108;dis:Colonic Diseases;g:MTHFR)(dui:D007414;dis:Intestinal Neoplasms;g:MTHFR)(dui:D015179;dis:Colorectal Neoplasms;g:MTHFR)(dui:D014565;dis:Urogenital Neoplasms;g:MTHFR)(dui:D018640;dis:Stomatognathic System Abnormalities;g:MTHFR)(dui:D019967;dis:Schizophrenia Spectrum and Other Psychotic Disorders;g:MTHFR)(dui:D003240;dis:Connective Tissue Diseases;g:MTHFR)(dui:D014570;dis:Urologic Diseases;g:MTHFR)(dui:D013927;dis:Thrombosis;g:MTHFR)(dui:D020521;dis:Stroke;g:MTHFR)(dui:D008223;dis:Lymphoma;g:MTHFR)(dui:D005831;dis:Genital Diseases, Female;g:MTHFR)(dui:D008107;dis:Liver Diseases;g:MTHFR)(dui:D009056;dis:Mouth Abnormalities;g:MTHFR)(dui:D025063;dis:Chromosome Disorders;g:MTHFR)(dui:D019954;dis:Neurobehavioral Manifestations;g:MTHFR)(dui:D008607;dis:Intellectual Disability;g:MTHFR)(dui:D000015;dis:Abnormalities, Multiple;g:MTHFR)(dui:D004314;dis:Down Syndrome;g:MTHFR)(dui:D019851;dis:Thrombophilia;g:MTHFR)(dui:D054198;dis:Precursor Cell Lymphoblastic Leukemia-Lymphoma;g:MTHFR)(dui:D007674;dis:Kidney Diseases;g:MTHFR)(dui:D013272;dis:Stomach Diseases;g:MTHFR)(dui:D020246;dis:Venous Thrombosis;g:MTHFR)(dui:D003920;dis:Diabetes Mellitus;g:MTHFR)(dui:D013274;dis:Stomach Neoplasms;g:MTHFR)(dui:D009139;dis:Musculoskeletal Abnormalities;g:MTHFR)(dui:D005832;dis:Genital Diseases, Male;g:MTHFR)(dui:D001327;dis:Autoimmune Diseases;g:MTHFR)(dui:D012559;dis:Schizophrenia;g:MTHFR)(dui:D007246;dis:Infertility;g:MTHFR)(dui:D012140;dis:Respiratory Tract Diseases;g:MTHFR)(dui:D008171;dis:Lung Diseases;g:MTHFR)(dui:D002545;dis:Brain Ischemia;g:MTHFR)(dui:D012002;dis:Rectal Diseases;g:MTHFR)(dui:D007592;dis:Joint Diseases;g:MTHFR)(dui:D001168;dis:Arthritis;g:MTHFR)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:MTHFR)(dui:D019636;dis:Neurodegenerative Diseases;g:MTHFR)(dui:D012216;dis:Rheumatic Diseases;g:MTHFR)(dui:D001172;dis:Arthritis, Rheumatoid;g:MTHFR)(dui:D005833;dis:Genital Neoplasms, Female;g:MTHFR)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MTHFR)(dui:D009008;dis:Abnormalities, Severe Teratoid;g:MTHFR)(dui:D000757;dis:Anencephaly;g:MTHFR)(dui:D003704;dis:Dementia;g:MTHFR)(dui:D019965;dis:Neurocognitive Disorders;g:MTHFR)(dui:D014591;dis:Uterine Diseases;g:MTHFR)(dui:D014594;dis:Uterine Neoplasms;g:MTHFR)(dui:D024801;dis:Tauopathies;g:MTHFR)(dui:D000544;dis:Alzheimer Disease;g:MTHFR)(dui:D007960;dis:Leukocyte Disorders;g:MTHFR)(dui:D007970;dis:Leukopenia;g:MTHFR)(dui:D013959;dis:Thyroid Diseases;g:MTHFR)(dui:D002277;dis:Carcinoma;g:MTHFR)(dui:D006967;dis:Hypersensitivity;g:MTHFR)(dui:D001157;dis:Arterial Occlusive Diseases;g:MTHFR)(dui:D008047;dis:Lip Diseases;g:MTHFR)(dui:D002971;dis:Cleft Lip;g:MTHFR)(dui:D019465;dis:Craniofacial Abnormalities;g:MTHFR)(dui:D019767;dis:Maxillofacial Abnormalities;g:MTHFR)(dui:D001161;dis:Arteriosclerosis;g:MTHFR)(dui:D018376;dis:Cardiovascular Abnormalities;g:MTHFR)(dui:D006330;dis:Heart Defects, Congenital;g:MTHFR)(dui:D013923;dis:Thromboembolism;g:MTHFR)(dui:D003110;dis:Colonic Neoplasms;g:MTHFR)(dui:D006980;dis:Hyperthyroidism;g:MTHFR)(dui:D048909;dis:Diabetes Complications;g:MTHFR)(dui:D001941;dis:Breast Diseases;g:MTHFR)(dui:D001943;dis:Breast Neoplasms;g:MTHFR)(dui:D001778;dis:Blood Coagulation Disorders;g:MTHFR)(dui:D007248;dis:Infertility, Male;g:MTHFR)(dui:D051437;dis:Renal Insufficiency;g:MTHFR)(dui:D025861;dis:Blood Coagulation Disorders, Inherited;g:MTHFR)(dui:D044882;dis:Glucose Metabolism Disorders;g:MTHFR)(dui:D000740;dis:Anemia;g:MTHFR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:MTHFR)(dui:D005759;dis:Gastroenteritis;g:MTHFR)(dui:D012678;dis:Sensation Disorders;g:MTHFR)(dui:D006086;dis:Graft vs Host Disease;g:MTHFR)(dui:D004427;dis:Ear Diseases;g:MTHFR)(dui:D006311;dis:Hearing Disorders;g:MTHFR)(dui:D034381;dis:Hearing Loss;g:MTHFR)(dui:D011248;dis:Pregnancy Complications;g:MTHFR)(dui:D000068105;dis:Bipolar and Related Disorders;g:MTHFR)(dui:D001714;dis:Bipolar Disorder;g:MTHFR)(dui:D011655;dis:Pulmonary Embolism;g:MTHFR)(dui:D004617;dis:Embolism;g:MTHFR)(dui:D003925;dis:Diabetic Angiopathies;g:MTHFR)(dui:D012142;dis:Respiratory Tract Neoplasms;g:MTHFR)(dui:D002577;dis:Uterine Cervical Diseases;g:MTHFR)(dui:D003639;dis:Hearing Loss, Sudden;g:MTHFR)(dui:D009385;dis:Neoplastic Processes;g:MTHFR)(dui:D002583;dis:Uterine Cervical Neoplasms;g:MTHFR)(dui:D013899;dis:Thoracic Neoplasms;g:MTHFR)(dui:D014571;dis:Urologic Neoplasms;g:MTHFR)(dui:D002278;dis:Carcinoma in Situ;g:MTHFR)(dui:D018290;dis:Cervical Intraepithelial Neoplasia;g:MTHFR)(dui:D005834;dis:Genital Neoplasms, Male;g:MTHFR)(dui:D011469;dis:Prostatic Diseases;g:MTHFR)(dui:D011471;dis:Prostatic Neoplasms;g:MTHFR)(dui:D008175;dis:Lung Neoplasms;g:MTHFR)(dui:D003324;dis:Coronary Artery Disease;g:MTHFR)(dui:D015448;dis:Leukemia, B-Cell;g:MTHFR)(dui:D015451;dis:Leukemia, Lymphocytic, Chronic, B-Cell;g:MTHFR)(dui:D001791;dis:Blood Platelet Disorders;g:MTHFR)(dui:D065886;dis:Neurodevelopmental Disorders;g:MTHFR)(dui:D001745;dis:Urinary Bladder Diseases;g:MTHFR)(dui:D001749;dis:Urinary Bladder Neoplasms;g:MTHFR)(dui:D056486;dis:Drug-Induced Liver Injury;g:MTHFR)(dui:D013921;dis:Thrombocytopenia;g:MTHFR)(dui:D002659;dis:Child Development Disorders, Pervasive;g:MTHFR)(dui:D002542;dis:Intracranial Embolism and Thrombosis;g:MTHFR)(dui:D020767;dis:Intracranial Thrombosis;g:MTHFR)(dui:D001321;dis:Autistic Disorder;g:MTHFR)(dui:D019964;dis:Mood Disorders;g:MTHFR)(dui:D003866;dis:Depressive Disorder;g:MTHFR)(dui:D000380;dis:Agranulocytosis;g:MTHFR)(dui:D009503;dis:Neutropenia;g:MTHFR)(dui:D023921;dis:Coronary Stenosis;g:MTHFR)(dui:D007247;dis:Infertility, Female;g:MTHFR)(dui:D012851;dis:Sinus Thrombosis, Intracranial;g:MTHFR)(dui:D001928;dis:Brain Diseases, Metabolic;g:MTHFR)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MTHFR)(dui:D018204;dis:Neoplasms, Connective and Soft Tissue;g:MTHFR)(dui:D008591;dis:Meningomyelocele;g:MTHFR)(dui:D008224;dis:Lymphoma, Follicular;g:MTHFR)(dui:D009372;dis:Neoplasms, Connective Tissue;g:MTHFR)(dui:D020258;dis:Neurotoxicity Syndromes;g:MTHFR)(dui:D052016;dis:Mucositis;g:MTHFR)(dui:D023903;dis:Coronary Restenosis;g:MTHFR)(dui:D009362;dis:Neoplasm Metastasis;g:MTHFR)(dui:D020879;dis:Neuromuscular Manifestations;g:MTHFR)(dui:D056784;dis:Leukoencephalopathies;g:MTHFR)(dui:D011618;dis:Psychotic Disorders;g:MTHFR)(dui:D009468;dis:Neuromuscular Diseases;g:MTHFR)(dui:D009135;dis:Muscular Diseases;g:MTHFR)(dui:D010523;dis:Peripheral Nervous System Diseases;g:MTHFR)(dui:D005530;dis:Foot Deformities;g:MTHFR)(dui:D005532;dis:Foot Deformities, Congenital;g:MTHFR)(dui:D006712;dis:Homocystinuria;g:MTHFR)(dui:D009128;dis:Muscle Spasticity;g:MTHFR)(dui:D017880;dis:Limb Deformities, Congenital;g:MTHFR)(dui:D000787;dis:Angina Pectoris;g:MTHFR)(dui:D003025;dis:Clubfoot;g:MTHFR)(dui:D009122;dis:Muscle Hypertonia;g:MTHFR)(dui:D038061;dis:Lower Extremity Deformities, Congenital;g:MTHFR)(dui:D017566;dis:Microvascular Angina;g:MTHFR)(dui:D001145;dis:Arrhythmias, Cardiac;g:MTHFR)(dui:D020260;dis:Heavy Metal Poisoning, Nervous System;g:MTHFR)(dui:D001281;dis:Atrial Fibrillation;g:MTHFR)(dui:D020261;dis:Arsenic Poisoning;g:MTHFR)(dui:D016889;dis:Endometrial Neoplasms;g:MTHFR)(dui:D013118;dis:Spinal Cord Diseases;g:MTHFR)(dui:D004342;dis:Drug Hypersensitivity;g:MTHFR)(dui:D007571;dis:Jaw Diseases;g:MTHFR)(dui:D007569;dis:Jaw Abnormalities;g:MTHFR)(dui:D002972;dis:Cleft Palate;g:MTHFR)(dui:D013971;dis:Thyrotoxicosis;g:MTHFR)(dui:D003872;dis:Dermatitis;g:MTHFR)(dui:D003875;dis:Drug Eruptions;g:MTHFR)(dui:D006201;dis:Hair Diseases;g:MTHFR)(dui:D007039;dis:Hypotrichosis;g:MTHFR)(dui:D046152;dis:Gastrointestinal Stromal Tumors;g:MTHFR)(dui:D000505;dis:Alopecia;g:MTHFR)(dui:D058186;dis:Acute Kidney Injury;g:MTHFR)(dui:D006973;dis:Hypertension;g:MTHFR)(dui:D008113;dis:Liver Neoplasms;g:MTHFR)	Tetrahydrofolic acid:Menadione:Methionine:Riboflavin:Benazepril:Methotrexate:Cyanocobalamin:Folic acid:Fluorouracil	GO:0031060:GO:0070829:GO:0043200:GO:0046655:GO:0045202:GO:0004489:GO:0044877:GO:0072341:GO:0001666:GO:0001843:GO:0005829:GO:0035999:GO:0009086:GO:0071949:GO:0033274:GO:0046500:GO:0006730:GO:0006555:GO:0050661:GO:0050660:GO:0042493:GO:0051593:GO:0070555:GO:0055114:GO:0050667	607093		0.14															M
chr1:11794419	SNV	T	1	G/G	PASS	0.0	3911.74		400	T=2,G=398	T=0.005,G=0.995	99.5	0.5	homozygous	37	0.249	3.0		MTHFR	NM_005957.5	MTHFR:exonic:NM_005957.5	missense	GCA	8	p.Glu429Ala	c.1286A>C	0.06	0.021	107.0	G	GMAF=0.2596:AMAF=0.155:EMAF=0.3131	0.96		Conflicting interpretations of pathogenicity, other	3735923	rs1801131		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MTHFR)(dui:NBS2;dis:Core Conditions;g:MTHFR)(dui:NBS11;dis:Amino Acid Disorder;g:MTHFR)(dui:NBS57;dis:Homocystinuria;g:MTHFR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MTHFR)(dui:D002318;dis:Cardiovascular Diseases;g:MTHFR)(dui:D009422;dis:Nervous System Diseases;g:MTHFR)(dui:D014652;dis:Vascular Diseases;g:MTHFR)(dui:D009369;dis:Neoplasms;g:MTHFR)(dui:D000013;dis:Congenital Abnormalities;g:MTHFR)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MTHFR)(dui:D030342;dis:Genetic Diseases, Inborn;g:MTHFR)(dui:D009371;dis:Neoplasms by Site;g:MTHFR)(dui:D002493;dis:Central Nervous System Diseases;g:MTHFR)(dui:D007154;dis:Immune System Diseases;g:MTHFR)(dui:D004066;dis:Digestive System Diseases;g:MTHFR)(dui:D001927;dis:Brain Diseases;g:MTHFR)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MTHFR)(dui:D009370;dis:Neoplasms by Histologic Type;g:MTHFR)(dui:D005767;dis:Gastrointestinal Diseases;g:MTHFR)(dui:D008659;dis:Metabolic Diseases;g:MTHFR)(dui:D006331;dis:Heart Diseases;g:MTHFR)(dui:D004067;dis:Digestive System Neoplasms;g:MTHFR)(dui:D001523;dis:Mental Disorders;g:MTHFR)(dui:D006402;dis:Hematologic Diseases;g:MTHFR)(dui:D009748;dis:Nutrition Disorders;g:MTHFR)(dui:D044342;dis:Malnutrition;g:MTHFR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:MTHFR)(dui:D007160;dis:Immunoproliferative Disorders;g:MTHFR)(dui:D008232;dis:Lymphoproliferative Disorders;g:MTHFR)(dui:D002561;dis:Cerebrovascular Disorders;g:MTHFR)(dui:D008206;dis:Lymphatic Diseases;g:MTHFR)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MTHFR)(dui:D008661;dis:Metabolism, Inborn Errors;g:MTHFR)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MTHFR)(dui:D020138;dis:Hyperhomocysteinemia;g:MTHFR)(dui:D017202;dis:Myocardial Ischemia;g:MTHFR)(dui:D003677;dis:Deficiency Diseases;g:MTHFR)(dui:D001361;dis:Avitaminosis;g:MTHFR)(dui:D014804;dis:Vitamin B Deficiency;g:MTHFR)(dui:D009421;dis:Nervous System Malformations;g:MTHFR)(dui:D009436;dis:Neural Tube Defects;g:MTHFR)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:MTHFR)(dui:D009140;dis:Musculoskeletal Diseases;g:MTHFR)(dui:D016769;dis:Embolism and Thrombosis;g:MTHFR)(dui:D009461;dis:Neurologic Manifestations;g:MTHFR)(dui:D003327;dis:Coronary Disease;g:MTHFR)(dui:D052776;dis:Female Urogenital Diseases;g:MTHFR)(dui:D052801;dis:Male Urogenital Diseases;g:MTHFR)(dui:D008286;dis:Malabsorption Syndromes;g:MTHFR)(dui:D007938;dis:Leukemia;g:MTHFR)(dui:D009057;dis:Stomatognathic Diseases;g:MTHFR)(dui:D007945;dis:Leukemia, Lymphoid;g:MTHFR)(dui:D007410;dis:Intestinal Diseases;g:MTHFR)(dui:D012871;dis:Skin Diseases;g:MTHFR)(dui:D009059;dis:Mouth Diseases;g:MTHFR)(dui:D004700;dis:Endocrine System Diseases;g:MTHFR)(dui:D003108;dis:Colonic Diseases;g:MTHFR)(dui:D007414;dis:Intestinal Neoplasms;g:MTHFR)(dui:D015179;dis:Colorectal Neoplasms;g:MTHFR)(dui:D014565;dis:Urogenital Neoplasms;g:MTHFR)(dui:D018640;dis:Stomatognathic System Abnormalities;g:MTHFR)(dui:D019967;dis:Schizophrenia Spectrum and Other Psychotic Disorders;g:MTHFR)(dui:D003240;dis:Connective Tissue Diseases;g:MTHFR)(dui:D014570;dis:Urologic Diseases;g:MTHFR)(dui:D013927;dis:Thrombosis;g:MTHFR)(dui:D020521;dis:Stroke;g:MTHFR)(dui:D008223;dis:Lymphoma;g:MTHFR)(dui:D005831;dis:Genital Diseases, Female;g:MTHFR)(dui:D008107;dis:Liver Diseases;g:MTHFR)(dui:D009056;dis:Mouth Abnormalities;g:MTHFR)(dui:D025063;dis:Chromosome Disorders;g:MTHFR)(dui:D019954;dis:Neurobehavioral Manifestations;g:MTHFR)(dui:D008607;dis:Intellectual Disability;g:MTHFR)(dui:D000015;dis:Abnormalities, Multiple;g:MTHFR)(dui:D004314;dis:Down Syndrome;g:MTHFR)(dui:D019851;dis:Thrombophilia;g:MTHFR)(dui:D054198;dis:Precursor Cell Lymphoblastic Leukemia-Lymphoma;g:MTHFR)(dui:D007674;dis:Kidney Diseases;g:MTHFR)(dui:D013272;dis:Stomach Diseases;g:MTHFR)(dui:D020246;dis:Venous Thrombosis;g:MTHFR)(dui:D003920;dis:Diabetes Mellitus;g:MTHFR)(dui:D013274;dis:Stomach Neoplasms;g:MTHFR)(dui:D009139;dis:Musculoskeletal Abnormalities;g:MTHFR)(dui:D005832;dis:Genital Diseases, Male;g:MTHFR)(dui:D001327;dis:Autoimmune Diseases;g:MTHFR)(dui:D012559;dis:Schizophrenia;g:MTHFR)(dui:D007246;dis:Infertility;g:MTHFR)(dui:D012140;dis:Respiratory Tract Diseases;g:MTHFR)(dui:D008171;dis:Lung Diseases;g:MTHFR)(dui:D002545;dis:Brain Ischemia;g:MTHFR)(dui:D012002;dis:Rectal Diseases;g:MTHFR)(dui:D007592;dis:Joint Diseases;g:MTHFR)(dui:D001168;dis:Arthritis;g:MTHFR)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:MTHFR)(dui:D019636;dis:Neurodegenerative Diseases;g:MTHFR)(dui:D012216;dis:Rheumatic Diseases;g:MTHFR)(dui:D001172;dis:Arthritis, Rheumatoid;g:MTHFR)(dui:D005833;dis:Genital Neoplasms, Female;g:MTHFR)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MTHFR)(dui:D009008;dis:Abnormalities, Severe Teratoid;g:MTHFR)(dui:D000757;dis:Anencephaly;g:MTHFR)(dui:D003704;dis:Dementia;g:MTHFR)(dui:D019965;dis:Neurocognitive Disorders;g:MTHFR)(dui:D014591;dis:Uterine Diseases;g:MTHFR)(dui:D014594;dis:Uterine Neoplasms;g:MTHFR)(dui:D024801;dis:Tauopathies;g:MTHFR)(dui:D000544;dis:Alzheimer Disease;g:MTHFR)(dui:D007960;dis:Leukocyte Disorders;g:MTHFR)(dui:D007970;dis:Leukopenia;g:MTHFR)(dui:D013959;dis:Thyroid Diseases;g:MTHFR)(dui:D002277;dis:Carcinoma;g:MTHFR)(dui:D006967;dis:Hypersensitivity;g:MTHFR)(dui:D001157;dis:Arterial Occlusive Diseases;g:MTHFR)(dui:D008047;dis:Lip Diseases;g:MTHFR)(dui:D002971;dis:Cleft Lip;g:MTHFR)(dui:D019465;dis:Craniofacial Abnormalities;g:MTHFR)(dui:D019767;dis:Maxillofacial Abnormalities;g:MTHFR)(dui:D001161;dis:Arteriosclerosis;g:MTHFR)(dui:D018376;dis:Cardiovascular Abnormalities;g:MTHFR)(dui:D006330;dis:Heart Defects, Congenital;g:MTHFR)(dui:D013923;dis:Thromboembolism;g:MTHFR)(dui:D003110;dis:Colonic Neoplasms;g:MTHFR)(dui:D006980;dis:Hyperthyroidism;g:MTHFR)(dui:D048909;dis:Diabetes Complications;g:MTHFR)(dui:D001941;dis:Breast Diseases;g:MTHFR)(dui:D001943;dis:Breast Neoplasms;g:MTHFR)(dui:D001778;dis:Blood Coagulation Disorders;g:MTHFR)(dui:D007248;dis:Infertility, Male;g:MTHFR)(dui:D051437;dis:Renal Insufficiency;g:MTHFR)(dui:D025861;dis:Blood Coagulation Disorders, Inherited;g:MTHFR)(dui:D044882;dis:Glucose Metabolism Disorders;g:MTHFR)(dui:D000740;dis:Anemia;g:MTHFR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:MTHFR)(dui:D005759;dis:Gastroenteritis;g:MTHFR)(dui:D012678;dis:Sensation Disorders;g:MTHFR)(dui:D006086;dis:Graft vs Host Disease;g:MTHFR)(dui:D004427;dis:Ear Diseases;g:MTHFR)(dui:D006311;dis:Hearing Disorders;g:MTHFR)(dui:D034381;dis:Hearing Loss;g:MTHFR)(dui:D011248;dis:Pregnancy Complications;g:MTHFR)(dui:D000068105;dis:Bipolar and Related Disorders;g:MTHFR)(dui:D001714;dis:Bipolar Disorder;g:MTHFR)(dui:D011655;dis:Pulmonary Embolism;g:MTHFR)(dui:D004617;dis:Embolism;g:MTHFR)(dui:D003925;dis:Diabetic Angiopathies;g:MTHFR)(dui:D012142;dis:Respiratory Tract Neoplasms;g:MTHFR)(dui:D002577;dis:Uterine Cervical Diseases;g:MTHFR)(dui:D003639;dis:Hearing Loss, Sudden;g:MTHFR)(dui:D009385;dis:Neoplastic Processes;g:MTHFR)(dui:D002583;dis:Uterine Cervical Neoplasms;g:MTHFR)(dui:D013899;dis:Thoracic Neoplasms;g:MTHFR)(dui:D014571;dis:Urologic Neoplasms;g:MTHFR)(dui:D002278;dis:Carcinoma in Situ;g:MTHFR)(dui:D018290;dis:Cervical Intraepithelial Neoplasia;g:MTHFR)(dui:D005834;dis:Genital Neoplasms, Male;g:MTHFR)(dui:D011469;dis:Prostatic Diseases;g:MTHFR)(dui:D011471;dis:Prostatic Neoplasms;g:MTHFR)(dui:D008175;dis:Lung Neoplasms;g:MTHFR)(dui:D003324;dis:Coronary Artery Disease;g:MTHFR)(dui:D015448;dis:Leukemia, B-Cell;g:MTHFR)(dui:D015451;dis:Leukemia, Lymphocytic, Chronic, B-Cell;g:MTHFR)(dui:D001791;dis:Blood Platelet Disorders;g:MTHFR)(dui:D065886;dis:Neurodevelopmental Disorders;g:MTHFR)(dui:D001745;dis:Urinary Bladder Diseases;g:MTHFR)(dui:D001749;dis:Urinary Bladder Neoplasms;g:MTHFR)(dui:D056486;dis:Drug-Induced Liver Injury;g:MTHFR)(dui:D013921;dis:Thrombocytopenia;g:MTHFR)(dui:D002659;dis:Child Development Disorders, Pervasive;g:MTHFR)(dui:D002542;dis:Intracranial Embolism and Thrombosis;g:MTHFR)(dui:D020767;dis:Intracranial Thrombosis;g:MTHFR)(dui:D001321;dis:Autistic Disorder;g:MTHFR)(dui:D019964;dis:Mood Disorders;g:MTHFR)(dui:D003866;dis:Depressive Disorder;g:MTHFR)(dui:D000380;dis:Agranulocytosis;g:MTHFR)(dui:D009503;dis:Neutropenia;g:MTHFR)(dui:D023921;dis:Coronary Stenosis;g:MTHFR)(dui:D007247;dis:Infertility, Female;g:MTHFR)(dui:D012851;dis:Sinus Thrombosis, Intracranial;g:MTHFR)(dui:D001928;dis:Brain Diseases, Metabolic;g:MTHFR)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MTHFR)(dui:D018204;dis:Neoplasms, Connective and Soft Tissue;g:MTHFR)(dui:D008591;dis:Meningomyelocele;g:MTHFR)(dui:D008224;dis:Lymphoma, Follicular;g:MTHFR)(dui:D009372;dis:Neoplasms, Connective Tissue;g:MTHFR)(dui:D020258;dis:Neurotoxicity Syndromes;g:MTHFR)(dui:D052016;dis:Mucositis;g:MTHFR)(dui:D023903;dis:Coronary Restenosis;g:MTHFR)(dui:D009362;dis:Neoplasm Metastasis;g:MTHFR)(dui:D020879;dis:Neuromuscular Manifestations;g:MTHFR)(dui:D056784;dis:Leukoencephalopathies;g:MTHFR)(dui:D011618;dis:Psychotic Disorders;g:MTHFR)(dui:D009468;dis:Neuromuscular Diseases;g:MTHFR)(dui:D009135;dis:Muscular Diseases;g:MTHFR)(dui:D010523;dis:Peripheral Nervous System Diseases;g:MTHFR)(dui:D005530;dis:Foot Deformities;g:MTHFR)(dui:D005532;dis:Foot Deformities, Congenital;g:MTHFR)(dui:D006712;dis:Homocystinuria;g:MTHFR)(dui:D009128;dis:Muscle Spasticity;g:MTHFR)(dui:D017880;dis:Limb Deformities, Congenital;g:MTHFR)(dui:D000787;dis:Angina Pectoris;g:MTHFR)(dui:D003025;dis:Clubfoot;g:MTHFR)(dui:D009122;dis:Muscle Hypertonia;g:MTHFR)(dui:D038061;dis:Lower Extremity Deformities, Congenital;g:MTHFR)(dui:D017566;dis:Microvascular Angina;g:MTHFR)(dui:D001145;dis:Arrhythmias, Cardiac;g:MTHFR)(dui:D020260;dis:Heavy Metal Poisoning, Nervous System;g:MTHFR)(dui:D001281;dis:Atrial Fibrillation;g:MTHFR)(dui:D020261;dis:Arsenic Poisoning;g:MTHFR)(dui:D016889;dis:Endometrial Neoplasms;g:MTHFR)(dui:D013118;dis:Spinal Cord Diseases;g:MTHFR)(dui:D004342;dis:Drug Hypersensitivity;g:MTHFR)(dui:D007571;dis:Jaw Diseases;g:MTHFR)(dui:D007569;dis:Jaw Abnormalities;g:MTHFR)(dui:D002972;dis:Cleft Palate;g:MTHFR)(dui:D013971;dis:Thyrotoxicosis;g:MTHFR)(dui:D003872;dis:Dermatitis;g:MTHFR)(dui:D003875;dis:Drug Eruptions;g:MTHFR)(dui:D006201;dis:Hair Diseases;g:MTHFR)(dui:D007039;dis:Hypotrichosis;g:MTHFR)(dui:D046152;dis:Gastrointestinal Stromal Tumors;g:MTHFR)(dui:D000505;dis:Alopecia;g:MTHFR)(dui:D058186;dis:Acute Kidney Injury;g:MTHFR)(dui:D006973;dis:Hypertension;g:MTHFR)(dui:D008113;dis:Liver Neoplasms;g:MTHFR)	Tetrahydrofolic acid:Menadione:Methionine:Riboflavin:Benazepril:Methotrexate:Cyanocobalamin:Folic acid:Fluorouracil	GO:0031060:GO:0070829:GO:0043200:GO:0046655:GO:0045202:GO:0004489:GO:0044877:GO:0072341:GO:0001666:GO:0001843:GO:0005829:GO:0035999:GO:0009086:GO:0071949:GO:0033274:GO:0046500:GO:0006730:GO:0006555:GO:0050661:GO:0050660:GO:0042493:GO:0051593:GO:0070555:GO:0055114:GO:0050667	607093		3.76															M
chr1:11800401	SNV	C	1	C/T	PASS	1.085425449306832e-74	739.644		400	C=218,T=182	C=0.545,T=0.455	45.5	54.5	heterozygous	23	0.114	4.0		MTHFR	NM_005957.5	MTHFR:intronic:NM_005957.5	unknown			p.?	c.476-79G>A				T						rs1553187148:rs1553187151:rs2066471		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MTHFR)(dui:NBS2;dis:Core Conditions;g:MTHFR)(dui:NBS11;dis:Amino Acid Disorder;g:MTHFR)(dui:NBS57;dis:Homocystinuria;g:MTHFR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MTHFR)(dui:D002318;dis:Cardiovascular Diseases;g:MTHFR)(dui:D009422;dis:Nervous System Diseases;g:MTHFR)(dui:D014652;dis:Vascular Diseases;g:MTHFR)(dui:D009369;dis:Neoplasms;g:MTHFR)(dui:D000013;dis:Congenital Abnormalities;g:MTHFR)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MTHFR)(dui:D030342;dis:Genetic Diseases, Inborn;g:MTHFR)(dui:D009371;dis:Neoplasms by Site;g:MTHFR)(dui:D002493;dis:Central Nervous System Diseases;g:MTHFR)(dui:D007154;dis:Immune System Diseases;g:MTHFR)(dui:D004066;dis:Digestive System Diseases;g:MTHFR)(dui:D001927;dis:Brain Diseases;g:MTHFR)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MTHFR)(dui:D009370;dis:Neoplasms by Histologic Type;g:MTHFR)(dui:D005767;dis:Gastrointestinal Diseases;g:MTHFR)(dui:D008659;dis:Metabolic Diseases;g:MTHFR)(dui:D006331;dis:Heart Diseases;g:MTHFR)(dui:D004067;dis:Digestive System Neoplasms;g:MTHFR)(dui:D001523;dis:Mental Disorders;g:MTHFR)(dui:D006402;dis:Hematologic Diseases;g:MTHFR)(dui:D009748;dis:Nutrition Disorders;g:MTHFR)(dui:D044342;dis:Malnutrition;g:MTHFR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:MTHFR)(dui:D007160;dis:Immunoproliferative Disorders;g:MTHFR)(dui:D008232;dis:Lymphoproliferative Disorders;g:MTHFR)(dui:D002561;dis:Cerebrovascular Disorders;g:MTHFR)(dui:D008206;dis:Lymphatic Diseases;g:MTHFR)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MTHFR)(dui:D008661;dis:Metabolism, Inborn Errors;g:MTHFR)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MTHFR)(dui:D020138;dis:Hyperhomocysteinemia;g:MTHFR)(dui:D017202;dis:Myocardial Ischemia;g:MTHFR)(dui:D003677;dis:Deficiency Diseases;g:MTHFR)(dui:D001361;dis:Avitaminosis;g:MTHFR)(dui:D014804;dis:Vitamin B Deficiency;g:MTHFR)(dui:D009421;dis:Nervous System Malformations;g:MTHFR)(dui:D009436;dis:Neural Tube Defects;g:MTHFR)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:MTHFR)(dui:D009140;dis:Musculoskeletal Diseases;g:MTHFR)(dui:D016769;dis:Embolism and Thrombosis;g:MTHFR)(dui:D009461;dis:Neurologic Manifestations;g:MTHFR)(dui:D003327;dis:Coronary Disease;g:MTHFR)(dui:D052776;dis:Female Urogenital Diseases;g:MTHFR)(dui:D052801;dis:Male Urogenital Diseases;g:MTHFR)(dui:D008286;dis:Malabsorption Syndromes;g:MTHFR)(dui:D007938;dis:Leukemia;g:MTHFR)(dui:D009057;dis:Stomatognathic Diseases;g:MTHFR)(dui:D007945;dis:Leukemia, Lymphoid;g:MTHFR)(dui:D007410;dis:Intestinal Diseases;g:MTHFR)(dui:D012871;dis:Skin Diseases;g:MTHFR)(dui:D009059;dis:Mouth Diseases;g:MTHFR)(dui:D004700;dis:Endocrine System Diseases;g:MTHFR)(dui:D003108;dis:Colonic Diseases;g:MTHFR)(dui:D007414;dis:Intestinal Neoplasms;g:MTHFR)(dui:D015179;dis:Colorectal Neoplasms;g:MTHFR)(dui:D014565;dis:Urogenital Neoplasms;g:MTHFR)(dui:D018640;dis:Stomatognathic System Abnormalities;g:MTHFR)(dui:D019967;dis:Schizophrenia Spectrum and Other Psychotic Disorders;g:MTHFR)(dui:D003240;dis:Connective Tissue Diseases;g:MTHFR)(dui:D014570;dis:Urologic Diseases;g:MTHFR)(dui:D013927;dis:Thrombosis;g:MTHFR)(dui:D020521;dis:Stroke;g:MTHFR)(dui:D008223;dis:Lymphoma;g:MTHFR)(dui:D005831;dis:Genital Diseases, Female;g:MTHFR)(dui:D008107;dis:Liver Diseases;g:MTHFR)(dui:D009056;dis:Mouth Abnormalities;g:MTHFR)(dui:D025063;dis:Chromosome Disorders;g:MTHFR)(dui:D019954;dis:Neurobehavioral Manifestations;g:MTHFR)(dui:D008607;dis:Intellectual Disability;g:MTHFR)(dui:D000015;dis:Abnormalities, Multiple;g:MTHFR)(dui:D004314;dis:Down Syndrome;g:MTHFR)(dui:D019851;dis:Thrombophilia;g:MTHFR)(dui:D054198;dis:Precursor Cell Lymphoblastic Leukemia-Lymphoma;g:MTHFR)(dui:D007674;dis:Kidney Diseases;g:MTHFR)(dui:D013272;dis:Stomach Diseases;g:MTHFR)(dui:D020246;dis:Venous Thrombosis;g:MTHFR)(dui:D003920;dis:Diabetes Mellitus;g:MTHFR)(dui:D013274;dis:Stomach Neoplasms;g:MTHFR)(dui:D009139;dis:Musculoskeletal Abnormalities;g:MTHFR)(dui:D005832;dis:Genital Diseases, Male;g:MTHFR)(dui:D001327;dis:Autoimmune Diseases;g:MTHFR)(dui:D012559;dis:Schizophrenia;g:MTHFR)(dui:D007246;dis:Infertility;g:MTHFR)(dui:D012140;dis:Respiratory Tract Diseases;g:MTHFR)(dui:D008171;dis:Lung Diseases;g:MTHFR)(dui:D002545;dis:Brain Ischemia;g:MTHFR)(dui:D012002;dis:Rectal Diseases;g:MTHFR)(dui:D007592;dis:Joint Diseases;g:MTHFR)(dui:D001168;dis:Arthritis;g:MTHFR)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:MTHFR)(dui:D019636;dis:Neurodegenerative Diseases;g:MTHFR)(dui:D012216;dis:Rheumatic Diseases;g:MTHFR)(dui:D001172;dis:Arthritis, Rheumatoid;g:MTHFR)(dui:D005833;dis:Genital Neoplasms, Female;g:MTHFR)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MTHFR)(dui:D009008;dis:Abnormalities, Severe Teratoid;g:MTHFR)(dui:D000757;dis:Anencephaly;g:MTHFR)(dui:D003704;dis:Dementia;g:MTHFR)(dui:D019965;dis:Neurocognitive Disorders;g:MTHFR)(dui:D014591;dis:Uterine Diseases;g:MTHFR)(dui:D014594;dis:Uterine Neoplasms;g:MTHFR)(dui:D024801;dis:Tauopathies;g:MTHFR)(dui:D000544;dis:Alzheimer Disease;g:MTHFR)(dui:D007960;dis:Leukocyte Disorders;g:MTHFR)(dui:D007970;dis:Leukopenia;g:MTHFR)(dui:D013959;dis:Thyroid Diseases;g:MTHFR)(dui:D002277;dis:Carcinoma;g:MTHFR)(dui:D006967;dis:Hypersensitivity;g:MTHFR)(dui:D001157;dis:Arterial Occlusive Diseases;g:MTHFR)(dui:D008047;dis:Lip Diseases;g:MTHFR)(dui:D002971;dis:Cleft Lip;g:MTHFR)(dui:D019465;dis:Craniofacial Abnormalities;g:MTHFR)(dui:D019767;dis:Maxillofacial Abnormalities;g:MTHFR)(dui:D001161;dis:Arteriosclerosis;g:MTHFR)(dui:D018376;dis:Cardiovascular Abnormalities;g:MTHFR)(dui:D006330;dis:Heart Defects, Congenital;g:MTHFR)(dui:D013923;dis:Thromboembolism;g:MTHFR)(dui:D003110;dis:Colonic Neoplasms;g:MTHFR)(dui:D006980;dis:Hyperthyroidism;g:MTHFR)(dui:D048909;dis:Diabetes Complications;g:MTHFR)(dui:D001941;dis:Breast Diseases;g:MTHFR)(dui:D001943;dis:Breast Neoplasms;g:MTHFR)(dui:D001778;dis:Blood Coagulation Disorders;g:MTHFR)(dui:D007248;dis:Infertility, Male;g:MTHFR)(dui:D051437;dis:Renal Insufficiency;g:MTHFR)(dui:D025861;dis:Blood Coagulation Disorders, Inherited;g:MTHFR)(dui:D044882;dis:Glucose Metabolism Disorders;g:MTHFR)(dui:D000740;dis:Anemia;g:MTHFR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:MTHFR)(dui:D005759;dis:Gastroenteritis;g:MTHFR)(dui:D012678;dis:Sensation Disorders;g:MTHFR)(dui:D006086;dis:Graft vs Host Disease;g:MTHFR)(dui:D004427;dis:Ear Diseases;g:MTHFR)(dui:D006311;dis:Hearing Disorders;g:MTHFR)(dui:D034381;dis:Hearing Loss;g:MTHFR)(dui:D011248;dis:Pregnancy Complications;g:MTHFR)(dui:D000068105;dis:Bipolar and Related Disorders;g:MTHFR)(dui:D001714;dis:Bipolar Disorder;g:MTHFR)(dui:D011655;dis:Pulmonary Embolism;g:MTHFR)(dui:D004617;dis:Embolism;g:MTHFR)(dui:D003925;dis:Diabetic Angiopathies;g:MTHFR)(dui:D012142;dis:Respiratory Tract Neoplasms;g:MTHFR)(dui:D002577;dis:Uterine Cervical Diseases;g:MTHFR)(dui:D003639;dis:Hearing Loss, Sudden;g:MTHFR)(dui:D009385;dis:Neoplastic Processes;g:MTHFR)(dui:D002583;dis:Uterine Cervical Neoplasms;g:MTHFR)(dui:D013899;dis:Thoracic Neoplasms;g:MTHFR)(dui:D014571;dis:Urologic Neoplasms;g:MTHFR)(dui:D002278;dis:Carcinoma in Situ;g:MTHFR)(dui:D018290;dis:Cervical Intraepithelial Neoplasia;g:MTHFR)(dui:D005834;dis:Genital Neoplasms, Male;g:MTHFR)(dui:D011469;dis:Prostatic Diseases;g:MTHFR)(dui:D011471;dis:Prostatic Neoplasms;g:MTHFR)(dui:D008175;dis:Lung Neoplasms;g:MTHFR)(dui:D003324;dis:Coronary Artery Disease;g:MTHFR)(dui:D015448;dis:Leukemia, B-Cell;g:MTHFR)(dui:D015451;dis:Leukemia, Lymphocytic, Chronic, B-Cell;g:MTHFR)(dui:D001791;dis:Blood Platelet Disorders;g:MTHFR)(dui:D065886;dis:Neurodevelopmental Disorders;g:MTHFR)(dui:D001745;dis:Urinary Bladder Diseases;g:MTHFR)(dui:D001749;dis:Urinary Bladder Neoplasms;g:MTHFR)(dui:D056486;dis:Drug-Induced Liver Injury;g:MTHFR)(dui:D013921;dis:Thrombocytopenia;g:MTHFR)(dui:D002659;dis:Child Development Disorders, Pervasive;g:MTHFR)(dui:D002542;dis:Intracranial Embolism and Thrombosis;g:MTHFR)(dui:D020767;dis:Intracranial Thrombosis;g:MTHFR)(dui:D001321;dis:Autistic Disorder;g:MTHFR)(dui:D019964;dis:Mood Disorders;g:MTHFR)(dui:D003866;dis:Depressive Disorder;g:MTHFR)(dui:D000380;dis:Agranulocytosis;g:MTHFR)(dui:D009503;dis:Neutropenia;g:MTHFR)(dui:D023921;dis:Coronary Stenosis;g:MTHFR)(dui:D007247;dis:Infertility, Female;g:MTHFR)(dui:D012851;dis:Sinus Thrombosis, Intracranial;g:MTHFR)(dui:D001928;dis:Brain Diseases, Metabolic;g:MTHFR)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MTHFR)(dui:D018204;dis:Neoplasms, Connective and Soft Tissue;g:MTHFR)(dui:D008591;dis:Meningomyelocele;g:MTHFR)(dui:D008224;dis:Lymphoma, Follicular;g:MTHFR)(dui:D009372;dis:Neoplasms, Connective Tissue;g:MTHFR)(dui:D020258;dis:Neurotoxicity Syndromes;g:MTHFR)(dui:D052016;dis:Mucositis;g:MTHFR)(dui:D023903;dis:Coronary Restenosis;g:MTHFR)(dui:D009362;dis:Neoplasm Metastasis;g:MTHFR)(dui:D020879;dis:Neuromuscular Manifestations;g:MTHFR)(dui:D056784;dis:Leukoencephalopathies;g:MTHFR)(dui:D011618;dis:Psychotic Disorders;g:MTHFR)(dui:D009468;dis:Neuromuscular Diseases;g:MTHFR)(dui:D009135;dis:Muscular Diseases;g:MTHFR)(dui:D010523;dis:Peripheral Nervous System Diseases;g:MTHFR)(dui:D005530;dis:Foot Deformities;g:MTHFR)(dui:D005532;dis:Foot Deformities, Congenital;g:MTHFR)(dui:D006712;dis:Homocystinuria;g:MTHFR)(dui:D009128;dis:Muscle Spasticity;g:MTHFR)(dui:D017880;dis:Limb Deformities, Congenital;g:MTHFR)(dui:D000787;dis:Angina Pectoris;g:MTHFR)(dui:D003025;dis:Clubfoot;g:MTHFR)(dui:D009122;dis:Muscle Hypertonia;g:MTHFR)(dui:D038061;dis:Lower Extremity Deformities, Congenital;g:MTHFR)(dui:D017566;dis:Microvascular Angina;g:MTHFR)(dui:D001145;dis:Arrhythmias, Cardiac;g:MTHFR)(dui:D020260;dis:Heavy Metal Poisoning, Nervous System;g:MTHFR)(dui:D001281;dis:Atrial Fibrillation;g:MTHFR)(dui:D020261;dis:Arsenic Poisoning;g:MTHFR)(dui:D016889;dis:Endometrial Neoplasms;g:MTHFR)(dui:D013118;dis:Spinal Cord Diseases;g:MTHFR)(dui:D004342;dis:Drug Hypersensitivity;g:MTHFR)(dui:D007571;dis:Jaw Diseases;g:MTHFR)(dui:D007569;dis:Jaw Abnormalities;g:MTHFR)(dui:D002972;dis:Cleft Palate;g:MTHFR)(dui:D013971;dis:Thyrotoxicosis;g:MTHFR)(dui:D003872;dis:Dermatitis;g:MTHFR)(dui:D003875;dis:Drug Eruptions;g:MTHFR)(dui:D006201;dis:Hair Diseases;g:MTHFR)(dui:D007039;dis:Hypotrichosis;g:MTHFR)(dui:D046152;dis:Gastrointestinal Stromal Tumors;g:MTHFR)(dui:D000505;dis:Alopecia;g:MTHFR)(dui:D058186;dis:Acute Kidney Injury;g:MTHFR)(dui:D006973;dis:Hypertension;g:MTHFR)(dui:D008113;dis:Liver Neoplasms;g:MTHFR)	Tetrahydrofolic acid:Menadione:Methionine:Riboflavin:Benazepril:Methotrexate:Cyanocobalamin:Folic acid:Fluorouracil	GO:0031060:GO:0070829:GO:0043200:GO:0046655:GO:0045202:GO:0004489:GO:0044877:GO:0072341:GO:0001666:GO:0001843:GO:0005829:GO:0035999:GO:0009086:GO:0071949:GO:0033274:GO:0046500:GO:0006730:GO:0006555:GO:0050661:GO:0050660:GO:0042493:GO:0051593:GO:0070555:GO:0055114:GO:0050667	607093		0.24															M
chr1:75728369	SNV	C	1	C/G	PASS	3.6948771225393724e-53	524.324		310	C=175,G=135	C=0.5645,G=0.4355	43.55	56.45	heterozygous	15	0.183	1.0		ACADM	NM_000016.6	ACADM:intronic:NM_000016.6	unknown			p.?	c.31-32C>G				G	GMAF=0.2535:AMAF=0.1614:EMAF=0.3007			Benign		rs7524467		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADM)(dui:NBS2;dis:Core Conditions;g:ACADM)(dui:NBS10;dis:Fatty Acid Oxidation Disorder;g:ACADM)(dui:NBS51;dis:Medium-chain acyl-CoA dehydrogenase deficiency;g:ACADM)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADM)(dui:D008659;dis:Metabolic Diseases;g:ACADM)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADM)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADM)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADM)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADM)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADM)(dui:D004066;dis:Digestive System Diseases;g:ACADM)(dui:D008107;dis:Liver Diseases;g:ACADM)(dui:D048550;dis:Hepatic Insufficiency;g:ACADM)(dui:D017093;dis:Liver Failure;g:ACADM)(dui:D005767;dis:Gastrointestinal Diseases;g:ACADM)(dui:D009748;dis:Nutrition Disorders;g:ACADM)(dui:D005759;dis:Gastroenteritis;g:ACADM)(dui:D007410;dis:Intestinal Diseases;g:ACADM)(dui:D044343;dis:Overnutrition;g:ACADM)(dui:D004760;dis:Enterocolitis;g:ACADM)(dui:D009765;dis:Obesity;g:ACADM)(dui:D020345;dis:Enterocolitis, Necrotizing;g:ACADM)	Octanoyl-Coenzyme A:3-thiaoctanoyl-CoA:Flavin adenine dinucleotide	GO:0042802:GO:0045329:GO:0003995:GO:0005634:GO:0006635:GO:0033539:GO:0031966:GO:0070991:GO:0005759:GO:0050660:GO:0051793:GO:0019254:GO:0005739:GO:0051791:GO:0055114:GO:0019216:GO:0030424	607008	PF02771:PF02770:PF00441:PF08028	0.31															M
chr1:75732751	SNV	T	1	T/C	PASS	4.785198963583442e-83	823.201		398	T=207,C=191	T=0.5201,C=0.4799	47.99	52.01	heterozygous	15	0.231	1.0		ACADM	NM_000016.6	ACADM:intronic:NM_000016.6	unknown			p.?	c.216+10T>C				C	GMAF=0.3176:AMAF=0.292:EMAF=0.3307			Benign		rs2275378		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADM)(dui:NBS2;dis:Core Conditions;g:ACADM)(dui:NBS10;dis:Fatty Acid Oxidation Disorder;g:ACADM)(dui:NBS51;dis:Medium-chain acyl-CoA dehydrogenase deficiency;g:ACADM)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADM)(dui:D008659;dis:Metabolic Diseases;g:ACADM)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADM)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADM)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADM)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADM)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADM)(dui:D004066;dis:Digestive System Diseases;g:ACADM)(dui:D008107;dis:Liver Diseases;g:ACADM)(dui:D048550;dis:Hepatic Insufficiency;g:ACADM)(dui:D017093;dis:Liver Failure;g:ACADM)(dui:D005767;dis:Gastrointestinal Diseases;g:ACADM)(dui:D009748;dis:Nutrition Disorders;g:ACADM)(dui:D005759;dis:Gastroenteritis;g:ACADM)(dui:D007410;dis:Intestinal Diseases;g:ACADM)(dui:D044343;dis:Overnutrition;g:ACADM)(dui:D004760;dis:Enterocolitis;g:ACADM)(dui:D009765;dis:Obesity;g:ACADM)(dui:D020345;dis:Enterocolitis, Necrotizing;g:ACADM)	Octanoyl-Coenzyme A:3-thiaoctanoyl-CoA:Flavin adenine dinucleotide	GO:0042802:GO:0045329:GO:0003995:GO:0005634:GO:0006635:GO:0033539:GO:0031966:GO:0070991:GO:0005759:GO:0050660:GO:0051793:GO:0019254:GO:0005739:GO:0051791:GO:0055114:GO:0019216:GO:0030424	607008	PF02771:PF02770:PF00441:PF08028	-0.01															M
chr1:75733100	SNV	G	1	G/A	PASS	1.0624292038711416e-85	849.737		394	G=199,A=195	G=0.5051,A=0.4949	49.49	50.51	heterozygous	15	0.231	1.0		ACADM	NM_000016.6	ACADM:intronic:NM_000016.6	unknown			p.?	c.286+178G>A				A	GMAF=0.3193:AMAF=0.29:EMAF=0.3322			Benign		rs3818855		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADM)(dui:NBS2;dis:Core Conditions;g:ACADM)(dui:NBS10;dis:Fatty Acid Oxidation Disorder;g:ACADM)(dui:NBS51;dis:Medium-chain acyl-CoA dehydrogenase deficiency;g:ACADM)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADM)(dui:D008659;dis:Metabolic Diseases;g:ACADM)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADM)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADM)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADM)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADM)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADM)(dui:D004066;dis:Digestive System Diseases;g:ACADM)(dui:D008107;dis:Liver Diseases;g:ACADM)(dui:D048550;dis:Hepatic Insufficiency;g:ACADM)(dui:D017093;dis:Liver Failure;g:ACADM)(dui:D005767;dis:Gastrointestinal Diseases;g:ACADM)(dui:D009748;dis:Nutrition Disorders;g:ACADM)(dui:D005759;dis:Gastroenteritis;g:ACADM)(dui:D007410;dis:Intestinal Diseases;g:ACADM)(dui:D044343;dis:Overnutrition;g:ACADM)(dui:D004760;dis:Enterocolitis;g:ACADM)(dui:D009765;dis:Obesity;g:ACADM)(dui:D020345;dis:Enterocolitis, Necrotizing;g:ACADM)	Octanoyl-Coenzyme A:3-thiaoctanoyl-CoA:Flavin adenine dinucleotide	GO:0042802:GO:0045329:GO:0003995:GO:0005634:GO:0006635:GO:0033539:GO:0031966:GO:0070991:GO:0005759:GO:0050660:GO:0051793:GO:0019254:GO:0005739:GO:0051791:GO:0055114:GO:0019216:GO:0030424	607008	PF02771:PF02770:PF00441:PF08028	0.64															M
chr1:75733660	SNV	C	1	C/G	PASS	1.714746795790132e-89	887.658		399	C=201,G=198	C=0.5038,G=0.4962	49.62	50.38	heterozygous	15	0.231	1.0		ACADM	NM_000016.6	ACADM:intronic:NM_000016.6	unknown			p.?	c.387+32C>G				G	GMAF=0.3174:AMAF=0.2912:EMAF=0.3308			Benign		rs2153126		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADM)(dui:NBS2;dis:Core Conditions;g:ACADM)(dui:NBS10;dis:Fatty Acid Oxidation Disorder;g:ACADM)(dui:NBS51;dis:Medium-chain acyl-CoA dehydrogenase deficiency;g:ACADM)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADM)(dui:D008659;dis:Metabolic Diseases;g:ACADM)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADM)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADM)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADM)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADM)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADM)(dui:D004066;dis:Digestive System Diseases;g:ACADM)(dui:D008107;dis:Liver Diseases;g:ACADM)(dui:D048550;dis:Hepatic Insufficiency;g:ACADM)(dui:D017093;dis:Liver Failure;g:ACADM)(dui:D005767;dis:Gastrointestinal Diseases;g:ACADM)(dui:D009748;dis:Nutrition Disorders;g:ACADM)(dui:D005759;dis:Gastroenteritis;g:ACADM)(dui:D007410;dis:Intestinal Diseases;g:ACADM)(dui:D044343;dis:Overnutrition;g:ACADM)(dui:D004760;dis:Enterocolitis;g:ACADM)(dui:D009765;dis:Obesity;g:ACADM)(dui:D020345;dis:Enterocolitis, Necrotizing;g:ACADM)	Octanoyl-Coenzyme A:3-thiaoctanoyl-CoA:Flavin adenine dinucleotide	GO:0042802:GO:0045329:GO:0003995:GO:0005634:GO:0006635:GO:0033539:GO:0031966:GO:0070991:GO:0005759:GO:0050660:GO:0051793:GO:0019254:GO:0005739:GO:0051791:GO:0055114:GO:0019216:GO:0030424	607008	PF02771:PF02770:PF00441:PF08028	-1.39															M
chr1:75739958	SNV	C	1	C/A	PASS	6.084151222917065e-98	972.158		400	C=193,A=207	C=0.4825,A=0.5175	51.75	48.25	heterozygous	15	0.19	1.0		ACADM	NM_000016.6	ACADM:intronic:NM_000016.6	unknown			p.?	c.469-22C>A				A	GMAF=0.2589:AMAF=0.1791:EMAF=0.2997			Benign		rs12127402		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADM)(dui:NBS2;dis:Core Conditions;g:ACADM)(dui:NBS10;dis:Fatty Acid Oxidation Disorder;g:ACADM)(dui:NBS51;dis:Medium-chain acyl-CoA dehydrogenase deficiency;g:ACADM)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADM)(dui:D008659;dis:Metabolic Diseases;g:ACADM)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADM)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADM)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADM)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADM)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADM)(dui:D004066;dis:Digestive System Diseases;g:ACADM)(dui:D008107;dis:Liver Diseases;g:ACADM)(dui:D048550;dis:Hepatic Insufficiency;g:ACADM)(dui:D017093;dis:Liver Failure;g:ACADM)(dui:D005767;dis:Gastrointestinal Diseases;g:ACADM)(dui:D009748;dis:Nutrition Disorders;g:ACADM)(dui:D005759;dis:Gastroenteritis;g:ACADM)(dui:D007410;dis:Intestinal Diseases;g:ACADM)(dui:D044343;dis:Overnutrition;g:ACADM)(dui:D004760;dis:Enterocolitis;g:ACADM)(dui:D009765;dis:Obesity;g:ACADM)(dui:D020345;dis:Enterocolitis, Necrotizing;g:ACADM)	Octanoyl-Coenzyme A:3-thiaoctanoyl-CoA:Flavin adenine dinucleotide	GO:0042802:GO:0045329:GO:0003995:GO:0005634:GO:0006635:GO:0033539:GO:0031966:GO:0070991:GO:0005759:GO:0050660:GO:0051793:GO:0019254:GO:0005739:GO:0051791:GO:0055114:GO:0019216:GO:0030424	607008	PF02771:PF02770:PF00441:PF08028	0.23															M
chr1:75761337	SNV	A	1	A/G	PASS	2.032357010936254e-63	626.92		397	A=229,G=168	A=0.5768,G=0.4232	42.32	57.68	heterozygous	15	0.174	1.0		ACADM	NM_000016.6	ACADM:exonic:NM_000016.6	synonymous	GTG	11	p.Val387=	c.1161A>G				G	GMAF=0.25:AMAF=0.1589:EMAF=0.2966	0.75		Benign	5038163	rs1061337:rs748826784		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADM)(dui:NBS2;dis:Core Conditions;g:ACADM)(dui:NBS10;dis:Fatty Acid Oxidation Disorder;g:ACADM)(dui:NBS51;dis:Medium-chain acyl-CoA dehydrogenase deficiency;g:ACADM)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADM)(dui:D008659;dis:Metabolic Diseases;g:ACADM)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADM)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADM)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADM)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADM)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADM)(dui:D004066;dis:Digestive System Diseases;g:ACADM)(dui:D008107;dis:Liver Diseases;g:ACADM)(dui:D048550;dis:Hepatic Insufficiency;g:ACADM)(dui:D017093;dis:Liver Failure;g:ACADM)(dui:D005767;dis:Gastrointestinal Diseases;g:ACADM)(dui:D009748;dis:Nutrition Disorders;g:ACADM)(dui:D005759;dis:Gastroenteritis;g:ACADM)(dui:D007410;dis:Intestinal Diseases;g:ACADM)(dui:D044343;dis:Overnutrition;g:ACADM)(dui:D004760;dis:Enterocolitis;g:ACADM)(dui:D009765;dis:Obesity;g:ACADM)(dui:D020345;dis:Enterocolitis, Necrotizing;g:ACADM)	Octanoyl-Coenzyme A:3-thiaoctanoyl-CoA:Flavin adenine dinucleotide	GO:0042802:GO:0045329:GO:0003995:GO:0005634:GO:0006635:GO:0033539:GO:0031966:GO:0070991:GO:0005759:GO:0050660:GO:0051793:GO:0019254:GO:0005739:GO:0051791:GO:0055114:GO:0019216:GO:0030424	607008	PF02771:PF02770:PF00441:PF08028	1.28															M
chr1:115033861	SNV	C	1	C/G	PASS	6.078550092365211e-98	972.162		400	C=193,G=207	C=0.4825,G=0.5175	51.75	48.25	heterozygous	15	0.439	3.0		TSHB	NM_000549.5	TSHB:intronic:NM_000549.5	unknown			p.?	c.163-112C>G				G						rs28566771		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TSHB)(dui:NBS2;dis:Core Conditions;g:TSHB)(dui:NBS12;dis:Endocrine Disorder;g:TSHB)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TSHB)(dui:D004700;dis:Endocrine System Diseases;g:TSHB)(dui:D013959;dis:Thyroid Diseases;g:TSHB)(dui:D007037;dis:Hypothyroidism;g:TSHB)(dui:D009140;dis:Musculoskeletal Diseases;g:TSHB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TSHB)(dui:D001847;dis:Bone Diseases;g:TSHB)(dui:D001849;dis:Bone Diseases, Endocrine;g:TSHB)(dui:D004392;dis:Dwarfism;g:TSHB)(dui:D030342;dis:Genetic Diseases, Inborn;g:TSHB)(dui:D001848;dis:Bone Diseases, Developmental;g:TSHB)(dui:D003409;dis:Congenital Hypothyroidism;g:TSHB)(dui:D009422;dis:Nervous System Diseases;g:TSHB)(dui:D001523;dis:Mental Disorders;g:TSHB)(dui:D000068105;dis:Bipolar and Related Disorders;g:TSHB)(dui:D009461;dis:Neurologic Manifestations;g:TSHB)(dui:D001714;dis:Bipolar Disorder;g:TSHB)(dui:D019954;dis:Neurobehavioral Manifestations;g:TSHB)(dui:D003244;dis:Consciousness Disorders;g:TSHB)(dui:D014474;dis:Unconsciousness;g:TSHB)(dui:D003128;dis:Coma;g:TSHB)		GO:0005615:GO:0043627:GO:0007186:GO:0005737:GO:0051592:GO:0007267:GO:0009653:GO:0016486:GO:0033189:GO:0005576:GO:0005179:GO:0009755	188540		-0.51															M
chr2:1414420	SNV	C	1	C/G	PASS	2.964148790458439e-89	885.281		400	C=202,G=198	C=0.505,G=0.495	49.5	50.5	heterozygous	22	0.312	1.0		TPO	NM_000547.5	TPO:exonic:NM_000547.5	synonymous	CTG	2	p.Leu4=	c.12C>G				G	GMAF=0.3553:AMAF=0.2905:EMAF=0.3885	0.01		Benign	1399678	rs9678281		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-3.72															M
chr3:183017423	SNV	T	1	G/G	PASS	0.0	3978.98		398	T=0,G=398	T=0.0,G=1.0	100.0	0.0	homozygous	21	0.303	1.0		MCCC1	NM_020166.5	MCCC1:intronic:NM_020166.5	unknown			p.?	c.1978-86A>C				G						rs2292056		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MCCC1)(dui:NBS2;dis:Core Conditions;g:MCCC1)(dui:NBS9;dis:Organic Acid Condition;g:MCCC1)(dui:NBS45;dis:3-Methylcrotonyl-CoA carboxylase deficiency;g:MCCC1)(dui:D009422;dis:Nervous System Diseases;g:MCCC1)(dui:D002493;dis:Central Nervous System Diseases;g:MCCC1)(dui:D001927;dis:Brain Diseases;g:MCCC1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MCCC1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MCCC1)(dui:D008659;dis:Metabolic Diseases;g:MCCC1)(dui:D030342;dis:Genetic Diseases, Inborn;g:MCCC1)(dui:D001928;dis:Brain Diseases, Metabolic;g:MCCC1)(dui:D008661;dis:Metabolism, Inborn Errors;g:MCCC1)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MCCC1)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MCCC1)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:MCCC1)(dui:D019636;dis:Neurodegenerative Diseases;g:MCCC1)(dui:D009069;dis:Movement Disorders;g:MCCC1)(dui:D010300;dis:Parkinson Disease;g:MCCC1)(dui:D001480;dis:Basal Ganglia Diseases;g:MCCC1)(dui:D020734;dis:Parkinsonian Disorders;g:MCCC1)	Biotin	GO:0009083:GO:0009374:GO:1905202:GO:0006552:GO:0004075:GO:0004485:GO:0002169:GO:0005524:GO:0005515:GO:0006768:GO:0005759:GO:0046872:GO:0005739:GO:0005829:GO:0016421	609010	PF08443:PF07478:PF02222:PF00364:PF02786:PF02785:PF00289:PF02655	-0.45															M
chr4:158680524	SNV	C	1	C/T	PASS	5.734558665459618e-95	942.415		400	C=196,T=204	C=0.49,T=0.51	51.0	49.0	heterozygous	47	0.327	1.0		ETFDH	NM_004453.4	ETFDH:exonic:NM_004453.4	missense	ATA	2	p.Thr31Ile	c.92C>T	0.1	0.0	89.0	T	GMAF=0.3434:AMAF=0.2596:EMAF=0.14	0.84		Benign	4158888	rs11559290		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ETFDH)(dui:NBS3;dis:Secondary Conditions;g:ETFDH)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ETFDH)(dui:NBS24;dis:Glutaric acidemia type II;g:ETFDH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ETFDH)(dui:D008659;dis:Metabolic Diseases;g:ETFDH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ETFDH)(dui:D030342;dis:Genetic Diseases, Inborn;g:ETFDH)(dui:D008661;dis:Metabolism, Inborn Errors;g:ETFDH)(dui:D028361;dis:Mitochondrial Diseases;g:ETFDH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ETFDH)(dui:D054069;dis:Multiple Acyl Coenzyme A Dehydrogenase Deficiency;g:ETFDH)(dui:D009748;dis:Nutrition Disorders;g:ETFDH)(dui:D044343;dis:Overnutrition;g:ETFDH)(dui:D009765;dis:Obesity;g:ETFDH)	Metformin:2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol	GO:0009055:GO:0022904:GO:0043783:GO:0004174:GO:0022900:GO:0048039:GO:0006979:GO:0031305:GO:0033539:GO:0005515:GO:0031966:GO:0048038:GO:0005759:GO:0016491:GO:0046872:GO:0050660:GO:0051539	231675	PF01946:PF13450:PF05187:PF00890	1.1															M
chr5:71632256	SNV	C	1	C/T	PASS	5.842517205360447e-97	962.334		400	C=194,T=206	C=0.485,T=0.515	51.5	48.5	heterozygous	36	0.39	1.0		MCCC2	NM_022132.5	MCCC2:intronic:NM_022132.5	unknown			p.?	c.803+71C>T				T						rs277981		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MCCC2)(dui:NBS2;dis:Core Conditions;g:MCCC2)(dui:NBS9;dis:Organic Acid Condition;g:MCCC2)(dui:NBS45;dis:3-Methylcrotonyl-CoA carboxylase deficiency;g:MCCC2)(dui:D009422;dis:Nervous System Diseases;g:MCCC2)(dui:D002493;dis:Central Nervous System Diseases;g:MCCC2)(dui:D001927;dis:Brain Diseases;g:MCCC2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MCCC2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MCCC2)(dui:D008659;dis:Metabolic Diseases;g:MCCC2)(dui:D030342;dis:Genetic Diseases, Inborn;g:MCCC2)(dui:D008661;dis:Metabolism, Inborn Errors;g:MCCC2)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MCCC2)(dui:D001928;dis:Brain Diseases, Metabolic;g:MCCC2)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MCCC2)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:MCCC2)	Biotin	GO:0002169:GO:0005524:GO:0005515:GO:0006768:GO:0009083:GO:0005759:GO:1905202:GO:0005739:GO:0006552:GO:0005829:GO:0015936:GO:0004485	609014	PF01039	-1.98															M
chr6:32038560	SNV	C	1	A/A	PASS	2.360478233180525e-221	2206.27		241	C=6,A=235	C=0.0249,A=0.9751	97.51	2.489999999999995	homozygous	54		4.0		CYP21A2	NM_000500.9	CYP21A2:exonic:NM_000500.9	synonymous	CCA	1	p.Pro46=	c.138C>A				A		0.05		Benign	4160892	rs6464		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	0.44															M
chr6:32038878	SNV	C	1	C/T	PASS	1.006583947027135e-09	89.9715		265	C=205,T=60	C=0.7736,T=0.2264	22.64	77.36	heterozygous	39	0.218	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.292+67C>T				T						rs6449		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-2.74															M
chr6:32038983	INDEL	TG	1	T/T	PASS	3.357376142429518e-111	1104.74		394	TG=57,T=337	TG=0.1447,T=0.8553	85.53	14.47	homozygous	8	0.26	7.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.293-110delG				T						rs1562755827:rs369651496:rs1197386901		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-1.9,0.58															M
chr7:117536538	INDEL	TGATT	4	TGATT/T	PASS	1.094712305620638e-68	679.607		307	TGATT=153,T=154	TGATT=0.4984,T=0.5016	50.16	49.84	heterozygous	47		1.0		CFTR	NM_000492.4	CFTR:intronic:NM_000492.4	unknown			p.?	c.744-9_744-6delGATT				T						rs1584787644:rs397508793:rs387906367:rs1584787639:rs1554380751:rs878854022		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		0.15,0.0,0.0,-0.48,2.25															M
chr7:117559403	SNV	A	1	A/G	PASS	2.6927745869589524e-97	965.698		399	A=193,G=206	A=0.4837,G=0.5163	51.63	48.37	heterozygous	47	0.337	1.0		CFTR|CFTR-AS1	NM_000492.4|NR_149084.1	CFTR:intronic:NM_000492.4|CFTR-AS1:intronic_nc:NR_149084.1	unknown|	|	|	p.?|	c.1393-61A>G|	|	|	|	G|				Benign		rs34855237		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		0.3															M
chr7:117559479	SNV	G	1	G/A	PASS	3.3265955329400893e-103	1024.78		399	G=187,A=212	G=0.4687,A=0.5313	53.13	46.87	heterozygous	47	0.418	2.0		CFTR|CFTR-AS1	NM_000492.4|NR_149084.1	CFTR:exonic:NM_000492.4|CFTR-AS1:intronic_nc:NR_149084.1	missense|	ATG|	11|	p.Val470Met|	c.1408G>A|	1.0|	0.0|	21.0|	A|	GMAF=0.4024:AMAF=0.1496:EMAF=0.4681	0.39	M470V	Benign/Likely benign	3762337	rs397508204:rs213950		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		2.57															M
chr7:117595001	SNV	T	1	T/G	PASS	4.6698184855782894e-73	723.307		399	T=219,G=180	T=0.5489,G=0.4511	45.11	54.89	heterozygous	47	0.479	1.0		CFTR	NM_000492.4	CFTR:exonic:NM_000492.4	synonymous	ACG	15	p.Thr854=	c.2562T>G				G	GMAF=0.4028:AMAF=0.3813:EMAF=0.2922	0.13		Benign/Likely benign	4161733	rs1584813846:rs1554389814:rs397508396:rs1042077		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		0.28															M
chr7:117606582	SNV	G	1	G/A	PASS	1.2773208461131612e-85	848.937		364	G=179,A=185	G=0.4918,A=0.5082	50.82	49.18	heterozygous	29	0.119	1.0		CFTR	NM_000492.4	CFTR:intronic:NM_000492.4	unknown			p.?	c.2909-92G>A				A				Benign		rs35050470		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		-0.23															M
chr7:117627457	SNV	C	1	C/A	PASS	4.509205208756533e-93	923.459		400	C=198,A=202	C=0.495,A=0.505	50.5	49.5	heterozygous	29	0.144	1.0		CFTR	NM_000492.4	CFTR:intronic:NM_000492.4	unknown			p.?	c.3469-65C>A				A				Benign		rs213989		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		-0.12															M
chr7:117667054	SNV	G	1	G/A	PASS	5.648069082416842e-96	952.481		400	G=195,A=205	G=0.4875,A=0.5125	51.25	48.75	heterozygous	36	0.186	1.0		CFTR	NM_000492.4	CFTR:exonic:NM_000492.4	synonymous	CAA	27	p.Gln1463=	c.4389G>A				A	GMAF=0.2259:AMAF=0.2444:EMAF=0.2164	0.11		Benign/Likely benign	3762339	rs1800136:rs1584850283		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		0.01															M
chr10:102831425	SNV	G	1	G/T	PASS	4.980810283567226e-74	733.027		400	G=219,T=181	G=0.5475,T=0.4525	45.25	54.75	heterozygous	37	0.142	2.0		CYP17A1	NM_000102.4	CYP17A1:intronic:NM_000102.4	unknown			p.?	c.1243+83C>A				T						rs284849		(dui:D004700;dis:Endocrine System Diseases;g:CYP17A1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP17A1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP17A1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP17A1)(dui:D006058;dis:Gonadal Disorders;g:CYP17A1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP17A1)(dui:D008659;dis:Metabolic Diseases;g:CYP17A1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP17A1)(dui:D000013;dis:Congenital Abnormalities;g:CYP17A1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP17A1)(dui:D012734;dis:Disorders of Sex Development;g:CYP17A1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP17A1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP17A1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP17A1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP17A1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP17A1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP17A1)(dui:D009369;dis:Neoplasms;g:CYP17A1)(dui:D009371;dis:Neoplasms by Site;g:CYP17A1)(dui:D004066;dis:Digestive System Diseases;g:CYP17A1)(dui:D008107;dis:Liver Diseases;g:CYP17A1)(dui:D009422;dis:Nervous System Diseases;g:CYP17A1)(dui:D005831;dis:Genital Diseases, Female;g:CYP17A1)(dui:D005832;dis:Genital Diseases, Male;g:CYP17A1)(dui:D002493;dis:Central Nervous System Diseases;g:CYP17A1)(dui:D001927;dis:Brain Diseases;g:CYP17A1)(dui:D007246;dis:Infertility;g:CYP17A1)(dui:D014565;dis:Urogenital Neoplasms;g:CYP17A1)(dui:D010049;dis:Ovarian Diseases;g:CYP17A1)(dui:D000291;dis:Adnexal Diseases;g:CYP17A1)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CYP17A1)(dui:D011469;dis:Prostatic Diseases;g:CYP17A1)(dui:D012871;dis:Skin Diseases;g:CYP17A1)(dui:D001941;dis:Breast Diseases;g:CYP17A1)(dui:D003560;dis:Cysts;g:CYP17A1)(dui:D010048;dis:Ovarian Cysts;g:CYP17A1)(dui:D001943;dis:Breast Neoplasms;g:CYP17A1)(dui:D005834;dis:Genital Neoplasms, Male;g:CYP17A1)(dui:D009370;dis:Neoplasms by Histologic Type;g:CYP17A1)(dui:D011471;dis:Prostatic Neoplasms;g:CYP17A1)(dui:D002318;dis:Cardiovascular Diseases;g:CYP17A1)(dui:D004067;dis:Digestive System Neoplasms;g:CYP17A1)(dui:D014652;dis:Vascular Diseases;g:CYP17A1)(dui:D019636;dis:Neurodegenerative Diseases;g:CYP17A1)(dui:D006973;dis:Hypertension;g:CYP17A1)(dui:D009069;dis:Movement Disorders;g:CYP17A1)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:CYP17A1)(dui:D001523;dis:Mental Disorders;g:CYP17A1)(dui:D002277;dis:Carcinoma;g:CYP17A1)(dui:D010300;dis:Parkinson Disease;g:CYP17A1)(dui:D001480;dis:Basal Ganglia Diseases;g:CYP17A1)(dui:D020734;dis:Parkinsonian Disorders;g:CYP17A1)(dui:D000230;dis:Adenocarcinoma;g:CYP17A1)(dui:D008113;dis:Liver Neoplasms;g:CYP17A1)(dui:D007247;dis:Infertility, Female;g:CYP17A1)(dui:D020018;dis:Sexual Dysfunctions, Psychological;g:CYP17A1)(dui:D006528;dis:Carcinoma, Hepatocellular;g:CYP17A1)(dui:D007006;dis:Hypogonadism;g:CYP17A1)(dui:D007248;dis:Infertility, Male;g:CYP17A1)(dui:D010900;dis:Pituitary Diseases;g:CYP17A1)(dui:D005234;dis:Fatty Liver;g:CYP17A1)(dui:D007018;dis:Hypopituitarism;g:CYP17A1)(dui:D008103;dis:Liver Cirrhosis;g:CYP17A1)(dui:D014883;dis:Water-Electrolyte Imbalance;g:CYP17A1)(dui:D006947;dis:Hyperkalemia;g:CYP17A1)(dui:D006974;dis:Hypertension, Malignant;g:CYP17A1)(dui:D007027;dis:Hypothalamic Diseases;g:CYP17A1)(dui:D008106;dis:Liver Cirrhosis, Experimental;g:CYP17A1)(dui:D065626;dis:Non-alcoholic Fatty Liver Disease;g:CYP17A1)	Stanolone:Dexamethasone:Ketoconazole:Nabiximols:Abiraterone:Medical Cannabis:Cannabidiol:Clomifene:Aldosterone:NADH:Spironolactone:Aminophenazone:Dexamethasone acetate:Progesterone:Prasterone	GO:0019825:GO:0042448:GO:0008202:GO:0005783:GO:0006694:GO:0043025:GO:0042446:GO:0020037:GO:0005789:GO:0006704:GO:0007548:GO:0006702:GO:0005506:GO:0004508:GO:0047442:GO:0055114:GO:0030424	609300	PF00067	-0.16															M
chr10:123009067	SNV	G	1	G/A	PASS	7.620790100253959e-106	1051.18		400	G=185,A=215	G=0.4625,A=0.5375	53.75	46.25	heterozygous	15	0.206	2.0		IKZF5|ACADSB	NM_001372127.1|NM_001609.4	IKZF5:upstream:NM_001372127.1|ACADSB:exonic:NM_001609.4	unknown|missense	|AAG	|1	p.?|p.Arg13Lys	c.-10442C>T|c.38G>A	|0.62	|0.012	|26.0	A|A	GMAF=0.2742:AMAF=0.1177:EMAF=0.3621	0.0		Benign	427201	rs12263012		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADSB)(dui:NBS3;dis:Secondary Conditions;g:ACADSB)(dui:NBS18;dis:2-Methylbutyrylglycinuria;g:ACADSB)(dui:NBS4;dis:Organic Acid Condition;g:ACADSB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADSB)(dui:D008659;dis:Metabolic Diseases;g:ACADSB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADSB)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADSB)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADSB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ACADSB)(dui:D001523;dis:Mental Disorders;g:ACADSB)(dui:D065886;dis:Neurodevelopmental Disorders;g:ACADSB)(dui:D002659;dis:Child Development Disorders, Pervasive;g:ACADSB)(dui:D001321;dis:Autistic Disorder;g:ACADSB)	Valproic acid:Isoleucine	GO:0003853:GO:0042802:GO:0009083:GO:0005759:GO:0050660:GO:0016937:GO:0005739:GO:0102035:GO:0006550:GO:0055114:GO:0006631	600301		0.03															M
chr11:108142366	SNV	A	1	A/G	PASS	5.556483128371233e-96	952.552		400	A=195,G=205	A=0.4875,G=0.5125	51.25	48.75	heterozygous	29	0.191	1.0		ACAT1	NM_000019.4	ACAT1:intronic:NM_000019.4	unknown			p.?	c.827-71A>G				G						rs10890818		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACAT1)(dui:NBS2;dis:Core Conditions;g:ACAT1)(dui:NBS48;dis:beta-Ketothiolase deficiency;g:ACAT1)(dui:NBS9;dis:Organic Acid Condition;g:ACAT1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACAT1)(dui:D008659;dis:Metabolic Diseases;g:ACAT1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACAT1)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACAT1)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACAT1)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ACAT1)(dui:D052801;dis:Male Urogenital Diseases;g:ACAT1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:ACAT1)(dui:D014570;dis:Urologic Diseases;g:ACAT1)(dui:D052776;dis:Female Urogenital Diseases;g:ACAT1)(dui:D007674;dis:Kidney Diseases;g:ACAT1)(dui:D051437;dis:Renal Insufficiency;g:ACAT1)(dui:D051436;dis:Renal Insufficiency, Chronic;g:ACAT1)(dui:D007676;dis:Kidney Failure, Chronic;g:ACAT1)(dui:D009422;dis:Nervous System Diseases;g:ACAT1)(dui:D002493;dis:Central Nervous System Diseases;g:ACAT1)(dui:D001927;dis:Brain Diseases;g:ACAT1)(dui:D009461;dis:Neurologic Manifestations;g:ACAT1)(dui:D012640;dis:Seizures;g:ACAT1)(dui:D004827;dis:Epilepsy;g:ACAT1)	Nabiximols:Sulfasalazine:Medical Cannabis:Cannabidiol	GO:0006085:GO:0042594:GO:0046952:GO:0046356:GO:0046951:GO:0003985:GO:0006635:GO:0070062:GO:0003988:GO:0001889:GO:0016453:GO:0072229:GO:0042802:GO:0009083:GO:1902860:GO:0006550:GO:1902224:GO:0007420:GO:0014070:GO:0009725:GO:0060612:GO:0030955:GO:0005759:GO:0005739:GO:0015937:GO:0034435:GO:0015936:GO:0019899	607809	PF02803:PF00108:PF00109	-0.34															M
chr11:108142634	SNV	C	1	C/T	PASS	1.0092528860766628e-77	769.96		400	C=214,T=186	C=0.535,T=0.465	46.5	53.5	heterozygous	25	0.262	1.0		ACAT1	NM_000019.4	ACAT1:intronic:NM_000019.4	unknown			p.?	c.940+84C>T				T						rs12794010		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACAT1)(dui:NBS2;dis:Core Conditions;g:ACAT1)(dui:NBS48;dis:beta-Ketothiolase deficiency;g:ACAT1)(dui:NBS9;dis:Organic Acid Condition;g:ACAT1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACAT1)(dui:D008659;dis:Metabolic Diseases;g:ACAT1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACAT1)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACAT1)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACAT1)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ACAT1)(dui:D052801;dis:Male Urogenital Diseases;g:ACAT1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:ACAT1)(dui:D014570;dis:Urologic Diseases;g:ACAT1)(dui:D052776;dis:Female Urogenital Diseases;g:ACAT1)(dui:D007674;dis:Kidney Diseases;g:ACAT1)(dui:D051437;dis:Renal Insufficiency;g:ACAT1)(dui:D051436;dis:Renal Insufficiency, Chronic;g:ACAT1)(dui:D007676;dis:Kidney Failure, Chronic;g:ACAT1)(dui:D009422;dis:Nervous System Diseases;g:ACAT1)(dui:D002493;dis:Central Nervous System Diseases;g:ACAT1)(dui:D001927;dis:Brain Diseases;g:ACAT1)(dui:D009461;dis:Neurologic Manifestations;g:ACAT1)(dui:D012640;dis:Seizures;g:ACAT1)(dui:D004827;dis:Epilepsy;g:ACAT1)	Nabiximols:Sulfasalazine:Medical Cannabis:Cannabidiol	GO:0006085:GO:0042594:GO:0046952:GO:0046356:GO:0046951:GO:0003985:GO:0006635:GO:0070062:GO:0003988:GO:0001889:GO:0016453:GO:0072229:GO:0042802:GO:0009083:GO:1902860:GO:0006550:GO:1902224:GO:0007420:GO:0014070:GO:0009725:GO:0060612:GO:0030955:GO:0005759:GO:0005739:GO:0015937:GO:0034435:GO:0015936:GO:0019899	607809	PF02803:PF00108:PF00109	0.95															M
chr12:109557065	SNV	A	1	A/T	PASS	1.0447202192208132e-76	759.81		395	A=212,T=183	A=0.5367,T=0.4633	46.33	53.67	heterozygous	30	0.487	1.0		MMAB	NM_052845.4	MMAB:exonic:NM_052845.4	missense	AAG	9	p.Met239Lys	c.716T>A	1.0	0.0	95.0	T	GMAF=0.4037:AMAF=0.2792:EMAF=0.4676	0.12		Benign	3752888	rs9593		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMAB)(dui:NBS2;dis:Core Conditions;g:MMAB)(dui:NBS9;dis:Organic Acid Condition;g:MMAB)(dui:NBS43;dis:Methylmalonic acidemia;g:MMAB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMAB)(dui:D008659;dis:Metabolic Diseases;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMAB)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMAB)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMAB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMAB)	Cyanocobalamin	GO:0005524:GO:0005515:GO:0005759:GO:0031419:GO:0008817:GO:0009235	607568	PF01923	-0.02															M
chr12:109565014	SNV	A	1	A/G	PASS	1.633804169300683e-88	877.868		399	A=202,G=197	A=0.5063,G=0.4937	49.37	50.63	heterozygous	30	0.482	2.0		MMAB	NM_052845.4	MMAB:intronic:NM_052845.4	unknown			p.?	c.348+105T>C				G				Benign		rs10850380		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMAB)(dui:NBS2;dis:Core Conditions;g:MMAB)(dui:NBS9;dis:Organic Acid Condition;g:MMAB)(dui:NBS43;dis:Methylmalonic acidemia;g:MMAB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMAB)(dui:D008659;dis:Metabolic Diseases;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMAB)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMAB)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMAB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMAB)	Cyanocobalamin	GO:0005524:GO:0005515:GO:0005759:GO:0031419:GO:0008817:GO:0009235	607568	PF01923	0.41															M
chr13:100368441	SNV	A	1	G/G	PASS	0.0	3993.12		399	A=0,G=399	A=0.0,G=1.0	100.0	0.0	homozygous	54	0.447	1.0		PCCA	NR_148031.2	PCCA:intronic_nc:NR_148031.2										GMAF=0.3177:AMAF=0.4921:EMAF=0.2284			Benign		rs9518061		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PCCA)(dui:NBS2;dis:Core Conditions;g:PCCA)(dui:NBS9;dis:Organic Acid Condition;g:PCCA)(dui:NBS42;dis:Propionic acidemia;g:PCCA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PCCA)(dui:D008659;dis:Metabolic Diseases;g:PCCA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PCCA)(dui:D030342;dis:Genetic Diseases, Inborn;g:PCCA)(dui:D008661;dis:Metabolism, Inborn Errors;g:PCCA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PCCA)(dui:D056693;dis:Propionic Acidemia;g:PCCA)(dui:D005128;dis:Eye Diseases;g:PCCA)(dui:D012030;dis:Refractive Errors;g:PCCA)	Biotin		232000	PF08443:PF07478:PF00364:PF02222:PF02786:PF02785:PF00289	2.28															M
chr15:40407805	INDEL	GTT	2	GTT/G	PASS	7.421641977388881e-16	151.295		336	GTT=205,G=131	GTT=0.6101,G=0.3899	38.99	61.01	heterozygous	8	0.353	4.0		IVD	NR_148925.2	IVD:intronic_nc:NR_148925.2															rs202212502:rs3214685		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:IVD)(dui:NBS2;dis:Core Conditions;g:IVD)(dui:NBS9;dis:Organic Acid Condition;g:IVD)(dui:NBS44;dis:Isovaleric acidemia;g:IVD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:IVD)(dui:D030342;dis:Genetic Diseases, Inborn;g:IVD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:IVD)(dui:D008659;dis:Metabolic Diseases;g:IVD)(dui:D008661;dis:Metabolism, Inborn Errors;g:IVD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:IVD)(dui:D012140;dis:Respiratory Tract Diseases;g:IVD)(dui:D008171;dis:Lung Diseases;g:IVD)(dui:D017563;dis:Lung Diseases, Interstitial;g:IVD)	Coenzyme A persulfide:Flavin adenine dinucleotide		607036		-0.84,-0.19,-0.06															M
chr15:76311338	SNV	G	1	C/C	PASS	0.0	3991.56		400	G=0,C=400	G=0.0,C=1.0	100.0	0.0	homozygous	8	0.151	1.0		ETFA	NM_000126.4	ETFA:intronic:NM_000126.4	unknown			p.?	c.39+12C>G				C	GMAF=0.1172:AMAF=0.1581:EMAF=0.0966			Benign		rs62027051		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ETFA)(dui:NBS3;dis:Secondary Conditions;g:ETFA)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ETFA)(dui:NBS24;dis:Glutaric acidemia type II;g:ETFA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ETFA)(dui:D008659;dis:Metabolic Diseases;g:ETFA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ETFA)(dui:D030342;dis:Genetic Diseases, Inborn;g:ETFA)(dui:D008661;dis:Metabolism, Inborn Errors;g:ETFA)(dui:D028361;dis:Mitochondrial Diseases;g:ETFA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ETFA)(dui:D054069;dis:Multiple Acyl Coenzyme A Dehydrogenase Deficiency;g:ETFA)(dui:D009140;dis:Musculoskeletal Diseases;g:ETFA)(dui:D007592;dis:Joint Diseases;g:ETFA)(dui:D012216;dis:Rheumatic Diseases;g:ETFA)(dui:D001168;dis:Arthritis;g:ETFA)(dui:D009369;dis:Neoplasms;g:ETFA)(dui:D009370;dis:Neoplasms by Histologic Type;g:ETFA)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:ETFA)(dui:D004066;dis:Digestive System Diseases;g:ETFA)(dui:D009371;dis:Neoplasms by Site;g:ETFA)(dui:D008107;dis:Liver Diseases;g:ETFA)(dui:D002277;dis:Carcinoma;g:ETFA)(dui:D000230;dis:Adenocarcinoma;g:ETFA)(dui:D004067;dis:Digestive System Neoplasms;g:ETFA)(dui:D008113;dis:Liver Neoplasms;g:ETFA)(dui:D010003;dis:Osteoarthritis;g:ETFA)(dui:D006528;dis:Carcinoma, Hepatocellular;g:ETFA)		GO:0033539:GO:0005515:GO:0005759:GO:0016491:GO:0050660:GO:0009055:GO:0005739:GO:0022904	608053	PF00766:PF01012	0.4															M
chr15:80153171	INDEL	GGGAGT	5	GGGAGT/G	PASS	1e-05	50.0		551	GGGAGT=443,G=108	GGGAGT=0.804,G=0.196	19.6	80.4	heterozygous	8	0.031			FAH	NM_000137.4	FAH:intronic:NM_000137.4	unknown			p.?	c.81+37_81+41delGGAGT				G						rs57837512:rs1555440095:rs1555440094:rs558321563:rs756381638:rs752679360:rs1555440100:rs554422109:rs777902403:rs71699670:rs767638459:rs762924131:rs869124015:rs757176902		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	0.92,0.14,0.14,-1.81,0.78,-0.07															M
chr15:80158047	SNV	G	1	A/A	PASS	0.0	3994.53		399	G=0,A=399	G=0.0,A=1.0	100.0	0.0	homozygous	39	0.493	1.0		FAH	NM_000137.4	FAH:intronic:NM_000137.4	unknown			p.?	c.82-13G>A				A	GMAF=0.4463:AMAF=0.3221:EMAF=0.49			Benign		rs1370275		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-4.7															M
chr15:80175284	SNV	G	1	T/T	PASS	0.0	3663.53		400	G=11,T=389	G=0.0275,T=0.9725	97.25	2.75	homozygous	46	0.447	3.0		FAH	NM_000137.4	FAH:intronic:NM_000137.4	unknown			p.?	c.913+193G>T				T						rs1863768		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-0.01															M
chr15:80180089	SNV	C	1	A/A	PASS	0.0	3956.71		399	C=1,A=398	C=0.0025,A=0.9975	99.75	0.25	homozygous	46	0.33	2.0		FAH	NM_000137.4	FAH:intronic:NM_000137.4	unknown			p.?	c.961-35C>A				A	GMAF=0.406:AMAF=0.4737:EMAF=0.3713			Benign		rs2043691		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.01															M
chr19:12891586	SNV	G	1	G/C	PASS	6.389987373482695e-100	991.945		400	G=191,C=209	G=0.4775,C=0.5225	52.25	47.75	heterozygous	29	0.253	2.0		GCDH	NR_102317.1	GCDH:exonic_nc:NR_102317.1			3							GMAF=0.3233:AMAF=0.2298:EMAF=0.3639					rs1799918		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:GCDH)(dui:NBS2;dis:Core Conditions;g:GCDH)(dui:NBS9;dis:Organic Acid Condition;g:GCDH)(dui:NBS49;dis:Glutaric acidemia type I;g:GCDH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:GCDH)(dui:D008659;dis:Metabolic Diseases;g:GCDH)(dui:D009422;dis:Nervous System Diseases;g:GCDH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:GCDH)(dui:D002493;dis:Central Nervous System Diseases;g:GCDH)(dui:D030342;dis:Genetic Diseases, Inborn;g:GCDH)(dui:D008661;dis:Metabolism, Inborn Errors;g:GCDH)(dui:D001927;dis:Brain Diseases;g:GCDH)(dui:D001928;dis:Brain Diseases, Metabolic;g:GCDH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:GCDH)	S-4-Nitrobutyryl-CoA:Flavin adenine dinucleotide		608801	PF02771:PF02770:PF00441:PF08028	0.59															M
chr19:12899706	SNV	A	1	A/G	PASS	4.879777272864875e-94	933.116		400	A=197,G=203	A=0.4925,G=0.5075	50.75	49.25	heterozygous	54	0.28	1.0		GCDH|SYCE2	NR_102317.1|NM_001105578.2	GCDH:exonic_nc:NR_102317.1|SYCE2:intronic:NM_001105578.2	|unknown	|	11|	|p.?	|c.612+298T>C	|	|	|	|G	GMAF=0.3611:AMAF=0.1756:EMAF=0.4546	0.11		Benign	7218541	rs8012		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:GCDH)(dui:NBS2;dis:Core Conditions;g:GCDH)(dui:NBS9;dis:Organic Acid Condition;g:GCDH)(dui:NBS49;dis:Glutaric acidemia type I;g:GCDH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:GCDH)(dui:D008659;dis:Metabolic Diseases;g:GCDH)(dui:D009422;dis:Nervous System Diseases;g:GCDH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:GCDH)(dui:D002493;dis:Central Nervous System Diseases;g:GCDH)(dui:D030342;dis:Genetic Diseases, Inborn;g:GCDH)(dui:D008661;dis:Metabolism, Inborn Errors;g:GCDH)(dui:D001927;dis:Brain Diseases;g:GCDH)(dui:D001928;dis:Brain Diseases, Metabolic;g:GCDH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:GCDH)	S-4-Nitrobutyryl-CoA:Flavin adenine dinucleotide	GO:0051301:GO:0005515:GO:0007130:GO:0000801:GO:0005654	611487:608801	PF02771:PF02770:PF01442:PF00441:PF08028	0.32															M
chr19:41397794	SNV	T	1	T/G	PASS	2.9709818591187966e-79	785.271		398	T=211,G=187	T=0.5302,G=0.4698	46.98	53.02	heterozygous	23	0.082	1.0		EXOSC5|BCKDHA	NM_020158.4|NM_001164783.2	EXOSC5:upstream:NM_020158.4|BCKDHA:upstream:NM_001164783.2	unknown|unknown	|	|	p.?|p.?	c.-466A>C|c.-34T>G	|	|	|	G|G	GMAF=0.1072:AMAF=0.0395:EMAF=0.1419			Likely benign		rs45500792		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHA)(dui:NBS2;dis:Core Conditions;g:BCKDHA)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHA)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHA)(dui:D008659;dis:Metabolic Diseases;g:BCKDHA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHA)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHA)(dui:D009422;dis:Nervous System Diseases;g:BCKDHA)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHA)(dui:D001927;dis:Brain Diseases;g:BCKDHA)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHA)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHA)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHA)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHA)(dui:D009369;dis:Neoplasms;g:EXOSC5)(dui:D009371;dis:Neoplasms by Site;g:EXOSC5)(dui:D004066;dis:Digestive System Diseases;g:EXOSC5)(dui:D004067;dis:Digestive System Neoplasms;g:EXOSC5)(dui:D005767;dis:Gastrointestinal Diseases;g:EXOSC5)(dui:D005770;dis:Gastrointestinal Neoplasms;g:EXOSC5)(dui:D013272;dis:Stomach Diseases;g:EXOSC5)(dui:D013274;dis:Stomach Neoplasms;g:EXOSC5)		GO:0034475:GO:0043928:GO:0045006:GO:0043488:GO:0006364:GO:0005730:GO:0000178:GO:0005654:GO:0003863:GO:0071051:GO:0003723:GO:0005947:GO:0003826:GO:0016075:GO:0005829:GO:0051607:GO:0034427:GO:0016831:GO:0090503:GO:0009083:GO:0004532:GO:0000177:GO:0000176:GO:0000175:GO:0005515:GO:0005759:GO:0046872:GO:0005737:GO:0005739:GO:0035327:GO:0071028:GO:0055114	606492:608348		-0.43															M
chr19:41410644	SNV	C	1	C/A	PASS	3.48337315036013e-101	1004.58		387	C=178,A=198	C=0.4734,A=0.5266	51.16	48.84	heterozygous	15	0.055	7.0		BCKDHA	NM_001164783.2	BCKDHA:exonic:NM_001164783.2	missense	CAC	2	p.Pro39His	c.116C>A	0.72	0.0	77.0	A	GMAF=0.098:AMAF=0.0238:EMAF=0.136	0.01		Benign/Likely benign	4131898	rs11549936:rs751877248		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHA)(dui:NBS2;dis:Core Conditions;g:BCKDHA)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHA)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHA)(dui:D008659;dis:Metabolic Diseases;g:BCKDHA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHA)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHA)(dui:D009422;dis:Nervous System Diseases;g:BCKDHA)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHA)(dui:D001927;dis:Brain Diseases;g:BCKDHA)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHA)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHA)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHA)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHA)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0046872:GO:0003826:GO:0005739:GO:0055114:GO:0016831	608348	PF00676	-1.8															M
chr19:51354484	SNV	G	1	G/A	PASS	5.377742459634542e-100	992.694		400	G=191,A=209	G=0.4775,A=0.5225	52.25	47.75	heterozygous	22	0.077	4.0		ETFB	NM_001985.3	ETFB:intronic:NM_001985.3	unknown			p.?	c.58-176C>T				A	GMAF=0.0605:AMAF=0.0445:EMAF=0.0687			Benign		rs79338777		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ETFB)(dui:NBS3;dis:Secondary Conditions;g:ETFB)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ETFB)(dui:NBS24;dis:Glutaric acidemia type II;g:ETFB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ETFB)(dui:D008659;dis:Metabolic Diseases;g:ETFB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ETFB)(dui:D030342;dis:Genetic Diseases, Inborn;g:ETFB)(dui:D008661;dis:Metabolism, Inborn Errors;g:ETFB)(dui:D028361;dis:Mitochondrial Diseases;g:ETFB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ETFB)(dui:D054069;dis:Multiple Acyl Coenzyme A Dehydrogenase Deficiency;g:ETFB)		GO:0033539:GO:0005515:GO:0005759:GO:0009055:GO:0005739:GO:0022904	130410	PF01012	-2.72															M
chrX:154532293	SNV	G	1	A/A	PASS	1.606941253012836e-136	1357.94		142	G=1,A=141	G=0.007,A=0.993	99.3	0.7000000000000028	hemizygous	45		2.0		G6PD	NM_001042351.3	G6PD:intronic:NM_001042351.3	unknown			p.?	c.1365-13C>T				A	GMAF=0.3923:AMAF=0.1523:EMAF=0.1327					rs2071429		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:G6PD)(dui:NBS3;dis:Secondary Conditions;g:G6PD)(dui:NBS39;dis:Hb carrier other than C,D,E,S,O-Arab;g:G6PD)(dui:NBS7;dis:Hemoglobin Disorder;g:G6PD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:G6PD)(dui:D030342;dis:Genetic Diseases, Inborn;g:G6PD)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:G6PD)(dui:D006402;dis:Hematologic Diseases;g:G6PD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:G6PD)(dui:D000740;dis:Anemia;g:G6PD)(dui:D008659;dis:Metabolic Diseases;g:G6PD)(dui:D000743;dis:Anemia, Hemolytic;g:G6PD)(dui:D000745;dis:Anemia, Hemolytic, Congenital;g:G6PD)(dui:D008661;dis:Metabolism, Inborn Errors;g:G6PD)(dui:D005955;dis:Glucosephosphate Dehydrogenase Deficiency;g:G6PD)(dui:D040181;dis:Genetic Diseases, X-Linked;g:G6PD)(dui:D002239;dis:Carbohydrate Metabolism, Inborn Errors;g:G6PD)(dui:D052801;dis:Male Urogenital Diseases;g:G6PD)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:G6PD)(dui:D014570;dis:Urologic Diseases;g:G6PD)(dui:D052776;dis:Female Urogenital Diseases;g:G6PD)(dui:D007674;dis:Kidney Diseases;g:G6PD)(dui:D004066;dis:Digestive System Diseases;g:G6PD)(dui:D002318;dis:Cardiovascular Diseases;g:G6PD)(dui:D014652;dis:Vascular Diseases;g:G6PD)(dui:D008107;dis:Liver Diseases;g:G6PD)(dui:D007154;dis:Immune System Diseases;g:G6PD)(dui:D007153;dis:Immunologic Deficiency Syndromes;g:G6PD)(dui:D007960;dis:Leukocyte Disorders;g:G6PD)(dui:D010585;dis:Phagocyte Bactericidal Dysfunction;g:G6PD)(dui:D009422;dis:Nervous System Diseases;g:G6PD)(dui:D002493;dis:Central Nervous System Diseases;g:G6PD)(dui:D001927;dis:Brain Diseases;g:G6PD)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:G6PD)(dui:D012871;dis:Skin Diseases;g:G6PD)(dui:D004700;dis:Endocrine System Diseases;g:G6PD)(dui:D044882;dis:Glucose Metabolism Disorders;g:G6PD)(dui:D005236;dis:Favism;g:G6PD)(dui:D000746;dis:Anemia, Hemolytic, Congenital Nonspherocytic;g:G6PD)(dui:D003920;dis:Diabetes Mellitus;g:G6PD)(dui:D002561;dis:Cerebrovascular Disorders;g:G6PD)(dui:D001928;dis:Brain Diseases, Metabolic;g:G6PD)(dui:D009748;dis:Nutrition Disorders;g:G6PD)(dui:D006105;dis:Granulomatous Disease, Chronic;g:G6PD)(dui:D052439;dis:Lipid Metabolism Disorders;g:G6PD)(dui:D002545;dis:Brain Ischemia;g:G6PD)(dui:D003872;dis:Dermatitis;g:G6PD)(dui:D017443;dis:Skin Diseases, Eczematous;g:G6PD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:G6PD)(dui:D003877;dis:Dermatitis, Contact;g:G6PD)(dui:D006946;dis:Hyperinsulinism;g:G6PD)(dui:D050171;dis:Dyslipidemias;g:G6PD)(dui:D051437;dis:Renal Insufficiency;g:G6PD)(dui:D006949;dis:Hyperlipidemias;g:G6PD)(dui:D007333;dis:Insulin Resistance;g:G6PD)(dui:D058186;dis:Acute Kidney Injury;g:G6PD)	Nicotinamide adenine dinucleotide phosphate:Glycolic acid:16-Bromoepiandrosterone:Artenimol	GO:0032094:GO:0010041:GO:0009051:GO:0061052:GO:0034451:GO:0006740:GO:0006006:GO:0043523:GO:0004345:GO:0009898:GO:0043249:GO:1904879:GO:0045471:GO:0070062:GO:0043231:GO:0006739:GO:0019322:GO:0005829:GO:0010734:GO:2000378:GO:0042802:GO:0042803:GO:0006098:GO:0006695:GO:0014070:GO:0021762:GO:0005536:GO:0005634:GO:0050661:GO:0051156:GO:0005515:GO:0005737:GO:0006749:GO:0006629:GO:0016020:GO:0034599:GO:0055114:GO:0046390	305900	PF00479:PF02781	-0.82															M
chr1:53210776	SNV	G	1	G/A	PASS	6.9023980384026245e-105	1041.61		400	G=186,A=214	G=0.465,A=0.535	53.5	46.5	heterozygous	8	0.413	1.0		CPT2	NM_000098.3	CPT2:exonic:NM_000098.3	missense	ATC	4	p.Val368Ile	c.1102G>A	1.0	0.011	29.0	A	GMAF=0.4564:AMAF=0.2901:EMAF=0.4584	0.11		Benign,risk factor	3751293.0	rs1799821		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT2)(dui:NBS3;dis:Secondary Conditions;g:CPT2)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT2)(dui:NBS28;dis:Carnitine palmitoyltransferase II deficiency;g:CPT2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT2)(dui:D008659;dis:Metabolic Diseases;g:CPT2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT2)(dui:D009422;dis:Nervous System Diseases;g:CPT2)(dui:D009140;dis:Musculoskeletal Diseases;g:CPT2)(dui:D009135;dis:Muscular Diseases;g:CPT2)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT2)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT2)(dui:D028361;dis:Mitochondrial Diseases;g:CPT2)(dui:D009468;dis:Neuromuscular Diseases;g:CPT2)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT2)(dui:D004066;dis:Digestive System Diseases;g:CPT2)(dui:D008107;dis:Liver Diseases;g:CPT2)(dui:D007003;dis:Hypoglycemia;g:CPT2)(dui:D007232;dis:Infant, Newborn, Diseases;g:CPT2)(dui:D002493;dis:Central Nervous System Diseases;g:CPT2)(dui:D001927;dis:Brain Diseases;g:CPT2)(dui:D001928;dis:Brain Diseases, Metabolic;g:CPT2)	Perhexiline:Levocarnitine	GO:0016746:GO:0004095:GO:0005730:GO:0006853:GO:0005743:GO:0009437:GO:0005654:GO:0001676:GO:0006635:GO:0005515:GO:0005739:GO:0019216:GO:0120162	600650	PF00755	-0.05															M
chr1:115033402	SNV	A	1	A/G	PASS	1.4608310795053982e-84	838.354		400	A=207,G=193	A=0.5175,G=0.4825	48.25	51.75	heterozygous	53	0.016	1.0		TSHB	NM_000549.5	TSHB:exonic:NM_000549.5	missense	GCA	2	p.Thr14Ala	c.40A>G	0.32	0.0	58.0	G	GMAF=0.0248:AMAF=0.0057:EMAF=0.0345			Benign		rs10776792		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TSHB)(dui:NBS2;dis:Core Conditions;g:TSHB)(dui:NBS12;dis:Endocrine Disorder;g:TSHB)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TSHB)(dui:D004700;dis:Endocrine System Diseases;g:TSHB)(dui:D013959;dis:Thyroid Diseases;g:TSHB)(dui:D007037;dis:Hypothyroidism;g:TSHB)(dui:D009140;dis:Musculoskeletal Diseases;g:TSHB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TSHB)(dui:D001847;dis:Bone Diseases;g:TSHB)(dui:D001849;dis:Bone Diseases, Endocrine;g:TSHB)(dui:D004392;dis:Dwarfism;g:TSHB)(dui:D030342;dis:Genetic Diseases, Inborn;g:TSHB)(dui:D001848;dis:Bone Diseases, Developmental;g:TSHB)(dui:D003409;dis:Congenital Hypothyroidism;g:TSHB)(dui:D009422;dis:Nervous System Diseases;g:TSHB)(dui:D001523;dis:Mental Disorders;g:TSHB)(dui:D000068105;dis:Bipolar and Related Disorders;g:TSHB)(dui:D009461;dis:Neurologic Manifestations;g:TSHB)(dui:D001714;dis:Bipolar Disorder;g:TSHB)(dui:D019954;dis:Neurobehavioral Manifestations;g:TSHB)(dui:D003244;dis:Consciousness Disorders;g:TSHB)(dui:D014474;dis:Unconsciousness;g:TSHB)(dui:D003128;dis:Coma;g:TSHB)		GO:0005615:GO:0043627:GO:0007186:GO:0005737:GO:0051592:GO:0007267:GO:0009653:GO:0016486:GO:0033189:GO:0005576:GO:0005179:GO:0009755	188540		0.21															M
chr2:1414420	SNV	C	1	G/G	PASS	0.0	4003.22		400	C=0,G=400	C=0.0,G=1.0	100.0	0.0	homozygous	22	0.312	1.0		TPO	NM_000547.5	TPO:exonic:NM_000547.5	synonymous	CTG	2	p.Leu4=	c.12C>G				G	GMAF=0.3553:AMAF=0.2905:EMAF=0.3885	0.01		Benign	1399678.0	rs9678281		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-3.72															M
chr2:1436306	SNV	C	1	C/A	PASS	3.9030130196420944e-57	564.086		294	C=158,A=136	C=0.5374,A=0.4626	46.26	53.74	heterozygous	8	0.009	3.0		TPO	NM_000547.5	TPO:exonic:NM_000547.5	missense	CAT	5	p.Pro135His	c.404C>A	0.03	0.999	77.0	A	GMAF=4.0E-4:AMAF=0.0:EMAF=6.0E-4			Benign/Likely benign		rs61758083		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	2.39															M
chr2:1484911	SNV	T	1	T/A	PASS	0.0004638526050622	33.3362		270	T=224,A=46	T=0.8296,A=0.1704	17.04	82.96000000000001	heterozygous	8		7.0		TPO	NM_000547.5	TPO:intronic:NM_000547.5	unknown			p.?	c.1597+57T>A				A						rs1227929517		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-0.3															M
chr3:15645269	SNV	T	1	T/C	PASS	1.6668633588877688e-85	847.781		400	T=206,C=194	T=0.515,C=0.485	48.5	51.5	heterozygous	8	0.164	1.0		BTD	NM_001281724.3	BTD:exonic:NM_001281724.3	synonymous	TGC	6	p.Cys451=	c.1353T>C				C	GMAF=0.0826:AMAF=0.0701:EMAF=0.089	0.59		Benign	4002499.0	rs3817641		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BTD)(dui:NBS2;dis:Core Conditions;g:BTD)(dui:NBS14;dis:Other Disorder;g:BTD)(dui:NBS70;dis:Biotinidase Deficiency;g:BTD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BTD)(dui:D030342;dis:Genetic Diseases, Inborn;g:BTD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BTD)(dui:D008659;dis:Metabolic Diseases;g:BTD)(dui:D008661;dis:Metabolism, Inborn Errors;g:BTD)(dui:D002239;dis:Carbohydrate Metabolism, Inborn Errors;g:BTD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BTD)(dui:D009100;dis:Multiple Carboxylase Deficiency;g:BTD)(dui:D028921;dis:Biotinidase Deficiency;g:BTD)(dui:D001523;dis:Mental Disorders;g:BTD)(dui:D004066;dis:Digestive System Diseases;g:BTD)(dui:D008107;dis:Liver Diseases;g:BTD)(dui:D065886;dis:Neurodevelopmental Disorders;g:BTD)(dui:D002659;dis:Child Development Disorders, Pervasive;g:BTD)(dui:D056486;dis:Drug-Induced Liver Injury;g:BTD)(dui:D001321;dis:Autistic Disorder;g:BTD)		GO:0047708:GO:0005615:GO:0006768:GO:0007417:GO:0070062:GO:0005759:GO:0005576	609019:608306	PF00795	-0.2															M
chr3:49419325	SNV	C	1	C/T	PASS	3.1397856482728466e-58	575.031		254	C=127,T=127	C=0.5,T=0.5	50.0	50.0	heterozygous	8	0.007	2.0		AMT	NR_028435.2	AMT:exonic_nc:NR_028435.2			6							GMAF=0.0065:AMAF=0.0016:EMAF=0.0091	0.64		Conflicting interpretations of pathogenicity	7355386.0	rs116192290		(dui:D009750;dis:Nutritional and Metabolic Diseases;g:AMT)(dui:D008659;dis:Metabolic Diseases;g:AMT)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:AMT)(dui:D009422;dis:Nervous System Diseases;g:AMT)(dui:D030342;dis:Genetic Diseases, Inborn;g:AMT)(dui:D008661;dis:Metabolism, Inborn Errors;g:AMT)(dui:D002493;dis:Central Nervous System Diseases;g:AMT)(dui:D001927;dis:Brain Diseases;g:AMT)(dui:D001928;dis:Brain Diseases, Metabolic;g:AMT)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:AMT)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:AMT)(dui:D020158;dis:Hyperglycinemia, Nonketotic;g:AMT)	Tetrahydrofolic acid:NADH:5-methyltetrahydrofolic acid:Glycine		238310		2.57															M
chr3:183017394	SNV	C	1	C/A	PASS	1.2621181145707582e-74	738.989		295	C=140,A=155	C=0.4746,A=0.5254	52.54	47.46	heterozygous	53	0.047	1.0		MCCC1	NM_020166.5	MCCC1:intronic:NM_020166.5	unknown			p.?	c.1978-57G>T				A	GMAF=0.0675:AMAF=0.065:EMAF=0.0685					rs6786878		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MCCC1)(dui:NBS2;dis:Core Conditions;g:MCCC1)(dui:NBS9;dis:Organic Acid Condition;g:MCCC1)(dui:NBS45;dis:3-Methylcrotonyl-CoA carboxylase deficiency;g:MCCC1)(dui:D009422;dis:Nervous System Diseases;g:MCCC1)(dui:D002493;dis:Central Nervous System Diseases;g:MCCC1)(dui:D001927;dis:Brain Diseases;g:MCCC1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MCCC1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MCCC1)(dui:D008659;dis:Metabolic Diseases;g:MCCC1)(dui:D030342;dis:Genetic Diseases, Inborn;g:MCCC1)(dui:D001928;dis:Brain Diseases, Metabolic;g:MCCC1)(dui:D008661;dis:Metabolism, Inborn Errors;g:MCCC1)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MCCC1)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MCCC1)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:MCCC1)(dui:D019636;dis:Neurodegenerative Diseases;g:MCCC1)(dui:D009069;dis:Movement Disorders;g:MCCC1)(dui:D010300;dis:Parkinson Disease;g:MCCC1)(dui:D001480;dis:Basal Ganglia Diseases;g:MCCC1)(dui:D020734;dis:Parkinsonian Disorders;g:MCCC1)	Biotin	GO:0009083:GO:0009374:GO:1905202:GO:0006552:GO:0004075:GO:0004485:GO:0002169:GO:0005524:GO:0005515:GO:0006768:GO:0005759:GO:0046872:GO:0005739:GO:0005829:GO:0016421	609010	PF08443:PF07478:PF02222:PF00364:PF02786:PF02785:PF00289:PF02655	-0.36															M
chr3:183072461	SNV	G	1	G/A	PASS	1.4275785044217623e-68	678.454		400	G=225,A=175	G=0.5625,A=0.4375	43.75	56.25	heterozygous	53	0.084	1.0		MCCC1	NM_020166.5	MCCC1:exonic:NM_020166.5	synonymous	CTT	5	p.Leu132=	c.396C>T				A	GMAF=0.1147:AMAF=0.2034:EMAF=0.0692			Benign		rs7622479		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MCCC1)(dui:NBS2;dis:Core Conditions;g:MCCC1)(dui:NBS9;dis:Organic Acid Condition;g:MCCC1)(dui:NBS45;dis:3-Methylcrotonyl-CoA carboxylase deficiency;g:MCCC1)(dui:D009422;dis:Nervous System Diseases;g:MCCC1)(dui:D002493;dis:Central Nervous System Diseases;g:MCCC1)(dui:D001927;dis:Brain Diseases;g:MCCC1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MCCC1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MCCC1)(dui:D008659;dis:Metabolic Diseases;g:MCCC1)(dui:D030342;dis:Genetic Diseases, Inborn;g:MCCC1)(dui:D001928;dis:Brain Diseases, Metabolic;g:MCCC1)(dui:D008661;dis:Metabolism, Inborn Errors;g:MCCC1)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MCCC1)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MCCC1)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:MCCC1)(dui:D019636;dis:Neurodegenerative Diseases;g:MCCC1)(dui:D009069;dis:Movement Disorders;g:MCCC1)(dui:D010300;dis:Parkinson Disease;g:MCCC1)(dui:D001480;dis:Basal Ganglia Diseases;g:MCCC1)(dui:D020734;dis:Parkinsonian Disorders;g:MCCC1)	Biotin	GO:0009083:GO:0009374:GO:1905202:GO:0006552:GO:0004075:GO:0004485:GO:0002169:GO:0005524:GO:0005515:GO:0006768:GO:0005759:GO:0046872:GO:0005739:GO:0005829:GO:0016421	609010	PF08443:PF07478:PF02222:PF00364:PF02786:PF02785:PF00289:PF02655	0.89															M
chr5:71632256	SNV	C	1	T/T	PASS	0.0	3394.66		341	C=0,T=341	C=0.0,T=1.0	100.0	0.0	homozygous	36	0.39	1.0		MCCC2	NM_022132.5	MCCC2:intronic:NM_022132.5	unknown			p.?	c.803+71C>T				T						rs277981		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MCCC2)(dui:NBS2;dis:Core Conditions;g:MCCC2)(dui:NBS9;dis:Organic Acid Condition;g:MCCC2)(dui:NBS45;dis:3-Methylcrotonyl-CoA carboxylase deficiency;g:MCCC2)(dui:D009422;dis:Nervous System Diseases;g:MCCC2)(dui:D002493;dis:Central Nervous System Diseases;g:MCCC2)(dui:D001927;dis:Brain Diseases;g:MCCC2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MCCC2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MCCC2)(dui:D008659;dis:Metabolic Diseases;g:MCCC2)(dui:D030342;dis:Genetic Diseases, Inborn;g:MCCC2)(dui:D008661;dis:Metabolism, Inborn Errors;g:MCCC2)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MCCC2)(dui:D001928;dis:Brain Diseases, Metabolic;g:MCCC2)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MCCC2)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:MCCC2)	Biotin	GO:0002169:GO:0005524:GO:0005515:GO:0006768:GO:0009083:GO:0005759:GO:1905202:GO:0005739:GO:0006552:GO:0005829:GO:0015936:GO:0004485	609014	PF01039	-1.98															M
chr6:32039081	SNV	C	1	C/A	PASS	1.1748975549395496e-103	1029.3		142	C=17,A=125	C=0.1197,A=0.8803	88.03	11.97	heterozygous	36	0.348	2.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.293-13C>A				A	GMAF=0.3707:AMAF=0.3445:EMAF=0.384			Conflicting interpretations of pathogenicity		rs6467:rs1267808195		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-0.23															M
chr6:32039847	MNV	AC	2	AC/GT	PASS	7.47825035045569e-69	681.262		309	AC=156,GT=153	AC=0.5049,GT=0.4951	49.51	50.49	0	1	0.173:0.174	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.738+12_738+13delinsGT				GT	GMAF=0.034:AMAF=0.0545:EMAF=0.0235			Uncertain significance		rs193922547:rs6458:rs6459:rs1554305325:rs71552100		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-1.57,-3.0															M
chr6:32040013	SNV	C	1	C/G	PASS	3.0394849687700947e-35	345.172		236	C=140,G=96	C=0.5932,G=0.4068	40.68	59.32	heterozygous	22	0.214	1.0		CYP21A2	NM_000500.9	CYP21A2:exonic:NM_000500.9	synonymous	CTG	7	p.Leu249=	c.747C>G				G		0.01		Benign	4003960.0	rs6477		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	0.02															M
chr6:49447650	SNV	A	1	A/G	PASS	8.439369461730709e-07	60.7369		95	A=69,G=26	A=0.7263,G=0.2737	27.37	72.63	heterozygous	8		16.0		MMUT	NM_000255.4	MMUT:intronic:NM_000255.4	unknown			p.?	c.1560+20T>C				G								.		GO:0019626:GO:0042802:GO:0042803:GO:0009791:GO:0004494:GO:0009235:GO:0043547:GO:0072341:GO:0005515:GO:0005737:GO:0005759:GO:0046872:GO:0003924:GO:0031419:GO:0005739:GO:0050667	609058	PF02310:PF01642	0.41															M
chr6:49447651	SNV	A	1	A/G	PASS	0.0023358233740013	26.3156		96	A=75,G=21	A=0.7813,G=0.2188	21.88	78.12	heterozygous	8		16.0		MMUT	NM_000255.4	MMUT:intronic:NM_000255.4	unknown			p.?	c.1560+19T>C				G								.		GO:0019626:GO:0042802:GO:0042803:GO:0009791:GO:0004494:GO:0009235:GO:0043547:GO:0072341:GO:0005515:GO:0005737:GO:0005759:GO:0046872:GO:0003924:GO:0031419:GO:0005739:GO:0050667	609058	PF02310:PF01642	-0.71															M
chr6:49453535	SNV	T	1	T/A	PASS	1.1486824875460957e-65	649.398		366	T=202,A=164	T=0.5519,A=0.4481	44.81	55.19	heterozygous	8	0.009	1.0		MMUT	NM_000255.4	MMUT:intronic:NM_000255.4	unknown			p.?	c.1083+50A>T				A						rs192976390:rs1396844853		.		GO:0019626:GO:0042802:GO:0042803:GO:0009791:GO:0004494:GO:0009235:GO:0043547:GO:0072341:GO:0005515:GO:0005737:GO:0005759:GO:0046872:GO:0003924:GO:0031419:GO:0005739:GO:0050667	609058	PF02310:PF01642	0.3															M
chr6:80168795	SNV	G	1	G/A	PASS	2.4587252428788657e-05	46.0929		7	G=1,A=6	G=0.1429,A=0.8571	85.71	14.290000000000006	heterozygous	18	0.0	3.0		BCKDHB	NM_000056.4	BCKDHB:intronic:NM_000056.4	unknown			p.?	c.478-80G>A				A						rs72908865		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHB)(dui:NBS2;dis:Core Conditions;g:BCKDHB)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHB)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHB)(dui:D008659;dis:Metabolic Diseases;g:BCKDHB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHB)(dui:D009422;dis:Nervous System Diseases;g:BCKDHB)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHB)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHB)(dui:D001927;dis:Brain Diseases;g:BCKDHB)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHB)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHB)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHB)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHB)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0005739:GO:0003826:GO:0007584:GO:0055114:GO:0005730	248611	PF02779:PF02780	0.72															M
chr7:117548629	INDEL	T	1	T/TG	PASS	3.8370724549228156e-77	764.16		213	T=72,TG=141	T=0.338,TG=0.662	66.2	33.8	heterozygous	25	0.071:0.003	0.0		CFTR|CFTR-AS1	NM_000492.4|NR_149084.1	CFTR:intronic:NM_000492.4|CFTR-AS1:intronic_nc:NR_149084.1	unknown|	|	|	p.?|	c.1210-12_1210-11insG|	|	|	|	TG|			5T	Uncertain significance		rs4148705:rs1584793368:rs1805177:rs765376630:rs1399483116		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		0.56															M
chr7:117548630	INDEL	T	2	T/TGT	PASS	6.449113198681056e-24	231.905		221	T=141,TGT=80	T=0.638,TGT=0.362	36.2	63.8	heterozygous	15	0.071:0.002	0.0		CFTR|CFTR-AS1	NM_000492.4|NR_149084.1	CFTR:intronic:NM_000492.4|CFTR-AS1:intronic_nc:NR_149084.1	unknown|	|	|	p.?|	c.1210-11_1210-10insGT|	|	|	|	TGT|	GMAF=0.0033:AMAF=0.0011:EMAF=0.0044					rs551227135:rs73715573:rs1584793368:rs1805177:rs765376630:rs1399483116		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		0.24															M
chr7:117606582	SNV	G	1	A/A	PASS	0.0	3313.7		333	G=0,A=333	G=0.0,A=1.0	100.0	0.0	homozygous	29	0.119	1.0		CFTR	NM_000492.4	CFTR:intronic:NM_000492.4	unknown			p.?	c.2909-92G>A				A				Benign		rs35050470		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		-0.23															M
chr7:117627457	SNV	C	1	A/A	PASS	4.4e-323	3223.3		324	C=0,A=324	C=0.0,A=1.0	100.0	0.0	homozygous	29	0.144	1.0		CFTR	NM_000492.4	CFTR:intronic:NM_000492.4	unknown			p.?	c.3469-65C>A				A				Benign		rs213989		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		-0.12															M
chr7:117667054	SNV	G	1	A/A	PASS	0.0	3998.78		400	G=0,A=400	G=0.0,A=1.0	100.0	0.0	homozygous	36	0.186	1.0		CFTR	NM_000492.4	CFTR:exonic:NM_000492.4	synonymous	CAA	27	p.Gln1463=	c.4389G>A				A	GMAF=0.2259:AMAF=0.2444:EMAF=0.2164	0.11		Benign/Likely benign	3762339.0	rs1800136:rs1584850283		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		0.01															M
chr8:142874241	SNV	A	1	A/G	PASS	7.045308260712095e-89	881.521		348	A=163,G=185	A=0.4684,G=0.5316	53.16	46.84	heterozygous	8	0.121	1.0		CYP11B1	NM_000497.4	CYP11B1:utr_3:NM_000497.4	unknown		9	p.?	c.*132T>C				G				Benign		rs5297		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		-0.32															M
chr8:142874500	SNV	C	1	C/G	PASS	2.5392180698867456e-80	795.953		319	C=152,G=167	C=0.4765,G=0.5235	52.35	47.65	heterozygous	8	0.114	2.0		CYP11B1	NM_000497.4	CYP11B1:intronic:NM_000497.4	unknown			p.?	c.1399-14G>C				G	GMAF=0.1352:AMAF=0.234:EMAF=0.0845			Benign		rs5295		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		-2.56															M
chr8:142875438	SNV	G	1	G/A	PASS	1.4845676750522655e-100	998.284		333	G=142,A=191	G=0.4264,A=0.5736	57.36	42.64	heterozygous	8	0.121	1.0		CYP11B1	NM_000497.4	CYP11B1:intronic:NM_000497.4	unknown			p.?	c.1122-126C>T				A						rs61752788		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		0.22															M
chr8:142876322	SNV	C	1	C/T	PASS	1.972876955525738e-86	857.049		400	C=205,T=195	C=0.5125,T=0.4875	48.75	51.25	heterozygous	8	0.114	2.0		CYP11B1	NM_000497.4	CYP11B1:exonic:NM_000497.4	synonymous	GCA	5	p.Ala291=	c.873G>A				T	GMAF=0.087:AMAF=0.2088:EMAF=0.0245	0.0		Benign	7249011.0	rs34570566		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		-3.62															M
chr8:142876926	SNV	G	1	G/A	PASS	2.844461107447873e-60	595.46		296	G=156,A=140	G=0.527,A=0.473	47.3	52.7	heterozygous	8	0.171	3.0		CYP11B1	NM_000497.4	CYP11B1:intronic:NM_000497.4	unknown			p.?	c.596-41C>T				A				Benign		rs113759408		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		-0.61															M
chr11:66850932	SNV	A	1	A/C	PASS	1.0000000000000001e-104	1040.0		357	A=155,C=202	A=0.4342,C=0.5658	56.58	43.42	heterozygous	15	0.026	2.0		PC	NM_001040716.2	PC:intronic:NM_001040716.2	unknown			p.?	c.2224-9T>G				C				Benign		rs45560936		(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PC)(dui:D008659;dis:Metabolic Diseases;g:PC)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PC)(dui:D030342;dis:Genetic Diseases, Inborn;g:PC)(dui:D009422;dis:Nervous System Diseases;g:PC)(dui:D008661;dis:Metabolism, Inborn Errors;g:PC)(dui:D002493;dis:Central Nervous System Diseases;g:PC)(dui:D001927;dis:Brain Diseases;g:PC)(dui:D001928;dis:Brain Diseases, Metabolic;g:PC)(dui:D002239;dis:Carbohydrate Metabolism, Inborn Errors;g:PC)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:PC)(dui:D028361;dis:Mitochondrial Diseases;g:PC)(dui:D015324;dis:Pyruvate Carboxylase Deficiency Disease;g:PC)(dui:D015323;dis:Pyruvate Metabolism, Inborn Errors;g:PC)(dui:D009369;dis:Neoplasms;g:PC)(dui:D009370;dis:Neoplasms by Histologic Type;g:PC)(dui:D007154;dis:Immune System Diseases;g:PC)(dui:D004700;dis:Endocrine System Diseases;g:PC)(dui:D044882;dis:Glucose Metabolism Disorders;g:PC)(dui:D004066;dis:Digestive System Diseases;g:PC)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:PC)(dui:D003920;dis:Diabetes Mellitus;g:PC)(dui:D007160;dis:Immunoproliferative Disorders;g:PC)(dui:D008107;dis:Liver Diseases;g:PC)(dui:D008206;dis:Lymphatic Diseases;g:PC)(dui:D008103;dis:Liver Cirrhosis;g:PC)(dui:D008223;dis:Lymphoma;g:PC)(dui:D008232;dis:Lymphoproliferative Disorders;g:PC)(dui:D008106;dis:Liver Cirrhosis, Experimental;g:PC)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:PC)(dui:D016393;dis:Lymphoma, B-Cell;g:PC)(dui:D002051;dis:Burkitt Lymphoma;g:PC)	5-(hexahydro-2-oxo-1H-thieno[3,4-D]imidazol-6-yl)pentanal:Pyruvic acid:Biotin	GO:0006094:GO:0042802:GO:0009374:GO:0044794:GO:0005524:GO:0010629:GO:0019074:GO:0005515:GO:0006768:GO:0044791:GO:0004736:GO:0005737:GO:0005759:GO:0046872:GO:0005739:GO:0006629:GO:0005829:GO:0006090	608786:612283	PF00682:PF07478:PF00364:PF02786:PF02785:PF00289:PF02436	0.91															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	4.854896771016029e-07	63.1382		7	AAA=0,GCT=7	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr11:108121585	SNV	C	1	G/G	PASS	0.0	3934.53		400	C=2,G=398	C=0.005,G=0.995	99.5	0.5	homozygous	28	0.095	2.0		ACAT1	NM_000019.4	ACAT1:utr_5:NM_000019.4	unknown		1	p.?	c.-22C>G				G	GMAF=0.1296:AMAF=0.0849:EMAF=0.1527			Benign		rs3741054		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACAT1)(dui:NBS2;dis:Core Conditions;g:ACAT1)(dui:NBS48;dis:beta-Ketothiolase deficiency;g:ACAT1)(dui:NBS9;dis:Organic Acid Condition;g:ACAT1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACAT1)(dui:D008659;dis:Metabolic Diseases;g:ACAT1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACAT1)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACAT1)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACAT1)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ACAT1)(dui:D052801;dis:Male Urogenital Diseases;g:ACAT1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:ACAT1)(dui:D014570;dis:Urologic Diseases;g:ACAT1)(dui:D052776;dis:Female Urogenital Diseases;g:ACAT1)(dui:D007674;dis:Kidney Diseases;g:ACAT1)(dui:D051437;dis:Renal Insufficiency;g:ACAT1)(dui:D051436;dis:Renal Insufficiency, Chronic;g:ACAT1)(dui:D007676;dis:Kidney Failure, Chronic;g:ACAT1)(dui:D009422;dis:Nervous System Diseases;g:ACAT1)(dui:D002493;dis:Central Nervous System Diseases;g:ACAT1)(dui:D001927;dis:Brain Diseases;g:ACAT1)(dui:D009461;dis:Neurologic Manifestations;g:ACAT1)(dui:D012640;dis:Seizures;g:ACAT1)(dui:D004827;dis:Epilepsy;g:ACAT1)	Nabiximols:Sulfasalazine:Medical Cannabis:Cannabidiol	GO:0006085:GO:0042594:GO:0046952:GO:0046356:GO:0046951:GO:0003985:GO:0006635:GO:0070062:GO:0003988:GO:0001889:GO:0016453:GO:0072229:GO:0042802:GO:0009083:GO:1902860:GO:0006550:GO:1902224:GO:0007420:GO:0014070:GO:0009725:GO:0060612:GO:0030955:GO:0005759:GO:0005739:GO:0015937:GO:0034435:GO:0015936:GO:0019899	607809	PF02803:PF00108:PF00109	-1.57															M
chr11:108138933	SNV	C	1	A/A	PASS	0.0	4002.56		400	C=0,A=400	C=0.0,A=1.0	100.0	0.0	homozygous	28	0.127	2.0		ACAT1	NM_000019.4	ACAT1:exonic:NM_000019.4	synonymous	TCA	6	p.Ser157=	c.471C>A				A	GMAF=0.1818:AMAF=0.1958:EMAF=0.1746	0.83		Benign	1350699.0	rs1591367422:rs35188041		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACAT1)(dui:NBS2;dis:Core Conditions;g:ACAT1)(dui:NBS48;dis:beta-Ketothiolase deficiency;g:ACAT1)(dui:NBS9;dis:Organic Acid Condition;g:ACAT1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACAT1)(dui:D008659;dis:Metabolic Diseases;g:ACAT1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACAT1)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACAT1)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACAT1)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ACAT1)(dui:D052801;dis:Male Urogenital Diseases;g:ACAT1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:ACAT1)(dui:D014570;dis:Urologic Diseases;g:ACAT1)(dui:D052776;dis:Female Urogenital Diseases;g:ACAT1)(dui:D007674;dis:Kidney Diseases;g:ACAT1)(dui:D051437;dis:Renal Insufficiency;g:ACAT1)(dui:D051436;dis:Renal Insufficiency, Chronic;g:ACAT1)(dui:D007676;dis:Kidney Failure, Chronic;g:ACAT1)(dui:D009422;dis:Nervous System Diseases;g:ACAT1)(dui:D002493;dis:Central Nervous System Diseases;g:ACAT1)(dui:D001927;dis:Brain Diseases;g:ACAT1)(dui:D009461;dis:Neurologic Manifestations;g:ACAT1)(dui:D012640;dis:Seizures;g:ACAT1)(dui:D004827;dis:Epilepsy;g:ACAT1)	Nabiximols:Sulfasalazine:Medical Cannabis:Cannabidiol	GO:0006085:GO:0042594:GO:0046952:GO:0046356:GO:0046951:GO:0003985:GO:0006635:GO:0070062:GO:0003988:GO:0001889:GO:0016453:GO:0072229:GO:0042802:GO:0009083:GO:1902860:GO:0006550:GO:1902224:GO:0007420:GO:0014070:GO:0009725:GO:0060612:GO:0030955:GO:0005759:GO:0005739:GO:0015937:GO:0034435:GO:0015936:GO:0019899	607809	PF02803:PF00108:PF00109	0.17															M
chr12:102843690	SNV	G	1	G/C	PASS	2.8379190284415753e-105	1045.47		399	G=185,C=214	G=0.4637,C=0.5363	53.63	46.37	heterozygous	53	0.16	1.0		PAH	NM_001354304.2	PAH:exonic:NM_001354304.2	synonymous	CTG	12	p.Leu385=	c.1155C>G				C	GMAF=0.1728:AMAF=0.1959:EMAF=0.161			Benign		rs772897		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PAH)(dui:NBS2;dis:Core Conditions;g:PAH)(dui:NBS11;dis:Amino Acid Disorder;g:PAH)(dui:NBS58;dis:Phenylketonuria;g:PAH)(dui:D009422;dis:Nervous System Diseases;g:PAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PAH)(dui:D008659;dis:Metabolic Diseases;g:PAH)(dui:D002493;dis:Central Nervous System Diseases;g:PAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:PAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:PAH)(dui:D001927;dis:Brain Diseases;g:PAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:PAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:PAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PAH)(dui:D010661;dis:Phenylketonurias;g:PAH)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:PAH)(dui:D011248;dis:Pregnancy Complications;g:PAH)(dui:D017042;dis:Phenylketonuria, Maternal;g:PAH)	Sapropterin:L-erythro-7,8-dihydrobiopterin:Quinonoid 7,8-Tetrahydrobiopterin:Phenylalanine:beta-2-Thienyl-L-alanine:Norepinephrine:Cupric sulfate:D-norleucine:Droxidopa		612349	PF00351:PF01842	-0.1															M
chr12:102855146	SNV	C	1	C/T	PASS	2.4043628000069348e-107	1066.19		399	C=183,T=216	C=0.4586,T=0.5414	54.14	45.86	heterozygous	53	0.454	1.0		PAH	NM_001354304.2	PAH:exonic:NM_001354304.2	synonymous	CAA	7	p.Gln232=	c.696G>A				T	GMAF=0.3465:AMAF=0.2317:EMAF=0.4052	0.02		Benign	7233325.0	rs1126758		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PAH)(dui:NBS2;dis:Core Conditions;g:PAH)(dui:NBS11;dis:Amino Acid Disorder;g:PAH)(dui:NBS58;dis:Phenylketonuria;g:PAH)(dui:D009422;dis:Nervous System Diseases;g:PAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PAH)(dui:D008659;dis:Metabolic Diseases;g:PAH)(dui:D002493;dis:Central Nervous System Diseases;g:PAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:PAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:PAH)(dui:D001927;dis:Brain Diseases;g:PAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:PAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:PAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PAH)(dui:D010661;dis:Phenylketonurias;g:PAH)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:PAH)(dui:D011248;dis:Pregnancy Complications;g:PAH)(dui:D017042;dis:Phenylketonuria, Maternal;g:PAH)	Sapropterin:L-erythro-7,8-dihydrobiopterin:Quinonoid 7,8-Tetrahydrobiopterin:Phenylalanine:beta-2-Thienyl-L-alanine:Norepinephrine:Cupric sulfate:D-norleucine:Droxidopa		612349	PF00351:PF01842	-2.59															M
chr12:102894571	SNV	A	1	A/T	PASS	9.545528969328564e-79	780.202		306	A=144,T=162	A=0.4706,T=0.5294	52.94	47.06	heterozygous	8	0.126	2.0		PAH	NM_001354304.2	PAH:intronic:NM_001354304.2	unknown			p.?	c.352+164T>A				T						rs78243047		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PAH)(dui:NBS2;dis:Core Conditions;g:PAH)(dui:NBS11;dis:Amino Acid Disorder;g:PAH)(dui:NBS58;dis:Phenylketonuria;g:PAH)(dui:D009422;dis:Nervous System Diseases;g:PAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PAH)(dui:D008659;dis:Metabolic Diseases;g:PAH)(dui:D002493;dis:Central Nervous System Diseases;g:PAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:PAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:PAH)(dui:D001927;dis:Brain Diseases;g:PAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:PAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:PAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PAH)(dui:D010661;dis:Phenylketonurias;g:PAH)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:PAH)(dui:D011248;dis:Pregnancy Complications;g:PAH)(dui:D017042;dis:Phenylketonuria, Maternal;g:PAH)	Sapropterin:L-erythro-7,8-dihydrobiopterin:Quinonoid 7,8-Tetrahydrobiopterin:Phenylalanine:beta-2-Thienyl-L-alanine:Norepinephrine:Cupric sulfate:D-norleucine:Droxidopa		612349	PF00351:PF01842	0.07															M
chr12:102917009	SNV	G	1	A/A	PASS	4.666593803143006e-101	1003.31		100	G=0,A=100	G=0.0,A=1.0	100.0	0.0	homozygous	29	0.364	2.0		PAH	NM_001354304.2	PAH:intronic:NM_001354304.2	unknown			p.?	c.60+62C>T				A	GMAF=0.3771:AMAF=0.487:EMAF=0.318			Benign		rs1522296		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PAH)(dui:NBS2;dis:Core Conditions;g:PAH)(dui:NBS11;dis:Amino Acid Disorder;g:PAH)(dui:NBS58;dis:Phenylketonuria;g:PAH)(dui:D009422;dis:Nervous System Diseases;g:PAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PAH)(dui:D008659;dis:Metabolic Diseases;g:PAH)(dui:D002493;dis:Central Nervous System Diseases;g:PAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:PAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:PAH)(dui:D001927;dis:Brain Diseases;g:PAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:PAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:PAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PAH)(dui:D010661;dis:Phenylketonurias;g:PAH)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:PAH)(dui:D011248;dis:Pregnancy Complications;g:PAH)(dui:D017042;dis:Phenylketonuria, Maternal;g:PAH)	Sapropterin:L-erythro-7,8-dihydrobiopterin:Quinonoid 7,8-Tetrahydrobiopterin:Phenylalanine:beta-2-Thienyl-L-alanine:Norepinephrine:Cupric sulfate:D-norleucine:Droxidopa		612349	PF00351:PF01842	-0.51															M
chr12:102917201	SNV	T	1	T/G	PASS	2.327555256554288e-54	536.331		175	T=74,G=101	T=0.4229,G=0.5771	57.71	42.29	heterozygous	8	0.126	1.0		PAH	NM_001354304.2	PAH:utr_5:NM_001354304.2	unknown		2	p.?	c.-71A>C				G	GMAF=0.1586:AMAF=0.185:EMAF=0.1471			Benign		rs2280615:rs1221435279		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PAH)(dui:NBS2;dis:Core Conditions;g:PAH)(dui:NBS11;dis:Amino Acid Disorder;g:PAH)(dui:NBS58;dis:Phenylketonuria;g:PAH)(dui:D009422;dis:Nervous System Diseases;g:PAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PAH)(dui:D008659;dis:Metabolic Diseases;g:PAH)(dui:D002493;dis:Central Nervous System Diseases;g:PAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:PAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:PAH)(dui:D001927;dis:Brain Diseases;g:PAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:PAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:PAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PAH)(dui:D010661;dis:Phenylketonurias;g:PAH)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:PAH)(dui:D011248;dis:Pregnancy Complications;g:PAH)(dui:D017042;dis:Phenylketonuria, Maternal;g:PAH)	Sapropterin:L-erythro-7,8-dihydrobiopterin:Quinonoid 7,8-Tetrahydrobiopterin:Phenylalanine:beta-2-Thienyl-L-alanine:Norepinephrine:Cupric sulfate:D-norleucine:Droxidopa		612349	PF00351:PF01842	-0.29															M
chr12:120738280	SNV	G	1	A/A	PASS	0.0	3851.8		399	G=4,A=395	G=0.01,A=0.99	99.0	1.0	homozygous	22	0.182	3.0		ACADS	NM_000017.4	ACADS:exonic:NM_000017.4	missense	AGC	6	p.Gly209Ser	c.625G>A	0.01	0.664	56.0	A	GMAF=0.1968:AMAF=0.0645:EMAF=0.2647	0.97		Benign/Likely benign	3752964.0	rs1799958		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADS)(dui:NBS21;dis:Short-chain acyl-CoA dehydrogenase deficiency;g:ACADS)(dui:NBS3;dis:Secondary Conditions;g:ACADS)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ACADS)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADS)(dui:D008659;dis:Metabolic Diseases;g:ACADS)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADS)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADS)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADS)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADS)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADS)	Acetoacetyl-CoA:NADH:Flavin adenine dinucleotide	GO:0003995:GO:0005634:GO:0005813:GO:0006635:GO:0033539:GO:0005759:GO:0050660:GO:0004085:GO:0005739:GO:0046359:GO:0005654	606885	PF02771:PF02770:PF00441:PF08028	9.56															M
chr12:120739469	SNV	G	1	C/C	PASS	4.197589839909983e-270	2693.77		271	G=0,C=271	G=0.0,C=1.0	100.0	0.0	homozygous	22	0.193	2.0		ACADS	NM_000017.4	ACADS:utr_3:NM_000017.4	unknown		10	p.?	c.*21G>C				C	GMAF=0.1979:AMAF=0.0849:EMAF=0.2557			Benign		rs3916		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADS)(dui:NBS21;dis:Short-chain acyl-CoA dehydrogenase deficiency;g:ACADS)(dui:NBS3;dis:Secondary Conditions;g:ACADS)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ACADS)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADS)(dui:D008659;dis:Metabolic Diseases;g:ACADS)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADS)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADS)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADS)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADS)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADS)	Acetoacetyl-CoA:NADH:Flavin adenine dinucleotide	GO:0003995:GO:0005634:GO:0005813:GO:0006635:GO:0033539:GO:0005759:GO:0050660:GO:0004085:GO:0005739:GO:0046359:GO:0005654	606885	PF02771:PF02770:PF00441:PF08028	-1.11															M
chr13:100089101	SNV	G	1	G/A	PASS	9.338991927414188e-70	690.297		345	G=182,A=163	G=0.5275,A=0.4725	47.25	52.75	heterozygous	8	0.001	4.0		PCCA-DT|PCCA	NR_132422.1|NR_148031.2	PCCA-DT:upstream:NR_132422.1|PCCA:exonic_nc:NR_148031.2	|	|	|1	|	|	|	|	|	|	GMAF=2.0E-4:AMAF=0.0:EMAF=4.0E-4			Conflicting interpretations of pathogenicity		rs1487281977:rs374941593		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PCCA)(dui:NBS2;dis:Core Conditions;g:PCCA)(dui:NBS9;dis:Organic Acid Condition;g:PCCA)(dui:NBS42;dis:Propionic acidemia;g:PCCA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PCCA)(dui:D008659;dis:Metabolic Diseases;g:PCCA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PCCA)(dui:D030342;dis:Genetic Diseases, Inborn;g:PCCA)(dui:D008661;dis:Metabolism, Inborn Errors;g:PCCA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PCCA)(dui:D056693;dis:Propionic Acidemia;g:PCCA)(dui:D005128;dis:Eye Diseases;g:PCCA)(dui:D012030;dis:Refractive Errors;g:PCCA)	Biotin		232000	PF08443:PF07478:PF00364:PF02222:PF02786:PF02785:PF00289	0.34															M
chr13:100157391	SNV	G	1	G/A	PASS	6.760829753919789e-101	1001.7		400	G=190,A=210	G=0.475,A=0.525	52.5	47.5	heterozygous	14	0.12	1.0		PCCA	NR_148031.2	PCCA:intronic_nc:NR_148031.2										GMAF=0.1706:AMAF=0.1707:EMAF=0.1705					rs35055557		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PCCA)(dui:NBS2;dis:Core Conditions;g:PCCA)(dui:NBS9;dis:Organic Acid Condition;g:PCCA)(dui:NBS42;dis:Propionic acidemia;g:PCCA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PCCA)(dui:D008659;dis:Metabolic Diseases;g:PCCA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PCCA)(dui:D030342;dis:Genetic Diseases, Inborn;g:PCCA)(dui:D008661;dis:Metabolism, Inborn Errors;g:PCCA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PCCA)(dui:D056693;dis:Propionic Acidemia;g:PCCA)(dui:D005128;dis:Eye Diseases;g:PCCA)(dui:D012030;dis:Refractive Errors;g:PCCA)	Biotin		232000	PF08443:PF07478:PF00364:PF02222:PF02786:PF02785:PF00289	-0.46															M
chr13:100235868	SNV	A	1	A/G	PASS	3.026216535763286e-77	765.191		395	A=211,G=184	A=0.5342,G=0.4658	46.58	53.42	heterozygous	14	0.103	2.0		PCCA	NR_148031.2	PCCA:exonic_nc:NR_148031.2			8							GMAF=0.1515:AMAF=0.1119:EMAF=0.1719	0.88		Benign	7248047.0	rs538229		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PCCA)(dui:NBS2;dis:Core Conditions;g:PCCA)(dui:NBS9;dis:Organic Acid Condition;g:PCCA)(dui:NBS42;dis:Propionic acidemia;g:PCCA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PCCA)(dui:D008659;dis:Metabolic Diseases;g:PCCA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PCCA)(dui:D030342;dis:Genetic Diseases, Inborn;g:PCCA)(dui:D008661;dis:Metabolism, Inborn Errors;g:PCCA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PCCA)(dui:D056693;dis:Propionic Acidemia;g:PCCA)(dui:D005128;dis:Eye Diseases;g:PCCA)(dui:D012030;dis:Refractive Errors;g:PCCA)	Biotin		232000	PF08443:PF07478:PF00364:PF02222:PF02786:PF02785:PF00289	5.13															M
chr13:100235980	SNV	A	1	A/G	PASS	1.3803842646028866e-77	768.6		399	A=214,G=185	A=0.5363,G=0.4637	46.37	53.63	heterozygous	14	0.103	2.0		PCCA	NR_148031.2	PCCA:intronic_nc:NR_148031.2															rs539158		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PCCA)(dui:NBS2;dis:Core Conditions;g:PCCA)(dui:NBS9;dis:Organic Acid Condition;g:PCCA)(dui:NBS42;dis:Propionic acidemia;g:PCCA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PCCA)(dui:D008659;dis:Metabolic Diseases;g:PCCA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PCCA)(dui:D030342;dis:Genetic Diseases, Inborn;g:PCCA)(dui:D008661;dis:Metabolism, Inborn Errors;g:PCCA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PCCA)(dui:D056693;dis:Propionic Acidemia;g:PCCA)(dui:D005128;dis:Eye Diseases;g:PCCA)(dui:D012030;dis:Refractive Errors;g:PCCA)	Biotin		232000	PF08443:PF07478:PF00364:PF02222:PF02786:PF02785:PF00289	1.6															M
chr13:100236000	SNV	C	1	C/G	PASS	6.381165375104247e-99	981.951		400	C=192,G=208	C=0.48,G=0.52	52.0	48.0	heterozygous	8	0.002	1.0		PCCA	NR_148031.2	PCCA:intronic_nc:NR_148031.2															rs558268563		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PCCA)(dui:NBS2;dis:Core Conditions;g:PCCA)(dui:NBS9;dis:Organic Acid Condition;g:PCCA)(dui:NBS42;dis:Propionic acidemia;g:PCCA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PCCA)(dui:D008659;dis:Metabolic Diseases;g:PCCA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PCCA)(dui:D030342;dis:Genetic Diseases, Inborn;g:PCCA)(dui:D008661;dis:Metabolism, Inborn Errors;g:PCCA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PCCA)(dui:D056693;dis:Propionic Acidemia;g:PCCA)(dui:D005128;dis:Eye Diseases;g:PCCA)(dui:D012030;dis:Refractive Errors;g:PCCA)	Biotin		232000	PF08443:PF07478:PF00364:PF02222:PF02786:PF02785:PF00289	0.82															M
chr15:80152950	SNV	G	1	C/C	PASS	3.491403154785913e-155	1544.57		164	G=3,C=161	G=0.0183,C=0.9817	98.17	1.8299999999999983	homozygous	39	0.186	5.0		FAH	NM_000137.4	FAH:upstream:NM_000137.4	unknown			p.?	c.-105G>C				C				Benign		rs112474268		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-2.77															M
chr15:80153176	INDEL	TGGAG	4	T/T	PASS	4.4668359215096896e-135	1343.5		204	TGGAG=0,T=204	TGGAG=0.0,T=1.0	100.0	0.0	homozygous	8	0.031	2.0		FAH	NM_000137.4	FAH:intronic:NM_000137.4	unknown			p.?	c.81+42_81+45delGGAG				T						rs777902403:rs57837512:rs767638459:rs762924131:rs558321563:rs756381638:rs752679360:rs1555440100:rs554422109		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-0.07,3.12,1.98,-0.67,1.26															M
chr15:80159830	SNV	G	1	C/C	PASS	2.1877616239495696e-158	1576.6		158	G=0,C=158	G=0.0,C=1.0	100.0	0.0	homozygous	25	0.06	1.0		FAH	NM_000137.4	FAH:exonic:NM_000137.4	synonymous	CTC	3	p.Leu89=	c.267G>C				C	GMAF=0.0822:AMAF=0.0774:EMAF=0.0847	0.74		Benign	3999621.0	rs33929922		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	1.56															M
chr15:80186247	MNV	ACCCC	5	CTTTG/CTTTG	PASS	0.0	3863.46		386	ACCCC=0,CTTTG=386	ACCCC=0.0,CTTTG=1.0	100.0	0.0	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															M
chr15:80186257	INDEL	AC	1	A/A	PASS	9.79489985408666e-276	2750.09		396	AC=0,A=396	AC=0.0,A=1.0	100.0	0.0	homozygous	25	0.112	3.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*48AC>A				A	GMAF=0.1042:AMAF=0.0643:EMAF=0.1249			Likely benign		rs200464452:rs755736456:rs749985438		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.97,0.39															M
chr15:80186303	SNV	T	1	C/C	PASS	0.0	3935.32		400	T=0,C=400	T=0.0,C=1.0	100.0	0.0	homozygous	25	0.113	2.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*94T>C				C				Benign		rs1049194		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-0.25															M
chr17:7221421	INDEL	ACTGCCCTAGGTCAGGAA	17	A/A	PASS	0.0	3363.98		336	ACTGCCCTAGGTCAGGAA=0,A=336	ACTGCCCTAGGTCAGGAA=0.0,A=1.0	100.0	0.0	homozygous	39	0.002	1.0		ACADVL	NM_000018.4	ACADVL:intronic:NM_000018.4	unknown			p.?	c.478-116_478-100delCTGCCCTAGGTCAGGAA				A						rs750835287:rs1567562754:rs80162838:rs78100429:rs535609436:rs35999860:rs147519793:rs1416225920:rs1184230081:rs1322109465:rs386795011:rs374828700:rs907034423:rs7503586:rs370388543:rs201760717:rs1031535036		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADVL)(dui:NBS2;dis:Core Conditions;g:ACADVL)(dui:NBS10;dis:Fatty Acid Oxidation Disorder;g:ACADVL)(dui:NBS52;dis:Very long-chain acyl-CoA dehydrogenase deficiency;g:ACADVL)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADVL)(dui:D008659;dis:Metabolic Diseases;g:ACADVL)(dui:D009422;dis:Nervous System Diseases;g:ACADVL)(dui:D009140;dis:Musculoskeletal Diseases;g:ACADVL)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADVL)(dui:D009135;dis:Muscular Diseases;g:ACADVL)(dui:D009468;dis:Neuromuscular Diseases;g:ACADVL)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADVL)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADVL)(dui:D028361;dis:Mitochondrial Diseases;g:ACADVL)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADVL)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADVL)		GO:0036498:GO:0005730:GO:0004466:GO:0005654:GO:0009409:GO:0006635:GO:0033539:GO:0000062:GO:0046322:GO:0005829:GO:0031314:GO:0045717:GO:0042802:GO:0015980:GO:0042645:GO:0090181:GO:0003995:GO:0030855:GO:0005515:GO:0031966:GO:0005759:GO:0050660:GO:0001659:GO:0005739:GO:0017099	609575	PF02771:PF02770:PF00441:PF08028	-0.78,0.12,0.1,-0.17,-0.72,-1.03,-0.35,-0.01,-1.94,-0.18,1.36,-1.92,-0.66,0.83,-0.02,0.03,-0.03,-0.45															M
chr17:7221449	SNV	T	1	C/C	PASS	0.0	3839.13		385	T=0,C=385	T=0.0,C=1.0	100.0	0.0	homozygous	46	0.478	1.0		ACADVL	NM_000018.4	ACADVL:intronic:NM_000018.4	unknown			p.?	c.478-89T>C				C						rs77493353:rs1416225920:rs9646410:rs386795011:rs386795012:rs374828700:rs1567562793		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADVL)(dui:NBS2;dis:Core Conditions;g:ACADVL)(dui:NBS10;dis:Fatty Acid Oxidation Disorder;g:ACADVL)(dui:NBS52;dis:Very long-chain acyl-CoA dehydrogenase deficiency;g:ACADVL)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADVL)(dui:D008659;dis:Metabolic Diseases;g:ACADVL)(dui:D009422;dis:Nervous System Diseases;g:ACADVL)(dui:D009140;dis:Musculoskeletal Diseases;g:ACADVL)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADVL)(dui:D009135;dis:Muscular Diseases;g:ACADVL)(dui:D009468;dis:Neuromuscular Diseases;g:ACADVL)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADVL)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADVL)(dui:D028361;dis:Mitochondrial Diseases;g:ACADVL)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADVL)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADVL)		GO:0036498:GO:0005730:GO:0004466:GO:0005654:GO:0009409:GO:0006635:GO:0033539:GO:0000062:GO:0046322:GO:0005829:GO:0031314:GO:0045717:GO:0042802:GO:0015980:GO:0042645:GO:0090181:GO:0003995:GO:0030855:GO:0005515:GO:0031966:GO:0005759:GO:0050660:GO:0001659:GO:0005739:GO:0017099	609575	PF02771:PF02770:PF00441:PF08028	0.0															M
chr19:51354360	INDEL	T	1	T/TG	PASS	0.0029172254922429	25.3503		342	T=238,TG=104	T=0.6959,TG=0.3041	30.41	69.59	heterozygous	8	0.024	5.0		ETFB	NM_001985.3	ETFB:intronic:NM_001985.3	unknown			p.?	c.58-53_58-52insC				TG	GMAF=0.0324:AMAF=0.008:EMAF=0.0451			Benign		rs74357706:rs141529162		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ETFB)(dui:NBS3;dis:Secondary Conditions;g:ETFB)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ETFB)(dui:NBS24;dis:Glutaric acidemia type II;g:ETFB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ETFB)(dui:D008659;dis:Metabolic Diseases;g:ETFB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ETFB)(dui:D030342;dis:Genetic Diseases, Inborn;g:ETFB)(dui:D008661;dis:Metabolism, Inborn Errors;g:ETFB)(dui:D028361;dis:Mitochondrial Diseases;g:ETFB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ETFB)(dui:D054069;dis:Multiple Acyl Coenzyme A Dehydrogenase Deficiency;g:ETFB)		GO:0033539:GO:0005515:GO:0005759:GO:0009055:GO:0005739:GO:0022904	130410	PF01012	-0.65															M
chr19:51366234	SNV	G	1	G/C	PASS	4.402506440739085e-96	953.563		366	G=169,C=197	G=0.4617,C=0.5383	53.83	46.17	heterozygous	8	0.002	3.0		ETFB|CLDND2	NM_001985.3|NM_152353.3	ETFB:intronic:NM_001985.3|CLDND2:downstream:NM_152353.3	unknown|unknown	|	|	p.?|p.?	c.57+36C>G|c.*908C>G	|	|	|	C|C	GMAF=0.002:AMAF=0.0059:EMAF=0.0					rs186691166		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ETFB)(dui:NBS3;dis:Secondary Conditions;g:ETFB)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ETFB)(dui:NBS24;dis:Glutaric acidemia type II;g:ETFB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ETFB)(dui:D008659;dis:Metabolic Diseases;g:ETFB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ETFB)(dui:D030342;dis:Genetic Diseases, Inborn;g:ETFB)(dui:D008661;dis:Metabolism, Inborn Errors;g:ETFB)(dui:D028361;dis:Mitochondrial Diseases;g:ETFB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ETFB)(dui:D054069;dis:Multiple Acyl Coenzyme A Dehydrogenase Deficiency;g:ETFB)		GO:0033539:GO:0005515:GO:0005759:GO:0009055:GO:0005739:GO:0022904:GO:0016021:GO:0005886	130410	PF01012	0.97															M
chr1:45508256	SNV	G	1	A/A	PASS	0.0	3968.05		400	G=1,A=399	G=0.0025,A=0.9975	99.75	0.25	homozygous	45	0.475	1.0		MMACHC	NM_015506.3	MMACHC:exonic:NM_015506.3	synonymous	GTA	3	p.Val107=	c.321G>A				A	GMAF=0.4162:AMAF=0.3723:EMAF=0.437	0.12		Benign	6288212	rs2275276		(dui:NBS9;dis:Organic Acid Condition;g:MMACHC)(dui:NBS11;dis:Amino Acid Disorder;g:MMACHC)(dui:NBS43;dis:Methylmalonic acidemia;g:MMACHC)(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMACHC)(dui:NBS2;dis:Core Conditions;g:MMACHC)(dui:NBS57;dis:Homocystinuria;g:MMACHC)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMACHC)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMACHC)(dui:D008659;dis:Metabolic Diseases;g:MMACHC)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMACHC)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMACHC)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMACHC)(dui:D009748;dis:Nutrition Disorders;g:MMACHC)(dui:D044342;dis:Malnutrition;g:MMACHC)(dui:D003677;dis:Deficiency Diseases;g:MMACHC)(dui:D020138;dis:Hyperhomocysteinemia;g:MMACHC)(dui:D001361;dis:Avitaminosis;g:MMACHC)(dui:D014804;dis:Vitamin B Deficiency;g:MMACHC)(dui:D009422;dis:Nervous System Diseases;g:MMACHC)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MMACHC)(dui:D002493;dis:Central Nervous System Diseases;g:MMACHC)(dui:D003240;dis:Connective Tissue Diseases;g:MMACHC)(dui:D001927;dis:Brain Diseases;g:MMACHC)(dui:D001928;dis:Brain Diseases, Metabolic;g:MMACHC)(dui:D006712;dis:Homocystinuria;g:MMACHC)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MMACHC)(dui:D014806;dis:Vitamin B 12 Deficiency;g:MMACHC)(dui:D005128;dis:Eye Diseases;g:MMACHC)(dui:D012164;dis:Retinal Diseases;g:MMACHC)(dui:D012162;dis:Retinal Degeneration;g:MMACHC)(dui:D008268;dis:Macular Degeneration;g:MMACHC)	Hydroxocobalamin:Cyanocobalamin	GO:0071949:GO:0042803:GO:0032451:GO:0009235:GO:0005515:GO:0043295:GO:0005737:GO:0016491:GO:0006749:GO:0031419:GO:0005829:GO:0055114:GO:0016740:GO:0070988:GO:0033787	609831	PF16690	-0.88															F
chr2:1423015	SNV	G	1	A/A	PASS	0.0	3966.98		400	G=1,A=399	G=0.0025,A=0.9975	99.75	0.25	homozygous	21	0.231	1.0		TPO	NM_000547.5	TPO:intronic:NM_000547.5	unknown			p.?	c.95-30G>A				A	GMAF=0.2137:AMAF=0.1841:EMAF=0.229					rs2276701		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	0.15															F
chr2:149576462	SNV	C	1	C/T	PASS	3.277177768051741e-84	834.845		400	C=207,T=193	C=0.5175,T=0.4825	48.25	51.75	heterozygous	52	0.24	1.0		MMADHC	NM_015702.3	MMADHC:exonic:NM_015702.3	synonymous	CAA	5	p.Gln151=	c.453G>A				T	GMAF=0.2261:AMAF=0.4839:EMAF=0.094	0.38		Benign	7128893	rs11545261		(dui:NBS9;dis:Organic Acid Condition;g:MMADHC)(dui:NBS11;dis:Amino Acid Disorder;g:MMADHC)(dui:NBS43;dis:Methylmalonic acidemia;g:MMADHC)(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMADHC)(dui:NBS2;dis:Core Conditions;g:MMADHC)(dui:NBS57;dis:Homocystinuria;g:MMADHC)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMADHC)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMADHC)(dui:D008659;dis:Metabolic Diseases;g:MMADHC)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMADHC)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMADHC)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMADHC)		GO:0005515:GO:0005737:GO:0005739:GO:0005829:GO:0009235	611935	PF10229	-0.09															F
chr2:149587175	SNV	C	1	C/G	PASS	1.4934820251270516e-75	748.258		400	C=217,G=183	C=0.5425,G=0.4575	45.75	54.25	heterozygous	52	0.311	1.0		MMADHC|MMADHC-DT	NM_015702.3|NR_110240.1	MMADHC:intronic:NM_015702.3|MMADHC-DT:upstream:NR_110240.1	unknown|	|	|	p.?|	c.-52-26G>C|	|	|	|	G|	GMAF=0.2632:AMAF=0.3497:EMAF=0.0949					rs4667420		(dui:NBS9;dis:Organic Acid Condition;g:MMADHC)(dui:NBS11;dis:Amino Acid Disorder;g:MMADHC)(dui:NBS43;dis:Methylmalonic acidemia;g:MMADHC)(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMADHC)(dui:NBS2;dis:Core Conditions;g:MMADHC)(dui:NBS57;dis:Homocystinuria;g:MMADHC)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMADHC)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMADHC)(dui:D008659;dis:Metabolic Diseases;g:MMADHC)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMADHC)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMADHC)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMADHC)		GO:0005515:GO:0005737:GO:0005739:GO:0005829:GO:0009235	611935	PF10229	-0.12															F
chr3:183017423	SNV	T	1	T/G	PASS	1.920878961752032e-78	777.165		399	T=213,G=186	T=0.5338,G=0.4662	46.62	53.38	heterozygous	21	0.303	1.0		MCCC1	NM_020166.5	MCCC1:intronic:NM_020166.5	unknown			p.?	c.1978-86A>C				G						rs2292056		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MCCC1)(dui:NBS2;dis:Core Conditions;g:MCCC1)(dui:NBS9;dis:Organic Acid Condition;g:MCCC1)(dui:NBS45;dis:3-Methylcrotonyl-CoA carboxylase deficiency;g:MCCC1)(dui:D009422;dis:Nervous System Diseases;g:MCCC1)(dui:D002493;dis:Central Nervous System Diseases;g:MCCC1)(dui:D001927;dis:Brain Diseases;g:MCCC1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MCCC1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MCCC1)(dui:D008659;dis:Metabolic Diseases;g:MCCC1)(dui:D030342;dis:Genetic Diseases, Inborn;g:MCCC1)(dui:D001928;dis:Brain Diseases, Metabolic;g:MCCC1)(dui:D008661;dis:Metabolism, Inborn Errors;g:MCCC1)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MCCC1)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MCCC1)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:MCCC1)(dui:D019636;dis:Neurodegenerative Diseases;g:MCCC1)(dui:D009069;dis:Movement Disorders;g:MCCC1)(dui:D010300;dis:Parkinson Disease;g:MCCC1)(dui:D001480;dis:Basal Ganglia Diseases;g:MCCC1)(dui:D020734;dis:Parkinsonian Disorders;g:MCCC1)	Biotin	GO:0009083:GO:0009374:GO:1905202:GO:0006552:GO:0004075:GO:0004485:GO:0002169:GO:0005524:GO:0005515:GO:0006768:GO:0005759:GO:0046872:GO:0005739:GO:0005829:GO:0016421	609010	PF08443:PF07478:PF02222:PF00364:PF02786:PF02785:PF00289:PF02655	-0.45															F
chr6:32039020	SNV	G	1	G/A	PASS	4.797334486366862e-101	1003.19		388	G=181,A=207	G=0.4665,A=0.5335	53.35	46.65	heterozygous	7	0.041	4.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.293-74G>A				A						rs6450		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-1.05															F
chr6:32039027	SNV	C	1	C/A	PASS	9.429746114599128e-69	680.255		386	C=214,A=172	C=0.5544,A=0.4456	44.56	55.44	heterozygous	14	0.176	2.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.293-67C>A				A						rs6451:rs1562756023		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-0.11															F
chr6:32039286	SNV	C	1	C/T	PASS	9.434089673230376e-82	810.253		309	C=143,T=166	C=0.4628,T=0.5372	53.72	46.28	heterozygous	21	0.313	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.447+38C>T				T	GMAF=0.2787:AMAF=0.295:EMAF=0.2704			Benign		rs6466		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	0.86															F
chr6:32041147	SNV	G	1	G/A	PASS	7.462769020181466e-58	571.271		287	G=152,A=135	G=0.5296,A=0.4704	47.04	52.96	heterozygous	7	0.025	1.0		CYP21A2|TNXB	NM_000500.9|NM_001365276.2	CYP21A2:utr_3:NM_000500.9|TNXB:downstream:NM_001365276.2	unknown|unknown	|	10|	p.?|p.?	c.*13G>A|c.*202C>T	|	|	|	A|A	GMAF=0.0095:AMAF=0.0038:EMAF=0.0126			Conflicting interpretations of pathogenicity		rs6447		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:TNXB)(dui:D003240;dis:Connective Tissue Diseases;g:TNXB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TNXB)(dui:D030342;dis:Genetic Diseases, Inborn;g:TNXB)(dui:D012871;dis:Skin Diseases;g:TNXB)(dui:D002318;dis:Cardiovascular Diseases;g:TNXB)(dui:D014652;dis:Vascular Diseases;g:TNXB)(dui:D012873;dis:Skin Diseases, Genetic;g:TNXB)(dui:D000013;dis:Congenital Abnormalities;g:TNXB)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:TNXB)(dui:D006402;dis:Hematologic Diseases;g:TNXB)(dui:D003095;dis:Collagen Diseases;g:TNXB)(dui:D006474;dis:Hemorrhagic Disorders;g:TNXB)(dui:D012868;dis:Skin Abnormalities;g:TNXB)(dui:D020141;dis:Hemostatic Disorders;g:TNXB)(dui:D004535;dis:Ehlers-Danlos Syndrome;g:TNXB)(dui:D007154;dis:Immune System Diseases;g:TNXB)(dui:D001327;dis:Autoimmune Diseases;g:TNXB)(dui:D008180;dis:Lupus Erythematosus, Systemic;g:TNXB)(dui:D005128;dis:Eye Diseases;g:TNXB)(dui:D012164;dis:Retinal Diseases;g:TNXB)(dui:D012162;dis:Retinal Degeneration;g:TNXB)(dui:D008268;dis:Macular Degeneration;g:TNXB)(dui:D006967;dis:Hypersensitivity;g:TNXB)(dui:D003872;dis:Dermatitis;g:TNXB)(dui:D006969;dis:Hypersensitivity, Immediate;g:TNXB)(dui:D006973;dis:Hypertension;g:TNXB)(dui:D017443;dis:Skin Diseases, Eczematous;g:TNXB)(dui:D003876;dis:Dermatitis, Atopic;g:TNXB)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	600985:613815	PF00067	-0.6															F
chr6:39927671	SNV	T	1	T/C	PASS	1.7611648132635764e-86	857.542		283	T=120,C=163	T=0.424,C=0.576	57.6	42.4	heterozygous	42	0.377	2.0		MOCS1	NM_001358530.2	MOCS1:intronic:NM_001358530.2	unknown			p.?	c.124-216A>G				C				Benign		rs3008822		(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MOCS1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MOCS1)(dui:D008659;dis:Metabolic Diseases;g:MOCS1)(dui:D030342;dis:Genetic Diseases, Inborn;g:MOCS1)(dui:D008661;dis:Metabolism, Inborn Errors;g:MOCS1)(dui:D008664;dis:Metal Metabolism, Inborn Errors;g:MOCS1)			603707	PF01967:PF04055:PF06463:PF13353	-0.93															F
chr6:49435569	SNV	T	1	T/C	PASS	2.261517746108353e-87	866.456		400	T=204,C=196	T=0.51,C=0.49	49.0	51.0	heterozygous	52	0.451	1.0		MMUT	NM_000255.4	MMUT:exonic:NM_000255.4	missense	GTA	12	p.Ile671Val	c.2011A>G	1.0	0.0	29.0	C	GMAF=0.393:AMAF=0.4122:EMAF=0.3833	0.25		Benign	4004063	rs8589		.		GO:0019626:GO:0042802:GO:0042803:GO:0009791:GO:0004494:GO:0009235:GO:0043547:GO:0072341:GO:0005515:GO:0005737:GO:0005759:GO:0046872:GO:0003924:GO:0031419:GO:0005739:GO:0050667	609058	PF02310:PF01642	3.9															F
chr6:49457808	SNV	C	1	C/T	PASS	1.1342270487116246e-82	819.453		400	C=209,T=191	C=0.5225,T=0.4775	47.75	52.25	heterozygous	52	0.449	1.0		MMUT	NM_000255.4	MMUT:exonic:NM_000255.4	synonymous	AAA	3	p.Lys212=	c.636G>A				T	GMAF=0.3984:AMAF=0.4274:EMAF=0.3836	0.39		Benign	6350580	rs2229384		.		GO:0019626:GO:0042802:GO:0042803:GO:0009791:GO:0004494:GO:0009235:GO:0043547:GO:0072341:GO:0005515:GO:0005737:GO:0005759:GO:0046872:GO:0003924:GO:0031419:GO:0005739:GO:0050667	609058	PF02310:PF01642	0.67															F
chr6:80127536	SNV	G	1	G/T	PASS	2.6958765435574333e-21	205.693		301	G=209,T=92	G=0.6944,T=0.3056	30.56	69.44	heterozygous	7	0.006:0.482	1.0		BCKDHB	NM_000056.4	BCKDHB:intronic:NM_000056.4	unknown			p.?	c.197-11G>T				T				Benign		rs9448894:rs749742327:rs1562068944:rs200609312:rs1266801799		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHB)(dui:NBS2;dis:Core Conditions;g:BCKDHB)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHB)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHB)(dui:D008659;dis:Metabolic Diseases;g:BCKDHB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHB)(dui:D009422;dis:Nervous System Diseases;g:BCKDHB)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHB)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHB)(dui:D001927;dis:Brain Diseases;g:BCKDHB)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHB)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHB)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHB)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHB)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0005739:GO:0003826:GO:0007584:GO:0055114:GO:0005730	248611	PF02779:PF02780	-0.22															F
chr7:117666855	SNV	C	1	C/T	PASS	8.625812229534799e-68	670.642		400	C=226,T=174	C=0.565,T=0.435	43.5	56.5	heterozygous	7	0.005	1.0		CFTR	NM_000492.4	CFTR:intronic:NM_000492.4	unknown			p.?	c.4243-53C>T				T						rs185664216		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		-0.04															F
chr8:142877205	SNV	C	1	C/T	PASS	5.228775553134446e-95	942.816		400	C=196,T=204	C=0.49,T=0.51	51.0	49.0	heterozygous	7		1.0		CYP11B1	NM_000497.4	CYP11B1:exonic:NM_000497.4	missense	CAC	3	p.Arg138His	c.413G>A	0.0	0.241	29.0	T		0.27		Conflicting interpretations of pathogenicity	1202812	rs193922540		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		0.49															F
chr8:142879562	SNV	G	1	G/T	PASS	1.9444644164481704e-74	737.112		333	G=168,T=165	G=0.5045,T=0.4955	49.55	50.45	heterozygous	7	0.025	3.0		CYP11B1	NM_000497.4	CYP11B1:intronic:NM_000497.4	unknown			p.?	c.239+13C>A				T	GMAF=0.0014:AMAF=7.0E-4:EMAF=0.0017			Benign		rs6402:rs1470690187		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		0.68															F
chr11:68780772	SNV	T	1	T/G	PASS	1.1186648701923065e-96	959.513		399	T=193,G=206	T=0.4837,G=0.5163	51.63	48.37	heterozygous	7	0.006	2.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.1353-27A>C				G						rs376706366		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	-2.49															F
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	2.4244319574912225e-08	76.1539		8	AAA=0,GCT=8	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															F
chr11:108121585	SNV	C	1	C/G	PASS	6.261811646156909e-97	962.033		400	C=194,G=206	C=0.485,G=0.515	51.5	48.5	heterozygous	28	0.095	2.0		ACAT1	NM_000019.4	ACAT1:utr_5:NM_000019.4	unknown		1	p.?	c.-22C>G				G	GMAF=0.1296:AMAF=0.0849:EMAF=0.1527			Benign		rs3741054		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACAT1)(dui:NBS2;dis:Core Conditions;g:ACAT1)(dui:NBS48;dis:beta-Ketothiolase deficiency;g:ACAT1)(dui:NBS9;dis:Organic Acid Condition;g:ACAT1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACAT1)(dui:D008659;dis:Metabolic Diseases;g:ACAT1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACAT1)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACAT1)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACAT1)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ACAT1)(dui:D052801;dis:Male Urogenital Diseases;g:ACAT1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:ACAT1)(dui:D014570;dis:Urologic Diseases;g:ACAT1)(dui:D052776;dis:Female Urogenital Diseases;g:ACAT1)(dui:D007674;dis:Kidney Diseases;g:ACAT1)(dui:D051437;dis:Renal Insufficiency;g:ACAT1)(dui:D051436;dis:Renal Insufficiency, Chronic;g:ACAT1)(dui:D007676;dis:Kidney Failure, Chronic;g:ACAT1)(dui:D009422;dis:Nervous System Diseases;g:ACAT1)(dui:D002493;dis:Central Nervous System Diseases;g:ACAT1)(dui:D001927;dis:Brain Diseases;g:ACAT1)(dui:D009461;dis:Neurologic Manifestations;g:ACAT1)(dui:D012640;dis:Seizures;g:ACAT1)(dui:D004827;dis:Epilepsy;g:ACAT1)	Nabiximols:Sulfasalazine:Medical Cannabis:Cannabidiol	GO:0006085:GO:0042594:GO:0046952:GO:0046356:GO:0046951:GO:0003985:GO:0006635:GO:0070062:GO:0003988:GO:0001889:GO:0016453:GO:0072229:GO:0042802:GO:0009083:GO:1902860:GO:0006550:GO:1902224:GO:0007420:GO:0014070:GO:0009725:GO:0060612:GO:0030955:GO:0005759:GO:0005739:GO:0015937:GO:0034435:GO:0015936:GO:0019899	607809	PF02803:PF00108:PF00109	-1.57															F
chr11:108138933	SNV	C	1	C/A	PASS	5.9979107625549765e-106	1052.22		400	C=185,A=215	C=0.4625,A=0.5375	53.75	46.25	heterozygous	28	0.127	2.0		ACAT1	NM_000019.4	ACAT1:exonic:NM_000019.4	synonymous	TCA	6	p.Ser157=	c.471C>A				A	GMAF=0.1818:AMAF=0.1958:EMAF=0.1746	0.83		Benign	1350699	rs1591367422:rs35188041		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACAT1)(dui:NBS2;dis:Core Conditions;g:ACAT1)(dui:NBS48;dis:beta-Ketothiolase deficiency;g:ACAT1)(dui:NBS9;dis:Organic Acid Condition;g:ACAT1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACAT1)(dui:D008659;dis:Metabolic Diseases;g:ACAT1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACAT1)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACAT1)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACAT1)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ACAT1)(dui:D052801;dis:Male Urogenital Diseases;g:ACAT1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:ACAT1)(dui:D014570;dis:Urologic Diseases;g:ACAT1)(dui:D052776;dis:Female Urogenital Diseases;g:ACAT1)(dui:D007674;dis:Kidney Diseases;g:ACAT1)(dui:D051437;dis:Renal Insufficiency;g:ACAT1)(dui:D051436;dis:Renal Insufficiency, Chronic;g:ACAT1)(dui:D007676;dis:Kidney Failure, Chronic;g:ACAT1)(dui:D009422;dis:Nervous System Diseases;g:ACAT1)(dui:D002493;dis:Central Nervous System Diseases;g:ACAT1)(dui:D001927;dis:Brain Diseases;g:ACAT1)(dui:D009461;dis:Neurologic Manifestations;g:ACAT1)(dui:D012640;dis:Seizures;g:ACAT1)(dui:D004827;dis:Epilepsy;g:ACAT1)	Nabiximols:Sulfasalazine:Medical Cannabis:Cannabidiol	GO:0006085:GO:0042594:GO:0046952:GO:0046356:GO:0046951:GO:0003985:GO:0006635:GO:0070062:GO:0003988:GO:0001889:GO:0016453:GO:0072229:GO:0042802:GO:0009083:GO:1902860:GO:0006550:GO:1902224:GO:0007420:GO:0014070:GO:0009725:GO:0060612:GO:0030955:GO:0005759:GO:0005739:GO:0015937:GO:0034435:GO:0015936:GO:0019899	607809	PF02803:PF00108:PF00109	0.17															F
chr12:102852922	SNV	C	1	C/T	PASS	4.415704473533229e-122	1213.55		399	C=169,T=230	C=0.4236,T=0.5764	57.64	42.36	heterozygous	28	0.315	2.0		PAH	NM_001354304.2	PAH:exonic:NM_001354304.2	synonymous	GTA	8	p.Val245=	c.735G>A				T	GMAF=0.1815:AMAF=0.0556:EMAF=0.246	0.39		Benign,Likely pathogenic	5618696	rs1042503:rs796052017		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PAH)(dui:NBS2;dis:Core Conditions;g:PAH)(dui:NBS11;dis:Amino Acid Disorder;g:PAH)(dui:NBS58;dis:Phenylketonuria;g:PAH)(dui:D009422;dis:Nervous System Diseases;g:PAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PAH)(dui:D008659;dis:Metabolic Diseases;g:PAH)(dui:D002493;dis:Central Nervous System Diseases;g:PAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:PAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:PAH)(dui:D001927;dis:Brain Diseases;g:PAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:PAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:PAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PAH)(dui:D010661;dis:Phenylketonurias;g:PAH)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:PAH)(dui:D011248;dis:Pregnancy Complications;g:PAH)(dui:D017042;dis:Phenylketonuria, Maternal;g:PAH)	Sapropterin:L-erythro-7,8-dihydrobiopterin:Quinonoid 7,8-Tetrahydrobiopterin:Phenylalanine:beta-2-Thienyl-L-alanine:Norepinephrine:Cupric sulfate:D-norleucine:Droxidopa		612349	PF00351:PF01842	-0.25															F
chr12:102877572	SNV	G	1	G/A	PASS	8.260379495771818e-119	1180.83		350	G=138,A=212	G=0.3943,A=0.6057	60.57	39.43	heterozygous	14	0.317	1.0		PAH	NM_001354304.2	PAH:intronic:NM_001354304.2	unknown			p.?	c.353-22C>T				A	GMAF=0.1968:AMAF=0.13:EMAF=0.2309			Benign		rs2037639		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PAH)(dui:NBS2;dis:Core Conditions;g:PAH)(dui:NBS11;dis:Amino Acid Disorder;g:PAH)(dui:NBS58;dis:Phenylketonuria;g:PAH)(dui:D009422;dis:Nervous System Diseases;g:PAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PAH)(dui:D008659;dis:Metabolic Diseases;g:PAH)(dui:D002493;dis:Central Nervous System Diseases;g:PAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:PAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:PAH)(dui:D001927;dis:Brain Diseases;g:PAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:PAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:PAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PAH)(dui:D010661;dis:Phenylketonurias;g:PAH)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:PAH)(dui:D011248;dis:Pregnancy Complications;g:PAH)(dui:D017042;dis:Phenylketonuria, Maternal;g:PAH)	Sapropterin:L-erythro-7,8-dihydrobiopterin:Quinonoid 7,8-Tetrahydrobiopterin:Phenylalanine:beta-2-Thienyl-L-alanine:Norepinephrine:Cupric sulfate:D-norleucine:Droxidopa		612349	PF00351:PF01842	-0.22															F
chr12:120737807	SNV	G	1	G/A	PASS	1.6443717232149625e-118	1177.84		400	G=173,A=227	G=0.4325,A=0.5675	56.75	43.25	heterozygous	14	0.027	1.0		ACADS	NM_000017.4	ACADS:intronic:NM_000017.4	unknown			p.?	c.473-30G>A				A	GMAF=0.0222:AMAF=0.007:EMAF=0.03					rs117000908		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADS)(dui:NBS21;dis:Short-chain acyl-CoA dehydrogenase deficiency;g:ACADS)(dui:NBS3;dis:Secondary Conditions;g:ACADS)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ACADS)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADS)(dui:D008659;dis:Metabolic Diseases;g:ACADS)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADS)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADS)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADS)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADS)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADS)	Acetoacetyl-CoA:NADH:Flavin adenine dinucleotide	GO:0003995:GO:0005634:GO:0005813:GO:0006635:GO:0033539:GO:0005759:GO:0050660:GO:0004085:GO:0005739:GO:0046359:GO:0005654	606885	PF02771:PF02770:PF00441:PF08028	-0.99															F
chr12:120738746	SNV	C	1	C/T	PASS	8.853194386974901e-74	730.529		400	C=219,T=181	C=0.5475,T=0.4525	45.25	54.75	heterozygous	7	0.075	2.0		ACADS	NM_000017.4	ACADS:intronic:NM_000017.4	unknown			p.?	c.934-74C>T				T						rs487915		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADS)(dui:NBS21;dis:Short-chain acyl-CoA dehydrogenase deficiency;g:ACADS)(dui:NBS3;dis:Secondary Conditions;g:ACADS)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ACADS)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADS)(dui:D008659;dis:Metabolic Diseases;g:ACADS)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADS)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADS)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADS)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADS)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADS)	Acetoacetyl-CoA:NADH:Flavin adenine dinucleotide	GO:0003995:GO:0005634:GO:0005813:GO:0006635:GO:0033539:GO:0005759:GO:0050660:GO:0004085:GO:0005739:GO:0046359:GO:0005654	606885	PF02771:PF02770:PF00441:PF08028	-4.4															F
chr13:100111823	INDEL	TGT	2	T/T	PASS	1.2359474334444664e-288	2879.08		295	TGT=0,T=295	TGT=0.0,T=1.0	100.0	0.0	homozygous	13		1.0		PCCA	NR_148031.2	PCCA:intronic_nc:NR_148031.2															rs770647056:rs201452244:rs60618091:rs757554291		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PCCA)(dui:NBS2;dis:Core Conditions;g:PCCA)(dui:NBS9;dis:Organic Acid Condition;g:PCCA)(dui:NBS42;dis:Propionic acidemia;g:PCCA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PCCA)(dui:D008659;dis:Metabolic Diseases;g:PCCA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PCCA)(dui:D030342;dis:Genetic Diseases, Inborn;g:PCCA)(dui:D008661;dis:Metabolism, Inborn Errors;g:PCCA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PCCA)(dui:D056693;dis:Propionic Acidemia;g:PCCA)(dui:D005128;dis:Eye Diseases;g:PCCA)(dui:D012030;dis:Refractive Errors;g:PCCA)	Biotin		232000	PF08443:PF07478:PF00364:PF02222:PF02786:PF02785:PF00289	2.51,-0.28,2.55															F
chr13:100111931	INDEL	TATTT	4	T/T	PASS	0.0	3569.83		359	TATTT=0,T=359	TATTT=0.0,T=1.0	100.0	0.0	homozygous	13	0.077	1.0		PCCA	NR_148031.2	PCCA:intronic_nc:NR_148031.2															rs201261215:rs762246120:rs147037340		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PCCA)(dui:NBS2;dis:Core Conditions;g:PCCA)(dui:NBS9;dis:Organic Acid Condition;g:PCCA)(dui:NBS42;dis:Propionic acidemia;g:PCCA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PCCA)(dui:D008659;dis:Metabolic Diseases;g:PCCA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PCCA)(dui:D030342;dis:Genetic Diseases, Inborn;g:PCCA)(dui:D008661;dis:Metabolism, Inborn Errors;g:PCCA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PCCA)(dui:D056693;dis:Propionic Acidemia;g:PCCA)(dui:D005128;dis:Eye Diseases;g:PCCA)(dui:D012030;dis:Refractive Errors;g:PCCA)	Biotin		232000	PF08443:PF07478:PF00364:PF02222:PF02786:PF02785:PF00289	-0.12,-0.79,0.07,0.17,1.2															F
chr13:100157391	SNV	G	1	A/A	PASS	0.0	4002.59		400	G=0,A=400	G=0.0,A=1.0	100.0	0.0	homozygous	14	0.12	1.0		PCCA	NR_148031.2	PCCA:intronic_nc:NR_148031.2										GMAF=0.1706:AMAF=0.1707:EMAF=0.1705					rs35055557		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PCCA)(dui:NBS2;dis:Core Conditions;g:PCCA)(dui:NBS9;dis:Organic Acid Condition;g:PCCA)(dui:NBS42;dis:Propionic acidemia;g:PCCA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PCCA)(dui:D008659;dis:Metabolic Diseases;g:PCCA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PCCA)(dui:D030342;dis:Genetic Diseases, Inborn;g:PCCA)(dui:D008661;dis:Metabolism, Inborn Errors;g:PCCA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PCCA)(dui:D056693;dis:Propionic Acidemia;g:PCCA)(dui:D005128;dis:Eye Diseases;g:PCCA)(dui:D012030;dis:Refractive Errors;g:PCCA)	Biotin		232000	PF08443:PF07478:PF00364:PF02222:PF02786:PF02785:PF00289	-0.46															F
chr13:100235868	SNV	A	1	G/G	PASS	0.0	3879.83		393	A=1,G=392	A=0.0025,G=0.9975	99.75	0.25	homozygous	14	0.103	2.0		PCCA	NR_148031.2	PCCA:exonic_nc:NR_148031.2			8							GMAF=0.1515:AMAF=0.1119:EMAF=0.1719	0.88		Benign	7248047	rs538229		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PCCA)(dui:NBS2;dis:Core Conditions;g:PCCA)(dui:NBS9;dis:Organic Acid Condition;g:PCCA)(dui:NBS42;dis:Propionic acidemia;g:PCCA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PCCA)(dui:D008659;dis:Metabolic Diseases;g:PCCA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PCCA)(dui:D030342;dis:Genetic Diseases, Inborn;g:PCCA)(dui:D008661;dis:Metabolism, Inborn Errors;g:PCCA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PCCA)(dui:D056693;dis:Propionic Acidemia;g:PCCA)(dui:D005128;dis:Eye Diseases;g:PCCA)(dui:D012030;dis:Refractive Errors;g:PCCA)	Biotin		232000	PF08443:PF07478:PF00364:PF02222:PF02786:PF02785:PF00289	5.13															F
chr13:100235980	SNV	A	1	G/G	PASS	0.0	3925.09		399	A=2,G=397	A=0.005,G=0.995	99.5	0.5	homozygous	14	0.103	2.0		PCCA	NR_148031.2	PCCA:intronic_nc:NR_148031.2															rs539158		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PCCA)(dui:NBS2;dis:Core Conditions;g:PCCA)(dui:NBS9;dis:Organic Acid Condition;g:PCCA)(dui:NBS42;dis:Propionic acidemia;g:PCCA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PCCA)(dui:D008659;dis:Metabolic Diseases;g:PCCA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PCCA)(dui:D030342;dis:Genetic Diseases, Inborn;g:PCCA)(dui:D008661;dis:Metabolism, Inborn Errors;g:PCCA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PCCA)(dui:D056693;dis:Propionic Acidemia;g:PCCA)(dui:D005128;dis:Eye Diseases;g:PCCA)(dui:D012030;dis:Refractive Errors;g:PCCA)	Biotin		232000	PF08443:PF07478:PF00364:PF02222:PF02786:PF02785:PF00289	1.6															F
chr13:100368672	SNV	T	1	A/A	PASS	0.0	3821.28		399	T=4,A=395	T=0.01,A=0.99	99.0	1.0	homozygous	7	0.096	3.0		PCCA	NR_148031.2	PCCA:intronic_nc:NR_148031.2													Benign		rs10508043		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PCCA)(dui:NBS2;dis:Core Conditions;g:PCCA)(dui:NBS9;dis:Organic Acid Condition;g:PCCA)(dui:NBS42;dis:Propionic acidemia;g:PCCA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PCCA)(dui:D008659;dis:Metabolic Diseases;g:PCCA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PCCA)(dui:D030342;dis:Genetic Diseases, Inborn;g:PCCA)(dui:D008661;dis:Metabolism, Inborn Errors;g:PCCA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PCCA)(dui:D056693;dis:Propionic Acidemia;g:PCCA)(dui:D005128;dis:Eye Diseases;g:PCCA)(dui:D012030;dis:Refractive Errors;g:PCCA)	Biotin		232000	PF08443:PF07478:PF00364:PF02222:PF02786:PF02785:PF00289	0.85															F
chr15:40407823	SNV	C	1	T/T	PASS	0.0	3239.66		332	C=1,T=331	C=0.003,T=0.997	99.7	0.2999999999999971	homozygous	45	0.473	2.0		IVD	NR_148925.2	IVD:intronic_nc:NR_148925.2															rs10518693:rs1566932254:rs1219352520		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:IVD)(dui:NBS2;dis:Core Conditions;g:IVD)(dui:NBS9;dis:Organic Acid Condition;g:IVD)(dui:NBS44;dis:Isovaleric acidemia;g:IVD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:IVD)(dui:D030342;dis:Genetic Diseases, Inborn;g:IVD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:IVD)(dui:D008659;dis:Metabolic Diseases;g:IVD)(dui:D008661;dis:Metabolism, Inborn Errors;g:IVD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:IVD)(dui:D012140;dis:Respiratory Tract Diseases;g:IVD)(dui:D008171;dis:Lung Diseases;g:IVD)(dui:D017563;dis:Lung Diseases, Interstitial;g:IVD)	Coenzyme A persulfide:Flavin adenine dinucleotide		607036		0.04															F
chr15:40412960	SNV	T	1	C/C	PASS	0.0	3967.05		400	T=1,C=399	T=0.0025,C=0.9975	99.75	0.25	homozygous	45	0.466	1.0		IVD	NR_148925.2	IVD:intronic_nc:NR_148925.2										GMAF=0.3293:AMAF=0.2031:EMAF=0.394			Benign		rs2289329		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:IVD)(dui:NBS2;dis:Core Conditions;g:IVD)(dui:NBS9;dis:Organic Acid Condition;g:IVD)(dui:NBS44;dis:Isovaleric acidemia;g:IVD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:IVD)(dui:D030342;dis:Genetic Diseases, Inborn;g:IVD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:IVD)(dui:D008659;dis:Metabolic Diseases;g:IVD)(dui:D008661;dis:Metabolism, Inborn Errors;g:IVD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:IVD)(dui:D012140;dis:Respiratory Tract Diseases;g:IVD)(dui:D008171;dis:Lung Diseases;g:IVD)(dui:D017563;dis:Lung Diseases, Interstitial;g:IVD)	Coenzyme A persulfide:Flavin adenine dinucleotide		607036		0.94															F
chr15:76285548	SNV	T	1	T/G	PASS	4.718456982481569e-51	503.262		170	T=74,G=96	T=0.4353,G=0.5647	56.47	43.53	heterozygous	7	0.0	1.0		ETFA	NM_000126.4	ETFA:intronic:NM_000126.4	unknown			p.?	c.664+89A>C				G						rs550306749		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ETFA)(dui:NBS3;dis:Secondary Conditions;g:ETFA)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ETFA)(dui:NBS24;dis:Glutaric acidemia type II;g:ETFA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ETFA)(dui:D008659;dis:Metabolic Diseases;g:ETFA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ETFA)(dui:D030342;dis:Genetic Diseases, Inborn;g:ETFA)(dui:D008661;dis:Metabolism, Inborn Errors;g:ETFA)(dui:D028361;dis:Mitochondrial Diseases;g:ETFA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ETFA)(dui:D054069;dis:Multiple Acyl Coenzyme A Dehydrogenase Deficiency;g:ETFA)(dui:D009140;dis:Musculoskeletal Diseases;g:ETFA)(dui:D007592;dis:Joint Diseases;g:ETFA)(dui:D012216;dis:Rheumatic Diseases;g:ETFA)(dui:D001168;dis:Arthritis;g:ETFA)(dui:D009369;dis:Neoplasms;g:ETFA)(dui:D009370;dis:Neoplasms by Histologic Type;g:ETFA)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:ETFA)(dui:D004066;dis:Digestive System Diseases;g:ETFA)(dui:D009371;dis:Neoplasms by Site;g:ETFA)(dui:D008107;dis:Liver Diseases;g:ETFA)(dui:D002277;dis:Carcinoma;g:ETFA)(dui:D000230;dis:Adenocarcinoma;g:ETFA)(dui:D004067;dis:Digestive System Neoplasms;g:ETFA)(dui:D008113;dis:Liver Neoplasms;g:ETFA)(dui:D010003;dis:Osteoarthritis;g:ETFA)(dui:D006528;dis:Carcinoma, Hepatocellular;g:ETFA)		GO:0033539:GO:0005515:GO:0005759:GO:0016491:GO:0050660:GO:0009055:GO:0005739:GO:0022904	608053	PF00766:PF01012	-1.73															F
chr15:80153172	INDEL	GGAGTGGAGTGGAGTGGAGT	19	GGAGTGGAGTGGAGTGGAGT/G	PASS	6.2445335028050755e-78	772.045		328	GGAGTGGAGTGGAGTGGAGT=162,G=166	GGAGTGGAGTGGAGTGGAGT=0.4939,G=0.5061	50.61	49.39	heterozygous	21	0.031	3.0		FAH	NM_000137.4	FAH:intronic:NM_000137.4	unknown			p.?	c.81+38_81+56delGAGTGGAGTGGAGTGGAGT				G						rs57837512:rs1434937359:rs1555440095:rs558321563:rs756381638:rs752679360:rs1186087842:rs1555440100:rs554422109:rs753734814:rs1355859470:rs777902403:rs767638459:rs762924131:rs1595888602:rs1595888601:rs757176902		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	0.14,0.14,-1.81,0.78,-0.07,3.12,1.98,-0.67,1.26,-0.7,1.29,-0.07,0.16,-0.13,-1.18,0.08,-0.13,0.08,1.37,0.71															F
chr15:80162365	SNV	G	1	G/A	PASS	5.099175975748821e-83	822.925		399	G=208,A=191	G=0.5213,A=0.4787	47.87	52.13	heterozygous	21	0.089	1.0		FAH	NM_000137.4	FAH:intronic:NM_000137.4	unknown			p.?	c.455+29G>A				A	GMAF=0.0033:AMAF=0.0054:EMAF=0.0022			Benign		rs2278204		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	0.2															F
chr15:80186297	SNV	C	1	C/T	PASS	2.801560464256905e-94	935.526		399	C=196,T=203	C=0.4912,T=0.5088	50.88	49.12	heterozygous	14	0.096	2.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*88C>T				T				Benign		rs113381157		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	0.16															F
chr19:45584569	SNV	C	1	C/G	PASS	5.649369748122964e-96	952.48		400	C=195,G=205	C=0.4875,G=0.5125	51.25	48.75	heterozygous	7	0.001	2.0		OPA3	NM_025136.4	OPA3:intronic:NM_025136.4	unknown			p.?	c.142+54G>C				G						rs538096384		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:OPA3)(dui:NBS3;dis:Secondary Conditions;g:OPA3)(dui:NBS4;dis:Organic Acid Condition;g:OPA3)(dui:NBS19;dis:3-Methylglutaconic aciduria;g:OPA3)(dui:D009422;dis:Nervous System Diseases;g:OPA3)(dui:D005128;dis:Eye Diseases;g:OPA3)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:OPA3)(dui:D030342;dis:Genetic Diseases, Inborn;g:OPA3)(dui:D003389;dis:Cranial Nerve Diseases;g:OPA3)(dui:D009901;dis:Optic Nerve Diseases;g:OPA3)(dui:D019636;dis:Neurodegenerative Diseases;g:OPA3)(dui:D009896;dis:Optic Atrophy;g:OPA3)(dui:D020271;dis:Heredodegenerative Disorders, Nervous System;g:OPA3)(dui:D015785;dis:Eye Diseases, Hereditary;g:OPA3)(dui:D015418;dis:Optic Atrophies, Hereditary;g:OPA3)(dui:D007905;dis:Lens Diseases;g:OPA3)(dui:D002386;dis:Cataract;g:OPA3)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:OPA3)(dui:D008659;dis:Metabolic Diseases;g:OPA3)(dui:D009461;dis:Neurologic Manifestations;g:OPA3)(dui:D000013;dis:Congenital Abnormalities;g:OPA3)(dui:D002493;dis:Central Nervous System Diseases;g:OPA3)(dui:D009421;dis:Nervous System Malformations;g:OPA3)(dui:D009468;dis:Neuromuscular Diseases;g:OPA3)(dui:D008661;dis:Metabolism, Inborn Errors;g:OPA3)(dui:D009069;dis:Movement Disorders;g:OPA3)(dui:D010523;dis:Peripheral Nervous System Diseases;g:OPA3)(dui:D015417;dis:Hereditary Sensory and Motor Neuropathy;g:OPA3)(dui:D020820;dis:Dyskinesias;g:OPA3)(dui:D002819;dis:Chorea;g:OPA3)(dui:D011115;dis:Polyneuropathies;g:OPA3)(dui:D015419;dis:Spastic Paraplegia, Hereditary;g:OPA3)		GO:0070584:GO:0005739:GO:0050905:GO:0045444:GO:0007601:GO:0019216:GO:0040008:GO:0050896:GO:0060348	606580	PF07047	1.47															F
chrX:38408967	SNV	A	1	A/G	PASS	8.487895030072351e-74	730.712		400	A=219,G=181	A=0.5475,G=0.4525	45.25	54.75	heterozygous	7	0.017	2.0		OTC	NM_000531.6	OTC:exonic:NM_000531.6	missense	CGA	8	p.Gln270Arg	c.809A>G	0.04	0.977	43.0	G	GMAF=0.0332:AMAF=0.0057:EMAF=0.0489	0.98		Benign/Likely benign	32797	rs1800328		(dui:ACMG59;dis:ACMG Recommendations...;g:OTC)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:OTC)(dui:D008659;dis:Metabolic Diseases;g:OTC)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:OTC)(dui:D009422;dis:Nervous System Diseases;g:OTC)(dui:D030342;dis:Genetic Diseases, Inborn;g:OTC)(dui:D002493;dis:Central Nervous System Diseases;g:OTC)(dui:D001927;dis:Brain Diseases;g:OTC)(dui:D008661;dis:Metabolism, Inborn Errors;g:OTC)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:OTC)(dui:D001928;dis:Brain Diseases, Metabolic;g:OTC)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:OTC)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:OTC)(dui:D040181;dis:Genetic Diseases, X-Linked;g:OTC)(dui:D020163;dis:Ornithine Carbamoyltransferase Deficiency Disease;g:OTC)(dui:D004066;dis:Digestive System Diseases;g:OTC)(dui:D008107;dis:Liver Diseases;g:OTC)	N-(Phosphonoacetyl)-L-Ornithine:Norvaline:Citrulline:Ornithine	GO:0042802:GO:0010043:GO:0007494:GO:0006593:GO:0005543:GO:0042301:GO:0097272:GO:0004585:GO:0005743:GO:0055081:GO:0032868:GO:0005759:GO:0019240:GO:0000050:GO:0001889:GO:0042493:GO:0043231:GO:0005739:GO:0042450:GO:0070781:GO:0016597	300461	PF02729:PF00185	8.81															F
chr1:11801426	SNV	G	1	G/A	PASS	3.1938903336759056e-08	74.9568		98	G=69,A=29	G=0.7041,A=0.2959	29.59	70.41	heterozygous	7		2.0		MTHFR	NM_005957.5	MTHFR:intronic:NM_005957.5	unknown			p.?	c.237-27C>T				A						rs1377686341		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MTHFR)(dui:NBS2;dis:Core Conditions;g:MTHFR)(dui:NBS11;dis:Amino Acid Disorder;g:MTHFR)(dui:NBS57;dis:Homocystinuria;g:MTHFR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MTHFR)(dui:D002318;dis:Cardiovascular Diseases;g:MTHFR)(dui:D009422;dis:Nervous System Diseases;g:MTHFR)(dui:D014652;dis:Vascular Diseases;g:MTHFR)(dui:D009369;dis:Neoplasms;g:MTHFR)(dui:D000013;dis:Congenital Abnormalities;g:MTHFR)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MTHFR)(dui:D030342;dis:Genetic Diseases, Inborn;g:MTHFR)(dui:D009371;dis:Neoplasms by Site;g:MTHFR)(dui:D002493;dis:Central Nervous System Diseases;g:MTHFR)(dui:D007154;dis:Immune System Diseases;g:MTHFR)(dui:D004066;dis:Digestive System Diseases;g:MTHFR)(dui:D001927;dis:Brain Diseases;g:MTHFR)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MTHFR)(dui:D009370;dis:Neoplasms by Histologic Type;g:MTHFR)(dui:D005767;dis:Gastrointestinal Diseases;g:MTHFR)(dui:D008659;dis:Metabolic Diseases;g:MTHFR)(dui:D006331;dis:Heart Diseases;g:MTHFR)(dui:D004067;dis:Digestive System Neoplasms;g:MTHFR)(dui:D001523;dis:Mental Disorders;g:MTHFR)(dui:D006402;dis:Hematologic Diseases;g:MTHFR)(dui:D009748;dis:Nutrition Disorders;g:MTHFR)(dui:D044342;dis:Malnutrition;g:MTHFR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:MTHFR)(dui:D007160;dis:Immunoproliferative Disorders;g:MTHFR)(dui:D008232;dis:Lymphoproliferative Disorders;g:MTHFR)(dui:D002561;dis:Cerebrovascular Disorders;g:MTHFR)(dui:D008206;dis:Lymphatic Diseases;g:MTHFR)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MTHFR)(dui:D008661;dis:Metabolism, Inborn Errors;g:MTHFR)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MTHFR)(dui:D020138;dis:Hyperhomocysteinemia;g:MTHFR)(dui:D017202;dis:Myocardial Ischemia;g:MTHFR)(dui:D003677;dis:Deficiency Diseases;g:MTHFR)(dui:D001361;dis:Avitaminosis;g:MTHFR)(dui:D014804;dis:Vitamin B Deficiency;g:MTHFR)(dui:D009421;dis:Nervous System Malformations;g:MTHFR)(dui:D009436;dis:Neural Tube Defects;g:MTHFR)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:MTHFR)(dui:D009140;dis:Musculoskeletal Diseases;g:MTHFR)(dui:D016769;dis:Embolism and Thrombosis;g:MTHFR)(dui:D009461;dis:Neurologic Manifestations;g:MTHFR)(dui:D003327;dis:Coronary Disease;g:MTHFR)(dui:D052776;dis:Female Urogenital Diseases;g:MTHFR)(dui:D052801;dis:Male Urogenital Diseases;g:MTHFR)(dui:D008286;dis:Malabsorption Syndromes;g:MTHFR)(dui:D007938;dis:Leukemia;g:MTHFR)(dui:D009057;dis:Stomatognathic Diseases;g:MTHFR)(dui:D007945;dis:Leukemia, Lymphoid;g:MTHFR)(dui:D007410;dis:Intestinal Diseases;g:MTHFR)(dui:D012871;dis:Skin Diseases;g:MTHFR)(dui:D009059;dis:Mouth Diseases;g:MTHFR)(dui:D004700;dis:Endocrine System Diseases;g:MTHFR)(dui:D003108;dis:Colonic Diseases;g:MTHFR)(dui:D007414;dis:Intestinal Neoplasms;g:MTHFR)(dui:D015179;dis:Colorectal Neoplasms;g:MTHFR)(dui:D014565;dis:Urogenital Neoplasms;g:MTHFR)(dui:D018640;dis:Stomatognathic System Abnormalities;g:MTHFR)(dui:D019967;dis:Schizophrenia Spectrum and Other Psychotic Disorders;g:MTHFR)(dui:D003240;dis:Connective Tissue Diseases;g:MTHFR)(dui:D014570;dis:Urologic Diseases;g:MTHFR)(dui:D013927;dis:Thrombosis;g:MTHFR)(dui:D020521;dis:Stroke;g:MTHFR)(dui:D008223;dis:Lymphoma;g:MTHFR)(dui:D005831;dis:Genital Diseases, Female;g:MTHFR)(dui:D008107;dis:Liver Diseases;g:MTHFR)(dui:D009056;dis:Mouth Abnormalities;g:MTHFR)(dui:D025063;dis:Chromosome Disorders;g:MTHFR)(dui:D019954;dis:Neurobehavioral Manifestations;g:MTHFR)(dui:D008607;dis:Intellectual Disability;g:MTHFR)(dui:D000015;dis:Abnormalities, Multiple;g:MTHFR)(dui:D004314;dis:Down Syndrome;g:MTHFR)(dui:D019851;dis:Thrombophilia;g:MTHFR)(dui:D054198;dis:Precursor Cell Lymphoblastic Leukemia-Lymphoma;g:MTHFR)(dui:D007674;dis:Kidney Diseases;g:MTHFR)(dui:D013272;dis:Stomach Diseases;g:MTHFR)(dui:D020246;dis:Venous Thrombosis;g:MTHFR)(dui:D003920;dis:Diabetes Mellitus;g:MTHFR)(dui:D013274;dis:Stomach Neoplasms;g:MTHFR)(dui:D009139;dis:Musculoskeletal Abnormalities;g:MTHFR)(dui:D005832;dis:Genital Diseases, Male;g:MTHFR)(dui:D001327;dis:Autoimmune Diseases;g:MTHFR)(dui:D012559;dis:Schizophrenia;g:MTHFR)(dui:D007246;dis:Infertility;g:MTHFR)(dui:D012140;dis:Respiratory Tract Diseases;g:MTHFR)(dui:D008171;dis:Lung Diseases;g:MTHFR)(dui:D002545;dis:Brain Ischemia;g:MTHFR)(dui:D012002;dis:Rectal Diseases;g:MTHFR)(dui:D007592;dis:Joint Diseases;g:MTHFR)(dui:D001168;dis:Arthritis;g:MTHFR)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:MTHFR)(dui:D019636;dis:Neurodegenerative Diseases;g:MTHFR)(dui:D012216;dis:Rheumatic Diseases;g:MTHFR)(dui:D001172;dis:Arthritis, Rheumatoid;g:MTHFR)(dui:D005833;dis:Genital Neoplasms, Female;g:MTHFR)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MTHFR)(dui:D009008;dis:Abnormalities, Severe Teratoid;g:MTHFR)(dui:D000757;dis:Anencephaly;g:MTHFR)(dui:D003704;dis:Dementia;g:MTHFR)(dui:D019965;dis:Neurocognitive Disorders;g:MTHFR)(dui:D014591;dis:Uterine Diseases;g:MTHFR)(dui:D014594;dis:Uterine Neoplasms;g:MTHFR)(dui:D024801;dis:Tauopathies;g:MTHFR)(dui:D000544;dis:Alzheimer Disease;g:MTHFR)(dui:D007960;dis:Leukocyte Disorders;g:MTHFR)(dui:D007970;dis:Leukopenia;g:MTHFR)(dui:D013959;dis:Thyroid Diseases;g:MTHFR)(dui:D002277;dis:Carcinoma;g:MTHFR)(dui:D006967;dis:Hypersensitivity;g:MTHFR)(dui:D001157;dis:Arterial Occlusive Diseases;g:MTHFR)(dui:D008047;dis:Lip Diseases;g:MTHFR)(dui:D002971;dis:Cleft Lip;g:MTHFR)(dui:D019465;dis:Craniofacial Abnormalities;g:MTHFR)(dui:D019767;dis:Maxillofacial Abnormalities;g:MTHFR)(dui:D001161;dis:Arteriosclerosis;g:MTHFR)(dui:D018376;dis:Cardiovascular Abnormalities;g:MTHFR)(dui:D006330;dis:Heart Defects, Congenital;g:MTHFR)(dui:D013923;dis:Thromboembolism;g:MTHFR)(dui:D003110;dis:Colonic Neoplasms;g:MTHFR)(dui:D006980;dis:Hyperthyroidism;g:MTHFR)(dui:D048909;dis:Diabetes Complications;g:MTHFR)(dui:D001941;dis:Breast Diseases;g:MTHFR)(dui:D001943;dis:Breast Neoplasms;g:MTHFR)(dui:D001778;dis:Blood Coagulation Disorders;g:MTHFR)(dui:D007248;dis:Infertility, Male;g:MTHFR)(dui:D051437;dis:Renal Insufficiency;g:MTHFR)(dui:D025861;dis:Blood Coagulation Disorders, Inherited;g:MTHFR)(dui:D044882;dis:Glucose Metabolism Disorders;g:MTHFR)(dui:D000740;dis:Anemia;g:MTHFR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:MTHFR)(dui:D005759;dis:Gastroenteritis;g:MTHFR)(dui:D012678;dis:Sensation Disorders;g:MTHFR)(dui:D006086;dis:Graft vs Host Disease;g:MTHFR)(dui:D004427;dis:Ear Diseases;g:MTHFR)(dui:D006311;dis:Hearing Disorders;g:MTHFR)(dui:D034381;dis:Hearing Loss;g:MTHFR)(dui:D011248;dis:Pregnancy Complications;g:MTHFR)(dui:D000068105;dis:Bipolar and Related Disorders;g:MTHFR)(dui:D001714;dis:Bipolar Disorder;g:MTHFR)(dui:D011655;dis:Pulmonary Embolism;g:MTHFR)(dui:D004617;dis:Embolism;g:MTHFR)(dui:D003925;dis:Diabetic Angiopathies;g:MTHFR)(dui:D012142;dis:Respiratory Tract Neoplasms;g:MTHFR)(dui:D002577;dis:Uterine Cervical Diseases;g:MTHFR)(dui:D003639;dis:Hearing Loss, Sudden;g:MTHFR)(dui:D009385;dis:Neoplastic Processes;g:MTHFR)(dui:D002583;dis:Uterine Cervical Neoplasms;g:MTHFR)(dui:D013899;dis:Thoracic Neoplasms;g:MTHFR)(dui:D014571;dis:Urologic Neoplasms;g:MTHFR)(dui:D002278;dis:Carcinoma in Situ;g:MTHFR)(dui:D018290;dis:Cervical Intraepithelial Neoplasia;g:MTHFR)(dui:D005834;dis:Genital Neoplasms, Male;g:MTHFR)(dui:D011469;dis:Prostatic Diseases;g:MTHFR)(dui:D011471;dis:Prostatic Neoplasms;g:MTHFR)(dui:D008175;dis:Lung Neoplasms;g:MTHFR)(dui:D003324;dis:Coronary Artery Disease;g:MTHFR)(dui:D015448;dis:Leukemia, B-Cell;g:MTHFR)(dui:D015451;dis:Leukemia, Lymphocytic, Chronic, B-Cell;g:MTHFR)(dui:D001791;dis:Blood Platelet Disorders;g:MTHFR)(dui:D065886;dis:Neurodevelopmental Disorders;g:MTHFR)(dui:D001745;dis:Urinary Bladder Diseases;g:MTHFR)(dui:D001749;dis:Urinary Bladder Neoplasms;g:MTHFR)(dui:D056486;dis:Drug-Induced Liver Injury;g:MTHFR)(dui:D013921;dis:Thrombocytopenia;g:MTHFR)(dui:D002659;dis:Child Development Disorders, Pervasive;g:MTHFR)(dui:D002542;dis:Intracranial Embolism and Thrombosis;g:MTHFR)(dui:D020767;dis:Intracranial Thrombosis;g:MTHFR)(dui:D001321;dis:Autistic Disorder;g:MTHFR)(dui:D019964;dis:Mood Disorders;g:MTHFR)(dui:D003866;dis:Depressive Disorder;g:MTHFR)(dui:D000380;dis:Agranulocytosis;g:MTHFR)(dui:D009503;dis:Neutropenia;g:MTHFR)(dui:D023921;dis:Coronary Stenosis;g:MTHFR)(dui:D007247;dis:Infertility, Female;g:MTHFR)(dui:D012851;dis:Sinus Thrombosis, Intracranial;g:MTHFR)(dui:D001928;dis:Brain Diseases, Metabolic;g:MTHFR)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MTHFR)(dui:D018204;dis:Neoplasms, Connective and Soft Tissue;g:MTHFR)(dui:D008591;dis:Meningomyelocele;g:MTHFR)(dui:D008224;dis:Lymphoma, Follicular;g:MTHFR)(dui:D009372;dis:Neoplasms, Connective Tissue;g:MTHFR)(dui:D020258;dis:Neurotoxicity Syndromes;g:MTHFR)(dui:D052016;dis:Mucositis;g:MTHFR)(dui:D023903;dis:Coronary Restenosis;g:MTHFR)(dui:D009362;dis:Neoplasm Metastasis;g:MTHFR)(dui:D020879;dis:Neuromuscular Manifestations;g:MTHFR)(dui:D056784;dis:Leukoencephalopathies;g:MTHFR)(dui:D011618;dis:Psychotic Disorders;g:MTHFR)(dui:D009468;dis:Neuromuscular Diseases;g:MTHFR)(dui:D009135;dis:Muscular Diseases;g:MTHFR)(dui:D010523;dis:Peripheral Nervous System Diseases;g:MTHFR)(dui:D005530;dis:Foot Deformities;g:MTHFR)(dui:D005532;dis:Foot Deformities, Congenital;g:MTHFR)(dui:D006712;dis:Homocystinuria;g:MTHFR)(dui:D009128;dis:Muscle Spasticity;g:MTHFR)(dui:D017880;dis:Limb Deformities, Congenital;g:MTHFR)(dui:D000787;dis:Angina Pectoris;g:MTHFR)(dui:D003025;dis:Clubfoot;g:MTHFR)(dui:D009122;dis:Muscle Hypertonia;g:MTHFR)(dui:D038061;dis:Lower Extremity Deformities, Congenital;g:MTHFR)(dui:D017566;dis:Microvascular Angina;g:MTHFR)(dui:D001145;dis:Arrhythmias, Cardiac;g:MTHFR)(dui:D020260;dis:Heavy Metal Poisoning, Nervous System;g:MTHFR)(dui:D001281;dis:Atrial Fibrillation;g:MTHFR)(dui:D020261;dis:Arsenic Poisoning;g:MTHFR)(dui:D016889;dis:Endometrial Neoplasms;g:MTHFR)(dui:D013118;dis:Spinal Cord Diseases;g:MTHFR)(dui:D004342;dis:Drug Hypersensitivity;g:MTHFR)(dui:D007571;dis:Jaw Diseases;g:MTHFR)(dui:D007569;dis:Jaw Abnormalities;g:MTHFR)(dui:D002972;dis:Cleft Palate;g:MTHFR)(dui:D013971;dis:Thyrotoxicosis;g:MTHFR)(dui:D003872;dis:Dermatitis;g:MTHFR)(dui:D003875;dis:Drug Eruptions;g:MTHFR)(dui:D006201;dis:Hair Diseases;g:MTHFR)(dui:D007039;dis:Hypotrichosis;g:MTHFR)(dui:D046152;dis:Gastrointestinal Stromal Tumors;g:MTHFR)(dui:D000505;dis:Alopecia;g:MTHFR)(dui:D058186;dis:Acute Kidney Injury;g:MTHFR)(dui:D006973;dis:Hypertension;g:MTHFR)(dui:D008113;dis:Liver Neoplasms;g:MTHFR)	Tetrahydrofolic acid:Menadione:Methionine:Riboflavin:Benazepril:Methotrexate:Cyanocobalamin:Folic acid:Fluorouracil	GO:0031060:GO:0070829:GO:0043200:GO:0046655:GO:0045202:GO:0004489:GO:0044877:GO:0072341:GO:0001666:GO:0001843:GO:0005829:GO:0035999:GO:0009086:GO:0071949:GO:0033274:GO:0046500:GO:0006730:GO:0006555:GO:0050661:GO:0050660:GO:0042493:GO:0051593:GO:0070555:GO:0055114:GO:0050667	607093		1.2															F
chr2:1477459	SNV	G	1	C/C	PASS	1.0303861204416285e-119	1189.87		119	G=0,C=119	G=0.0,C=1.0	100.0	0.0	homozygous	51	0.29	1.0		TPO	NM_000547.5	TPO:exonic:NM_000547.5	missense	ACC	8	p.Ser398Thr	c.1193G>C	0.05	0.999	58.0	C	GMAF=0.2184:AMAF=0.1362:EMAF=0.2602	0.89		Benign	1579950	rs2175977		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	1.05															F
chr2:1484559	SNV	C	1	C/A	PASS	2.254239212152437e-22	216.47		103	C=54,A=49	C=0.5243,A=0.4757	47.57	52.43	heterozygous	7	0.002	2.0		TPO	NM_000547.5	TPO:intronic:NM_000547.5	unknown			p.?	c.1339-37C>A				A	GMAF=8.0E-4:AMAF=0.0025:EMAF=0.0					rs373327555		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-0.5															F
chr2:1484823	SNV	T	1	T/C	PASS	3.39468905380078e-22	214.692		67	T=28,C=39	T=0.4179,C=0.5821	58.21	41.79	heterozygous	7	0.019	3.0		TPO	NM_000547.5	TPO:exonic:NM_000547.5	synonymous	GCC	9	p.Ala522=	c.1566T>C				C	GMAF=0.0167:AMAF=0.0488:EMAF=2.0E-4			Benign/Likely benign		rs17091745		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-0.12															F
chr2:1484842	SNV	T	1	T/C	PASS	2.8707805820247043e-20	195.42		66	T=29,C=37	T=0.4394,C=0.5606	56.06	43.94	heterozygous	7	0.019	2.0		TPO	NM_000547.5	TPO:exonic:NM_000547.5	synonymous	CTA	9	p.Leu529=	c.1585T>C				C	GMAF=0.0161:AMAF=0.047:EMAF=2.0E-4	0.55		Benign	716480	rs114401108:rs386642298		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	0.18															F
chr2:1484844	SNV	A	1	A/C	PASS	2.8960096188517144e-20	195.382		66	A=29,C=37	A=0.4394,C=0.5606	56.06	43.94	heterozygous	7	0.019	1.0		TPO	NM_000547.5	TPO:exonic:NM_000547.5	missense	TTC	9	p.Leu529Phe	c.1587A>C	0.0	0.732	22.0	C	GMAF=0.0165:AMAF=0.0484:EMAF=2.0E-4			Benign/Likely benign		rs114796303:rs386642298		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-1.02															F
chr2:1484941	SNV	T	1	T/C	PASS	5.182030920072284e-18	172.855		46	T=17,C=29	T=0.3696,C=0.6304	63.04	36.96	heterozygous	7	0.019	1.0		TPO	NM_000547.5	TPO:intronic:NM_000547.5	unknown			p.?	c.1597+87T>C				C						rs140382650		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-0.23															F
chr3:49417897	SNV	C	1	C/T	PASS	9.132716996648156e-27	260.394		115	C=58,T=57	C=0.5043,T=0.4957	49.57	50.43	heterozygous	14	0.201	2.0		AMT	NR_028435.2	AMT:exonic_nc:NR_028435.2			8							GMAF=0.2889:AMAF=0.2408:EMAF=0.3136	0.9		Benign	4158145	rs11715915		(dui:D009750;dis:Nutritional and Metabolic Diseases;g:AMT)(dui:D008659;dis:Metabolic Diseases;g:AMT)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:AMT)(dui:D009422;dis:Nervous System Diseases;g:AMT)(dui:D030342;dis:Genetic Diseases, Inborn;g:AMT)(dui:D008661;dis:Metabolism, Inborn Errors;g:AMT)(dui:D002493;dis:Central Nervous System Diseases;g:AMT)(dui:D001927;dis:Brain Diseases;g:AMT)(dui:D001928;dis:Brain Diseases, Metabolic;g:AMT)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:AMT)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:AMT)(dui:D020158;dis:Hyperglycinemia, Nonketotic;g:AMT)	Tetrahydrofolic acid:NADH:5-methyltetrahydrofolic acid:Glycine		238310		0.89															F
chr3:49421681	SNV	A	1	A/C	PASS	1.8745628243283807e-12	117.271		77	A=46,C=31	A=0.5974,C=0.4026	40.26	59.74	heterozygous	51	0.417	3.0		AMT|NICN1	NR_028435.2|NM_032316.3	AMT:intronic_nc:NR_028435.2|NICN1:downstream:NM_032316.3	|unknown	|	|	|p.?	|c.*3152T>G	|	|	|	|C						rs4855873		(dui:D009750;dis:Nutritional and Metabolic Diseases;g:AMT)(dui:D008659;dis:Metabolic Diseases;g:AMT)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:AMT)(dui:D009422;dis:Nervous System Diseases;g:AMT)(dui:D030342;dis:Genetic Diseases, Inborn;g:AMT)(dui:D008661;dis:Metabolism, Inborn Errors;g:AMT)(dui:D002493;dis:Central Nervous System Diseases;g:AMT)(dui:D001927;dis:Brain Diseases;g:AMT)(dui:D001928;dis:Brain Diseases, Metabolic;g:AMT)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:AMT)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:AMT)(dui:D020158;dis:Hyperglycinemia, Nonketotic;g:AMT)	Tetrahydrofolic acid:NADH:5-methyltetrahydrofolic acid:Glycine	GO:0005515:GO:0005654:GO:0005874	238310:611516		1.08															F
chr4:145651075	SNV	G	1	G/A	PASS	1.2061463307641095e-48	479.186		261	G=143,A=118	G=0.5479,A=0.4521	45.21	54.79	heterozygous	14	0.049	2.0		MMAA	NM_001375644.1	MMAA:exonic:NM_001375644.1	synonymous	TCA	5	p.Ser249=	c.747G>A				A	GMAF=0.0895:AMAF=0.0622:EMAF=0.1035	0.14		Benign	3760417	rs11721553		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMAA)(dui:NBS2;dis:Core Conditions;g:MMAA)(dui:NBS9;dis:Organic Acid Condition;g:MMAA)(dui:NBS43;dis:Methylmalonic acidemia;g:MMAA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMAA)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMAA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMAA)(dui:D008659;dis:Metabolic Diseases;g:MMAA)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMAA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMAA)	Hydroxocobalamin:Cyanocobalamin		607481		-1.51															F
chr6:32039046	SNV	A	1	A/G	PASS	2.280972240856881e-08	76.4188		38	A=21,G=17	A=0.5526,G=0.4474	44.74	55.26	heterozygous	7	0.038	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.293-48A>G				G	GMAF=0.0115:AMAF=0.0135:EMAF=0.0105					rs66933575:rs59064806		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	1.41															F
chr6:32039050	SNV	G	1	G/T	PASS	2.2789773033335592e-08	76.4226		38	G=21,T=17	G=0.5526,T=0.4474	44.74	55.26	heterozygous	7	0.038	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.293-44G>T				T						rs66933575:rs6453		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-0.25															F
chr6:32039055	MNV	CA	2	CA/GG	PASS	2.2799220561535425e-08	76.4208		38	CA=21,GG=17	CA=0.5526,GG=0.4474	44.74	55.26	0	1	0.036	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.293-39_293-38delinsGG				GG						rs58256870:rs66933575:rs35147842:rs202093120		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-0.34,-0.29															F
chr6:32039847	MNV	AC	2	AC/GT	PASS	5.487821792914582e-21	202.606		90	AC=46,GT=44	AC=0.5111,GT=0.4889	48.89	51.11	0	1	0.173:0.174	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.738+12_738+13delinsGT				GT	GMAF=0.034:AMAF=0.0545:EMAF=0.0235			Uncertain significance		rs193922547:rs6458:rs6459:rs1554305325:rs71552100		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-1.57,-3.0															F
chr7:117610711	SNV	A	1	A/T	PASS	1.3161336711857372e-25	248.807		91	A=42,T=49	A=0.4615,T=0.5385	53.85	46.15	heterozygous	7	0.038	1.0		CFTR	NM_000492.4	CFTR:intronic:NM_000492.4	unknown			p.?	c.3139+42A>T				T	GMAF=0.0381:AMAF=0.1021:EMAF=0.0054			Benign		rs28517401		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		0.17															F
chr7:117611489	SNV	T	1	T/C	PASS	1.6413454667021253e-42	417.848		129	T=53,C=76	T=0.4109,C=0.5891	58.91	41.09	heterozygous	7	0.121	2.0		CFTR	NM_000492.4	CFTR:intronic:NM_000492.4	unknown			p.?	c.3140-92T>C				C				Benign		rs4148717		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		-1.79															F
chr7:117642590	SNV	A	1	A/G	PASS	6.365023332473091e-32	311.962		98	A=41,G=57	A=0.4184,G=0.5816	58.16	41.84	heterozygous	7	0.068	1.0		CFTR	NM_000492.4	CFTR:exonic:NM_000492.4	synonymous	CCG	23	p.Pro1290=	c.3870A>G				G	GMAF=0.0707:AMAF=0.1509:EMAF=0.0297			Benign		rs1800130		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		-0.24															F
chr7:117642710	SNV	T	1	T/G	PASS	8.031561699226598e-28	270.952		108	T=52,G=56	T=0.4815,G=0.5185	51.85	48.15	heterozygous	7	0.039	1.0		CFTR	NM_000492.4	CFTR:intronic:NM_000492.4	unknown			p.?	c.3873+117T>G				G						rs10155917:rs1562923376		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		0.47															F
chr8:142876102	SNV	A	1	A/T	PASS	4.891026321245946e-15	143.106		76	A=42,T=34	A=0.5526,T=0.4474	44.74	55.26	heterozygous	7	0.011	1.0		CYP11B1	NM_000497.4	CYP11B1:intronic:NM_000497.4	unknown			p.?	c.954+139T>A				T						rs62524999		(dui:D004700;dis:Endocrine System Diseases;g:CYP11B1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP11B1)(dui:D006058;dis:Gonadal Disorders;g:CYP11B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP11B1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP11B1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP11B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP11B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP11B1)(dui:D000013;dis:Congenital Abnormalities;g:CYP11B1)(dui:D008659;dis:Metabolic Diseases;g:CYP11B1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP11B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP11B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP11B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP11B1)(dui:D012734;dis:Disorders of Sex Development;g:CYP11B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP11B1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP11B1)(dui:D000308;dis:Adrenocortical Hyperfunction;g:CYP11B1)(dui:D006929;dis:Hyperaldosteronism;g:CYP11B1)	Hydrocortisone acetate:Mibefradil:Dexamethasone:Ketoconazole:Cimetidine:Metyrapone:Hydrocortisone butyrate:Hydrocortisone:Hydrocortisone valerate:Aldosterone:Etomidate:Levoketoconazole:Spironolactone:Osilodrostat:Mitotane:Dexamethasone acetate:Hydrocortisone succinate:Miconazole:Phenytoin:Hydrocortisone probutate	GO:0034651:GO:0034650:GO:0008203:GO:0006700:GO:0008217:GO:0005743:GO:0020037:GO:0006704:GO:0006955:GO:0005506:GO:0047783:GO:0004507:GO:0005739:GO:0042593:GO:0071375:GO:0032342:GO:0032870:GO:0055114:GO:0016125:GO:0035865	610613		-1.34															F
chr11:66852947	SNV	G	1	G/A	PASS	1.4561294986160562e-19	188.368		70	G=33,A=37	G=0.4714,A=0.5286	52.86	47.14	heterozygous	7		3.0		PC	NM_001040716.2	PC:intronic:NM_001040716.2	unknown			p.?	c.1514-111C>T				A						rs1228166786		(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PC)(dui:D008659;dis:Metabolic Diseases;g:PC)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PC)(dui:D030342;dis:Genetic Diseases, Inborn;g:PC)(dui:D009422;dis:Nervous System Diseases;g:PC)(dui:D008661;dis:Metabolism, Inborn Errors;g:PC)(dui:D002493;dis:Central Nervous System Diseases;g:PC)(dui:D001927;dis:Brain Diseases;g:PC)(dui:D001928;dis:Brain Diseases, Metabolic;g:PC)(dui:D002239;dis:Carbohydrate Metabolism, Inborn Errors;g:PC)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:PC)(dui:D028361;dis:Mitochondrial Diseases;g:PC)(dui:D015324;dis:Pyruvate Carboxylase Deficiency Disease;g:PC)(dui:D015323;dis:Pyruvate Metabolism, Inborn Errors;g:PC)(dui:D009369;dis:Neoplasms;g:PC)(dui:D009370;dis:Neoplasms by Histologic Type;g:PC)(dui:D007154;dis:Immune System Diseases;g:PC)(dui:D004700;dis:Endocrine System Diseases;g:PC)(dui:D044882;dis:Glucose Metabolism Disorders;g:PC)(dui:D004066;dis:Digestive System Diseases;g:PC)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:PC)(dui:D003920;dis:Diabetes Mellitus;g:PC)(dui:D007160;dis:Immunoproliferative Disorders;g:PC)(dui:D008107;dis:Liver Diseases;g:PC)(dui:D008206;dis:Lymphatic Diseases;g:PC)(dui:D008103;dis:Liver Cirrhosis;g:PC)(dui:D008223;dis:Lymphoma;g:PC)(dui:D008232;dis:Lymphoproliferative Disorders;g:PC)(dui:D008106;dis:Liver Cirrhosis, Experimental;g:PC)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:PC)(dui:D016393;dis:Lymphoma, B-Cell;g:PC)(dui:D002051;dis:Burkitt Lymphoma;g:PC)	5-(hexahydro-2-oxo-1H-thieno[3,4-D]imidazol-6-yl)pentanal:Pyruvic acid:Biotin	GO:0006094:GO:0042802:GO:0009374:GO:0044794:GO:0005524:GO:0010629:GO:0019074:GO:0005515:GO:0006768:GO:0044791:GO:0004736:GO:0005737:GO:0005759:GO:0046872:GO:0005739:GO:0006629:GO:0005829:GO:0006090	608786:612283	PF00682:PF07478:PF00364:PF02786:PF02785:PF00289:PF02436	-1.43															F
chr12:102917211	SNV	G	1	G/A	PASS	4.1209751909733207e-26	253.85		119	G=62,A=57	G=0.521,A=0.479	47.9	52.1	heterozygous	7	0.028	2.0		PAH	NM_001354304.2	PAH:utr_5:NM_001354304.2	unknown		2	p.?	c.-81C>T				A				Benign		rs7954004		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PAH)(dui:NBS2;dis:Core Conditions;g:PAH)(dui:NBS11;dis:Amino Acid Disorder;g:PAH)(dui:NBS58;dis:Phenylketonuria;g:PAH)(dui:D009422;dis:Nervous System Diseases;g:PAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PAH)(dui:D008659;dis:Metabolic Diseases;g:PAH)(dui:D002493;dis:Central Nervous System Diseases;g:PAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:PAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:PAH)(dui:D001927;dis:Brain Diseases;g:PAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:PAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:PAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PAH)(dui:D010661;dis:Phenylketonurias;g:PAH)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:PAH)(dui:D011248;dis:Pregnancy Complications;g:PAH)(dui:D017042;dis:Phenylketonuria, Maternal;g:PAH)	Sapropterin:L-erythro-7,8-dihydrobiopterin:Quinonoid 7,8-Tetrahydrobiopterin:Phenylalanine:beta-2-Thienyl-L-alanine:Norepinephrine:Cupric sulfate:D-norleucine:Droxidopa		612349	PF00351:PF01842	0.44															F
chr12:109573489	SNV	C	1	C/A	PASS	4.456562483975042e-30	293.51		144	C=76,A=68	C=0.5278,A=0.4722	47.22	52.78	heterozygous	7	0.004	1.0		MMAB|MVK	NM_052845.4|NM_001114185.3	MMAB:utr_5:NM_052845.4|MVK:upstream:NM_001114185.3	unknown|unknown	|	1|	p.?|p.?	c.-9G>T|c.-1334C>A	|	|	|	A|A				Conflicting interpretations of pathogenicity		rs554831769		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMAB)(dui:NBS2;dis:Core Conditions;g:MMAB)(dui:NBS9;dis:Organic Acid Condition;g:MMAB)(dui:NBS43;dis:Methylmalonic acidemia;g:MMAB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMAB)(dui:D008659;dis:Metabolic Diseases;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMAB)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMAB)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMAB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MVK)(dui:D030342;dis:Genetic Diseases, Inborn;g:MVK)(dui:D009422;dis:Nervous System Diseases;g:MVK)(dui:D056660;dis:Hereditary Autoinflammatory Diseases;g:MVK)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MVK)(dui:D008659;dis:Metabolic Diseases;g:MVK)(dui:D002493;dis:Central Nervous System Diseases;g:MVK)(dui:D001927;dis:Brain Diseases;g:MVK)(dui:D008661;dis:Metabolism, Inborn Errors;g:MVK)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MVK)(dui:D007154;dis:Immune System Diseases;g:MVK)(dui:D006402;dis:Hematologic Diseases;g:MVK)(dui:D007160;dis:Immunoproliferative Disorders;g:MVK)(dui:D001796;dis:Blood Protein Disorders;g:MVK)(dui:D001928;dis:Brain Diseases, Metabolic;g:MVK)(dui:D006942;dis:Hypergammaglobulinemia;g:MVK)(dui:D018901;dis:Peroxisomal Disorders;g:MVK)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MVK)(dui:D054078;dis:Mevalonate Kinase Deficiency;g:MVK)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MVK)(dui:D012871;dis:Skin Diseases;g:MVK)(dui:D012873;dis:Skin Diseases, Genetic;g:MVK)(dui:D007642;dis:Keratosis;g:MVK)(dui:D017499;dis:Porokeratosis;g:MVK)(dui:D009461;dis:Neurologic Manifestations;g:MVK)(dui:D004066;dis:Digestive System Diseases;g:MVK)(dui:D010146;dis:Pain;g:MVK)(dui:D009369;dis:Neoplasms;g:MVK)(dui:D008107;dis:Liver Diseases;g:MVK)(dui:D009371;dis:Neoplasms by Site;g:MVK)(dui:D004067;dis:Digestive System Neoplasms;g:MVK)(dui:D008113;dis:Liver Neoplasms;g:MVK)(dui:D009370;dis:Neoplasms by Histologic Type;g:MVK)(dui:D009140;dis:Musculoskeletal Diseases;g:MVK)(dui:D007592;dis:Joint Diseases;g:MVK)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MVK)(dui:D002277;dis:Carcinoma;g:MVK)(dui:D006528;dis:Carcinoma, Hepatocellular;g:MVK)(dui:D000230;dis:Adenocarcinoma;g:MVK)(dui:D018771;dis:Arthralgia;g:MVK)(dui:D005076;dis:Exanthema;g:MVK)	Farnesyl thiopyrophosphate:Cyanocobalamin	GO:0042802:GO:0050728:GO:0006695:GO:0004496:GO:0009235:GO:0008299:GO:0000287:GO:0005524:GO:0005777:GO:0005515:GO:0045540:GO:0005759:GO:0019287:GO:0043231:GO:0031419:GO:0008817:GO:0005829:GO:0016310	251170:607568	PF01923	-1.22															F
chr12:120737135	SNV	C	1	C/T	PASS	5.82773774796363e-28	272.345		103	C=48,T=55	C=0.466,T=0.534	53.4	46.6	heterozygous	14	0.076	1.0		ACADS	NM_000017.4	ACADS:exonic:NM_000017.4	synonymous	AAT	3	p.Asn120=	c.360C>T				T	GMAF=0.0069:AMAF=0.0041:EMAF=0.0084	0.02		Benign	1359402	rs76543640		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADS)(dui:NBS21;dis:Short-chain acyl-CoA dehydrogenase deficiency;g:ACADS)(dui:NBS3;dis:Secondary Conditions;g:ACADS)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ACADS)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADS)(dui:D008659;dis:Metabolic Diseases;g:ACADS)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADS)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADS)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADS)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADS)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADS)	Acetoacetyl-CoA:NADH:Flavin adenine dinucleotide	GO:0003995:GO:0005634:GO:0005813:GO:0006635:GO:0033539:GO:0005759:GO:0050660:GO:0004085:GO:0005739:GO:0046359:GO:0005654	606885	PF02771:PF02770:PF00441:PF08028	-2.97															F
chr12:120738490	SNV	C	1	C/T	PASS	3.6182619073243023e-16	154.415		110	C=67,T=43	C=0.6091,T=0.3909	39.09	60.91	heterozygous	14	0.075	3.0		ACADS	NM_000017.4	ACADS:intronic:NM_000017.4	unknown			p.?	c.795+40C>T				T	GMAF=0.0068:AMAF=0.0034:EMAF=0.0085					rs17848090		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADS)(dui:NBS21;dis:Short-chain acyl-CoA dehydrogenase deficiency;g:ACADS)(dui:NBS3;dis:Secondary Conditions;g:ACADS)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ACADS)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADS)(dui:D008659;dis:Metabolic Diseases;g:ACADS)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADS)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADS)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADS)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADS)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADS)	Acetoacetyl-CoA:NADH:Flavin adenine dinucleotide	GO:0003995:GO:0005634:GO:0005813:GO:0006635:GO:0033539:GO:0005759:GO:0050660:GO:0004085:GO:0005739:GO:0046359:GO:0005654	606885	PF02771:PF02770:PF00441:PF08028	-0.76															F
chr12:120738967	SNV	C	1	C/T	PASS	1.655769963469526e-11	107.81		61	C=35,T=26	C=0.5738,T=0.4262	42.62	57.38	heterozygous	14	0.075	1.0		ACADS	NM_000017.4	ACADS:intronic:NM_000017.4	unknown			p.?	c.1029+52C>T				T	GMAF=0.0054:AMAF=0.0027:EMAF=0.0069					rs2071266		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADS)(dui:NBS21;dis:Short-chain acyl-CoA dehydrogenase deficiency;g:ACADS)(dui:NBS3;dis:Secondary Conditions;g:ACADS)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ACADS)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADS)(dui:D008659;dis:Metabolic Diseases;g:ACADS)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADS)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADS)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADS)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADS)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADS)	Acetoacetyl-CoA:NADH:Flavin adenine dinucleotide	GO:0003995:GO:0005634:GO:0005813:GO:0006635:GO:0033539:GO:0005759:GO:0050660:GO:0004085:GO:0005739:GO:0046359:GO:0005654	606885	PF02771:PF02770:PF00441:PF08028	-0.87															F
chr12:120739563	SNV	G	1	G/A	PASS	1.1371035097106448e-17	169.442		76	G=39,A=37	G=0.5132,A=0.4868	48.68	51.32	heterozygous	14	0.075	3.0		ACADS	NM_000017.4	ACADS:utr_3:NM_000017.4	unknown		10	p.?	c.*115G>A				A				Benign		rs2229534		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADS)(dui:NBS21;dis:Short-chain acyl-CoA dehydrogenase deficiency;g:ACADS)(dui:NBS3;dis:Secondary Conditions;g:ACADS)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ACADS)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADS)(dui:D008659;dis:Metabolic Diseases;g:ACADS)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADS)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADS)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADS)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADS)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADS)	Acetoacetyl-CoA:NADH:Flavin adenine dinucleotide	GO:0003995:GO:0005634:GO:0005813:GO:0006635:GO:0033539:GO:0005759:GO:0050660:GO:0004085:GO:0005739:GO:0046359:GO:0005654	606885	PF02771:PF02770:PF00441:PF08028	-0.87															F
chr13:20189202	SNV	C	1	T/T	PASS	1.030386120441696e-286	2859.87		294	C=2,T=292	C=0.0068,T=0.9932	99.32	0.6800000000000068	homozygous	31	0.027	1.0		GJB2	NM_004004.6	GJB2:exonic:NM_004004.6	missense	CAC	2	p.Arg127His	c.380G>A			29.0	T	GMAF=0.0023:AMAF=9.0E-4:EMAF=0.003	0.45		Conflicting interpretations of pathogenicity	5052088	rs111033196		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:GJB2)(dui:NBS2;dis:Core Conditions;g:GJB2)(dui:NBS14;dis:Other Disorder;g:GJB2)(dui:NBS75;dis:Hearing Loss;g:GJB2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:GJB2)(dui:D000013;dis:Congenital Abnormalities;g:GJB2)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:GJB2)(dui:D012871;dis:Skin Diseases;g:GJB2)(dui:D009422;dis:Nervous System Diseases;g:GJB2)(dui:D009461;dis:Neurologic Manifestations;g:GJB2)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:GJB2)(dui:D004427;dis:Ear Diseases;g:GJB2)(dui:D012678;dis:Sensation Disorders;g:GJB2)(dui:D006311;dis:Hearing Disorders;g:GJB2)(dui:D034381;dis:Hearing Loss;g:GJB2)(dui:D007642;dis:Keratosis;g:GJB2)(dui:D006319;dis:Hearing Loss, Sensorineural;g:GJB2)(dui:D030342;dis:Genetic Diseases, Inborn;g:GJB2)(dui:D000015;dis:Abnormalities, Multiple;g:GJB2)(dui:D012873;dis:Skin Diseases, Genetic;g:GJB2)(dui:D009140;dis:Musculoskeletal Diseases;g:GJB2)(dui:D007645;dis:Keratoderma, Palmoplantar;g:GJB2)(dui:D006226;dis:Hand Deformities;g:GJB2)(dui:D009139;dis:Musculoskeletal Abnormalities;g:GJB2)(dui:D006228;dis:Hand Deformities, Congenital;g:GJB2)(dui:D017880;dis:Limb Deformities, Congenital;g:GJB2)(dui:D038062;dis:Upper Extremity Deformities, Congenital;g:GJB2)(dui:D012868;dis:Skin Abnormalities;g:GJB2)(dui:D007232;dis:Infant, Newborn, Diseases;g:GJB2)(dui:D007057;dis:Ichthyosis;g:GJB2)(dui:D005128;dis:Eye Diseases;g:GJB2)(dui:D003638;dis:Deafness;g:GJB2)(dui:D003316;dis:Corneal Diseases;g:GJB2)(dui:D007634;dis:Keratitis;g:GJB2)(dui:D009369;dis:Neoplasms;g:GJB2)(dui:D009371;dis:Neoplasms by Site;g:GJB2)(dui:D004066;dis:Digestive System Diseases;g:GJB2)(dui:D017444;dis:Skin Diseases, Papulosquamous;g:GJB2)(dui:D011565;dis:Psoriasis;g:GJB2)(dui:D004700;dis:Endocrine System Diseases;g:GJB2)(dui:D003240;dis:Connective Tissue Diseases;g:GJB2)(dui:D012874;dis:Skin Diseases, Infectious;g:GJB2)(dui:D002481;dis:Cellulitis;g:GJB2)(dui:D012878;dis:Skin Neoplasms;g:GJB2)(dui:D013543;dis:Sweat Gland Diseases;g:GJB2)(dui:D016575;dis:Hidradenitis;g:GJB2)(dui:D017192;dis:Skin Diseases, Bacterial;g:GJB2)(dui:D017497;dis:Hidradenitis Suppurativa;g:GJB2)		GO:0016328:GO:0048839:GO:1903763:GO:0032570:GO:0046677:GO:1905867:GO:0046697:GO:0005793:GO:0044752:GO:0005921:GO:0007605:GO:0005887:GO:0032526:GO:0002931:GO:0005922:GO:0071377:GO:0005509:GO:1990349:GO:0097449:GO:0005829:GO:0042802:GO:0055085:GO:0007267:GO:0005243:GO:0007568:GO:0005886:GO:0005515:GO:0048471:GO:0044297:GO:0010644:GO:0032355:GO:0016264:GO:0034599:GO:0032496:GO:0071549	121011	PF00029	0.67															F
chr13:100111917	SNV	T	1	T/A	PASS	2.123244462000228e-18	176.73		77	T=39,A=38	T=0.5065,A=0.4935	49.35	50.65	heterozygous	7	0.003	4.0		PCCA	NR_148031.2	PCCA:intronic_nc:NR_148031.2										GMAF=0.0031:AMAF=0.0011:EMAF=0.0041					rs184412459		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PCCA)(dui:NBS2;dis:Core Conditions;g:PCCA)(dui:NBS9;dis:Organic Acid Condition;g:PCCA)(dui:NBS42;dis:Propionic acidemia;g:PCCA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PCCA)(dui:D008659;dis:Metabolic Diseases;g:PCCA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PCCA)(dui:D030342;dis:Genetic Diseases, Inborn;g:PCCA)(dui:D008661;dis:Metabolism, Inborn Errors;g:PCCA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PCCA)(dui:D056693;dis:Propionic Acidemia;g:PCCA)(dui:D005128;dis:Eye Diseases;g:PCCA)(dui:D012030;dis:Refractive Errors;g:PCCA)	Biotin		232000	PF08443:PF07478:PF00364:PF02222:PF02786:PF02785:PF00289	2.19															F
chr15:80153175	INDEL	GT	1	GT/G	PASS	0.0107359381289608	19.6916		24	GT=18,G=6	GT=0.75,G=0.25	25.0	75.0	heterozygous	7	0.031	1.0		FAH	NM_000137.4	FAH:intronic:NM_000137.4	unknown			p.?	c.81+41delT				G						rs777902403:rs57837512:rs767638459:rs762924131:rs558321563:rs756381638:rs752679360:rs1555440100:rs554422109:rs757176902		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	0.78,-0.07															F
chr15:80175247	SNV	G	1	G/C	PASS	6.305216450900441e-24	232.003		124	G=68,C=56	G=0.5484,C=0.4516	45.16	54.84	heterozygous	7	0.061	4.0		FAH	NM_000137.4	FAH:intronic:NM_000137.4	unknown			p.?	c.913+156G>C				C						rs79745256		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	0.46															F
chr15:80180219	SNV	C	1	C/T	PASS	8.085371885255472e-12	110.923		67	C=39,T=28	C=0.5821,T=0.4179	41.79	58.21	heterozygous	7	0.06	1.0		FAH	NM_000137.4	FAH:exonic:NM_000137.4	synonymous	AGT	12	p.Ser352=	c.1056C>T				T	GMAF=0.0416:AMAF=0.0334:EMAF=0.0458	0.24		Benign	5619276	rs1801374:rs1292305529		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	0.69															F
chr15:80186247	MNV	ACCCC	5	ACCCC/CTTTG	PASS	2.3856130399309183e-36	356.224		185	ACCCC=100,CTTTG=85	ACCCC=0.5405,CTTTG=0.4595	45.95	54.05	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															F
chr19:41411106	INDEL	CT	1	CT/C	PASS	0.0001317831851279	38.8014		67	CT=35,C=32	CT=0.5224,C=0.4776	47.76	52.24	heterozygous	7		6.0		BCKDHA	NM_001164783.2	BCKDHA:intronic:NM_001164783.2	unknown			p.?	c.375+98delT				C						rs746587969		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHA)(dui:NBS2;dis:Core Conditions;g:BCKDHA)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHA)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHA)(dui:D008659;dis:Metabolic Diseases;g:BCKDHA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHA)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHA)(dui:D009422;dis:Nervous System Diseases;g:BCKDHA)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHA)(dui:D001927;dis:Brain Diseases;g:BCKDHA)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHA)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHA)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHA)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHA)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0046872:GO:0003826:GO:0005739:GO:0055114:GO:0016831	608348	PF00676	-1.16,0.73															F
chr19:45553823	SNV	A	1	A/G	PASS	7.850548482379835e-56	551.051		231	A=113,G=118	A=0.4892,G=0.5108	51.08	48.92	heterozygous	45	0.233	1.0		OPA3	NM_025136.4	OPA3:exonic:NM_025136.4	synonymous	GCC	2	p.Ala77=	c.231T>C				G	GMAF=0.3174:AMAF=0.2398:EMAF=0.3572	0.09		Benign	439792	rs3826860		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:OPA3)(dui:NBS3;dis:Secondary Conditions;g:OPA3)(dui:NBS4;dis:Organic Acid Condition;g:OPA3)(dui:NBS19;dis:3-Methylglutaconic aciduria;g:OPA3)(dui:D009422;dis:Nervous System Diseases;g:OPA3)(dui:D005128;dis:Eye Diseases;g:OPA3)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:OPA3)(dui:D030342;dis:Genetic Diseases, Inborn;g:OPA3)(dui:D003389;dis:Cranial Nerve Diseases;g:OPA3)(dui:D009901;dis:Optic Nerve Diseases;g:OPA3)(dui:D019636;dis:Neurodegenerative Diseases;g:OPA3)(dui:D009896;dis:Optic Atrophy;g:OPA3)(dui:D020271;dis:Heredodegenerative Disorders, Nervous System;g:OPA3)(dui:D015785;dis:Eye Diseases, Hereditary;g:OPA3)(dui:D015418;dis:Optic Atrophies, Hereditary;g:OPA3)(dui:D007905;dis:Lens Diseases;g:OPA3)(dui:D002386;dis:Cataract;g:OPA3)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:OPA3)(dui:D008659;dis:Metabolic Diseases;g:OPA3)(dui:D009461;dis:Neurologic Manifestations;g:OPA3)(dui:D000013;dis:Congenital Abnormalities;g:OPA3)(dui:D002493;dis:Central Nervous System Diseases;g:OPA3)(dui:D009421;dis:Nervous System Malformations;g:OPA3)(dui:D009468;dis:Neuromuscular Diseases;g:OPA3)(dui:D008661;dis:Metabolism, Inborn Errors;g:OPA3)(dui:D009069;dis:Movement Disorders;g:OPA3)(dui:D010523;dis:Peripheral Nervous System Diseases;g:OPA3)(dui:D015417;dis:Hereditary Sensory and Motor Neuropathy;g:OPA3)(dui:D020820;dis:Dyskinesias;g:OPA3)(dui:D002819;dis:Chorea;g:OPA3)(dui:D011115;dis:Polyneuropathies;g:OPA3)(dui:D015419;dis:Spastic Paraplegia, Hereditary;g:OPA3)		GO:0070584:GO:0005739:GO:0050905:GO:0045444:GO:0007601:GO:0019216:GO:0040008:GO:0050896:GO:0060348	606580	PF07047	-0.93															F
chr19:45584839	SNV	C	1	C/T	PASS	6.05898671138969e-35	342.176		125	C=57,T=68	C=0.456,T=0.544	54.4	45.6	heterozygous	7	0.072	3.0		OPA3	NM_025136.4	OPA3:upstream:NM_025136.4	unknown			p.?	c.-75G>A				T				Benign		rs45598532		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:OPA3)(dui:NBS3;dis:Secondary Conditions;g:OPA3)(dui:NBS4;dis:Organic Acid Condition;g:OPA3)(dui:NBS19;dis:3-Methylglutaconic aciduria;g:OPA3)(dui:D009422;dis:Nervous System Diseases;g:OPA3)(dui:D005128;dis:Eye Diseases;g:OPA3)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:OPA3)(dui:D030342;dis:Genetic Diseases, Inborn;g:OPA3)(dui:D003389;dis:Cranial Nerve Diseases;g:OPA3)(dui:D009901;dis:Optic Nerve Diseases;g:OPA3)(dui:D019636;dis:Neurodegenerative Diseases;g:OPA3)(dui:D009896;dis:Optic Atrophy;g:OPA3)(dui:D020271;dis:Heredodegenerative Disorders, Nervous System;g:OPA3)(dui:D015785;dis:Eye Diseases, Hereditary;g:OPA3)(dui:D015418;dis:Optic Atrophies, Hereditary;g:OPA3)(dui:D007905;dis:Lens Diseases;g:OPA3)(dui:D002386;dis:Cataract;g:OPA3)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:OPA3)(dui:D008659;dis:Metabolic Diseases;g:OPA3)(dui:D009461;dis:Neurologic Manifestations;g:OPA3)(dui:D000013;dis:Congenital Abnormalities;g:OPA3)(dui:D002493;dis:Central Nervous System Diseases;g:OPA3)(dui:D009421;dis:Nervous System Malformations;g:OPA3)(dui:D009468;dis:Neuromuscular Diseases;g:OPA3)(dui:D008661;dis:Metabolism, Inborn Errors;g:OPA3)(dui:D009069;dis:Movement Disorders;g:OPA3)(dui:D010523;dis:Peripheral Nervous System Diseases;g:OPA3)(dui:D015417;dis:Hereditary Sensory and Motor Neuropathy;g:OPA3)(dui:D020820;dis:Dyskinesias;g:OPA3)(dui:D002819;dis:Chorea;g:OPA3)(dui:D011115;dis:Polyneuropathies;g:OPA3)(dui:D015419;dis:Spastic Paraplegia, Hereditary;g:OPA3)		GO:0070584:GO:0005739:GO:0050905:GO:0045444:GO:0007601:GO:0019216:GO:0040008:GO:0050896:GO:0060348	606580		1.29															F
chr19:51354620	INDEL	C	6	C/CCCACAG	PASS	2.4093505913355045e-29	286.181		171	C=97,CCCACAG=74	C=0.5673,CCCACAG=0.4327	43.27	56.73	heterozygous	7	0.082	3.0		ETFB	NM_001985.3	ETFB:intronic:NM_001985.3	unknown			p.?	c.58-313_58-312insCTGTGG				CCCACAG	GMAF=0.0866:AMAF=0.2446:EMAF=0.005			Benign		rs61361626:rs1568468379:rs869162765		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ETFB)(dui:NBS3;dis:Secondary Conditions;g:ETFB)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ETFB)(dui:NBS24;dis:Glutaric acidemia type II;g:ETFB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ETFB)(dui:D008659;dis:Metabolic Diseases;g:ETFB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ETFB)(dui:D030342;dis:Genetic Diseases, Inborn;g:ETFB)(dui:D008661;dis:Metabolism, Inborn Errors;g:ETFB)(dui:D028361;dis:Mitochondrial Diseases;g:ETFB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ETFB)(dui:D054069;dis:Multiple Acyl Coenzyme A Dehydrogenase Deficiency;g:ETFB)		GO:0033539:GO:0005515:GO:0005759:GO:0009055:GO:0005739:GO:0022904	130410	PF01012	-0.54															F
chrX:154532293	SNV	G	1	G/A	PASS	2.8326962002808964e-15	145.478		88	G=51,A=37	G=0.5795,A=0.4205	42.05	57.95	heterozygous	44		2.0		G6PD	NM_001042351.3	G6PD:intronic:NM_001042351.3	unknown			p.?	c.1365-13C>T				A	GMAF=0.3923:AMAF=0.1523:EMAF=0.1327					rs2071429		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:G6PD)(dui:NBS3;dis:Secondary Conditions;g:G6PD)(dui:NBS39;dis:Hb carrier other than C,D,E,S,O-Arab;g:G6PD)(dui:NBS7;dis:Hemoglobin Disorder;g:G6PD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:G6PD)(dui:D030342;dis:Genetic Diseases, Inborn;g:G6PD)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:G6PD)(dui:D006402;dis:Hematologic Diseases;g:G6PD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:G6PD)(dui:D000740;dis:Anemia;g:G6PD)(dui:D008659;dis:Metabolic Diseases;g:G6PD)(dui:D000743;dis:Anemia, Hemolytic;g:G6PD)(dui:D000745;dis:Anemia, Hemolytic, Congenital;g:G6PD)(dui:D008661;dis:Metabolism, Inborn Errors;g:G6PD)(dui:D005955;dis:Glucosephosphate Dehydrogenase Deficiency;g:G6PD)(dui:D040181;dis:Genetic Diseases, X-Linked;g:G6PD)(dui:D002239;dis:Carbohydrate Metabolism, Inborn Errors;g:G6PD)(dui:D052801;dis:Male Urogenital Diseases;g:G6PD)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:G6PD)(dui:D014570;dis:Urologic Diseases;g:G6PD)(dui:D052776;dis:Female Urogenital Diseases;g:G6PD)(dui:D007674;dis:Kidney Diseases;g:G6PD)(dui:D004066;dis:Digestive System Diseases;g:G6PD)(dui:D002318;dis:Cardiovascular Diseases;g:G6PD)(dui:D014652;dis:Vascular Diseases;g:G6PD)(dui:D008107;dis:Liver Diseases;g:G6PD)(dui:D007154;dis:Immune System Diseases;g:G6PD)(dui:D007153;dis:Immunologic Deficiency Syndromes;g:G6PD)(dui:D007960;dis:Leukocyte Disorders;g:G6PD)(dui:D010585;dis:Phagocyte Bactericidal Dysfunction;g:G6PD)(dui:D009422;dis:Nervous System Diseases;g:G6PD)(dui:D002493;dis:Central Nervous System Diseases;g:G6PD)(dui:D001927;dis:Brain Diseases;g:G6PD)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:G6PD)(dui:D012871;dis:Skin Diseases;g:G6PD)(dui:D004700;dis:Endocrine System Diseases;g:G6PD)(dui:D044882;dis:Glucose Metabolism Disorders;g:G6PD)(dui:D005236;dis:Favism;g:G6PD)(dui:D000746;dis:Anemia, Hemolytic, Congenital Nonspherocytic;g:G6PD)(dui:D003920;dis:Diabetes Mellitus;g:G6PD)(dui:D002561;dis:Cerebrovascular Disorders;g:G6PD)(dui:D001928;dis:Brain Diseases, Metabolic;g:G6PD)(dui:D009748;dis:Nutrition Disorders;g:G6PD)(dui:D006105;dis:Granulomatous Disease, Chronic;g:G6PD)(dui:D052439;dis:Lipid Metabolism Disorders;g:G6PD)(dui:D002545;dis:Brain Ischemia;g:G6PD)(dui:D003872;dis:Dermatitis;g:G6PD)(dui:D017443;dis:Skin Diseases, Eczematous;g:G6PD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:G6PD)(dui:D003877;dis:Dermatitis, Contact;g:G6PD)(dui:D006946;dis:Hyperinsulinism;g:G6PD)(dui:D050171;dis:Dyslipidemias;g:G6PD)(dui:D051437;dis:Renal Insufficiency;g:G6PD)(dui:D006949;dis:Hyperlipidemias;g:G6PD)(dui:D007333;dis:Insulin Resistance;g:G6PD)(dui:D058186;dis:Acute Kidney Injury;g:G6PD)	Nicotinamide adenine dinucleotide phosphate:Glycolic acid:16-Bromoepiandrosterone:Artenimol	GO:0032094:GO:0010041:GO:0009051:GO:0061052:GO:0034451:GO:0006740:GO:0006006:GO:0043523:GO:0004345:GO:0009898:GO:0043249:GO:1904879:GO:0045471:GO:0070062:GO:0043231:GO:0006739:GO:0019322:GO:0005829:GO:0010734:GO:2000378:GO:0042802:GO:0042803:GO:0006098:GO:0006695:GO:0014070:GO:0021762:GO:0005536:GO:0005634:GO:0050661:GO:0051156:GO:0005515:GO:0005737:GO:0006749:GO:0006629:GO:0016020:GO:0034599:GO:0055114:GO:0046390	305900	PF00479:PF02781	-0.82															F
chrX:154532439	SNV	A	1	A/G	PASS	8.655656238626578e-42	410.627		232	A=129,G=103	A=0.556,G=0.444	44.4	55.6	heterozygous	44		1.0		G6PD	NM_001042351.3	G6PD:exonic:NM_001042351.3	synonymous	TAC	11	p.Tyr437=	c.1311T>C				G	GMAF=0.1667:AMAF=0.2605:EMAF=0.1133			Benign		rs2230037		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:G6PD)(dui:NBS3;dis:Secondary Conditions;g:G6PD)(dui:NBS39;dis:Hb carrier other than C,D,E,S,O-Arab;g:G6PD)(dui:NBS7;dis:Hemoglobin Disorder;g:G6PD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:G6PD)(dui:D030342;dis:Genetic Diseases, Inborn;g:G6PD)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:G6PD)(dui:D006402;dis:Hematologic Diseases;g:G6PD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:G6PD)(dui:D000740;dis:Anemia;g:G6PD)(dui:D008659;dis:Metabolic Diseases;g:G6PD)(dui:D000743;dis:Anemia, Hemolytic;g:G6PD)(dui:D000745;dis:Anemia, Hemolytic, Congenital;g:G6PD)(dui:D008661;dis:Metabolism, Inborn Errors;g:G6PD)(dui:D005955;dis:Glucosephosphate Dehydrogenase Deficiency;g:G6PD)(dui:D040181;dis:Genetic Diseases, X-Linked;g:G6PD)(dui:D002239;dis:Carbohydrate Metabolism, Inborn Errors;g:G6PD)(dui:D052801;dis:Male Urogenital Diseases;g:G6PD)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:G6PD)(dui:D014570;dis:Urologic Diseases;g:G6PD)(dui:D052776;dis:Female Urogenital Diseases;g:G6PD)(dui:D007674;dis:Kidney Diseases;g:G6PD)(dui:D004066;dis:Digestive System Diseases;g:G6PD)(dui:D002318;dis:Cardiovascular Diseases;g:G6PD)(dui:D014652;dis:Vascular Diseases;g:G6PD)(dui:D008107;dis:Liver Diseases;g:G6PD)(dui:D007154;dis:Immune System Diseases;g:G6PD)(dui:D007153;dis:Immunologic Deficiency Syndromes;g:G6PD)(dui:D007960;dis:Leukocyte Disorders;g:G6PD)(dui:D010585;dis:Phagocyte Bactericidal Dysfunction;g:G6PD)(dui:D009422;dis:Nervous System Diseases;g:G6PD)(dui:D002493;dis:Central Nervous System Diseases;g:G6PD)(dui:D001927;dis:Brain Diseases;g:G6PD)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:G6PD)(dui:D012871;dis:Skin Diseases;g:G6PD)(dui:D004700;dis:Endocrine System Diseases;g:G6PD)(dui:D044882;dis:Glucose Metabolism Disorders;g:G6PD)(dui:D005236;dis:Favism;g:G6PD)(dui:D000746;dis:Anemia, Hemolytic, Congenital Nonspherocytic;g:G6PD)(dui:D003920;dis:Diabetes Mellitus;g:G6PD)(dui:D002561;dis:Cerebrovascular Disorders;g:G6PD)(dui:D001928;dis:Brain Diseases, Metabolic;g:G6PD)(dui:D009748;dis:Nutrition Disorders;g:G6PD)(dui:D006105;dis:Granulomatous Disease, Chronic;g:G6PD)(dui:D052439;dis:Lipid Metabolism Disorders;g:G6PD)(dui:D002545;dis:Brain Ischemia;g:G6PD)(dui:D003872;dis:Dermatitis;g:G6PD)(dui:D017443;dis:Skin Diseases, Eczematous;g:G6PD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:G6PD)(dui:D003877;dis:Dermatitis, Contact;g:G6PD)(dui:D006946;dis:Hyperinsulinism;g:G6PD)(dui:D050171;dis:Dyslipidemias;g:G6PD)(dui:D051437;dis:Renal Insufficiency;g:G6PD)(dui:D006949;dis:Hyperlipidemias;g:G6PD)(dui:D007333;dis:Insulin Resistance;g:G6PD)(dui:D058186;dis:Acute Kidney Injury;g:G6PD)	Nicotinamide adenine dinucleotide phosphate:Glycolic acid:16-Bromoepiandrosterone:Artenimol	GO:0032094:GO:0010041:GO:0009051:GO:0061052:GO:0034451:GO:0006740:GO:0006006:GO:0043523:GO:0004345:GO:0009898:GO:0043249:GO:1904879:GO:0045471:GO:0070062:GO:0043231:GO:0006739:GO:0019322:GO:0005829:GO:0010734:GO:2000378:GO:0042802:GO:0042803:GO:0006098:GO:0006695:GO:0014070:GO:0021762:GO:0005536:GO:0005634:GO:0050661:GO:0051156:GO:0005515:GO:0005737:GO:0006749:GO:0006629:GO:0016020:GO:0034599:GO:0055114:GO:0046390	305900	PF00479:PF02781	-2.64															F
chrX:154533044	SNV	C	1	C/T	PASS	2.0849709101237404e-52	516.809		164	C=68,T=96	C=0.4146,T=0.5854	58.54	41.46	heterozygous	13	0.002	1.0		G6PD	NM_001042351.3	G6PD:exonic:NM_001042351.3	missense	AAG	9	p.Glu317Lys	c.949G>A	0.05	0.837	56.0	T		0.92		Conflicting interpretations of pathogenicity	9230996	rs137852339		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:G6PD)(dui:NBS3;dis:Secondary Conditions;g:G6PD)(dui:NBS39;dis:Hb carrier other than C,D,E,S,O-Arab;g:G6PD)(dui:NBS7;dis:Hemoglobin Disorder;g:G6PD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:G6PD)(dui:D030342;dis:Genetic Diseases, Inborn;g:G6PD)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:G6PD)(dui:D006402;dis:Hematologic Diseases;g:G6PD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:G6PD)(dui:D000740;dis:Anemia;g:G6PD)(dui:D008659;dis:Metabolic Diseases;g:G6PD)(dui:D000743;dis:Anemia, Hemolytic;g:G6PD)(dui:D000745;dis:Anemia, Hemolytic, Congenital;g:G6PD)(dui:D008661;dis:Metabolism, Inborn Errors;g:G6PD)(dui:D005955;dis:Glucosephosphate Dehydrogenase Deficiency;g:G6PD)(dui:D040181;dis:Genetic Diseases, X-Linked;g:G6PD)(dui:D002239;dis:Carbohydrate Metabolism, Inborn Errors;g:G6PD)(dui:D052801;dis:Male Urogenital Diseases;g:G6PD)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:G6PD)(dui:D014570;dis:Urologic Diseases;g:G6PD)(dui:D052776;dis:Female Urogenital Diseases;g:G6PD)(dui:D007674;dis:Kidney Diseases;g:G6PD)(dui:D004066;dis:Digestive System Diseases;g:G6PD)(dui:D002318;dis:Cardiovascular Diseases;g:G6PD)(dui:D014652;dis:Vascular Diseases;g:G6PD)(dui:D008107;dis:Liver Diseases;g:G6PD)(dui:D007154;dis:Immune System Diseases;g:G6PD)(dui:D007153;dis:Immunologic Deficiency Syndromes;g:G6PD)(dui:D007960;dis:Leukocyte Disorders;g:G6PD)(dui:D010585;dis:Phagocyte Bactericidal Dysfunction;g:G6PD)(dui:D009422;dis:Nervous System Diseases;g:G6PD)(dui:D002493;dis:Central Nervous System Diseases;g:G6PD)(dui:D001927;dis:Brain Diseases;g:G6PD)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:G6PD)(dui:D012871;dis:Skin Diseases;g:G6PD)(dui:D004700;dis:Endocrine System Diseases;g:G6PD)(dui:D044882;dis:Glucose Metabolism Disorders;g:G6PD)(dui:D005236;dis:Favism;g:G6PD)(dui:D000746;dis:Anemia, Hemolytic, Congenital Nonspherocytic;g:G6PD)(dui:D003920;dis:Diabetes Mellitus;g:G6PD)(dui:D002561;dis:Cerebrovascular Disorders;g:G6PD)(dui:D001928;dis:Brain Diseases, Metabolic;g:G6PD)(dui:D009748;dis:Nutrition Disorders;g:G6PD)(dui:D006105;dis:Granulomatous Disease, Chronic;g:G6PD)(dui:D052439;dis:Lipid Metabolism Disorders;g:G6PD)(dui:D002545;dis:Brain Ischemia;g:G6PD)(dui:D003872;dis:Dermatitis;g:G6PD)(dui:D017443;dis:Skin Diseases, Eczematous;g:G6PD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:G6PD)(dui:D003877;dis:Dermatitis, Contact;g:G6PD)(dui:D006946;dis:Hyperinsulinism;g:G6PD)(dui:D050171;dis:Dyslipidemias;g:G6PD)(dui:D051437;dis:Renal Insufficiency;g:G6PD)(dui:D006949;dis:Hyperlipidemias;g:G6PD)(dui:D007333;dis:Insulin Resistance;g:G6PD)(dui:D058186;dis:Acute Kidney Injury;g:G6PD)	Nicotinamide adenine dinucleotide phosphate:Glycolic acid:16-Bromoepiandrosterone:Artenimol	GO:0032094:GO:0010041:GO:0009051:GO:0061052:GO:0034451:GO:0006740:GO:0006006:GO:0043523:GO:0004345:GO:0009898:GO:0043249:GO:1904879:GO:0045471:GO:0070062:GO:0043231:GO:0006739:GO:0019322:GO:0005829:GO:0010734:GO:2000378:GO:0042802:GO:0042803:GO:0006098:GO:0006695:GO:0014070:GO:0021762:GO:0005536:GO:0005634:GO:0050661:GO:0051156:GO:0005515:GO:0005737:GO:0006749:GO:0006629:GO:0016020:GO:0034599:GO:0055114:GO:0046390	305900	PF00479:PF02781	2.83															F
chrX:154546029	SNV	T	1	T/G	PASS	4.892152651344186e-15	143.105		76	T=42,G=34	T=0.5526,G=0.4474	44.74	55.26	heterozygous	7	0.007	1.0		G6PD|IKBKG	NM_001042351.3|NM_001321396.3	G6PD:intronic:NM_001042351.3|IKBKG:intronic:NM_001321396.3	unknown|unknown	|	|	p.?|p.?	c.120+7A>C|c.-16+3642T>G	|	|	|	G|G	GMAF=3.0E-4:AMAF=8.0E-4:EMAF=0.0			Conflicting interpretations of pathogenicity		rs369904290		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:G6PD)(dui:NBS3;dis:Secondary Conditions;g:G6PD)(dui:NBS39;dis:Hb carrier other than C,D,E,S,O-Arab;g:G6PD)(dui:NBS7;dis:Hemoglobin Disorder;g:G6PD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:G6PD)(dui:D030342;dis:Genetic Diseases, Inborn;g:G6PD)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:G6PD)(dui:D006402;dis:Hematologic Diseases;g:G6PD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:G6PD)(dui:D000740;dis:Anemia;g:G6PD)(dui:D008659;dis:Metabolic Diseases;g:G6PD)(dui:D000743;dis:Anemia, Hemolytic;g:G6PD)(dui:D000745;dis:Anemia, Hemolytic, Congenital;g:G6PD)(dui:D008661;dis:Metabolism, Inborn Errors;g:G6PD)(dui:D005955;dis:Glucosephosphate Dehydrogenase Deficiency;g:G6PD)(dui:D040181;dis:Genetic Diseases, X-Linked;g:G6PD)(dui:D002239;dis:Carbohydrate Metabolism, Inborn Errors;g:G6PD)(dui:D052801;dis:Male Urogenital Diseases;g:G6PD)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:G6PD)(dui:D014570;dis:Urologic Diseases;g:G6PD)(dui:D052776;dis:Female Urogenital Diseases;g:G6PD)(dui:D007674;dis:Kidney Diseases;g:G6PD)(dui:D004066;dis:Digestive System Diseases;g:G6PD)(dui:D002318;dis:Cardiovascular Diseases;g:G6PD)(dui:D014652;dis:Vascular Diseases;g:G6PD)(dui:D008107;dis:Liver Diseases;g:G6PD)(dui:D007154;dis:Immune System Diseases;g:G6PD)(dui:D007153;dis:Immunologic Deficiency Syndromes;g:G6PD)(dui:D007960;dis:Leukocyte Disorders;g:G6PD)(dui:D010585;dis:Phagocyte Bactericidal Dysfunction;g:G6PD)(dui:D009422;dis:Nervous System Diseases;g:G6PD)(dui:D002493;dis:Central Nervous System Diseases;g:G6PD)(dui:D001927;dis:Brain Diseases;g:G6PD)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:G6PD)(dui:D012871;dis:Skin Diseases;g:G6PD)(dui:D004700;dis:Endocrine System Diseases;g:G6PD)(dui:D044882;dis:Glucose Metabolism Disorders;g:G6PD)(dui:D005236;dis:Favism;g:G6PD)(dui:D000746;dis:Anemia, Hemolytic, Congenital Nonspherocytic;g:G6PD)(dui:D003920;dis:Diabetes Mellitus;g:G6PD)(dui:D002561;dis:Cerebrovascular Disorders;g:G6PD)(dui:D001928;dis:Brain Diseases, Metabolic;g:G6PD)(dui:D009748;dis:Nutrition Disorders;g:G6PD)(dui:D006105;dis:Granulomatous Disease, Chronic;g:G6PD)(dui:D052439;dis:Lipid Metabolism Disorders;g:G6PD)(dui:D002545;dis:Brain Ischemia;g:G6PD)(dui:D003872;dis:Dermatitis;g:G6PD)(dui:D017443;dis:Skin Diseases, Eczematous;g:G6PD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:G6PD)(dui:D003877;dis:Dermatitis, Contact;g:G6PD)(dui:D006946;dis:Hyperinsulinism;g:G6PD)(dui:D050171;dis:Dyslipidemias;g:G6PD)(dui:D051437;dis:Renal Insufficiency;g:G6PD)(dui:D006949;dis:Hyperlipidemias;g:G6PD)(dui:D007333;dis:Insulin Resistance;g:G6PD)(dui:D058186;dis:Acute Kidney Injury;g:G6PD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:IKBKG)(dui:D030342;dis:Genetic Diseases, Inborn;g:IKBKG)(dui:D000013;dis:Congenital Abnormalities;g:IKBKG)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:IKBKG)(dui:D012871;dis:Skin Diseases;g:IKBKG)(dui:D012873;dis:Skin Diseases, Genetic;g:IKBKG)(dui:D000015;dis:Abnormalities, Multiple;g:IKBKG)(dui:D012868;dis:Skin Abnormalities;g:IKBKG)(dui:D040181;dis:Genetic Diseases, X-Linked;g:IKBKG)(dui:D010859;dis:Pigmentation Disorders;g:IKBKG)(dui:D007184;dis:Incontinentia Pigmenti;g:IKBKG)(dui:D004476;dis:Ectodermal Dysplasia;g:IKBKG)(dui:D007154;dis:Immune System Diseases;g:IKBKG)(dui:D007153;dis:Immunologic Deficiency Syndromes;g:IKBKG)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:IKBKG)(dui:D009140;dis:Musculoskeletal Diseases;g:IKBKG)(dui:D008206;dis:Lymphatic Diseases;g:IKBKG)(dui:D001847;dis:Bone Diseases;g:IKBKG)(dui:D001848;dis:Bone Diseases, Developmental;g:IKBKG)(dui:D008209;dis:Lymphedema;g:IKBKG)(dui:D010009;dis:Osteochondrodysplasias;g:IKBKG)(dui:D010026;dis:Osteosclerosis;g:IKBKG)(dui:D010022;dis:Osteopetrosis;g:IKBKG)(dui:D009369;dis:Neoplasms;g:IKBKG)(dui:D004066;dis:Digestive System Diseases;g:IKBKG)(dui:D008107;dis:Liver Diseases;g:IKBKG)(dui:D009371;dis:Neoplasms by Site;g:IKBKG)(dui:D005234;dis:Fatty Liver;g:IKBKG)(dui:D012140;dis:Respiratory Tract Diseases;g:IKBKG)(dui:D008171;dis:Lung Diseases;g:IKBKG)(dui:D012142;dis:Respiratory Tract Neoplasms;g:IKBKG)(dui:D008175;dis:Lung Neoplasms;g:IKBKG)(dui:D013899;dis:Thoracic Neoplasms;g:IKBKG)(dui:D065626;dis:Non-alcoholic Fatty Liver Disease;g:IKBKG)	Tarenflurbil:Nicotinamide adenine dinucleotide phosphate:Glycolic acid:16-Bromoepiandrosterone:AGRO100:Artenimol	GO:0032094:GO:0061052:GO:0008385:GO:0007254:GO:0006006:GO:0051092:GO:1990450:GO:0004345:GO:0042975:GO:0044877:GO:0000187:GO:0002479:GO:0006954:GO:0006955:GO:0002756:GO:0046982:GO:0043231:GO:0006915:GO:0019322:GO:0005829:GO:0010734:GO:0051403:GO:0016239:GO:0019904:GO:0065003:GO:0006098:GO:0006695:GO:0043276:GO:0014070:GO:0006974:GO:0005634:GO:0005515:GO:0031625:GO:0000151:GO:0046872:GO:0051650:GO:1990459:GO:0032991:GO:0046390:GO:0035666:GO:0010041:GO:0009051:GO:0034451:GO:0038095:GO:0043123:GO:0006740:GO:0043122:GO:0043523:GO:0009615:GO:0045944:GO:0009898:GO:0043249:GO:1904879:GO:0002223:GO:0005654:GO:0045471:GO:0070062:GO:0072686:GO:0006739:GO:0016032:GO:0070423:GO:0050852:GO:2000378:GO:0016579:GO:0042802:GO:0042803:GO:0000922:GO:1901215:GO:0007249:GO:0021762:GO:0005536:GO:0050661:GO:0051156:GO:0005737:GO:0070530:GO:0006749:GO:0045087:GO:0006629:GO:0016020:GO:0010803:GO:0034599:GO:0055114:GO:0070498	300248:305900	PF00479:PF02781	0.07															F
chr1:75733668	SNV	G	1	G/A	PASS	9.229963848404523e-29	280.348		139	G=74,A=65	G=0.5324,A=0.4676	46.76	53.24	heterozygous	7	0.003	1.0		ACADM	NM_000016.6	ACADM:intronic:NM_000016.6	unknown			p.?	c.387+40G>A				A	GMAF=0.0026:AMAF=5.0E-4:EMAF=0.0037					rs187510227:rs767532171		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADM)(dui:NBS2;dis:Core Conditions;g:ACADM)(dui:NBS10;dis:Fatty Acid Oxidation Disorder;g:ACADM)(dui:NBS51;dis:Medium-chain acyl-CoA dehydrogenase deficiency;g:ACADM)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADM)(dui:D008659;dis:Metabolic Diseases;g:ACADM)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADM)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADM)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADM)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADM)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADM)(dui:D004066;dis:Digestive System Diseases;g:ACADM)(dui:D008107;dis:Liver Diseases;g:ACADM)(dui:D048550;dis:Hepatic Insufficiency;g:ACADM)(dui:D017093;dis:Liver Failure;g:ACADM)(dui:D005767;dis:Gastrointestinal Diseases;g:ACADM)(dui:D009748;dis:Nutrition Disorders;g:ACADM)(dui:D005759;dis:Gastroenteritis;g:ACADM)(dui:D007410;dis:Intestinal Diseases;g:ACADM)(dui:D044343;dis:Overnutrition;g:ACADM)(dui:D004760;dis:Enterocolitis;g:ACADM)(dui:D009765;dis:Obesity;g:ACADM)(dui:D020345;dis:Enterocolitis, Necrotizing;g:ACADM)	Octanoyl-Coenzyme A:3-thiaoctanoyl-CoA:Flavin adenine dinucleotide	GO:0042802:GO:0045329:GO:0003995:GO:0005634:GO:0006635:GO:0033539:GO:0031966:GO:0070991:GO:0005759:GO:0050660:GO:0051793:GO:0019254:GO:0005739:GO:0051791:GO:0055114:GO:0019216:GO:0030424	607008	PF02771:PF02770:PF00441:PF08028	-1.25															F
chr1:115034033	SNV	A	1	A/G	PASS	1.9902150222793503e-53	527.011		213	A=102,G=111	A=0.4789,G=0.5211	52.11	47.89	heterozygous	7	0.002	1.0		TSHB	NM_000549.5	TSHB:exonic:NM_000549.5	missense	GGA	3	p.Arg75Gly	c.223A>G	0.17	0.0	125.0	G				Benign/Likely benign		rs201857310		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TSHB)(dui:NBS2;dis:Core Conditions;g:TSHB)(dui:NBS12;dis:Endocrine Disorder;g:TSHB)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TSHB)(dui:D004700;dis:Endocrine System Diseases;g:TSHB)(dui:D013959;dis:Thyroid Diseases;g:TSHB)(dui:D007037;dis:Hypothyroidism;g:TSHB)(dui:D009140;dis:Musculoskeletal Diseases;g:TSHB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TSHB)(dui:D001847;dis:Bone Diseases;g:TSHB)(dui:D001849;dis:Bone Diseases, Endocrine;g:TSHB)(dui:D004392;dis:Dwarfism;g:TSHB)(dui:D030342;dis:Genetic Diseases, Inborn;g:TSHB)(dui:D001848;dis:Bone Diseases, Developmental;g:TSHB)(dui:D003409;dis:Congenital Hypothyroidism;g:TSHB)(dui:D009422;dis:Nervous System Diseases;g:TSHB)(dui:D001523;dis:Mental Disorders;g:TSHB)(dui:D000068105;dis:Bipolar and Related Disorders;g:TSHB)(dui:D009461;dis:Neurologic Manifestations;g:TSHB)(dui:D001714;dis:Bipolar Disorder;g:TSHB)(dui:D019954;dis:Neurobehavioral Manifestations;g:TSHB)(dui:D003244;dis:Consciousness Disorders;g:TSHB)(dui:D014474;dis:Unconsciousness;g:TSHB)(dui:D003128;dis:Coma;g:TSHB)		GO:0005615:GO:0043627:GO:0007186:GO:0005737:GO:0051592:GO:0007267:GO:0009653:GO:0016486:GO:0033189:GO:0005576:GO:0005179:GO:0009755	188540		1.25															F
chr2:1494031	SNV	C	1	T/T	PASS	1.2647363474711626e-130	1298.98		134	C=0,T=134	C=0.0,T=1.0	100.0	0.0	homozygous	44	0.359	1.0		TPO	NM_000547.5	TPO:exonic:NM_000547.5	synonymous	GAT	11	p.Asp666=	c.1998C>T				T	GMAF=0.3505:AMAF=0.3221:EMAF=0.3651	0.01		Benign	3757660	rs780537993:rs1126797		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-5.14															F
chr2:1496127	SNV	C	1	T/T	PASS	2.4093505913355044e-31	306.181		32	C=0,T=32	C=0.0,T=1.0	100.0	0.0	homozygous	44	0.439	4.0		TPO	NM_000547.5	TPO:exonic:NM_000547.5	synonymous	CCT	12	p.Pro715=	c.2145C>T				T	GMAF=0.413:AMAF=0.4414:EMAF=0.3985	0.04		Benign	1685440	rs732608		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-2.72															F
chr2:1496155	SNV	A	1	C/C	PASS	2.4087958817256997e-31	306.182		32	A=0,C=32	A=0.0,C=1.0	100.0	0.0	homozygous	50	0.498	1.0		TPO	NM_000547.5	TPO:exonic:NM_000547.5	missense	CCT	12	p.Thr725Pro	c.2173A>C	1.0	0.0	38.0	C	GMAF=0.4703:AMAF=0.3926:EMAF=0.4001	0.03		Benign	3812428	rs732609		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	2.92															F
chr2:1542529	SNV	G	1	G/A	PASS	5.217951042390037e-45	442.825		141	G=59,A=82	G=0.4184,A=0.5816	58.16	41.84	heterozygous	7	0.0	1.0		TPO	NM_000547.5	TPO:utr_3:NM_000547.5	unknown		17	p.?	c.*55G>A				A				Uncertain significance		rs529769659:rs777904360:rs1434198939:rs756202105		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-2.48															F
chr5:71626885	SNV	C	1	C/T	PASS	5.751749984619472e-25	242.402		85	C=38,T=47	C=0.4471,T=0.5529	55.29	44.71	heterozygous	7	0.099	2.0		MCCC2	NM_022132.5	MCCC2:intronic:NM_022132.5	unknown			p.?	c.738+132C>T				T						rs77085070		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MCCC2)(dui:NBS2;dis:Core Conditions;g:MCCC2)(dui:NBS9;dis:Organic Acid Condition;g:MCCC2)(dui:NBS45;dis:3-Methylcrotonyl-CoA carboxylase deficiency;g:MCCC2)(dui:D009422;dis:Nervous System Diseases;g:MCCC2)(dui:D002493;dis:Central Nervous System Diseases;g:MCCC2)(dui:D001927;dis:Brain Diseases;g:MCCC2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MCCC2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MCCC2)(dui:D008659;dis:Metabolic Diseases;g:MCCC2)(dui:D030342;dis:Genetic Diseases, Inborn;g:MCCC2)(dui:D008661;dis:Metabolism, Inborn Errors;g:MCCC2)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MCCC2)(dui:D001928;dis:Brain Diseases, Metabolic;g:MCCC2)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MCCC2)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:MCCC2)	Biotin	GO:0002169:GO:0005524:GO:0005515:GO:0006768:GO:0009083:GO:0005759:GO:1905202:GO:0005739:GO:0006552:GO:0005829:GO:0015936:GO:0004485	609014	PF01039	-0.29															F
chr6:32038844	SNV	A	1	A/C	PASS	0.0001107337480741	39.5572		23	A=14,C=9	A=0.6087,C=0.3913	39.13	60.87	heterozygous	24	0.218	7.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.292+33A>C				C	GMAF=0.2224:AMAF=0.0745:EMAF=0.2975					rs755425808:rs6463		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	1.04															F
chr6:32039143	SNV	C	1	C/T	PASS	3.8344228144309077e-16	154.163		63	C=31,T=32	C=0.4921,T=0.5079	50.79	49.21	heterozygous	7		3.0		CYP21A2	NM_000500.9	CYP21A2:exonic:NM_000500.9	synonymous	TCT	3	p.Ser114=	c.342C>T				T				Benign/Likely benign		rs193922546		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-0.68															F
chr6:39913090	INDEL	A	1	A/AC	PASS	3.675107101541509e-05	44.3473		58	A=29,AC=29	A=0.5,AC=0.5	50.0	50.0	heterozygous	7		0.0		MOCS1	NM_001358530.2	MOCS1:intronic:NM_001358530.2	unknown			p.?	c.758-87_758-86insG				AC						rs1354991463		(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MOCS1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MOCS1)(dui:D008659;dis:Metabolic Diseases;g:MOCS1)(dui:D030342;dis:Genetic Diseases, Inborn;g:MOCS1)(dui:D008661;dis:Metabolism, Inborn Errors;g:MOCS1)(dui:D008664;dis:Metal Metabolism, Inborn Errors;g:MOCS1)			603707	PF01967:PF04055:PF06463:PF13353	-0.81															F
chr7:117480087	SNV	G	1	G/C	PASS	1.4477714229790894e-28	278.393		120	G=60,C=60	G=0.5,C=0.5	50.0	50.0	heterozygous	7	0.027	1.0		CFTR	NM_000492.4	CFTR:utr_5:NM_000492.4	unknown		1	p.?	c.-8G>C				C	GMAF=0.0406:AMAF=0.0116:EMAF=0.0555			Benign/Likely benign		rs1800501:rs397508136		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		0.21															F
chr10:123009098	SNV	G	1	G/A	PASS	8.693606925094154e-25	240.608		87	G=40,A=47	G=0.4598,A=0.5402	54.02	45.98	heterozygous	7	0.048	5.0		IKZF5|ACADSB	NM_001372127.1|NM_001609.4	IKZF5:upstream:NM_001372127.1|ACADSB:intronic:NM_001609.4	unknown|unknown	|	|	p.?|p.?	c.-10473C>T|c.42+27G>A	|	|	|	A|A						rs1355506920:rs117921026		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADSB)(dui:NBS3;dis:Secondary Conditions;g:ACADSB)(dui:NBS18;dis:2-Methylbutyrylglycinuria;g:ACADSB)(dui:NBS4;dis:Organic Acid Condition;g:ACADSB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADSB)(dui:D008659;dis:Metabolic Diseases;g:ACADSB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADSB)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADSB)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADSB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ACADSB)(dui:D001523;dis:Mental Disorders;g:ACADSB)(dui:D065886;dis:Neurodevelopmental Disorders;g:ACADSB)(dui:D002659;dis:Child Development Disorders, Pervasive;g:ACADSB)(dui:D001321;dis:Autistic Disorder;g:ACADSB)	Valproic acid:Isoleucine	GO:0003853:GO:0042802:GO:0009083:GO:0005759:GO:0050660:GO:0016937:GO:0005739:GO:0102035:GO:0006550:GO:0055114:GO:0006631	600301		-0.16															F
chr10:123041337	SNV	C	1	C/T	PASS	1.5187979420318118e-22	218.185		104	C=54,T=50	C=0.5192,T=0.4808	48.08	51.92	heterozygous	31	0.228	1.0		ACADSB	NM_001609.4	ACADSB:exonic:NM_001609.4	synonymous	CAT	5	p.His213=	c.639C>T				T	GMAF=0.2281:AMAF=0.2156:EMAF=0.2345	0.02		Benign	3997809	rs1140591		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADSB)(dui:NBS3;dis:Secondary Conditions;g:ACADSB)(dui:NBS18;dis:2-Methylbutyrylglycinuria;g:ACADSB)(dui:NBS4;dis:Organic Acid Condition;g:ACADSB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADSB)(dui:D008659;dis:Metabolic Diseases;g:ACADSB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADSB)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADSB)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADSB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:ACADSB)(dui:D001523;dis:Mental Disorders;g:ACADSB)(dui:D065886;dis:Neurodevelopmental Disorders;g:ACADSB)(dui:D002659;dis:Child Development Disorders, Pervasive;g:ACADSB)(dui:D001321;dis:Autistic Disorder;g:ACADSB)	Valproic acid:Isoleucine	GO:0003853:GO:0042802:GO:0009083:GO:0005759:GO:0050660:GO:0016937:GO:0005739:GO:0102035:GO:0006550:GO:0055114:GO:0006631	600301		-1.56															F
chr12:109573424	MNV	GC	2	GC/TT	PASS	1.110708255918865e-26	259.544		97	GC=45,TT=52	GC=0.4639,TT=0.5361	53.61	46.39	0	1	0.285	1.0		MMAB|MVK	NM_052845.4|NM_001114185.3	MMAB:exonic:NM_052845.4|MVK:upstream:NM_001114185.3	missense|unknown	|	1|	p.Arg19Gln|p.?	c.56_57delGCinsAA|c.-1399GC>TT	0.07|	0.873|	43.0|	TT|TT	GMAF=0.3091:AMAF=0.3917:EMAF=0.267	0.71		Benign/Likely benign	3752891	rs10774774:rs10774775:rs36013132:rs748526009:rs879684260:rs1555276196:rs1555276197		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMAB)(dui:NBS2;dis:Core Conditions;g:MMAB)(dui:NBS9;dis:Organic Acid Condition;g:MMAB)(dui:NBS43;dis:Methylmalonic acidemia;g:MMAB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMAB)(dui:D008659;dis:Metabolic Diseases;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMAB)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMAB)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMAB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MVK)(dui:D030342;dis:Genetic Diseases, Inborn;g:MVK)(dui:D009422;dis:Nervous System Diseases;g:MVK)(dui:D056660;dis:Hereditary Autoinflammatory Diseases;g:MVK)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MVK)(dui:D008659;dis:Metabolic Diseases;g:MVK)(dui:D002493;dis:Central Nervous System Diseases;g:MVK)(dui:D001927;dis:Brain Diseases;g:MVK)(dui:D008661;dis:Metabolism, Inborn Errors;g:MVK)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MVK)(dui:D007154;dis:Immune System Diseases;g:MVK)(dui:D006402;dis:Hematologic Diseases;g:MVK)(dui:D007160;dis:Immunoproliferative Disorders;g:MVK)(dui:D001796;dis:Blood Protein Disorders;g:MVK)(dui:D001928;dis:Brain Diseases, Metabolic;g:MVK)(dui:D006942;dis:Hypergammaglobulinemia;g:MVK)(dui:D018901;dis:Peroxisomal Disorders;g:MVK)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MVK)(dui:D054078;dis:Mevalonate Kinase Deficiency;g:MVK)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MVK)(dui:D012871;dis:Skin Diseases;g:MVK)(dui:D012873;dis:Skin Diseases, Genetic;g:MVK)(dui:D007642;dis:Keratosis;g:MVK)(dui:D017499;dis:Porokeratosis;g:MVK)(dui:D009461;dis:Neurologic Manifestations;g:MVK)(dui:D004066;dis:Digestive System Diseases;g:MVK)(dui:D010146;dis:Pain;g:MVK)(dui:D009369;dis:Neoplasms;g:MVK)(dui:D008107;dis:Liver Diseases;g:MVK)(dui:D009371;dis:Neoplasms by Site;g:MVK)(dui:D004067;dis:Digestive System Neoplasms;g:MVK)(dui:D008113;dis:Liver Neoplasms;g:MVK)(dui:D009370;dis:Neoplasms by Histologic Type;g:MVK)(dui:D009140;dis:Musculoskeletal Diseases;g:MVK)(dui:D007592;dis:Joint Diseases;g:MVK)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MVK)(dui:D002277;dis:Carcinoma;g:MVK)(dui:D006528;dis:Carcinoma, Hepatocellular;g:MVK)(dui:D000230;dis:Adenocarcinoma;g:MVK)(dui:D018771;dis:Arthralgia;g:MVK)(dui:D005076;dis:Exanthema;g:MVK)	Farnesyl thiopyrophosphate:Cyanocobalamin	GO:0042802:GO:0050728:GO:0006695:GO:0004496:GO:0009235:GO:0008299:GO:0000287:GO:0005524:GO:0005777:GO:0005515:GO:0045540:GO:0005759:GO:0019287:GO:0043231:GO:0031419:GO:0008817:GO:0005829:GO:0016310	251170:607568	PF01923	-0.05,1.26															F
chr12:120739231	INDEL	TGCCCCTTCTCCAGCT	15	TGCCCCTTCTCCAGCT/T	PASS	5.013026495398042e-33	322.999		147	TGCCCCTTCTCCAGCT=75,T=72	TGCCCCTTCTCCAGCT=0.5102,T=0.4898	48.98	51.02	heterozygous	7		1.0		ACADS	NM_000017.4	ACADS:intronic:NM_000017.4	unknown			p.?	c.1086+36_1086+50delGCCCCTTCTCCAGCT				T						rs936141551:rs1304846112:rs1466572677:rs1338771119		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:ACADS)(dui:NBS21;dis:Short-chain acyl-CoA dehydrogenase deficiency;g:ACADS)(dui:NBS3;dis:Secondary Conditions;g:ACADS)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:ACADS)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:ACADS)(dui:D008659;dis:Metabolic Diseases;g:ACADS)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:ACADS)(dui:D030342;dis:Genetic Diseases, Inborn;g:ACADS)(dui:D008661;dis:Metabolism, Inborn Errors;g:ACADS)(dui:D052439;dis:Lipid Metabolism Disorders;g:ACADS)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:ACADS)	Acetoacetyl-CoA:NADH:Flavin adenine dinucleotide	GO:0003995:GO:0005634:GO:0005813:GO:0006635:GO:0033539:GO:0005759:GO:0050660:GO:0004085:GO:0005739:GO:0046359:GO:0005654	606885	PF02771:PF02770:PF00441:PF08028	-0.75,0.93,-0.4,-0.28,-0.05,-1.58,-0.86,-1.07,0.28,0.52,0.58,-1.19,-2.25,-0.27,0.03,-1.41															F
chr15:80186158	SNV	C	1	C/T	PASS	3.268887692472733e-26	254.856		122	C=64,T=58	C=0.5246,T=0.4754	47.54	52.46	heterozygous	7	0.017	1.0		FAH	NM_000137.4	FAH:exonic:NM_000137.4	synonymous	ATT	14	p.Ile403=	c.1209C>T				T	GMAF=2.0E-4:AMAF=0.0:EMAF=2.0E-4	0.02		Benign	2011629	rs111345782		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-0.69															F
chrX:30309250	SNV	G	1	G/A	PASS	3.118889584093935e-36	355.06		153	G=76,A=77	G=0.4967,A=0.5033	50.33	49.67	heterozygous	7	0.096	1.0		NR0B1	NM_000475.5	NR0B1:exonic:NM_000475.5	synonymous	TGT	1	p.Cys38=	c.114C>T				A	GMAF=0.1425:AMAF=0.0409:EMAF=0.2001	0.42		Benign	6350501	rs6150		(dui:D004700;dis:Endocrine System Diseases;g:NR0B1)(dui:D006058;dis:Gonadal Disorders;g:NR0B1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:NR0B1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:NR0B1)(dui:D052776;dis:Female Urogenital Diseases;g:NR0B1)(dui:D052801;dis:Male Urogenital Diseases;g:NR0B1)(dui:D000013;dis:Congenital Abnormalities;g:NR0B1)(dui:D014564;dis:Urogenital Abnormalities;g:NR0B1)(dui:D012734;dis:Disorders of Sex Development;g:NR0B1)(dui:D006059;dis:Gonadal Dysgenesis;g:NR0B1)(dui:D030342;dis:Genetic Diseases, Inborn;g:NR0B1)(dui:D000307;dis:Adrenal Gland Diseases;g:NR0B1)(dui:D007006;dis:Hypogonadism;g:NR0B1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:NR0B1)(dui:D008659;dis:Metabolic Diseases;g:NR0B1)(dui:D000309;dis:Adrenal Insufficiency;g:NR0B1)(dui:D058490;dis:46, XY Disorders of Sex Development;g:NR0B1)(dui:D008661;dis:Metabolism, Inborn Errors;g:NR0B1)(dui:D040181;dis:Genetic Diseases, X-Linked;g:NR0B1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:NR0B1)(dui:D011629;dis:Puberty, Precocious;g:NR0B1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:NR0B1)(dui:D047808;dis:Adrenogenital Syndrome;g:NR0B1)(dui:D006061;dis:Gonadal Dysgenesis, 46,XY;g:NR0B1)	Dexamethasone:Dexamethasone acetate	GO:0008584:GO:0033144:GO:0016607:GO:0034451:GO:0008104:GO:0060008:GO:0021854:GO:0006367:GO:0005654:GO:0000122:GO:0003723:GO:0045892:GO:0043231:GO:0032448:GO:0035258:GO:0030325:GO:0010894:GO:0019904:GO:0042803:GO:0007283:GO:0043433:GO:0008134:GO:0021983:GO:0042788:GO:0005634:GO:0030238:GO:0005515:GO:0000790:GO:0008406:GO:0005737:GO:0050682:GO:0003714:GO:0016020:GO:0035902:GO:0033327	300473	PF14046:PF00104	0.98															F
chr1:11791178	SNV	C	1	C/T	PASS	1.5156537556969718e-66	658.194		328	C=169,T=159	C=0.5152,T=0.4848	48.48	51.52	heterozygous	7	0.001	1.0		MTHFR	NM_005957.5	MTHFR:intronic:NM_005957.5	unknown			p.?	c.1752+29G>A				T	GMAF=0.0025:AMAF=9.0E-4:EMAF=0.0034					rs45483798		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MTHFR)(dui:NBS2;dis:Core Conditions;g:MTHFR)(dui:NBS11;dis:Amino Acid Disorder;g:MTHFR)(dui:NBS57;dis:Homocystinuria;g:MTHFR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MTHFR)(dui:D002318;dis:Cardiovascular Diseases;g:MTHFR)(dui:D009422;dis:Nervous System Diseases;g:MTHFR)(dui:D014652;dis:Vascular Diseases;g:MTHFR)(dui:D009369;dis:Neoplasms;g:MTHFR)(dui:D000013;dis:Congenital Abnormalities;g:MTHFR)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MTHFR)(dui:D030342;dis:Genetic Diseases, Inborn;g:MTHFR)(dui:D009371;dis:Neoplasms by Site;g:MTHFR)(dui:D002493;dis:Central Nervous System Diseases;g:MTHFR)(dui:D007154;dis:Immune System Diseases;g:MTHFR)(dui:D004066;dis:Digestive System Diseases;g:MTHFR)(dui:D001927;dis:Brain Diseases;g:MTHFR)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MTHFR)(dui:D009370;dis:Neoplasms by Histologic Type;g:MTHFR)(dui:D005767;dis:Gastrointestinal Diseases;g:MTHFR)(dui:D008659;dis:Metabolic Diseases;g:MTHFR)(dui:D006331;dis:Heart Diseases;g:MTHFR)(dui:D004067;dis:Digestive System Neoplasms;g:MTHFR)(dui:D001523;dis:Mental Disorders;g:MTHFR)(dui:D006402;dis:Hematologic Diseases;g:MTHFR)(dui:D009748;dis:Nutrition Disorders;g:MTHFR)(dui:D044342;dis:Malnutrition;g:MTHFR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:MTHFR)(dui:D007160;dis:Immunoproliferative Disorders;g:MTHFR)(dui:D008232;dis:Lymphoproliferative Disorders;g:MTHFR)(dui:D002561;dis:Cerebrovascular Disorders;g:MTHFR)(dui:D008206;dis:Lymphatic Diseases;g:MTHFR)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MTHFR)(dui:D008661;dis:Metabolism, Inborn Errors;g:MTHFR)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MTHFR)(dui:D020138;dis:Hyperhomocysteinemia;g:MTHFR)(dui:D017202;dis:Myocardial Ischemia;g:MTHFR)(dui:D003677;dis:Deficiency Diseases;g:MTHFR)(dui:D001361;dis:Avitaminosis;g:MTHFR)(dui:D014804;dis:Vitamin B Deficiency;g:MTHFR)(dui:D009421;dis:Nervous System Malformations;g:MTHFR)(dui:D009436;dis:Neural Tube Defects;g:MTHFR)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:MTHFR)(dui:D009140;dis:Musculoskeletal Diseases;g:MTHFR)(dui:D016769;dis:Embolism and Thrombosis;g:MTHFR)(dui:D009461;dis:Neurologic Manifestations;g:MTHFR)(dui:D003327;dis:Coronary Disease;g:MTHFR)(dui:D052776;dis:Female Urogenital Diseases;g:MTHFR)(dui:D052801;dis:Male Urogenital Diseases;g:MTHFR)(dui:D008286;dis:Malabsorption Syndromes;g:MTHFR)(dui:D007938;dis:Leukemia;g:MTHFR)(dui:D009057;dis:Stomatognathic Diseases;g:MTHFR)(dui:D007945;dis:Leukemia, Lymphoid;g:MTHFR)(dui:D007410;dis:Intestinal Diseases;g:MTHFR)(dui:D012871;dis:Skin Diseases;g:MTHFR)(dui:D009059;dis:Mouth Diseases;g:MTHFR)(dui:D004700;dis:Endocrine System Diseases;g:MTHFR)(dui:D003108;dis:Colonic Diseases;g:MTHFR)(dui:D007414;dis:Intestinal Neoplasms;g:MTHFR)(dui:D015179;dis:Colorectal Neoplasms;g:MTHFR)(dui:D014565;dis:Urogenital Neoplasms;g:MTHFR)(dui:D018640;dis:Stomatognathic System Abnormalities;g:MTHFR)(dui:D019967;dis:Schizophrenia Spectrum and Other Psychotic Disorders;g:MTHFR)(dui:D003240;dis:Connective Tissue Diseases;g:MTHFR)(dui:D014570;dis:Urologic Diseases;g:MTHFR)(dui:D013927;dis:Thrombosis;g:MTHFR)(dui:D020521;dis:Stroke;g:MTHFR)(dui:D008223;dis:Lymphoma;g:MTHFR)(dui:D005831;dis:Genital Diseases, Female;g:MTHFR)(dui:D008107;dis:Liver Diseases;g:MTHFR)(dui:D009056;dis:Mouth Abnormalities;g:MTHFR)(dui:D025063;dis:Chromosome Disorders;g:MTHFR)(dui:D019954;dis:Neurobehavioral Manifestations;g:MTHFR)(dui:D008607;dis:Intellectual Disability;g:MTHFR)(dui:D000015;dis:Abnormalities, Multiple;g:MTHFR)(dui:D004314;dis:Down Syndrome;g:MTHFR)(dui:D019851;dis:Thrombophilia;g:MTHFR)(dui:D054198;dis:Precursor Cell Lymphoblastic Leukemia-Lymphoma;g:MTHFR)(dui:D007674;dis:Kidney Diseases;g:MTHFR)(dui:D013272;dis:Stomach Diseases;g:MTHFR)(dui:D020246;dis:Venous Thrombosis;g:MTHFR)(dui:D003920;dis:Diabetes Mellitus;g:MTHFR)(dui:D013274;dis:Stomach Neoplasms;g:MTHFR)(dui:D009139;dis:Musculoskeletal Abnormalities;g:MTHFR)(dui:D005832;dis:Genital Diseases, Male;g:MTHFR)(dui:D001327;dis:Autoimmune Diseases;g:MTHFR)(dui:D012559;dis:Schizophrenia;g:MTHFR)(dui:D007246;dis:Infertility;g:MTHFR)(dui:D012140;dis:Respiratory Tract Diseases;g:MTHFR)(dui:D008171;dis:Lung Diseases;g:MTHFR)(dui:D002545;dis:Brain Ischemia;g:MTHFR)(dui:D012002;dis:Rectal Diseases;g:MTHFR)(dui:D007592;dis:Joint Diseases;g:MTHFR)(dui:D001168;dis:Arthritis;g:MTHFR)(dui:D008228;dis:Lymphoma, Non-Hodgkin;g:MTHFR)(dui:D019636;dis:Neurodegenerative Diseases;g:MTHFR)(dui:D012216;dis:Rheumatic Diseases;g:MTHFR)(dui:D001172;dis:Arthritis, Rheumatoid;g:MTHFR)(dui:D005833;dis:Genital Neoplasms, Female;g:MTHFR)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MTHFR)(dui:D009008;dis:Abnormalities, Severe Teratoid;g:MTHFR)(dui:D000757;dis:Anencephaly;g:MTHFR)(dui:D003704;dis:Dementia;g:MTHFR)(dui:D019965;dis:Neurocognitive Disorders;g:MTHFR)(dui:D014591;dis:Uterine Diseases;g:MTHFR)(dui:D014594;dis:Uterine Neoplasms;g:MTHFR)(dui:D024801;dis:Tauopathies;g:MTHFR)(dui:D000544;dis:Alzheimer Disease;g:MTHFR)(dui:D007960;dis:Leukocyte Disorders;g:MTHFR)(dui:D007970;dis:Leukopenia;g:MTHFR)(dui:D013959;dis:Thyroid Diseases;g:MTHFR)(dui:D002277;dis:Carcinoma;g:MTHFR)(dui:D006967;dis:Hypersensitivity;g:MTHFR)(dui:D001157;dis:Arterial Occlusive Diseases;g:MTHFR)(dui:D008047;dis:Lip Diseases;g:MTHFR)(dui:D002971;dis:Cleft Lip;g:MTHFR)(dui:D019465;dis:Craniofacial Abnormalities;g:MTHFR)(dui:D019767;dis:Maxillofacial Abnormalities;g:MTHFR)(dui:D001161;dis:Arteriosclerosis;g:MTHFR)(dui:D018376;dis:Cardiovascular Abnormalities;g:MTHFR)(dui:D006330;dis:Heart Defects, Congenital;g:MTHFR)(dui:D013923;dis:Thromboembolism;g:MTHFR)(dui:D003110;dis:Colonic Neoplasms;g:MTHFR)(dui:D006980;dis:Hyperthyroidism;g:MTHFR)(dui:D048909;dis:Diabetes Complications;g:MTHFR)(dui:D001941;dis:Breast Diseases;g:MTHFR)(dui:D001943;dis:Breast Neoplasms;g:MTHFR)(dui:D001778;dis:Blood Coagulation Disorders;g:MTHFR)(dui:D007248;dis:Infertility, Male;g:MTHFR)(dui:D051437;dis:Renal Insufficiency;g:MTHFR)(dui:D025861;dis:Blood Coagulation Disorders, Inherited;g:MTHFR)(dui:D044882;dis:Glucose Metabolism Disorders;g:MTHFR)(dui:D000740;dis:Anemia;g:MTHFR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:MTHFR)(dui:D005759;dis:Gastroenteritis;g:MTHFR)(dui:D012678;dis:Sensation Disorders;g:MTHFR)(dui:D006086;dis:Graft vs Host Disease;g:MTHFR)(dui:D004427;dis:Ear Diseases;g:MTHFR)(dui:D006311;dis:Hearing Disorders;g:MTHFR)(dui:D034381;dis:Hearing Loss;g:MTHFR)(dui:D011248;dis:Pregnancy Complications;g:MTHFR)(dui:D000068105;dis:Bipolar and Related Disorders;g:MTHFR)(dui:D001714;dis:Bipolar Disorder;g:MTHFR)(dui:D011655;dis:Pulmonary Embolism;g:MTHFR)(dui:D004617;dis:Embolism;g:MTHFR)(dui:D003925;dis:Diabetic Angiopathies;g:MTHFR)(dui:D012142;dis:Respiratory Tract Neoplasms;g:MTHFR)(dui:D002577;dis:Uterine Cervical Diseases;g:MTHFR)(dui:D003639;dis:Hearing Loss, Sudden;g:MTHFR)(dui:D009385;dis:Neoplastic Processes;g:MTHFR)(dui:D002583;dis:Uterine Cervical Neoplasms;g:MTHFR)(dui:D013899;dis:Thoracic Neoplasms;g:MTHFR)(dui:D014571;dis:Urologic Neoplasms;g:MTHFR)(dui:D002278;dis:Carcinoma in Situ;g:MTHFR)(dui:D018290;dis:Cervical Intraepithelial Neoplasia;g:MTHFR)(dui:D005834;dis:Genital Neoplasms, Male;g:MTHFR)(dui:D011469;dis:Prostatic Diseases;g:MTHFR)(dui:D011471;dis:Prostatic Neoplasms;g:MTHFR)(dui:D008175;dis:Lung Neoplasms;g:MTHFR)(dui:D003324;dis:Coronary Artery Disease;g:MTHFR)(dui:D015448;dis:Leukemia, B-Cell;g:MTHFR)(dui:D015451;dis:Leukemia, Lymphocytic, Chronic, B-Cell;g:MTHFR)(dui:D001791;dis:Blood Platelet Disorders;g:MTHFR)(dui:D065886;dis:Neurodevelopmental Disorders;g:MTHFR)(dui:D001745;dis:Urinary Bladder Diseases;g:MTHFR)(dui:D001749;dis:Urinary Bladder Neoplasms;g:MTHFR)(dui:D056486;dis:Drug-Induced Liver Injury;g:MTHFR)(dui:D013921;dis:Thrombocytopenia;g:MTHFR)(dui:D002659;dis:Child Development Disorders, Pervasive;g:MTHFR)(dui:D002542;dis:Intracranial Embolism and Thrombosis;g:MTHFR)(dui:D020767;dis:Intracranial Thrombosis;g:MTHFR)(dui:D001321;dis:Autistic Disorder;g:MTHFR)(dui:D019964;dis:Mood Disorders;g:MTHFR)(dui:D003866;dis:Depressive Disorder;g:MTHFR)(dui:D000380;dis:Agranulocytosis;g:MTHFR)(dui:D009503;dis:Neutropenia;g:MTHFR)(dui:D023921;dis:Coronary Stenosis;g:MTHFR)(dui:D007247;dis:Infertility, Female;g:MTHFR)(dui:D012851;dis:Sinus Thrombosis, Intracranial;g:MTHFR)(dui:D001928;dis:Brain Diseases, Metabolic;g:MTHFR)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MTHFR)(dui:D018204;dis:Neoplasms, Connective and Soft Tissue;g:MTHFR)(dui:D008591;dis:Meningomyelocele;g:MTHFR)(dui:D008224;dis:Lymphoma, Follicular;g:MTHFR)(dui:D009372;dis:Neoplasms, Connective Tissue;g:MTHFR)(dui:D020258;dis:Neurotoxicity Syndromes;g:MTHFR)(dui:D052016;dis:Mucositis;g:MTHFR)(dui:D023903;dis:Coronary Restenosis;g:MTHFR)(dui:D009362;dis:Neoplasm Metastasis;g:MTHFR)(dui:D020879;dis:Neuromuscular Manifestations;g:MTHFR)(dui:D056784;dis:Leukoencephalopathies;g:MTHFR)(dui:D011618;dis:Psychotic Disorders;g:MTHFR)(dui:D009468;dis:Neuromuscular Diseases;g:MTHFR)(dui:D009135;dis:Muscular Diseases;g:MTHFR)(dui:D010523;dis:Peripheral Nervous System Diseases;g:MTHFR)(dui:D005530;dis:Foot Deformities;g:MTHFR)(dui:D005532;dis:Foot Deformities, Congenital;g:MTHFR)(dui:D006712;dis:Homocystinuria;g:MTHFR)(dui:D009128;dis:Muscle Spasticity;g:MTHFR)(dui:D017880;dis:Limb Deformities, Congenital;g:MTHFR)(dui:D000787;dis:Angina Pectoris;g:MTHFR)(dui:D003025;dis:Clubfoot;g:MTHFR)(dui:D009122;dis:Muscle Hypertonia;g:MTHFR)(dui:D038061;dis:Lower Extremity Deformities, Congenital;g:MTHFR)(dui:D017566;dis:Microvascular Angina;g:MTHFR)(dui:D001145;dis:Arrhythmias, Cardiac;g:MTHFR)(dui:D020260;dis:Heavy Metal Poisoning, Nervous System;g:MTHFR)(dui:D001281;dis:Atrial Fibrillation;g:MTHFR)(dui:D020261;dis:Arsenic Poisoning;g:MTHFR)(dui:D016889;dis:Endometrial Neoplasms;g:MTHFR)(dui:D013118;dis:Spinal Cord Diseases;g:MTHFR)(dui:D004342;dis:Drug Hypersensitivity;g:MTHFR)(dui:D007571;dis:Jaw Diseases;g:MTHFR)(dui:D007569;dis:Jaw Abnormalities;g:MTHFR)(dui:D002972;dis:Cleft Palate;g:MTHFR)(dui:D013971;dis:Thyrotoxicosis;g:MTHFR)(dui:D003872;dis:Dermatitis;g:MTHFR)(dui:D003875;dis:Drug Eruptions;g:MTHFR)(dui:D006201;dis:Hair Diseases;g:MTHFR)(dui:D007039;dis:Hypotrichosis;g:MTHFR)(dui:D046152;dis:Gastrointestinal Stromal Tumors;g:MTHFR)(dui:D000505;dis:Alopecia;g:MTHFR)(dui:D058186;dis:Acute Kidney Injury;g:MTHFR)(dui:D006973;dis:Hypertension;g:MTHFR)(dui:D008113;dis:Liver Neoplasms;g:MTHFR)	Tetrahydrofolic acid:Menadione:Methionine:Riboflavin:Benazepril:Methotrexate:Cyanocobalamin:Folic acid:Fluorouracil	GO:0031060:GO:0070829:GO:0043200:GO:0046655:GO:0045202:GO:0004489:GO:0044877:GO:0072341:GO:0001666:GO:0001843:GO:0005829:GO:0035999:GO:0009086:GO:0071949:GO:0033274:GO:0046500:GO:0006730:GO:0006555:GO:0050661:GO:0050660:GO:0042493:GO:0051593:GO:0070555:GO:0055114:GO:0050667	607093		-0.33															M
chr2:1433638	SNV	C	1	T/T	PASS	0.0	3965.16		400	C=1,T=399	C=0.0025,T=0.9975	99.75	0.25	homozygous	26	0.437	1.0		TPO	NM_000547.5	TPO:intronic:NM_000547.5	unknown			p.?	c.349+31C>T				T	GMAF=0.4955:AMAF=0.2935:EMAF=0.4009					rs4927578		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:TPO)(dui:NBS2;dis:Core Conditions;g:TPO)(dui:NBS12;dis:Endocrine Disorder;g:TPO)(dui:NBS61;dis:Primary Congenital Hypothyroidism;g:TPO)(dui:D004700;dis:Endocrine System Diseases;g:TPO)(dui:D013959;dis:Thyroid Diseases;g:TPO)(dui:D007037;dis:Hypothyroidism;g:TPO)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:TPO)(dui:D030342;dis:Genetic Diseases, Inborn;g:TPO)(dui:D009140;dis:Musculoskeletal Diseases;g:TPO)(dui:D001847;dis:Bone Diseases;g:TPO)(dui:D001848;dis:Bone Diseases, Developmental;g:TPO)(dui:D001849;dis:Bone Diseases, Endocrine;g:TPO)(dui:D004392;dis:Dwarfism;g:TPO)(dui:D003409;dis:Congenital Hypothyroidism;g:TPO)(dui:D006042;dis:Goiter;g:TPO)(dui:D009422;dis:Nervous System Diseases;g:TPO)(dui:D009468;dis:Neuromuscular Diseases;g:TPO)(dui:D010523;dis:Peripheral Nervous System Diseases;g:TPO)	Methimazole:Carbimazole:Propylthiouracil:2-mercaptobenzothiazole:Triclosan:Dextrothyroxine:Iodine:Resorcinol	GO:0035162:GO:0006590:GO:0005886:GO:0042446:GO:0009986:GO:0020037:GO:0042744:GO:0004447:GO:0004601:GO:0005887:GO:0006979:GO:0005615:GO:0005509:GO:0098869:GO:0055114	606765:600044	PF03098:PF00084:PF07645	-0.12															M
chr6:32039109	SNV	G	1	A/A	PASS	3.1117163371059817e-168	1675.07		212	G=18,A=194	G=0.0849,A=0.9151	91.51	8.489999999999995	homozygous	24	0.215	2.0		CYP21A2	NM_000500.9	CYP21A2:exonic:NM_000500.9	missense	AAG	3	p.Arg103Lys	c.308G>A	0.48	0.0	26.0	A	GMAF=0.2315:AMAF=0.0693:EMAF=0.3145	0		Benign	1319109	rs6474		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-0.6															M
chr6:39909177	INDEL	A	1	A/AC	PASS	0.016654055207776	17.7848		5	A=2,AC=3	A=0.4,AC=0.6	60.0	40.0	heterozygous	7		0.0		MOCS1	NM_001358530.2	MOCS1:intronic:NM_001358530.2	unknown			p.?	c.1103-76_1103-75insG				AC						rs1582803997		(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MOCS1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MOCS1)(dui:D008659;dis:Metabolic Diseases;g:MOCS1)(dui:D030342;dis:Genetic Diseases, Inborn;g:MOCS1)(dui:D008661;dis:Metabolism, Inborn Errors;g:MOCS1)(dui:D008664;dis:Metal Metabolism, Inborn Errors;g:MOCS1)			603707	PF01967:PF04055:PF06463:PF13353	-0.62															M
chr6:49440256	SNV	T	1	T/C	PASS	6.283476569844692e-100	992.018		400	T=191,C=209	T=0.4775,C=0.5225	52.25	47.75	heterozygous	7	0.0	1.0		MMUT	NM_000255.4	MMUT:exonic:NM_000255.4	missense	GCA	11	p.Thr636Ala	c.1906A>G	0.0	0.887	58.0	C						rs569669261		.		GO:0019626:GO:0042802:GO:0042803:GO:0009791:GO:0004494:GO:0009235:GO:0043547:GO:0072341:GO:0005515:GO:0005737:GO:0005759:GO:0046872:GO:0003924:GO:0031419:GO:0005739:GO:0050667	609058	PF02310:PF01642	7.67															M
chr6:49457733	SNV	T	1	T/C	PASS	1.9493956831325725e-86	857.101		400	T=205,C=195	T=0.5125,C=0.4875	48.75	51.25	heterozygous	7	0.011	1.0		MMUT	NM_000255.4	MMUT:exonic:NM_000255.4	synonymous	CCG	3	p.Pro237=	c.711A>G				C	GMAF=0.0106:AMAF=0.0052:EMAF=0.0134			Benign		rs138085432		.		GO:0019626:GO:0042802:GO:0042803:GO:0009791:GO:0004494:GO:0009235:GO:0043547:GO:0072341:GO:0005515:GO:0005737:GO:0005759:GO:0046872:GO:0003924:GO:0031419:GO:0005739:GO:0050667	609058	PF02310:PF01642	0.87															M
chr6:80107031	SNV	T	1	C/C	PASS	0.0	3996.93		400	T=0,C=400	T=0.0,C=1.0	100.0	0.0	homozygous	43	0.388	1.0		BCKDHB	NM_000056.4	BCKDHB:intronic:NM_000056.4	unknown			p.?	c.196+142T>C				C						rs35447745		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHB)(dui:NBS2;dis:Core Conditions;g:BCKDHB)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHB)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHB)(dui:D008659;dis:Metabolic Diseases;g:BCKDHB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHB)(dui:D009422;dis:Nervous System Diseases;g:BCKDHB)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHB)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHB)(dui:D001927;dis:Brain Diseases;g:BCKDHB)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHB)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHB)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHB)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHB)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0005739:GO:0003826:GO:0007584:GO:0055114:GO:0005730	248611	PF02779:PF02780	-1.0															M
chr6:80127522	SNV	A	1	G/G	PASS	0.0	3647.02		400	A=12,G=388	A=0.03,G=0.97	97.0	3.0	homozygous	43	0.388	3.0		BCKDHB	NM_000056.4	BCKDHB:intronic:NM_000056.4	unknown			p.?	c.197-25A>G				G	GMAF=0.323:AMAF=0.1148:EMAF=0.4297			Benign		rs9448893		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHB)(dui:NBS2;dis:Core Conditions;g:BCKDHB)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHB)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHB)(dui:D008659;dis:Metabolic Diseases;g:BCKDHB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHB)(dui:D009422;dis:Nervous System Diseases;g:BCKDHB)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHB)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHB)(dui:D001927;dis:Brain Diseases;g:BCKDHB)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHB)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHB)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHB)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHB)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0005739:GO:0003826:GO:0007584:GO:0055114:GO:0005730	248611	PF02779:PF02780	0.45															M
chr6:80272984	SNV	G	1	A/A	PASS	0.0	4003.2		400	G=0,A=400	G=0.0,A=1.0	100.0	0.0	homozygous	43	0.403	1.0		BCKDHB	NM_000056.4	BCKDHB:intronic:NM_000056.4	unknown			p.?	c.952-151G>A				A						rs9341811		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHB)(dui:NBS2;dis:Core Conditions;g:BCKDHB)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHB)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHB)(dui:D008659;dis:Metabolic Diseases;g:BCKDHB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHB)(dui:D009422;dis:Nervous System Diseases;g:BCKDHB)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHB)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHB)(dui:D001927;dis:Brain Diseases;g:BCKDHB)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHB)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHB)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHB)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHB)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0005739:GO:0003826:GO:0007584:GO:0055114:GO:0005730	248611	PF02779:PF02780	-0.85															M
chr7:117531068	SNV	T	1	T/C	PASS	4.602565735813676e-108	1073.37		400	T=183,C=217	T=0.4575,C=0.5425	54.25	45.75	heterozygous	7	0.001	2.0		CFTR	NM_000492.4	CFTR:exonic:NM_000492.4	missense	ACT	4	p.Ile148Thr	c.443T>C	0.0	0.29	89.0	C	GMAF=5.0E-4:AMAF=0.0:EMAF=8.0E-4		I148T	Conflicting interpretations of pathogenicity		rs35516286		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		7.61															M
chr7:117548607	INDEL	TG	1	TG/T	PASS	9.473271845042453e-19	180.235		209	TG=142,T=67	TG=0.6794,T=0.3206	32.06	67.94	heterozygous	7	0.017	1.0		CFTR|CFTR-AS1	NM_000492.4|NR_149084.1	CFTR:intronic:NM_000492.4|CFTR-AS1:intronic_nc:NR_149084.1	unknown|	|	|	p.?|	c.1210-33delG|	|	|	|	T|						rs1584793309:rs3832534		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		0.07,0.07															M
chr7:117548625	INDEL	TG	1	TG/T	PASS	1.9310788175580915e-46	457.142		290	TG=140,T=150	TG=0.4828,T=0.5172	51.72	48.28	heterozygous	7		1.0		CFTR|CFTR-AS1	NM_000492.4|NR_149084.1	CFTR:intronic:NM_000492.4|CFTR-AS1:intronic_nc:NR_149084.1	unknown|	|	|	p.?|	c.1210-15delG|	|	|	|	T|				Likely benign		rs1230197379:rs947648829:rs775751830:rs371831442:rs1584793324:rs1584793326:rs765376630:rs1399483116		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CFTR)(dui:NBS2;dis:Core Conditions;g:CFTR)(dui:NBS14;dis:Other Disorder;g:CFTR)(dui:D004066;dis:Digestive System Diseases;g:CFTR)(dui:NBS72;dis:Cystic fibrosis;g:CFTR)(dui:D010182;dis:Pancreatic Diseases;g:CFTR)(dui:D012140;dis:Respiratory Tract Diseases;g:CFTR)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CFTR)(dui:D030342;dis:Genetic Diseases, Inborn;g:CFTR)(dui:D008171;dis:Lung Diseases;g:CFTR)(dui:D007232;dis:Infant, Newborn, Diseases;g:CFTR)(dui:D003550;dis:Cystic Fibrosis;g:CFTR)(dui:D052801;dis:Male Urogenital Diseases;g:CFTR)(dui:D010195;dis:Pancreatitis;g:CFTR)(dui:D005832;dis:Genital Diseases, Male;g:CFTR)(dui:D007246;dis:Infertility;g:CFTR)(dui:D007248;dis:Infertility, Male;g:CFTR)(dui:D010038;dis:Otorhinolaryngologic Diseases;g:CFTR)(dui:D009668;dis:Nose Diseases;g:CFTR)(dui:D012141;dis:Respiratory Tract Infections;g:CFTR)(dui:D050500;dis:Pancreatitis, Chronic;g:CFTR)(dui:D005767;dis:Gastrointestinal Diseases;g:CFTR)(dui:D007410;dis:Intestinal Diseases;g:CFTR)(dui:D001982;dis:Bronchial Diseases;g:CFTR)(dui:D053713;dis:Azoospermia;g:CFTR)(dui:D001987;dis:Bronchiectasis;g:CFTR)(dui:D010254;dis:Paranasal Sinus Diseases;g:CFTR)(dui:D009369;dis:Neoplasms;g:CFTR)(dui:D012852;dis:Sinusitis;g:CFTR)(dui:D012220;dis:Rhinitis;g:CFTR)(dui:D009371;dis:Neoplasms by Site;g:CFTR)(dui:D004067;dis:Digestive System Neoplasms;g:CFTR)(dui:D001523;dis:Mental Disorders;g:CFTR)(dui:D019966;dis:Substance-Related Disorders;g:CFTR)(dui:D003108;dis:Colonic Diseases;g:CFTR)(dui:D005770;dis:Gastrointestinal Neoplasms;g:CFTR)(dui:D007414;dis:Intestinal Neoplasms;g:CFTR)(dui:D012002;dis:Rectal Diseases;g:CFTR)(dui:D015179;dis:Colorectal Neoplasms;g:CFTR)	Ivacaftor:Colforsin:Crofelemer:Elexacaftor:Dexibuprofen:Lumacaftor:Glyburide:Ibuprofen:Lonidamine:Phosphoaminophosphonic Acid-Adenylate Ester:Bumetanide:Tezacaftor:ATP:Dexfosfoserine	GO:0016887:GO:1902476:GO:0045921:GO:0005789:GO:0034707:GO:0048240:GO:0051087:GO:0030660:GO:0005829:GO:0106138:GO:0015108:GO:0030301:GO:0015701:GO:0015106:GO:0016853:GO:0030665:GO:0019869:GO:0042626:GO:1902161:GO:0006695:GO:0005765:GO:0005886:GO:0031901:GO:0005634:GO:0005515:GO:0051454:GO:0071320:GO:0060081:GO:0032991:GO:0016324:GO:0034976:GO:0005254:GO:0005524:GO:0005887:GO:0017081:GO:0005769:GO:0050891:GO:0030165:GO:0035774:GO:0016579:GO:0061024:GO:0035377:GO:0055085:GO:0005260:GO:1904322:GO:1902943:GO:0009986:GO:0005737:GO:0006904:GO:0016020:GO:0016021:GO:0010008:GO:0055037:GO:0055038:GO:0019899	602421		-0.38,-1.27															M
chr10:102831079	INDEL	AGGGAACCCTGATCTGAGGATGTAGCCTTATTATGG	35	AGGGAACCCTGATCTGAGGATGTAGCCTTATTATGG/A	PASS	1e-05	50.0		693	AGGGAACCCTGATCTGAGGATGTAGCCTTATTATGG=364,A=329	AGGGAACCCTGATCTGAGGATGTAGCCTTATTATGG=0.5253,A=0.4747	47.47	52.53	heterozygous	7	0.0:0.004:0.169			CYP17A1	NM_000102.4	CYP17A1:intronic:NM_000102.4	unknown			p.?	c.1244-129_1244-95delCCATAATAAGGCTACATCCTCAGATCAGGGTTCCC				A						rs869228446:rs1406908533:rs562963192:rs1276663458:rs915546176:rs908055791:rs1284547910:rs139275291:rs1590202473:rs1279313673:rs561699026:rs1399856034:rs1590202460		(dui:D004700;dis:Endocrine System Diseases;g:CYP17A1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP17A1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP17A1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP17A1)(dui:D006058;dis:Gonadal Disorders;g:CYP17A1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP17A1)(dui:D008659;dis:Metabolic Diseases;g:CYP17A1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP17A1)(dui:D000013;dis:Congenital Abnormalities;g:CYP17A1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP17A1)(dui:D012734;dis:Disorders of Sex Development;g:CYP17A1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP17A1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP17A1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP17A1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP17A1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP17A1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP17A1)(dui:D009369;dis:Neoplasms;g:CYP17A1)(dui:D009371;dis:Neoplasms by Site;g:CYP17A1)(dui:D004066;dis:Digestive System Diseases;g:CYP17A1)(dui:D008107;dis:Liver Diseases;g:CYP17A1)(dui:D009422;dis:Nervous System Diseases;g:CYP17A1)(dui:D005831;dis:Genital Diseases, Female;g:CYP17A1)(dui:D005832;dis:Genital Diseases, Male;g:CYP17A1)(dui:D002493;dis:Central Nervous System Diseases;g:CYP17A1)(dui:D001927;dis:Brain Diseases;g:CYP17A1)(dui:D007246;dis:Infertility;g:CYP17A1)(dui:D014565;dis:Urogenital Neoplasms;g:CYP17A1)(dui:D010049;dis:Ovarian Diseases;g:CYP17A1)(dui:D000291;dis:Adnexal Diseases;g:CYP17A1)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CYP17A1)(dui:D011469;dis:Prostatic Diseases;g:CYP17A1)(dui:D012871;dis:Skin Diseases;g:CYP17A1)(dui:D001941;dis:Breast Diseases;g:CYP17A1)(dui:D003560;dis:Cysts;g:CYP17A1)(dui:D010048;dis:Ovarian Cysts;g:CYP17A1)(dui:D001943;dis:Breast Neoplasms;g:CYP17A1)(dui:D005834;dis:Genital Neoplasms, Male;g:CYP17A1)(dui:D009370;dis:Neoplasms by Histologic Type;g:CYP17A1)(dui:D011471;dis:Prostatic Neoplasms;g:CYP17A1)(dui:D002318;dis:Cardiovascular Diseases;g:CYP17A1)(dui:D004067;dis:Digestive System Neoplasms;g:CYP17A1)(dui:D014652;dis:Vascular Diseases;g:CYP17A1)(dui:D019636;dis:Neurodegenerative Diseases;g:CYP17A1)(dui:D006973;dis:Hypertension;g:CYP17A1)(dui:D009069;dis:Movement Disorders;g:CYP17A1)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:CYP17A1)(dui:D001523;dis:Mental Disorders;g:CYP17A1)(dui:D002277;dis:Carcinoma;g:CYP17A1)(dui:D010300;dis:Parkinson Disease;g:CYP17A1)(dui:D001480;dis:Basal Ganglia Diseases;g:CYP17A1)(dui:D020734;dis:Parkinsonian Disorders;g:CYP17A1)(dui:D000230;dis:Adenocarcinoma;g:CYP17A1)(dui:D008113;dis:Liver Neoplasms;g:CYP17A1)(dui:D007247;dis:Infertility, Female;g:CYP17A1)(dui:D020018;dis:Sexual Dysfunctions, Psychological;g:CYP17A1)(dui:D006528;dis:Carcinoma, Hepatocellular;g:CYP17A1)(dui:D007006;dis:Hypogonadism;g:CYP17A1)(dui:D007248;dis:Infertility, Male;g:CYP17A1)(dui:D010900;dis:Pituitary Diseases;g:CYP17A1)(dui:D005234;dis:Fatty Liver;g:CYP17A1)(dui:D007018;dis:Hypopituitarism;g:CYP17A1)(dui:D008103;dis:Liver Cirrhosis;g:CYP17A1)(dui:D014883;dis:Water-Electrolyte Imbalance;g:CYP17A1)(dui:D006947;dis:Hyperkalemia;g:CYP17A1)(dui:D006974;dis:Hypertension, Malignant;g:CYP17A1)(dui:D007027;dis:Hypothalamic Diseases;g:CYP17A1)(dui:D008106;dis:Liver Cirrhosis, Experimental;g:CYP17A1)(dui:D065626;dis:Non-alcoholic Fatty Liver Disease;g:CYP17A1)	Stanolone:Dexamethasone:Ketoconazole:Nabiximols:Abiraterone:Medical Cannabis:Cannabidiol:Clomifene:Aldosterone:NADH:Spironolactone:Aminophenazone:Dexamethasone acetate:Progesterone:Prasterone	GO:0019825:GO:0042448:GO:0008202:GO:0005783:GO:0006694:GO:0043025:GO:0042446:GO:0020037:GO:0005789:GO:0006704:GO:0007548:GO:0006702:GO:0005506:GO:0004508:GO:0047442:GO:0055114:GO:0030424	609300	PF00067	-2.03,-0.36,0.4,0.19,-0.39,-0.53,-0.41,1.02,1.7,-0.55,-3.0,-0.28,-1.25,-0.01,0.01,-0.04,-1.26,-0.03,-0.55,0.06,-0.54,-0.01,-0.19,0.08,0.12,0.93,-0.69,0.6,-0.73,-0.35,-0.94,-0.21,-0.35,0.53,0.81,0.02															M
chr10:102831395	SNV	T	1	T/A	PASS	2.9040226544645045e-113	1125.37		400	T=178,A=222	T=0.445,A=0.555	55.5	44.5	heterozygous	7	0.187	2.0		CYP17A1	NM_000102.4	CYP17A1:intronic:NM_000102.4	unknown			p.?	c.1243+113A>T				A						rs10883783		(dui:D004700;dis:Endocrine System Diseases;g:CYP17A1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP17A1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP17A1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP17A1)(dui:D006058;dis:Gonadal Disorders;g:CYP17A1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP17A1)(dui:D008659;dis:Metabolic Diseases;g:CYP17A1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP17A1)(dui:D000013;dis:Congenital Abnormalities;g:CYP17A1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP17A1)(dui:D012734;dis:Disorders of Sex Development;g:CYP17A1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP17A1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP17A1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP17A1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP17A1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP17A1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP17A1)(dui:D009369;dis:Neoplasms;g:CYP17A1)(dui:D009371;dis:Neoplasms by Site;g:CYP17A1)(dui:D004066;dis:Digestive System Diseases;g:CYP17A1)(dui:D008107;dis:Liver Diseases;g:CYP17A1)(dui:D009422;dis:Nervous System Diseases;g:CYP17A1)(dui:D005831;dis:Genital Diseases, Female;g:CYP17A1)(dui:D005832;dis:Genital Diseases, Male;g:CYP17A1)(dui:D002493;dis:Central Nervous System Diseases;g:CYP17A1)(dui:D001927;dis:Brain Diseases;g:CYP17A1)(dui:D007246;dis:Infertility;g:CYP17A1)(dui:D014565;dis:Urogenital Neoplasms;g:CYP17A1)(dui:D010049;dis:Ovarian Diseases;g:CYP17A1)(dui:D000291;dis:Adnexal Diseases;g:CYP17A1)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CYP17A1)(dui:D011469;dis:Prostatic Diseases;g:CYP17A1)(dui:D012871;dis:Skin Diseases;g:CYP17A1)(dui:D001941;dis:Breast Diseases;g:CYP17A1)(dui:D003560;dis:Cysts;g:CYP17A1)(dui:D010048;dis:Ovarian Cysts;g:CYP17A1)(dui:D001943;dis:Breast Neoplasms;g:CYP17A1)(dui:D005834;dis:Genital Neoplasms, Male;g:CYP17A1)(dui:D009370;dis:Neoplasms by Histologic Type;g:CYP17A1)(dui:D011471;dis:Prostatic Neoplasms;g:CYP17A1)(dui:D002318;dis:Cardiovascular Diseases;g:CYP17A1)(dui:D004067;dis:Digestive System Neoplasms;g:CYP17A1)(dui:D014652;dis:Vascular Diseases;g:CYP17A1)(dui:D019636;dis:Neurodegenerative Diseases;g:CYP17A1)(dui:D006973;dis:Hypertension;g:CYP17A1)(dui:D009069;dis:Movement Disorders;g:CYP17A1)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:CYP17A1)(dui:D001523;dis:Mental Disorders;g:CYP17A1)(dui:D002277;dis:Carcinoma;g:CYP17A1)(dui:D010300;dis:Parkinson Disease;g:CYP17A1)(dui:D001480;dis:Basal Ganglia Diseases;g:CYP17A1)(dui:D020734;dis:Parkinsonian Disorders;g:CYP17A1)(dui:D000230;dis:Adenocarcinoma;g:CYP17A1)(dui:D008113;dis:Liver Neoplasms;g:CYP17A1)(dui:D007247;dis:Infertility, Female;g:CYP17A1)(dui:D020018;dis:Sexual Dysfunctions, Psychological;g:CYP17A1)(dui:D006528;dis:Carcinoma, Hepatocellular;g:CYP17A1)(dui:D007006;dis:Hypogonadism;g:CYP17A1)(dui:D007248;dis:Infertility, Male;g:CYP17A1)(dui:D010900;dis:Pituitary Diseases;g:CYP17A1)(dui:D005234;dis:Fatty Liver;g:CYP17A1)(dui:D007018;dis:Hypopituitarism;g:CYP17A1)(dui:D008103;dis:Liver Cirrhosis;g:CYP17A1)(dui:D014883;dis:Water-Electrolyte Imbalance;g:CYP17A1)(dui:D006947;dis:Hyperkalemia;g:CYP17A1)(dui:D006974;dis:Hypertension, Malignant;g:CYP17A1)(dui:D007027;dis:Hypothalamic Diseases;g:CYP17A1)(dui:D008106;dis:Liver Cirrhosis, Experimental;g:CYP17A1)(dui:D065626;dis:Non-alcoholic Fatty Liver Disease;g:CYP17A1)	Stanolone:Dexamethasone:Ketoconazole:Nabiximols:Abiraterone:Medical Cannabis:Cannabidiol:Clomifene:Aldosterone:NADH:Spironolactone:Aminophenazone:Dexamethasone acetate:Progesterone:Prasterone	GO:0019825:GO:0042448:GO:0008202:GO:0005783:GO:0006694:GO:0043025:GO:0042446:GO:0020037:GO:0005789:GO:0006704:GO:0007548:GO:0006702:GO:0005506:GO:0004508:GO:0047442:GO:0055114:GO:0030424	609300	PF00067	0.44															M
chr10:102832492	SNV	A	1	A/C	PASS	8.36565595755809e-99	980.775		400	A=192,C=208	A=0.48,C=0.52	52.0	48.0	heterozygous	7	0.139	1.0		CYP17A1	NM_000102.4	CYP17A1:intronic:NM_000102.4	unknown			p.?	c.1139+19T>G				C	GMAF=0.2204:AMAF=0.0744:EMAF=0.2952			Benign		rs4919686		(dui:D004700;dis:Endocrine System Diseases;g:CYP17A1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP17A1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP17A1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP17A1)(dui:D006058;dis:Gonadal Disorders;g:CYP17A1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP17A1)(dui:D008659;dis:Metabolic Diseases;g:CYP17A1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP17A1)(dui:D000013;dis:Congenital Abnormalities;g:CYP17A1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP17A1)(dui:D012734;dis:Disorders of Sex Development;g:CYP17A1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP17A1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP17A1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP17A1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP17A1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP17A1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP17A1)(dui:D009369;dis:Neoplasms;g:CYP17A1)(dui:D009371;dis:Neoplasms by Site;g:CYP17A1)(dui:D004066;dis:Digestive System Diseases;g:CYP17A1)(dui:D008107;dis:Liver Diseases;g:CYP17A1)(dui:D009422;dis:Nervous System Diseases;g:CYP17A1)(dui:D005831;dis:Genital Diseases, Female;g:CYP17A1)(dui:D005832;dis:Genital Diseases, Male;g:CYP17A1)(dui:D002493;dis:Central Nervous System Diseases;g:CYP17A1)(dui:D001927;dis:Brain Diseases;g:CYP17A1)(dui:D007246;dis:Infertility;g:CYP17A1)(dui:D014565;dis:Urogenital Neoplasms;g:CYP17A1)(dui:D010049;dis:Ovarian Diseases;g:CYP17A1)(dui:D000291;dis:Adnexal Diseases;g:CYP17A1)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CYP17A1)(dui:D011469;dis:Prostatic Diseases;g:CYP17A1)(dui:D012871;dis:Skin Diseases;g:CYP17A1)(dui:D001941;dis:Breast Diseases;g:CYP17A1)(dui:D003560;dis:Cysts;g:CYP17A1)(dui:D010048;dis:Ovarian Cysts;g:CYP17A1)(dui:D001943;dis:Breast Neoplasms;g:CYP17A1)(dui:D005834;dis:Genital Neoplasms, Male;g:CYP17A1)(dui:D009370;dis:Neoplasms by Histologic Type;g:CYP17A1)(dui:D011471;dis:Prostatic Neoplasms;g:CYP17A1)(dui:D002318;dis:Cardiovascular Diseases;g:CYP17A1)(dui:D004067;dis:Digestive System Neoplasms;g:CYP17A1)(dui:D014652;dis:Vascular Diseases;g:CYP17A1)(dui:D019636;dis:Neurodegenerative Diseases;g:CYP17A1)(dui:D006973;dis:Hypertension;g:CYP17A1)(dui:D009069;dis:Movement Disorders;g:CYP17A1)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:CYP17A1)(dui:D001523;dis:Mental Disorders;g:CYP17A1)(dui:D002277;dis:Carcinoma;g:CYP17A1)(dui:D010300;dis:Parkinson Disease;g:CYP17A1)(dui:D001480;dis:Basal Ganglia Diseases;g:CYP17A1)(dui:D020734;dis:Parkinsonian Disorders;g:CYP17A1)(dui:D000230;dis:Adenocarcinoma;g:CYP17A1)(dui:D008113;dis:Liver Neoplasms;g:CYP17A1)(dui:D007247;dis:Infertility, Female;g:CYP17A1)(dui:D020018;dis:Sexual Dysfunctions, Psychological;g:CYP17A1)(dui:D006528;dis:Carcinoma, Hepatocellular;g:CYP17A1)(dui:D007006;dis:Hypogonadism;g:CYP17A1)(dui:D007248;dis:Infertility, Male;g:CYP17A1)(dui:D010900;dis:Pituitary Diseases;g:CYP17A1)(dui:D005234;dis:Fatty Liver;g:CYP17A1)(dui:D007018;dis:Hypopituitarism;g:CYP17A1)(dui:D008103;dis:Liver Cirrhosis;g:CYP17A1)(dui:D014883;dis:Water-Electrolyte Imbalance;g:CYP17A1)(dui:D006947;dis:Hyperkalemia;g:CYP17A1)(dui:D006974;dis:Hypertension, Malignant;g:CYP17A1)(dui:D007027;dis:Hypothalamic Diseases;g:CYP17A1)(dui:D008106;dis:Liver Cirrhosis, Experimental;g:CYP17A1)(dui:D065626;dis:Non-alcoholic Fatty Liver Disease;g:CYP17A1)	Stanolone:Dexamethasone:Ketoconazole:Nabiximols:Abiraterone:Medical Cannabis:Cannabidiol:Clomifene:Aldosterone:NADH:Spironolactone:Aminophenazone:Dexamethasone acetate:Progesterone:Prasterone	GO:0019825:GO:0042448:GO:0008202:GO:0005783:GO:0006694:GO:0043025:GO:0042446:GO:0020037:GO:0005789:GO:0006704:GO:0007548:GO:0006702:GO:0005506:GO:0004508:GO:0047442:GO:0055114:GO:0030424	609300	PF00067	-1.55															M
chr10:102835491	SNV	G	1	G/A	PASS	7.798301105232513e-103	1021.08		400	G=188,A=212	G=0.47,A=0.53	53.0	47.0	heterozygous	7	0.187	2.0		CYP17A1	NM_000102.4	CYP17A1:intronic:NM_000102.4	unknown			p.?	c.298-99C>T				A						rs4919687		(dui:D004700;dis:Endocrine System Diseases;g:CYP17A1)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP17A1)(dui:D052776;dis:Female Urogenital Diseases;g:CYP17A1)(dui:D052801;dis:Male Urogenital Diseases;g:CYP17A1)(dui:D006058;dis:Gonadal Disorders;g:CYP17A1)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP17A1)(dui:D008659;dis:Metabolic Diseases;g:CYP17A1)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP17A1)(dui:D000013;dis:Congenital Abnormalities;g:CYP17A1)(dui:D014564;dis:Urogenital Abnormalities;g:CYP17A1)(dui:D012734;dis:Disorders of Sex Development;g:CYP17A1)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP17A1)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP17A1)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP17A1)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP17A1)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP17A1)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP17A1)(dui:D009369;dis:Neoplasms;g:CYP17A1)(dui:D009371;dis:Neoplasms by Site;g:CYP17A1)(dui:D004066;dis:Digestive System Diseases;g:CYP17A1)(dui:D008107;dis:Liver Diseases;g:CYP17A1)(dui:D009422;dis:Nervous System Diseases;g:CYP17A1)(dui:D005831;dis:Genital Diseases, Female;g:CYP17A1)(dui:D005832;dis:Genital Diseases, Male;g:CYP17A1)(dui:D002493;dis:Central Nervous System Diseases;g:CYP17A1)(dui:D001927;dis:Brain Diseases;g:CYP17A1)(dui:D007246;dis:Infertility;g:CYP17A1)(dui:D014565;dis:Urogenital Neoplasms;g:CYP17A1)(dui:D010049;dis:Ovarian Diseases;g:CYP17A1)(dui:D000291;dis:Adnexal Diseases;g:CYP17A1)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CYP17A1)(dui:D011469;dis:Prostatic Diseases;g:CYP17A1)(dui:D012871;dis:Skin Diseases;g:CYP17A1)(dui:D001941;dis:Breast Diseases;g:CYP17A1)(dui:D003560;dis:Cysts;g:CYP17A1)(dui:D010048;dis:Ovarian Cysts;g:CYP17A1)(dui:D001943;dis:Breast Neoplasms;g:CYP17A1)(dui:D005834;dis:Genital Neoplasms, Male;g:CYP17A1)(dui:D009370;dis:Neoplasms by Histologic Type;g:CYP17A1)(dui:D011471;dis:Prostatic Neoplasms;g:CYP17A1)(dui:D002318;dis:Cardiovascular Diseases;g:CYP17A1)(dui:D004067;dis:Digestive System Neoplasms;g:CYP17A1)(dui:D014652;dis:Vascular Diseases;g:CYP17A1)(dui:D019636;dis:Neurodegenerative Diseases;g:CYP17A1)(dui:D006973;dis:Hypertension;g:CYP17A1)(dui:D009069;dis:Movement Disorders;g:CYP17A1)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:CYP17A1)(dui:D001523;dis:Mental Disorders;g:CYP17A1)(dui:D002277;dis:Carcinoma;g:CYP17A1)(dui:D010300;dis:Parkinson Disease;g:CYP17A1)(dui:D001480;dis:Basal Ganglia Diseases;g:CYP17A1)(dui:D020734;dis:Parkinsonian Disorders;g:CYP17A1)(dui:D000230;dis:Adenocarcinoma;g:CYP17A1)(dui:D008113;dis:Liver Neoplasms;g:CYP17A1)(dui:D007247;dis:Infertility, Female;g:CYP17A1)(dui:D020018;dis:Sexual Dysfunctions, Psychological;g:CYP17A1)(dui:D006528;dis:Carcinoma, Hepatocellular;g:CYP17A1)(dui:D007006;dis:Hypogonadism;g:CYP17A1)(dui:D007248;dis:Infertility, Male;g:CYP17A1)(dui:D010900;dis:Pituitary Diseases;g:CYP17A1)(dui:D005234;dis:Fatty Liver;g:CYP17A1)(dui:D007018;dis:Hypopituitarism;g:CYP17A1)(dui:D008103;dis:Liver Cirrhosis;g:CYP17A1)(dui:D014883;dis:Water-Electrolyte Imbalance;g:CYP17A1)(dui:D006947;dis:Hyperkalemia;g:CYP17A1)(dui:D006974;dis:Hypertension, Malignant;g:CYP17A1)(dui:D007027;dis:Hypothalamic Diseases;g:CYP17A1)(dui:D008106;dis:Liver Cirrhosis, Experimental;g:CYP17A1)(dui:D065626;dis:Non-alcoholic Fatty Liver Disease;g:CYP17A1)	Stanolone:Dexamethasone:Ketoconazole:Nabiximols:Abiraterone:Medical Cannabis:Cannabidiol:Clomifene:Aldosterone:NADH:Spironolactone:Aminophenazone:Dexamethasone acetate:Progesterone:Prasterone	GO:0019825:GO:0042448:GO:0008202:GO:0005783:GO:0006694:GO:0043025:GO:0042446:GO:0020037:GO:0005789:GO:0006704:GO:0007548:GO:0006702:GO:0005506:GO:0004508:GO:0047442:GO:0055114:GO:0030424	609300	PF00067	0.95															M
chr11:68760132	SNV	G	1	A/A	PASS	3.013006024186017e-308	3075.21		349	G=1,A=348	G=0.0029,A=0.9971	99.71	0.2900000000000062	homozygous	7	0.338	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.2142+93C>T				A						rs3019598		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	-0.34															M
chr11:68793312	SNV	C	1	C/T	PASS	3.6441815078885976e-88	874.384		395	C=200,T=195	C=0.5063,T=0.4937	49.37	50.63	heterozygous	7	0.038	1.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.967+3G>A				T	GMAF=0.0127:AMAF=0.0068:EMAF=0.0157			Benign		rs75677837		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	3.19															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	1.0641920249497412e-09	89.7298		9	AAA=0,GCT=9	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr13:100111823	INDEL	TGT	2	TGT/T	PASS	2.666244668312505e-91	905.741		392	TGT=189,T=203	TGT=0.4821,T=0.5179	51.79	48.21	heterozygous	13		1.0		PCCA	NR_148031.2	PCCA:intronic_nc:NR_148031.2															rs770647056:rs201452244:rs60618091:rs757554291		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PCCA)(dui:NBS2;dis:Core Conditions;g:PCCA)(dui:NBS9;dis:Organic Acid Condition;g:PCCA)(dui:NBS42;dis:Propionic acidemia;g:PCCA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PCCA)(dui:D008659;dis:Metabolic Diseases;g:PCCA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PCCA)(dui:D030342;dis:Genetic Diseases, Inborn;g:PCCA)(dui:D008661;dis:Metabolism, Inborn Errors;g:PCCA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PCCA)(dui:D056693;dis:Propionic Acidemia;g:PCCA)(dui:D005128;dis:Eye Diseases;g:PCCA)(dui:D012030;dis:Refractive Errors;g:PCCA)	Biotin		232000	PF08443:PF07478:PF00364:PF02222:PF02786:PF02785:PF00289	2.51,-0.28,2.55															M
chr13:100111931	INDEL	TATTT	4	TATTT/T	PASS	8.912509381337514e-103	1020.5		390	TATTT=181,T=209	TATTT=0.4641,T=0.5359	53.59	46.41	heterozygous	13	0.077	1.0		PCCA	NR_148031.2	PCCA:intronic_nc:NR_148031.2															rs201261215:rs762246120:rs147037340		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:PCCA)(dui:NBS2;dis:Core Conditions;g:PCCA)(dui:NBS9;dis:Organic Acid Condition;g:PCCA)(dui:NBS42;dis:Propionic acidemia;g:PCCA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:PCCA)(dui:D008659;dis:Metabolic Diseases;g:PCCA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:PCCA)(dui:D030342;dis:Genetic Diseases, Inborn;g:PCCA)(dui:D008661;dis:Metabolism, Inborn Errors;g:PCCA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:PCCA)(dui:D056693;dis:Propionic Acidemia;g:PCCA)(dui:D005128;dis:Eye Diseases;g:PCCA)(dui:D012030;dis:Refractive Errors;g:PCCA)	Biotin		232000	PF08443:PF07478:PF00364:PF02222:PF02786:PF02785:PF00289	-0.12,-0.79,0.07,0.17,1.2															M
chr19:41410927	SNV	C	1	C/T	PASS	2.787404520323769e-83	825.548		400	C=208,T=192	C=0.52,T=0.48	48.0	52.0	heterozygous	7	0.001	2.0		BCKDHA	NM_001164783.2	BCKDHA:exonic:NM_001164783.2	missense	CTG	3	p.Pro98Leu	c.293C>T	0.0	0.835	98.0	T				Uncertain significance		rs532803527		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:BCKDHA)(dui:NBS2;dis:Core Conditions;g:BCKDHA)(dui:NBS11;dis:Amino Acid Disorder;g:BCKDHA)(dui:NBS56;dis:Maple syrup urine disease;g:BCKDHA)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:BCKDHA)(dui:D008659;dis:Metabolic Diseases;g:BCKDHA)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:BCKDHA)(dui:D030342;dis:Genetic Diseases, Inborn;g:BCKDHA)(dui:D009422;dis:Nervous System Diseases;g:BCKDHA)(dui:D002493;dis:Central Nervous System Diseases;g:BCKDHA)(dui:D001927;dis:Brain Diseases;g:BCKDHA)(dui:D001928;dis:Brain Diseases, Metabolic;g:BCKDHA)(dui:D008661;dis:Metabolism, Inborn Errors;g:BCKDHA)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:BCKDHA)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:BCKDHA)(dui:D008375;dis:Maple Syrup Urine Disease;g:BCKDHA)		GO:0003863:GO:0005515:GO:0009083:GO:0005947:GO:0005759:GO:0046872:GO:0003826:GO:0005739:GO:0055114:GO:0016831	608348	PF00676	5.65															M
chr19:45584554	SNV	C	1	C/G	PASS	3.6466996889423397e-81	804.381		399	C=210,G=189	C=0.5263,G=0.4737	47.37	52.63	heterozygous	7	0.023	4.0		OPA3	NM_025136.4	OPA3:intronic:NM_025136.4	unknown			p.?	c.142+69G>C				G						rs62111684		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:OPA3)(dui:NBS3;dis:Secondary Conditions;g:OPA3)(dui:NBS4;dis:Organic Acid Condition;g:OPA3)(dui:NBS19;dis:3-Methylglutaconic aciduria;g:OPA3)(dui:D009422;dis:Nervous System Diseases;g:OPA3)(dui:D005128;dis:Eye Diseases;g:OPA3)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:OPA3)(dui:D030342;dis:Genetic Diseases, Inborn;g:OPA3)(dui:D003389;dis:Cranial Nerve Diseases;g:OPA3)(dui:D009901;dis:Optic Nerve Diseases;g:OPA3)(dui:D019636;dis:Neurodegenerative Diseases;g:OPA3)(dui:D009896;dis:Optic Atrophy;g:OPA3)(dui:D020271;dis:Heredodegenerative Disorders, Nervous System;g:OPA3)(dui:D015785;dis:Eye Diseases, Hereditary;g:OPA3)(dui:D015418;dis:Optic Atrophies, Hereditary;g:OPA3)(dui:D007905;dis:Lens Diseases;g:OPA3)(dui:D002386;dis:Cataract;g:OPA3)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:OPA3)(dui:D008659;dis:Metabolic Diseases;g:OPA3)(dui:D009461;dis:Neurologic Manifestations;g:OPA3)(dui:D000013;dis:Congenital Abnormalities;g:OPA3)(dui:D002493;dis:Central Nervous System Diseases;g:OPA3)(dui:D009421;dis:Nervous System Malformations;g:OPA3)(dui:D009468;dis:Neuromuscular Diseases;g:OPA3)(dui:D008661;dis:Metabolism, Inborn Errors;g:OPA3)(dui:D009069;dis:Movement Disorders;g:OPA3)(dui:D010523;dis:Peripheral Nervous System Diseases;g:OPA3)(dui:D015417;dis:Hereditary Sensory and Motor Neuropathy;g:OPA3)(dui:D020820;dis:Dyskinesias;g:OPA3)(dui:D002819;dis:Chorea;g:OPA3)(dui:D011115;dis:Polyneuropathies;g:OPA3)(dui:D015419;dis:Spastic Paraplegia, Hereditary;g:OPA3)		GO:0070584:GO:0005739:GO:0050905:GO:0045444:GO:0007601:GO:0019216:GO:0040008:GO:0050896:GO:0060348	606580	PF07047	1.45															M
chrX:38367350	SNV	A	1	G/G	PASS	0.0	3700.5		399	A=10,G=389	A=0.0251,G=0.9749	97.49	2.510000000000005	homozygous	7	0.184	6.0		OTC	NM_000531.6	OTC:exonic:NM_000531.6	missense	AGA	2	p.Lys46Arg	c.137A>G	0.13	0.185	26.0	G	GMAF=0.2903:AMAF=0.3765:EMAF=0.2413	0.95:0.94		Benign	3759494:3766934	rs1800321		(dui:ACMG59;dis:ACMG Recommendations...;g:OTC)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:OTC)(dui:D008659;dis:Metabolic Diseases;g:OTC)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:OTC)(dui:D009422;dis:Nervous System Diseases;g:OTC)(dui:D030342;dis:Genetic Diseases, Inborn;g:OTC)(dui:D002493;dis:Central Nervous System Diseases;g:OTC)(dui:D001927;dis:Brain Diseases;g:OTC)(dui:D008661;dis:Metabolism, Inborn Errors;g:OTC)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:OTC)(dui:D001928;dis:Brain Diseases, Metabolic;g:OTC)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:OTC)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:OTC)(dui:D040181;dis:Genetic Diseases, X-Linked;g:OTC)(dui:D020163;dis:Ornithine Carbamoyltransferase Deficiency Disease;g:OTC)(dui:D004066;dis:Digestive System Diseases;g:OTC)(dui:D008107;dis:Liver Diseases;g:OTC)	N-(Phosphonoacetyl)-L-Ornithine:Norvaline:Citrulline:Ornithine	GO:0042802:GO:0010043:GO:0007494:GO:0006593:GO:0005543:GO:0042301:GO:0097272:GO:0004585:GO:0005743:GO:0055081:GO:0032868:GO:0005759:GO:0019240:GO:0000050:GO:0001889:GO:0042493:GO:0043231:GO:0005739:GO:0042450:GO:0070781:GO:0016597	300461	PF02729:PF00185	7.43															M
chrX:38381334	SNV	T	1	A/A	PASS	1.9620045039256622e-53	527.073		64	T=4,A=60	T=0.0625,A=0.9375	93.75	6.25	homozygous	7	0.077	10.0		OTC	NM_000531.6	OTC:intronic:NM_000531.6	unknown			p.?	c.299-8T>A				A	GMAF=0.1565:AMAF=0.035:EMAF=0.2257			Benign		rs73196229:rs374145788		(dui:ACMG59;dis:ACMG Recommendations...;g:OTC)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:OTC)(dui:D008659;dis:Metabolic Diseases;g:OTC)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:OTC)(dui:D009422;dis:Nervous System Diseases;g:OTC)(dui:D030342;dis:Genetic Diseases, Inborn;g:OTC)(dui:D002493;dis:Central Nervous System Diseases;g:OTC)(dui:D001927;dis:Brain Diseases;g:OTC)(dui:D008661;dis:Metabolism, Inborn Errors;g:OTC)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:OTC)(dui:D001928;dis:Brain Diseases, Metabolic;g:OTC)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:OTC)(dui:D056806;dis:Urea Cycle Disorders, Inborn;g:OTC)(dui:D040181;dis:Genetic Diseases, X-Linked;g:OTC)(dui:D020163;dis:Ornithine Carbamoyltransferase Deficiency Disease;g:OTC)(dui:D004066;dis:Digestive System Diseases;g:OTC)(dui:D008107;dis:Liver Diseases;g:OTC)	N-(Phosphonoacetyl)-L-Ornithine:Norvaline:Citrulline:Ornithine	GO:0042802:GO:0010043:GO:0007494:GO:0006593:GO:0005543:GO:0042301:GO:0097272:GO:0004585:GO:0005743:GO:0055081:GO:0032868:GO:0005759:GO:0019240:GO:0000050:GO:0001889:GO:0042493:GO:0043231:GO:0005739:GO:0042450:GO:0070781:GO:0016597	300461	PF02729:PF00185	-0.1															M
chrX:154533044	SNV	C	1	T/T	PASS	0.0	3975.03		400	C=0,T=400	C=0.0,T=1.0	100.0	0.0	hemizygous	13	0.002	1.0		G6PD	NM_001042351.3	G6PD:exonic:NM_001042351.3	missense	AAG	9	p.Glu317Lys	c.949G>A	0.05	0.837	56.0	T		0.92		Conflicting interpretations of pathogenicity	9230996	rs137852339		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:G6PD)(dui:NBS3;dis:Secondary Conditions;g:G6PD)(dui:NBS39;dis:Hb carrier other than C,D,E,S,O-Arab;g:G6PD)(dui:NBS7;dis:Hemoglobin Disorder;g:G6PD)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:G6PD)(dui:D030342;dis:Genetic Diseases, Inborn;g:G6PD)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:G6PD)(dui:D006402;dis:Hematologic Diseases;g:G6PD)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:G6PD)(dui:D000740;dis:Anemia;g:G6PD)(dui:D008659;dis:Metabolic Diseases;g:G6PD)(dui:D000743;dis:Anemia, Hemolytic;g:G6PD)(dui:D000745;dis:Anemia, Hemolytic, Congenital;g:G6PD)(dui:D008661;dis:Metabolism, Inborn Errors;g:G6PD)(dui:D005955;dis:Glucosephosphate Dehydrogenase Deficiency;g:G6PD)(dui:D040181;dis:Genetic Diseases, X-Linked;g:G6PD)(dui:D002239;dis:Carbohydrate Metabolism, Inborn Errors;g:G6PD)(dui:D052801;dis:Male Urogenital Diseases;g:G6PD)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:G6PD)(dui:D014570;dis:Urologic Diseases;g:G6PD)(dui:D052776;dis:Female Urogenital Diseases;g:G6PD)(dui:D007674;dis:Kidney Diseases;g:G6PD)(dui:D004066;dis:Digestive System Diseases;g:G6PD)(dui:D002318;dis:Cardiovascular Diseases;g:G6PD)(dui:D014652;dis:Vascular Diseases;g:G6PD)(dui:D008107;dis:Liver Diseases;g:G6PD)(dui:D007154;dis:Immune System Diseases;g:G6PD)(dui:D007153;dis:Immunologic Deficiency Syndromes;g:G6PD)(dui:D007960;dis:Leukocyte Disorders;g:G6PD)(dui:D010585;dis:Phagocyte Bactericidal Dysfunction;g:G6PD)(dui:D009422;dis:Nervous System Diseases;g:G6PD)(dui:D002493;dis:Central Nervous System Diseases;g:G6PD)(dui:D001927;dis:Brain Diseases;g:G6PD)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:G6PD)(dui:D012871;dis:Skin Diseases;g:G6PD)(dui:D004700;dis:Endocrine System Diseases;g:G6PD)(dui:D044882;dis:Glucose Metabolism Disorders;g:G6PD)(dui:D005236;dis:Favism;g:G6PD)(dui:D000746;dis:Anemia, Hemolytic, Congenital Nonspherocytic;g:G6PD)(dui:D003920;dis:Diabetes Mellitus;g:G6PD)(dui:D002561;dis:Cerebrovascular Disorders;g:G6PD)(dui:D001928;dis:Brain Diseases, Metabolic;g:G6PD)(dui:D009748;dis:Nutrition Disorders;g:G6PD)(dui:D006105;dis:Granulomatous Disease, Chronic;g:G6PD)(dui:D052439;dis:Lipid Metabolism Disorders;g:G6PD)(dui:D002545;dis:Brain Ischemia;g:G6PD)(dui:D003872;dis:Dermatitis;g:G6PD)(dui:D017443;dis:Skin Diseases, Eczematous;g:G6PD)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:G6PD)(dui:D003877;dis:Dermatitis, Contact;g:G6PD)(dui:D006946;dis:Hyperinsulinism;g:G6PD)(dui:D050171;dis:Dyslipidemias;g:G6PD)(dui:D051437;dis:Renal Insufficiency;g:G6PD)(dui:D006949;dis:Hyperlipidemias;g:G6PD)(dui:D007333;dis:Insulin Resistance;g:G6PD)(dui:D058186;dis:Acute Kidney Injury;g:G6PD)	Nicotinamide adenine dinucleotide phosphate:Glycolic acid:16-Bromoepiandrosterone:Artenimol	GO:0032094:GO:0010041:GO:0009051:GO:0061052:GO:0034451:GO:0006740:GO:0006006:GO:0043523:GO:0004345:GO:0009898:GO:0043249:GO:1904879:GO:0045471:GO:0070062:GO:0043231:GO:0006739:GO:0019322:GO:0005829:GO:0010734:GO:2000378:GO:0042802:GO:0042803:GO:0006098:GO:0006695:GO:0014070:GO:0021762:GO:0005536:GO:0005634:GO:0050661:GO:0051156:GO:0005515:GO:0005737:GO:0006749:GO:0006629:GO:0016020:GO:0034599:GO:0055114:GO:0046390	305900	PF00479:PF02781	2.83															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	4.854896771016029e-07	63.1382		7	AAA=0,GCT=7	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr15:80186247	MNV	ACCCC	5	ACCCC/CTTTG	PASS	7.903145908644514e-73	721.022		387	ACCCC=210,CTTTG=177	ACCCC=0.5426,CTTTG=0.4574	45.74	54.26	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															M
chr6:32039847	MNV	AC	2	AC/GT	PASS	7.47825035045569e-69	681.262		309	AC=156,GT=153	AC=0.5049,GT=0.4951	49.51	50.49	0	1	0.173:0.174	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.738+12_738+13delinsGT				GT	GMAF=0.034:AMAF=0.0545:EMAF=0.0235			Uncertain significance		rs193922547:rs6458:rs6459:rs1554305325:rs71552100		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-1.57,-3.0															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	4.854896771016029e-07	63.1382		7	AAA=0,GCT=7	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr15:80186247	MNV	ACCCC	5	CTTTG/CTTTG	PASS	0.0	3863.46		386	ACCCC=0,CTTTG=386	ACCCC=0.0,CTTTG=1.0	100.0	0.0	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	2.4244319574912225e-08	76.1539		8	AAA=0,GCT=8	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															F
chr6:32039055	MNV	CA	2	CA/GG	PASS	2.2799220561535425e-08	76.4208		38	CA=21,GG=17	CA=0.5526,GG=0.4474	44.74	55.26	0	1	0.036	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.293-39_293-38delinsGG				GG						rs58256870:rs66933575:rs35147842:rs202093120		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-0.34,-0.29															F
chr6:32039847	MNV	AC	2	AC/GT	PASS	5.487821792914582e-21	202.606		90	AC=46,GT=44	AC=0.5111,GT=0.4889	48.89	51.11	0	1	0.173:0.174	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.738+12_738+13delinsGT				GT	GMAF=0.034:AMAF=0.0545:EMAF=0.0235			Uncertain significance		rs193922547:rs6458:rs6459:rs1554305325:rs71552100		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-1.57,-3.0															F
chr15:80186247	MNV	ACCCC	5	ACCCC/CTTTG	PASS	2.3856130399309183e-36	356.224		185	ACCCC=100,CTTTG=85	ACCCC=0.5405,CTTTG=0.4595	45.95	54.05	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															F
chr12:109573424	MNV	GC	2	GC/TT	PASS	1.110708255918865e-26	259.544		97	GC=45,TT=52	GC=0.4639,TT=0.5361	53.61	46.39	0	1	0.285	1.0		MMAB|MVK	NM_052845.4|NM_001114185.3	MMAB:exonic:NM_052845.4|MVK:upstream:NM_001114185.3	missense|unknown	|	1|	p.Arg19Gln|p.?	c.56_57delGCinsAA|c.-1399GC>TT	0.07|	0.873|	43.0|	TT|TT	GMAF=0.3091:AMAF=0.3917:EMAF=0.267	0.71		Benign/Likely benign	3752891	rs10774774:rs10774775:rs36013132:rs748526009:rs879684260:rs1555276196:rs1555276197		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMAB)(dui:NBS2;dis:Core Conditions;g:MMAB)(dui:NBS9;dis:Organic Acid Condition;g:MMAB)(dui:NBS43;dis:Methylmalonic acidemia;g:MMAB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMAB)(dui:D008659;dis:Metabolic Diseases;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMAB)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMAB)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMAB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MVK)(dui:D030342;dis:Genetic Diseases, Inborn;g:MVK)(dui:D009422;dis:Nervous System Diseases;g:MVK)(dui:D056660;dis:Hereditary Autoinflammatory Diseases;g:MVK)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MVK)(dui:D008659;dis:Metabolic Diseases;g:MVK)(dui:D002493;dis:Central Nervous System Diseases;g:MVK)(dui:D001927;dis:Brain Diseases;g:MVK)(dui:D008661;dis:Metabolism, Inborn Errors;g:MVK)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MVK)(dui:D007154;dis:Immune System Diseases;g:MVK)(dui:D006402;dis:Hematologic Diseases;g:MVK)(dui:D007160;dis:Immunoproliferative Disorders;g:MVK)(dui:D001796;dis:Blood Protein Disorders;g:MVK)(dui:D001928;dis:Brain Diseases, Metabolic;g:MVK)(dui:D006942;dis:Hypergammaglobulinemia;g:MVK)(dui:D018901;dis:Peroxisomal Disorders;g:MVK)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MVK)(dui:D054078;dis:Mevalonate Kinase Deficiency;g:MVK)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MVK)(dui:D012871;dis:Skin Diseases;g:MVK)(dui:D012873;dis:Skin Diseases, Genetic;g:MVK)(dui:D007642;dis:Keratosis;g:MVK)(dui:D017499;dis:Porokeratosis;g:MVK)(dui:D009461;dis:Neurologic Manifestations;g:MVK)(dui:D004066;dis:Digestive System Diseases;g:MVK)(dui:D010146;dis:Pain;g:MVK)(dui:D009369;dis:Neoplasms;g:MVK)(dui:D008107;dis:Liver Diseases;g:MVK)(dui:D009371;dis:Neoplasms by Site;g:MVK)(dui:D004067;dis:Digestive System Neoplasms;g:MVK)(dui:D008113;dis:Liver Neoplasms;g:MVK)(dui:D009370;dis:Neoplasms by Histologic Type;g:MVK)(dui:D009140;dis:Musculoskeletal Diseases;g:MVK)(dui:D007592;dis:Joint Diseases;g:MVK)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MVK)(dui:D002277;dis:Carcinoma;g:MVK)(dui:D006528;dis:Carcinoma, Hepatocellular;g:MVK)(dui:D000230;dis:Adenocarcinoma;g:MVK)(dui:D018771;dis:Arthralgia;g:MVK)(dui:D005076;dis:Exanthema;g:MVK)	Farnesyl thiopyrophosphate:Cyanocobalamin	GO:0042802:GO:0050728:GO:0006695:GO:0004496:GO:0009235:GO:0008299:GO:0000287:GO:0005524:GO:0005777:GO:0005515:GO:0045540:GO:0005759:GO:0019287:GO:0043231:GO:0031419:GO:0008817:GO:0005829:GO:0016310	251170:607568	PF01923	-0.05,1.26															F
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	1.0641920249497412e-09	89.7298		9	AAA=0,GCT=9	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	4.854896771016029e-07	63.1382		7	AAA=0,GCT=7	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr15:80186247	MNV	ACCCC	5	ACCCC/CTTTG	PASS	7.903145908644514e-73	721.022		387	ACCCC=210,CTTTG=177	ACCCC=0.5426,CTTTG=0.4574	45.74	54.26	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	4.854896771016029e-07	63.1382		7	AAA=0,GCT=7	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr15:80186247	MNV	ACCCC	5	ACCCC/CTTTG	PASS	7.903145908644514e-73	721.022		387	ACCCC=210,CTTTG=177	ACCCC=0.5426,CTTTG=0.4574	45.74	54.26	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	4.854896771016029e-07	63.1382		7	AAA=0,GCT=7	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr15:80186247	MNV	ACCCC	5	ACCCC/CTTTG	PASS	7.903145908644514e-73	721.022		387	ACCCC=210,CTTTG=177	ACCCC=0.5426,CTTTG=0.4574	45.74	54.26	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															M
chr6:32039847	MNV	AC	2	AC/GT	PASS	7.47825035045569e-69	681.262		309	AC=156,GT=153	AC=0.5049,GT=0.4951	49.51	50.49	0	1	0.173:0.174	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.738+12_738+13delinsGT				GT	GMAF=0.034:AMAF=0.0545:EMAF=0.0235			Uncertain significance		rs193922547:rs6458:rs6459:rs1554305325:rs71552100		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-1.57,-3.0															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	4.854896771016029e-07	63.1382		7	AAA=0,GCT=7	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr15:80186247	MNV	ACCCC	5	CTTTG/CTTTG	PASS	0.0	3863.46		386	ACCCC=0,CTTTG=386	ACCCC=0.0,CTTTG=1.0	100.0	0.0	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	2.4244319574912225e-08	76.1539		8	AAA=0,GCT=8	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															F
chr6:32039055	MNV	CA	2	CA/GG	PASS	2.2799220561535425e-08	76.4208		38	CA=21,GG=17	CA=0.5526,GG=0.4474	44.74	55.26	0	1	0.036	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.293-39_293-38delinsGG				GG						rs58256870:rs66933575:rs35147842:rs202093120		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-0.34,-0.29															F
chr6:32039847	MNV	AC	2	AC/GT	PASS	5.487821792914582e-21	202.606		90	AC=46,GT=44	AC=0.5111,GT=0.4889	48.89	51.11	0	1	0.173:0.174	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.738+12_738+13delinsGT				GT	GMAF=0.034:AMAF=0.0545:EMAF=0.0235			Uncertain significance		rs193922547:rs6458:rs6459:rs1554305325:rs71552100		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-1.57,-3.0															F
chr15:80186247	MNV	ACCCC	5	ACCCC/CTTTG	PASS	2.3856130399309183e-36	356.224		185	ACCCC=100,CTTTG=85	ACCCC=0.5405,CTTTG=0.4595	45.95	54.05	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															F
chr12:109573424	MNV	GC	2	GC/TT	PASS	1.110708255918865e-26	259.544		97	GC=45,TT=52	GC=0.4639,TT=0.5361	53.61	46.39	0	1	0.285	1.0		MMAB|MVK	NM_052845.4|NM_001114185.3	MMAB:exonic:NM_052845.4|MVK:upstream:NM_001114185.3	missense|unknown	|	1|	p.Arg19Gln|p.?	c.56_57delGCinsAA|c.-1399GC>TT	0.07|	0.873|	43.0|	TT|TT	GMAF=0.3091:AMAF=0.3917:EMAF=0.267	0.71		Benign/Likely benign	3752891	rs10774774:rs10774775:rs36013132:rs748526009:rs879684260:rs1555276196:rs1555276197		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMAB)(dui:NBS2;dis:Core Conditions;g:MMAB)(dui:NBS9;dis:Organic Acid Condition;g:MMAB)(dui:NBS43;dis:Methylmalonic acidemia;g:MMAB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMAB)(dui:D008659;dis:Metabolic Diseases;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMAB)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMAB)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMAB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MVK)(dui:D030342;dis:Genetic Diseases, Inborn;g:MVK)(dui:D009422;dis:Nervous System Diseases;g:MVK)(dui:D056660;dis:Hereditary Autoinflammatory Diseases;g:MVK)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MVK)(dui:D008659;dis:Metabolic Diseases;g:MVK)(dui:D002493;dis:Central Nervous System Diseases;g:MVK)(dui:D001927;dis:Brain Diseases;g:MVK)(dui:D008661;dis:Metabolism, Inborn Errors;g:MVK)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MVK)(dui:D007154;dis:Immune System Diseases;g:MVK)(dui:D006402;dis:Hematologic Diseases;g:MVK)(dui:D007160;dis:Immunoproliferative Disorders;g:MVK)(dui:D001796;dis:Blood Protein Disorders;g:MVK)(dui:D001928;dis:Brain Diseases, Metabolic;g:MVK)(dui:D006942;dis:Hypergammaglobulinemia;g:MVK)(dui:D018901;dis:Peroxisomal Disorders;g:MVK)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MVK)(dui:D054078;dis:Mevalonate Kinase Deficiency;g:MVK)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MVK)(dui:D012871;dis:Skin Diseases;g:MVK)(dui:D012873;dis:Skin Diseases, Genetic;g:MVK)(dui:D007642;dis:Keratosis;g:MVK)(dui:D017499;dis:Porokeratosis;g:MVK)(dui:D009461;dis:Neurologic Manifestations;g:MVK)(dui:D004066;dis:Digestive System Diseases;g:MVK)(dui:D010146;dis:Pain;g:MVK)(dui:D009369;dis:Neoplasms;g:MVK)(dui:D008107;dis:Liver Diseases;g:MVK)(dui:D009371;dis:Neoplasms by Site;g:MVK)(dui:D004067;dis:Digestive System Neoplasms;g:MVK)(dui:D008113;dis:Liver Neoplasms;g:MVK)(dui:D009370;dis:Neoplasms by Histologic Type;g:MVK)(dui:D009140;dis:Musculoskeletal Diseases;g:MVK)(dui:D007592;dis:Joint Diseases;g:MVK)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MVK)(dui:D002277;dis:Carcinoma;g:MVK)(dui:D006528;dis:Carcinoma, Hepatocellular;g:MVK)(dui:D000230;dis:Adenocarcinoma;g:MVK)(dui:D018771;dis:Arthralgia;g:MVK)(dui:D005076;dis:Exanthema;g:MVK)	Farnesyl thiopyrophosphate:Cyanocobalamin	GO:0042802:GO:0050728:GO:0006695:GO:0004496:GO:0009235:GO:0008299:GO:0000287:GO:0005524:GO:0005777:GO:0005515:GO:0045540:GO:0005759:GO:0019287:GO:0043231:GO:0031419:GO:0008817:GO:0005829:GO:0016310	251170:607568	PF01923	-0.05,1.26															F
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	1.0641920249497412e-09	89.7298		9	AAA=0,GCT=9	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	4.854896771016029e-07	63.1382		7	AAA=0,GCT=7	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr15:80186247	MNV	ACCCC	5	ACCCC/CTTTG	PASS	7.903145908644514e-73	721.022		387	ACCCC=210,CTTTG=177	ACCCC=0.5426,CTTTG=0.4574	45.74	54.26	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															M
chr6:32039847	MNV	AC	2	AC/GT	PASS	7.47825035045569e-69	681.262		309	AC=156,GT=153	AC=0.5049,GT=0.4951	49.51	50.49	0	1	0.173:0.174	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.738+12_738+13delinsGT				GT	GMAF=0.034:AMAF=0.0545:EMAF=0.0235			Uncertain significance		rs193922547:rs6458:rs6459:rs1554305325:rs71552100		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-1.57,-3.0															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	4.854896771016029e-07	63.1382		7	AAA=0,GCT=7	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr15:80186247	MNV	ACCCC	5	CTTTG/CTTTG	PASS	0.0	3863.46		386	ACCCC=0,CTTTG=386	ACCCC=0.0,CTTTG=1.0	100.0	0.0	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	4.854896771016029e-07	63.1382		7	AAA=0,GCT=7	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr15:80186247	MNV	ACCCC	5	ACCCC/CTTTG	PASS	7.903145908644514e-73	721.022		387	ACCCC=210,CTTTG=177	ACCCC=0.5426,CTTTG=0.4574	45.74	54.26	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															M
chr6:32039847	MNV	AC	2	AC/GT	PASS	7.47825035045569e-69	681.262		309	AC=156,GT=153	AC=0.5049,GT=0.4951	49.51	50.49	0	1	0.173:0.174	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.738+12_738+13delinsGT				GT	GMAF=0.034:AMAF=0.0545:EMAF=0.0235			Uncertain significance		rs193922547:rs6458:rs6459:rs1554305325:rs71552100		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-1.57,-3.0															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	4.854896771016029e-07	63.1382		7	AAA=0,GCT=7	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr15:80186247	MNV	ACCCC	5	CTTTG/CTTTG	PASS	0.0	3863.46		386	ACCCC=0,CTTTG=386	ACCCC=0.0,CTTTG=1.0	100.0	0.0	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	2.4244319574912225e-08	76.1539		8	AAA=0,GCT=8	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															F
chr6:32039055	MNV	CA	2	CA/GG	PASS	2.2799220561535425e-08	76.4208		38	CA=21,GG=17	CA=0.5526,GG=0.4474	44.74	55.26	0	1	0.036	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.293-39_293-38delinsGG				GG						rs58256870:rs66933575:rs35147842:rs202093120		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-0.34,-0.29															F
chr6:32039847	MNV	AC	2	AC/GT	PASS	5.487821792914582e-21	202.606		90	AC=46,GT=44	AC=0.5111,GT=0.4889	48.89	51.11	0	1	0.173:0.174	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.738+12_738+13delinsGT				GT	GMAF=0.034:AMAF=0.0545:EMAF=0.0235			Uncertain significance		rs193922547:rs6458:rs6459:rs1554305325:rs71552100		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-1.57,-3.0															F
chr15:80186247	MNV	ACCCC	5	ACCCC/CTTTG	PASS	2.3856130399309183e-36	356.224		185	ACCCC=100,CTTTG=85	ACCCC=0.5405,CTTTG=0.4595	45.95	54.05	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															F
chr12:109573424	MNV	GC	2	GC/TT	PASS	1.110708255918865e-26	259.544		97	GC=45,TT=52	GC=0.4639,TT=0.5361	53.61	46.39	0	1	0.285	1.0		MMAB|MVK	NM_052845.4|NM_001114185.3	MMAB:exonic:NM_052845.4|MVK:upstream:NM_001114185.3	missense|unknown	|	1|	p.Arg19Gln|p.?	c.56_57delGCinsAA|c.-1399GC>TT	0.07|	0.873|	43.0|	TT|TT	GMAF=0.3091:AMAF=0.3917:EMAF=0.267	0.71		Benign/Likely benign	3752891	rs10774774:rs10774775:rs36013132:rs748526009:rs879684260:rs1555276196:rs1555276197		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMAB)(dui:NBS2;dis:Core Conditions;g:MMAB)(dui:NBS9;dis:Organic Acid Condition;g:MMAB)(dui:NBS43;dis:Methylmalonic acidemia;g:MMAB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMAB)(dui:D008659;dis:Metabolic Diseases;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMAB)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMAB)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMAB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MVK)(dui:D030342;dis:Genetic Diseases, Inborn;g:MVK)(dui:D009422;dis:Nervous System Diseases;g:MVK)(dui:D056660;dis:Hereditary Autoinflammatory Diseases;g:MVK)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MVK)(dui:D008659;dis:Metabolic Diseases;g:MVK)(dui:D002493;dis:Central Nervous System Diseases;g:MVK)(dui:D001927;dis:Brain Diseases;g:MVK)(dui:D008661;dis:Metabolism, Inborn Errors;g:MVK)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MVK)(dui:D007154;dis:Immune System Diseases;g:MVK)(dui:D006402;dis:Hematologic Diseases;g:MVK)(dui:D007160;dis:Immunoproliferative Disorders;g:MVK)(dui:D001796;dis:Blood Protein Disorders;g:MVK)(dui:D001928;dis:Brain Diseases, Metabolic;g:MVK)(dui:D006942;dis:Hypergammaglobulinemia;g:MVK)(dui:D018901;dis:Peroxisomal Disorders;g:MVK)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MVK)(dui:D054078;dis:Mevalonate Kinase Deficiency;g:MVK)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MVK)(dui:D012871;dis:Skin Diseases;g:MVK)(dui:D012873;dis:Skin Diseases, Genetic;g:MVK)(dui:D007642;dis:Keratosis;g:MVK)(dui:D017499;dis:Porokeratosis;g:MVK)(dui:D009461;dis:Neurologic Manifestations;g:MVK)(dui:D004066;dis:Digestive System Diseases;g:MVK)(dui:D010146;dis:Pain;g:MVK)(dui:D009369;dis:Neoplasms;g:MVK)(dui:D008107;dis:Liver Diseases;g:MVK)(dui:D009371;dis:Neoplasms by Site;g:MVK)(dui:D004067;dis:Digestive System Neoplasms;g:MVK)(dui:D008113;dis:Liver Neoplasms;g:MVK)(dui:D009370;dis:Neoplasms by Histologic Type;g:MVK)(dui:D009140;dis:Musculoskeletal Diseases;g:MVK)(dui:D007592;dis:Joint Diseases;g:MVK)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MVK)(dui:D002277;dis:Carcinoma;g:MVK)(dui:D006528;dis:Carcinoma, Hepatocellular;g:MVK)(dui:D000230;dis:Adenocarcinoma;g:MVK)(dui:D018771;dis:Arthralgia;g:MVK)(dui:D005076;dis:Exanthema;g:MVK)	Farnesyl thiopyrophosphate:Cyanocobalamin	GO:0042802:GO:0050728:GO:0006695:GO:0004496:GO:0009235:GO:0008299:GO:0000287:GO:0005524:GO:0005777:GO:0005515:GO:0045540:GO:0005759:GO:0019287:GO:0043231:GO:0031419:GO:0008817:GO:0005829:GO:0016310	251170:607568	PF01923	-0.05,1.26															F
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	1.0641920249497412e-09	89.7298		9	AAA=0,GCT=9	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	4.854896771016029e-07	63.1382		7	AAA=0,GCT=7	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr15:80186247	MNV	ACCCC	5	ACCCC/CTTTG	PASS	7.903145908644514e-73	721.022		387	ACCCC=210,CTTTG=177	ACCCC=0.5426,CTTTG=0.4574	45.74	54.26	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															M
chr6:32039847	MNV	AC	2	AC/GT	PASS	7.47825035045569e-69	681.262		309	AC=156,GT=153	AC=0.5049,GT=0.4951	49.51	50.49	0	1	0.173:0.174	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.738+12_738+13delinsGT				GT	GMAF=0.034:AMAF=0.0545:EMAF=0.0235			Uncertain significance		rs193922547:rs6458:rs6459:rs1554305325:rs71552100		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-1.57,-3.0															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	4.854896771016029e-07	63.1382		7	AAA=0,GCT=7	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr15:80186247	MNV	ACCCC	5	CTTTG/CTTTG	PASS	0.0	3863.46		386	ACCCC=0,CTTTG=386	ACCCC=0.0,CTTTG=1.0	100.0	0.0	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	2.4244319574912225e-08	76.1539		8	AAA=0,GCT=8	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															F
chr6:32039055	MNV	CA	2	CA/GG	PASS	2.2799220561535425e-08	76.4208		38	CA=21,GG=17	CA=0.5526,GG=0.4474	44.74	55.26	0	1	0.036	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.293-39_293-38delinsGG				GG						rs58256870:rs66933575:rs35147842:rs202093120		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-0.34,-0.29															F
chr6:32039847	MNV	AC	2	AC/GT	PASS	5.487821792914582e-21	202.606		90	AC=46,GT=44	AC=0.5111,GT=0.4889	48.89	51.11	0	1	0.173:0.174	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.738+12_738+13delinsGT				GT	GMAF=0.034:AMAF=0.0545:EMAF=0.0235			Uncertain significance		rs193922547:rs6458:rs6459:rs1554305325:rs71552100		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-1.57,-3.0															F
chr15:80186247	MNV	ACCCC	5	ACCCC/CTTTG	PASS	2.3856130399309183e-36	356.224		185	ACCCC=100,CTTTG=85	ACCCC=0.5405,CTTTG=0.4595	45.95	54.05	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															F
chr12:109573424	MNV	GC	2	GC/TT	PASS	1.110708255918865e-26	259.544		97	GC=45,TT=52	GC=0.4639,TT=0.5361	53.61	46.39	0	1	0.285	1.0		MMAB|MVK	NM_052845.4|NM_001114185.3	MMAB:exonic:NM_052845.4|MVK:upstream:NM_001114185.3	missense|unknown	|	1|	p.Arg19Gln|p.?	c.56_57delGCinsAA|c.-1399GC>TT	0.07|	0.873|	43.0|	TT|TT	GMAF=0.3091:AMAF=0.3917:EMAF=0.267	0.71		Benign/Likely benign	3752891	rs10774774:rs10774775:rs36013132:rs748526009:rs879684260:rs1555276196:rs1555276197		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMAB)(dui:NBS2;dis:Core Conditions;g:MMAB)(dui:NBS9;dis:Organic Acid Condition;g:MMAB)(dui:NBS43;dis:Methylmalonic acidemia;g:MMAB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMAB)(dui:D008659;dis:Metabolic Diseases;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMAB)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMAB)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMAB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MVK)(dui:D030342;dis:Genetic Diseases, Inborn;g:MVK)(dui:D009422;dis:Nervous System Diseases;g:MVK)(dui:D056660;dis:Hereditary Autoinflammatory Diseases;g:MVK)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MVK)(dui:D008659;dis:Metabolic Diseases;g:MVK)(dui:D002493;dis:Central Nervous System Diseases;g:MVK)(dui:D001927;dis:Brain Diseases;g:MVK)(dui:D008661;dis:Metabolism, Inborn Errors;g:MVK)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MVK)(dui:D007154;dis:Immune System Diseases;g:MVK)(dui:D006402;dis:Hematologic Diseases;g:MVK)(dui:D007160;dis:Immunoproliferative Disorders;g:MVK)(dui:D001796;dis:Blood Protein Disorders;g:MVK)(dui:D001928;dis:Brain Diseases, Metabolic;g:MVK)(dui:D006942;dis:Hypergammaglobulinemia;g:MVK)(dui:D018901;dis:Peroxisomal Disorders;g:MVK)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MVK)(dui:D054078;dis:Mevalonate Kinase Deficiency;g:MVK)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MVK)(dui:D012871;dis:Skin Diseases;g:MVK)(dui:D012873;dis:Skin Diseases, Genetic;g:MVK)(dui:D007642;dis:Keratosis;g:MVK)(dui:D017499;dis:Porokeratosis;g:MVK)(dui:D009461;dis:Neurologic Manifestations;g:MVK)(dui:D004066;dis:Digestive System Diseases;g:MVK)(dui:D010146;dis:Pain;g:MVK)(dui:D009369;dis:Neoplasms;g:MVK)(dui:D008107;dis:Liver Diseases;g:MVK)(dui:D009371;dis:Neoplasms by Site;g:MVK)(dui:D004067;dis:Digestive System Neoplasms;g:MVK)(dui:D008113;dis:Liver Neoplasms;g:MVK)(dui:D009370;dis:Neoplasms by Histologic Type;g:MVK)(dui:D009140;dis:Musculoskeletal Diseases;g:MVK)(dui:D007592;dis:Joint Diseases;g:MVK)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MVK)(dui:D002277;dis:Carcinoma;g:MVK)(dui:D006528;dis:Carcinoma, Hepatocellular;g:MVK)(dui:D000230;dis:Adenocarcinoma;g:MVK)(dui:D018771;dis:Arthralgia;g:MVK)(dui:D005076;dis:Exanthema;g:MVK)	Farnesyl thiopyrophosphate:Cyanocobalamin	GO:0042802:GO:0050728:GO:0006695:GO:0004496:GO:0009235:GO:0008299:GO:0000287:GO:0005524:GO:0005777:GO:0005515:GO:0045540:GO:0005759:GO:0019287:GO:0043231:GO:0031419:GO:0008817:GO:0005829:GO:0016310	251170:607568	PF01923	-0.05,1.26															F
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	1.0641920249497412e-09	89.7298		9	AAA=0,GCT=9	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	4.854896771016029e-07	63.1382		7	AAA=0,GCT=7	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr15:80186247	MNV	ACCCC	5	ACCCC/CTTTG	PASS	7.903145908644514e-73	721.022		387	ACCCC=210,CTTTG=177	ACCCC=0.5426,CTTTG=0.4574	45.74	54.26	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															M
chr6:32039847	MNV	AC	2	AC/GT	PASS	7.47825035045569e-69	681.262		309	AC=156,GT=153	AC=0.5049,GT=0.4951	49.51	50.49	0	1	0.173:0.174	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.738+12_738+13delinsGT				GT	GMAF=0.034:AMAF=0.0545:EMAF=0.0235			Uncertain significance		rs193922547:rs6458:rs6459:rs1554305325:rs71552100		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-1.57,-3.0															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	4.854896771016029e-07	63.1382		7	AAA=0,GCT=7	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr15:80186247	MNV	ACCCC	5	CTTTG/CTTTG	PASS	0.0	3863.46		386	ACCCC=0,CTTTG=386	ACCCC=0.0,CTTTG=1.0	100.0	0.0	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	2.4244319574912225e-08	76.1539		8	AAA=0,GCT=8	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															F
chr6:32039055	MNV	CA	2	CA/GG	PASS	2.2799220561535425e-08	76.4208		38	CA=21,GG=17	CA=0.5526,GG=0.4474	44.74	55.26	0	1	0.036	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.293-39_293-38delinsGG				GG						rs58256870:rs66933575:rs35147842:rs202093120		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-0.34,-0.29															F
chr6:32039847	MNV	AC	2	AC/GT	PASS	5.487821792914582e-21	202.606		90	AC=46,GT=44	AC=0.5111,GT=0.4889	48.89	51.11	0	1	0.173:0.174	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.738+12_738+13delinsGT				GT	GMAF=0.034:AMAF=0.0545:EMAF=0.0235			Uncertain significance		rs193922547:rs6458:rs6459:rs1554305325:rs71552100		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-1.57,-3.0															F
chr15:80186247	MNV	ACCCC	5	ACCCC/CTTTG	PASS	2.3856130399309183e-36	356.224		185	ACCCC=100,CTTTG=85	ACCCC=0.5405,CTTTG=0.4595	45.95	54.05	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															F
chr12:109573424	MNV	GC	2	GC/TT	PASS	1.110708255918865e-26	259.544		97	GC=45,TT=52	GC=0.4639,TT=0.5361	53.61	46.39	0	1	0.285	1.0		MMAB|MVK	NM_052845.4|NM_001114185.3	MMAB:exonic:NM_052845.4|MVK:upstream:NM_001114185.3	missense|unknown	|	1|	p.Arg19Gln|p.?	c.56_57delGCinsAA|c.-1399GC>TT	0.07|	0.873|	43.0|	TT|TT	GMAF=0.3091:AMAF=0.3917:EMAF=0.267	0.71		Benign/Likely benign	3752891	rs10774774:rs10774775:rs36013132:rs748526009:rs879684260:rs1555276196:rs1555276197		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMAB)(dui:NBS2;dis:Core Conditions;g:MMAB)(dui:NBS9;dis:Organic Acid Condition;g:MMAB)(dui:NBS43;dis:Methylmalonic acidemia;g:MMAB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMAB)(dui:D008659;dis:Metabolic Diseases;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMAB)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMAB)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMAB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MVK)(dui:D030342;dis:Genetic Diseases, Inborn;g:MVK)(dui:D009422;dis:Nervous System Diseases;g:MVK)(dui:D056660;dis:Hereditary Autoinflammatory Diseases;g:MVK)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MVK)(dui:D008659;dis:Metabolic Diseases;g:MVK)(dui:D002493;dis:Central Nervous System Diseases;g:MVK)(dui:D001927;dis:Brain Diseases;g:MVK)(dui:D008661;dis:Metabolism, Inborn Errors;g:MVK)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MVK)(dui:D007154;dis:Immune System Diseases;g:MVK)(dui:D006402;dis:Hematologic Diseases;g:MVK)(dui:D007160;dis:Immunoproliferative Disorders;g:MVK)(dui:D001796;dis:Blood Protein Disorders;g:MVK)(dui:D001928;dis:Brain Diseases, Metabolic;g:MVK)(dui:D006942;dis:Hypergammaglobulinemia;g:MVK)(dui:D018901;dis:Peroxisomal Disorders;g:MVK)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MVK)(dui:D054078;dis:Mevalonate Kinase Deficiency;g:MVK)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MVK)(dui:D012871;dis:Skin Diseases;g:MVK)(dui:D012873;dis:Skin Diseases, Genetic;g:MVK)(dui:D007642;dis:Keratosis;g:MVK)(dui:D017499;dis:Porokeratosis;g:MVK)(dui:D009461;dis:Neurologic Manifestations;g:MVK)(dui:D004066;dis:Digestive System Diseases;g:MVK)(dui:D010146;dis:Pain;g:MVK)(dui:D009369;dis:Neoplasms;g:MVK)(dui:D008107;dis:Liver Diseases;g:MVK)(dui:D009371;dis:Neoplasms by Site;g:MVK)(dui:D004067;dis:Digestive System Neoplasms;g:MVK)(dui:D008113;dis:Liver Neoplasms;g:MVK)(dui:D009370;dis:Neoplasms by Histologic Type;g:MVK)(dui:D009140;dis:Musculoskeletal Diseases;g:MVK)(dui:D007592;dis:Joint Diseases;g:MVK)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MVK)(dui:D002277;dis:Carcinoma;g:MVK)(dui:D006528;dis:Carcinoma, Hepatocellular;g:MVK)(dui:D000230;dis:Adenocarcinoma;g:MVK)(dui:D018771;dis:Arthralgia;g:MVK)(dui:D005076;dis:Exanthema;g:MVK)	Farnesyl thiopyrophosphate:Cyanocobalamin	GO:0042802:GO:0050728:GO:0006695:GO:0004496:GO:0009235:GO:0008299:GO:0000287:GO:0005524:GO:0005777:GO:0005515:GO:0045540:GO:0005759:GO:0019287:GO:0043231:GO:0031419:GO:0008817:GO:0005829:GO:0016310	251170:607568	PF01923	-0.05,1.26															F
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	1.0641920249497412e-09	89.7298		9	AAA=0,GCT=9	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	4.854896771016029e-07	63.1382		7	AAA=0,GCT=7	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr15:80186247	MNV	ACCCC	5	ACCCC/CTTTG	PASS	7.903145908644514e-73	721.022		387	ACCCC=210,CTTTG=177	ACCCC=0.5426,CTTTG=0.4574	45.74	54.26	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	4.854896771016029e-07	63.1382		7	AAA=0,GCT=7	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr15:80186247	MNV	ACCCC	5	ACCCC/CTTTG	PASS	7.903145908644514e-73	721.022		387	ACCCC=210,CTTTG=177	ACCCC=0.5426,CTTTG=0.4574	45.74	54.26	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															M
chr6:32039847	MNV	AC	2	AC/GT	PASS	7.47825035045569e-69	681.262		309	AC=156,GT=153	AC=0.5049,GT=0.4951	49.51	50.49	0	1	0.173:0.174	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.738+12_738+13delinsGT				GT	GMAF=0.034:AMAF=0.0545:EMAF=0.0235			Uncertain significance		rs193922547:rs6458:rs6459:rs1554305325:rs71552100		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-1.57,-3.0															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	4.854896771016029e-07	63.1382		7	AAA=0,GCT=7	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
chr15:80186247	MNV	ACCCC	5	CTTTG/CTTTG	PASS	0.0	3863.46		386	ACCCC=0,CTTTG=386	ACCCC=0.0,CTTTG=1.0	100.0	0.0	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															M
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	2.4244319574912225e-08	76.1539		8	AAA=0,GCT=8	AAA=0.0,GCT=1.0	100.0	0.0	0	1	0.436:0.281:0.157	5.0		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															F
chr6:32039055	MNV	CA	2	CA/GG	PASS	2.2799220561535425e-08	76.4208		38	CA=21,GG=17	CA=0.5526,GG=0.4474	44.74	55.26	0	1	0.036	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.293-39_293-38delinsGG				GG						rs58256870:rs66933575:rs35147842:rs202093120		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-0.34,-0.29															F
chr6:32039847	MNV	AC	2	AC/GT	PASS	5.487821792914582e-21	202.606		90	AC=46,GT=44	AC=0.5111,GT=0.4889	48.89	51.11	0	1	0.173:0.174	1.0		CYP21A2	NM_000500.9	CYP21A2:intronic:NM_000500.9	unknown			p.?	c.738+12_738+13delinsGT				GT	GMAF=0.034:AMAF=0.0545:EMAF=0.0235			Uncertain significance		rs193922547:rs6458:rs6459:rs1554305325:rs71552100		(dui:D004700;dis:Endocrine System Diseases;g:CYP21A2)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CYP21A2)(dui:D006058;dis:Gonadal Disorders;g:CYP21A2)(dui:D052776;dis:Female Urogenital Diseases;g:CYP21A2)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CYP21A2)(dui:D000013;dis:Congenital Abnormalities;g:CYP21A2)(dui:D052801;dis:Male Urogenital Diseases;g:CYP21A2)(dui:D014564;dis:Urogenital Abnormalities;g:CYP21A2)(dui:D012734;dis:Disorders of Sex Development;g:CYP21A2)(dui:D047808;dis:Adrenogenital Syndrome;g:CYP21A2)(dui:D000307;dis:Adrenal Gland Diseases;g:CYP21A2)(dui:D030342;dis:Genetic Diseases, Inborn;g:CYP21A2)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CYP21A2)(dui:D008659;dis:Metabolic Diseases;g:CYP21A2)(dui:D008661;dis:Metabolism, Inborn Errors;g:CYP21A2)(dui:D000312;dis:Adrenal Hyperplasia, Congenital;g:CYP21A2)(dui:D043202;dis:Steroid Metabolism, Inborn Errors;g:CYP21A2)(dui:D058489;dis:46, XX Disorders of Sex Development;g:CYP21A2)(dui:D017588;dis:Hyperandrogenism;g:CYP21A2)	Ketoconazole	GO:0016705:GO:0008395:GO:0008202:GO:0005496:GO:0006694:GO:0004497:GO:0020037:GO:0005789:GO:0006704:GO:0005506:GO:0006705:GO:0004509:GO:0055114:GO:0016125	613815	PF00067	-1.57,-3.0															F
chr15:80186247	MNV	ACCCC	5	ACCCC/CTTTG	PASS	2.3856130399309183e-36	356.224		185	ACCCC=100,CTTTG=85	ACCCC=0.5405,CTTTG=0.4595	45.95	54.05	0	1	0.112	1.0		FAH	NM_000137.4	FAH:utr_3:NM_000137.4	unknown		14	p.?	c.*38ACCCC>CTTTG				CTTTG						rs3210172:rs1049181:rs374309326:rs751787251:rs370537299:rs199626920:rs377100715:rs369845634:rs386785740		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:FAH)(dui:NBS2;dis:Core Conditions;g:FAH)(dui:NBS11;dis:Amino Acid Disorder;g:FAH)(dui:NBS59;dis:Tyrosinemia type I;g:FAH)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:FAH)(dui:D008659;dis:Metabolic Diseases;g:FAH)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:FAH)(dui:D030342;dis:Genetic Diseases, Inborn;g:FAH)(dui:D008661;dis:Metabolism, Inborn Errors;g:FAH)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:FAH)(dui:D009422;dis:Nervous System Diseases;g:FAH)(dui:D002493;dis:Central Nervous System Diseases;g:FAH)(dui:D001927;dis:Brain Diseases;g:FAH)(dui:D001928;dis:Brain Diseases, Metabolic;g:FAH)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:FAH)(dui:D020176;dis:Tyrosinemias;g:FAH)	Fumaric Acid:4-[Hydroxy-[Methyl-Phosphinoyl]]-3-Oxo-Butanoic Acid:Acetoacetic acid	GO:0006527:GO:0005515:GO:0006559:GO:0070062:GO:0046872:GO:1902000:GO:0005829:GO:0006572:GO:0004334	613871	PF01557:PF09298	-1.95,0.27,0.04,0.13,0.06															F
chr12:109573424	MNV	GC	2	GC/TT	PASS	1.110708255918865e-26	259.544		97	GC=45,TT=52	GC=0.4639,TT=0.5361	53.61	46.39	0	1	0.285	1.0		MMAB|MVK	NM_052845.4|NM_001114185.3	MMAB:exonic:NM_052845.4|MVK:upstream:NM_001114185.3	missense|unknown	|	1|	p.Arg19Gln|p.?	c.56_57delGCinsAA|c.-1399GC>TT	0.07|	0.873|	43.0|	TT|TT	GMAF=0.3091:AMAF=0.3917:EMAF=0.267	0.71		Benign/Likely benign	3752891	rs10774774:rs10774775:rs36013132:rs748526009:rs879684260:rs1555276196:rs1555276197		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:MMAB)(dui:NBS2;dis:Core Conditions;g:MMAB)(dui:NBS9;dis:Organic Acid Condition;g:MMAB)(dui:NBS43;dis:Methylmalonic acidemia;g:MMAB)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MMAB)(dui:D008659;dis:Metabolic Diseases;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MMAB)(dui:D030342;dis:Genetic Diseases, Inborn;g:MMAB)(dui:D008661;dis:Metabolism, Inborn Errors;g:MMAB)(dui:D000592;dis:Amino Acid Metabolism, Inborn Errors;g:MMAB)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:MVK)(dui:D030342;dis:Genetic Diseases, Inborn;g:MVK)(dui:D009422;dis:Nervous System Diseases;g:MVK)(dui:D056660;dis:Hereditary Autoinflammatory Diseases;g:MVK)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:MVK)(dui:D008659;dis:Metabolic Diseases;g:MVK)(dui:D002493;dis:Central Nervous System Diseases;g:MVK)(dui:D001927;dis:Brain Diseases;g:MVK)(dui:D008661;dis:Metabolism, Inborn Errors;g:MVK)(dui:D006425;dis:Hemic and Lymphatic Diseases;g:MVK)(dui:D007154;dis:Immune System Diseases;g:MVK)(dui:D006402;dis:Hematologic Diseases;g:MVK)(dui:D007160;dis:Immunoproliferative Disorders;g:MVK)(dui:D001796;dis:Blood Protein Disorders;g:MVK)(dui:D001928;dis:Brain Diseases, Metabolic;g:MVK)(dui:D006942;dis:Hypergammaglobulinemia;g:MVK)(dui:D018901;dis:Peroxisomal Disorders;g:MVK)(dui:D020739;dis:Brain Diseases, Metabolic, Inborn;g:MVK)(dui:D054078;dis:Mevalonate Kinase Deficiency;g:MVK)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:MVK)(dui:D012871;dis:Skin Diseases;g:MVK)(dui:D012873;dis:Skin Diseases, Genetic;g:MVK)(dui:D007642;dis:Keratosis;g:MVK)(dui:D017499;dis:Porokeratosis;g:MVK)(dui:D009461;dis:Neurologic Manifestations;g:MVK)(dui:D004066;dis:Digestive System Diseases;g:MVK)(dui:D010146;dis:Pain;g:MVK)(dui:D009369;dis:Neoplasms;g:MVK)(dui:D008107;dis:Liver Diseases;g:MVK)(dui:D009371;dis:Neoplasms by Site;g:MVK)(dui:D004067;dis:Digestive System Neoplasms;g:MVK)(dui:D008113;dis:Liver Neoplasms;g:MVK)(dui:D009370;dis:Neoplasms by Histologic Type;g:MVK)(dui:D009140;dis:Musculoskeletal Diseases;g:MVK)(dui:D007592;dis:Joint Diseases;g:MVK)(dui:D009375;dis:Neoplasms, Glandular and Epithelial;g:MVK)(dui:D002277;dis:Carcinoma;g:MVK)(dui:D006528;dis:Carcinoma, Hepatocellular;g:MVK)(dui:D000230;dis:Adenocarcinoma;g:MVK)(dui:D018771;dis:Arthralgia;g:MVK)(dui:D005076;dis:Exanthema;g:MVK)	Farnesyl thiopyrophosphate:Cyanocobalamin	GO:0042802:GO:0050728:GO:0006695:GO:0004496:GO:0009235:GO:0008299:GO:0000287:GO:0005524:GO:0005777:GO:0005515:GO:0045540:GO:0005759:GO:0019287:GO:0043231:GO:0031419:GO:0008817:GO:0005829:GO:0016310	251170:607568	PF01923	-0.05,1.26															F
chr11:68799181	MNV	AAA	3	GCT/GCT	PASS	1.0641920249497412e-09	89.7298		9	AAA=0,GCT=9	AAA=0.0,GCT=1.0	100.00	0.0	0	1	0.436:0.281:0.157	5		CPT1A	NM_001876.4	CPT1A:intronic:NM_001876.4	unknown			p.?	c.693+35_693+37delinsAGC				GCT						rs61887062:rs373853770:rs61887064:rs200844352:rs67266031:rs1302471537:rs61887063:rs1555230749:rs371123694:rs753779449:rs776600347		(dui:NBS1;dis:Recommended Newborn Screening Panels;g:CPT1A)(dui:NBS3;dis:Secondary Conditions;g:CPT1A)(dui:NBS5;dis:Fatty Acid Oxidation Disorder;g:CPT1A)(dui:NBS27;dis:Carnitine palmitoyltransferase I deficiency;g:CPT1A)(dui:D009750;dis:Nutritional and Metabolic Diseases;g:CPT1A)(dui:D008659;dis:Metabolic Diseases;g:CPT1A)(dui:D044882;dis:Glucose Metabolism Disorders;g:CPT1A)(dui:D009358;dis:Congenital, Hereditary, and Neonatal Diseases and Abnormalities;g:CPT1A)(dui:D030342;dis:Genetic Diseases, Inborn;g:CPT1A)(dui:D008661;dis:Metabolism, Inborn Errors;g:CPT1A)(dui:D052439;dis:Lipid Metabolism Disorders;g:CPT1A)(dui:D007003;dis:Hypoglycemia;g:CPT1A)(dui:D008052;dis:Lipid Metabolism, Inborn Errors;g:CPT1A)(dui:D004700;dis:Endocrine System Diseases;g:CPT1A)(dui:D003920;dis:Diabetes Mellitus;g:CPT1A)(dui:D003924;dis:Diabetes Mellitus, Type 2;g:CPT1A)(dui:D009369;dis:Neoplasms;g:CPT1A)(dui:D052801;dis:Male Urogenital Diseases;g:CPT1A)(dui:D005261;dis:Female Urogenital Diseases and Pregnancy Complications;g:CPT1A)(dui:D014570;dis:Urologic Diseases;g:CPT1A)(dui:D052776;dis:Female Urogenital Diseases;g:CPT1A)(dui:D007674;dis:Kidney Diseases;g:CPT1A)(dui:D051437;dis:Renal Insufficiency;g:CPT1A)(dui:D051436;dis:Renal Insufficiency, Chronic;g:CPT1A)(dui:D007676;dis:Kidney Failure, Chronic;g:CPT1A)(dui:D009371;dis:Neoplasms by Site;g:CPT1A)(dui:D017437;dis:Skin and Connective Tissue Diseases;g:CPT1A)(dui:D012871;dis:Skin Diseases;g:CPT1A)(dui:D001941;dis:Breast Diseases;g:CPT1A)(dui:D001943;dis:Breast Neoplasms;g:CPT1A)(dui:D003921;dis:Diabetes Mellitus, Experimental;g:CPT1A)	Glyburide:Perhexiline:Levocarnitine	GO:0006641:GO:0006006:GO:0009437:GO:0042755:GO:0045471:GO:0050796:GO:0006635:GO:0071398:GO:0042802:GO:0032000:GO:0004095:GO:0014070:GO:0005741:GO:0006853:GO:0007623:GO:0006631:GO:0030855:GO:0031307:GO:0001676:GO:1990698:GO:0042493:GO:0005739:GO:0016020:GO:0019216:GO:0010883	600528	PF00755:PF16484	0.35,0.91,0.14															M
